{"9e3ef9aa272b41c7292092f7b58b5504b210b0a2": [["Introduction and main resultsThe theory of differential equations with fractional derivatives has gained significant popularity and importance in the last few decades, mainly due to its applications in many seemingly distant fields of science and technology (see, for example, [1] - [6] ).Introduction and main resultsOne of the most important time-fractional equations is the subdiffusion equation, which models anomalous or slow diffusion processes.", [["[1] - [6]", "SIMPLE_CHEMICAL", 277, 286], ["fractional derivatives", "PROBLEM", 71, 93], ["the subdiffusion equation", "TEST", 373, 398], ["slow diffusion processes", "PROBLEM", 426, 450], ["significant", "OBSERVATION_MODIFIER", 105, 116], ["popularity", "OBSERVATION_MODIFIER", 117, 127], ["anomalous", "OBSERVATION", 413, 422], ["slow", "OBSERVATION_MODIFIER", 426, 430], ["diffusion processes", "OBSERVATION", 431, 450]]], ["This equation is a partial integro-differential equation obtained from the classical heat equation by replacing the first-order derivative with a time-fractional derivative of the order \u03c1 \u2208 (0, 1).Introduction and main resultsWhen considering the subdiffusion equation as a model equation in the analysis of anomalous diffusion processes, the order of the fractional derivative is often unknown and difficult to measure directly.", [["a partial integro-differential equation", "PROBLEM", 17, 56], ["the subdiffusion equation", "TEST", 243, 268], ["anomalous diffusion processes", "PROBLEM", 308, 337], ["the fractional derivative", "TREATMENT", 352, 377], ["anomalous", "OBSERVATION", 308, 317], ["diffusion processes", "OBSERVATION", 318, 337]]], ["To determine this parameter, it is necessary to investigate the inverse problems of identifying these physical quantities based on some indirectly observable information about solutions (see a survey paper Li, Liu and Yamamoto [7] ).Introduction and main resultsIn this paper, we investigate the existence and uniqueness of solutions to initial-boundary value problems for subdiffusion equations with the Caputo derivative and the elliptic operator A(D) in R N with constant coefficients.", [["boundary value problems", "PROBLEM", 345, 368], ["subdiffusion equations", "PROBLEM", 373, 395], ["the Caputo derivative", "TREATMENT", 401, 422]]], ["The inverse problems of determining the order of the fractional derivative with respect to time and with respect to the spatial variable will also be investigated.Introduction and main resultsLet us proceed to a rigorous formulation of the main results of this article. h(\u03be) (t \u2212 \u03be) \u03c1+1 d\u03be, t > 0, provided the right-hand side exists.", [["right-hand", "ANATOMY", 311, 321], ["the fractional derivative", "TREATMENT", 49, 74], ["right", "ANATOMY_MODIFIER", 311, 316]]], ["Here \u0393(\u03c1) is Euler's gamma function.", [["\u0393(\u03c1)", "PROTEIN", 5, 9]]], ["Using this definition one can define the Caputo fractional derivative of order \u03c1, 0 < \u03c1 < 1, asIntroduction and main resultsLet \u03c1 \u2208 (0, 1) be a given number.", [["asIntroduction", "TEST", 93, 107]]], ["We call problem (1.1) -(1.3) the forward problem.", [["the forward problem", "PROBLEM", 29, 48]]], ["Denoting the Sobolev classes by L \u03c4 2 (R N ) (see the definition in the next section), we can state an existence theorem for this problem.Introduction and main resultsThen the forward problem has a solution in the formIntroduction and main resultsThe integral uniformly converges with respect to x \u2208 R N and for each t \u2208 (0, T ], where\u03c6(\u03be) is the Fourier transform of \u03d5.Introduction and main resultsIf the solution of the forward problem u(x, t) \u2208 L2(R N ), t \u2208 (0, T ], then we may define the Fourier transform\u00fbIntroduction and main resultsThe corresponding uniqueness theorem has the form.", [["a solution", "TREATMENT", 196, 206], ["the forward problem u(x, t)", "TEST", 418, 445], ["L2", "ANATOMY", 448, 450]]], ["Theorem 1.3.", [["Theorem", "TEST", 0, 7]]], ["We will prove that under the condition of Theorem 1.2 for initial function \u03d5, all four conditions of Theorem 1.3 are also satisfied.", [["Theorem", "TEST", 42, 49]]], ["Thus, if we add these four conditions to Definition 1.1, then Theorem 1.2 guarantees both the existence and the uniqueness of such a solution.Introduction and main resultsIn recent years, numerous works of specialists have appeared, where they study various initialboundary value problems for various subdiffusion equations.", [["Definition", "TEST", 41, 51], ["Theorem", "TEST", 62, 69], ["such a solution", "TREATMENT", 126, 141], ["various subdiffusion equations", "PROBLEM", 293, 323]]], ["Basically, the case of one spatial variable x \u2208 R and subdiffusion equation with \"the elliptical part\" uxx were considered (see, for example, handbook Machado, aditor [1] , book of A.A. Kilbas et al. [3] and monograph of A. V. Pskhu [8] , and references in these works).", [["subdiffusion equation", "PROBLEM", 54, 75]]], ["The paper Gorenflo, Luchko and Yamamoto [9] is devoted to the study of subdiffusion equations in Sobelev spaces.", [["the study", "TEST", 58, 67], ["subdiffusion equations", "PROBLEM", 71, 93]]], ["In the paper by Kubica and Yamamoto [10] , initial-boundary value problems for equations with time-dependent coefficients are considered.", [["boundary value problems", "PROBLEM", 51, 74]]], ["In the last paper the initial function \u03d5 \u2208 Lp(R N ) is such, that the Fourier transform\u03c6 is compactly supported.", [["Lp", "PROTEIN", 43, 45], ["the Fourier transform\u03c6", "TREATMENT", 66, 88]]], ["The authors of the recent paper [15] considered initialboundary value problems for subdiffusion equations with arbitrary elliptic differential operators in bounded domains.Introduction and main results2.", [["initialboundary value problems", "PROBLEM", 48, 78], ["subdiffusion equations", "PROBLEM", 83, 105], ["arbitrary elliptic differential operators", "TREATMENT", 111, 152]]], ["Determining the correct order of an equation in applied fractional modeling plays an important role.", [["an equation in applied fractional modeling", "TREATMENT", 33, 75]]], ["The corresponding inverse problem for subdiffusion equations has been considered by a number of authors (see a survey paper Li, Liu and Yamamoto [7] and references therein, [16] - [21] ).", [["[16] - [21]", "SIMPLE_CHEMICAL", 173, 184], ["subdiffusion equations", "PROBLEM", 38, 60]]], ["Note that in all known works the subdiffusion equation was considered in a bounded domain \u2126 \u2282 R N .", [["\u2282 R N", "CELL_LINE", 92, 97], ["the subdiffusion equation", "PROBLEM", 29, 54]]], ["Authors of paper Ashurov and Umarov [20] considered as an additional information the value of projection of the solution onto the first eigenfunction of the elliptic part of subdiffusion equation.", [["elliptic", "OBSERVATION_MODIFIER", 157, 165], ["subdiffusion equation", "OBSERVATION", 174, 195]]], ["The uniqueness and existence of an unknown order of the fractional derivative in the subdiffusion equation were proved in the recent work of Alimov and Ashurov [21] .", [["the fractional derivative", "TREATMENT", 52, 77], ["the subdiffusion equation", "TEST", 81, 106]]], ["In this case, the additional condition is ||u(x, t0)|| 2 = d0, and the boundary condition is not necessarily homogeneous.", [["the boundary condition", "TEST", 67, 89], ["not necessarily", "UNCERTAINTY", 93, 108], ["homogeneous", "OBSERVATION", 109, 120]]], ["Now let us consider the order of fractional derivative \u03c1 in equation (1.1) as an unknown parameter.", [["fractional derivative \u03c1 in equation", "TREATMENT", 33, 68]]], ["To determine the order \u03c1 of the fractional derivative in (1.1) we use the following extra data: Let us denote by E\u03c1(t) the Mittag-Leffler function of the formIntroduction and main results.Introduction and main resultsTo solve the inverse problem fix the number \u03c10 \u2208 (0, 1) and consider the problem for \u03c1 \u2208 [\u03c10, 1).", [["the fractional derivative", "TREATMENT", 28, 53]]], ["Lemma 1.6.", [["Lemma", "TEST", 0, 5]]], ["For \u03c10 from the interval 0 < \u03c10 < 1, there is a number T0 = T0(\u03bb0, \u03c10) such that for all t0 \u2265 T0 and for arbitrary \u03d5 \u2208 L2(R N ) the function U (t0, \u03c1) decreases monotonically with respect to \u03c1 \u2208 [\u03c10, 1].Introduction and main resultsRemark 1.7.", [["\u03c1", "PROTEIN", 191, 192], ["the interval", "TEST", 12, 24], ["arbitrary", "TEST", 105, 114], ["L2", "ANATOMY", 119, 121]]], ["The number T0(\u03bb0, \u03c10) can be chosen asIntroduction and main resultswhere B1 = 43 and B2 = 4.6.", [["The number T0", "TEST", 0, 13], ["B1", "TEST", 73, 75], ["B2", "TEST", 85, 87]]], ["But if \u03c10\u03bb0 > 0.0075, then you can just put T0 = 2.Introduction and main resultsThe result related to the inverse problem has the form.Introduction and main results3.", [["the inverse problem", "PROBLEM", 102, 121]]], ["Finally, we will consider another inverse problem of determining both the orders of fractional derivatives with respect to time and the spatial derivatives in the subdiffusion equations.Introduction and main resultsFor the best of our knowledge, only in the following two papers [22] and [23] such inverse problems were studied and only the uniqueness theorems ware proved (note that uniqueness is a very important property of a solution from an application point of view).", [["fractional derivatives", "TREATMENT", 84, 106], ["the spatial derivatives", "TREATMENT", 132, 155], ["the subdiffusion equations", "TEST", 159, 185], ["such inverse problems", "PROBLEM", 293, 314], ["a solution", "TREATMENT", 427, 437]]], ["In paper [22] by Tatar and Ulusoy it is considered the initial-boundary value problem for differential equationIntroduction and main resultswhere \u25b3 \u03c3 is the one-dimensional fractional Laplace operator, \u03c1 \u2208 (0, 1) and \u03c3 \u2208 (1/4, 1).", [["\u03c3", "PROTEIN", 148, 149]]], ["The authors have proved that if the initial function \u03d5(x) is sufficiently smooth and all its Fourier coefficients are positive, then the two-parameter inverse problem with additional information (1.5) has a unique solution.", [["Fourier coefficients", "TEST", 93, 113], ["the two-parameter inverse problem", "PROBLEM", 133, 166], ["a unique solution", "TREATMENT", 205, 222], ["positive", "OBSERVATION", 118, 126]]], ["As for physical backgrounds for two-parameter differential equations, see, for example, [24] .Introduction and main resultsIn [23] , M. Yamamoto proved the uniqueness theorem for the above two-parameter inverse problem in N -dimensional bounded domain \u2126 with smooth boundary \u2202\u2126.", [["N -dimensional bounded domain", "PROTEIN", 222, 251], ["physical backgrounds", "TEST", 7, 27], ["the above two-parameter inverse problem", "TREATMENT", 179, 218]]], ["The conditions on the initial function found in this work are less restrictive, for example, if \u03d5 is zero on \u2202\u2126, \u03d5 \u2208 L \u03c4 2 (\u2126), \u03c4 > N/2, \u03d5 \u2265 0 in \u2126 and \u03d5(x0) = 0, then the uniqueness theorem is true.Introduction and main resultsIt is easy to verify that the closure\u00c2 of operator A is positive and selfadjoint.", [["the initial function", "TEST", 18, 38], ["zero", "TEST", 101, 105], ["\u03c4", "TEST", 128, 129], ["the uniqueness theorem", "TEST", 168, 190], ["selfadjoint", "PROBLEM", 297, 308], ["positive", "OBSERVATION", 284, 292]]], ["Therefore, by virtue of the von Neumann theorem, for any \u03c3 > 0, we can introduce the degree of the operator\u00c2 a\u015dIntroduction and main resultswhere projectors P \u03bb defined asIntroduction and main resultsThe domain of definition of this operator is determined from the condition\u00c2 \u03c3 f (x) \u2208 L2(R N ) and has the formIntroduction and main resultsSuppose first that \u03c1 \u2208 (\u03c10, 1) and \u03c3 \u2208 (0, 1) are given numbers and consider the initialboundary value (the second forward ) problemIntroduction and main resultswhere \u03d5(x) is a given continuous function.", [["the initialboundary value", "TEST", 417, 442], ["L2", "ANATOMY", 286, 288]]], ["The solution to this problem is defined similarly to the solution to problem (1.1) -(1.3) (see Definition 1.1).", [["The solution", "TREATMENT", 0, 12]]], ["In exactly the same way as Theorem 1.2, it is proved that if a \u03d5 \u2208 L \u03c4 2 (R N ) and \u03c4 > N 2 , then the solution of the second forward problem has the formIntroduction and main resultswhere the integral uniformly converges in x \u2208 R N and for each t \u2208 (0, T ].", [["N", "CHEMICAL", 76, 77], ["a \u03d5 \u2208 L \u03c4", "TEST", 61, 70]]], ["Now suppose, that parameters \u03c1 and \u03c3 are unknown.", [["\u03c1", "GENE_OR_GENE_PRODUCT", 29, 30], ["\u03c3", "GENE_OR_GENE_PRODUCT", 35, 36], ["\u03c3", "PROTEIN", 35, 36]]], ["Let \u03be0 be one of such a vector.", [["Let \u03be0", "GENE_OR_GENE_PRODUCT", 0, 6], ["\u03be0", "DNA", 4, 6]]], ["We consider the following information as additional conditions: (1.12) V (\u03be0, t0, \u03c1, \u03c3) = |v(\u03be0, t0)| = d0, t0 \u2265 T0(1, \u03c10),Introduction and main resultswhere \u03be1 is such that\u03c6(\u03be1) = 0 and \u039b1 is defined in (4.2).Introduction and main resultsWe call problem (1.8) -(1.10) together with extra conditions (1.12) and (1.13) the second inverse problem.Introduction and main resultsNote that V (\u03be0, t0, \u03c1, \u03c3) is actually independent of \u03c3.", [["\u03be1", "PROTEIN", 158, 160], ["\u039b1", "PROTEIN", 187, 189], ["t0", "TEST", 78, 80], ["\u03c1", "TEST", 82, 83], ["v", "TEST", 91, 92], ["d0", "TEST", 104, 106], ["Introduction", "TEST", 123, 135], ["the second inverse problem", "PROBLEM", 318, 344]]], ["Theorem 1.9.", [["Theorem", "TEST", 0, 7]]], ["Let \u03d5 \u2208 L \u03c4 2 (R N ) and \u03c4 > N 2 .", [["Let", "TEST", 0, 3]]], ["For \u03c3 \u22c6 to exist, it is necessary and sufficient that d1 satisfies the inequalitiesIntroduction and main resultsIt should also be noted that the theory and applications of various inverse problems, on determining the coefficients of the equation, the right-hand side, and also on determining the initial or boundary functions for differential equations of integer order are discussed in Kabanikhin [25] (see also references therein).Forward problemsIn the present section we prove Theorems 1.2 and 1.3 and equation (1.11).", [["right-hand", "ANATOMY", 251, 261], ["\u03c3", "PROTEIN", 4, 5], ["various inverse problems", "PROBLEM", 172, 196], ["Theorems", "TEST", 481, 489], ["right", "ANATOMY_MODIFIER", 251, 256]]], ["The class of functions L2(R N ) which for a given fixed number a > 0 make the normForward problemsfinite is termed the Sobolev class L a 2 (R N ).", [["L2", "ANATOMY", 23, 25]]], ["Since for \u03c4 > 0 and some constants c1 and c2 one has the inequalityForward problemsthen D(\u00c2 \u03c4 ) = L \u03c4 m 2 (R N ).", [["some constants c1 and c2", "PROBLEM", 20, 44], ["D", "TEST", 88, 89], ["c2", "ANATOMY", 42, 44]]], ["Let I be the identity operator in L2(R N ).", [["Let I", "GENE_OR_GENE_PRODUCT", 0, 5], ["L2", "ANATOMY", 34, 36]]], ["Operator (\u00c2 + I) \u03c4 is defined in the same way as operator\u00c2 \u03c3 .Forward problemsProof of Theorem 1.2 is based on the following lemma (see M.A. Krasnoselski et al. [26] , p.", [["operator\u00c2 \u03c3", "PROTEIN", 49, 60], ["Forward problems", "PROBLEM", 62, 78]]], ["453), which is a simple consequence of the Sobolev embedding theorem.Forward problemsLemma 2.1.", [["the Sobolev embedding theorem", "TREATMENT", 39, 68], ["Forward problemsLemma", "PROBLEM", 69, 90]]], ["Let \u03bd > 1 + N 2m .", [["Let \u03bd", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Then for any |\u03b1| \u2264 m operator D \u03b1 (\u00c2 + I) \u2212\u03bd continuously maps from L2(R N ) into C(R N ) and moreover the following estimate holds trueForward problemsProof.", [["continuously maps", "TEST", 45, 62], ["trueForward problems", "PROBLEM", 132, 152], ["L2", "ANATOMY", 68, 70]]], ["For any a > N/2 one has the Sobolev embedding theorem:Forward problems.", [["Forward problems", "PROBLEM", 54, 70]]], ["Therefore, it is sufficient to prove the inequalityBut this is a consequence of the estimateTo prove the existence of the forward problem's solution we remind the following estimate of the Mittag-Leffler function with a negative argument (see, for example, [6] , p.29)But this is a consequence of the estimateIn accordance with Definition 1.1, we will first show that for function (1.4) one has A(D)u(x, t) \u2208 C(R N \u00d7 (0, T ]) (that is one can validly apply the operators D \u03b1 , |\u03b1| \u2264 m, to the series in (1.4) term-by-term).Consider the truncated integralLet \u03c4 > N 2 and \u03bd = 1 + \u03c4 m > 1 + N 2m .", [["truncated integralLet \u03c4", "PROTEIN", 536, 559], ["N 2", "PROTEIN", 562, 565], ["the forward problem's solution", "TREATMENT", 118, 148], ["function", "TEST", 372, 380], ["C", "TEST", 409, 410], ["\u00d7", "TEST", 415, 416], ["the series", "TEST", 489, 499], ["the truncated integralLet", "TEST", 532, 557], ["\u03bd", "TEST", 570, 571], ["m", "TEST", 580, 581]]], ["ThenConsider the truncated integralTherefore by virtue of Lemma 2.1 one hasConsider the truncated integralUsing the Parseval equality, we will haveApplying the inequality (2.3) gives |(A(\u03be)This implies the uniform in x \u2208 R N convergence of the differentiated sum (2.4) in the variables xj for each t \u2208 (0, T ].", [["uniform", "OBSERVATION_MODIFIER", 206, 213]]], ["Further, from equation (1.1) one has D \u03c1 t S\u00b5(x, t) = \u2212A(D)S\u00b5(x, t).", [["equation", "TEST", 14, 22], ["S\u00b5", "TEST", 59, 61]]], ["Therefore, proceeding the above reasoning, we arrive at D \u03c1 t u(x, t) \u2208 C(R N \u00d7 (0.T ]).", [["C", "TEST", 72, 73]]], ["It is not difficult to verify that equation (1.1) and the initial condition (1.3) are satisfied (see, for example, [6] , page 173 and [27] ).Applying the inequality (2.3) gives |(A(\u03be)Let us show that the inclusion \u03d5 \u2208 L \u03c4 2 (R N ), \u03c4 > N/2, implies\u03c6 \u2208 L1(R N ).", [["\u03c6", "PROTEIN", 248, 249], ["L1", "PROTEIN", 252, 254], ["R N", "PROTEIN", 255, 258], ["equation", "TEST", 35, 43], ["Let us", "TEST", 183, 189], ["the inclusion", "TEST", 200, 213], ["\u03c4", "TEST", 232, 233], ["L1", "ANATOMY_MODIFIER", 252, 254]]], ["Indeed,Therefore, by virtue of inequality (2.3), one hasThe property of function \u03d5 :\u03c6 \u2208 L1(R N ), established above, implies condition (4):Therefore, by virtue of inequality (2.3), one hasAs regards condition (1) of Theorem 1.3, it is a direct consequence of the Sobolev embedding theorem and the condition \u03d5 \u2208 L \u03c4 2 (R N ), \u03c4 > N 2 , of Theorem 1.2.Therefore, by virtue of inequality (2.3), one hasProof of Theorem 1.3.", [["L1", "PROTEIN", 88, 90], ["the condition", "TEST", 293, 306], ["\u03c4", "TEST", 325, 326], ["Theorem", "TEST", 338, 345], ["Theorem", "TEST", 408, 415], ["L1", "ANATOMY", 88, 90]]], ["Our aim is to prove that u(x, t) = u1(x, t) \u2212 u2(x, t) \u2261 0.", [["u", "TEST", 25, 26], ["u1", "TEST", 35, 37]]], ["Since the problem is linear, then we have the following homogenous problem for u(x, t):Therefore, by virtue of inequality (2.3), one hasLet u(x, t) be a solution of problem (2.5)-(2.7).", [["a solution of problem", "TREATMENT", 151, 172], ["linear", "OBSERVATION_MODIFIER", 21, 27]]], ["Since u(x, t) \u2208 L2(R N ), t \u2208 (0, T ] (see condition (3) of Theorem 1.3), we may define the Fourier transform\u00fb(\u03be, t) and according to condition (4) one has\u00fb(\u03be, t) \u2208 L1(R N ).", [["L1", "PROTEIN", 165, 167], ["u(x, t)", "TEST", 6, 13], ["t \u2208", "TEST", 26, 29], ["Theorem", "TEST", 60, 67], ["L2", "ANATOMY", 16, 18], ["L1", "ANATOMY", 165, 167]]], ["Therefore, by virtue of Fubini's theorem, the following function of t exists for almost all \u03bb:Therefore, by virtue of inequality (2.3), one haswhere d\u03c3 \u03bb (\u03be) is the corresponding surface element.Therefore, by virtue of inequality (2.3), one hasSince u(x, t) is a solution of equation (2.5), then (note,Therefore, by virtue of inequality (2.3), one hasThe inner integral exists as the Fourier transform of L2-function.", [["surface", "ANATOMY", 179, 186], ["L2", "DNA", 405, 407], ["Fubini's theorem", "TEST", 24, 40], ["surface element", "OBSERVATION", 179, 194], ["inner", "ANATOMY_MODIFIER", 355, 360], ["L2", "ANATOMY", 405, 407]]], ["We will take into account the following: A(D) is a homogeneous symmetric and even order differential expression; conditions (2) of Theorem 1.3; and (2.6).", [["Theorem", "TEST", 131, 138], ["homogeneous", "OBSERVATION_MODIFIER", 51, 62], ["symmetric", "OBSERVATION", 63, 72]]], ["ThenTherefore, by virtue of inequality (2.3), one hasTherefore, we have the following Cauchy problem for w \u03bb (t):Therefore, by virtue of inequality (2.3), one hasD \u03c1 t w \u03bb (t) + \u03bbw \u03bb (t) = 0, t > 0; w \u03bb (0) = 0.", [["inequality", "TEST", 137, 147], ["t", "TEST", 192, 193]]], ["This problem has the unique solution; hence, the function defined by (2.8), is identically zero (see, for example, [6] , p.", [["the unique solution", "TREATMENT", 17, 36]]], ["Integrating the equation (2.8) with respect to \u03bb over the domain (0, +\u221e) we obtain R N\u00fb (\u03be, t)d\u03be = 0, t > 0.", [["\u03bb", "PROTEIN", 47, 48], ["Integrating the equation", "TEST", 0, 24]]], ["Thus Theorem 1.3 is proved.Therefore, by virtue of inequality (2.3), one hasFormula (1.11) for the solution of the second forward problem is established in exactly the same way with formula (1.4).First inverse problemLemma 3.1.", [["First inverse problemLemma", "PROBLEM", 196, 222]]], ["Given \u03c10 from the interval 0 < \u03c10 < 1, there exists a number T0 = T0(\u03bb0, \u03c10), such that for all t0 \u2265 T0 and \u03bb \u2265 \u03bb0 function e \u03bb (\u03c1) = E\u03c1(\u2212\u03bbt \u03c1 0 ) is positive and monotonically decreasing with respect to \u03c1 \u2208 [\u03c10, 1) and e \u03bb (1) < e \u03bb (\u03c1) \u2264 e \u03bb (\u03c10).First inverse problemProof.", [["\u03c10", "PROTEIN", 6, 8], ["E\u03c1", "PROTEIN", 134, 136], ["\u03c1", "PROTEIN", 204, 205], ["T0", "TEST", 101, 103], ["\u03bb", "TEST", 108, 109], ["function", "TEST", 115, 123], ["e", "TEST", 124, 125], ["\u03c1", "TEST", 129, 130], ["E\u03c1", "TEST", 134, 136], ["\u2212\u03bbt", "TEST", 137, 140], ["monotonically", "TEST", 163, 176], ["respect", "TEST", 193, 200], ["\u03c1", "TEST", 204, 205], ["\u2208", "TEST", 206, 207], ["e", "TEST", 230, 231], ["\u03c1", "TEST", 235, 236], ["\u2264 e \u03bb", "TEST", 238, 243], ["First inverse problemProof", "PROBLEM", 249, 275], ["positive", "OBSERVATION", 150, 158]]], ["Let us denote by \u03b4(1; \u03b2) a contour oriented by non-decreasing arg \u03b6 consisting of the following parts: the ray arg \u03b6 = \u2212\u03b2 with |\u03b6| \u2265 1, the arc \u2212\u03b2 \u2264 arg \u03b6 \u2264 \u03b2, |\u03b6| = 1, and the ray arg \u03b6 = \u03b2, |\u03b6| \u2265 1.", [["arg \u03b6", "PROTEIN", 62, 67], ["ray arg \u03b6 = \u2212\u03b2", "PROTEIN", 107, 121], ["\u03b6", "PROTEIN", 128, 129], ["arc", "PROTEIN", 140, 143], ["\u2212\u03b2", "PROTEIN", 144, 146], ["arg", "PROTEIN", 149, 152], ["\u03b6", "PROTEIN", 153, 154], ["\u03b2", "PROTEIN", 157, 158], ["|\u03b6", "PROTEIN", 160, 162], ["\u03b2", "PROTEIN", 189, 190], ["|\u03b6", "PROTEIN", 192, 194], ["the ray arg", "TEST", 103, 114], ["the arc", "TEST", 136, 143], ["arg", "TEST", 149, 152], ["\u03b2", "TEST", 157, 158], ["|\u03b6", "TEST", 160, 162], ["the ray arg", "TEST", 173, 184], ["ray arg", "ANATOMY", 177, 184]]], ["If 0 < \u03b2 < \u03c0, then the contour \u03b4(1; \u03b2) divides the complex \u03b6-plane into two unbounded parts, namely G (\u2212) (1; \u03b2) to the left of \u03b4(1; \u03b2) by orientation, and G (+) (1; \u03b2) to the right of it.", [["\u03c0", "PROTEIN", 11, 12], ["complex \u03b6-plane", "PROTEIN", 51, 66], ["orientation", "TEST", 139, 150], ["G", "TEST", 156, 157], ["contour", "OBSERVATION_MODIFIER", 23, 30], ["left", "ANATOMY_MODIFIER", 120, 124], ["right", "ANATOMY_MODIFIER", 176, 181]]], ["The contour \u03b4(1; \u03b2) is called the Hankel path.First inverse problemLet \u03b2 = 3\u03c0 4 \u03c1, \u03c1 \u2208 [\u03c10, 1).", [["\u03c1", "PROTEIN", 83, 84], ["First inverse problemLet", "TEST", 46, 70], ["contour", "OBSERVATION_MODIFIER", 4, 11]]], ["Then by the definition of this contour \u03b4(1; \u03b2), we arrive at (note, \u2212\u03bbt \u03c1 0 \u2208 G (\u2212) (1; \u03b2), see [6] , p.", [["\u2212\u03bbt", "TEST", 68, 71]]], ["Then \u0393 \u2032 (\u03c1) = \u0393(\u03c1)\u03a8(\u03c1), and therefore,First inverse problem.First inverse problemthe function f \u2032 1 (\u03c1) can be represented as followsFirst inverse problemIf \u03b3 \u2248 0, 57722 is the Euler-Mascheroni constant, then \u2212\u03b3 < \u03a8(2 \u2212 \u03c1) < 1 \u2212 \u03b3.", [["\u03b3 \u2248 0, 57722", "CHEMICAL", 158, 170], ["f \u2032 1", "GENE_OR_GENE_PRODUCT", 95, 100], ["First inverse problem", "PROBLEM", 39, 60], ["First inverse problem", "PROBLEM", 134, 155]]], ["By virtue of this estimate we may writeFirst inverse problemOn the other hand one hasFirst inverse problemNote, since \u03b2 = 3\u03c0 4 \u03c1 and \u03c10 \u2264 \u03c1 < 1, then for a negative number z < 0 the following inequality holds minFirst inverse problemTherefore,First inverse problemwhere I = 2\u03c0\u03c1(\u03bbt \u03c1 0 ) 2 .", [["First inverse problem", "PROBLEM", 85, 106], ["inverse problem", "PROBLEM", 218, 233]]], ["Let us denote the last three integrals by Jj, j = 1, 2, 3, correspondingly.", [["Jj", "ANATOMY", 42, 44]]], ["Therefore,First inverse problemIt is not hard to verify, thatFirst inverse problemConsider the integral J1.", [["integral J1", "PROTEIN", 95, 106], ["integral J1", "OBSERVATION", 95, 106]]], ["Due to the presence of ln |\u03b6|, the integrand J1 is equal to 0 for |\u03b6| = 1.", [["ln |\u03b6|", "GENE_OR_GENE_PRODUCT", 23, 29], ["integrand J1", "DNA", 35, 47], ["ln", "OBSERVATION", 23, 25]]], ["Moreover, on the rays arg \u03b6 = \u00b1\u03b2, \u03b2 = 3\u03c0 4 \u03c1, one hasFirst inverse problemHence (note ln |\u03b6|First inverse problemThe integrands in J2 and J3 do not vanish on the sphere {|\u03b6| = 1} and the measure of the corresponding arc \u2212\u03b2 \u2264 arg \u03b6 \u2264 \u03b2, |\u03b6| = 1, is equal to 2\u03b2.", [["arc", "PROTEIN", 216, 219], ["\u2212\u03b2", "PROTEIN", 220, 222], ["arg", "PROTEIN", 225, 228], ["\u03b6", "PROTEIN", 229, 230], ["\u03b2", "PROTEIN", 233, 234], ["|\u03b6", "PROTEIN", 236, 238], ["\u03b2", "PROTEIN", 258, 259], ["the rays arg", "TEST", 13, 25], ["\u00b1\u03b2", "TEST", 30, 32], ["\u03b2", "TEST", 34, 35], ["First inverse problem", "PROBLEM", 92, 113], ["the measure", "TEST", 183, 194], ["arg", "TEST", 225, 228], ["\u03b2", "TEST", 233, 234], ["J2", "ANATOMY", 131, 133]]], ["Therefore, using the same technique as above, we obtainFirst inverse problemwhere B1 = 43 and B2 = 4.6.", [["B1", "TEST", 82, 84], ["B2", "TEST", 94, 96]]], ["Therefore, taking into account estimate (3.2), we haveFirst inverse problemIn other words, this derivative is negative if 1) or, which is the same,First inverse problemNext, consider two cases: B1/\u03c10 > B2 ln t0 and B1/\u03c10 \u2264 B2 ln t0.", [["B1", "PROTEIN", 194, 196], ["B2", "PROTEIN", 202, 204], ["B1", "PROTEIN", 215, 217], ["\u03c10", "PROTEIN", 218, 220], ["B2", "PROTEIN", 223, 225], ["t0", "PROTEIN", 229, 231], ["B1", "TEST", 194, 196], ["B2", "TEST", 202, 204], ["B1", "TEST", 215, 217], ["ln", "ANATOMY", 226, 228]]], ["Let B1/\u03c10 > B2 ln t0.", [["Let B1", "GENE_OR_GENE_PRODUCT", 0, 6], ["B1", "PROTEIN", 4, 6], ["B2", "DNA", 12, 14], ["t0", "DNA", 18, 20], ["B1", "TEST", 4, 6], ["ln", "ANATOMY", 15, 17]]], ["ThenFirst inverse problem(the latter inequality is satisfied, say if t0 \u2264 e B 1 /B 2 ).", [["ThenFirst inverse problem", "PROBLEM", 0, 25]]], ["Therefore, inequality (3.4) is satisfied ifFirst inverse problemThus, from the last two inequalities it follows that if If \u03c10 and \u03bb1 are such small numbers, that the first inequality of (3.5) does not hold true, then consider Case 2.", [["\u03c10", "GENE_OR_GENE_PRODUCT", 123, 125], ["\u03bb1", "GENE_OR_GENE_PRODUCT", 130, 132], ["\u03bb1", "PROTEIN", 130, 132], ["First inverse problem", "PROBLEM", 43, 64], ["such small numbers", "PROBLEM", 137, 155]]], ["In this case, t0 should be chosen large enough.First inverse problemThus, in Case 2 in order for the derivative (3.3) to be negative for all \u03bb \u2265 \u03bb0 and \u03c1 \u2208 [\u03c10, 1), it is sufficient that the following inequality takes place t0 \u2265 T0, where (see Remark 1.7)First inverse problemFinally, by virtue of inequality e \u03bb (1) = e \u2212\u03bbt > 0, one has e \u03bb (\u03c1) > 0.First inverse problemSinceFirst inverse problemLemma 1.6 follows immediately from Lemma 3.1.", [["\u03bb", "PROTEIN", 141, 142], ["\u03bb0", "PROTEIN", 145, 147], ["inequality", "TEST", 298, 308], ["\u2212\u03bbt", "TEST", 321, 324], ["First inverse problemSinceFirst inverse problemLemma", "PROBLEM", 350, 402]]], ["Theorem 1.8 is an easy consequence of these two lemmas.First inverse problemIn conclusion, we make the following remark.", [["these two lemmas", "PROBLEM", 38, 54], ["two lemmas", "OBSERVATION", 44, 54]]], ["If the elliptic polynomial A(\u03be) is nonhomogeneous, that is A(\u03be) = |\u03b1|\u2264m a\u03b1\u03be \u03b1 and moreover, A(\u03be) \u2265 \u03bb0 > 0, then from Lemma 3.1 it follows:First inverse problemIf t0 \u2265 T0 and T0 is as above, then E\u03c1(\u2212A(\u03be)t \u03c1 ), as a function of \u03c1, is positive and decreases monotonically in \u03c1 \u2208 [\u03c10, 1] for any \u03be \u2208 R N .", [["\u03b1", "PROTEIN", 67, 68], ["a\u03b1\u03be \u03b1", "PROTEIN", 72, 77], ["E\u03c1", "PROTEIN", 195, 197], ["\u03c1", "PROTEIN", 227, 228], ["a\u03b1\u03be", "TEST", 72, 75], ["\u03b1", "TEST", 76, 77], ["moreover", "TEST", 82, 90], ["Lemma", "TEST", 117, 122], ["First inverse problemIf", "TEST", 138, 161], ["positive", "OBSERVATION", 233, 241], ["decreases", "OBSERVATION_MODIFIER", 246, 255], ["monotonically", "OBSERVATION_MODIFIER", 256, 269]]], ["Examples U (t, \u03c1) = ||Au(x, t)|| 2 , U (t, \u03c1) = ||u(x, t)|| 2 , U (t, \u03c1) = (u, \u03d5).Second inverse problemTo prove Theorem 1.9, we first find the unknown parameter \u03c1.", [["Au", "CHEMICAL", 22, 24], ["Examples", "TEST", 0, 8], ["t", "TEST", 12, 13], ["\u03c1", "TEST", 15, 16], ["Au", "TEST", 22, 24], ["t", "TEST", 28, 29], ["U", "TEST", 37, 38], ["t", "TEST", 40, 41], ["\u03c1", "TEST", 43, 44], ["u", "TEST", 50, 51], ["t", "TEST", 55, 56], ["U", "TEST", 64, 65], ["t", "TEST", 67, 68], ["\u03c1", "TEST", 70, 71], ["u", "TEST", 76, 77], ["Second inverse problem", "PROBLEM", 82, 104]]], ["Then, as it follows from Lemma 3.1, for all t0 \u2265 T0(1, \u03c10) the equation V (\u03be0, t0, \u03c1, \u03c3) = |v(\u03be0, t0)| = E\u03c1(\u2212t \u03c1 )|\u03d5(\u03be0)| = d0 has the unique solution \u03c1 \u22c6 \u2208 (\u03c10, 1).", [["Lemma", "TEST", 25, 30], ["the equation V", "TEST", 59, 73], ["t0", "TEST", 79, 81], ["\u03c1", "TEST", 83, 84], ["E\u03c1", "TEST", 105, 107], ["\u2212t", "TEST", 108, 110], ["\u03d5", "TEST", 115, 116], ["the unique solution", "TEST", 131, 150], ["\u2208", "TEST", 155, 156]]], ["Now let us define \u03c3 \u22c6 \u2208 [\u03c30, 1), which corresponds to the already found \u03c1 \u22c6 and satisfies condition (1.13).", [["\u03c3", "PROTEIN", 18, 19]]], ["Then formula (3.1) will have the formOne hasIt is not hard to verify, that g \u2032 2 (\u03bb) has the estimate (is proved in a completely similar way to estimate of J3)One hasTherefore, for all t0 > 1 we haveOne hasHence this derivative is negative ifOne hasThus, if \u03bb1 \u2265 \u039b1, where (see Remark 1.7) (4.2) \u039b1 = e n , n \u2265 ln(5 \u0393(1 \u2212 \u03c1 \u22c6 )) \u03c30 , then e \u03bb \u03c3 1 (\u03c1 \u22c6 ), as a function of \u03c3 \u2208 [\u03c30, 1), strictly decreases for all t0 > 1.", [["\u03c3", "PROTEIN", 372, 373], ["\u22c6", "TEST", 324, 325], ["\u03c3", "TEST", 329, 330], ["a function", "TEST", 358, 368], ["\u2208", "TEST", 374, 375], ["\u03c30", "TEST", 377, 379]]], ["Moreover, for all \u03bb1 \u2265 \u039b1 and \u03c3 \u2208 [\u03c30, 1) the following estimate is fulfilled e \u03bb 1 (\u03c1 \u22c6 ) < e \u03bb \u03c3 1 (\u03c1 \u22c6 ) < e1(\u03c1 \u22c6 ).", [["\u039b1", "PROTEIN", 23, 25], ["\u03c3", "PROTEIN", 30, 31]]], ["The last estimate shows that if d1 satisfies condition (1.14), then, assuming \u03c1 \u22c6 has already been found, we can easily determine the parameter \u03c3 \u22c6 from equality (1.13), that is, from e \u03bb \u03c3 1 (\u03c1 \u22c6 )|\u03c6(\u03be1)| = d1.AcknowledgementThe authors convey thanks to Sh.", [["\u03c1", "PROTEIN", 78, 79], ["equality", "TEST", 153, 161]]]], "9b1b665e6ea27f485898427a23df51c18ed0ebb7": [["IntroductionIn 2007, the fever, thrombocytopenia and leukopenia syndrome (FTLS; also called severe fever with thrombocytopenia syndrome, SFTS) was first reported in Henan province, China [1, 2] .", [["fever", "DISEASE", 25, 30], ["thrombocytopenia", "DISEASE", 32, 48], ["leukopenia", "DISEASE", 53, 63], ["FTLS", "DISEASE", 74, 78], ["fever", "DISEASE", 99, 104], ["thrombocytopenia", "DISEASE", 110, 126], ["SFTS", "DISEASE", 137, 141], ["IntroductionIn", "TREATMENT", 0, 14], ["the fever", "PROBLEM", 21, 30], ["thrombocytopenia", "PROBLEM", 32, 48], ["leukopenia syndrome", "PROBLEM", 53, 72], ["FTLS", "PROBLEM", 74, 78], ["severe fever", "PROBLEM", 92, 104], ["thrombocytopenia syndrome", "PROBLEM", 110, 135], ["SFTS", "PROBLEM", 137, 141], ["thrombocytopenia", "OBSERVATION", 32, 48], ["leukopenia syndrome", "OBSERVATION", 53, 72], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["fever", "OBSERVATION", 99, 104], ["thrombocytopenia syndrome", "OBSERVATION", 110, 135]]], ["Since then, this life-threatening disease has been reported in many Chinese provinces, including Hubei, Anhui, Jiangsu, Liaoning and Shandong.", [["this life-threatening disease", "PROBLEM", 12, 41]]], ["The main clinical symptoms are sudden onset of fever (.37.5uC), fatigue, marked anorexia, headache, myalgia, arthralgia, dizziness, lymphadenopathy, vomiting, and diarrhea.", [["fever", "DISEASE", 47, 52], ["fatigue", "DISEASE", 64, 71], ["anorexia", "DISEASE", 80, 88], ["headache", "DISEASE", 90, 98], ["myalgia", "DISEASE", 100, 107], ["arthralgia", "DISEASE", 109, 119], ["dizziness", "DISEASE", 121, 130], ["lymphadenopathy", "DISEASE", 132, 147], ["vomiting", "DISEASE", 149, 157], ["diarrhea", "DISEASE", 163, 171], ["The main clinical symptoms", "PROBLEM", 0, 26], ["fever", "PROBLEM", 47, 52], ["uC", "PROBLEM", 59, 61], ["fatigue", "PROBLEM", 64, 71], ["marked anorexia", "PROBLEM", 73, 88], ["headache", "PROBLEM", 90, 98], ["myalgia", "PROBLEM", 100, 107], ["arthralgia", "PROBLEM", 109, 119], ["dizziness", "PROBLEM", 121, 130], ["lymphadenopathy", "PROBLEM", 132, 147], ["vomiting", "PROBLEM", 149, 157], ["diarrhea", "PROBLEM", 163, 171], ["main", "OBSERVATION_MODIFIER", 4, 8], ["fever", "OBSERVATION", 47, 52], ["marked", "OBSERVATION_MODIFIER", 73, 79], ["anorexia", "OBSERVATION", 80, 88], ["myalgia", "OBSERVATION", 100, 107], ["arthralgia", "OBSERVATION", 109, 119], ["lymphadenopathy", "OBSERVATION", 132, 147], ["diarrhea", "OBSERVATION", 163, 171]]], ["Laboratory tests show thrombocytopenia, leukopenia, increased urine protein, and elevated serum aspartate aminotransferase and alanine aminotransferase.", [["urine", "ANATOMY", 62, 67], ["serum", "ANATOMY", 90, 95], ["thrombocytopenia", "DISEASE", 22, 38], ["leukopenia", "DISEASE", 40, 50], ["aspartate", "CHEMICAL", 96, 105], ["alanine", "CHEMICAL", 127, 134], ["aspartate", "CHEMICAL", 96, 105], ["alanine", "CHEMICAL", 127, 134], ["urine", "ORGANISM_SUBSTANCE", 62, 67], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["aspartate", "SIMPLE_CHEMICAL", 96, 105], ["aminotransferase", "SIMPLE_CHEMICAL", 106, 122], ["alanine", "AMINO_ACID", 127, 134], ["aminotransferase", "AMINO_ACID", 135, 151], ["urine protein", "PROTEIN", 62, 75], ["serum aspartate aminotransferase", "PROTEIN", 90, 122], ["alanine aminotransferase", "PROTEIN", 127, 151], ["Laboratory tests", "TEST", 0, 16], ["thrombocytopenia", "PROBLEM", 22, 38], ["leukopenia", "PROBLEM", 40, 50], ["increased urine protein", "PROBLEM", 52, 75], ["elevated serum aspartate aminotransferase", "PROBLEM", 81, 122], ["alanine aminotransferase", "TEST", 127, 151], ["thrombocytopenia", "OBSERVATION", 22, 38], ["leukopenia", "OBSERVATION", 40, 50], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["urine protein", "OBSERVATION", 62, 75]]], ["Initially, this disease was diagnosed as suspended human granulocytic anaplasmosis (HGA) infection [3] .", [["human granulocytic anaplasmosis", "DISEASE", 51, 82], ["HGA", "DISEASE", 84, 87], ["infection", "DISEASE", 89, 98], ["human", "ORGANISM", 51, 56], ["HGA", "CANCER", 84, 87], ["human", "SPECIES", 51, 56], ["human granulocytic anaplasmosis", "SPECIES", 51, 82], ["HGA", "SPECIES", 84, 87], ["this disease", "PROBLEM", 11, 23], ["suspended human granulocytic anaplasmosis (HGA) infection", "PROBLEM", 41, 98], ["granulocytic anaplasmosis", "OBSERVATION", 57, 82]]], ["However, only 8% of patients were positive for HGA infection, indicating that other pathogens likely contribute to this syndrome.", [["infection", "DISEASE", 51, 60], ["patients", "ORGANISM", 20, 28], ["HGA", "GENE_OR_GENE_PRODUCT", 47, 50], ["patients", "SPECIES", 20, 28], ["HGA infection", "PROBLEM", 47, 60], ["other pathogens", "PROBLEM", 78, 93], ["this syndrome", "PROBLEM", 115, 128], ["infection", "OBSERVATION", 51, 60]]], ["Samples collected in 2009 identified a novel virus in the Bunyaviridae family, genus Phlebovirus in FTLS cases; the virus has been named several times including severe fever with thrombocytopenia syndrome virus (SFSTV), Henan fever virus (HFV), fever, thrombocytopenia and leukopenia syndrome virus (FTLSV), and Huaiyangshan virus (HYSV) [1, 2, 4] .", [["Samples", "ANATOMY", 0, 7], ["Bunyaviridae", "DISEASE", 58, 70], ["fever", "DISEASE", 168, 173], ["thrombocytopenia syndrome", "DISEASE", 179, 204], ["Henan fever", "DISEASE", 220, 231], ["fever", "DISEASE", 245, 250], ["thrombocytopenia", "DISEASE", 252, 268], ["leukopenia syndrome", "DISEASE", 273, 292], ["FTLS", "CANCER", 100, 104], ["Henan fever virus", "ORGANISM", 220, 237], ["Huaiyangshan virus", "ORGANISM", 312, 330], ["Henan fever virus", "SPECIES", 220, 237], ["Huaiyangshan virus", "SPECIES", 312, 330], ["severe fever with thrombocytopenia syndrome virus", "SPECIES", 161, 210], ["SFSTV", "SPECIES", 212, 217], ["Henan fever virus", "SPECIES", 220, 237], ["HFV", "SPECIES", 239, 242], ["FTLSV", "SPECIES", 300, 305], ["Huaiyangshan virus", "SPECIES", 312, 330], ["HYSV", "SPECIES", 332, 336], ["Samples", "TEST", 0, 7], ["a novel virus", "PROBLEM", 37, 50], ["genus Phlebovirus", "PROBLEM", 79, 96], ["the virus", "PROBLEM", 112, 121], ["severe fever", "PROBLEM", 161, 173], ["thrombocytopenia syndrome virus (SFSTV)", "PROBLEM", 179, 218], ["Henan fever virus (HFV)", "PROBLEM", 220, 243], ["fever", "PROBLEM", 245, 250], ["thrombocytopenia", "PROBLEM", 252, 268], ["leukopenia syndrome virus (FTLSV)", "PROBLEM", 273, 306], ["Huaiyangshan virus", "PROBLEM", 312, 330], ["Phlebovirus", "OBSERVATION", 85, 96], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["fever", "OBSERVATION", 168, 173], ["thrombocytopenia", "OBSERVATION", 179, 195], ["thrombocytopenia", "OBSERVATION", 252, 268], ["leukopenia syndrome", "OBSERVATION", 273, 292]]], ["Serosurveillance has shown that 1 to3.8% of examined populations in hilly areas had FTLSV antibodies, suggesting that SFTSV has circulated widely in China but only a small proportion of infected individuals develop disease.", [["SFTSV", "CHEMICAL", 118, 123], ["individuals", "ORGANISM", 195, 206], ["FTLSV antibodies", "PROTEIN", 84, 100], ["FTLSV", "SPECIES", 84, 89], ["SFTSV", "SPECIES", 118, 123], ["FTLSV antibodies", "PROBLEM", 84, 100], ["SFTSV", "PROBLEM", 118, 123], ["infected individuals develop disease", "PROBLEM", 186, 222], ["SFTSV", "OBSERVATION", 118, 123], ["small", "OBSERVATION_MODIFIER", 166, 171], ["proportion", "OBSERVATION_MODIFIER", 172, 182], ["infected", "OBSERVATION", 186, 194]]], ["The overall mortality of FTLSV infection in China is about 7.3% (2391 cases and 174 deaths),but ranges from 6.3% to 30% in various studies [5] .IntroductionThe genome of FTLSV is similar to that of other Bunyaviridae; it is composed of three segments, designated L, M and S. The L segment contains 6391 nucleotides encoding an RNA-dependent RNA polymerase; the M segment contains 3366 nucleotides encoding glycoproteins Gn and Gc; and the S segment contains 1760 nucleotides of antisense RNA encoding a nonstructural protein (NS) and a nucleocapsid protein (N) in opposite orientations.", [["FTLSV infection", "DISEASE", 25, 40], ["deaths", "DISEASE", 84, 90], ["Bunyaviridae", "DISEASE", 204, 216], ["nucleotides", "CHEMICAL", 463, 474], ["FTLSV", "CANCER", 25, 30], ["FTLSV", "GENE_OR_GENE_PRODUCT", 170, 175], ["Gn", "GENE_OR_GENE_PRODUCT", 420, 422], ["Gc", "GENE_OR_GENE_PRODUCT", 427, 429], ["FTLSV", "DNA", 170, 175], ["L segment", "DNA", 279, 288], ["RNA-dependent RNA polymerase", "PROTEIN", 327, 355], ["M segment", "DNA", 361, 370], ["glycoproteins", "PROTEIN", 406, 419], ["Gn", "PROTEIN", 420, 422], ["Gc", "PROTEIN", 427, 429], ["S segment", "PROTEIN", 439, 448], ["antisense RNA", "RNA", 478, 491], ["nonstructural protein", "PROTEIN", 503, 524], ["NS", "PROTEIN", 526, 528], ["nucleocapsid protein", "PROTEIN", 536, 556], ["N", "PROTEIN", 558, 559], ["FTLSV", "SPECIES", 25, 30], ["FTLSV infection", "PROBLEM", 25, 40], ["various studies", "TEST", 123, 138], ["Bunyaviridae", "TREATMENT", 204, 216], ["an RNA-dependent RNA polymerase", "PROBLEM", 324, 355], ["nucleotides encoding glycoproteins Gn", "TEST", 385, 422], ["Gc", "TEST", 427, 429], ["antisense RNA", "PROBLEM", 478, 491], ["a nonstructural protein (NS", "TREATMENT", 501, 528], ["a nucleocapsid protein", "TEST", 534, 556], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["mortality", "OBSERVATION_MODIFIER", 12, 21], ["FTLSV", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40], ["L", "ANATOMY_MODIFIER", 263, 264], ["L", "ANATOMY_MODIFIER", 279, 280], ["segment", "ANATOMY_MODIFIER", 281, 288], ["glycoproteins Gn", "OBSERVATION", 406, 422]]], ["Partial sequencing of L and S segments from human cases and ticks confirmed that FTLSV is a novel Phlebovirus and is most closely related to the non-pathogenic Uukuniemi virus (the pairwise nucleotide similarities for the L, M and S segments are 34%, 24% and 29%, respectively) [4] .", [["human", "ORGANISM", 44, 49], ["FTLSV", "GENE_OR_GENE_PRODUCT", 81, 86], ["Phlebovirus", "CANCER", 98, 109], ["Uukuniemi virus", "ORGANISM", 160, 175], ["L and S segments", "DNA", 22, 38], ["human", "SPECIES", 44, 49], ["Uukuniemi virus", "SPECIES", 160, 175], ["human", "SPECIES", 44, 49], ["FTLSV", "SPECIES", 81, 86], ["Uukuniemi virus", "SPECIES", 160, 175], ["Partial sequencing of L and S segments from human cases", "PROBLEM", 0, 55], ["a novel Phlebovirus", "PROBLEM", 90, 109], ["the non-pathogenic Uukuniemi virus", "PROBLEM", 141, 175], ["L", "ANATOMY_MODIFIER", 22, 23], ["Phlebovirus", "OBSERVATION", 98, 109]]], ["All FTLSV sequences currently available in GenBank are similar regardless of their sampling locations (.90% sequence similarity), suggesting that they descended from a relatively recent common ancestor.IntroductionOnly a few members of the Phlebovirus genus use ticks as a vector; FTLSV is likely to be transmitted to human populations from an animal reservoir via feeding of infected ticks [6] .", [["Phlebovirus genus", "ORGANISM", 240, 257], ["ticks", "ORGANISM", 262, 267], ["FTLSV", "GENE_OR_GENE_PRODUCT", 281, 286], ["human", "ORGANISM", 318, 323], ["FTLSV sequences", "DNA", 4, 19], ["human", "SPECIES", 318, 323], ["FTLSV", "SPECIES", 281, 286], ["human", "SPECIES", 318, 323], ["All FTLSV sequences", "TEST", 0, 19], ["the Phlebovirus genus", "TREATMENT", 236, 257], ["an animal reservoir", "TREATMENT", 341, 360]]], ["FTLSV has been detected in Haemaphysalis longicornis and Rhipicephalus microplus ticks collected from a number of domestic animals, including cattle, buffalo, goats, cats and dogs [4, 7, 8] .", [["FTLSV", "CHEMICAL", 0, 5], ["FTLSV", "GENE_OR_GENE_PRODUCT", 0, 5], ["Haemaphysalis longicornis", "ORGANISM", 27, 52], ["Rhipicephalus microplus ticks", "ORGANISM", 57, 86], ["cattle", "ORGANISM", 142, 148], ["buffalo", "ORGANISM", 150, 157], ["goats", "ORGANISM", 159, 164], ["cats", "ORGANISM", 166, 170], ["dogs", "ORGANISM", 175, 179], ["FTLSV", "PROTEIN", 0, 5], ["Haemaphysalis longicornis", "SPECIES", 27, 52], ["Rhipicephalus microplus", "SPECIES", 57, 80], ["cattle", "SPECIES", 142, 148], ["buffalo", "SPECIES", 150, 157], ["goats", "SPECIES", 159, 164], ["cats", "SPECIES", 166, 170], ["dogs", "SPECIES", 175, 179], ["FTLSV", "SPECIES", 0, 5], ["Haemaphysalis longicornis", "SPECIES", 27, 52], ["Rhipicephalus microplus", "SPECIES", 57, 80], ["cattle", "SPECIES", 142, 148], ["buffalo", "SPECIES", 150, 157], ["goats", "SPECIES", 159, 164], ["Haemaphysalis longicornis", "PROBLEM", 27, 52], ["Rhipicephalus microplus ticks", "PROBLEM", 57, 86]]], ["The potential for human-to-human transmission has also been shown [9, 10, 11] , and phylogenetic analysis of partial L, M and S sequences has indicated that there are five phylogenetic groups circulating in China [4] .", [["human", "ORGANISM", 18, 23], ["human", "ORGANISM", 27, 32], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 27, 32], ["phylogenetic analysis", "TEST", 84, 105], ["partial L, M and S sequences", "TEST", 109, 137]]], ["However, more detailed genetic information is needed to fully characterize the history of FTLSV and elucidate its transmission dynamics in China.", [["FTLSV", "CANCER", 90, 95], ["FTLSV", "SPECIES", 90, 95], ["FTLSV", "TREATMENT", 90, 95]]], ["Such studies could facilitate the future development of new strategies for controlling FTLSV.IntroductionIn the present study, a powerful Bayesian phylogeographic approach to reconstruct the transmission of FTLSV through space and time was used to infer the geographic locations of ancestral viral lineages.", [["FTLSV", "CANCER", 87, 92], ["FTLSV", "CANCER", 207, 212], ["FTLSV", "PROTEIN", 87, 92], ["FTLSV", "DNA", 207, 212], ["ancestral viral lineages", "CELL_TYPE", 282, 306], ["FTLSV", "SPECIES", 87, 92], ["FTLSV", "SPECIES", 207, 212], ["Such studies", "TEST", 0, 12], ["new strategies", "TREATMENT", 56, 70], ["controlling FTLSV", "TREATMENT", 75, 92], ["the present study", "TEST", 108, 125], ["FTLSV through space", "TREATMENT", 207, 226], ["ancestral viral lineages", "PROBLEM", 282, 306], ["ancestral", "OBSERVATION", 282, 291], ["viral lineages", "OBSERVATION", 292, 306]]], ["In addition estimates of viral evolution rate and the divergence date of FTLSV were calculated.Isolation and sequencing of virusesSerum samples from FTLSV-infected patients (n = 12) were obtained by disease control and prevention workers in the Xinyang and Nanyang counties of Henan Province, China, during 2011-2012, and viral isolates were cultured from the sera [2] .", [["virusesSerum samples", "ANATOMY", 123, 143], ["sera", "ANATOMY", 360, 364], ["FTLSV-infected", "DISEASE", 149, 163], ["virusesSerum samples", "CANCER", 123, 143], ["FTLSV", "ORGANISM", 149, 154], ["patients", "ORGANISM", 164, 172], ["sera", "ORGANISM_SUBSTANCE", 360, 364], ["FTLSV", "PROTEIN", 73, 78], ["patients", "SPECIES", 164, 172], ["FTLSV", "SPECIES", 149, 154], ["viral evolution rate", "PROBLEM", 25, 45], ["FTLSV", "TEST", 73, 78], ["Isolation", "TREATMENT", 95, 104], ["virusesSerum samples", "TEST", 123, 143], ["FTLSV", "TEST", 149, 154], ["viral isolates", "TEST", 322, 336], ["viral", "OBSERVATION", 25, 30]]], ["All laboratory procedures involving viral cultures were performed under Biosafety Level-2 containment.", [["All laboratory procedures", "TEST", 0, 25], ["viral cultures", "TEST", 36, 50], ["Biosafety Level", "TEST", 72, 87]]], ["All patients provided written informed consent for the research use of their samples.", [["samples", "ANATOMY", 77, 84], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["their samples", "TEST", 71, 84]]], ["This research was approved by the Review Board of the Institute of Microbiology and Epidemiology [Beijing] and the Center for Disease Control and Prevention of Henan Province.Isolation and sequencing of virusesFor sequencing, total RNA was extracted from 140 ml aliquots of cell culture supernatant obtained from each sample using a QIAamp viral RNA Mini Kit (Qiagen) according to the manufacturer's instructions. cDNA was reverse transcribed from 6 ml of RNA at 45uC for 50 min in a 20 ml solution containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM DTT, 100 ng of random hexamer primers, 200 units of Superscript II (Invitrogen), 25 units of RNasin (Promega) and 0.5 mM dNTPs.", [["cell", "ANATOMY", 274, 278], ["supernatant", "ANATOMY", 287, 298], ["sample", "ANATOMY", 318, 324], ["Tris-HCl", "CHEMICAL", 516, 524], ["KCl", "CHEMICAL", 541, 544], ["MgCl", "CHEMICAL", 551, 555], ["dNTPs", "CHEMICAL", 687, 692], ["Tris-HCl", "CHEMICAL", 516, 524], ["KCl", "CHEMICAL", 541, 544], ["MgCl 2", "CHEMICAL", 551, 557], ["DTT", "CHEMICAL", 566, 569], ["dNTPs", "CHEMICAL", 687, 692], ["cell", "CELL", 274, 278], ["Tris-HCl", "SIMPLE_CHEMICAL", 516, 524], ["DTT", "SIMPLE_CHEMICAL", 566, 569], ["RNasin", "SIMPLE_CHEMICAL", 659, 665], ["cDNA", "DNA", 414, 418], ["Superscript II", "PROTEIN", 618, 632], ["Disease Control", "TREATMENT", 126, 141], ["Isolation", "TREATMENT", 175, 184], ["viruses", "PROBLEM", 203, 210], ["sequencing", "TEST", 214, 224], ["total RNA", "TEST", 226, 235], ["cell culture", "TEST", 274, 286], ["a QIAamp viral RNA Mini Kit (Qiagen)", "TREATMENT", 331, 367], ["RNA", "TREATMENT", 456, 459], ["pH", "TEST", 526, 528], ["KCl", "TEST", 541, 544], ["3 mM MgCl", "TREATMENT", 546, 555], ["random hexamer primers", "TREATMENT", 581, 603], ["Superscript II (Invitrogen)", "TREATMENT", 618, 645], ["RNasin (Promega)", "TREATMENT", 659, 675], ["0.5 mM dNTPs", "TREATMENT", 680, 692], ["viruses", "OBSERVATION", 203, 210]]], ["Overlapping PCR was performed, and products were subjected to Sanger sequencing [12] .", [["Overlapping PCR", "TEST", 0, 15]]], ["Whole genome sequences were assembled using the SeqMan package in the DNASTAR 6.0 software.Sequence datasetSequences of FTLSV isolates available in the GenBank were downloaded and used in phylogenetic analyses.", [["SeqMan package", "DNA", 48, 62], ["FTLSV isolates", "DNA", 120, 134], ["FTLSV", "SPECIES", 120, 125], ["Whole genome sequences", "TEST", 0, 22], ["the SeqMan package", "TREATMENT", 44, 62], ["Sequence datasetSequences", "TEST", 91, 116], ["FTLSV isolates", "TREATMENT", 120, 134], ["phylogenetic analyses", "TEST", 188, 209]]], ["Only full-length S, M and L segment sequences with available collection dates and locations were included.", [["full-length S, M and L segment sequences", "DNA", 5, 45], ["L segment sequences", "TEST", 26, 45]]], ["The viral sequences that were newly determined in this study have been deposited in GenBank under accession numbers KF356517 to KF356552.", [["KF356552", "CHEMICAL", 128, 136], ["KF356552", "SIMPLE_CHEMICAL", 128, 136], ["viral sequences", "DNA", 4, 19], ["The viral sequences", "TEST", 0, 19], ["this study", "TEST", 50, 60]]], ["Recombination events were screened using the Recombination Detection Program (RDP) version 4.16 [14] , under both the default and triplet settings.", [["Recombination events", "PROBLEM", 0, 20]]], ["RDP implements a combination of methods, including RDP [14] , CHIMAERA [15] , BootSCAN [16] , MAXCHI [17] ,GENE-CONV [18] and 3Seq [19] for recombination detection.", [["a combination of methods", "TREATMENT", 15, 39], ["BootSCAN", "TEST", 78, 86], ["MAXCHI", "TEST", 94, 100], ["recombination detection", "TEST", 140, 163]]], ["Recombinant sequences were excluded before phylogenetic and phylogeographic analyses.", [["Recombinant sequences", "TEST", 0, 21], ["phylogenetic and phylogeographic analyses", "TEST", 43, 84]]], ["A total of 84 S-segment sequences, 72 M-segment sequences, and 68 L-segment sequences were included in our analysis.Phylogenetic analysisPhylogenetic trees for the three viral RNA segments were constructed using the maximum likelihood (ML) method, a feature of the software MEGA 5 [20] , and the Bayesian MCMC method applied using MrBayes 3.2.1 [21] .", [["S-segment sequences", "DNA", 14, 33], ["M-segment sequences", "DNA", 38, 57], ["68 L-segment sequences", "DNA", 63, 85], ["viral RNA segments", "DNA", 170, 188], ["segment sequences", "TEST", 16, 33], ["segment sequences", "TEST", 40, 57], ["68 L-segment sequences", "TEST", 63, 85], ["our analysis", "TEST", 103, 115], ["Phylogenetic analysis", "TEST", 116, 137], ["Phylogenetic trees", "PROBLEM", 137, 155], ["the Bayesian MCMC method", "TREATMENT", 292, 316]]], ["The general time reversible (GTR) model with gamma distribution (GTR+G) was used for both methods.", [["The general time reversible (GTR", "TREATMENT", 0, 32], ["gamma distribution (GTR+G)", "TREATMENT", 45, 71]]], ["The reliability of the ML analysis was evaluated by a bootstrap test with 1000 replicates.", [["the ML analysis", "TEST", 19, 34], ["a bootstrap test", "TEST", 52, 68]]], ["The Bayesian MCMC method was run for 500,000 generations per segment.Analysis of evolutionary rates and divergence timesEvolution rates and estimates of time since the most recent common ancestor (MRCA) were generated via Bayesian coalescent phylogenetic analysis using the BEAST software package version 2.0.2 [22] and Tracer version 1.4 [23] .", [["evolutionary rates", "TEST", 81, 99], ["Evolution rates", "TEST", 120, 135], ["Bayesian coalescent phylogenetic analysis", "TEST", 222, 263], ["the BEAST software package version", "TEST", 270, 304], ["Tracer version", "TEST", 320, 334]]], ["The jModelTest version 2.1.7 program [24] was used to examine possible nucleotide substitution models, and the most appropriate model for each dataset was selected based on Akaike's Information Criterion (AIC).", [["nucleotide", "CHEMICAL", 71, 81], ["nucleotide", "CHEMICAL", 71, 81], ["The jModelTest version", "TEST", 0, 22], ["nucleotide substitution models", "PROBLEM", 71, 101]]], ["GTR+G was selected for all three segments.", [["GTR+G", "GENE_OR_GENE_PRODUCT", 0, 5], ["GTR", "TREATMENT", 0, 3], ["segments", "ANATOMY_MODIFIER", 33, 41]]], ["Preliminary analyses were conducted to determine which clock (strict versus relaxed) and demographic (constant versus Bayesian Skyline population size) models were most appropriate for the datasets, with runs initially consisting of 10,000,000 generations.", [["Preliminary analyses", "TEST", 0, 20], ["demographic (constant versus Bayesian Skyline population size)", "TREATMENT", 89, 151]]], ["An analysis of marginal likelihoods [25] indicated that the relaxed uncorrelated lognormal clock [26] and constant population size model were most appropriate for all three segments (log10 Bayes Factors .2 inAuthor SummaryFTLSV is novel bunyavirus belonging to genus Phlebovirus and was first found in Huaiyangshan area.", [["An analysis", "TEST", 0, 11], ["marginal likelihoods", "PROBLEM", 15, 35], ["constant population size model", "TREATMENT", 106, 136], ["novel bunyavirus", "PROBLEM", 231, 247], ["genus Phlebovirus", "PROBLEM", 261, 278], ["marginal", "OBSERVATION_MODIFIER", 15, 23], ["size", "OBSERVATION_MODIFIER", 126, 130]]], ["The epidemiology and pathogenesis of FTLSV remain poorly understood.", [["FTLSV", "DISEASE", 37, 42], ["FTLSV", "CANCER", 37, 42], ["FTLSV", "SPECIES", 37, 42]]], ["This lack of information underscores the importance of analyzing the movement and genetic history of FTLSV in China.", [["FTLSV", "CANCER", 101, 106], ["FTLSV", "SPECIES", 101, 106]]], ["Recent advances in Bayesian coalescent phylogenetic analyses have resulted in more sophisticated methods being available for determining the relative age of emerging pathogens.", [["Bayesian coalescent phylogenetic analyses", "TEST", 19, 60], ["emerging pathogens", "PROBLEM", 157, 175]]], ["In this study, a phylogenetic and Bayesian phylogeographic analysis was performed for FTLSV whole genomic sequences isolated from China.", [["FTLSV whole genomic sequences", "DNA", 86, 115], ["FTLSV", "SPECIES", 86, 91], ["this study", "TEST", 3, 13], ["Bayesian phylogeographic analysis", "TEST", 34, 67], ["FTLSV whole genomic sequences", "PROBLEM", 86, 115]]], ["Results identified the Huaiyangshan area as the most probable origin of FTLSV and suggested migrating routes of the virus.", [["FTLSV", "CHEMICAL", 72, 77], ["FTLSV", "CANCER", 72, 77], ["FTLSV", "SPECIES", 72, 77], ["the Huaiyangshan area", "PROBLEM", 19, 40], ["the virus", "PROBLEM", 112, 121], ["most probable", "UNCERTAINTY", 48, 61], ["virus", "OBSERVATION", 116, 121]]], ["RNA segment reassortment was found in FTLSV; purifying selection appears to have been the dominant force driving the evolution of this virus.", [["FTLSV", "SPECIES", 38, 43], ["RNA segment reassortment", "PROBLEM", 0, 24], ["this virus", "PROBLEM", 130, 140], ["segment", "OBSERVATION_MODIFIER", 4, 11], ["reassortment", "OBSERVATION", 12, 24], ["dominant", "OBSERVATION_MODIFIER", 90, 98], ["force", "OBSERVATION", 99, 104]]], ["The results of this study could be used to facilitate the development of new strategies for controlling FTLSV.Author Summaryall cases).", [["FTLSV", "CANCER", 104, 109], ["FTLSV", "PROTEIN", 104, 109], ["FTLSV", "SPECIES", 104, 109], ["this study", "TEST", 15, 25], ["new strategies", "TREATMENT", 73, 87]]], ["Thus, the final Bayesian coalescent analyses used the GTR+G substitution model, a relaxed uncorrelated lognormal clock, and a constant population size.", [["the final Bayesian coalescent analyses", "TEST", 6, 44], ["the GTR", "TREATMENT", 50, 57], ["G substitution model", "TREATMENT", 58, 78], ["lognormal clock", "OBSERVATION", 103, 118], ["size", "OBSERVATION_MODIFIER", 146, 150]]], ["The S and L segment datasets were run for 50,000,000 generations, whereas the M segment dataset was run for 40,000,000 generations to ensure effective sample sizes (ESSs) of at least 200.", [["sample", "ANATOMY", 151, 157], ["The S and L segment datasets", "PROBLEM", 0, 28], ["ESSs", "TEST", 165, 169]]], ["FTLSV (SFTSV) sequences from Japan (AB817979-AB818002) were excluded from this analysis because the isolation time was not provided.Phylogeographic analysis based on the L segmentTo investigate the phylogeographic diffusion process along the posterior sets of the trees, relationships between locations were identified using the Bayesian stochastic variable search selection (BSSVS) applications in BEAST version 2.0.2 [22] .", [["FTLSV", "GENE_OR_GENE_PRODUCT", 0, 5], ["FTLSV (SFTSV) sequences", "DNA", 0, 23], ["L segment", "DNA", 170, 179], ["FTLSV", "SPECIES", 0, 5], ["SFTSV", "SPECIES", 7, 12], ["FTLSV (SFTSV) sequences", "TEST", 0, 23], ["this analysis", "TEST", 74, 87], ["Phylogeographic analysis", "TEST", 132, 156], ["the phylogeographic diffusion process", "PROBLEM", 194, 231], ["L", "ANATOMY_MODIFIER", 170, 171], ["segment", "ANATOMY_MODIFIER", 172, 179], ["posterior", "ANATOMY_MODIFIER", 242, 251], ["trees", "ANATOMY_MODIFIER", 264, 269]]], ["A Hasegawa-Kishino-Yano (HKY) substitution model, a constant population size tree prior, and a strict molecular clock were used.", [["A Hasegawa", "TEST", 0, 10], ["Yano (HKY) substitution model", "TREATMENT", 19, 48], ["a strict molecular clock", "TREATMENT", 93, 117], ["constant", "OBSERVATION_MODIFIER", 52, 60], ["population", "OBSERVATION_MODIFIER", 61, 71], ["size", "OBSERVATION_MODIFIER", 72, 76], ["tree", "OBSERVATION_MODIFIER", 77, 81], ["molecular clock", "OBSERVATION", 102, 117]]], ["A standard discrete phylogeographic analysis using continuous-time Markov chains (CTMCs) to estimate the migration events between major geographic regions was set up [27] .", [["A standard discrete phylogeographic analysis", "TEST", 0, 44], ["continuous-time Markov chains (CTMCs", "TREATMENT", 51, 87], ["the migration events", "PROBLEM", 101, 121], ["migration", "OBSERVATION_MODIFIER", 105, 114]]], ["This method can be used to infer the location state of the ancestral-branch geographic states, detect non-zero rates of state-transition over the whole tree, and build a reversible diffusion rate matrix between previously defined locations identified using the BSSVS applications.", [["This method", "TREATMENT", 0, 11], ["a reversible diffusion rate matrix", "PROBLEM", 168, 202], ["the BSSVS applications", "TREATMENT", 257, 279], ["branch", "ANATOMY_MODIFIER", 69, 75], ["reversible", "OBSERVATION_MODIFIER", 170, 180]]], ["Following our discrete phylogeographic visualizations, we used SPREAD 1.04 [28] to estimate the putative spatiotemporal pattern of the spread and visualize the diffusion of the virus.", [["the virus", "PROBLEM", 173, 182]]], ["The Bayes factor (BF) test, which determines statistically significant phylogeographic links, was performed using SPREAD 1.04.", [["Bayes factor", "PROTEIN", 4, 16], ["The Bayes factor (BF) test", "TEST", 0, 26]]], ["If BF.3, the phylogeographic link between two locations was considered to be statistically significant.Phylogeographic analysis based on the L segmentFor phylogeographic analysis, each FTLSV sequence (or isolate/ strain) was first assigned a character state reflecting its location of origin.", [["L segment", "DNA", 141, 150], ["FTLSV sequence", "DNA", 185, 199], ["BF", "TEST", 3, 5], ["Phylogeographic analysis", "TEST", 103, 127], ["phylogeographic analysis", "TEST", 154, 178], ["each FTLSV sequence", "TEST", 180, 199], ["L", "ANATOMY_MODIFIER", 141, 142], ["segment", "ANATOMY_MODIFIER", 143, 150], ["origin", "ANATOMY_MODIFIER", 285, 291]]], ["Because the FTLS cases reported in Henan and Hubei province were located near the border of Tongboshan, belonging to the Huaiyangshan Mountain region, Henan and Hubei Provinces were combined into the Huaiyangshan (HYS) region in the analysis.", [["Huaiyangshan (HYS) region", "DNA", 200, 225], ["the analysis", "TEST", 229, 241], ["border", "ANATOMY_MODIFIER", 82, 88]]], ["Based on the geographic locations from which the studied isolates were obtained, migration was considered among four provinces (Anhui, Jiangsu, Shandong, and Liaoning) and one area (Huaiyangshan).", [["the studied isolates", "TEST", 45, 65]]], ["FTLSV strains isolated from Japan (AB817979-AB818002) were excluded from this analysis because isolation times were not available.Phylogeny-trait association analysisTo determine the extent of geographic structure of FTLSV in China (by sampling locality), the association index (AI) and parsimony score (PS) statistics of clustering strength was computed using the BaTS (Bayesian tip-association significance testing) method [29] that examines all the plausible trees produced based on 60 L segment sequences of FTLSV strains by BEAST.Selection pressure analysesSelection analyses were performed on the full dataset using the Datamonkey server implementation of HyPhy [30] .", [["60 L segment sequences", "DNA", 486, 508], ["FTLSV", "SPECIES", 0, 5], ["FTLSV", "SPECIES", 217, 222], ["FTLSV strains", "PROBLEM", 0, 13], ["this analysis", "TEST", 73, 86], ["parsimony score", "TEST", 287, 302], ["clustering strength", "PROBLEM", 322, 341], ["the BaTS", "TEST", 361, 369], ["FTLSV strains", "PROBLEM", 512, 525], ["Selection pressure analyses", "TEST", 535, 562], ["Selection analyses", "TEST", 562, 580], ["geographic", "OBSERVATION_MODIFIER", 193, 203], ["structure", "OBSERVATION", 204, 213]]], ["Single Likelihood Ancestor Counting (SLAC), Fixed Effects Likelihood (FEL), and Random-Effects Likelihood (REL) algorithms were used to assess the presence of selected sites in the L, M and S alignments.", [["Likelihood (REL) algorithms", "TEST", 95, 122], ["Ancestor Counting", "OBSERVATION", 18, 35], ["L", "ANATOMY_MODIFIER", 181, 182]]], ["For the SLAC, FEL and IFEL results, a p-value cutoff of 0.05 was used; results of REL were considered significant if BF.100.0.Phylogenetic relationships of FTLSV genotypesIn this study, whole genome sequencing was performed on 12 FLTSV strains isolated in Henan Province, China.", [["FTLSV", "GENE_OR_GENE_PRODUCT", 156, 161], ["REL", "PROTEIN", 82, 85], ["FTLSV genotypes", "DNA", 156, 171], ["FLTSV", "SPECIES", 230, 235], ["a p-value cutoff", "TEST", 36, 52], ["Phylogenetic relationships of FTLSV genotypes", "PROBLEM", 126, 171], ["this study", "TEST", 174, 184], ["whole genome sequencing", "TEST", 186, 209]]], ["And the sequences were submitted into the Genebank (KF356517 to KF356552).", [["KF356552", "CHEMICAL", 64, 72], ["the sequences", "TEST", 4, 17]]], ["Little variation was observed in the overall nucleotide lengths of the S, M, and L segments from viruses circulating in Henan from 2011 to 2012, and pairwise differences in the percent nucleotide identities were low, ranging from 0.1%-4.2%, 0.2%-4.7% and 0.1%-5.8% for the L, M, and S segments, respectively.Phylogenetic relationships of FTLSV genotypesFor the three viral RNA segments, Bayesian analysis yielded highly supported tree topologies that were consistent with the ML results (Figures 1, 2 and 3 ).", [["nucleotide", "CHEMICAL", 45, 55], ["nucleotide", "CHEMICAL", 185, 195], ["nucleotide", "CHEMICAL", 45, 55], ["nucleotide", "CHEMICAL", 185, 195], ["FTLSV", "GENE_OR_GENE_PRODUCT", 338, 343], ["viral RNA segments", "DNA", 367, 385], ["Little variation", "PROBLEM", 0, 16], ["the percent nucleotide identities", "TEST", 173, 206], ["FTLSV genotypes", "PROBLEM", 338, 353], ["Bayesian analysis", "TEST", 387, 404], ["Figures", "TEST", 488, 495], ["variation", "OBSERVATION_MODIFIER", 7, 16], ["lengths", "OBSERVATION_MODIFIER", 56, 63], ["L segments", "ANATOMY_MODIFIER", 81, 91], ["viruses", "OBSERVATION", 97, 104], ["low", "OBSERVATION_MODIFIER", 212, 215], ["L", "ANATOMY_MODIFIER", 273, 274], ["segments", "ANATOMY_MODIFIER", 285, 293], ["tree topologies", "OBSERVATION", 430, 445]]], ["Phylogenetic analysis confirmed the presence of the five genotypes previously identified in China (designated A-E) [4, 31] and clustered the Japanese FTLSV strains, into a novel genotypic group.", [["A-E", "GENE_OR_GENE_PRODUCT", 110, 113], ["Phylogenetic analysis", "TEST", 0, 21], ["the five genotypes", "PROBLEM", 48, 66], ["the Japanese FTLSV strains", "PROBLEM", 137, 163]]], ["The Chinese genotypes were representive of the locations in China with the greatest burden of FTLS (Jiangsu, Henan, Liaoning, Shandong, Anhui, and Hubei Provinces and the Huaiyangshan region).", [["FTLS", "DISEASE", 94, 98], ["greatest", "OBSERVATION_MODIFIER", 75, 83]]], ["Strains isolated from animals mainly clustered into the A lineage based on L and M analysis; however, the analysis of the S segments indicated that animal-isolated strains also included B and C genotypes.", [["A lineage", "CELL", 56, 65], ["B", "CELL", 186, 187], ["C", "GENE_OR_GENE_PRODUCT", 192, 193], ["S segments", "DNA", 122, 132], ["Strains", "PROBLEM", 0, 7], ["L and M analysis", "TEST", 75, 91], ["the analysis", "TEST", 102, 114], ["animal-isolated strains", "PROBLEM", 148, 171], ["B and C genotypes", "PROBLEM", 186, 203]]], ["Strains isolated as part of this study were classified into A, B, D and E genotypes (Figures 1, 2 and 3 ).Evidence of RNA segment reassortmentTree topologies obtained from the L segment analysis were similar to those generated using the M and S segments, but a more detailed analysis revealed some inconsistencies that seemed to indicate reassortment events.", [["B", "CELL", 63, 64], ["Strains", "PROBLEM", 0, 7], ["this study", "TEST", 28, 38], ["A, B, D and E genotypes", "TEST", 60, 83], ["Figures", "TEST", 85, 92], ["RNA segment reassortment", "PROBLEM", 118, 142], ["Tree topologies", "TEST", 142, 157], ["the L segment analysis", "TEST", 172, 194], ["a more detailed analysis", "TEST", 259, 283], ["reassortment events", "PROBLEM", 338, 357], ["RNA segment reassortment", "OBSERVATION", 118, 142]]], ["Two typical reassortment events appear to have occurred: 1) in the AHL/2011 strains, the L and M segments belonged to the D genotype, while the S segment fell into the B linage (Figures 1, 2 and 3) ; and in the YSC3 strains isolated from Henan, the L and M segments belonged to the A lineage, while the S segment belonged to the E lineage.Selection pressure on FTLSVAnalysis with the SLAC algorithm showed that the global ratio of nonsynonymous to synonymous nucleotide substitutions (dN/ dS) in the L segment was 0.0480, suggesting the presence of predominantly purifying selection.", [["A lineage", "ANATOMY", 282, 291], ["E lineage", "ANATOMY", 329, 338], ["nucleotide", "CHEMICAL", 459, 469], ["nucleotide", "CHEMICAL", 459, 469], ["3", "GENE_OR_GENE_PRODUCT", 195, 196], ["YSC3", "GENE_OR_GENE_PRODUCT", 211, 215], ["A lineage", "CELL", 282, 291], ["E lineage", "CELL", 329, 338], ["S segment", "DNA", 144, 153], ["S segment", "DNA", 303, 312], ["E lineage", "CELL_TYPE", 329, 338], ["L segment", "DNA", 500, 509], ["the L and M segments", "TREATMENT", 85, 105], ["the D genotype", "TEST", 118, 132], ["the YSC3 strains", "PROBLEM", 207, 223], ["the L and M segments", "TREATMENT", 245, 265], ["Selection pressure on FTLSVAnalysis", "TEST", 339, 374], ["the SLAC algorithm", "TEST", 380, 398], ["synonymous nucleotide substitutions", "PROBLEM", 448, 483], ["L", "ANATOMY_MODIFIER", 89, 90], ["L", "ANATOMY_MODIFIER", 249, 250], ["E lineage", "OBSERVATION", 329, 338], ["synonymous nucleotide substitutions", "OBSERVATION", 448, 483], ["L", "ANATOMY_MODIFIER", 500, 501], ["segment", "ANATOMY_MODIFIER", 502, 509], ["suggesting the presence of", "UNCERTAINTY", 522, 548], ["predominantly", "OBSERVATION_MODIFIER", 549, 562], ["purifying selection", "OBSERVATION", 563, 582]]], ["The SLAC algorithm further identified 72 sites in the L segment that appeared to be under negative selection, while the FEL, IFEL and REL analyses detected one site (positions D691E/G) that appeared to be under positive selection in this segment.", [["SLAC algorithm", "DNA", 4, 18], ["L segment", "DNA", 54, 63], ["FEL", "DNA", 120, 123], ["IFEL", "DNA", 125, 129], ["REL", "DNA", 134, 137], ["The SLAC algorithm", "TEST", 0, 18], ["REL analyses", "TEST", 134, 146], ["SLAC", "OBSERVATION", 4, 8], ["72 sites", "OBSERVATION_MODIFIER", 38, 46], ["L", "ANATOMY_MODIFIER", 54, 55], ["segment", "ANATOMY_MODIFIER", 56, 63], ["appeared to be", "UNCERTAINTY", 69, 83], ["negative", "OBSERVATION", 90, 98], ["positive selection", "OBSERVATION", 211, 229], ["segment", "ANATOMY_MODIFIER", 238, 245]]], ["For the M segment, the SLAC algorithm analysis showed that the dN/dS was 0.0909 and detected 76 sites under negative selection.", [["SLAC algorithm", "DNA", 23, 37], ["dN", "DNA", 63, 65], ["the SLAC algorithm analysis", "TEST", 19, 46], ["the dN/dS", "PROBLEM", 59, 68], ["negative selection", "OBSERVATION", 108, 126]]], ["With respect to sites that appeared to be under positive selection, the FEL, IFEL and REL algorithms agreed on two sites (positions D37G/A and T501A/S); FEL and REL indicated one site (V323I); the REL algorithm alone detected one site (position I11T/V); and the IFEL method alone identified one site (T960I/S).", [["FEL, IFEL and REL algorithms", "DNA", 72, 100], ["FEL", "DNA", 153, 156], ["REL", "DNA", 161, 164], ["V323I", "DNA", 185, 190], ["REL algorithm", "DNA", 197, 210], ["position I11T/V", "DNA", 236, 251], ["IFEL", "DNA", 262, 266], ["REL algorithms", "TEST", 86, 100], ["T501A/S", "TREATMENT", 143, 150], ["the REL algorithm", "TEST", 193, 210], ["the IFEL method", "TREATMENT", 258, 273]]], ["For N and NS (encoded by the S segment), the dN/dS ratios were 0.0367 and 0.0991, respectively, and the SLAC, FEL, IFEL and REL methods failed to identify any sites that appeared to be under positive selection.Evolutionary rates and time since the MRCA of FTLSVThe mean molecular evolutionary rate estimates and 95% highest posterior density (HPD) intervals based on the Bayesian coalescent analyses were S = 3.17t10 24 (1.58610 25 -6.46610 24 ), M = 3.086FTLSV probably originated from Huaiyangshan in the 18 th centuryTo determine the geographic origins and movements of FLTSV in China, the results of the Bayesian phylogeographic analyses were summarized by annotating the MCC tree nodes with their most probable location states via color labeling (Figure 4) .", [["MCC", "MULTI-TISSUE_STRUCTURE", 676, 679], ["tree nodes", "MULTI-TISSUE_STRUCTURE", 680, 690], ["S segment", "DNA", 29, 38], ["SLAC, FEL, IFEL and REL methods", "DNA", 104, 135], ["FLTSV", "SPECIES", 573, 578], ["NS", "TREATMENT", 10, 12], ["the dN/dS ratios", "TEST", 41, 57], ["REL methods", "TEST", 124, 135], ["any sites", "PROBLEM", 155, 164], ["Evolutionary rates", "TEST", 210, 228], ["the MRCA", "TEST", 244, 252], ["the Bayesian coalescent analyses", "TEST", 367, 399], ["S", "TEST", 405, 406], ["the Bayesian phylogeographic analyses", "TEST", 604, 641], ["SLAC", "ANATOMY", 104, 108], ["density", "OBSERVATION", 334, 341], ["tree nodes", "OBSERVATION", 680, 690]]], ["The colors of the tree branches represent the most probable locations of their associated viral lineages (i.e., those supported by the highest probabilities), and a color change between two connected nodes implies a probable migration event.", [["tree branches", "ANATOMY", 18, 31], ["nodes", "ANATOMY", 200, 205], ["tree branches", "MULTI-TISSUE_STRUCTURE", 18, 31], ["nodes", "MULTI-TISSUE_STRUCTURE", 200, 205], ["viral lineages", "CELL_TYPE", 90, 104], ["their associated viral lineages", "PROBLEM", 73, 104], ["a color change between two connected nodes", "PROBLEM", 163, 205], ["a probable migration event", "PROBLEM", 214, 240], ["colors", "OBSERVATION_MODIFIER", 4, 10], ["tree", "ANATOMY_MODIFIER", 18, 22], ["branches", "ANATOMY_MODIFIER", 23, 31], ["viral lineages", "OBSERVATION", 90, 104], ["nodes", "OBSERVATION", 200, 205], ["probable", "UNCERTAINTY", 216, 224], ["migration event", "OBSERVATION", 225, 240]]], ["Simulative spatiotemporal pattern of FLTSV movements in China since the time of the MRCA was also visualized in Google Earth.", [["FLTSV movements in China", "PROBLEM", 37, 61], ["spatiotemporal", "OBSERVATION_MODIFIER", 11, 25], ["pattern", "OBSERVATION_MODIFIER", 26, 33], ["FLTSV movements", "OBSERVATION", 37, 52]]], ["The phylogeographic analysis showed the Huaiyangshan area appears to have been the origin of FLTSV in China ( Figure 5 ).", [["FLTSV", "SPECIES", 93, 98], ["The phylogeographic analysis", "TEST", 0, 28], ["the Huaiyangshan area", "PROBLEM", 36, 57], ["origin", "OBSERVATION_MODIFIER", 83, 89]]], ["The root state posterior probabilities for all locations ranged between 9.21% for Liaoning and 37.40% for Huaiyangshan.", [["root", "ANATOMY", 4, 8], ["root", "MULTI-TISSUE_STRUCTURE", 4, 8], ["root", "ANATOMY", 4, 8], ["posterior", "ANATOMY_MODIFIER", 15, 24]]], ["Two main spread routes were observed ( Figure 5A , Figure 5B , Figure 5C ).", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["FLTSV initially spread from the Huaiyangshan region into the surrounding provinces: eastward to Anhui and Jiangsu Provinces, and northward to Liaoning and Shandong Provinces.", [["FLTSV", "CHEMICAL", 0, 5], ["FLTSV", "SPECIES", 0, 5], ["FLTSV", "PROBLEM", 0, 5], ["spread", "OBSERVATION_MODIFIER", 16, 22]]], ["Thereafter, FTLSV is predicted to have spread from the Jiangsu Province to Liaoning, Shandong, and Anhui Provinces.", [["FTLSV", "PROTEIN", 12, 17]]], ["In a further investigation of these diffusion patterns, the BF test identified three wellsupported (BF.3) migration routes for FTLSV ( Figure 5D ): from The extent of geographic structure in the FTLSV L phylogeny Both the AI and PS statistics indicated that there was very strong geographic clustering of FTLSV strains by province or area of origin (P,0.05) ( Table 2 ).", [["FTLSV L phylogeny", "DNA", 195, 212], ["these diffusion patterns", "TEST", 30, 54], ["the BF test", "TEST", 56, 67], ["PS statistics", "TEST", 229, 242], ["FTLSV strains", "PROBLEM", 305, 318], ["extent", "OBSERVATION_MODIFIER", 157, 163], ["geographic structure", "OBSERVATION", 167, 187], ["very", "OBSERVATION_MODIFIER", 268, 272], ["strong", "OBSERVATION_MODIFIER", 273, 279], ["geographic", "OBSERVATION_MODIFIER", 280, 290], ["origin", "ANATOMY_MODIFIER", 342, 348]]], ["When the extent of phylogenetic clustering of individual province was tested, geographic clustering was significant for Huaiyangshan and Jiangsu except for Anhui, Liaoning, and Shandong, for which there was evidence of significant gene flow to and from other regions of China (P. 0.05).", [["Anhui", "PROBLEM", 156, 161], ["significant gene flow", "PROBLEM", 219, 240], ["phylogenetic", "OBSERVATION_MODIFIER", 19, 31], ["clustering", "OBSERVATION_MODIFIER", 32, 42], ["significant", "OBSERVATION_MODIFIER", 219, 230], ["gene flow", "OBSERVATION", 231, 240]]], ["These results suggest that the genetic diversity of FTLSV in Huaiyangshan and Jiangsu is shaped primarily by in situ evolution rather than extensive migration.", [["FTLSV", "CHEMICAL", 52, 57], ["FTLSV", "SPECIES", 52, 57], ["FTLSV in Huaiyangshan", "TREATMENT", 52, 73], ["shaped", "OBSERVATION_MODIFIER", 89, 95], ["extensive", "OBSERVATION_MODIFIER", 139, 148], ["migration", "OBSERVATION", 149, 158]]], ["However, the number of sequences from Anhui, Liaoning and Shandong was small, which may bias the result.DiscussionFTLS represents a threat to public health, and understanding the how the causative virus sustains and spreads in the environment is important to implementing effective prevention and control measures.", [["control measures", "TREATMENT", 297, 313], ["small", "OBSERVATION_MODIFIER", 71, 76]]], ["Currently, however, the mechanisms underlying the emergence and spread of FTLSV are unknown.", [["FTLSV", "DISEASE", 74, 79], ["FTLSV", "CANCER", 74, 79]]], ["The virus was first reported in 2007 [9] ; at least 11 provinces in China including Beijing [32] , and three countries, Korea [33] , Japan (AB817979-AB818002) FTLSV-infected cases These reports demonstrated the regional threat of this pathogen and indicate that enhanced surveillance is needed to gain a better understanding of its evolutionary history, geographic spread and evolving virulence.", [["FTLSV-infected", "DISEASE", 159, 173], ["The virus", "PROBLEM", 0, 9], ["Japan", "TEST", 133, 138], ["FTLSV", "TEST", 159, 164], ["this pathogen", "PROBLEM", 230, 243], ["virus", "OBSERVATION", 4, 9], ["infected", "OBSERVATION", 165, 173], ["virulence", "OBSERVATION_MODIFIER", 385, 394]]], ["Using a powerful and robust Bayesian phylogenetic and phylogeographic approach, we reconstructed the spatial and temporal spread of FTLSV in China.DiscussionThe phylogenetic relationships between strains circulating in China and Japan were reconfirmed as a part of this study, as were identification of the five genotypes already identified as circulating in China, consistent with the results reported by Zhang and Lam et al [4, 31] .", [["FTLSV", "SPECIES", 132, 137], ["this study", "TEST", 265, 275], ["spatial", "OBSERVATION_MODIFIER", 101, 108], ["temporal", "OBSERVATION_MODIFIER", 113, 121], ["spread", "OBSERVATION_MODIFIER", 122, 128], ["FTLSV", "OBSERVATION", 132, 137], ["consistent with", "UNCERTAINTY", 366, 381]]], ["For our comparison, FTLSV sequences were mainly derived from viruses isolated from Henan, Hubei, Jiangsu, Anhui, Liaoning and Shandong Provinces, and the close phylogenetic relationship among them indicated that the movement of FTLSV is common in China.", [["FTLSV", "CHEMICAL", 228, 233], ["FTLSV", "GENE_OR_GENE_PRODUCT", 20, 25], ["FTLSV", "GENE_OR_GENE_PRODUCT", 228, 233], ["FTLSV sequences", "DNA", 20, 35], ["FTLSV", "SPECIES", 228, 233], ["our comparison, FTLSV sequences", "TEST", 4, 35]]], ["At least two possible reasons for unencumbered movement of FTLSV: 1) there are no obvious physical barriers to prevent viral transmission, as the locations all correspond to plains or hilly regions of China; and 2) these regions share similar enzootic vectors and potential primate and non-primate reservoirs.", [["FTLSV", "DISEASE", 59, 64], ["obvious physical barriers", "PROBLEM", 82, 107], ["viral transmission", "PROBLEM", 119, 137], ["no obvious", "UNCERTAINTY", 79, 89], ["enzootic vectors", "OBSERVATION", 243, 259], ["non-primate reservoirs", "OBSERVATION", 286, 308]]], ["Several papers have reported the isolation of FTLSV from two tick species (Haemaphysalis longicornis and Rhipicephalus microplus) and domestic animals such as sheep, goat and cattle [4, 7, 8] .", [["FTLSV", "GENE_OR_GENE_PRODUCT", 46, 51], ["Haemaphysalis longicornis", "ORGANISM", 75, 100], ["Rhipicephalus microplus", "ORGANISM", 105, 128], ["sheep", "ORGANISM", 159, 164], ["goat", "ORGANISM", 166, 170], ["Haemaphysalis longicornis", "SPECIES", 75, 100], ["Rhipicephalus microplus", "SPECIES", 105, 128], ["sheep", "SPECIES", 159, 164], ["goat", "SPECIES", 166, 170], ["cattle", "SPECIES", 175, 181], ["FTLSV", "SPECIES", 46, 51], ["Haemaphysalis longicornis", "SPECIES", 75, 100], ["Rhipicephalus microplus", "SPECIES", 105, 128], ["sheep", "SPECIES", 159, 164], ["goat", "SPECIES", 166, 170], ["cattle", "SPECIES", 175, 181], ["the isolation of FTLSV", "PROBLEM", 29, 51], ["two tick species", "PROBLEM", 57, 73], ["Haemaphysalis longicornis and Rhipicephalus microplus", "TREATMENT", 75, 128]]], ["Furthermore, the analysis performed in this study suggest that FTLSV strains from Japan share a common ancestor with viral genotypes circulating in China, indicating that the virus has crossed the sea between China and Japan, forming the Japanese linage.DiscussionEvolution of FTLSV has impacted the sequence of all three viral RNA segments, creating unique viral genotypes and S, M and L RNA segment phylogenetic topologies indicate that FTLSV reassortment (particularly in the S segment) is not uncommon.", [["FTLSV", "CHEMICAL", 277, 282], ["FTLSV strains", "ORGANISM", 63, 76], ["FTLSV", "CANCER", 277, 282], ["FTLSV", "GENE_OR_GENE_PRODUCT", 439, 444], ["FTLSV", "DNA", 277, 282], ["viral RNA segments", "RNA", 322, 340], ["FTLSV", "SPECIES", 63, 68], ["the analysis", "TEST", 13, 25], ["this study", "TEST", 39, 49], ["FTLSV strains", "PROBLEM", 63, 76], ["viral genotypes circulating in China", "PROBLEM", 117, 153], ["the virus", "PROBLEM", 171, 180], ["FTLSV", "TREATMENT", 277, 282], ["creating unique viral genotypes and S, M and L RNA segment phylogenetic topologies", "PROBLEM", 342, 424], ["FTLSV reassortment", "PROBLEM", 439, 457], ["viral RNA segments", "OBSERVATION", 322, 340], ["viral genotypes", "OBSERVATION", 358, 373], ["FTLSV reassortment", "OBSERVATION", 439, 457], ["not uncommon", "UNCERTAINTY", 493, 505]]], ["Genetic reassortment can profoundly affect the pathogenicity and diversity of RNA viruses [34, 35, 36, 37, 38, 39] .", [["the pathogenicity", "PROBLEM", 43, 60], ["RNA viruses", "PROBLEM", 78, 89], ["RNA viruses", "OBSERVATION", 78, 89]]], ["For example, reassortment among influenza virus strains (another RNA virus with a segmented genome) results in antigenic shift and the emergence of new pandemic strains [40] .", [["influenza virus", "DISEASE", 32, 47], ["pandemic", "DISEASE", 152, 160], ["influenza virus strains", "ORGANISM", 32, 55], ["influenza virus", "SPECIES", 32, 47], ["influenza virus", "SPECIES", 32, 47], ["influenza virus strains", "PROBLEM", 32, 55], ["another RNA virus", "PROBLEM", 57, 74], ["new pandemic strains", "PROBLEM", 148, 168]]], ["The S segment of FTLSV encodes the N protein, which binds viral RNAs and encapsidates them in to ribonucleoprotein complexes (RNPs) as well as the NS protein, which prevents the host interferon response by interfering with the cellular mRNAs and protein synthesis machineries of host cells.", [["cellular", "ANATOMY", 227, 235], ["cells", "ANATOMY", 284, 289], ["FTLSV", "GENE_OR_GENE_PRODUCT", 17, 22], ["RNPs", "CELLULAR_COMPONENT", 126, 130], ["cellular", "CELL", 227, 235], ["host cells", "CELL", 279, 289], ["S segment", "DNA", 4, 13], ["FTLSV", "PROTEIN", 17, 22], ["N protein", "PROTEIN", 35, 44], ["viral RNAs", "RNA", 58, 68], ["ribonucleoprotein complexes", "PROTEIN", 97, 124], ["RNPs", "PROTEIN", 126, 130], ["NS protein", "PROTEIN", 147, 157], ["interferon", "PROTEIN", 183, 193], ["cellular mRNAs", "RNA", 227, 241], ["host cells", "CELL_TYPE", 279, 289], ["the N protein", "TREATMENT", 31, 44], ["binds viral RNAs", "PROBLEM", 52, 68], ["the NS protein", "TREATMENT", 143, 157], ["the host interferon response", "TREATMENT", 174, 202], ["the cellular mRNAs", "TREATMENT", 223, 241], ["viral RNAs", "OBSERVATION", 58, 68], ["host interferon", "OBSERVATION", 178, 193], ["cellular mRNAs", "OBSERVATION", 227, 241], ["host cells", "OBSERVATION", 279, 289]]], ["Reassortment of the S segment, therefore, could influence the replication and immunogenicity of the virus.", [["S segment", "DNA", 20, 29], ["the replication", "TREATMENT", 58, 73], ["the virus", "PROBLEM", 96, 105], ["S segment", "OBSERVATION_MODIFIER", 20, 29]]], ["The existence of many circulating genotypes in China and the wide distribution of potential vectors may increase the opportunity for reassortment to occur in FTLSV.", [["FTLSV", "CANCER", 158, 163], ["FTLSV", "SPECIES", 158, 163], ["many circulating genotypes in China", "PROBLEM", 17, 52], ["potential vectors", "TREATMENT", 82, 99], ["many", "OBSERVATION_MODIFIER", 17, 21], ["circulating", "OBSERVATION_MODIFIER", 22, 33], ["genotypes", "OBSERVATION", 34, 43], ["wide", "OBSERVATION_MODIFIER", 61, 65]]], ["Surveillance for detection of viruses with enhanced pathogenicity is critical to implementing control and prevention measures reducing the impact of FTLSV infection.DiscussionPurifying selection also appears to be another potential force in the evolution of FTLSV, although some sites were also found to be under positive selection.", [["infection", "DISEASE", 155, 164], ["FTLSV", "GENE_OR_GENE_PRODUCT", 149, 154], ["FTLSV", "GENE_OR_GENE_PRODUCT", 258, 263], ["FTLSV", "DNA", 258, 263], ["FTLSV", "SPECIES", 149, 154], ["Surveillance", "TEST", 0, 12], ["viruses", "PROBLEM", 30, 37], ["enhanced pathogenicity", "PROBLEM", 43, 65], ["prevention measures", "TREATMENT", 106, 125], ["FTLSV infection", "PROBLEM", 149, 164], ["FTLSV", "PROBLEM", 258, 263], ["viruses", "OBSERVATION", 30, 37], ["infection", "OBSERVATION", 155, 164], ["appears to be", "UNCERTAINTY", 200, 213]]], ["These results indicated that nucleotide fixation events are due primarily to genetic drift and stochastic processes, which may be important in the evolution of FTLSV.DiscussionStrong purifying selection can maintain evidence of sequence homology long after saturation has occurred at synonymous sites [41, 42] .", [["nucleotide", "CHEMICAL", 29, 39], ["nucleotide", "CHEMICAL", 29, 39], ["FTLSV", "CANCER", 160, 165], ["nucleotide fixation events", "TREATMENT", 29, 55], ["genetic drift and stochastic processes", "PROBLEM", 77, 115], ["nucleotide fixation", "OBSERVATION", 29, 48], ["stochastic processes", "OBSERVATION", 95, 115], ["may be", "UNCERTAINTY", 123, 129]]], ["But purifying selection can obscure the age of viral lineages (e.g., as observed with measles, Ebola, and avian influenza viruses) [41, 42] .", [["measles, Ebola, and avian influenza viruses", "DISEASE", 86, 129], ["Ebola", "ORGANISM", 95, 100], ["avian influenza viruses", "ORGANISM", 106, 129], ["avian influenza viruses", "SPECIES", 106, 129], ["viral lineages", "PROBLEM", 47, 61], ["measles", "PROBLEM", 86, 93], ["Ebola", "PROBLEM", 95, 100], ["avian influenza viruses", "PROBLEM", 106, 129], ["viral lineages", "OBSERVATION", 47, 61]]], ["Unfortunately, there is not a answer to the problem of underestimated the tMRCA due to purifying selection in molecular clock analysis of virus evolution.", [["underestimated the tMRCA", "PROBLEM", 55, 79], ["virus evolution", "PROBLEM", 138, 153], ["molecular clock", "OBSERVATION", 110, 125], ["virus", "OBSERVATION", 138, 143]]], ["However, with advances currently being made in the development of increasingly more realistic evolutionary models, the bias imposed by the purifying selection may be solved in the foreseeable future.", [["the purifying selection", "TREATMENT", 135, 158]]], ["Still, given the apparent recent history of FTLSV, it is possible that the presence of purifying selection may not have a significant impact of the current evolution of the virus.DiscussionAlthough the emergence of FTLSV and its association with FTLS was first confirmed during the summer of 2009 [1] , similar symptoms had been reported by hospitals near Huaiyangshan since 2007 [1] .", [["FTLSV", "CANCER", 44, 49], ["FTLSV", "CANCER", 215, 220], ["the virus", "PROBLEM", 169, 178], ["similar symptoms", "PROBLEM", 303, 319], ["significant", "OBSERVATION_MODIFIER", 122, 133], ["virus", "OBSERVATION", 173, 178]]], ["Consistent with this, these results indicate that FTLSV has been circulating in China for many years.", [["FTLSV", "CHEMICAL", 50, 55], ["FTLSV", "GENE_OR_GENE_PRODUCT", 50, 55], ["FTLSV", "PROTEIN", 50, 55], ["FTLSV", "SPECIES", 50, 55]]], ["The reconstructed epidemic history of FTLSV suggests that the virus is a recently emerged pathogen that originated around the 18 th century.", [["FTLSV", "CHEMICAL", 38, 43], ["the virus", "PROBLEM", 58, 67], ["pathogen", "PROBLEM", 90, 98], ["virus", "OBSERVATION", 62, 67]]], ["Bayesian analysis indicated that the most recent common ancestor of the FTLSV strains existed an estimated 117 to 195 year prior to 2012.", [["FTLSV", "GENE_OR_GENE_PRODUCT", 72, 77], ["Bayesian analysis", "TEST", 0, 17], ["the FTLSV strains", "PROBLEM", 68, 85]]], ["Lam et al. [31] reported that FTLSV originated from a common ancestor and most likely existed between 1817 and 1895, which is somewhat more recent estimate than the one proposed in this analysis.", [["FTLSV", "GENE_OR_GENE_PRODUCT", 30, 35], ["this analysis", "TEST", 181, 194], ["most likely", "UNCERTAINTY", 74, 85]]], ["First, the evolutionary rate of Rift Valley Fever Virus (RVFV) was used as a model for the FTLSV analysis of Lam et al. Although RVFV and FTLSV both belong to the family Bunyaviridae, RVFV is mosquito-borne while FTLSV is tick-borne, and mosquito-borne RNA viruses are believed to evolve more rapidly than tick-borne viruses within the same family [43, 44] .", [["Rift Valley Fever", "DISEASE", 32, 49], ["Bunyaviridae", "DISEASE", 170, 182], ["RVFV", "DISEASE", 184, 188], ["Rift Valley Fever Virus", "ORGANISM", 32, 55], ["RVFV", "ORGANISM", 57, 61], ["RVFV", "ORGANISM", 129, 133], ["FTLSV", "GENE_OR_GENE_PRODUCT", 138, 143], ["RVFV", "ORGANISM", 184, 188], ["tick-borne viruses", "ORGANISM", 306, 324], ["Rift Valley Fever Virus", "SPECIES", 32, 55], ["Rift Valley Fever Virus", "SPECIES", 32, 55], ["RVFV", "SPECIES", 57, 61], ["RVFV", "SPECIES", 129, 133], ["FTLSV", "SPECIES", 138, 143], ["RVFV", "SPECIES", 184, 188], ["FTLSV", "SPECIES", 213, 218], ["tick-borne viruses", "SPECIES", 306, 324], ["Rift Valley Fever Virus (RVFV)", "TREATMENT", 32, 62], ["the FTLSV analysis", "TEST", 87, 105], ["RVFV", "PROBLEM", 129, 133], ["RVFV", "PROBLEM", 184, 188], ["mosquito-borne RNA viruses", "PROBLEM", 238, 264], ["RVFV", "OBSERVATION", 129, 133]]], ["Second, our analysis used full-length sequences of the three segments, and included many more sequences than were available in GenBank at the time of the previous study.DiscussionBayesian phylogeographic analysis indicated that the Huaiyangshan area might be the origin of FTLSV.", [["Huaiyangshan area", "ANATOMY", 232, 249], ["FTLSV", "CANCER", 273, 278], ["our analysis", "TEST", 8, 20], ["the previous study", "TEST", 150, 168], ["phylogeographic analysis", "TEST", 188, 212], ["the Huaiyangshan area", "PROBLEM", 228, 249]]], ["This biologically diverse region has been and remains a home to cultural and economic exchanges between the two halves of China.", [["economic exchanges", "TREATMENT", 77, 95], ["diverse", "OBSERVATION_MODIFIER", 18, 25]]], ["As FTLSV has been detected in the circulating tick vectors Haemaphysalis longicornis and Rhipicephalus microplus, which are widely distributed across China and globally, conditions exist for FTLSV to have been transmitted from Huaiyangshan to neighboring provinces in China [4] .", [["FTLSV", "CHEMICAL", 3, 8], ["FTLSV", "GENE_OR_GENE_PRODUCT", 3, 8], ["Haemaphysalis longicornis", "ORGANISM", 59, 84], ["Rhipicephalus microplus", "ORGANISM", 89, 112], ["FTLSV", "PROTEIN", 3, 8], ["Haemaphysalis longicornis", "SPECIES", 59, 84], ["Rhipicephalus microplus", "SPECIES", 89, 112], ["FTLSV", "SPECIES", 3, 8], ["Haemaphysalis longicornis", "SPECIES", 59, 84], ["Rhipicephalus microplus", "SPECIES", 89, 112], ["FTLSV", "SPECIES", 191, 196], ["Rhipicephalus microplus", "PROBLEM", 89, 112], ["FTLSV", "TREATMENT", 191, 196], ["widely", "OBSERVATION_MODIFIER", 124, 130]]], ["BaTS analysis detected strong structuring of the FTLSV phylogeny by provinces or area, suggesting that in situ evolution has played an important role in the maintenance of FTLSV in China.", [["FTLSV", "GENE_OR_GENE_PRODUCT", 49, 54], ["FTLSV", "GENE_OR_GENE_PRODUCT", 172, 177], ["FTLSV phylogeny", "DNA", 49, 64], ["FTLSV", "SPECIES", 172, 177], ["BaTS analysis", "TEST", 0, 13], ["strong", "OBSERVATION_MODIFIER", 23, 29], ["structuring", "OBSERVATION_MODIFIER", 30, 41]]], ["Additionally, the results of the BaTS analysis that considered the extent of population subdivision between individual provinces or areas and all others as a group indicate that for two of the five provinces or areas sampled (i.e., Huaiyangshan, and Jiangsu), the observed FTLSV genetic diversity was shaped primarily by in situ evolution as opposed to extensive migration.", [["the BaTS analysis", "TEST", 29, 46], ["the observed FTLSV genetic diversity", "PROBLEM", 260, 296], ["extensive", "OBSERVATION_MODIFIER", 353, 362], ["migration", "OBSERVATION", 363, 372]]], ["Our results indicate that this movement was slow during the early years of the spread, but has increasingly become more rapid in recent decades.", [["more", "OBSERVATION_MODIFIER", 115, 119], ["rapid", "OBSERVATION_MODIFIER", 120, 125]]], ["Bayesian phylogeographic analysis showed that FTLSV arose in Huaiyangshan between 1756 and 1817, and then moved into the Jiangsu and Anhui Provinces between 1773 and 1834.", [["Bayesian phylogeographic analysis", "TEST", 0, 33]]], ["Over the next hundred years, FTLSV continued to circulate through Jiangsu, Anhui and the Huaiyangshan region.", [["FTLSV", "TREATMENT", 29, 34], ["Anhui and the Huaiyangshan region", "TREATMENT", 75, 108]]], ["Once FTLSV reached Jiangsu Province, this province became a secondary source of FTLSV spread, as the virus moved from Jiangsu Province into Liaoning Province between 1905 and 1943.", [["FTLSV", "CANCER", 80, 85], ["FTLSV", "SPECIES", 5, 10], ["FTLSV", "SPECIES", 80, 85], ["FTLSV spread", "PROBLEM", 80, 92], ["the virus", "PROBLEM", 97, 106]]], ["In the past 50 or 60 years FTLSV has moved more rapidly, as the MCC tree shows that many strains isolated from Shandong, Liaoning and Anhui were recently introduced from Huaiyangshan and Jiangsu.", [["FTLSV", "SPECIES", 27, 32], ["many strains", "PROBLEM", 84, 96]]], ["Finally, the Bayesian test provided statistical support for three transmission routes: from Huaiyangshan to Jiangsu, from Jiangsu to Shandong and from Jiangsu to Liaoning.DiscussionCollectively, these findings indicate that Huaiyangshan and Jiangsu may be the two major origins of FTLSV in China.", [["FTLSV", "CANCER", 281, 286], ["FTLSV", "SPECIES", 281, 286], ["the Bayesian test", "TEST", 9, 26], ["FTLSV", "OBSERVATION", 281, 286]]], ["It is likely that an animal infected with FTLSV or carrying virus-infected ticks introduce FTLSV into Liaoning Province.", [["FTLSV", "CHEMICAL", 42, 47], ["FTLSV", "GENE_OR_GENE_PRODUCT", 42, 47], ["ticks", "ORGANISM", 75, 80], ["FTLSV", "SPECIES", 42, 47], ["FTLSV", "SPECIES", 91, 96], ["an animal infected with FTLSV", "PROBLEM", 18, 47], ["carrying virus", "PROBLEM", 51, 65], ["is likely", "UNCERTAINTY", 3, 12], ["infected", "OBSERVATION", 28, 36]]], ["The recent dramatic increases in unregulated wildlife trade, livestock import/ export, and global human movement are likely to have created additional opportunities for spread of this severe disease.", [["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["this severe disease", "PROBLEM", 179, 198], ["dramatic", "OBSERVATION_MODIFIER", 11, 19], ["increases", "OBSERVATION_MODIFIER", 20, 29], ["unregulated", "OBSERVATION_MODIFIER", 33, 44], ["wildlife trade", "OBSERVATION", 45, 59], ["severe", "OBSERVATION_MODIFIER", 184, 190], ["disease", "OBSERVATION", 191, 198]]], ["In addition, expanding urban populations have triggered ecosystem changes that may have promoted the emergence of FTLSV by increasing human exposure to the natural reservoir or vector.DiscussionIn conclusion, our results provide new insights into the origin and spread of FTLSV in China.", [["FTLSV", "CHEMICAL", 114, 119], ["FTLSV", "CHEMICAL", 272, 277], ["FTLSV", "GENE_OR_GENE_PRODUCT", 114, 119], ["human", "ORGANISM", 134, 139], ["FTLSV", "CANCER", 272, 277], ["human", "SPECIES", 134, 139], ["FTLSV", "SPECIES", 114, 119], ["human", "SPECIES", 134, 139], ["FTLSV", "SPECIES", 272, 277], ["expanding urban populations", "PROBLEM", 13, 40], ["ecosystem changes", "PROBLEM", 56, 73], ["ecosystem changes", "OBSERVATION", 56, 73]]], ["Further studies are needed to obtain complete FTLSV genomes from other countries in which the virus is endemic, and to elucidate the dynamics of the worldwide dispersion of FTLSV.", [["FTLSV", "CANCER", 173, 178], ["FTLSV genomes", "DNA", 46, 59], ["FTLSV", "SPECIES", 173, 178], ["Further studies", "TEST", 0, 15], ["the virus", "PROBLEM", 90, 99]]]], "PMC2874622": [["IntroductionThe mammalian innate immune system acts as the first line of defense against microbial attack.", [["The mammalian innate immune system", "TREATMENT", 12, 46], ["microbial attack", "PROBLEM", 89, 105], ["microbial attack", "OBSERVATION", 89, 105]]], ["On encountering viral or bacterial intruders, this system activates numerous signaling pathways that result in the production of anti-microbial compounds designed to mitigate damage, in effect by preventing both the replication and spread of the pathogen.", [["bacterial intruders", "PROBLEM", 25, 44], ["anti-microbial compounds", "TREATMENT", 129, 153], ["damage", "PROBLEM", 175, 181], ["the pathogen", "PROBLEM", 242, 254], ["viral", "OBSERVATION", 16, 21], ["bacterial intruders", "OBSERVATION", 25, 44], ["replication", "OBSERVATION", 216, 227]]], ["Initiation of an immune response relies on numerous pattern-recognition proteins (PRPs) \u2013 a group of proteins shared by animals and plants (Janeway and Medzhitov, 2002) \u2013 which recognize the molecular markers of invaders (e.g. dsRNA, lipopolysaccharide, unmethylated CpG DNA) and signal to downstream members of the immune system.", [["immune system", "ANATOMY", 316, 329], ["lipopolysaccharide", "CHEMICAL", 234, 252], ["pattern-recognition proteins", "GENE_OR_GENE_PRODUCT", 52, 80], ["PRPs", "GENE_OR_GENE_PRODUCT", 82, 86], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 234, 252], ["DNA", "CELLULAR_COMPONENT", 271, 274], ["pattern-recognition proteins", "PROTEIN", 52, 80], ["PRPs", "PROTEIN", 82, 86], ["unmethylated CpG DNA", "DNA", 254, 274], ["lipopolysaccharide", "TREATMENT", 234, 252], ["unmethylated CpG DNA", "TREATMENT", 254, 274]]], ["PRPs can be placed into two general groups, based on where they function.", [["PRPs", "SIMPLE_CHEMICAL", 0, 4]]], ["Extracellular pathogens are recognized by the toll-like receptor (TLR) proteins, which are either expressed on the cell membrane facing the extracellular matrix, or in endosomes (reviewed in Kawai and Akira, 2006).", [["Extracellular", "ANATOMY", 0, 13], ["cell membrane", "ANATOMY", 115, 128], ["extracellular matrix", "ANATOMY", 140, 160], ["endosomes", "ANATOMY", 168, 177], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 46, 64], ["TLR", "GENE_OR_GENE_PRODUCT", 66, 69], ["cell membrane", "CELLULAR_COMPONENT", 115, 128], ["extracellular matrix", "CELLULAR_COMPONENT", 140, 160], ["endosomes", "CELLULAR_COMPONENT", 168, 177], ["toll-like receptor (TLR) proteins", "PROTEIN", 46, 79], ["Extracellular pathogens", "PROBLEM", 0, 23], ["pathogens", "OBSERVATION", 14, 23], ["cell membrane", "OBSERVATION", 115, 128], ["extracellular matrix", "OBSERVATION", 140, 160]]], ["Once a pathogen is bound the TLR proteins signal through cytoplasmic adapter proteins, such as TRIF and MyD88, to initiate the production of nuclear encoded pro-immune cytokines.", [["cytoplasmic", "ANATOMY", 57, 68], ["nuclear", "ANATOMY", 141, 148], ["TLR", "GENE_OR_GENE_PRODUCT", 29, 32], ["cytoplasmic", "ORGANISM_SUBSTANCE", 57, 68], ["TRIF", "GENE_OR_GENE_PRODUCT", 95, 99], ["MyD88", "GENE_OR_GENE_PRODUCT", 104, 109], ["nuclear", "CELLULAR_COMPONENT", 141, 148], ["TLR proteins", "PROTEIN", 29, 41], ["cytoplasmic adapter proteins", "PROTEIN", 57, 85], ["TRIF", "PROTEIN", 95, 99], ["MyD88", "PROTEIN", 104, 109], ["nuclear encoded pro-immune cytokines", "PROTEIN", 141, 177], ["cytoplasmic adapter proteins", "PROBLEM", 57, 85], ["TRIF", "TREATMENT", 95, 99], ["MyD88", "TREATMENT", 104, 109], ["nuclear encoded pro-immune cytokines", "TREATMENT", 141, 177]]], ["Intracellular pathogens are recognized by several groups of PRPs, including protein kinase R (PKR), the NOD-like protein family, and the more recently-identified RIG-I-like helicase (RLH) pathway (Janeway and Medzhitov, 2002, Meylan and Tschopp, 2008, Yoneyama and Fujita, 2009).", [["Intracellular", "ANATOMY", 0, 13], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["PRPs", "GENE_OR_GENE_PRODUCT", 60, 64], ["protein kinase R", "GENE_OR_GENE_PRODUCT", 76, 92], ["PKR", "GENE_OR_GENE_PRODUCT", 94, 97], ["NOD-like protein", "GENE_OR_GENE_PRODUCT", 104, 120], ["RIG-I-like helicase", "GENE_OR_GENE_PRODUCT", 162, 181], ["RLH", "GENE_OR_GENE_PRODUCT", 183, 186], ["PRPs", "PROTEIN", 60, 64], ["protein kinase R", "PROTEIN", 76, 92], ["PKR", "PROTEIN", 94, 97], ["NOD-like protein family", "PROTEIN", 104, 127], ["RIG-I-like helicase", "PROTEIN", 162, 181], ["RLH", "PROTEIN", 183, 186], ["Intracellular pathogens", "PROBLEM", 0, 23], ["PRPs", "TEST", 60, 64], ["protein kinase", "TEST", 76, 90], ["PKR", "TEST", 94, 97], ["the NOD", "TEST", 100, 107], ["RIG", "TEST", 162, 165], ["Medzhitov", "TEST", 209, 218], ["pathogens", "OBSERVATION", 14, 23]]], ["The RLH pathway is composed of three RNA helicase proteins which bind virally-produced nucleic acids, and a number of downstream signaling molecules (Fig. 1).", [["RLH", "GENE_OR_GENE_PRODUCT", 4, 7], ["nucleic acids", "SIMPLE_CHEMICAL", 87, 100], ["RLH", "PROTEIN", 4, 7], ["RNA helicase proteins", "PROTEIN", 37, 58], ["downstream signaling molecules", "PROTEIN", 118, 148], ["three RNA helicase proteins", "PROBLEM", 31, 58], ["nucleic acids", "TEST", 87, 100], ["nucleic acids", "OBSERVATION", 87, 100]]], ["The prototypic member of the family is RIG-I, a protein which consists of twin N-terminal caspase activation and recruitment (CARD) domains, and a C-terminal RNA helicase domain (Yoneyama et al., 2004).", [["N", "CHEMICAL", 79, 80], ["RIG-I", "GENE_OR_GENE_PRODUCT", 39, 44], ["caspase", "GENE_OR_GENE_PRODUCT", 90, 97], ["CARD", "GENE_OR_GENE_PRODUCT", 126, 130], ["RIG-I", "PROTEIN", 39, 44], ["twin N-terminal caspase activation and recruitment (CARD) domains", "PROTEIN", 74, 139], ["C-terminal RNA helicase domain", "PROTEIN", 147, 177], ["terminal caspase activation", "TREATMENT", 81, 108], ["recruitment (CARD) domains", "TREATMENT", 113, 139], ["a C-terminal RNA helicase domain", "PROBLEM", 145, 177], ["terminal caspase", "OBSERVATION", 81, 97]]], ["RIG-I binds viral dsRNA at its helicase domain, which stimulates a conformational change that exposes the twin CARD domains, to allow downstream signaling through direct protein:protein interactions.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["CARD", "GENE_OR_GENE_PRODUCT", 111, 115], ["RIG-I", "PROTEIN", 0, 5], ["helicase domain", "PROTEIN", 31, 46], ["twin CARD domains", "PROTEIN", 106, 123], ["RIG-I binds viral dsRNA", "TREATMENT", 0, 23], ["a conformational change", "PROBLEM", 65, 88], ["viral dsRNA", "OBSERVATION", 12, 23]]], ["The other two helicases are MDA-5, which is similar in structure and function to RIG-I, but which recognizes other viral substrates; and LGP2, which has a homologous helicase domain, but lacks the CARD domains and can act as a negative regulator of RLH signaling during infection by certain viruses, particularly those sensed by RIG-I (Yoneyama et al., 2004, Venkataraman et al., 2007, Yoneyama and Fujita, 2009).Identification of the mitochondrial antiviral signaling protein, MAVS ::: MAVS \u2013 the first mitochondrial protein identified in the innate immune systemIn the year following the identification of RIG-I, four groups simultaneously reported a novel member of the RLH signaling pathway, with each group choosing a different name for the new protein.", [["mitochondrial", "ANATOMY", 435, 448], ["mitochondrial", "ANATOMY", 504, 517], ["MDA-5", "CHEMICAL", 28, 33], ["infection", "DISEASE", 270, 279], ["MDA-5", "GENE_OR_GENE_PRODUCT", 28, 33], ["RIG-I", "GENE_OR_GENE_PRODUCT", 81, 86], ["LGP2", "GENE_OR_GENE_PRODUCT", 137, 141], ["CARD", "GENE_OR_GENE_PRODUCT", 197, 201], ["RLH", "GENE_OR_GENE_PRODUCT", 249, 252], ["RIG-I", "GENE_OR_GENE_PRODUCT", 329, 334], ["mitochondrial", "CELLULAR_COMPONENT", 435, 448], ["MAVS", "GENE_OR_GENE_PRODUCT", 478, 482], ["MAVS", "GENE_OR_GENE_PRODUCT", 487, 491], ["mitochondrial", "CELLULAR_COMPONENT", 504, 517], ["RIG-I", "GENE_OR_GENE_PRODUCT", 608, 613], ["RLH", "GENE_OR_GENE_PRODUCT", 673, 676], ["MDA", "PROTEIN", 28, 31], ["RIG-I", "PROTEIN", 81, 86], ["viral substrates", "PROTEIN", 115, 131], ["LGP2", "PROTEIN", 137, 141], ["homologous helicase domain", "PROTEIN", 155, 181], ["CARD domains", "PROTEIN", 197, 209], ["RLH", "PROTEIN", 249, 252], ["mitochondrial antiviral signaling protein", "PROTEIN", 435, 476], ["MAVS", "PROTEIN", 478, 482], ["MAVS", "PROTEIN", 487, 491], ["mitochondrial protein", "PROTEIN", 504, 525], ["RIG-I", "PROTEIN", 608, 613], ["RLH", "PROTEIN", 673, 676], ["MDA", "TEST", 28, 31], ["a homologous helicase domain", "PROBLEM", 153, 181], ["RLH signaling during infection", "PROBLEM", 249, 279], ["certain viruses", "PROBLEM", 283, 298], ["MAVS", "PROBLEM", 487, 491], ["the first mitochondrial protein", "PROBLEM", 494, 525], ["two", "OBSERVATION_MODIFIER", 10, 13], ["helicases", "OBSERVATION", 14, 23], ["MDA", "OBSERVATION_MODIFIER", 28, 31], ["similar", "OBSERVATION_MODIFIER", 44, 51], ["structure", "OBSERVATION_MODIFIER", 55, 64], ["function", "OBSERVATION_MODIFIER", 69, 77], ["to RIG", "OBSERVATION_MODIFIER", 78, 84], ["viral substrates", "OBSERVATION", 115, 131], ["RLH", "OBSERVATION", 249, 252], ["mitochondrial antiviral", "OBSERVATION", 435, 458]]], ["Kawai et al. (2005) found Interferon-\u03b2 Promoter Stimulator 1 (IPS-1) by screening multiple cDNA pools for novel inducers of the IFN-\u03b2 promoter.", [["Interferon-\u03b2 Promoter Stimulator 1", "GENE_OR_GENE_PRODUCT", 26, 60], ["IPS-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 128, 133], ["Interferon-\u03b2 Promoter Stimulator 1", "DNA", 26, 60], ["IPS-1", "DNA", 62, 67], ["IFN-\u03b2 promoter", "DNA", 128, 142], ["Interferon-\u03b2 Promoter Stimulator", "TREATMENT", 26, 58], ["multiple cDNA pools", "TREATMENT", 82, 101], ["novel inducers", "TREATMENT", 106, 120], ["the IFN-\u03b2 promoter", "TREATMENT", 124, 142]]], ["They reported that IPS-1 could activate the pro-immune transcription factors IRF3, IRF7 and NF-\u03baB to induce type 1 interferon production, and that it interacted with RIG-I and MDA-5 through its CARD domain.", [["IPS-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["IRF3", "GENE_OR_GENE_PRODUCT", 77, 81], ["IRF7", "GENE_OR_GENE_PRODUCT", 83, 87], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 92, 97], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 108, 125], ["RIG-I", "GENE_OR_GENE_PRODUCT", 166, 171], ["MDA-5", "GENE_OR_GENE_PRODUCT", 176, 181], ["CARD", "GENE_OR_GENE_PRODUCT", 194, 198], ["IPS", "PROTEIN", 19, 22], ["pro-immune transcription factors", "PROTEIN", 44, 76], ["IRF3", "PROTEIN", 77, 81], ["IRF7", "PROTEIN", 83, 87], ["NF-\u03baB", "PROTEIN", 92, 97], ["interferon", "PROTEIN", 115, 125], ["RIG-I", "PROTEIN", 166, 171], ["MDA", "PROTEIN", 176, 179], ["CARD domain", "PROTEIN", 194, 205], ["IPS", "TEST", 19, 22], ["IRF7", "TEST", 83, 87], ["NF", "TEST", 92, 94], ["type 1 interferon production", "PROBLEM", 108, 136]]], ["Xu et al. (2005) made expression constructs of 12 unknown cDNAs from a previous study that had identified a large number of novel NK-\u03baB activators (Matsuda et al., 2003).", [["NK", "ANATOMY", 130, 132], ["NK-\u03baB", "GENE_OR_GENE_PRODUCT", 130, 135], ["cDNAs", "DNA", 58, 63], ["\u03baB", "PROTEIN", 133, 135], ["a previous study", "TEST", 69, 85], ["large", "OBSERVATION_MODIFIER", 108, 113]]], ["In their system, Virus-triggered IFN-\u03b2 Signaling (VISA) was the only one of these cDNAs to significantly induce NK-\u03baB signaling (Xu et al., 2005).", [["NK", "ANATOMY", 112, 114], ["Virus", "ORGANISM", 17, 22], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 33, 38], ["VISA", "GENE_OR_GENE_PRODUCT", 50, 54], ["NK-\u03baB", "GENE_OR_GENE_PRODUCT", 112, 117], ["IFN", "PROTEIN", 33, 36], ["\u03b2 Signaling", "PROTEIN", 37, 48], ["VISA", "PROTEIN", 50, 54], ["cDNAs", "DNA", 82, 87], ["\u03baB", "PROTEIN", 115, 117], ["Virus", "PROBLEM", 17, 22], ["these cDNAs", "TEST", 76, 87], ["NK", "TEST", 112, 114]]], ["Using a combination of mammalian coimmunoprecipitation and yeast two-hybrid studies, they found that VISA interacted with both TRAF2 and TRAF6, potentially implicating it in TLR-mediated pathways (Xu et al., 2005).", [["VISA", "GENE_OR_GENE_PRODUCT", 101, 105], ["TRAF2", "GENE_OR_GENE_PRODUCT", 127, 132], ["TRAF6", "GENE_OR_GENE_PRODUCT", 137, 142], ["TLR", "GENE_OR_GENE_PRODUCT", 174, 177], ["VISA", "PROTEIN", 101, 105], ["TRAF2", "PROTEIN", 127, 132], ["TRAF6", "PROTEIN", 137, 142], ["TLR", "PROTEIN", 174, 177], ["yeast", "SPECIES", 59, 64], ["mammalian coimmunoprecipitation", "TREATMENT", 23, 54], ["yeast two-hybrid studies", "TEST", 59, 83], ["VISA", "PROBLEM", 101, 105], ["both TRAF2", "TREATMENT", 122, 132], ["TRAF6", "TREATMENT", 137, 142]]], ["Meylan et al. (2005) found CARD Adaptor Inducing IFN-\u03b2 (CARDIF) using bioinformatic searches for novel CARD domain proteins.", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 49, 54], ["CARDIF", "GENE_OR_GENE_PRODUCT", 56, 62], ["CARD", "GENE_OR_GENE_PRODUCT", 103, 107], ["CARD Adaptor", "PROTEIN", 27, 39], ["IFN", "PROTEIN", 49, 52], ["\u03b2", "PROTEIN", 53, 54], ["CARDIF", "PROTEIN", 56, 62], ["CARD domain proteins", "PROTEIN", 103, 123], ["bioinformatic searches", "TEST", 70, 92], ["novel CARD domain proteins", "PROBLEM", 97, 123]]], ["They showed that it could recruit the signaling kinases IKK\u03b1, IKK\u03b2 and IKK\u03b5, which led to the activation of the IRF3 and NK-\u03baB transcription factors.", [["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 56, 60], ["IKK\u03b2", "GENE_OR_GENE_PRODUCT", 62, 66], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 71, 75], ["IRF3", "GENE_OR_GENE_PRODUCT", 112, 116], ["NK-\u03baB", "GENE_OR_GENE_PRODUCT", 121, 126], ["signaling kinases", "PROTEIN", 38, 55], ["IKK\u03b1", "PROTEIN", 56, 60], ["IKK\u03b2", "PROTEIN", 62, 66], ["IKK\u03b5", "PROTEIN", 71, 75], ["IRF3 and NK-\u03baB", "PROTEIN", 112, 126], ["transcription factors", "PROTEIN", 127, 148], ["IKK", "TEST", 62, 65], ["IKK\u03b5", "TEST", 71, 75], ["the IRF3", "TEST", 108, 116], ["NK", "TEST", 121, 123], ["B transcription factors", "PROBLEM", 125, 148], ["IRF3", "OBSERVATION", 112, 116]]], ["The authors also employed an in vitro system to demonstrate that CARDIF is cleaved by a protease encoded by the hepatitis C virus, showing for the first time that viruses could specifically disrupt CARDIF signaling (Meylan et al., 2005).", [["CARDIF", "CHEMICAL", 65, 71], ["hepatitis C", "DISEASE", 112, 123], ["CARDIF", "GENE_OR_GENE_PRODUCT", 65, 71], ["hepatitis C virus", "ORGANISM", 112, 129], ["CARDIF", "GENE_OR_GENE_PRODUCT", 198, 204], ["CARDIF", "PROTEIN", 65, 71], ["protease", "PROTEIN", 88, 96], ["CARDIF", "PROTEIN", 198, 204], ["hepatitis C virus", "SPECIES", 112, 129], ["hepatitis C virus", "SPECIES", 112, 129], ["the hepatitis C virus", "PROBLEM", 108, 129], ["viruses", "PROBLEM", 163, 170], ["viruses", "OBSERVATION", 163, 170]]], ["Finally, Seth et al. (2005) discovered the Mitochondrial Antiviral Signaling protein (MAVS) by performing sequence similarity searches, using the CARD domain of MDA-5 as bait.", [["Mitochondrial", "ANATOMY", 43, 56], ["MDA-5", "CHEMICAL", 161, 166], ["Mitochondrial", "CELLULAR_COMPONENT", 43, 56], ["MAVS", "GENE_OR_GENE_PRODUCT", 86, 90], ["MDA-5", "GENE_OR_GENE_PRODUCT", 161, 166], ["Mitochondrial Antiviral Signaling protein", "PROTEIN", 43, 84], ["MAVS", "PROTEIN", 86, 90], ["CARD domain", "PROTEIN", 146, 157], ["MDA", "PROTEIN", 161, 164], ["the Mitochondrial Antiviral Signaling protein (MAVS", "TREATMENT", 39, 90], ["the CARD domain of MDA", "TREATMENT", 142, 164]]], ["They reported that overexpression of MAVS activated IRF3 and NK-\u03baB, and that its presence was required for a response to Sendai virus infection.", [["NK", "ANATOMY", 61, 63], ["Sendai virus infection", "DISEASE", 121, 143], ["MAVS", "GENE_OR_GENE_PRODUCT", 37, 41], ["IRF3", "GENE_OR_GENE_PRODUCT", 52, 56], ["NK-\u03baB", "GENE_OR_GENE_PRODUCT", 61, 66], ["Sendai virus", "ORGANISM", 121, 133], ["MAVS", "PROTEIN", 37, 41], ["IRF3", "PROTEIN", 52, 56], ["NK-\u03baB", "PROTEIN", 61, 66], ["Sendai virus", "SPECIES", 121, 133], ["MAVS", "PROBLEM", 37, 41], ["NK", "TEST", 61, 63], ["Sendai virus infection", "PROBLEM", 121, 143], ["Sendai virus", "OBSERVATION", 121, 133]]], ["Importantly, only Seth et al. (2005) in these primary papers localized this novel protein to mitochondria, therefore for this reason (and general simplicity) IPS-1/VISA/CARDIF/MAVS will be referred to as \u2018\u2018MAVS\u2019\u2019 below.Structure and function of MAVS ::: MAVS \u2013 the first mitochondrial protein identified in the innate immune systemMAVS is a predicted 57 kDa protein consisting of three functional domains \u2013 a single N-terminal CARD domain (10\u201377 aa), a medial proline-rich region (PRR; 107\u2013173 aa) and a C-terminal transmembrane domain (TM; 514\u2013535 aa) that anchors it to the outer mitochondrial membrane (Seth et al., 2005).", [["mitochondria", "ANATOMY", 93, 105], ["mitochondrial", "ANATOMY", 271, 284], ["outer mitochondrial membrane", "ANATOMY", 576, 604], ["proline", "CHEMICAL", 460, 467], ["proline", "CHEMICAL", 460, 467], ["C", "CHEMICAL", 504, 505], ["mitochondria", "CELLULAR_COMPONENT", 93, 105], ["IPS-1", "GENE_OR_GENE_PRODUCT", 158, 163], ["VISA", "GENE_OR_GENE_PRODUCT", 164, 168], ["CARDIF", "GENE_OR_GENE_PRODUCT", 169, 175], ["MAVS", "GENE_OR_GENE_PRODUCT", 176, 180], ["MAVS", "GENE_OR_GENE_PRODUCT", 206, 210], ["MAVS", "GENE_OR_GENE_PRODUCT", 245, 249], ["MAVS", "GENE_OR_GENE_PRODUCT", 254, 258], ["mitochondrial", "CELLULAR_COMPONENT", 271, 284], ["outer", "CELLULAR_COMPONENT", 576, 581], ["mitochondrial membrane", "CELLULAR_COMPONENT", 582, 604], ["VISA", "PROTEIN", 164, 168], ["CARDIF", "PROTEIN", 169, 175], ["MAVS", "PROTEIN", 176, 180], ["MAVS", "PROTEIN", 206, 210], ["MAVS", "PROTEIN", 245, 249], ["MAVS", "PROTEIN", 254, 258], ["mitochondrial protein", "PROTEIN", 271, 292], ["innate immune systemMAVS", "PROTEIN", 311, 335], ["57 kDa protein", "PROTEIN", 351, 365], ["N-terminal CARD domain", "PROTEIN", 416, 438], ["10\u201377 aa", "PROTEIN", 440, 448], ["medial proline-rich region", "PROTEIN", 453, 479], ["PRR", "PROTEIN", 481, 484], ["C-terminal transmembrane domain", "PROTEIN", 504, 535], ["TM", "PROTEIN", 537, 539], ["514\u2013535 aa", "PROTEIN", 541, 551], ["MAVS", "PROBLEM", 254, 258], ["the first mitochondrial protein", "TEST", 261, 292], ["kDa protein", "TEST", 354, 365], ["a single N-terminal CARD domain", "PROBLEM", 407, 438], ["PRR", "TEST", 481, 484], ["aa", "TEST", 494, 496], ["a C-terminal transmembrane domain (TM", "TREATMENT", 502, 539], ["medial", "ANATOMY_MODIFIER", 453, 459], ["outer", "ANATOMY_MODIFIER", 576, 581], ["mitochondrial membrane", "ANATOMY", 582, 604]]], ["The N-terminal CARD domain shares high similarity to the CARD domains found in RIG-I and MDA-5 (Potter et al., 2008), and these proteins are predicted to bind with MAVS homotypically at this domain, following activation by viruses.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 79, 84], ["MDA-5", "GENE_OR_GENE_PRODUCT", 89, 94], ["MAVS", "GENE_OR_GENE_PRODUCT", 164, 168], ["N-terminal CARD domain", "PROTEIN", 4, 26], ["CARD domains", "PROTEIN", 57, 69], ["RIG", "PROTEIN", 79, 82], ["MDA", "PROTEIN", 89, 92], ["MAVS", "PROTEIN", 164, 168], ["The N-terminal CARD domain", "PROBLEM", 0, 26], ["the CARD domains", "TEST", 53, 69], ["MDA", "TEST", 89, 92], ["MAVS", "PROBLEM", 164, 168]]], ["As such, removal of the MAVS CARD domain appears to prevent this interaction and ablates its signaling function (Seth et al., 2005, Meylan et al., 2005, Kawai et al., 2005).", [["MAVS", "GENE_OR_GENE_PRODUCT", 24, 28], ["MAVS CARD domain", "PROTEIN", 24, 40], ["removal", "TREATMENT", 9, 16], ["the MAVS CARD domain", "TREATMENT", 20, 40]]], ["The PRR section of MAVS contains consensus binding sites for many proline-associated immune proteins, such as members of the tumor necrosis factor receptor associated factor (TRAF) family like TRAF2, TRAF3 and TRAF6 (Xu et al., 2005, Saha et al., 2006).", [["proline", "CHEMICAL", 66, 73], ["tumor", "DISEASE", 125, 130], ["proline", "CHEMICAL", 66, 73], ["MAVS", "GENE_OR_GENE_PRODUCT", 19, 23], ["proline", "AMINO_ACID", 66, 73], ["tumor necrosis factor receptor associated factor", "GENE_OR_GENE_PRODUCT", 125, 173], ["TRAF", "GENE_OR_GENE_PRODUCT", 175, 179], ["TRAF2", "GENE_OR_GENE_PRODUCT", 193, 198], ["TRAF3", "GENE_OR_GENE_PRODUCT", 200, 205], ["TRAF6", "GENE_OR_GENE_PRODUCT", 210, 215], ["PRR", "PROTEIN", 4, 7], ["MAVS", "PROTEIN", 19, 23], ["consensus binding sites", "DNA", 33, 56], ["proline-associated immune proteins", "PROTEIN", 66, 100], ["tumor necrosis factor receptor associated factor (TRAF) family", "PROTEIN", 125, 187], ["TRAF2", "PROTEIN", 193, 198], ["TRAF3", "PROTEIN", 200, 205], ["TRAF6", "PROTEIN", 210, 215], ["The PRR section", "TREATMENT", 0, 15], ["MAVS", "PROBLEM", 19, 23], ["consensus binding sites", "PROBLEM", 33, 56], ["many proline-associated immune proteins", "PROBLEM", 61, 100], ["the tumor necrosis", "PROBLEM", 121, 139], ["MAVS", "OBSERVATION", 19, 23], ["immune proteins", "OBSERVATION", 85, 100], ["tumor", "OBSERVATION_MODIFIER", 125, 130], ["necrosis", "OBSERVATION", 131, 139]]], ["In the context of this review, perhaps the most interesting domain however is the C-terminal TM domain that directs MAVS to mitochondria.", [["mitochondria", "ANATOMY", 124, 136], ["MAVS", "GENE_OR_GENE_PRODUCT", 116, 120], ["mitochondria", "CELLULAR_COMPONENT", 124, 136], ["C-terminal TM domain", "PROTEIN", 82, 102], ["MAVS", "PROTEIN", 116, 120], ["the C-terminal TM domain", "PROBLEM", 78, 102]]], ["Removal of the TM prevents both its mitochondrial localization and signaling function, restricting the truncated protein to the cytosol (Seth et al., 2005, Xu et al., 2005).", [["mitochondrial", "ANATOMY", 36, 49], ["cytosol", "ANATOMY", 128, 135], ["TM", "CELLULAR_COMPONENT", 15, 17], ["mitochondrial", "CELLULAR_COMPONENT", 36, 49], ["cytosol", "CELLULAR_COMPONENT", 128, 135], ["TM", "PROTEIN", 15, 17], ["truncated protein", "PROTEIN", 103, 120], ["Removal", "TREATMENT", 0, 7], ["the TM", "TREATMENT", 11, 17], ["signaling function", "OBSERVATION", 67, 85]]], ["The TM domain has similarities to those found in the outer mitochondrial membrane proteins TOM20, Bcl-2 and Bcl-xL, and replacing the TM of MAVS with those from Bcl-2 or Bcl-xL restores both its function and mitochondrial localization (Seth et al., 2005).", [["mitochondrial membrane", "ANATOMY", 59, 81], ["mitochondrial", "ANATOMY", 208, 221], ["outer", "CELLULAR_COMPONENT", 53, 58], ["mitochondrial membrane", "CELLULAR_COMPONENT", 59, 81], ["TOM20", "GENE_OR_GENE_PRODUCT", 91, 96], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 98, 103], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 108, 114], ["MAVS", "GENE_OR_GENE_PRODUCT", 140, 144], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 161, 166], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 170, 176], ["mitochondrial", "CELLULAR_COMPONENT", 208, 221], ["TM domain", "PROTEIN", 4, 13], ["outer mitochondrial membrane proteins", "PROTEIN", 53, 90], ["TOM20", "PROTEIN", 91, 96], ["Bcl-2", "PROTEIN", 98, 103], ["Bcl-xL", "PROTEIN", 108, 114], ["TM", "PROTEIN", 134, 136], ["MAVS", "PROTEIN", 140, 144], ["Bcl-2", "PROTEIN", 161, 166], ["Bcl-xL", "PROTEIN", 170, 176], ["the outer mitochondrial membrane proteins", "TEST", 49, 90], ["Bcl", "TEST", 98, 101], ["Bcl-xL", "TEST", 108, 114], ["MAVS", "PROBLEM", 140, 144], ["Bcl", "TEST", 161, 164], ["Bcl-xL", "PROBLEM", 170, 176], ["mitochondrial localization", "TEST", 208, 234], ["outer", "ANATOMY_MODIFIER", 53, 58], ["mitochondrial membrane", "ANATOMY", 59, 81], ["MAVS", "OBSERVATION", 140, 144]]], ["This suggests that the TM domain of MAVS has no other role in the antiviral function of the protein, other than to ensure correct placement at the outer mitochondrial membrane.", [["outer mitochondrial membrane", "ANATOMY", 147, 175], ["MAVS", "GENE_OR_GENE_PRODUCT", 36, 40], ["outer", "CELLULAR_COMPONENT", 147, 152], ["mitochondrial membrane", "CELLULAR_COMPONENT", 153, 175], ["TM domain", "PROTEIN", 23, 32], ["MAVS", "PROTEIN", 36, 40], ["the TM domain of MAVS", "PROBLEM", 19, 40], ["correct placement at the outer mitochondrial membrane", "TREATMENT", 122, 175], ["MAVS", "OBSERVATION", 36, 40], ["no other", "UNCERTAINTY", 45, 53], ["antiviral", "OBSERVATION", 66, 75], ["placement", "OBSERVATION", 130, 139], ["outer", "ANATOMY_MODIFIER", 147, 152], ["mitochondrial membrane", "OBSERVATION", 153, 175]]], ["When overexpressed, a construct containing just the CARD and TM domains of MAVS had a similar ability to activate the IFN-\u03b2 promoter as the whole protein (Seth et al., 2005), indicating that these two domains are the most important for MAVS function.Regulation of MAVS downstream signaling ::: MAVS \u2013 the first mitochondrial protein identified in the innate immune systemThere have been several (sometimes conflicting) reports of proteins that interact with MAVS, either to aid downstream signaling, or to regulate its function.", [["mitochondrial", "ANATOMY", 311, 324], ["CARD", "GENE_OR_GENE_PRODUCT", 52, 56], ["MAVS", "GENE_OR_GENE_PRODUCT", 75, 79], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 118, 123], ["MAVS", "GENE_OR_GENE_PRODUCT", 236, 240], ["MAVS", "GENE_OR_GENE_PRODUCT", 264, 268], ["MAVS", "GENE_OR_GENE_PRODUCT", 294, 298], ["mitochondrial", "CELLULAR_COMPONENT", 311, 324], ["MAVS", "GENE_OR_GENE_PRODUCT", 458, 462], ["CARD and TM domains", "PROTEIN", 52, 71], ["MAVS", "PROTEIN", 75, 79], ["IFN-\u03b2 promoter", "DNA", 118, 132], ["MAVS", "PROTEIN", 236, 240], ["MAVS", "PROTEIN", 264, 268], ["MAVS", "PROTEIN", 294, 298], ["mitochondrial protein", "PROTEIN", 311, 332], ["MAVS", "PROTEIN", 458, 462], ["these two domains", "PROBLEM", 191, 208], ["MAVS", "PROBLEM", 294, 298], ["the first mitochondrial protein", "PROBLEM", 301, 332], ["MAVS", "TREATMENT", 458, 462], ["MAVS", "OBSERVATION", 264, 268]]], ["Downstream signaling, resulting in the production of cytokines, has been linked to a number of pathways that converge on the pro-immune transcription factors IRF3, IRF7 and NF-\u03baB.", [["IRF3", "GENE_OR_GENE_PRODUCT", 158, 162], ["IRF7", "GENE_OR_GENE_PRODUCT", 164, 168], ["NF-\u03baB.", "GENE_OR_GENE_PRODUCT", 173, 179], ["cytokines", "PROTEIN", 53, 62], ["pro-immune transcription factors", "PROTEIN", 125, 157], ["IRF3", "PROTEIN", 158, 162], ["IRF7", "PROTEIN", 164, 168], ["NF-\u03baB.", "PROTEIN", 173, 179], ["Downstream signaling", "PROBLEM", 0, 20], ["cytokines", "PROBLEM", 53, 62], ["NF", "TEST", 173, 175], ["signaling", "OBSERVATION_MODIFIER", 11, 20], ["cytokines", "OBSERVATION", 53, 62]]], ["MAVS has been shown to associate with FADD and RIP1 (Matsuda et al., 2003, Lad et al., 2008), adapter proteins involved in the IKK complex that activates NF-\u03baB.", [["MAVS", "GENE_OR_GENE_PRODUCT", 0, 4], ["FADD", "GENE_OR_GENE_PRODUCT", 38, 42], ["RIP1", "GENE_OR_GENE_PRODUCT", 47, 51], ["IKK", "GENE_OR_GENE_PRODUCT", 127, 130], ["NF-\u03baB.", "GENE_OR_GENE_PRODUCT", 154, 160], ["MAVS", "PROTEIN", 0, 4], ["FADD", "PROTEIN", 38, 42], ["RIP1", "PROTEIN", 47, 51], ["adapter proteins", "PROTEIN", 94, 110], ["IKK complex", "PROTEIN", 127, 138], ["NF-\u03baB.", "PROTEIN", 154, 160], ["MAVS", "PROBLEM", 0, 4], ["Lad et al.", "TEST", 75, 85], ["adapter proteins", "TEST", 94, 110], ["Lad", "ANATOMY", 75, 78]]], ["However, the requirement for RIP1 in MAVS-associated cytokine production is questioned by the finding that there is normal IFN-\u03b2 activation in RIP1\u2212/\u2212 mouse embryonic fibroblasts (MEFs; Seth et al., 2005).", [["embryonic fibroblasts", "ANATOMY", 157, 178], ["MEFs", "ANATOMY", 180, 184], ["RIP1", "GENE_OR_GENE_PRODUCT", 29, 33], ["MAVS", "GENE_OR_GENE_PRODUCT", 37, 41], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 123, 128], ["RIP1\u2212", "GENE_OR_GENE_PRODUCT", 143, 148], ["mouse", "ORGANISM", 151, 156], ["embryonic fibroblasts", "CELL", 157, 178], ["MEFs", "CELL", 180, 184], ["RIP1", "PROTEIN", 29, 33], ["MAVS", "PROTEIN", 37, 41], ["cytokine", "PROTEIN", 53, 61], ["IFN", "PROTEIN", 123, 126], ["\u03b2", "PROTEIN", 127, 128], ["RIP1\u2212/\u2212 mouse embryonic fibroblasts", "CELL_LINE", 143, 178], ["MEFs", "CELL_TYPE", 180, 184], ["mouse", "SPECIES", 151, 156], ["mouse", "SPECIES", 151, 156], ["RIP1 in MAVS", "TREATMENT", 29, 41], ["cytokine production", "PROBLEM", 53, 72], ["cytokine production", "OBSERVATION", 53, 72], ["normal", "OBSERVATION_MODIFIER", 116, 122], ["IFN", "OBSERVATION_MODIFIER", 123, 126], ["embryonic fibroblasts", "OBSERVATION", 157, 178]]], ["Binding of TRAF-family members (e.g. TRAF2, TRAF3 and TRAF6) to the proline-rich region of MAVS has been shown to be necessary for the downstream phosphorylation of NF-\u03baB and IRF3/7 (Seth et al., 2005, Xu et al., 2005, Saha et al., 2006), although a deletion-mutant of MAVS without the binding sites still has the capacity to activate IFN-\u03b2 (Seth et al., 2005).", [["proline", "CHEMICAL", 68, 75], ["proline", "CHEMICAL", 68, 75], ["TRAF", "GENE_OR_GENE_PRODUCT", 11, 15], ["TRAF2", "GENE_OR_GENE_PRODUCT", 37, 42], ["TRAF3", "GENE_OR_GENE_PRODUCT", 44, 49], ["TRAF6", "GENE_OR_GENE_PRODUCT", 54, 59], ["MAVS", "GENE_OR_GENE_PRODUCT", 91, 95], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 165, 170], ["IRF3/7", "GENE_OR_GENE_PRODUCT", 175, 181], ["MAVS", "GENE_OR_GENE_PRODUCT", 269, 273], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 335, 340], ["TRAF-family members", "PROTEIN", 11, 30], ["TRAF2", "PROTEIN", 37, 42], ["TRAF3", "PROTEIN", 44, 49], ["TRAF6", "PROTEIN", 54, 59], ["proline-rich region", "PROTEIN", 68, 87], ["MAVS", "PROTEIN", 91, 95], ["NF-\u03baB", "PROTEIN", 165, 170], ["IRF3", "PROTEIN", 175, 179], ["MAVS", "PROTEIN", 269, 273], ["IFN", "PROTEIN", 335, 338], ["MAVS", "PROBLEM", 91, 95], ["Saha et al.", "TEST", 219, 230], ["a deletion", "PROBLEM", 248, 258], ["mutant of MAVS", "PROBLEM", 259, 273], ["the binding sites", "PROBLEM", 282, 299], ["the capacity", "PROBLEM", 310, 322]]], ["Kinases such as IKK\u03b5, have been shown to physically interact with MAVS at the outer mitochondrial membrane (Lin et al., 2006), and this leads to the phosphorylation and activation of IRF3.", [["outer mitochondrial membrane", "ANATOMY", 78, 106], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 16, 20], ["MAVS", "GENE_OR_GENE_PRODUCT", 66, 70], ["outer", "CELLULAR_COMPONENT", 78, 83], ["mitochondrial membrane", "CELLULAR_COMPONENT", 84, 106], ["IRF3", "GENE_OR_GENE_PRODUCT", 183, 187], ["IKK\u03b5", "PROTEIN", 16, 20], ["MAVS", "PROTEIN", 66, 70], ["IRF3", "PROTEIN", 183, 187], ["the phosphorylation", "TREATMENT", 145, 164], ["IRF3", "PROBLEM", 183, 187], ["outer", "ANATOMY_MODIFIER", 78, 83], ["mitochondrial membrane", "ANATOMY", 84, 106]]], ["In contrast, the mitotic polo-like kinase 1 (PLK1) has been shown to inhibit MAVS signaling and IFN-\u03b2 activation, by blocking the TRAF3 binding site on MAVS in a phospho-independent manner (Vitour et al., 2009).Regulation of MAVS downstream signaling ::: MAVS \u2013 the first mitochondrial protein identified in the innate immune systemSimilar to other biological \u201carms race\u201d scenarios, pathogenic persistence relies on the ability of microbes to overcome the host-cell defenses.", [["mitochondrial", "ANATOMY", 272, 285], ["cell", "ANATOMY", 461, 465], ["polo-like kinase 1", "GENE_OR_GENE_PRODUCT", 25, 43], ["PLK1", "GENE_OR_GENE_PRODUCT", 45, 49], ["MAVS", "GENE_OR_GENE_PRODUCT", 77, 81], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 96, 101], ["TRAF3", "GENE_OR_GENE_PRODUCT", 130, 135], ["MAVS", "GENE_OR_GENE_PRODUCT", 152, 156], ["MAVS", "GENE_OR_GENE_PRODUCT", 225, 229], ["MAVS", "GENE_OR_GENE_PRODUCT", 255, 259], ["mitochondrial", "CELLULAR_COMPONENT", 272, 285], ["cell", "CELL", 461, 465], ["mitotic polo-like kinase 1", "PROTEIN", 17, 43], ["PLK1", "PROTEIN", 45, 49], ["MAVS", "PROTEIN", 77, 81], ["IFN", "PROTEIN", 96, 99], ["\u03b2", "PROTEIN", 100, 101], ["TRAF3 binding site", "DNA", 130, 148], ["MAVS", "PROTEIN", 152, 156], ["MAVS", "PROTEIN", 225, 229], ["MAVS", "PROTEIN", 255, 259], ["mitochondrial protein", "PROTEIN", 272, 293], ["the mitotic polo", "TEST", 13, 29], ["MAVS signaling", "PROBLEM", 77, 91], ["IFN-\u03b2 activation", "PROBLEM", 96, 112], ["the TRAF3 binding site", "PROBLEM", 126, 148], ["MAVS", "PROBLEM", 255, 259], ["the first mitochondrial protein", "PROBLEM", 262, 293], ["MAVS", "OBSERVATION", 225, 229], ["cell defenses", "OBSERVATION", 461, 474]]], ["Hepatitis C virus (HCV) encodes NS3/4A, a serine protease that blocks RLH signaling by cleaving MAVS from the outer mitochondrial membrane at Cys-508 (Meylan et al., 2005, Lin et al., 2006).", [["outer mitochondrial membrane", "ANATOMY", 110, 138], ["Hepatitis C", "DISEASE", 0, 11], ["Cys-508", "CHEMICAL", 142, 149], ["serine", "CHEMICAL", 42, 48], ["Cys", "CHEMICAL", 142, 145], ["Hepatitis C virus", "ORGANISM", 0, 17], ["HCV", "ORGANISM", 19, 22], ["NS3/4A", "GENE_OR_GENE_PRODUCT", 32, 38], ["serine", "AMINO_ACID", 42, 48], ["RLH", "GENE_OR_GENE_PRODUCT", 70, 73], ["MAVS", "GENE_OR_GENE_PRODUCT", 96, 100], ["outer", "CELLULAR_COMPONENT", 110, 115], ["mitochondrial membrane", "CELLULAR_COMPONENT", 116, 138], ["Cys-508", "AMINO_ACID", 142, 149], ["NS3/4A", "PROTEIN", 32, 38], ["serine protease", "PROTEIN", 42, 57], ["RLH", "PROTEIN", 70, 73], ["MAVS", "PROTEIN", 96, 100], ["Hepatitis C virus", "SPECIES", 0, 17], ["Hepatitis C virus", "SPECIES", 0, 17], ["HCV", "SPECIES", 19, 22], ["Hepatitis C virus", "PROBLEM", 0, 17], ["NS3", "PROBLEM", 32, 35], ["a serine protease", "TREATMENT", 40, 57], ["blocks RLH signaling", "PROBLEM", 63, 83], ["outer", "ANATOMY_MODIFIER", 110, 115], ["mitochondrial membrane", "ANATOMY", 116, 138]]], ["Like other truncation mutants that prevent its mitochondrial localization (Seth et al., 2005, Lad et al., 2008), this cleavage prevents MAVS from signaling to downstream immune effectors.", [["mitochondrial", "ANATOMY", 47, 60], ["mitochondrial", "CELLULAR_COMPONENT", 47, 60], ["MAVS", "GENE_OR_GENE_PRODUCT", 136, 140], ["truncation mutants", "PROTEIN", 11, 29], ["MAVS", "PROTEIN", 136, 140], ["downstream immune effectors", "PROTEIN", 159, 186], ["other truncation mutants", "PROBLEM", 5, 29], ["this cleavage", "PROBLEM", 113, 126], ["MAVS", "PROBLEM", 136, 140], ["Lad", "ANATOMY", 94, 97]]], ["The evolutionarily-unrelated hepatitis A virus (HAV) cleaves MAVS from mitochondria at Gln-428, using its 3ABC cysteine protease (Yang et al., 2007), indicating that numerous viruses may have evolved strategies to block the immune system at this point.Regulation of MAVS downstream signaling ::: MAVS \u2013 the first mitochondrial protein identified in the innate immune systemInterestingly, two mammalian proteins have recently been shown to be involved in MAVS degradation in response to viral infection, potentially acting as a negative-feedback system to fine-tune interferon production.", [["mitochondria", "ANATOMY", 71, 83], ["mitochondrial", "ANATOMY", 313, 326], ["hepatitis A", "DISEASE", 29, 40], ["Gln-428", "CHEMICAL", 87, 94], ["viral infection", "DISEASE", 486, 501], ["Gln", "CHEMICAL", 87, 90], ["cysteine", "CHEMICAL", 111, 119], ["hepatitis A virus", "ORGANISM", 29, 46], ["HAV", "ORGANISM", 48, 51], ["MAVS", "GENE_OR_GENE_PRODUCT", 61, 65], ["mitochondria", "CELLULAR_COMPONENT", 71, 83], ["Gln-428", "AMINO_ACID", 87, 94], ["MAVS", "GENE_OR_GENE_PRODUCT", 266, 270], ["MAVS", "GENE_OR_GENE_PRODUCT", 296, 300], ["mitochondrial", "CELLULAR_COMPONENT", 313, 326], ["MAVS", "GENE_OR_GENE_PRODUCT", 454, 458], ["interferon", "GENE_OR_GENE_PRODUCT", 565, 575], ["MAVS", "PROTEIN", 61, 65], ["MAVS", "PROTEIN", 266, 270], ["MAVS", "PROTEIN", 296, 300], ["mitochondrial protein", "PROTEIN", 313, 334], ["mammalian proteins", "PROTEIN", 392, 410], ["MAVS", "PROTEIN", 454, 458], ["interferon", "PROTEIN", 565, 575], ["hepatitis A virus", "SPECIES", 29, 46], ["hepatitis A virus", "SPECIES", 29, 46], ["HAV", "SPECIES", 48, 51], ["unrelated hepatitis A virus (HAV) cleaves MAVS", "PROBLEM", 19, 65], ["mitochondria at Gln", "TEST", 71, 90], ["its 3ABC cysteine protease", "TREATMENT", 102, 128], ["numerous viruses", "PROBLEM", 166, 182], ["block the immune system", "PROBLEM", 214, 237], ["MAVS", "PROBLEM", 296, 300], ["the first mitochondrial protein", "PROBLEM", 303, 334], ["MAVS degradation", "PROBLEM", 454, 470], ["viral infection", "PROBLEM", 486, 501], ["hepatitis", "OBSERVATION", 29, 38], ["viruses", "OBSERVATION", 175, 182], ["MAVS", "OBSERVATION", 266, 270], ["viral infection", "OBSERVATION", 486, 501], ["tune interferon", "OBSERVATION", 560, 575]]], ["A subunit of the proteasome, PSMA7, interacts with MAVS in vivo and in vitro, and its overexpression leads to a reduction in endogenous MAVS levels (Jia et al., 2009).", [["PSMA7", "GENE_OR_GENE_PRODUCT", 29, 34], ["MAVS", "GENE_OR_GENE_PRODUCT", 51, 55], ["MAVS", "GENE_OR_GENE_PRODUCT", 136, 140], ["proteasome", "PROTEIN", 17, 27], ["PSMA7", "PROTEIN", 29, 34], ["MAVS", "PROTEIN", 51, 55], ["MAVS", "PROTEIN", 136, 140], ["the proteasome", "TREATMENT", 13, 27], ["MAVS", "TREATMENT", 51, 55], ["a reduction in endogenous MAVS levels", "PROBLEM", 110, 147], ["endogenous MAVS", "OBSERVATION", 125, 140]]], ["Importantly, there is also a transient increase in PSMA7 levels during viral infection, indicating that the MAVS degradation is not just experimental artifact.", [["viral infection", "DISEASE", 71, 86], ["PSMA7", "GENE_OR_GENE_PRODUCT", 51, 56], ["MAVS", "GENE_OR_GENE_PRODUCT", 108, 112], ["PSMA7", "PROTEIN", 51, 56], ["MAVS", "PROTEIN", 108, 112], ["a transient increase in PSMA7 levels", "PROBLEM", 27, 63], ["viral infection", "PROBLEM", 71, 86], ["the MAVS degradation", "PROBLEM", 104, 124], ["transient", "OBSERVATION_MODIFIER", 29, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["PSMA7 levels", "OBSERVATION", 51, 63], ["viral", "OBSERVATION_MODIFIER", 71, 76], ["infection", "OBSERVATION", 77, 86], ["MAVS", "OBSERVATION", 108, 112], ["artifact", "OBSERVATION", 150, 158]]], ["Potentially upstream of this protein is PCBP2, which interacts with MAVS and acts as a negative regulator of its function (You et al., 2009).", [["PCBP2", "GENE_OR_GENE_PRODUCT", 40, 45], ["MAVS", "GENE_OR_GENE_PRODUCT", 68, 72], ["PCBP2", "PROTEIN", 40, 45], ["MAVS", "PROTEIN", 68, 72]]], ["PCBP2 is upregulated during viral infection, and appears to target MAVS for degradation via the ubiquitin\u2013proteasome system.", [["PCBP2", "CHEMICAL", 0, 5], ["viral infection", "DISEASE", 28, 43], ["PCBP2", "GENE_OR_GENE_PRODUCT", 0, 5], ["MAVS", "GENE_OR_GENE_PRODUCT", 67, 71], ["PCBP2", "PROTEIN", 0, 5], ["MAVS", "PROTEIN", 67, 71], ["PCBP2", "TEST", 0, 5], ["viral infection", "PROBLEM", 28, 43], ["the ubiquitin\u2013proteasome system", "TREATMENT", 92, 123], ["upregulated", "OBSERVATION_MODIFIER", 9, 20], ["viral", "OBSERVATION_MODIFIER", 28, 33], ["infection", "OBSERVATION", 34, 43], ["MAVS", "OBSERVATION", 67, 71]]], ["Following viral infection, PCBP2 recruits the HECT E3 ubiquitin ligase AIP4 to MAVS, resulting in its polyubiquitination and degradation (You et al., 2009).MAVS, immunity and apoptosis ::: MAVS \u2013 the first mitochondrial protein identified in the innate immune systemA familiar aspect of mitochondrial biology is the role the organelle plays in apoptosis.", [["mitochondrial", "ANATOMY", 206, 219], ["mitochondrial", "ANATOMY", 287, 300], ["organelle", "ANATOMY", 325, 334], ["viral infection", "DISEASE", 10, 25], ["PCBP2", "GENE_OR_GENE_PRODUCT", 27, 32], ["HECT", "GENE_OR_GENE_PRODUCT", 46, 50], ["AIP4", "GENE_OR_GENE_PRODUCT", 71, 75], ["MAVS", "GENE_OR_GENE_PRODUCT", 79, 83], ["MAVS", "GENE_OR_GENE_PRODUCT", 156, 160], ["MAVS", "GENE_OR_GENE_PRODUCT", 189, 193], ["mitochondrial", "CELLULAR_COMPONENT", 206, 219], ["mitochondrial", "CELLULAR_COMPONENT", 287, 300], ["organelle", "CELLULAR_COMPONENT", 325, 334], ["PCBP2", "PROTEIN", 27, 32], ["HECT E3 ubiquitin ligase", "PROTEIN", 46, 70], ["AIP4", "PROTEIN", 71, 75], ["MAVS", "PROTEIN", 79, 83], ["MAVS", "PROTEIN", 156, 160], ["MAVS", "PROTEIN", 189, 193], ["mitochondrial protein", "PROTEIN", 206, 227], ["viral infection", "PROBLEM", 10, 25], ["PCBP2", "TREATMENT", 27, 32], ["the HECT E3 ubiquitin ligase", "TREATMENT", 42, 70], ["MAVS", "PROBLEM", 79, 83], ["its polyubiquitination", "PROBLEM", 98, 120], ["MAVS", "PROBLEM", 189, 193], ["the first mitochondrial protein", "TEST", 196, 227], ["apoptosis", "PROBLEM", 344, 353], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["infection", "OBSERVATION", 16, 25], ["polyubiquitination", "OBSERVATION_MODIFIER", 102, 120], ["apoptosis", "OBSERVATION", 344, 353]]], ["Mitochondria are an integral part of the intrinsic apoptotic pathway, being the location of many proteins involved in the early stages of cell death.", [["Mitochondria", "ANATOMY", 0, 12], ["cell", "ANATOMY", 138, 142], ["death", "DISEASE", 143, 148], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["cell", "CELL", 138, 142], ["cell death", "PROBLEM", 138, 148], ["apoptotic pathway", "OBSERVATION", 51, 68], ["many", "OBSERVATION_MODIFIER", 92, 96], ["proteins", "OBSERVATION", 97, 105], ["early stages", "OBSERVATION_MODIFIER", 122, 134], ["cell death", "OBSERVATION", 138, 148]]], ["For example, the Bcl-2 family of proteins (including the pro-apoptotic Bax and Bak, and the anti-apoptotic Bcl-2 and Bcl-xL) act at the outer mitochondrial membrane in response to stress stimuli, and help to regulate whether the cell enters the later stages of programmed cell death (for review, see Youle and Strasser, 2008).", [["outer mitochondrial membrane", "ANATOMY", 136, 164], ["cell", "ANATOMY", 229, 233], ["cell", "ANATOMY", 272, 276], ["programmed cell death", "DISEASE", 261, 282], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 17, 22], ["Bax", "GENE_OR_GENE_PRODUCT", 71, 74], ["Bak", "GENE_OR_GENE_PRODUCT", 79, 82], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 107, 112], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 117, 123], ["outer mitochondrial membrane", "CELLULAR_COMPONENT", 136, 164], ["cell", "CELL", 229, 233], ["cell", "CELL", 272, 276], ["Bcl-2 family", "PROTEIN", 17, 29], ["pro-apoptotic Bax", "PROTEIN", 57, 74], ["Bak", "PROTEIN", 79, 82], ["anti-apoptotic Bcl-2", "PROTEIN", 92, 112], ["Bcl", "PROTEIN", 117, 120], ["xL", "PROTEIN", 121, 123], ["the Bcl", "TEST", 13, 20], ["the pro-apoptotic Bax", "TEST", 53, 74], ["Bak", "TREATMENT", 79, 82], ["the anti-apoptotic Bcl", "TEST", 88, 110], ["Bcl", "TEST", 117, 120], ["stress stimuli", "TEST", 180, 194], ["programmed cell death", "PROBLEM", 261, 282], ["outer", "ANATOMY_MODIFIER", 136, 141], ["mitochondrial membrane", "ANATOMY", 142, 164], ["stress stimuli", "OBSERVATION", 180, 194]]], ["If the cell receives sufficient pro-apoptotic signals, Bax and Bak aid the release of cytochrome c from the mitochondrial inter membrane space, which leads to the induction of caspases and the orderly destruction of the cell.", [["cell", "ANATOMY", 7, 11], ["mitochondrial", "ANATOMY", 108, 121], ["membrane space", "ANATOMY", 128, 142], ["cell", "ANATOMY", 220, 224], ["cell", "CELL", 7, 11], ["Bax", "GENE_OR_GENE_PRODUCT", 55, 58], ["Bak", "GENE_OR_GENE_PRODUCT", 63, 66], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 86, 98], ["mitochondrial", "CELLULAR_COMPONENT", 108, 121], ["membrane space", "CELLULAR_COMPONENT", 128, 142], ["caspases", "GENE_OR_GENE_PRODUCT", 176, 184], ["cell", "CELL", 220, 224], ["Bax", "PROTEIN", 55, 58], ["Bak", "PROTEIN", 63, 66], ["cytochrome c", "PROTEIN", 86, 98], ["caspases", "PROTEIN", 176, 184], ["Bax", "TREATMENT", 55, 58], ["Bak", "TREATMENT", 63, 66], ["cytochrome c", "PROBLEM", 86, 98], ["caspases", "TREATMENT", 176, 184], ["the orderly destruction of the cell", "PROBLEM", 189, 224], ["orderly", "OBSERVATION_MODIFIER", 193, 200], ["destruction", "OBSERVATION", 201, 212], ["cell", "OBSERVATION", 220, 224]]], ["Apoptosis is also an important aspect of the immune system, as it can help to prevent the movement of pathogens between tissues, and many viruses (such as human immunodeficiency virus and cytomegalovirus) produce proteins that interfere with this process (Boya et al., 2003).", [["immune system", "ANATOMY", 45, 58], ["tissues", "ANATOMY", 120, 127], ["Apoptosis", "DISEASE", 0, 9], ["human immunodeficiency virus and cytomegalovirus)", "DISEASE", 155, 204], ["tissues", "TISSUE", 120, 127], ["human immunodeficiency virus", "ORGANISM", 155, 183], ["cytomegalovirus", "ORGANISM", 188, 203], ["human immunodeficiency virus", "SPECIES", 155, 183], ["human immunodeficiency virus", "SPECIES", 155, 183], ["Apoptosis", "PROBLEM", 0, 9], ["pathogens between tissues", "PROBLEM", 102, 127], ["many viruses", "PROBLEM", 133, 145], ["human immunodeficiency virus", "PROBLEM", 155, 183], ["cytomegalovirus) produce proteins", "PROBLEM", 188, 221], ["viruses", "OBSERVATION", 138, 145]]], ["For example, the 2\u20325\u2032-oligoadenylate synthetase/RNaseL pathway induces apoptosis in response to viral infection, by using the endoribonuclease RNaseL to cleave all cellular RNA (host and viral), which shuts down protein synthesis and kills the cell (Castelli et al., 1998, Malathi et al., 2007).MAVS, immunity and apoptosis ::: MAVS \u2013 the first mitochondrial protein identified in the innate immune systemIn their initial paper, Seth et al. (2005) speculated that MAVS may have a role in apoptosis induction, as siRNA knockdown of protein levels led to the cleavage of PARP, a known marker of cell death; although a follow-up report by the same group found no difference in MAVS\u2212/\u2212 MEFs following apoptosis (Sun et al., 2006).", [["cellular", "ANATOMY", 164, 172], ["cell", "ANATOMY", 244, 248], ["mitochondrial", "ANATOMY", 345, 358], ["cell", "ANATOMY", 593, 597], ["MEFs", "ANATOMY", 682, 686], ["2\u20325\u2032-oligoadenylate", "CHEMICAL", 17, 36], ["viral infection", "DISEASE", 96, 111], ["death", "DISEASE", 598, 603], ["2\u20325\u2032-oligoadenylate", "CHEMICAL", 17, 36], ["2\u20325\u2032-oligoadenylate synthetase", "GENE_OR_GENE_PRODUCT", 17, 47], ["RNaseL", "GENE_OR_GENE_PRODUCT", 48, 54], ["RNaseL", "GENE_OR_GENE_PRODUCT", 143, 149], ["cellular", "CELL", 164, 172], ["cell", "CELL", 244, 248], ["MAVS", "GENE_OR_GENE_PRODUCT", 295, 299], ["MAVS", "GENE_OR_GENE_PRODUCT", 328, 332], ["mitochondrial", "CELLULAR_COMPONENT", 345, 358], ["MAVS", "GENE_OR_GENE_PRODUCT", 464, 468], ["PARP", "GENE_OR_GENE_PRODUCT", 569, 573], ["cell", "CELL", 593, 597], ["MAVS", "GENE_OR_GENE_PRODUCT", 674, 678], ["2\u20325\u2032-oligoadenylate synthetase", "PROTEIN", 17, 47], ["RNaseL", "PROTEIN", 48, 54], ["endoribonuclease", "PROTEIN", 126, 142], ["RNaseL", "PROTEIN", 143, 149], ["cellular RNA", "RNA", 164, 176], ["MAVS", "PROTEIN", 295, 299], ["MAVS", "PROTEIN", 328, 332], ["mitochondrial protein", "PROTEIN", 345, 366], ["MAVS", "PROTEIN", 464, 468], ["PARP", "PROTEIN", 569, 573], ["MAVS", "PROTEIN", 674, 678], ["oligoadenylate synthetase/RNaseL pathway", "TREATMENT", 22, 62], ["apoptosis", "PROBLEM", 71, 80], ["viral infection", "PROBLEM", 96, 111], ["the endoribonuclease RNaseL", "TREATMENT", 122, 149], ["protein synthesis", "TREATMENT", 212, 229], ["MAVS", "PROBLEM", 328, 332], ["the first mitochondrial protein", "PROBLEM", 335, 366], ["apoptosis induction", "TREATMENT", 488, 507], ["siRNA knockdown of protein levels", "PROBLEM", 512, 545], ["PARP", "PROBLEM", 569, 573], ["cell death", "PROBLEM", 593, 603], ["MAVS", "TEST", 674, 678], ["apoptosis", "PROBLEM", 697, 706], ["viral infection", "OBSERVATION", 96, 111], ["cellular RNA", "OBSERVATION", 164, 176], ["cell death", "OBSERVATION", 593, 603]]], ["However, a number of recent studies have indicated that MAVS may have pro-apoptotic roles in immunity outside of cytokine production.", [["MAVS", "GENE_OR_GENE_PRODUCT", 56, 60], ["MAVS", "PROTEIN", 56, 60], ["cytokine", "PROTEIN", 113, 121], ["recent studies", "TEST", 21, 35], ["MAVS", "PROBLEM", 56, 60], ["cytokine production", "PROBLEM", 113, 132]]], ["Induction of apoptosis following reovirus infection is reduced in MAVS knockdown cells (Holm et al., 2007), while MAVS\u2212/\u2212 MEFs show reduced apoptosis in response to infection by Sendai virus (Lei et al., 2009).", [["cells", "ANATOMY", 81, 86], ["MAVS\u2212/\u2212 MEFs", "ANATOMY", 114, 126], ["reovirus infection", "DISEASE", 33, 51], ["infection", "DISEASE", 165, 174], ["reovirus", "ORGANISM", 33, 41], ["MAVS", "GENE_OR_GENE_PRODUCT", 66, 70], ["cells", "CELL", 81, 86], ["MAVS", "GENE_OR_GENE_PRODUCT", 114, 118], ["Sendai virus", "ORGANISM", 178, 190], ["MAVS knockdown cells", "CELL_LINE", 66, 86], ["MAVS", "PROTEIN", 114, 118], ["Sendai virus", "SPECIES", 178, 190], ["Sendai virus", "SPECIES", 178, 190], ["apoptosis", "PROBLEM", 13, 22], ["reovirus infection", "PROBLEM", 33, 51], ["MAVS", "TEST", 114, 118], ["MEFs", "PROBLEM", 122, 126], ["reduced apoptosis", "PROBLEM", 132, 149], ["infection", "PROBLEM", 165, 174], ["Sendai virus", "PROBLEM", 178, 190], ["apoptosis", "OBSERVATION_MODIFIER", 13, 22], ["following reovirus", "OBSERVATION_MODIFIER", 23, 41], ["infection", "OBSERVATION", 42, 51], ["reduced", "OBSERVATION_MODIFIER", 55, 62], ["knockdown cells", "OBSERVATION", 71, 86], ["reduced", "OBSERVATION_MODIFIER", 132, 139], ["apoptosis", "OBSERVATION", 140, 149], ["infection", "OBSERVATION", 165, 174]]], ["These data are complimented by studies showing that overexpression of MAVS induces apoptosis by activation of caspase-3, -8 and -9 (Li et al., 2009, Lei et al., 2009, Yu et al., in press).MAVS, immunity and apoptosis ::: MAVS \u2013 the first mitochondrial protein identified in the innate immune systemGiven the role that MAVS may play in immune-related apoptosis, it is perhaps unsurprising that the protein is heavily regulated during apoptosis.", [["mitochondrial", "ANATOMY", 238, 251], ["MAVS", "GENE_OR_GENE_PRODUCT", 70, 74], ["caspase-3", "GENE_OR_GENE_PRODUCT", 110, 119], ["-8", "GENE_OR_GENE_PRODUCT", 121, 123], ["-9", "GENE_OR_GENE_PRODUCT", 128, 130], ["MAVS", "GENE_OR_GENE_PRODUCT", 188, 192], ["MAVS", "GENE_OR_GENE_PRODUCT", 221, 225], ["mitochondrial", "CELLULAR_COMPONENT", 238, 251], ["MAVS", "GENE_OR_GENE_PRODUCT", 318, 322], ["MAVS", "PROTEIN", 70, 74], ["caspase-3, -8 and -9", "PROTEIN", 110, 130], ["MAVS", "PROTEIN", 188, 192], ["MAVS", "PROTEIN", 221, 225], ["mitochondrial protein", "PROTEIN", 238, 259], ["MAVS", "PROTEIN", 318, 322], ["These data", "TEST", 0, 10], ["overexpression of MAVS", "PROBLEM", 52, 74], ["apoptosis", "PROBLEM", 83, 92], ["caspase", "TEST", 110, 117], ["MAVS", "PROBLEM", 221, 225], ["the first mitochondrial protein", "PROBLEM", 228, 259], ["MAVS", "PROBLEM", 318, 322], ["immune-related apoptosis", "PROBLEM", 335, 359], ["the protein", "PROBLEM", 393, 404]]], ["Upstream members of the RLH pathway such as RIG-I and MDA-5 are degraded by caspases during apoptosis which, in the case of MDA-5, can be induced by poliovirus infection (Barral et al., 2007, Scott, 2009).", [["MDA-5", "CHEMICAL", 124, 129], ["poliovirus infection", "DISEASE", 149, 169], ["RLH", "GENE_OR_GENE_PRODUCT", 24, 27], ["RIG-I", "GENE_OR_GENE_PRODUCT", 44, 49], ["MDA-5", "GENE_OR_GENE_PRODUCT", 54, 59], ["caspases", "GENE_OR_GENE_PRODUCT", 76, 84], ["MDA-5", "GENE_OR_GENE_PRODUCT", 124, 129], ["poliovirus", "ORGANISM", 149, 159], ["RLH", "PROTEIN", 24, 27], ["RIG-I", "PROTEIN", 44, 49], ["MDA-5", "PROTEIN", 54, 59], ["caspases", "PROTEIN", 76, 84], ["poliovirus", "SPECIES", 149, 159], ["MDA", "TEST", 54, 57], ["apoptosis", "PROBLEM", 92, 101], ["MDA", "TEST", 124, 127], ["poliovirus infection", "PROBLEM", 149, 169], ["poliovirus infection", "OBSERVATION", 149, 169]]], ["MAVS is cleaved at Asp-429 by caspases during apoptosis, a process which can be blocked by the addition of the caspase inhibitor zVAD-fmk, or expression of the anti-apoptotic protein Bcl-xL (Scott and Norris, 2008, Rebsamen et al., 2008).", [["Asp-429", "CHEMICAL", 19, 26], ["Asp", "CHEMICAL", 19, 22], ["MAVS", "GENE_OR_GENE_PRODUCT", 0, 4], ["Asp-429", "AMINO_ACID", 19, 26], ["caspases", "GENE_OR_GENE_PRODUCT", 30, 38], ["caspase", "GENE_OR_GENE_PRODUCT", 111, 118], ["zVAD-fmk", "GENE_OR_GENE_PRODUCT", 129, 137], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 183, 189], ["MAVS", "PROTEIN", 0, 4], ["caspases", "PROTEIN", 30, 38], ["caspase inhibitor zVAD-fmk", "PROTEIN", 111, 137], ["anti-apoptotic protein", "PROTEIN", 160, 182], ["Bcl-xL", "PROTEIN", 183, 189], ["MAVS", "PROBLEM", 0, 4], ["Asp", "TEST", 19, 22], ["the caspase inhibitor zVAD", "TREATMENT", 107, 133], ["the anti-apoptotic protein Bcl-xL", "TREATMENT", 156, 189]]], ["Cleavage of these proteins during the early stages of cell death has the potential to aid viral replication, as it may prevent RLH proteins from signaling to downstream immune proteins, or delay completion of the apoptotic program.", [["cell", "ANATOMY", 54, 58], ["death", "DISEASE", 59, 64], ["cell", "CELL", 54, 58], ["RLH", "GENE_OR_GENE_PRODUCT", 127, 130], ["RLH proteins", "PROTEIN", 127, 139], ["downstream immune proteins", "PROTEIN", 158, 184], ["these proteins", "PROBLEM", 12, 26], ["cell death", "PROBLEM", 54, 64], ["viral replication", "TREATMENT", 90, 107], ["RLH proteins", "PROBLEM", 127, 139], ["downstream immune proteins", "PROBLEM", 158, 184], ["the apoptotic program", "TREATMENT", 209, 230]]], ["Initial studies of MDA-5 cleavage during poliovirus infection did not detect a benefit to the invading virus from inducing apoptosis, as there were no increases in viral replication or reduction in cytokine production (Barral et al., 2007).", [["MDA-5", "CHEMICAL", 19, 24], ["poliovirus infection", "DISEASE", 41, 61], ["MDA-5", "CHEMICAL", 19, 24], ["MDA-5", "GENE_OR_GENE_PRODUCT", 19, 24], ["poliovirus", "ORGANISM", 41, 51], ["cytokine", "PROTEIN", 198, 206], ["poliovirus", "SPECIES", 41, 51], ["Initial studies", "TEST", 0, 15], ["MDA", "TEST", 19, 22], ["poliovirus infection", "PROBLEM", 41, 61], ["the invading virus", "PROBLEM", 90, 108], ["increases in viral replication", "PROBLEM", 151, 181], ["reduction in cytokine production", "PROBLEM", 185, 217], ["no", "UNCERTAINTY", 148, 150], ["increases", "OBSERVATION_MODIFIER", 151, 160], ["viral replication", "OBSERVATION", 164, 181], ["reduction", "OBSERVATION_MODIFIER", 185, 194], ["cytokine production", "OBSERVATION", 198, 217]]], ["However, a recent study by Lei et al. (2009) has provided direct evidence of a viral protein targeting MAVS-induced apoptosis.", [["MAVS", "GENE_OR_GENE_PRODUCT", 103, 107], ["viral protein", "PROTEIN", 79, 92], ["MAVS", "PROTEIN", 103, 107], ["a recent study", "TEST", 9, 23], ["a viral protein targeting MAVS", "PROBLEM", 77, 107], ["apoptosis", "PROBLEM", 116, 125], ["apoptosis", "OBSERVATION_MODIFIER", 116, 125]]], ["The anti-apoptotic SARS-CoV protein NSP15 prevents apoptosis as a result of MAVS expression, but does not mediate apoptosis induced by staurosporine treatment, indicating that it has evolved as a MAVS-specific strategy (Lei et al., 2009).", [["staurosporine", "CHEMICAL", 135, 148], ["staurosporine", "CHEMICAL", 135, 148], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["NSP15", "GENE_OR_GENE_PRODUCT", 36, 41], ["MAVS", "GENE_OR_GENE_PRODUCT", 76, 80], ["staurosporine", "SIMPLE_CHEMICAL", 135, 148], ["MAVS", "GENE_OR_GENE_PRODUCT", 196, 200], ["anti-apoptotic SARS-CoV protein", "PROTEIN", 4, 35], ["NSP15", "PROTEIN", 36, 41], ["MAVS", "PROTEIN", 76, 80], ["MAVS", "PROTEIN", 196, 200], ["SARS-CoV", "SPECIES", 19, 27], ["The anti-apoptotic SARS", "TEST", 0, 23], ["CoV protein NSP15", "TREATMENT", 24, 41], ["apoptosis", "PROBLEM", 51, 60], ["MAVS expression", "PROBLEM", 76, 91], ["staurosporine treatment", "TREATMENT", 135, 158]]], ["Further studies will help to elucidate the extent to which viruses target this interferon-independent aspect of MAVS biology.Discovery and conflicting functions of NLRX1 ::: NLRX1 \u2013 MAVS regulator or innocent bystander?As mentioned above, one of the other groups of intracellular PRPs is the NOD-like receptor family of proteins.", [["intracellular", "ANATOMY", 266, 279], ["MAVS", "GENE_OR_GENE_PRODUCT", 112, 116], ["NLRX1", "GENE_OR_GENE_PRODUCT", 164, 169], ["NLRX1", "GENE_OR_GENE_PRODUCT", 174, 179], ["MAVS", "GENE_OR_GENE_PRODUCT", 182, 186], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 266, 279], ["PRPs", "GENE_OR_GENE_PRODUCT", 280, 284], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 292, 309], ["interferon", "PROTEIN", 79, 89], ["MAVS", "PROTEIN", 112, 116], ["NLRX1", "PROTEIN", 164, 169], ["NLRX1", "PROTEIN", 174, 179], ["MAVS regulator", "PROTEIN", 182, 196], ["intracellular PRPs", "PROTEIN", 266, 284], ["NOD-like receptor family", "PROTEIN", 292, 316], ["Further studies", "TEST", 0, 15], ["viruses", "PROBLEM", 59, 66], ["intracellular PRPs", "TREATMENT", 266, 284]]], ["These leucine-rich repeat proteins are receptors involved in sensing numerous pathogen markers, such as bacterial lipopolysaccharide, leading to the activation of NF-\u03baB; and also as part of the inflammasome complexes which regulate caspase-1 activation and production of inflammatory cytokines (Janeway and Medzhitov, 2002, O\u2019Neill, 2008).", [["leucine", "CHEMICAL", 6, 13], ["lipopolysaccharide", "CHEMICAL", 114, 132], ["leucine", "CHEMICAL", 6, 13], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 114, 132], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 163, 168], ["caspase-1", "GENE_OR_GENE_PRODUCT", 232, 241], ["leucine-rich repeat proteins", "PROTEIN", 6, 34], ["NF-\u03baB", "PROTEIN", 163, 168], ["inflammasome complexes", "PROTEIN", 194, 216], ["caspase-1", "PROTEIN", 232, 241], ["inflammatory cytokines", "PROTEIN", 271, 293], ["These leucine", "TEST", 0, 13], ["sensing numerous pathogen markers", "PROBLEM", 61, 94], ["bacterial lipopolysaccharide", "PROBLEM", 104, 132], ["NF", "PROBLEM", 163, 165], ["the inflammasome complexes", "PROBLEM", 190, 216], ["caspase", "TEST", 232, 239], ["inflammatory cytokines", "PROBLEM", 271, 293], ["pathogen markers", "OBSERVATION", 78, 94], ["inflammasome", "OBSERVATION", 194, 206], ["inflammatory", "OBSERVATION_MODIFIER", 271, 283]]], ["Recently two research groups characterized a new member of the family, NLRX1, which was found to have a mitochondrial localization, in contrast to the cytosolic nature of the other family members.", [["mitochondrial", "ANATOMY", 104, 117], ["cytosolic", "ANATOMY", 151, 160], ["NLRX1", "GENE_OR_GENE_PRODUCT", 71, 76], ["mitochondrial", "CELLULAR_COMPONENT", 104, 117], ["NLRX1", "PROTEIN", 71, 76], ["a mitochondrial localization", "TEST", 102, 130], ["new", "OBSERVATION_MODIFIER", 45, 48]]], ["Moore et al. (2008) reported that NLRX1 was targeted to the mitochondrial outer membrane by a putative N-terminal localization sequence (Fig. 2), and had the ability to down-regulate RLH signaling by interacting with MAVS.", [["mitochondrial outer membrane", "ANATOMY", 60, 88], ["N", "CHEMICAL", 103, 104], ["NLRX1", "GENE_OR_GENE_PRODUCT", 34, 39], ["mitochondrial", "CELLULAR_COMPONENT", 60, 73], ["outer membrane", "CELLULAR_COMPONENT", 74, 88], ["RLH", "GENE_OR_GENE_PRODUCT", 183, 186], ["MAVS", "GENE_OR_GENE_PRODUCT", 217, 221], ["NLRX1", "PROTEIN", 34, 39], ["N-terminal localization sequence", "PROTEIN", 103, 135], ["RLH", "PROTEIN", 183, 186], ["MAVS", "PROTEIN", 217, 221], ["RLH", "OBSERVATION", 183, 186]]], ["This regulation was hypothesized to act as a brake on MAVS function, with the NACHT domain of NLRX1 reversibly binding to the CARD domain of MAVS \u2013 in effect blocking its ability to interact with RIG-I or MDA-5 (Moore et al., 2008).", [["MAVS", "GENE_OR_GENE_PRODUCT", 54, 58], ["NLRX1", "GENE_OR_GENE_PRODUCT", 94, 99], ["MAVS", "GENE_OR_GENE_PRODUCT", 141, 145], ["RIG-I", "GENE_OR_GENE_PRODUCT", 196, 201], ["MDA-5", "GENE_OR_GENE_PRODUCT", 205, 210], ["MAVS", "PROTEIN", 54, 58], ["NACHT domain", "PROTEIN", 78, 90], ["NLRX1", "PROTEIN", 94, 99], ["CARD domain", "PROTEIN", 126, 137], ["MAVS", "PROTEIN", 141, 145], ["RIG-I", "PROTEIN", 196, 201], ["MDA", "TEST", 205, 208]]], ["The second group also implicated NLRX1 in innate immunity, however with a greatly contrasting function.", [["NLRX1", "GENE_OR_GENE_PRODUCT", 33, 38], ["NLRX1", "PROTEIN", 33, 38]]], ["Tattoli et al. (2008) demonstrated that the mitochondrial localization of NLRX1 was dependent on a N-terminal addressing sequence, and that its expression did not lead to direct NF-\u03baB activation.", [["mitochondrial", "ANATOMY", 44, 57], ["N", "CHEMICAL", 99, 100], ["mitochondrial", "CELLULAR_COMPONENT", 44, 57], ["NLRX1", "GENE_OR_GENE_PRODUCT", 74, 79], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 178, 183], ["NLRX1", "PROTEIN", 74, 79], ["N-terminal addressing sequence", "PROTEIN", 99, 129], ["NF-\u03baB", "PROTEIN", 178, 183], ["the mitochondrial localization of NLRX1", "PROBLEM", 40, 79]]], ["However, it was shown that NLRX1 could amplify reactive oxygen species production in response to Shigella infection and tumor necrosis factor \u03b1, which led to an increase in pro-immune NF-\u03baB and JUN kinase signaling (Tattoli et al., 2008).The matrix, not the membrane ::: NLRX1 \u2013 MAVS regulator or innocent bystander?Clearly the functions ascribed to NLRX1, as both a repressor and activator of innate immunity, pose some problems.", [["matrix", "ANATOMY", 242, 248], ["membrane", "ANATOMY", 258, 266], ["NLRX1", "CHEMICAL", 27, 32], ["oxygen", "CHEMICAL", 56, 62], ["infection", "DISEASE", 106, 115], ["tumor", "DISEASE", 120, 125], ["necrosis", "DISEASE", 126, 134], ["oxygen", "CHEMICAL", 56, 62], ["NLRX1", "GENE_OR_GENE_PRODUCT", 27, 32], ["reactive oxygen species", "SIMPLE_CHEMICAL", 47, 70], ["tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 120, 143], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 184, 189], ["JUN kinase", "GENE_OR_GENE_PRODUCT", 194, 204], ["matrix", "CELLULAR_COMPONENT", 242, 248], ["membrane", "CELLULAR_COMPONENT", 258, 266], ["NLRX1", "GENE_OR_GENE_PRODUCT", 271, 276], ["MAVS", "GENE_OR_GENE_PRODUCT", 279, 283], ["NLRX1", "GENE_OR_GENE_PRODUCT", 350, 355], ["NLRX1", "PROTEIN", 27, 32], ["tumor necrosis factor \u03b1", "PROTEIN", 120, 143], ["pro-immune NF-\u03baB", "PROTEIN", 173, 189], ["JUN kinase", "PROTEIN", 194, 204], ["NLRX1", "PROTEIN", 271, 276], ["MAVS regulator", "PROTEIN", 279, 293], ["NLRX1", "PROTEIN", 350, 355], ["reactive oxygen species production", "PROBLEM", 47, 81], ["Shigella infection", "PROBLEM", 97, 115], ["tumor necrosis factor", "PROBLEM", 120, 141], ["an increase in pro-immune NF", "PROBLEM", 158, 186], ["JUN kinase signaling", "TEST", 194, 214], ["a repressor and activator of innate immunity", "TREATMENT", 365, 409], ["some problems", "PROBLEM", 416, 429], ["reactive", "OBSERVATION_MODIFIER", 47, 55], ["oxygen species", "OBSERVATION", 56, 70], ["Shigella", "OBSERVATION_MODIFIER", 97, 105], ["infection", "OBSERVATION", 106, 115], ["tumor", "OBSERVATION_MODIFIER", 120, 125], ["necrosis", "OBSERVATION", 126, 134], ["increase", "OBSERVATION_MODIFIER", 161, 169]]], ["While these may be accounted for by differences in experimental model or cell type, further research was required to elucidate NLRX1 function.", [["cell", "ANATOMY", 73, 77], ["cell", "CELL", 73, 77], ["NLRX1", "GENE_OR_GENE_PRODUCT", 127, 132], ["NLRX1", "PROTEIN", 127, 132], ["may be accounted for", "UNCERTAINTY", 12, 32]]], ["Both groups reported that NLRX1 had a N-terminal mitochondrial targeting sequence, a feature which is normally associated with proteins that are imported into mitochondria via membrane translocases, as opposed to outer membrane proteins, which tend to have internal localization markers (Wiedemann et al., 2004).", [["mitochondrial", "ANATOMY", 49, 62], ["mitochondria", "ANATOMY", 159, 171], ["membrane", "ANATOMY", 176, 184], ["outer membrane", "ANATOMY", 213, 227], ["N", "CHEMICAL", 38, 39], ["NLRX1", "GENE_OR_GENE_PRODUCT", 26, 31], ["mitochondrial", "CELLULAR_COMPONENT", 49, 62], ["mitochondria", "CELLULAR_COMPONENT", 159, 171], ["membrane", "CELLULAR_COMPONENT", 176, 184], ["outer membrane", "CELLULAR_COMPONENT", 213, 227], ["NLRX1", "PROTEIN", 26, 31], ["N-terminal mitochondrial targeting sequence", "PROTEIN", 38, 81], ["membrane translocases", "PROTEIN", 176, 197], ["outer membrane proteins", "PROTEIN", 213, 236], ["internal localization markers", "PROTEIN", 257, 286], ["a N-terminal mitochondrial targeting sequence", "PROBLEM", 36, 81], ["outer membrane proteins", "TEST", 213, 236]]], ["A thorough biochemical analysis of NLRX1 in HeLa and HEK293 cells indicated that NLRX1 is indeed imported into the mitochondrial matrix, a process which requires the removal of the N-terminal pre-sequence and an intact transmembrane potential (Arnoult et al., 2009).", [["HeLa", "ANATOMY", 44, 48], ["HEK293 cells", "ANATOMY", 53, 65], ["mitochondrial matrix", "ANATOMY", 115, 135], ["transmembrane", "ANATOMY", 219, 232], ["N", "CHEMICAL", 181, 182], ["NLRX1", "GENE_OR_GENE_PRODUCT", 35, 40], ["HeLa", "CELL", 44, 48], ["HEK293 cells", "CELL", 53, 65], ["NLRX1", "GENE_OR_GENE_PRODUCT", 81, 86], ["mitochondrial matrix", "CELLULAR_COMPONENT", 115, 135], ["NLRX1", "PROTEIN", 35, 40], ["HeLa", "CELL_LINE", 44, 48], ["HEK293 cells", "CELL_LINE", 53, 65], ["NLRX1", "PROTEIN", 81, 86], ["N-terminal pre-sequence", "PROTEIN", 181, 204], ["A thorough biochemical analysis", "TEST", 0, 31], ["NLRX1 in HeLa", "TREATMENT", 35, 48], ["HEK293 cells", "TEST", 53, 65], ["NLRX1", "TREATMENT", 81, 86], ["the removal", "TREATMENT", 162, 173], ["the N-terminal pre-sequence", "TREATMENT", 177, 204], ["mitochondrial matrix", "OBSERVATION", 115, 135], ["intact", "OBSERVATION", 212, 218]]], ["In addition, the authors demonstrated that NLRX1 coimmunoprecipitates with UQCRC2, a subunit of the respiratory chain complex III, which is localized on the matrix-facing side of the inner mitochondrial membrane.", [["matrix", "ANATOMY", 157, 163], ["inner mitochondrial membrane", "ANATOMY", 183, 211], ["NLRX1", "GENE_OR_GENE_PRODUCT", 43, 48], ["UQCRC2", "GENE_OR_GENE_PRODUCT", 75, 81], ["respiratory chain complex III", "GENE_OR_GENE_PRODUCT", 100, 129], ["matrix", "CELLULAR_COMPONENT", 157, 163], ["inner mitochondrial membrane", "CELLULAR_COMPONENT", 183, 211], ["NLRX1", "PROTEIN", 43, 48], ["UQCRC2", "PROTEIN", 75, 81], ["respiratory chain complex III", "PROTEIN", 100, 129], ["UQCRC2", "TREATMENT", 75, 81], ["respiratory chain", "OBSERVATION", 100, 117], ["matrix", "OBSERVATION_MODIFIER", 157, 163], ["inner", "ANATOMY_MODIFIER", 183, 188], ["mitochondrial membrane", "OBSERVATION", 189, 211]]], ["As complex III is involved in reactive oxygen species production, this finding substantiates both the matrix localization of NLRX1, and its involvement in reactive oxygen signaling (Arnoult et al., 2009).The matrix, not the membrane ::: NLRX1 \u2013 MAVS regulator or innocent bystander?Given the differences in localization between MAVS and NLRX1, at least in this system, it would appear unlikely that there could be a strong interaction between the two proteins in vivo.", [["matrix", "ANATOMY", 102, 108], ["matrix", "ANATOMY", 208, 214], ["membrane", "ANATOMY", 224, 232], ["oxygen", "CHEMICAL", 39, 45], ["oxygen", "CHEMICAL", 164, 170], ["oxygen", "CHEMICAL", 39, 45], ["oxygen", "CHEMICAL", 164, 170], ["complex III", "GENE_OR_GENE_PRODUCT", 3, 14], ["reactive oxygen species", "SIMPLE_CHEMICAL", 30, 53], ["matrix", "CELLULAR_COMPONENT", 102, 108], ["NLRX1", "GENE_OR_GENE_PRODUCT", 125, 130], ["oxygen", "SIMPLE_CHEMICAL", 164, 170], ["matrix", "CELLULAR_COMPONENT", 208, 214], ["membrane", "CELLULAR_COMPONENT", 224, 232], ["NLRX1", "GENE_OR_GENE_PRODUCT", 237, 242], ["MAVS", "GENE_OR_GENE_PRODUCT", 245, 249], ["MAVS", "GENE_OR_GENE_PRODUCT", 328, 332], ["NLRX1", "GENE_OR_GENE_PRODUCT", 337, 342], ["complex III", "PROTEIN", 3, 14], ["NLRX1", "PROTEIN", 125, 130], ["NLRX1", "PROTEIN", 237, 242], ["MAVS regulator", "PROTEIN", 245, 259], ["MAVS", "PROTEIN", 328, 332], ["NLRX1", "PROTEIN", 337, 342], ["reactive oxygen species production", "PROBLEM", 30, 64], ["reactive oxygen signaling", "PROBLEM", 155, 180], ["MAVS", "TEST", 328, 332], ["reactive", "OBSERVATION_MODIFIER", 30, 38], ["oxygen species production", "OBSERVATION", 39, 64], ["reactive", "OBSERVATION_MODIFIER", 155, 163], ["oxygen signaling", "OBSERVATION", 164, 180], ["strong", "OBSERVATION_MODIFIER", 416, 422], ["interaction", "OBSERVATION", 423, 434]]], ["As noted by Arnoult et al. (2009), there is likely to be considerable physical distances between the NACHT domain of NLRX1 and the CARD domain of MAVS under normal physiological conditions, even at points where the inner and outer mitochondrial membranes are closely apposed.", [["inner", "ANATOMY", 215, 220], ["mitochondrial membranes", "ANATOMY", 231, 254], ["NLRX1", "GENE_OR_GENE_PRODUCT", 117, 122], ["MAVS", "GENE_OR_GENE_PRODUCT", 146, 150], ["inner", "CELLULAR_COMPONENT", 215, 220], ["outer", "CELLULAR_COMPONENT", 225, 230], ["mitochondrial membranes", "CELLULAR_COMPONENT", 231, 254], ["NACHT domain", "PROTEIN", 101, 113], ["NLRX1", "PROTEIN", 117, 122], ["CARD domain", "PROTEIN", 131, 142], ["MAVS", "PROTEIN", 146, 150], ["NLRX1", "TREATMENT", 117, 122], ["the inner and outer mitochondrial membranes", "TREATMENT", 211, 254], ["likely to be", "UNCERTAINTY", 44, 56], ["MAVS", "OBSERVATION", 146, 150], ["normal physiological conditions", "OBSERVATION", 157, 188], ["inner", "ANATOMY_MODIFIER", 215, 220], ["outer", "ANATOMY_MODIFIER", 225, 230], ["mitochondrial membranes", "ANATOMY", 231, 254]]], ["Further work will be required to understand if there is a change in NLRX1 localization under stressful conditions that would allow this molecular interaction to occur.Other mitochondrial proteins and pathways in the innate immune systemTwo other mitochondrial proteins have recently been linked to innate immunity (Fig. 2).", [["mitochondrial", "ANATOMY", 173, 186], ["mitochondrial", "ANATOMY", 246, 259], ["NLRX1", "GENE_OR_GENE_PRODUCT", 68, 73], ["mitochondrial", "CELLULAR_COMPONENT", 173, 186], ["mitochondrial", "CELLULAR_COMPONENT", 246, 259], ["NLRX1", "PROTEIN", 68, 73], ["mitochondrial proteins", "PROTEIN", 173, 195], ["mitochondrial proteins", "PROTEIN", 246, 268], ["a change in NLRX1 localization", "PROBLEM", 56, 86], ["Other mitochondrial proteins", "TEST", 167, 195], ["mitochondrial proteins", "PROBLEM", 246, 268], ["mitochondrial proteins", "OBSERVATION", 173, 195]]], ["STING/MITA was discovered simultaneously by two independent groups, and has been shown to interact with both RIG-I and MAVS (Ishikawa and Barber, 2008, Zhong et al., 2008).", [["STING", "GENE_OR_GENE_PRODUCT", 0, 5], ["MITA", "GENE_OR_GENE_PRODUCT", 6, 10], ["RIG-I", "GENE_OR_GENE_PRODUCT", 109, 114], ["MAVS", "GENE_OR_GENE_PRODUCT", 119, 123], ["STING", "PROTEIN", 0, 5], ["MITA", "PROTEIN", 6, 10], ["RIG-I", "PROTEIN", 109, 114], ["MAVS", "PROTEIN", 119, 123]]], ["While both groups showed that it was required for downstream RLH-pathway signaling (by connecting upstream activator proteins like MAVS to downstream signaling kinases), and that it could activate reporter constructs for immune proteins like ISRE, they differed on the localization of the protein.", [["RLH", "GENE_OR_GENE_PRODUCT", 61, 64], ["MAVS", "GENE_OR_GENE_PRODUCT", 131, 135], ["ISRE", "GENE_OR_GENE_PRODUCT", 242, 246], ["RLH", "PROTEIN", 61, 64], ["upstream activator proteins", "PROTEIN", 98, 125], ["MAVS", "PROTEIN", 131, 135], ["downstream signaling kinases", "PROTEIN", 139, 167], ["reporter constructs", "DNA", 197, 216], ["immune proteins", "PROTEIN", 221, 236], ["ISRE", "PROTEIN", 242, 246], ["immune proteins like ISRE", "PROBLEM", 221, 246]]], ["Using similar techniques, the same protein was localized to mitochondria (MITA) and the endoplasmic reticulum (STING) by biochemical and microscopical analysis (Ishikawa and Barber, 2008, Zhong et al., 2008).", [["mitochondria", "ANATOMY", 60, 72], ["endoplasmic reticulum", "ANATOMY", 88, 109], ["mitochondria", "CELLULAR_COMPONENT", 60, 72], ["MITA", "GENE_OR_GENE_PRODUCT", 74, 78], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 88, 109], ["STING", "GENE_OR_GENE_PRODUCT", 111, 116], ["MITA", "PROTEIN", 74, 78], ["STING", "PROTEIN", 111, 116], ["microscopical analysis", "TEST", 137, 159], ["endoplasmic reticulum", "ANATOMY", 88, 109]]], ["Recent studies from two other groups have strengthened the case for the endoplasmic reticulum localization of STING/MITA (Sun et al., 2009, Castanier et al., in press); and it has been shown further that STING/MITA is involved in the response to intracellular viral DNA produced by herpes simplex-1 virus, where it translocates from the endoplasmic reticulum (with the signaling kinase TBK-1) to perinuclear vesicles during infection (Ishikawa et al., 2009).", [["endoplasmic reticulum", "ANATOMY", 72, 93], ["intracellular", "ANATOMY", 246, 259], ["endoplasmic reticulum", "ANATOMY", 337, 358], ["perinuclear vesicles", "ANATOMY", 396, 416], ["herpes simplex", "DISEASE", 282, 296], ["infection", "DISEASE", 424, 433], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 72, 93], ["STING", "GENE_OR_GENE_PRODUCT", 110, 115], ["MITA", "GENE_OR_GENE_PRODUCT", 116, 120], ["STING", "GENE_OR_GENE_PRODUCT", 204, 209], ["MITA", "GENE_OR_GENE_PRODUCT", 210, 214], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 246, 259], ["DNA", "CELLULAR_COMPONENT", 266, 269], ["herpes simplex-1 virus", "ORGANISM", 282, 304], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 337, 358], ["TBK-1", "GENE_OR_GENE_PRODUCT", 386, 391], ["perinuclear vesicles", "CELLULAR_COMPONENT", 396, 416], ["STING", "PROTEIN", 110, 115], ["MITA", "PROTEIN", 116, 120], ["STING", "PROTEIN", 204, 209], ["MITA", "PROTEIN", 210, 214], ["intracellular viral DNA", "DNA", 246, 269], ["signaling kinase TBK-1", "PROTEIN", 369, 391], ["herpes simplex-1 virus", "SPECIES", 282, 304], ["herpes simplex-1 virus", "SPECIES", 282, 304], ["Recent studies", "TEST", 0, 14], ["intracellular viral DNA", "PROBLEM", 246, 269], ["herpes simplex-1 virus", "PROBLEM", 282, 304], ["the signaling kinase TBK", "TEST", 365, 389], ["perinuclear vesicles during infection", "PROBLEM", 396, 433], ["viral DNA", "OBSERVATION", 260, 269], ["endoplasmic reticulum", "ANATOMY", 337, 358], ["perinuclear vesicles", "ANATOMY", 396, 416], ["infection", "OBSERVATION", 424, 433]]], ["While these data suggest that the endoplasmic reticulum localization of STING/MITA is correct, there are many regions of close apposition between this organelle and mitochondria, known as mitochondria-associated membranes (MAMs; Vance, 1990), which can make unequivocal findings difficult.", [["endoplasmic reticulum", "ANATOMY", 34, 55], ["organelle", "ANATOMY", 151, 160], ["mitochondria", "ANATOMY", 165, 177], ["mitochondria", "ANATOMY", 188, 200], ["membranes", "ANATOMY", 212, 221], ["MAMs", "ANATOMY", 223, 227], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 34, 55], ["STING", "GENE_OR_GENE_PRODUCT", 72, 77], ["MITA", "GENE_OR_GENE_PRODUCT", 78, 82], ["organelle", "CELLULAR_COMPONENT", 151, 160], ["mitochondria", "CELLULAR_COMPONENT", 165, 177], ["mitochondria", "CELLULAR_COMPONENT", 188, 200], ["membranes", "CELLULAR_COMPONENT", 212, 221], ["STING", "PROTEIN", 72, 77], ["MITA", "PROTEIN", 78, 82], ["close apposition", "OBSERVATION", 121, 137]]], ["It is likely that these MAMs are important regions for the interaction between MAVS and STING/MITA (Castanier et al., in press).Other mitochondrial proteins and pathways in the innate immune systemThe second protein implicated in regulating innate immunity is gC1qR, also known as p32, a receptor for the globular head component factor gC1.", [["mitochondrial", "ANATOMY", 134, 147], ["MAMs", "GENE_OR_GENE_PRODUCT", 24, 28], ["MAVS", "GENE_OR_GENE_PRODUCT", 79, 83], ["STING", "GENE_OR_GENE_PRODUCT", 88, 93], ["mitochondrial", "CELLULAR_COMPONENT", 134, 147], ["gC1qR", "GENE_OR_GENE_PRODUCT", 260, 265], ["p32", "GENE_OR_GENE_PRODUCT", 281, 284], ["gC1", "GENE_OR_GENE_PRODUCT", 336, 339], ["MAMs", "DNA", 24, 28], ["MAVS", "PROTEIN", 79, 83], ["STING", "PROTEIN", 88, 93], ["MITA", "PROTEIN", 94, 98], ["mitochondrial proteins", "PROTEIN", 134, 156], ["gC1qR", "PROTEIN", 260, 265], ["p32", "PROTEIN", 281, 284], ["globular head component factor", "PROTEIN", 305, 335], ["gC1", "PROTEIN", 336, 339], ["Other mitochondrial proteins", "TEST", 128, 156], ["is likely", "UNCERTAINTY", 3, 12], ["mitochondrial proteins", "OBSERVATION", 134, 156]]], ["Overexpression of gC1qR has been shown to inhibit RLH signaling and IFN-\u03b2 activation during Sendai virus infection, while knockdown of the endogenous protein by siRNA has the opposite effect (Xu et al., 2009).", [["gC1qR", "CHEMICAL", 18, 23], ["Sendai virus infection", "DISEASE", 92, 114], ["gC1qR", "GENE_OR_GENE_PRODUCT", 18, 23], ["RLH", "GENE_OR_GENE_PRODUCT", 50, 53], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 68, 73], ["Sendai virus", "ORGANISM", 92, 104], ["gC1qR", "PROTEIN", 18, 23], ["RLH", "PROTEIN", 50, 53], ["IFN", "PROTEIN", 68, 71], ["endogenous protein", "PROTEIN", 139, 157], ["Sendai virus", "SPECIES", 92, 104], ["Sendai virus", "SPECIES", 92, 104], ["RLH signaling", "PROBLEM", 50, 63], ["IFN-\u03b2 activation", "PROBLEM", 68, 84], ["Sendai virus infection", "PROBLEM", 92, 114]]], ["The authors show that the inhibition of RLH signaling occurs via the binding of gC1qR to MAVS at the outer mitochondrial membrane (Xu et al., 2009), presumably in a similar manner to that postulated for MAVS regulation by NLRX1 (Moore et al., 2008).", [["outer mitochondrial membrane", "ANATOMY", 101, 129], ["RLH", "GENE_OR_GENE_PRODUCT", 40, 43], ["gC1qR", "GENE_OR_GENE_PRODUCT", 80, 85], ["MAVS", "GENE_OR_GENE_PRODUCT", 89, 93], ["outer", "CELLULAR_COMPONENT", 101, 106], ["mitochondrial membrane", "CELLULAR_COMPONENT", 107, 129], ["MAVS", "GENE_OR_GENE_PRODUCT", 203, 207], ["NLRX1", "GENE_OR_GENE_PRODUCT", 222, 227], ["RLH", "PROTEIN", 40, 43], ["gC1qR", "PROTEIN", 80, 85], ["MAVS", "PROTEIN", 89, 93], ["MAVS", "PROTEIN", 203, 207], ["NLRX1", "PROTEIN", 222, 227], ["RLH signaling", "PROBLEM", 40, 53], ["RLH", "OBSERVATION", 40, 43], ["outer", "ANATOMY_MODIFIER", 101, 106], ["mitochondrial membrane", "ANATOMY", 107, 129]]], ["However, several previous papers have shown that gC1qR is imported into the mitochondrial matrix using a N-terminal localization sequence (Muta et al., 1997, Dedio et al., 1998), which would keep it away from MAVS under physiological conditions.", [["mitochondrial matrix", "ANATOMY", 76, 96], ["N", "CHEMICAL", 105, 106], ["gC1qR", "GENE_OR_GENE_PRODUCT", 49, 54], ["mitochondrial matrix", "CELLULAR_COMPONENT", 76, 96], ["MAVS", "GENE_OR_GENE_PRODUCT", 209, 213], ["gC1qR", "PROTEIN", 49, 54], ["N-terminal localization sequence", "PROTEIN", 105, 137], ["MAVS", "PROTEIN", 209, 213]]], ["As with NLRX1, more work is required to further elucidate the connection between this protein and the RLH pathway.Mitochondrial dynamics and innate immunity \u2013 where form meets functionA new avenue of research in this growing field is the interplay between mitochondrial morphology and the innate immune system.", [["Mitochondrial", "ANATOMY", 114, 127], ["mitochondrial", "ANATOMY", 256, 269], ["NLRX1", "GENE_OR_GENE_PRODUCT", 8, 13], ["RLH", "GENE_OR_GENE_PRODUCT", 102, 105], ["Mitochondrial", "CELLULAR_COMPONENT", 114, 127], ["mitochondrial", "CELLULAR_COMPONENT", 256, 269], ["NLRX1", "PROTEIN", 8, 13], ["RLH", "PROTEIN", 102, 105], ["Mitochondrial dynamics", "PROBLEM", 114, 136], ["new", "OBSERVATION_MODIFIER", 186, 189]]], ["Mitochondria are dynamic organelles, undergoing constant fission and fusion in many cell types, and a balance between these two processes controls the overall mitochondrial morphology in any individual cell (for review, see Suen et al., 2008).", [["Mitochondria", "ANATOMY", 0, 12], ["organelles", "ANATOMY", 25, 35], ["cell", "ANATOMY", 84, 88], ["mitochondrial", "ANATOMY", 159, 172], ["cell", "ANATOMY", 202, 206], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["organelles", "CELLULAR_COMPONENT", 25, 35], ["cell", "CELL", 84, 88], ["mitochondrial", "CELLULAR_COMPONENT", 159, 172], ["cell", "CELL", 202, 206], ["Mitochondria", "CELL_TYPE", 0, 12], ["dynamic organelles", "PROBLEM", 17, 35], ["constant fission", "TREATMENT", 48, 64], ["fusion", "TREATMENT", 69, 75], ["dynamic organelles", "OBSERVATION", 17, 35], ["cell types", "OBSERVATION", 84, 94]]], ["A recent study has shown that there is an interaction between MAVS and Mfn2, a dynamin-like GTPase involved in mitochondrial fusion (Yasukawa et al., 2009), demonstrating the first potential connection between mitochondrial morphology and immunity.", [["mitochondrial", "ANATOMY", 111, 124], ["mitochondrial", "ANATOMY", 210, 223], ["MAVS", "GENE_OR_GENE_PRODUCT", 62, 66], ["Mfn2", "GENE_OR_GENE_PRODUCT", 71, 75], ["dynamin", "GENE_OR_GENE_PRODUCT", 79, 86], ["mitochondrial", "CELLULAR_COMPONENT", 111, 124], ["mitochondrial", "CELLULAR_COMPONENT", 210, 223], ["MAVS", "PROTEIN", 62, 66], ["Mfn2", "PROTEIN", 71, 75], ["dynamin", "PROTEIN", 79, 86], ["GTPase", "PROTEIN", 92, 98], ["A recent study", "TEST", 0, 14], ["an interaction between MAVS", "PROBLEM", 39, 66], ["Mfn2", "PROBLEM", 71, 75], ["a dynamin-like GTPase", "PROBLEM", 77, 98], ["mitochondrial fusion", "TREATMENT", 111, 131], ["mitochondrial fusion", "OBSERVATION", 111, 131], ["mitochondrial morphology", "OBSERVATION", 210, 234]]], ["Overexpression of Mfn2 blocked MAVS signaling, while knockdown of the endogenous protein increased interferon production during viral infection, indicating that Mfn2 may act as a negative regulator of the RLH pathway.", [["viral infection", "DISEASE", 128, 143], ["Mfn2", "GENE_OR_GENE_PRODUCT", 18, 22], ["MAVS", "GENE_OR_GENE_PRODUCT", 31, 35], ["interferon", "GENE_OR_GENE_PRODUCT", 99, 109], ["Mfn2", "GENE_OR_GENE_PRODUCT", 161, 165], ["RLH", "GENE_OR_GENE_PRODUCT", 205, 208], ["Mfn2", "PROTEIN", 18, 22], ["MAVS", "PROTEIN", 31, 35], ["endogenous protein", "PROTEIN", 70, 88], ["interferon", "PROTEIN", 99, 109], ["Mfn2", "PROTEIN", 161, 165], ["RLH", "PROTEIN", 205, 208], ["Mfn2 blocked MAVS signaling", "PROBLEM", 18, 45], ["the endogenous protein increased interferon production", "PROBLEM", 66, 120], ["viral infection", "PROBLEM", 128, 143], ["Mfn2", "PROBLEM", 161, 165], ["endogenous protein", "OBSERVATION", 70, 88], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["interferon production", "OBSERVATION", 99, 120], ["viral infection", "OBSERVATION", 128, 143]]], ["However, the authors suggested that the Mfn2-MAVS link may be separate from the role of Mfn2 in mitochondrial fusion (Yasukawa et al., 2009).Mitochondrial dynamics and innate immunity \u2013 where form meets functionA more direct link between the two processes comes from an elegant study by Castanier et al. (2009), which found that activation of the RLH signaling pathway led to mitochondrial elongation.", [["mitochondrial", "ANATOMY", 96, 109], ["Mitochondrial", "ANATOMY", 141, 154], ["mitochondrial", "ANATOMY", 376, 389], ["Mfn2", "GENE_OR_GENE_PRODUCT", 40, 44], ["MAVS", "GENE_OR_GENE_PRODUCT", 45, 49], ["Mfn2", "GENE_OR_GENE_PRODUCT", 88, 92], ["mitochondrial", "CELLULAR_COMPONENT", 96, 109], ["Mitochondrial", "CELLULAR_COMPONENT", 141, 154], ["RLH", "GENE_OR_GENE_PRODUCT", 347, 350], ["mitochondrial", "CELLULAR_COMPONENT", 376, 389], ["Mfn2", "PROTEIN", 40, 44], ["MAVS", "PROTEIN", 45, 49], ["Mfn2", "PROTEIN", 88, 92], ["RLH", "PROTEIN", 347, 350], ["mitochondrial fusion", "TREATMENT", 96, 116], ["the RLH signaling pathway", "PROBLEM", 343, 368], ["mitochondrial elongation", "PROBLEM", 376, 400], ["mitochondrial fusion", "OBSERVATION", 96, 116], ["mitochondrial elongation", "OBSERVATION", 376, 400]]], ["Altering mitochondrial morphology, by down-regulating mitochondrial fission and fusion genes using RNAi, regulated the antiviral response to Sendai virus infection.", [["mitochondrial", "ANATOMY", 9, 22], ["mitochondrial", "ANATOMY", 54, 67], ["Sendai virus infection", "DISEASE", 141, 163], ["mitochondrial", "CELLULAR_COMPONENT", 9, 22], ["mitochondrial", "CELLULAR_COMPONENT", 54, 67], ["Sendai virus", "ORGANISM", 141, 153], ["fusion genes", "DNA", 80, 92], ["Sendai virus", "SPECIES", 141, 153], ["Sendai virus", "SPECIES", 141, 153], ["Altering mitochondrial morphology", "PROBLEM", 0, 33], ["mitochondrial fission", "TREATMENT", 54, 75], ["fusion genes", "TREATMENT", 80, 92], ["RNAi", "TREATMENT", 99, 103], ["Sendai virus infection", "PROBLEM", 141, 163], ["mitochondrial morphology", "OBSERVATION", 9, 33], ["mitochondrial fission", "OBSERVATION", 54, 75], ["fusion genes", "OBSERVATION", 80, 92], ["Sendai virus", "OBSERVATION", 141, 153]]], ["In cells with depleted mitochondrial fission (which led to elongated mitochondria), there was enhanced activation of the IFN-\u03b2 and NF-\u03baB promoters during infection; conversely, in cells with fragmented mitochondria (caused by the down-regulation of mitochondrial fusion genes), the antiviral response to infection was attenuated (Castanier et al., in press).", [["cells", "ANATOMY", 3, 8], ["mitochondrial", "ANATOMY", 23, 36], ["mitochondria", "ANATOMY", 69, 81], ["cells", "ANATOMY", 180, 185], ["mitochondria", "ANATOMY", 202, 214], ["mitochondrial", "ANATOMY", 249, 262], ["infection", "DISEASE", 154, 163], ["infection", "DISEASE", 304, 313], ["cells", "CELL", 3, 8], ["mitochondrial", "CELLULAR_COMPONENT", 23, 36], ["mitochondria", "CELLULAR_COMPONENT", 69, 81], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 121, 126], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 131, 136], ["cells", "CELL", 180, 185], ["mitochondria", "CELLULAR_COMPONENT", 202, 214], ["mitochondrial", "CELLULAR_COMPONENT", 249, 262], ["IFN-\u03b2 and NF-\u03baB promoters", "DNA", 121, 146], ["mitochondrial fusion genes", "DNA", 249, 275], ["depleted mitochondrial fission", "PROBLEM", 14, 44], ["elongated mitochondria", "PROBLEM", 59, 81], ["the IFN", "TEST", 117, 124], ["NF", "TEST", 131, 133], ["infection", "PROBLEM", 154, 163], ["fragmented mitochondria", "PROBLEM", 191, 214], ["mitochondrial fusion genes", "TREATMENT", 249, 275], ["infection", "PROBLEM", 304, 313], ["depleted mitochondrial fission", "OBSERVATION", 14, 44], ["infection", "OBSERVATION", 154, 163], ["infection", "OBSERVATION", 304, 313]]], ["The authors further showed that MAVS interacts with, and may regulate, the function of a mitochondrial fusion protein, Mfn1 (a homologue of Mfn2), and that this may be the cause of the observed mitochondrial elongation during infection.", [["mitochondrial", "ANATOMY", 89, 102], ["mitochondrial", "ANATOMY", 194, 207], ["infection", "DISEASE", 226, 235], ["MAVS", "GENE_OR_GENE_PRODUCT", 32, 36], ["mitochondrial", "CELLULAR_COMPONENT", 89, 102], ["Mfn1", "GENE_OR_GENE_PRODUCT", 119, 123], ["Mfn2", "GENE_OR_GENE_PRODUCT", 140, 144], ["mitochondrial", "CELLULAR_COMPONENT", 194, 207], ["MAVS", "PROTEIN", 32, 36], ["mitochondrial fusion protein", "PROTEIN", 89, 117], ["Mfn1", "PROTEIN", 119, 123], ["Mfn2", "PROTEIN", 140, 144], ["a mitochondrial fusion protein", "TREATMENT", 87, 117], ["the observed mitochondrial elongation during infection", "PROBLEM", 181, 235], ["mitochondrial elongation", "OBSERVATION", 194, 218], ["infection", "OBSERVATION", 226, 235]]], ["Finally, it was demonstrated that the change in mitochondrial morphology aided the interaction between MAVS and STING/MITA on the endoplasmic reticulum, suggesting that the elongation promotes the physical interaction of the two organelles during the antiviral response (Castanier et al., in press).", [["mitochondrial", "ANATOMY", 48, 61], ["endoplasmic reticulum", "ANATOMY", 130, 151], ["organelles", "ANATOMY", 229, 239], ["mitochondrial", "CELLULAR_COMPONENT", 48, 61], ["MAVS", "GENE_OR_GENE_PRODUCT", 103, 107], ["STING", "GENE_OR_GENE_PRODUCT", 112, 117], ["MITA", "GENE_OR_GENE_PRODUCT", 118, 122], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 130, 151], ["organelles", "CELLULAR_COMPONENT", 229, 239], ["MAVS", "PROTEIN", 103, 107], ["STING", "PROTEIN", 112, 117], ["MITA", "PROTEIN", 118, 122], ["the change in mitochondrial morphology", "PROBLEM", 34, 72], ["the elongation", "PROBLEM", 169, 183], ["mitochondrial morphology", "OBSERVATION", 48, 72], ["endoplasmic reticulum", "ANATOMY", 130, 151], ["elongation", "OBSERVATION_MODIFIER", 173, 183]]], ["In summary, it is clear that mitochondrial dynamics may play an important part in MAVS function, and it is likely that we have much more to learn about the role of mitochondrial morphology in this regard.ConclusionsPrior to the discovery of MAVS, the closest links between mitochondria and the innate immune system came from mitochondrial involvement in apoptosis and reactive oxygen species production.", [["mitochondrial", "ANATOMY", 29, 42], ["mitochondrial", "ANATOMY", 164, 177], ["mitochondria", "ANATOMY", 273, 285], ["mitochondrial", "ANATOMY", 325, 338], ["oxygen", "CHEMICAL", 377, 383], ["mitochondrial", "CELLULAR_COMPONENT", 29, 42], ["MAVS", "GENE_OR_GENE_PRODUCT", 82, 86], ["mitochondrial", "CELLULAR_COMPONENT", 164, 177], ["MAVS", "GENE_OR_GENE_PRODUCT", 241, 245], ["mitochondria", "CELLULAR_COMPONENT", 273, 285], ["mitochondrial", "CELLULAR_COMPONENT", 325, 338], ["reactive oxygen species", "SIMPLE_CHEMICAL", 368, 391], ["MAVS", "PROTEIN", 82, 86], ["MAVS", "PROTEIN", 241, 245], ["mitochondrial dynamics", "PROBLEM", 29, 51], ["MAVS", "PROBLEM", 241, 245], ["apoptosis", "PROBLEM", 354, 363], ["reactive oxygen species production", "PROBLEM", 368, 402], ["reactive", "OBSERVATION_MODIFIER", 368, 376], ["oxygen species", "OBSERVATION", 377, 391]]], ["However, it is now clear that mitochondria are more intimately linked to antiviral defenses than these important, yet slightly indirect processes.", [["mitochondria", "ANATOMY", 30, 42], ["mitochondria", "CELLULAR_COMPONENT", 30, 42], ["slightly indirect processes", "PROBLEM", 118, 145], ["clear", "OBSERVATION", 19, 24]]], ["With MAVS and STING/MITA, we have direct and integral members of a crucial innate immune signaling pathway localized at the mitochondria; while the data on NLRX1 shows that a NOD protein (from a family that is involved in the immune systems of both plants and animals; Janeway and Medzhitov, 2002) has evolved to use mitochondria as a specific reactive oxygen species-producing factory to aid anti-microbial defenses.", [["mitochondria", "ANATOMY", 124, 136], ["mitochondria", "ANATOMY", 317, 329], ["oxygen", "CHEMICAL", 353, 359], ["oxygen", "CHEMICAL", 353, 359], ["MAVS", "GENE_OR_GENE_PRODUCT", 5, 9], ["STING", "GENE_OR_GENE_PRODUCT", 14, 19], ["mitochondria", "CELLULAR_COMPONENT", 124, 136], ["NLRX1", "GENE_OR_GENE_PRODUCT", 156, 161], ["NOD", "GENE_OR_GENE_PRODUCT", 175, 178], ["mitochondria", "CELLULAR_COMPONENT", 317, 329], ["reactive oxygen species", "SIMPLE_CHEMICAL", 344, 367], ["MAVS", "PROTEIN", 5, 9], ["STING", "PROTEIN", 14, 19], ["MITA", "PROTEIN", 20, 24], ["NLRX1", "PROTEIN", 156, 161], ["NOD protein", "PROTEIN", 175, 186], ["MAVS", "PROBLEM", 5, 9], ["a NOD protein", "PROBLEM", 173, 186], ["a specific reactive oxygen species", "PROBLEM", 333, 367], ["reactive", "OBSERVATION_MODIFIER", 344, 352], ["oxygen species", "OBSERVATION", 353, 367]]], ["It will be interesting to see if there are other aspects of mitochondrial biology involved in the innate immune system, either involving the discovery of new mitochondrial proteins, or by finding a role for known mitochondrial processes in novel immune pathways.", [["mitochondrial", "ANATOMY", 60, 73], ["mitochondrial", "ANATOMY", 158, 171], ["mitochondrial", "ANATOMY", 213, 226], ["mitochondrial", "CELLULAR_COMPONENT", 60, 73], ["mitochondrial", "CELLULAR_COMPONENT", 158, 171], ["mitochondrial", "CELLULAR_COMPONENT", 213, 226], ["mitochondrial proteins", "PROTEIN", 158, 180], ["new mitochondrial proteins", "PROBLEM", 154, 180], ["known mitochondrial processes", "PROBLEM", 207, 236], ["mitochondrial processes", "OBSERVATION", 213, 236]]]], "d33b4c790ab41862a0099663523b8e1916731525": [["BackgroundRift Valley Fever virus (RVFV) is an arbovirus, mainly transmitted by mosquitoes, responsible for a zoonosis disease that affects cattle, sheep, camels and goats.", [["Rift Valley Fever", "DISEASE", 10, 27], ["arbovirus, mainly transmitted by mosquitoes", "DISEASE", 47, 90], ["zoonosis disease", "DISEASE", 110, 126], ["Background", "ORGANISM", 0, 10], ["Rift Valley Fever virus", "ORGANISM", 10, 33], ["RVFV", "ORGANISM", 35, 39], ["cattle", "ORGANISM", 140, 146], ["sheep", "ORGANISM", 148, 153], ["camels", "ORGANISM_SUBDIVISION", 155, 161], ["goats", "ORGANISM", 166, 171], ["Rift Valley Fever virus", "SPECIES", 10, 33], ["cattle", "SPECIES", 140, 146], ["sheep", "SPECIES", 148, 153], ["goats", "SPECIES", 166, 171], ["Rift Valley Fever virus", "SPECIES", 10, 33], ["RVFV", "SPECIES", 35, 39], ["cattle", "SPECIES", 140, 146], ["sheep", "SPECIES", 148, 153], ["goats", "SPECIES", 166, 171], ["BackgroundRift Valley Fever virus (RVFV", "PROBLEM", 0, 39], ["an arbovirus", "PROBLEM", 44, 56], ["a zoonosis disease", "PROBLEM", 108, 126], ["Rift", "OBSERVATION_MODIFIER", 10, 14], ["arbovirus", "OBSERVATION", 47, 56]]], ["It was first identified in 1931 during an investigation into an epidemic among sheep on a farm in the Rift Valley of Kenya [1] .", [["sheep", "ORGANISM", 79, 84], ["sheep", "SPECIES", 79, 84], ["sheep", "SPECIES", 79, 84], ["an investigation", "TEST", 39, 55]]], ["The virus infects also humans through inoculation after contact with infected animals or through ingestion of unpasteurized or uncooked by-products of infected animals, or also through inhalation of aerosols produced during the slaughter of infected animals.", [["humans", "ORGANISM", 23, 29], ["humans", "SPECIES", 23, 29], ["humans", "SPECIES", 23, 29], ["The virus infects", "PROBLEM", 0, 17], ["virus infects", "OBSERVATION", 4, 17], ["inoculation", "OBSERVATION_MODIFIER", 38, 49], ["infected", "OBSERVATION", 151, 159], ["infected", "OBSERVATION", 241, 249]]], ["However, human infections occurred also from the bites of infected mosquitoes, mainly Aedes and Culex but also Anopheles or Mansonia, and other blood-feeding vectors such as flies and ticks have been identified [2] [3] [4] .", [["blood", "ANATOMY", 144, 149], ["infections", "DISEASE", 15, 25], ["infected mosquitoes", "DISEASE", 58, 77], ["human", "ORGANISM", 9, 14], ["mosquitoes", "ORGANISM", 67, 77], ["Mansonia", "ORGANISM", 124, 132], ["blood", "ORGANISM_SUBSTANCE", 144, 149], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 211, 222], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["human infections", "PROBLEM", 9, 25], ["infected mosquitoes", "PROBLEM", 58, 77], ["Mansonia", "PROBLEM", 124, 132], ["other blood-feeding vectors", "TREATMENT", 138, 165], ["infections", "OBSERVATION", 15, 25], ["infected", "OBSERVATION", 58, 66]]], ["To date, no human-to-human transmission of RVFV has been documented.BackgroundRVFV belongs to the Phenuiviridae family (formerly Bunyaviridae), member of the phlebovirus genus.", [["RVFV", "DISEASE", 43, 47], ["human", "ORGANISM", 12, 17], ["human", "ORGANISM", 21, 26], ["RVFV", "ORGANISM", 43, 47], ["BackgroundRVFV", "GENE_OR_GENE_PRODUCT", 68, 82], ["Phenuiviridae", "GENE_OR_GENE_PRODUCT", 98, 111], ["phlebovirus genus", "ORGANISM", 158, 175], ["BackgroundRVFV", "PROTEIN", 68, 82], ["Phenuiviridae family", "PROTEIN", 98, 118], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 21, 26], ["RVFV", "SPECIES", 43, 47], ["RVFV", "PROBLEM", 43, 47], ["the phlebovirus genus", "PROBLEM", 154, 175], ["phlebovirus genus", "ANATOMY", 158, 175]]], ["The enveloped virion contains a tripartite, predominantly negative-sense, single-stranded RNA genome, which codes for structural and non-structural proteins the virus needs to replicate both in mammalian hosts and insect vectors.", [["mammalian hosts", "ORGANISM", 194, 209], ["tripartite, predominantly negative-sense, single-stranded RNA genome", "DNA", 32, 100], ["structural and non-structural proteins", "PROTEIN", 118, 156], ["single-stranded RNA genome", "PROBLEM", 74, 100], ["structural and non-structural proteins the virus", "PROBLEM", 118, 166], ["enveloped virion", "OBSERVATION", 4, 20], ["predominantly", "OBSERVATION_MODIFIER", 44, 57], ["negative", "OBSERVATION", 58, 66]]], ["RVFV attach to cells via the interaction between the viral structural proteins Gn and Gc and C-type lectins, DC-SIGN and I-SIGN [5] .", [["cells", "ANATOMY", 15, 20], ["RVFV", "ORGANISM", 0, 4], ["cells", "CELL", 15, 20], ["Gn", "GENE_OR_GENE_PRODUCT", 79, 81], ["Gc", "GENE_OR_GENE_PRODUCT", 86, 88], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 93, 107], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 109, 116], ["I-SIGN", "GENE_OR_GENE_PRODUCT", 121, 127], ["viral structural proteins", "PROTEIN", 53, 78], ["Gn", "PROTEIN", 79, 81], ["Gc", "PROTEIN", 86, 88], ["C-type lectins", "PROTEIN", 93, 107], ["DC", "PROTEIN", 109, 111], ["SIGN", "PROTEIN", 112, 116], ["SIGN", "PROTEIN", 123, 127], ["RVFV", "SPECIES", 0, 4], ["the interaction", "PROBLEM", 25, 40], ["the viral structural proteins", "TEST", 49, 78], ["Gn", "TEST", 79, 81], ["Gc", "TEST", 86, 88], ["viral structural", "OBSERVATION", 53, 69], ["proteins Gn", "OBSERVATION", 70, 81]]], ["Cells become infected with RVFV by receptor-mediated endocytosis, followed by pH-mediated fusion of virus-endosomal membranes to release nucleocapsids into the cell cytoplasm.", [["Cells", "ANATOMY", 0, 5], ["endosomal membranes", "ANATOMY", 106, 125], ["nucleocapsids", "ANATOMY", 137, 150], ["cell cytoplasm", "ANATOMY", 160, 174], ["Cells", "CELL", 0, 5], ["RVFV", "ORGANISM", 27, 31], ["endosomal membranes", "CELLULAR_COMPONENT", 106, 125], ["nucleocapsids", "CELLULAR_COMPONENT", 137, 150], ["cell", "CELLULAR_COMPONENT", 160, 164], ["cytoplasm", "ORGANISM_SUBSTANCE", 165, 174], ["RVFV", "SPECIES", 27, 31], ["infected", "PROBLEM", 13, 21], ["RVFV", "PROBLEM", 27, 31], ["mediated endocytosis", "PROBLEM", 44, 64], ["pH-mediated fusion of virus", "TREATMENT", 78, 105], ["endosomal membranes", "TREATMENT", 106, 125], ["infected", "OBSERVATION", 13, 21], ["endocytosis", "OBSERVATION", 53, 64], ["endosomal membranes", "OBSERVATION", 106, 125], ["cell cytoplasm", "OBSERVATION", 160, 174]]], ["Transcription, translation, and genome replication occur in the cytoplasm.", [["cytoplasm", "ANATOMY", 64, 73], ["genome", "CELLULAR_COMPONENT", 32, 38], ["cytoplasm", "ORGANISM_SUBSTANCE", 64, 73], ["Transcription", "TREATMENT", 0, 13]]], ["The non-structural protein NSs is known to be a major virulence factor allowing the virus to escape host innate immune response.", [["NSs", "GENE_OR_GENE_PRODUCT", 27, 30], ["non-structural protein NSs", "PROTEIN", 4, 30], ["virulence factor", "PROTEIN", 54, 70], ["The non-structural protein NSs", "PROBLEM", 0, 30], ["a major virulence factor", "PROBLEM", 46, 70], ["non-structural protein NSs", "OBSERVATION", 4, 30]]], ["Only one serotype is recognized but strains exist of variable virulence.", [["variable virulence", "PROBLEM", 53, 71], ["one", "OBSERVATION_MODIFIER", 5, 8], ["serotype", "OBSERVATION", 9, 17], ["variable", "OBSERVATION_MODIFIER", 53, 61], ["virulence", "OBSERVATION", 62, 71]]], ["Moreover, RVFV is classified as a Risk Group 3 agent, and biosafetyAnnals of Clinical Microbiology and AntimicrobialsPage 2 of 18 Javelle et al. Ann Clin Microbiol Antimicrob (2020) 19:4 level (BSL)-3 containment requirements are needed to work with the virus in the laboratory [6] .", [["RVFV", "DISEASE", 10, 14], ["RVFV", "ORGANISM", 10, 14], ["RVFV", "SPECIES", 10, 14], ["RVFV", "PROBLEM", 10, 14]]], ["As other arboviral infections including dengue, chikungunya and zika, RVF is emerging worldwide, due to the globalization of arthropod vectors, mainly mosquitoes, which efficiently transmit an increasing number of old, unrecognized and new viruses.", [["arboviral infections", "DISEASE", 9, 29], ["dengue", "DISEASE", 40, 46], ["chikungunya", "DISEASE", 48, 59], ["zika", "DISEASE", 64, 68], ["RVF", "DISEASE", 70, 73], ["RVF", "SPECIES", 70, 73], ["other arboviral infections", "PROBLEM", 3, 29], ["dengue", "PROBLEM", 40, 46], ["chikungunya", "PROBLEM", 48, 59], ["zika", "PROBLEM", 64, 68], ["RVF", "PROBLEM", 70, 73], ["arthropod vectors", "TREATMENT", 125, 142], ["mainly mosquitoes", "PROBLEM", 144, 161], ["new viruses", "PROBLEM", 236, 247], ["arboviral", "OBSERVATION_MODIFIER", 9, 18], ["infections", "OBSERVATION", 19, 29], ["increasing", "OBSERVATION_MODIFIER", 193, 203], ["number", "OBSERVATION_MODIFIER", 204, 210], ["new", "OBSERVATION_MODIFIER", 236, 239], ["viruses", "OBSERVATION", 240, 247]]], ["Arboviruses pose a major threat of introduction to several continents, including Europe and North America, with the possibility of cocirculation [7] .", [["Arboviruses", "DISEASE", 0, 11], ["Arboviruses", "TREATMENT", 0, 11]]], ["The widespread presence of competent vectors, the high viral load in infected animals, trade and global travel, all increase the likelihood of RVFV exportation and establishment outside endemic regions [8] [9] [10] .", [["RVFV", "ORGANISM", 143, 147], ["RVFV", "SPECIES", 143, 147], ["competent vectors", "PROBLEM", 27, 44], ["the high viral load in infected animals", "PROBLEM", 46, 85], ["RVFV exportation", "TREATMENT", 143, 159], ["competent vectors", "OBSERVATION", 27, 44], ["high", "OBSERVATION_MODIFIER", 50, 54], ["viral load", "OBSERVATION", 55, 65], ["RVFV", "OBSERVATION", 143, 147]]], ["Such an introduction would cause significant losses to the livestock industry and substantial human morbidity and mortality [16] .", [["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["significant losses", "PROBLEM", 33, 51], ["substantial human morbidity", "PROBLEM", 82, 109]]], ["Clinicians need to consider RVF in the differential diagnosis for febrile illnesses in a suitable context, however manifestations of RVFV in humans are varied and unspecific including hepatitis, encephalitis, hemorrhagic disease, and retinitis with potential dramatic consequences.", [["RVF", "DISEASE", 28, 31], ["febrile illnesses", "DISEASE", 66, 83], ["RVFV", "DISEASE", 133, 137], ["hepatitis", "DISEASE", 184, 193], ["encephalitis", "DISEASE", 195, 207], ["hemorrhagic disease", "DISEASE", 209, 228], ["retinitis", "DISEASE", 234, 243], ["RVFV", "ORGANISM", 133, 137], ["humans", "ORGANISM", 141, 147], ["humans", "SPECIES", 141, 147], ["RVFV", "SPECIES", 133, 137], ["humans", "SPECIES", 141, 147], ["RVF", "PROBLEM", 28, 31], ["febrile illnesses", "PROBLEM", 66, 83], ["RVFV", "PROBLEM", 133, 137], ["hepatitis", "PROBLEM", 184, 193], ["encephalitis", "PROBLEM", 195, 207], ["hemorrhagic disease", "PROBLEM", 209, 228], ["retinitis", "PROBLEM", 234, 243], ["potential dramatic consequences", "PROBLEM", 249, 280], ["RVFV", "OBSERVATION", 133, 137], ["hepatitis", "OBSERVATION", 184, 193], ["encephalitis", "OBSERVATION", 195, 207], ["hemorrhagic", "OBSERVATION_MODIFIER", 209, 220], ["retinitis", "OBSERVATION", 234, 243], ["dramatic", "OBSERVATION_MODIFIER", 259, 267]]], ["The overall case fatality rate is estimated from 0.5 to 2% [8, 17] , but higher mortality rates were recorded, as for example 18% by the Saudi Health Ministry in 2000 [18] , around 22% in East Africa, West Africa, South Africa and Madagascar from 2006 to 2010 [16] , and 28% in Tanzania in 2007 [19] .Annals of Clinical Microbiology and AntimicrobialsIn 2019 RVFV emerged in Mayotte, a French overseas department and region and gave growth to this work [20] .", [["RVFV", "DISEASE", 359, 363], ["RVFV", "SPECIES", 359, 363]]], ["Strategies of RVFV control appeared us challenging because of its complex biological cycle and its multiple routes of transmission to humans [21] .", [["RVFV", "ORGANISM", 14, 18], ["humans", "ORGANISM", 134, 140], ["humans", "SPECIES", 134, 140], ["RVFV", "SPECIES", 14, 18], ["humans", "SPECIES", 134, 140], ["RVFV control", "TREATMENT", 14, 26], ["RVFV", "OBSERVATION", 14, 18]]], ["Besides, the wide clinical spectrum over a long-period of time made very difficult the establishment of standard definitions of human cases and recommendations for their management.", [["human", "ORGANISM", 128, 133], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["their management", "TREATMENT", 164, 180], ["wide", "OBSERVATION_MODIFIER", 13, 17]]], ["We conducted a literature review on the RVF clinical disease and treatments in humans.", [["RVF", "DISEASE", 40, 43], ["humans", "ORGANISM", 79, 85], ["humans", "SPECIES", 79, 85], ["humans", "SPECIES", 79, 85], ["the RVF clinical disease", "PROBLEM", 36, 60]]], ["Lacking guidelines on the RVF human disease, we proposed an algorithm to assist physicians on the field in the evaluation of cases.", [["RVF human disease", "DISEASE", 26, 43], ["human", "ORGANISM", 30, 35], ["human", "SPECIES", 30, 35], ["RVF human", "SPECIES", 26, 35], ["the RVF human disease", "PROBLEM", 22, 43], ["the evaluation", "TEST", 107, 121]]], ["This algorithm could help and be improved during next epidemics.MethodsWe based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to conduct this clinical review and build the flow diagram ( Fig. 1) [22] .MethodsWe did a literature search for English and French language studies published in electronic databases for an unlimited period until December, 2019: PubMed Central, Embase, Medline and Scopus.", [["Systematic Reviews", "TEST", 113, 131], ["French language studies", "TEST", 295, 318]]], ["We used the keywords \"rift valley fever\" and \"human\".", [["fever", "DISEASE", 34, 39], ["human", "ORGANISM", 46, 51], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["fever", "PROBLEM", 34, 39]]], ["Along with this, we conducted targeted search within the online archives of journals of tropical medicine, which published the first clinical reports of RVF in humans since 1930s, i.e.", [["RVF", "DISEASE", 153, 156], ["RVF", "ORGANISM", 153, 156], ["humans", "ORGANISM", 160, 166], ["humans", "SPECIES", 160, 166], ["RVF", "SPECIES", 153, 156], ["humans", "SPECIES", 160, 166], ["tropical medicine", "TREATMENT", 88, 105], ["RVF", "PROBLEM", 153, 156], ["RVF", "OBSERVATION", 153, 156]]], ["\"South African Medical Journal\" and \"Transaction of the Royal Society of Tropical Medicine and Hygiene\".", [["Tropical Medicine", "TREATMENT", 73, 90]]], ["Besides, we consulted the databases, datasets and official reports of the World Health Organization (WHO) and the Centre for Disease Control (CDC) on their official websites and the mentioned references.MethodsWe removed duplicates and screened titles and abstracts of all these records to include manuscripts reporting clinical descriptions and/or treatments of RVF in humans (case reports and case series).", [["RVF", "DISEASE", 363, 366], ["humans", "ORGANISM", 370, 376], ["humans", "SPECIES", 370, 376], ["humans", "SPECIES", 370, 376], ["RVF", "PROBLEM", 363, 366], ["RVF", "OBSERVATION", 363, 366]]], ["Animal models for RVFV pathogenicity studies published during the last 10 years were also considered.", [["RVFV", "ORGANISM", 18, 22], ["RVFV", "SPECIES", 18, 22], ["Animal models", "TEST", 0, 13], ["RVFV pathogenicity studies", "PROBLEM", 18, 44]]], ["Serological surveys, works on vaccines, immunology, biology, veterinary science and entomology were excluded.MethodsTotally, 129 articles resulting from these searches with full-text available were assessed for eligibility.", [["Serological surveys", "TEST", 0, 19], ["these searches", "TEST", 153, 167]]], ["Among them, 35 with uncertain RVF diagnosis or without significant content or input were removed.MethodsRelevant references cited in the eligible articles were reviewed and other records were manually searched and added for specific purposes of our article using the following terms \"Rift Valley Fever\" and \"severity\", \"severe\", \"prognosis\", \"death\", \"fatal\", \"risk factors\" and \"scores\".", [["RVF", "DISEASE", 30, 33], ["Fever", "DISEASE", 296, 301], ["death", "DISEASE", 343, 348], ["significant content", "PROBLEM", 55, 74], ["Valley Fever", "PROBLEM", 289, 301]]], ["At the end, 107 articles were referenced in the final review ( Fig. 1) .MethodsWe used data on RVF human cases reported by the WHO in the rubric \"disease outbreak news\" [23] and the CDC outbreak summaries [24] to build an epidemiological overview and we used the software Adobe Illustrator 22.1 and macrovector official freepik for figures.EpidemiologyHuman cases have been reported from many African countries following the virus introduction via infected livestock trade [25] .", [["human", "ORGANISM", 99, 104], ["Human", "ORGANISM", 352, 357], ["human", "SPECIES", 99, 104], ["Human", "SPECIES", 352, 357], ["human", "SPECIES", 99, 104], ["the virus introduction", "TREATMENT", 421, 443]]], ["Since the end of 1900s, the virus has extended outside the African continent to Indian Ocean Islands: Madagascar [26] , Comoros, and Mayotte [27] [28] [29] [32, 33] , but methods used to calculate this basic reproductive ratio have some limits [34] .The typical benign diseaseInfection with RVFV is mostly pauci-symptomatic in humans.", [["RVFV", "DISEASE", 291, 295], ["benign diseaseInfection", "CANCER", 262, 285], ["RVFV", "ORGANISM", 291, 295], ["humans", "ORGANISM", 327, 333], ["humans", "SPECIES", 327, 333], ["RVFV", "SPECIES", 291, 295], ["humans", "SPECIES", 327, 333], ["the virus", "PROBLEM", 24, 33], ["Comoros", "TEST", 120, 127], ["this basic reproductive ratio", "TEST", 197, 226], ["The typical benign diseaseInfection", "PROBLEM", 250, 285], ["RVFV", "PROBLEM", 291, 295], ["virus", "OBSERVATION", 28, 33], ["typical", "OBSERVATION_MODIFIER", 254, 261], ["benign", "OBSERVATION_MODIFIER", 262, 268], ["diseaseInfection", "OBSERVATION", 269, 285], ["RVFV", "OBSERVATION", 291, 295], ["mostly", "OBSERVATION_MODIFIER", 299, 305], ["pauci-symptomatic", "OBSERVATION_MODIFIER", 306, 323]]], ["General signs may occur in 50 to 95% of infected cases after an incubation period of 2 to 6 days.", [["General signs", "PROBLEM", 0, 13]]], ["The typical presentation includes headache, fever, backache and generalized aches in muscles and joints, lasting 4 to 7 days [4, 17, 35, 36] also reported [17, 37] .", [["muscles", "ANATOMY", 85, 92], ["joints", "ANATOMY", 97, 103], ["headache", "DISEASE", 34, 42], ["fever", "DISEASE", 44, 49], ["backache", "DISEASE", 51, 59], ["aches", "DISEASE", 76, 81], ["aches", "ORGANISM_SUBDIVISION", 76, 81], ["muscles", "ORGANISM_SUBDIVISION", 85, 92], ["joints", "MULTI-TISSUE_STRUCTURE", 97, 103], ["headache", "PROBLEM", 34, 42], ["fever", "PROBLEM", 44, 49], ["backache", "PROBLEM", 51, 59], ["generalized aches in muscles and joints", "PROBLEM", 64, 103], ["headache", "OBSERVATION", 34, 42], ["backache", "ANATOMY", 51, 59], ["generalized", "OBSERVATION_MODIFIER", 64, 75], ["aches", "OBSERVATION", 76, 81], ["muscles", "ANATOMY", 85, 92], ["joints", "ANATOMY", 97, 103]]], ["RVF differs from influenza, dengue and chikungunya as to whether cough, skin involvement (i.e. rash or pruritus) and arthritis are respectively uncommon signs.", [["skin", "ANATOMY", 72, 76], ["RVF", "DISEASE", 0, 3], ["influenza", "DISEASE", 17, 26], ["dengue", "DISEASE", 28, 34], ["chikungunya", "DISEASE", 39, 50], ["cough", "DISEASE", 65, 70], ["rash", "DISEASE", 95, 99], ["pruritus", "DISEASE", 103, 111], ["arthritis", "DISEASE", 117, 126], ["skin", "ORGAN", 72, 76], ["dengue", "SPECIES", 28, 34], ["RVF", "PROBLEM", 0, 3], ["influenza", "PROBLEM", 17, 26], ["dengue", "PROBLEM", 28, 34], ["chikungunya", "PROBLEM", 39, 50], ["cough", "PROBLEM", 65, 70], ["skin involvement", "PROBLEM", 72, 88], ["rash", "PROBLEM", 95, 99], ["pruritus", "PROBLEM", 103, 111], ["arthritis", "PROBLEM", 117, 126], ["uncommon signs", "PROBLEM", 144, 158], ["influenza", "OBSERVATION", 17, 26], ["skin", "ANATOMY", 72, 76], ["arthritis", "OBSERVATION", 117, 126]]], ["A slight meningism at the acute stage is not rare, however its prognosis value has never been evaluated [37] .", [["meningism", "DISEASE", 9, 18], ["meningism", "CANCER", 9, 18], ["A slight meningism", "PROBLEM", 0, 18], ["slight", "OBSERVATION_MODIFIER", 2, 8], ["meningism", "OBSERVATION", 9, 18], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["stage", "OBSERVATION", 32, 37], ["not", "UNCERTAINTY", 41, 44], ["rare", "OBSERVATION_MODIFIER", 45, 49]]], ["Basically, retro-orbital pains and neck stiffness are features hard to classify because both of them were commonly reported in uncomplicated RVF cases [36] , but were also associated with the occurrence of complications [37, 38] .Complicated and severe expressionIncidences of complications are uncertain because RVFV infection can go unrecognized or be misdiagnosed considering the unspecific symptoms of suspected cases, which overlap with many other co-circulating pathogens [39] .", [["retro-orbital", "ANATOMY", 11, 24], ["neck", "ANATOMY", 35, 39], ["retro-orbital pains", "DISEASE", 11, 30], ["neck stiffness", "DISEASE", 35, 49], ["RVF", "DISEASE", 141, 144], ["infection", "DISEASE", 318, 327], ["neck", "ORGANISM_SUBDIVISION", 35, 39], ["RVFV", "ORGANISM", 313, 317], ["RVFV", "SPECIES", 313, 317], ["retro-orbital pains", "PROBLEM", 11, 30], ["neck stiffness", "PROBLEM", 35, 49], ["complications", "PROBLEM", 206, 219], ["complications", "PROBLEM", 277, 290], ["RVFV infection", "PROBLEM", 313, 327], ["the unspecific symptoms", "PROBLEM", 379, 402], ["many other co-circulating pathogens", "PROBLEM", 442, 477], ["retro-orbital", "ANATOMY", 11, 24], ["pains", "OBSERVATION", 25, 30], ["neck", "ANATOMY", 35, 39], ["stiffness", "OBSERVATION", 40, 49], ["severe", "OBSERVATION_MODIFIER", 246, 252], ["complications", "OBSERVATION", 277, 290]]], ["No standard definition of suspected cases exists.", [["cases", "OBSERVATION", 36, 41]]], ["Rates of complications measured in studies depend on the definitions and methods of recruitment.", [["complications", "PROBLEM", 9, 22], ["complications", "OBSERVATION", 9, 22], ["recruitment", "OBSERVATION", 84, 95]]], ["Indeed, the use of clinical or biological criteria specific to RVF complications to define suspected cases could lead to underestimate the mild forms [40] [41] [42] .", [["RVF", "DISEASE", 63, 66], ["RVF", "ORGANISM", 63, 66], ["RVF complications", "PROBLEM", 63, 80], ["underestimate the mild forms", "PROBLEM", 121, 149], ["mild", "OBSERVATION_MODIFIER", 139, 143]]], ["Globally, since the first description of the spectrum of RVF in humans by Laughlin et al. during the major outbreak in Egypt in 1977, it is considered that less than 5% of symptomatic cases will present complications including ocular, neurologic and hemorrhagic symptoms, while favorable outcome will occur within 1 week for the others [17] .", [["ocular", "ANATOMY", 227, 233], ["neurologic", "ANATOMY", 235, 245], ["RVF", "DISEASE", 57, 60], ["ocular, neurologic and hemorrhagic", "DISEASE", 227, 261], ["humans", "ORGANISM", 64, 70], ["humans", "SPECIES", 64, 70], ["humans", "SPECIES", 64, 70], ["RVF", "PROBLEM", 57, 60], ["symptomatic cases", "PROBLEM", 172, 189], ["complications", "PROBLEM", 203, 216], ["ocular, neurologic and hemorrhagic symptoms", "PROBLEM", 227, 270], ["RVF", "OBSERVATION", 57, 60], ["ocular", "ANATOMY", 227, 233], ["hemorrhagic", "OBSERVATION_MODIFIER", 250, 261]]], ["In this historical series, the different known complications occurred in equal proportions (30-35%), but hepatic or renal failures were not identified.", [["hepatic", "ANATOMY", 105, 112], ["renal", "ANATOMY", 116, 121], ["hepatic or renal failures", "DISEASE", 105, 130], ["hepatic", "ORGAN", 105, 112], ["renal", "ORGAN", 116, 121], ["the different known complications", "PROBLEM", 27, 60], ["hepatic or renal failures", "PROBLEM", 105, 130], ["complications", "OBSERVATION", 47, 60], ["hepatic", "ANATOMY", 105, 112], ["renal", "ANATOMY", 116, 121], ["failures", "OBSERVATION", 122, 130]]], ["During the 2007 Kenyan outbreak, Kahlon et al. described a clinical syndrome suggestive of severe RVF, characterized by fever, large-joint arthralgia, and gastrointestinal complaints, later followed by jaundice, right upper-quadrant pain, and delirium, often coinciding with hemorrhagic manifestations [43] .", [["joint", "ANATOMY", 133, 138], ["gastrointestinal", "ANATOMY", 155, 171], ["right upper-quadrant", "ANATOMY", 212, 232], ["RVF", "DISEASE", 98, 101], ["fever", "DISEASE", 120, 125], ["arthralgia", "DISEASE", 139, 149], ["gastrointestinal complaints", "DISEASE", 155, 182], ["jaundice", "DISEASE", 202, 210], ["right upper-quadrant pain", "DISEASE", 212, 237], ["delirium", "DISEASE", 243, 251], ["hemorrhagic", "DISEASE", 275, 286], ["gastrointestinal", "ORGAN", 155, 171], ["a clinical syndrome", "PROBLEM", 57, 76], ["severe RVF", "PROBLEM", 91, 101], ["fever", "PROBLEM", 120, 125], ["large-joint arthralgia", "PROBLEM", 127, 149], ["gastrointestinal complaints", "PROBLEM", 155, 182], ["jaundice", "PROBLEM", 202, 210], ["right upper-quadrant pain", "PROBLEM", 212, 237], ["delirium", "PROBLEM", 243, 251], ["hemorrhagic manifestations", "PROBLEM", 275, 301], ["suggestive of", "UNCERTAINTY", 77, 90], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["RVF", "OBSERVATION", 98, 101], ["fever", "OBSERVATION", 120, 125], ["large", "OBSERVATION_MODIFIER", 127, 132], ["joint", "ANATOMY", 133, 138], ["arthralgia", "OBSERVATION", 139, 149], ["gastrointestinal", "ANATOMY", 155, 171], ["jaundice", "OBSERVATION", 202, 210], ["right", "ANATOMY_MODIFIER", 212, 217], ["upper-quadrant", "ANATOMY", 218, 232], ["pain", "OBSERVATION", 233, 237], ["delirium", "OBSERVATION", 243, 251], ["hemorrhagic", "OBSERVATION_MODIFIER", 275, 286]]], ["Complicated forms could have represented up to 20% of symptomatic cases during recent epidemics [36] .", [["symptomatic cases", "PROBLEM", 54, 71]]], ["Morbidity, as well as mortality, varied from one to another outbreak.", [["Morbidity", "PROBLEM", 0, 9]]], ["For example, in South Africa in 1975 [44] and in Tanzania in 2007 [19] most of RVF severe cases presented with encephalopathy (respectively 71% and 89%), whereas hemorrhagic manifestations predominated in Mauritania in 2015 (81%) [45] and Madagascar in 2008 (88%) [46] .", [["RVF", "DISEASE", 79, 82], ["encephalopathy", "DISEASE", 111, 125], ["hemorrhagic", "DISEASE", 162, 173], ["RVF severe cases", "PROBLEM", 79, 95], ["encephalopathy", "PROBLEM", 111, 125], ["hemorrhagic manifestations", "PROBLEM", 162, 188], ["Madagascar", "TEST", 239, 249], ["encephalopathy", "OBSERVATION", 111, 125], ["hemorrhagic", "OBSERVATION_MODIFIER", 162, 173]]], ["In Saudi Arabia in 2000, hepatic insufficiency (75%) and renal failures (41%) were the most frequent complications [47] .", [["hepatic", "ANATOMY", 25, 32], ["renal", "ANATOMY", 57, 62], ["hepatic insufficiency", "DISEASE", 25, 46], ["renal failures", "DISEASE", 57, 71], ["hepatic", "ORGAN", 25, 32], ["renal", "ORGAN", 57, 62], ["hepatic insufficiency", "PROBLEM", 25, 46], ["renal failures", "PROBLEM", 57, 71], ["hepatic", "ANATOMY", 25, 32], ["insufficiency", "OBSERVATION", 33, 46], ["renal", "ANATOMY", 57, 62], ["failures", "OBSERVATION", 63, 71]]], ["Moreover, during the epidemic in Madagascar, highly fatal associations of two or more complications were highlighted.", [["fatal", "OBSERVATION_MODIFIER", 52, 57]]], ["These occurred in 11/16 (69%) severe cases, of whom 5 (45%) had encephalitis with hemorrhagic symptoms which were lethal in 2/5 (40%), representing half of the deaths (4/16) [46] .", [["encephalitis", "DISEASE", 64, 76], ["hemorrhagic symptoms", "DISEASE", 82, 102], ["deaths", "DISEASE", 160, 166], ["encephalitis", "PROBLEM", 64, 76], ["hemorrhagic symptoms", "PROBLEM", 82, 102], ["encephalitis", "OBSERVATION", 64, 76], ["hemorrhagic", "OBSERVATION_MODIFIER", 82, 93]]], ["Variations in the RVFV tropism and virulence are hypothesized according to the lineage involved and the possible accumulation of genetic mutations or genomic reassortments [17, [48] [49] [50] , despite a low overall genomic diversity (\u223c 5%) at the nucleotide level [51] .", [["nucleotide", "CHEMICAL", 248, 258], ["nucleotide", "CHEMICAL", 248, 258], ["RVFV", "ORGANISM", 18, 22], ["RVFV", "SPECIES", 18, 22], ["Variations in the RVFV tropism", "PROBLEM", 0, 30], ["virulence", "PROBLEM", 35, 44], ["genetic mutations", "PROBLEM", 129, 146], ["genomic reassortments", "TEST", 150, 171], ["a low overall genomic diversity", "PROBLEM", 202, 233], ["RVFV tropism", "OBSERVATION", 18, 30]]], ["Genetic, ethnic or epidemiologic factors in the population exposed to the virus, as well as access to care also play a role [17, 52] .Complicated and severe expressionManifestations of RVF in humans are represented in Fig. 3 .", [["RVF", "DISEASE", 185, 188], ["humans", "ORGANISM", 192, 198], ["humans", "SPECIES", 192, 198], ["humans", "SPECIES", 192, 198], ["epidemiologic factors", "PROBLEM", 19, 40], ["RVF", "PROBLEM", 185, 188], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["RVF", "OBSERVATION", 185, 188]]], ["Alternative diagnoses concern a broad array of conditions which may be worldwide distributed or restricted to endemic areas.", [["may be", "UNCERTAINTY", 64, 70], ["endemic", "OBSERVATION_MODIFIER", 110, 117]]], ["Characteristics and differential diagnoses of RVF manifestations are summed-up in Table 2 .Risk factors for severe diseaseDeterminants for severe RVF outcome are poorly known.", [["RVF", "DISEASE", 46, 49], ["diseaseDeterminants", "DISEASE", 115, 134], ["RVF", "DISEASE", 146, 149], ["RVF manifestations", "PROBLEM", 46, 64], ["Risk factors", "PROBLEM", 91, 103], ["severe diseaseDeterminants", "PROBLEM", 108, 134], ["severe RVF outcome", "PROBLEM", 139, 157], ["RVF", "OBSERVATION", 46, 49], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["RVF", "OBSERVATION", 146, 149]]], ["A number of retrospective studies suggest that touching, handling, living close to, and consuming animal products are factors associated with increased likelihood of RVF virus infection and possibly more severe outcomes [19, 53] .", [["RVF virus infection", "DISEASE", 166, 185], ["RVF virus", "ORGANISM", 166, 175], ["RVF virus", "SPECIES", 166, 175], ["retrospective studies", "TEST", 12, 33], ["RVF virus infection", "PROBLEM", 166, 185], ["RVF virus infection", "OBSERVATION", 166, 185]]], ["This is probably linked with a significant exposure to the virus that results in higher inoculation rate.", [["the virus", "PROBLEM", 55, 64], ["higher inoculation rate", "PROBLEM", 81, 104], ["probably linked with", "UNCERTAINTY", 8, 28], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["exposure", "OBSERVATION", 43, 51], ["higher", "OBSERVATION_MODIFIER", 81, 87], ["inoculation rate", "OBSERVATION", 88, 104]]], ["Indeed viremic loads have been reported correlated with severe RVF diseases [54] .", [["RVF diseases", "DISEASE", 63, 75], ["Indeed viremic loads", "PROBLEM", 0, 20], ["severe RVF diseases", "PROBLEM", 56, 75], ["viremic", "OBSERVATION", 7, 14], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["RVF", "OBSERVATION", 63, 66]]], ["Single nucleotide polymorphisms (TLR3, TLR7, TLR8, MyD88, TRIF, MAVS, and RIG-I) were also associated with severe symptomatology [55] .", [["TLR3", "GENE_OR_GENE_PRODUCT", 33, 37], ["TLR7", "GENE_OR_GENE_PRODUCT", 39, 43], ["TLR8", "GENE_OR_GENE_PRODUCT", 45, 49], ["MyD88", "GENE_OR_GENE_PRODUCT", 51, 56], ["TRIF", "GENE_OR_GENE_PRODUCT", 58, 62], ["MAVS", "GENE_OR_GENE_PRODUCT", 64, 68], ["RIG-I", "GENE_OR_GENE_PRODUCT", 74, 79], ["TLR3", "DNA", 33, 37], ["TLR7", "DNA", 39, 43], ["TLR8", "DNA", 45, 49], ["MyD88", "DNA", 51, 56], ["TRIF", "DNA", 58, 62], ["MAVS", "PROTEIN", 64, 68], ["RIG-I", "DNA", 74, 79], ["Single nucleotide polymorphisms (TLR3, TLR7, TLR8", "TREATMENT", 0, 49], ["MyD88", "TEST", 51, 56], ["TRIF", "TREATMENT", 58, 62], ["MAVS", "TEST", 64, 68], ["severe symptomatology", "PROBLEM", 107, 128]]], ["Acute malaria co-occurrence was observed in severe forms and HIV-positive status was associated with a 75% case fatality rate in Tanzania in 2007 [19] .", [["malaria", "DISEASE", 6, 13], ["HIV-positive", "DISEASE", 61, 73], ["HIV", "ORGANISM", 61, 64], ["HIV", "SPECIES", 61, 64], ["Acute malaria co-occurrence", "PROBLEM", 0, 27], ["HIV", "PROBLEM", 61, 64], ["malaria", "OBSERVATION", 6, 13], ["severe", "OBSERVATION_MODIFIER", 44, 50]]], ["Schistosomal liver co-involvement and bacterial or fungal co-infections were also documented in fatal cases [37] .Hepatic manifestationsLiver is the primary site of RVFV replication, so that it is frequently early involved during RVFV acute infection [56, 57] .", [["liver", "ANATOMY", 13, 18], ["Hepatic", "ANATOMY", 114, 121], ["Liver", "ANATOMY", 136, 141], ["Schistosomal liver co-involvement", "DISEASE", 0, 33], ["bacterial or fungal co-infections", "DISEASE", 38, 71], ["RVFV acute infection", "DISEASE", 230, 250], ["liver", "ORGAN", 13, 18], ["Hepatic", "ORGAN", 114, 121], ["Liver", "ORGAN", 136, 141], ["RVFV", "ORGANISM", 165, 169], ["RVFV", "ORGANISM", 230, 234], ["RVFV", "SPECIES", 165, 169], ["RVFV", "SPECIES", 230, 234], ["Schistosomal liver co-involvement", "PROBLEM", 0, 33], ["bacterial or fungal co-infections", "PROBLEM", 38, 71], ["Hepatic manifestations", "PROBLEM", 114, 136], ["RVFV replication", "TREATMENT", 165, 181], ["RVFV acute infection", "PROBLEM", 230, 250], ["liver", "ANATOMY", 13, 18], ["co-involvement", "OBSERVATION", 19, 33], ["bacterial", "OBSERVATION_MODIFIER", 38, 47], ["fungal", "OBSERVATION_MODIFIER", 51, 57], ["co-infections", "OBSERVATION", 58, 71], ["manifestations", "OBSERVATION", 122, 136], ["RVFV replication", "OBSERVATION", 165, 181], ["acute", "OBSERVATION_MODIFIER", 235, 240], ["infection", "OBSERVATION", 241, 250]]], ["A severe acute hepatotropic disease may occur with liver failure and jaundice within the first 3 weeks of the disease [43] .", [["liver", "ANATOMY", 51, 56], ["liver failure", "DISEASE", 51, 64], ["jaundice", "DISEASE", 69, 77], ["liver", "ORGAN", 51, 56], ["A severe acute hepatotropic disease", "PROBLEM", 0, 35], ["liver failure", "PROBLEM", 51, 64], ["jaundice", "PROBLEM", 69, 77], ["the disease", "PROBLEM", 106, 117], ["severe", "OBSERVATION_MODIFIER", 2, 8], ["acute", "OBSERVATION_MODIFIER", 9, 14], ["hepatotropic disease", "OBSERVATION", 15, 35], ["liver", "ANATOMY", 51, 56], ["failure", "OBSERVATION", 57, 64], ["jaundice", "OBSERVATION", 69, 77]]], ["Tenderness, palpable enlargement and more than threefold elevation in transaminases are criteria of severity [42, 58] .", [["Tenderness", "DISEASE", 0, 10], ["transaminases", "SIMPLE_CHEMICAL", 70, 83], ["Tenderness", "PROBLEM", 0, 10], ["palpable enlargement", "PROBLEM", 12, 32], ["threefold elevation in transaminases", "PROBLEM", 47, 83], ["severity", "TEST", 100, 108], ["palpable", "OBSERVATION_MODIFIER", 12, 20], ["enlargement", "OBSERVATION", 21, 32], ["more", "OBSERVATION_MODIFIER", 37, 41], ["than threefold", "OBSERVATION_MODIFIER", 42, 56], ["elevation", "OBSERVATION_MODIFIER", 57, 66], ["transaminases", "ANATOMY", 70, 83]]], ["Jaundice was proved to be independently associated with a high mortality rate [40] .", [["Jaundice", "DISEASE", 0, 8], ["Jaundice", "PROBLEM", 0, 8]]], ["Acute hepatitis may complicate with prolonged blood coagulation times and may occur together with or precede fatal hemorrhages or neurologic complications.", [["blood", "ANATOMY", 46, 51], ["neurologic", "ANATOMY", 130, 140], ["hepatitis", "DISEASE", 6, 15], ["prolonged blood coagulation", "DISEASE", 36, 63], ["hemorrhages", "DISEASE", 115, 126], ["neurologic complications", "DISEASE", 130, 154], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["Acute hepatitis", "PROBLEM", 0, 15], ["prolonged blood coagulation times", "TREATMENT", 36, 69], ["precede fatal hemorrhages", "PROBLEM", 101, 126], ["neurologic complications", "PROBLEM", 130, 154], ["hepatitis", "OBSERVATION", 6, 15]]], ["Autopsy studies and pathogenesis characterization in mouse model found evidence of liver necrosis with RVF viral antigens identified within hepatocytes and K\u00fcpffer cells, arguing for a direct virus-induced cellular necrosis [19, 37, 44, 57, 59, 60] .", [["liver", "ANATOMY", 83, 88], ["hepatocytes", "ANATOMY", 140, 151], ["K\u00fcpffer cells", "ANATOMY", 156, 169], ["cellular", "ANATOMY", 206, 214], ["liver necrosis", "DISEASE", 83, 97], ["necrosis", "DISEASE", 215, 223], ["mouse", "ORGANISM", 53, 58], ["liver", "ORGAN", 83, 88], ["hepatocytes", "CELL", 140, 151], ["K\u00fcpffer cells", "CELL", 156, 169], ["cellular", "CELL", 206, 214], ["RVF viral antigens", "PROTEIN", 103, 121], ["hepatocytes", "CELL_TYPE", 140, 151], ["K\u00fcpffer cells", "CELL_LINE", 156, 169], ["mouse", "SPECIES", 53, 58], ["mouse", "SPECIES", 53, 58], ["Autopsy studies", "TEST", 0, 15], ["pathogenesis characterization", "TEST", 20, 49], ["mouse model", "TEST", 53, 64], ["liver necrosis", "PROBLEM", 83, 97], ["RVF viral antigens", "PROBLEM", 103, 121], ["a direct virus", "PROBLEM", 183, 197], ["cellular necrosis", "PROBLEM", 206, 223], ["evidence of", "UNCERTAINTY", 71, 82], ["liver", "ANATOMY", 83, 88], ["necrosis", "OBSERVATION", 89, 97], ["hepatocytes", "ANATOMY", 140, 151], ["cellular", "OBSERVATION_MODIFIER", 206, 214], ["necrosis", "OBSERVATION", 215, 223]]], ["A RVF case with a co-existing condition of cirrhosis after hepatitis B infection died as a result of gastrointestinal bleeding and hepatic encephalitis in Mayotte [28] , and 4/31 (13%) severe cases described during the epidemic in Mauritania in 2015 had chronic hepatitis B [61] , suggesting that patients with chronic hepatic ACUTE OR DELAYED ENCEPHALITIS day VISION DISORDERS day [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] disorders-mainly hepatitis B chronic infection-could be at higher risk of unfavorable outcome.Hemorrhagic feverSoon after the onset of flu-like illness or acute hepatitis, patients may present bleeding from the nose or gums (gingivorrhagia being a key early warning sign) [62] , hematemesis or melaena, petechial/purpuric rash or ecchymoses, menorrhagia, hematuria, or bleeding from venipuncture sites [46, 63] .", [["gastrointestinal", "ANATOMY", 101, 117], ["hepatic", "ANATOMY", 131, 138], ["hepatic", "ANATOMY", 319, 326], ["nose", "ANATOMY", 672, 676], ["gums", "ANATOMY", 680, 684], ["petechial", "ANATOMY", 764, 773], ["purpuric", "ANATOMY", 774, 782], ["ecchymoses", "ANATOMY", 791, 801], ["RVF", "DISEASE", 2, 5], ["cirrhosis", "DISEASE", 43, 52], ["hepatitis B infection", "DISEASE", 59, 80], ["gastrointestinal bleeding", "DISEASE", 101, 126], ["hepatic encephalitis", "DISEASE", 131, 151], ["chronic hepatitis B", "DISEASE", 254, 273], ["[4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20", "CHEMICAL", 382, 459], ["hepatitis B chronic infection", "DISEASE", 478, 507], ["Hemorrhagic feverSoon", "DISEASE", 555, 576], ["flu-like illness", "DISEASE", 596, 612], ["acute hepatitis", "DISEASE", 616, 631], ["bleeding", "DISEASE", 654, 662], ["gingivorrhagia", "DISEASE", 686, 700], ["hematemesis", "DISEASE", 740, 751], ["melaena", "DISEASE", 755, 762], ["rash", "DISEASE", 783, 787], ["ecchymoses", "DISEASE", 791, 801], ["menorrhagia", "DISEASE", 803, 814], ["hematuria", "DISEASE", 816, 825], ["bleeding", "DISEASE", 830, 838], ["gastrointestinal", "ORGANISM_SUBDIVISION", 101, 117], ["hepatic", "ORGAN", 131, 138], ["patients", "ORGANISM", 297, 305], ["hepatic", "ORGAN", 319, 326], ["5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20]", "SIMPLE_CHEMICAL", 387, 460], ["patients", "ORGANISM", 633, 641], ["nose", "ORGANISM_SUBDIVISION", 672, 676], ["gums", "ORGANISM_SUBDIVISION", 680, 684], ["patients", "SPECIES", 297, 305], ["patients", "SPECIES", 633, 641], ["hepatitis B", "SPECIES", 59, 70], ["A RVF case", "PROBLEM", 0, 10], ["a co-existing condition", "PROBLEM", 16, 39], ["cirrhosis", "PROBLEM", 43, 52], ["hepatitis B infection", "PROBLEM", 59, 80], ["gastrointestinal bleeding", "PROBLEM", 101, 126], ["hepatic encephalitis", "PROBLEM", 131, 151], ["severe cases", "PROBLEM", 185, 197], ["chronic hepatitis B", "PROBLEM", 254, 273], ["chronic hepatic ACUTE", "PROBLEM", 311, 332], ["DELAYED ENCEPHALITIS", "PROBLEM", 336, 356], ["20] disorders", "PROBLEM", 457, 470], ["hepatitis B chronic infection", "PROBLEM", 478, 507], ["unfavorable outcome", "PROBLEM", 535, 554], ["Hemorrhagic feverSoon", "PROBLEM", 555, 576], ["flu-like illness", "PROBLEM", 596, 612], ["acute hepatitis", "PROBLEM", 616, 631], ["bleeding from the nose or gums", "PROBLEM", 654, 684], ["gingivorrhagia", "PROBLEM", 686, 700], ["hematemesis", "PROBLEM", 740, 751], ["melaena", "PROBLEM", 755, 762], ["petechial/purpuric rash", "PROBLEM", 764, 787], ["ecchymoses", "PROBLEM", 791, 801], ["menorrhagia", "PROBLEM", 803, 814], ["hematuria", "PROBLEM", 816, 825], ["bleeding from venipuncture sites", "PROBLEM", 830, 862], ["RVF", "OBSERVATION", 2, 5], ["cirrhosis", "OBSERVATION", 43, 52], ["infection", "OBSERVATION", 71, 80], ["gastrointestinal", "ANATOMY", 101, 117], ["bleeding", "OBSERVATION", 118, 126], ["hepatic", "ANATOMY", 131, 138], ["encephalitis", "OBSERVATION", 139, 151], ["chronic", "OBSERVATION_MODIFIER", 254, 261], ["hepatitis", "OBSERVATION", 262, 271], ["chronic", "OBSERVATION_MODIFIER", 311, 318], ["hepatic", "ANATOMY", 319, 326], ["ACUTE", "OBSERVATION_MODIFIER", 327, 332], ["ENCEPHALITIS", "OBSERVATION", 344, 356], ["hepatitis", "OBSERVATION", 478, 487], ["chronic", "OBSERVATION_MODIFIER", 490, 497], ["infection", "OBSERVATION", 498, 507], ["unfavorable", "OBSERVATION", 535, 546], ["flu", "OBSERVATION", 596, 599], ["acute", "OBSERVATION_MODIFIER", 616, 621], ["hepatitis", "OBSERVATION", 622, 631], ["bleeding", "OBSERVATION", 654, 662], ["nose", "ANATOMY", 672, 676], ["gums", "ANATOMY", 680, 684], ["melaena", "ANATOMY", 755, 762], ["petechial", "OBSERVATION_MODIFIER", 764, 773], ["purpuric", "OBSERVATION_MODIFIER", 774, 782], ["rash", "OBSERVATION", 783, 787], ["ecchymoses", "OBSERVATION", 791, 801], ["menorrhagia", "OBSERVATION", 803, 814], ["hematuria", "OBSERVATION", 816, 825], ["bleeding", "OBSERVATION", 830, 838]]], ["Yellow fever-like expression were also reported with a first improvement at day 3 followed by a rebound of fever [62] .", [["Yellow fever", "DISEASE", 0, 12], ["fever", "DISEASE", 107, 112], ["Yellow fever", "ORGANISM", 0, 12], ["Yellow fever", "PROBLEM", 0, 12], ["fever", "PROBLEM", 107, 112], ["fever", "OBSERVATION", 7, 12]]], ["Epistaxis is not considered a reliable sign of how serious the illness is [64, 65] .", [["Epistaxis", "DISEASE", 0, 9], ["illness", "DISEASE", 63, 70], ["Epistaxis", "PROBLEM", 0, 9]]], ["Thrombocytopenia is invariably present.", [["Thrombocytopenia", "DISEASE", 0, 16], ["Thrombocytopenia", "PROBLEM", 0, 16]]], ["Hepato-renal failure with jaundice, disseminated intravascular coagulation and encephalitis can be associated [44, 66] .", [["renal", "ANATOMY", 7, 12], ["intravascular", "ANATOMY", 49, 62], ["Hepato-renal failure", "DISEASE", 0, 20], ["jaundice", "DISEASE", 26, 34], ["disseminated intravascular coagulation", "DISEASE", 36, 74], ["encephalitis", "DISEASE", 79, 91], ["renal", "ORGAN", 7, 12], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 62], ["Hepato", "TEST", 0, 6], ["renal failure", "PROBLEM", 7, 20], ["jaundice", "PROBLEM", 26, 34], ["disseminated intravascular coagulation", "PROBLEM", 36, 74], ["encephalitis", "PROBLEM", 79, 91], ["renal", "ANATOMY", 7, 12], ["failure", "OBSERVATION", 13, 20], ["jaundice", "OBSERVATION", 26, 34], ["disseminated", "OBSERVATION_MODIFIER", 36, 48], ["intravascular coagulation", "OBSERVATION", 49, 74], ["encephalitis", "OBSERVATION", 79, 91]]], ["A population-based survey during the 2007 outbreak in Kenya even reported 26% of hemorrhagic RVF disease with a mortality of 23% in this group of cases [67] .", [["hemorrhagic RVF disease", "DISEASE", 81, 104], ["hemorrhagic RVF disease", "PROBLEM", 81, 104], ["a mortality", "TEST", 110, 121], ["hemorrhagic", "OBSERVATION_MODIFIER", 81, 92], ["RVF", "OBSERVATION", 93, 96]]], ["Indeed, the mortality rate associated with bleeding manifestations is the highest, up to 65% [40, 68] .", [["bleeding", "DISEASE", 43, 51], ["bleeding manifestations", "PROBLEM", 43, 66], ["bleeding", "OBSERVATION", 43, 51]]], ["Viral load could play an important role in the hemorrhagic expression.", [["hemorrhagic", "DISEASE", 47, 58], ["Viral", "ORGANISM", 0, 5], ["Viral load", "PROBLEM", 0, 10], ["the hemorrhagic expression", "PROBLEM", 43, 69], ["hemorrhagic", "OBSERVATION_MODIFIER", 47, 58], ["expression", "OBSERVATION", 59, 69]]], ["In humans studies, it exhibited positive correlation with markers of inflammation (IP-10, CRP, Eotaxin, MCP-2 and Granzyme B), markers of fibrinolysis (tPA and D-dimer), and markers of endothelial function (sICAM-1), but a negative correlation with P-selectin, ADAMTS13, and fibrinogen, which are associated with coagulation pathways occurring on the endothelial surface [69] .MeningoencephalitisThe onset of meningoencephalitis usually occurs 1 to 4 weeks after the first symptoms (which may be very mild or subclinical), and in some cases neurological complications can manifest beyond 60 days after the initial symptoms of RVF.", [["endothelial", "ANATOMY", 185, 196], ["endothelial surface", "ANATOMY", 351, 370], ["neurological", "ANATOMY", 541, 553], ["inflammation", "DISEASE", 69, 81], ["Meningoencephalitis", "DISEASE", 377, 396], ["meningoencephalitis", "DISEASE", 409, 428], ["neurological complications", "DISEASE", 541, 567], ["RVF", "DISEASE", 626, 629], ["humans", "ORGANISM", 3, 9], ["IP-10", "GENE_OR_GENE_PRODUCT", 83, 88], ["CRP", "GENE_OR_GENE_PRODUCT", 90, 93], ["Eotaxin", "GENE_OR_GENE_PRODUCT", 95, 102], ["MCP-2", "GENE_OR_GENE_PRODUCT", 104, 109], ["Granzyme B", "GENE_OR_GENE_PRODUCT", 114, 124], ["tPA", "GENE_OR_GENE_PRODUCT", 152, 155], ["D-dimer", "GENE_OR_GENE_PRODUCT", 160, 167], ["endothelial", "CELL", 185, 196], ["sICAM-1", "GENE_OR_GENE_PRODUCT", 207, 214], ["P-selectin", "GENE_OR_GENE_PRODUCT", 249, 259], ["ADAMTS13", "GENE_OR_GENE_PRODUCT", 261, 269], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 275, 285], ["endothelial surface", "CELLULAR_COMPONENT", 351, 370], ["CRP", "PROTEIN", 90, 93], ["Eotaxin", "PROTEIN", 95, 102], ["MCP", "PROTEIN", 104, 107], ["Granzyme B", "PROTEIN", 114, 124], ["D-dimer", "PROTEIN", 160, 167], ["sICAM", "PROTEIN", 207, 212], ["P-selectin", "PROTEIN", 249, 259], ["ADAMTS13", "PROTEIN", 261, 269], ["fibrinogen", "PROTEIN", 275, 285], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["humans studies", "TEST", 3, 17], ["inflammation", "PROBLEM", 69, 81], ["IP", "TEST", 83, 85], ["CRP", "TEST", 90, 93], ["Eotaxin", "TEST", 95, 102], ["MCP", "TEST", 104, 107], ["fibrinolysis", "PROBLEM", 138, 150], ["tPA and D-dimer", "TEST", 152, 167], ["endothelial function", "TEST", 185, 205], ["sICAM", "TEST", 207, 212], ["P", "TEST", 249, 250], ["ADAMTS13", "TEST", 261, 269], ["fibrinogen", "TEST", 275, 285], ["coagulation pathways", "PROBLEM", 313, 333], ["the endothelial surface", "TEST", 347, 370], ["Meningoencephalitis", "PROBLEM", 377, 396], ["meningoencephalitis", "PROBLEM", 409, 428], ["the first symptoms", "PROBLEM", 463, 481], ["some cases neurological complications", "PROBLEM", 530, 567], ["the initial symptoms", "PROBLEM", 602, 622], ["RVF", "PROBLEM", 626, 629], ["inflammation", "OBSERVATION", 69, 81], ["endothelial", "ANATOMY", 185, 196], ["fibrinogen", "ANATOMY", 275, 285], ["meningoencephalitis", "OBSERVATION", 409, 428], ["RVF", "OBSERVATION", 626, 629]]], ["Clinical features may include intense headache, neurological deficit, rigor, neck rigidity, hyperreflexia, hypersalivation, choreiform movements, loss of memory, hallucinations, confusion, disorientation, vertigo, convulsions, ataxia, lethargy, decerebrate posturing, locked-in syndrome and coma [17, 35, 44, [70] [71] [72] [73] .MeningoencephalitisIn a human outbreak in Mauritania in 1989, up to 5% of observed infections had encephalitis [71] .", [["neurological", "ANATOMY", 48, 60], ["neck", "ANATOMY", 77, 81], ["choreiform", "ANATOMY", 124, 134], ["headache", "DISEASE", 38, 46], ["neurological deficit", "DISEASE", 48, 68], ["neck rigidity", "DISEASE", 77, 90], ["hyperreflexia", "DISEASE", 92, 105], ["hypersalivation", "DISEASE", 107, 122], ["choreiform movements", "DISEASE", 124, 144], ["loss of memory", "DISEASE", 146, 160], ["hallucinations", "DISEASE", 162, 176], ["confusion", "DISEASE", 178, 187], ["disorientation", "DISEASE", 189, 203], ["vertigo", "DISEASE", 205, 212], ["convulsions", "DISEASE", 214, 225], ["ataxia", "DISEASE", 227, 233], ["lethargy", "DISEASE", 235, 243], ["decerebrate posturing", "DISEASE", 245, 266], ["locked-in syndrome", "DISEASE", 268, 286], ["coma", "DISEASE", 291, 295], ["infections", "DISEASE", 413, 423], ["encephalitis", "DISEASE", 428, 440], ["neck", "ORGANISM_SUBDIVISION", 77, 81], ["human", "ORGANISM", 354, 359], ["human", "SPECIES", 354, 359], ["human", "SPECIES", 354, 359], ["intense headache", "PROBLEM", 30, 46], ["neurological deficit", "PROBLEM", 48, 68], ["rigor", "PROBLEM", 70, 75], ["neck rigidity", "PROBLEM", 77, 90], ["hyperreflexia", "PROBLEM", 92, 105], ["hypersalivation", "PROBLEM", 107, 122], ["choreiform movements", "PROBLEM", 124, 144], ["loss of memory", "PROBLEM", 146, 160], ["hallucinations", "PROBLEM", 162, 176], ["confusion", "PROBLEM", 178, 187], ["disorientation", "PROBLEM", 189, 203], ["vertigo", "PROBLEM", 205, 212], ["convulsions", "PROBLEM", 214, 225], ["ataxia", "PROBLEM", 227, 233], ["lethargy", "PROBLEM", 235, 243], ["decerebrate posturing", "PROBLEM", 245, 266], ["locked-in syndrome", "PROBLEM", 268, 286], ["coma", "PROBLEM", 291, 295], ["observed infections", "PROBLEM", 404, 423], ["encephalitis", "PROBLEM", 428, 440], ["may include", "UNCERTAINTY", 18, 29], ["intense", "OBSERVATION_MODIFIER", 30, 37], ["neck rigidity", "ANATOMY", 77, 90], ["hyperreflexia", "OBSERVATION", 92, 105], ["infections", "OBSERVATION", 413, 423]]], ["Two types of pure encephalitis were described: acute febrile forms with short duration and possibility of death, and subacute forms with a longer duration, a lower fatality rate but frequent sequelae [71] .", [["encephalitis", "DISEASE", 18, 30], ["death", "DISEASE", 106, 111], ["pure encephalitis", "PROBLEM", 13, 30], ["acute febrile forms", "PROBLEM", 47, 66], ["death", "PROBLEM", 106, 111], ["a lower fatality rate", "PROBLEM", 156, 177], ["pure", "OBSERVATION_MODIFIER", 13, 17], ["encephalitis", "OBSERVATION", 18, 30], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["febrile", "OBSERVATION", 53, 60], ["short duration", "OBSERVATION_MODIFIER", 72, 86], ["subacute", "OBSERVATION_MODIFIER", 117, 125]]], ["Pulmonary complications may occur [71, 74] , and malaria can worsen the severity of neurologic symptoms [19] .", [["Pulmonary", "ANATOMY", 0, 9], ["neurologic", "ANATOMY", 84, 94], ["Pulmonary complications", "DISEASE", 0, 23], ["malaria", "DISEASE", 49, 56], ["neurologic symptoms", "DISEASE", 84, 103], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary complications", "PROBLEM", 0, 23], ["malaria", "PROBLEM", 49, 56], ["neurologic symptoms", "PROBLEM", 84, 103], ["complications", "OBSERVATION", 10, 23]]], ["Lethality may be as high as 50% in this form [40] .", [["Lethality", "DISEASE", 0, 9], ["Lethality", "PROBLEM", 0, 9], ["high", "OBSERVATION_MODIFIER", 20, 24]]], ["From Mauritania in 1989, clear a cellular CSF were documented in all cases with encephalitis [71] .", [["cellular", "ANATOMY", 33, 41], ["encephalitis", "DISEASE", 80, 92], ["cellular", "CELL", 33, 41], ["CSF", "ORGANISM_SUBSTANCE", 42, 45], ["cellular CSF", "PROTEIN", 33, 45], ["a cellular CSF", "TEST", 31, 45], ["encephalitis", "PROBLEM", 80, 92], ["encephalitis", "OBSERVATION", 80, 92]]], ["In a 18-year old woman treated for chronic myeloid leukemia with acute RVFV encephalitis acquired in Saudi Arabia, CSF was documented predominantly with polynuclear leukocytes.", [["chronic myeloid leukemia", "ANATOMY", 35, 59], ["polynuclear leukocytes", "ANATOMY", 153, 175], ["chronic myeloid leukemia", "DISEASE", 35, 59], ["RVFV encephalitis", "DISEASE", 71, 88], ["woman", "ORGANISM", 17, 22], ["chronic myeloid leukemia", "CANCER", 35, 59], ["CSF", "ORGANISM_SUBSTANCE", 115, 118], ["polynuclear leukocytes", "CELL", 153, 175], ["polynuclear leukocytes", "CELL_TYPE", 153, 175], ["woman", "SPECIES", 17, 22], ["chronic myeloid leukemia", "PROBLEM", 35, 59], ["acute RVFV encephalitis", "PROBLEM", 65, 88], ["CSF", "TEST", 115, 118], ["polynuclear leukocytes", "PROBLEM", 153, 175], ["chronic", "OBSERVATION_MODIFIER", 35, 42], ["myeloid leukemia", "OBSERVATION", 43, 59], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["RVFV", "OBSERVATION_MODIFIER", 71, 75], ["encephalitis", "OBSERVATION", 76, 88], ["polynuclear leukocytes", "OBSERVATION", 153, 175]]], ["Magnetic resonance imaging (MRI) showed high signal intensity on T2-weighted images in frontoparietal and thalamic regions, with multiple bilateral asymmetrical cortical hyperintense areas consistent with inflammation or ischemia in axial diffusion, while changes in CT-scan of her brain appeared much later [70] .", [["frontoparietal", "ANATOMY", 87, 101], ["thalamic regions", "ANATOMY", 106, 122], ["cortical hyperintense areas", "ANATOMY", 161, 188], ["brain", "ANATOMY", 282, 287], ["inflammation", "DISEASE", 205, 217], ["ischemia", "DISEASE", 221, 229], ["frontoparietal", "MULTI-TISSUE_STRUCTURE", 87, 101], ["brain", "ORGAN", 282, 287], ["T2", "DNA", 65, 67], ["Magnetic resonance imaging", "TEST", 0, 26], ["MRI", "TEST", 28, 31], ["high signal intensity", "PROBLEM", 40, 61], ["multiple bilateral asymmetrical cortical hyperintense areas", "PROBLEM", 129, 188], ["inflammation", "PROBLEM", 205, 217], ["ischemia in axial diffusion", "PROBLEM", 221, 248], ["CT-scan of her brain", "TEST", 267, 287], ["high signal", "OBSERVATION", 40, 51], ["intensity", "OBSERVATION_MODIFIER", 52, 61], ["frontoparietal", "ANATOMY_MODIFIER", 87, 101], ["thalamic", "ANATOMY", 106, 114], ["regions", "ANATOMY_MODIFIER", 115, 122], ["multiple", "OBSERVATION_MODIFIER", 129, 137], ["bilateral", "ANATOMY_MODIFIER", 138, 147], ["asymmetrical", "OBSERVATION_MODIFIER", 148, 160], ["cortical", "OBSERVATION_MODIFIER", 161, 169], ["hyperintense", "OBSERVATION_MODIFIER", 170, 182], ["areas", "OBSERVATION", 183, 188], ["consistent with", "UNCERTAINTY", 189, 204], ["inflammation", "OBSERVATION", 205, 217], ["ischemia", "OBSERVATION", 221, 229], ["axial", "OBSERVATION_MODIFIER", 233, 238], ["diffusion", "OBSERVATION_MODIFIER", 239, 248], ["brain", "ANATOMY", 282, 287]]], ["In delayed meningoencephalitis normal glucose and protein concentrations will lymphocytic pleocytosis were found in CSF [17] .", [["lymphocytic", "ANATOMY", 78, 89], ["meningoencephalitis", "DISEASE", 11, 30], ["glucose", "CHEMICAL", 38, 45], ["pleocytosis", "DISEASE", 90, 101], ["glucose", "CHEMICAL", 38, 45], ["glucose", "SIMPLE_CHEMICAL", 38, 45], ["CSF", "ORGANISM_SUBSTANCE", 116, 119], ["delayed meningoencephalitis", "PROBLEM", 3, 30], ["protein concentrations", "TEST", 50, 72], ["lymphocytic pleocytosis", "PROBLEM", 78, 101], ["CSF", "TEST", 116, 119], ["delayed", "OBSERVATION_MODIFIER", 3, 10], ["meningoencephalitis", "OBSERVATION", 11, 30], ["glucose", "OBSERVATION_MODIFIER", 38, 45]]], ["In a kidney transplant recipient with cured hepatitis B, presenting acute hepatitis followed by delayed pachymeningitis, specific RVF-IgM were detected in lymphocytic CSF at day 58, while IgG were positive in blood at the first screening at day 44 [74] , which was consistent with the first neurologic description in literature [72] .MeningoencephalitisIn a mouse model of RVF infection, survivors to primarily hepatitis cleared the virus from liver and blood, but exhibited neuro-invasion and fatal encephalitis [57] .", [["kidney", "ANATOMY", 5, 11], ["lymphocytic CSF", "ANATOMY", 155, 170], ["blood", "ANATOMY", 209, 214], ["neurologic", "ANATOMY", 291, 301], ["liver", "ANATOMY", 444, 449], ["blood", "ANATOMY", 454, 459], ["hepatitis B", "DISEASE", 44, 55], ["hepatitis", "DISEASE", 74, 83], ["pachymeningitis", "DISEASE", 104, 119], ["RVF infection", "DISEASE", 373, 386], ["hepatitis", "DISEASE", 411, 420], ["encephalitis", "DISEASE", 500, 512], ["kidney", "ORGAN", 5, 11], ["RVF", "ORGANISM", 130, 133], ["IgM", "GENE_OR_GENE_PRODUCT", 134, 137], ["lymphocytic CSF", "ORGANISM_SUBSTANCE", 155, 170], ["IgG", "GENE_OR_GENE_PRODUCT", 188, 191], ["blood", "ORGANISM_SUBSTANCE", 209, 214], ["mouse", "ORGANISM", 358, 363], ["RVF", "ORGANISM", 373, 376], ["liver", "ORGAN", 444, 449], ["blood", "ORGANISM_SUBSTANCE", 454, 459], ["IgM", "PROTEIN", 134, 137], ["IgG", "PROTEIN", 188, 191], ["mouse", "SPECIES", 358, 363], ["hepatitis B", "SPECIES", 44, 55], ["mouse", "SPECIES", 358, 363], ["RVF", "SPECIES", 373, 376], ["a kidney transplant recipient", "TREATMENT", 3, 32], ["cured hepatitis B", "PROBLEM", 38, 55], ["acute hepatitis", "PROBLEM", 68, 83], ["delayed pachymeningitis", "PROBLEM", 96, 119], ["specific RVF", "PROBLEM", 121, 133], ["IgM", "PROBLEM", 134, 137], ["lymphocytic CSF", "TEST", 155, 170], ["IgG", "TEST", 188, 191], ["the first screening", "TEST", 218, 237], ["RVF infection", "PROBLEM", 373, 386], ["primarily hepatitis", "PROBLEM", 401, 420], ["the virus from liver and blood", "PROBLEM", 429, 459], ["neuro-invasion", "PROBLEM", 475, 489], ["fatal encephalitis", "PROBLEM", 494, 512], ["kidney", "ANATOMY", 5, 11], ["transplant", "OBSERVATION", 12, 22], ["hepatitis", "OBSERVATION", 44, 53], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["hepatitis", "OBSERVATION", 74, 83], ["pachymeningitis", "OBSERVATION", 104, 119], ["lymphocytic CSF", "OBSERVATION", 155, 170], ["consistent with", "UNCERTAINTY", 265, 280], ["mouse model", "OBSERVATION_MODIFIER", 358, 369], ["RVF", "OBSERVATION_MODIFIER", 373, 376], ["infection", "OBSERVATION", 377, 386], ["liver", "ANATOMY", 444, 449], ["blood", "ANATOMY", 454, 459], ["fatal", "OBSERVATION_MODIFIER", 494, 499], ["encephalitis", "OBSERVATION", 500, 512]]], ["Active viral replication in brain leading to necrotizing encephalitis was documented in several animal models [75, 76] .", [["brain", "ANATOMY", 28, 33], ["encephalitis", "DISEASE", 57, 69], ["brain", "ORGAN", 28, 33], ["Active viral replication in brain", "PROBLEM", 0, 33], ["necrotizing encephalitis", "PROBLEM", 45, 69], ["viral replication", "OBSERVATION", 7, 24], ["brain", "ANATOMY", 28, 33], ["necrotizing", "OBSERVATION_MODIFIER", 45, 56], ["encephalitis", "OBSERVATION", 57, 69]]], ["The route of transmission and prompt robust immune response could be a determining factor of the RVF neurologic disease course [77] .", [["neurologic", "ANATOMY", 101, 111], ["RVF neurologic disease", "DISEASE", 97, 119], ["the RVF neurologic disease course", "PROBLEM", 93, 126]]], ["Indeed, whatever the routes of inoculation, RVFV RNA was detected in the brain of infected rats confirming the virus neurotropism [78] , but aerosol exposure to RVFV caused earlier and more severe neuropathology in the murine model and fatal encephalitis in primates [75, 76] .", [["brain", "ANATOMY", 73, 78], ["RVFV", "DISEASE", 161, 165], ["neuropathology", "DISEASE", 197, 211], ["encephalitis", "DISEASE", 242, 254], ["RVFV", "ORGANISM", 44, 48], ["brain", "ORGAN", 73, 78], ["rats", "ORGANISM", 91, 95], ["RVFV", "ORGANISM", 161, 165], ["murine", "ORGANISM", 219, 225], ["primates", "ORGANISM", 258, 266], ["RVFV RNA", "RNA", 44, 52], ["rats", "SPECIES", 91, 95], ["murine", "SPECIES", 219, 225], ["RVFV", "SPECIES", 44, 48], ["RVFV", "SPECIES", 161, 165], ["inoculation", "PROBLEM", 31, 42], ["RVFV RNA", "PROBLEM", 44, 52], ["infected rats", "PROBLEM", 82, 95], ["the virus neurotropism", "PROBLEM", 107, 129], ["RVFV", "PROBLEM", 161, 165], ["more severe neuropathology in the murine model", "PROBLEM", 185, 231], ["fatal encephalitis", "PROBLEM", 236, 254], ["brain", "ANATOMY", 73, 78], ["infected", "OBSERVATION", 82, 90], ["more severe", "OBSERVATION_MODIFIER", 185, 196], ["fatal", "OBSERVATION_MODIFIER", 236, 241], ["encephalitis", "OBSERVATION", 242, 254]]], ["In aerosol-infected rats with lethal encephalitis, neutrophils and macrophages were the major cell types infiltrating the CNS, and this was concomitant with microglia activation and extensive cytokine inflammation [78] .", [["neutrophils", "ANATOMY", 51, 62], ["macrophages", "ANATOMY", 67, 78], ["cell", "ANATOMY", 94, 98], ["CNS", "ANATOMY", 122, 125], ["microglia", "ANATOMY", 157, 166], ["encephalitis", "DISEASE", 37, 49], ["inflammation", "DISEASE", 201, 213], ["rats", "ORGANISM", 20, 24], ["neutrophils", "CELL", 51, 62], ["macrophages", "CELL", 67, 78], ["cell", "CELL", 94, 98], ["CNS", "ANATOMICAL_SYSTEM", 122, 125], ["microglia", "CELL", 157, 166], ["neutrophils", "CELL_TYPE", 51, 62], ["macrophages", "CELL_TYPE", 67, 78], ["cytokine", "PROTEIN", 192, 200], ["rats", "SPECIES", 20, 24], ["lethal encephalitis", "PROBLEM", 30, 49], ["neutrophils", "PROBLEM", 51, 62], ["macrophages", "PROBLEM", 67, 78], ["microglia activation", "PROBLEM", 157, 177], ["extensive cytokine inflammation", "PROBLEM", 182, 213], ["lethal", "OBSERVATION_MODIFIER", 30, 36], ["encephalitis", "OBSERVATION", 37, 49], ["CNS", "ANATOMY", 122, 125], ["microglia activation", "OBSERVATION", 157, 177], ["extensive", "OBSERVATION_MODIFIER", 182, 191], ["cytokine inflammation", "OBSERVATION", 192, 213]]], ["Differences in the peripheral blood biomarkers during the course of the neurological disease in African green monkeys were measured with defect in early T-cells, proinflammatory and antiviral responses in lethal encephalitis [79] .", [["peripheral blood", "ANATOMY", 19, 35], ["neurological", "ANATOMY", 72, 84], ["T-cells", "ANATOMY", 153, 160], ["neurological disease", "DISEASE", 72, 92], ["encephalitis", "DISEASE", 212, 224], ["peripheral blood", "MULTI-TISSUE_STRUCTURE", 19, 35], ["green monkeys", "ORGANISM", 104, 117], ["T-cells", "CELL", 153, 160], ["early T-cells", "CELL_TYPE", 147, 160], ["African green monkeys", "SPECIES", 96, 117], ["African green monkeys", "SPECIES", 96, 117], ["the peripheral blood biomarkers", "TEST", 15, 46], ["the neurological disease", "PROBLEM", 68, 92], ["defect in early T-cells", "PROBLEM", 137, 160], ["proinflammatory and antiviral responses", "PROBLEM", 162, 201], ["lethal encephalitis", "PROBLEM", 205, 224], ["peripheral", "ANATOMY_MODIFIER", 19, 29], ["defect", "OBSERVATION", 137, 143]]], ["Other immune disorders and alteration in vascular permeability in the brain could be more involved in delayed forms [80] .Other organic failuresDuring RVFV infection, elevated urea and creatinine levels may be secondary to hypovolemia, multipleorgan dysfunction, or hepatorenal syndrome [39, 81] .", [["vascular", "ANATOMY", 41, 49], ["brain", "ANATOMY", 70, 75], ["multipleorgan", "ANATOMY", 236, 249], ["immune disorders", "DISEASE", 6, 22], ["RVFV infection", "DISEASE", 151, 165], ["urea", "CHEMICAL", 176, 180], ["creatinine", "CHEMICAL", 185, 195], ["hypovolemia", "DISEASE", 223, 234], ["multipleorgan dysfunction", "DISEASE", 236, 261], ["hepatorenal syndrome", "DISEASE", 266, 286], ["urea", "CHEMICAL", 176, 180], ["creatinine", "CHEMICAL", 185, 195], ["vascular", "MULTI-TISSUE_STRUCTURE", 41, 49], ["brain", "ORGAN", 70, 75], ["RVFV", "ORGANISM", 151, 155], ["urea", "SIMPLE_CHEMICAL", 176, 180], ["creatinine", "SIMPLE_CHEMICAL", 185, 195], ["RVFV", "SPECIES", 151, 155], ["Other immune disorders", "PROBLEM", 0, 22], ["alteration in vascular permeability in the brain", "PROBLEM", 27, 75], ["Other organic failures", "PROBLEM", 122, 144], ["RVFV infection", "PROBLEM", 151, 165], ["elevated urea", "PROBLEM", 167, 180], ["creatinine levels", "TEST", 185, 202], ["hypovolemia", "PROBLEM", 223, 234], ["multipleorgan dysfunction", "PROBLEM", 236, 261], ["hepatorenal syndrome", "PROBLEM", 266, 286], ["immune disorders", "OBSERVATION", 6, 22], ["vascular", "ANATOMY", 41, 49], ["permeability", "OBSERVATION", 50, 62], ["brain", "ANATOMY", 70, 75], ["organic failures", "OBSERVATION", 128, 144], ["RVFV", "OBSERVATION_MODIFIER", 151, 155], ["infection", "OBSERVATION", 156, 165], ["hypovolemia", "OBSERVATION", 223, 234], ["multipleorgan dysfunction", "OBSERVATION", 236, 261], ["hepatorenal syndrome", "OBSERVATION", 266, 286]]], ["Acute hepatonephritis, possibly related to direct RVFV injury, characterized by proteinuria and oliguria were also reported with a bad prognosis [62] .", [["hepatonephritis", "DISEASE", 6, 21], ["RVFV injury", "DISEASE", 50, 61], ["proteinuria", "DISEASE", 80, 91], ["oliguria", "DISEASE", 96, 104], ["RVFV", "ORGANISM", 50, 54], ["RVFV", "SPECIES", 50, 54], ["Acute hepatonephritis", "PROBLEM", 0, 21], ["direct RVFV injury", "PROBLEM", 43, 61], ["proteinuria", "PROBLEM", 80, 91], ["oliguria", "PROBLEM", 96, 104], ["hepatonephritis", "OBSERVATION", 6, 21], ["possibly related to", "UNCERTAINTY", 23, 42], ["RVFV", "OBSERVATION", 50, 54], ["proteinuria", "OBSERVATION", 80, 91], ["oliguria", "OBSERVATION", 96, 104]]], ["In Mauritania in 2015, creatininemia was meanly more than fourfold upper the reference range in severe cases [61] .", [["creatininemia", "DISEASE", 23, 36], ["creatininemia", "TEST", 23, 36]]], ["In Saudi Arabia in 2000, renal impairment concerned up to 60% of RVF inpatients and dialysis was needed in 90% of them [81] .", [["renal", "ANATOMY", 25, 30], ["renal impairment", "DISEASE", 25, 41], ["RVF", "DISEASE", 65, 68], ["renal", "ORGAN", 25, 30], ["RVF", "SPECIES", 65, 68], ["renal impairment", "PROBLEM", 25, 41], ["dialysis", "TREATMENT", 84, 92], ["renal", "ANATOMY", 25, 30], ["impairment", "OBSERVATION", 31, 41]]], ["The mortality rate was 31% in patients with acute renal failure, 25% in those with hepatorenal syndrome, and 31% in patients with primary hepatic involvement and mild renal impairment [81] .", [["renal", "ANATOMY", 50, 55], ["hepatic", "ANATOMY", 138, 145], ["renal", "ANATOMY", 167, 172], ["acute renal failure", "DISEASE", 44, 63], ["hepatorenal syndrome", "DISEASE", 83, 103], ["primary hepatic involvement", "DISEASE", 130, 157], ["renal impairment", "DISEASE", 167, 183], ["patients", "ORGANISM", 30, 38], ["renal", "ORGAN", 50, 55], ["patients", "ORGANISM", 116, 124], ["hepatic", "ORGAN", 138, 145], ["renal", "ORGAN", 167, 172], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 116, 124], ["The mortality rate", "TEST", 0, 18], ["acute renal failure", "PROBLEM", 44, 63], ["hepatorenal syndrome", "PROBLEM", 83, 103], ["primary hepatic involvement", "PROBLEM", 130, 157], ["mild renal impairment", "PROBLEM", 162, 183], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["renal", "ANATOMY", 50, 55], ["failure", "OBSERVATION", 56, 63], ["hepatorenal syndrome", "OBSERVATION", 83, 103], ["hepatic", "ANATOMY", 138, 145], ["involvement", "OBSERVATION", 146, 157], ["mild", "OBSERVATION_MODIFIER", 162, 166], ["renal", "ANATOMY", 167, 172], ["impairment", "OBSERVATION", 173, 183]]], ["Progression to chronic renal failure was not seen [40, 47, 81] .Other organic failuresIn 2008 in Mayotte, an acute pericarditis with symptoms of right-sided heart failure, relapsing at 1 month, was documented in a 53-year old farmer diagnosed with RVFV infection [28] .", [["renal", "ANATOMY", 23, 28], ["heart", "ANATOMY", 157, 162], ["chronic renal failure", "DISEASE", 15, 36], ["pericarditis", "DISEASE", 115, 127], ["heart failure", "DISEASE", 157, 170], ["RVFV infection", "DISEASE", 248, 262], ["renal", "ORGAN", 23, 28], ["heart", "ORGAN", 157, 162], ["RVFV", "ORGANISM", 248, 252], ["RVFV", "SPECIES", 248, 252], ["chronic renal failure", "PROBLEM", 15, 36], ["Other organic failures", "PROBLEM", 64, 86], ["an acute pericarditis", "PROBLEM", 106, 127], ["symptoms", "PROBLEM", 133, 141], ["right-sided heart failure", "PROBLEM", 145, 170], ["RVFV infection", "PROBLEM", 248, 262], ["chronic", "OBSERVATION_MODIFIER", 15, 22], ["renal", "ANATOMY", 23, 28], ["failure", "OBSERVATION", 29, 36], ["organic failures", "OBSERVATION", 70, 86], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["pericarditis", "OBSERVATION", 115, 127], ["right", "ANATOMY_MODIFIER", 145, 150], ["sided", "ANATOMY_MODIFIER", 151, 156], ["heart", "ANATOMY", 157, 162], ["failure", "OBSERVATION", 163, 170], ["RVFV", "OBSERVATION_MODIFIER", 248, 252], ["infection", "OBSERVATION", 253, 262]]], ["In historical post-mortem examinations, fragmentation in myocardial muscle was found in two cases and RVFV was isolated from one pericardial fluid [37, 44] .Ocular complicationsMacular exudates with potential permanent loss of central visual acuity were firstly described in 7 among 20,000 estimated cases (< 0.05%) during the 1950-51 outbreak in South Africa [82, 83] .", [["myocardial muscle", "ANATOMY", 57, 74], ["pericardial fluid", "ANATOMY", 129, 146], ["Ocular", "ANATOMY", 157, 163], ["Macular", "ANATOMY", 177, 184], ["myocardial muscle", "DISEASE", 57, 74], ["loss of central visual acuity", "DISEASE", 219, 248], ["myocardial muscle", "TISSUE", 57, 74], ["RVFV", "ORGANISM", 102, 106], ["RVFV", "SPECIES", 102, 106], ["historical post-mortem examinations", "TEST", 3, 38], ["fragmentation in myocardial muscle", "PROBLEM", 40, 74], ["RVFV", "PROBLEM", 102, 106], ["one pericardial fluid", "TEST", 125, 146], ["Ocular complications", "PROBLEM", 157, 177], ["Macular exudates", "PROBLEM", 177, 193], ["potential permanent loss of central visual acuity", "PROBLEM", 199, 248], ["myocardial muscle", "ANATOMY", 57, 74], ["pericardial", "ANATOMY", 129, 140], ["fluid", "OBSERVATION", 141, 146], ["complications", "OBSERVATION", 164, 177], ["exudates", "OBSERVATION", 185, 193], ["permanent", "OBSERVATION_MODIFIER", 209, 218], ["loss", "OBSERVATION_MODIFIER", 219, 223], ["central", "ANATOMY_MODIFIER", 227, 234], ["visual acuity", "OBSERVATION", 235, 248]]], ["The prevalence of ocular manifestations has been estimated to 1% during epidemic outbreaks in Egypt in 1977, and up to 15% both in patients with mild and severe RVF disease during the 2000 outbreak in southwest Saudi Arabia [84] .", [["ocular", "ANATOMY", 18, 24], ["ocular manifestations", "DISEASE", 18, 39], ["RVF disease", "DISEASE", 161, 172], ["ocular", "ORGAN", 18, 24], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["ocular manifestations", "PROBLEM", 18, 39], ["mild and severe RVF disease", "PROBLEM", 145, 172], ["ocular manifestations", "OBSERVATION", 18, 39], ["mild", "OBSERVATION_MODIFIER", 145, 149], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["RVF", "OBSERVATION", 161, 164]]], ["Unilateral or bilateral symptoms generally occur 5 to 14 days after the RVFV infection, but can be more delayed, and may include decreased visual acuity, scotoma, acute hemorrhagic conjunctivitis and retro-orbital pain [85] .", [["retro-orbital", "ANATOMY", 200, 213], ["infection", "DISEASE", 77, 86], ["decreased visual acuity", "DISEASE", 129, 152], ["scotoma", "DISEASE", 154, 161], ["hemorrhagic conjunctivitis", "DISEASE", 169, 195], ["retro-orbital pain", "DISEASE", 200, 218], ["RVFV", "ORGANISM", 72, 76], ["RVFV", "SPECIES", 72, 76], ["Unilateral or bilateral symptoms", "PROBLEM", 0, 32], ["the RVFV infection", "PROBLEM", 68, 86], ["decreased visual acuity", "PROBLEM", 129, 152], ["scotoma", "PROBLEM", 154, 161], ["acute hemorrhagic conjunctivitis", "PROBLEM", 163, 195], ["retro-orbital pain", "PROBLEM", 200, 218], ["bilateral", "ANATOMY_MODIFIER", 14, 23], ["symptoms", "OBSERVATION", 24, 32], ["infection", "OBSERVATION", 77, 86], ["decreased", "OBSERVATION_MODIFIER", 129, 138], ["visual acuity", "OBSERVATION", 139, 152], ["scotoma", "OBSERVATION", 154, 161], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["hemorrhagic", "OBSERVATION_MODIFIER", 169, 180], ["conjunctivitis", "OBSERVATION", 181, 195], ["retro-orbital", "ANATOMY", 200, 213]]], ["The most frequent and most specific ocular lesion is a macular or paramacular retinitis [86, 87] .", [["ocular lesion", "ANATOMY", 36, 49], ["macular", "ANATOMY", 55, 62], ["paramacular", "ANATOMY", 66, 77], ["ocular lesion", "DISEASE", 36, 49], ["paramacular retinitis", "DISEASE", 66, 87], ["ocular lesion", "CANCER", 36, 49], ["macular", "TISSUE", 55, 62], ["The most frequent and most specific ocular lesion", "PROBLEM", 0, 49], ["a macular or paramacular retinitis", "PROBLEM", 53, 87], ["most frequent", "OBSERVATION_MODIFIER", 4, 17], ["ocular", "ANATOMY", 36, 42], ["lesion", "OBSERVATION", 43, 49], ["macular", "OBSERVATION_MODIFIER", 55, 62], ["paramacular retinitis", "OBSERVATION", 66, 87]]], ["The funduscopy by indirect ophthalmoscopy usually shows a single well demarcated necrotic lesion with ill-defined creamy-white patchy lesions of macular retinitis with hemorrhages [84] .", [["necrotic lesion", "ANATOMY", 81, 96], ["lesions", "ANATOMY", 134, 141], ["macular", "ANATOMY", 145, 152], ["necrotic", "DISEASE", 81, 89], ["macular retinitis", "DISEASE", 145, 162], ["hemorrhages", "DISEASE", 168, 179], ["necrotic lesion", "CANCER", 81, 96], ["patchy lesions", "PATHOLOGICAL_FORMATION", 127, 141], ["macular", "TISSUE", 145, 152], ["The funduscopy", "TEST", 0, 14], ["indirect ophthalmoscopy", "TEST", 18, 41], ["a single well demarcated necrotic lesion", "PROBLEM", 56, 96], ["ill-defined creamy-white patchy lesions", "PROBLEM", 102, 141], ["macular retinitis", "PROBLEM", 145, 162], ["hemorrhages", "PROBLEM", 168, 179], ["demarcated", "OBSERVATION_MODIFIER", 70, 80], ["necrotic", "OBSERVATION_MODIFIER", 81, 89], ["lesion", "OBSERVATION", 90, 96], ["ill-defined", "OBSERVATION_MODIFIER", 102, 113], ["creamy", "OBSERVATION_MODIFIER", 114, 120], ["white", "OBSERVATION_MODIFIER", 121, 126], ["patchy", "OBSERVATION_MODIFIER", 127, 133], ["lesions", "OBSERVATION", 134, 141], ["macular retinitis", "OBSERVATION", 145, 162], ["hemorrhages", "OBSERVATION", 168, 179]]], ["The other retinal signs include arterial occlusions, vasculitis (mostly phlebitis and sometimes arteritis) [84] , sheathing of the vessels, which are best explored using fluorescein angiography.", [["retinal", "ANATOMY", 10, 17], ["arterial", "ANATOMY", 32, 40], ["vessels", "ANATOMY", 131, 138], ["retinal signs", "DISEASE", 10, 23], ["arterial occlusions", "DISEASE", 32, 51], ["vasculitis", "DISEASE", 53, 63], ["phlebitis", "DISEASE", 72, 81], ["arteritis", "DISEASE", 96, 105], ["fluorescein", "CHEMICAL", 170, 181], ["fluorescein", "CHEMICAL", 170, 181], ["retinal", "MULTI-TISSUE_STRUCTURE", 10, 17], ["arterial", "MULTI-TISSUE_STRUCTURE", 32, 40], ["vessels", "MULTI-TISSUE_STRUCTURE", 131, 138], ["fluorescein", "SIMPLE_CHEMICAL", 170, 181], ["The other retinal signs", "TEST", 0, 23], ["arterial occlusions", "PROBLEM", 32, 51], ["vasculitis", "PROBLEM", 53, 63], ["phlebitis", "PROBLEM", 72, 81], ["sometimes arteritis", "PROBLEM", 86, 105], ["fluorescein angiography", "TEST", 170, 193], ["retinal", "ANATOMY", 10, 17], ["arterial", "ANATOMY", 32, 40], ["occlusions", "OBSERVATION", 41, 51], ["vasculitis", "OBSERVATION", 53, 63], ["mostly", "OBSERVATION_MODIFIER", 65, 71], ["phlebitis", "OBSERVATION", 72, 81], ["vessels", "ANATOMY", 131, 138]]], ["In series, vitreous reaction with vitreal haze or vitritis occurred in less than one third of patients, optic-nerve head edema or palor were described in 15% of cases with retinal involvement, and no infectious optic neuropathy was reported [84, 85] .", [["vitreous", "ANATOMY", 11, 19], ["vitreal", "ANATOMY", 34, 41], ["optic-nerve head edema", "ANATOMY", 104, 126], ["palor", "ANATOMY", 130, 135], ["retinal", "ANATOMY", 172, 179], ["vitreous reaction", "DISEASE", 11, 28], ["vitritis", "DISEASE", 50, 58], ["optic-nerve head edema", "DISEASE", 104, 126], ["retinal involvement", "DISEASE", 172, 191], ["optic neuropathy", "DISEASE", 211, 227], ["vitreal", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 41], ["patients", "ORGANISM", 94, 102], ["retinal", "MULTI-TISSUE_STRUCTURE", 172, 179], ["patients", "SPECIES", 94, 102], ["vitreous reaction", "PROBLEM", 11, 28], ["vitreal haze", "PROBLEM", 34, 46], ["vitritis", "PROBLEM", 50, 58], ["optic-nerve head edema", "PROBLEM", 104, 126], ["palor", "PROBLEM", 130, 135], ["retinal involvement", "PROBLEM", 172, 191], ["infectious optic neuropathy", "PROBLEM", 200, 227], ["vitreous reaction", "OBSERVATION", 11, 28], ["vitreal haze", "OBSERVATION", 34, 46], ["vitritis", "OBSERVATION", 50, 58], ["nerve", "ANATOMY_MODIFIER", 110, 115], ["head", "ANATOMY", 116, 120], ["edema", "OBSERVATION", 121, 126], ["retinal", "ANATOMY", 172, 179], ["involvement", "OBSERVATION", 180, 191], ["no", "UNCERTAINTY", 197, 199], ["infectious", "OBSERVATION_MODIFIER", 200, 210]]], ["Anterior uveitis was associated with a posterior uveitis, defining a panuveitis with aqueous flare and fine non-granulomatous keratic precipitates [84, 85] .", [["Anterior uveitis", "DISEASE", 0, 16], ["uveitis", "DISEASE", 49, 56], ["panuveitis", "DISEASE", 69, 79], ["Anterior uveitis", "PROBLEM", 0, 16], ["a posterior uveitis", "PROBLEM", 37, 56], ["a panuveitis", "PROBLEM", 67, 79], ["aqueous flare", "PROBLEM", 85, 98], ["fine non-granulomatous keratic precipitates", "PROBLEM", 103, 146], ["uveitis", "OBSERVATION", 9, 16], ["posterior", "ANATOMY_MODIFIER", 39, 48], ["uveitis", "OBSERVATION", 49, 56], ["panuveitis", "OBSERVATION", 69, 79]]], ["Fluorescein angiography performed during the active phase of the disease may show early hypofluorescence with delayed filling of the arterioles and venules, associated with late staining of the lesions [84] .", [["arterioles", "ANATOMY", 133, 143], ["venules", "ANATOMY", 148, 155], ["lesions", "ANATOMY", 194, 201], ["Fluorescein", "CHEMICAL", 0, 11], ["Fluorescein", "CHEMICAL", 0, 11], ["Fluorescein", "SIMPLE_CHEMICAL", 0, 11], ["arterioles", "MULTI-TISSUE_STRUCTURE", 133, 143], ["venules", "MULTI-TISSUE_STRUCTURE", 148, 155], ["lesions", "PATHOLOGICAL_FORMATION", 194, 201], ["Fluorescein angiography", "TEST", 0, 23], ["the disease", "PROBLEM", 61, 72], ["early hypofluorescence", "PROBLEM", 82, 104], ["delayed filling of the arterioles and venules", "PROBLEM", 110, 155], ["late staining of the lesions", "PROBLEM", 173, 201], ["disease", "OBSERVATION", 65, 72], ["early", "OBSERVATION_MODIFIER", 82, 87], ["hypofluorescence", "OBSERVATION", 88, 104], ["delayed filling", "OBSERVATION", 110, 125], ["arterioles", "ANATOMY", 133, 143], ["venules", "ANATOMY", 148, 155], ["late", "OBSERVATION_MODIFIER", 173, 177], ["staining", "OBSERVATION_MODIFIER", 178, 186], ["lesions", "OBSERVATION", 194, 201]]], ["It also helps for the diagnosis of vasculitis, showing vessels sheathing and staining, and vascular occlusions when present.", [["vessels", "ANATOMY", 55, 62], ["vascular", "ANATOMY", 91, 99], ["vasculitis", "DISEASE", 35, 45], ["vascular occlusions", "DISEASE", 91, 110], ["vessels", "MULTI-TISSUE_STRUCTURE", 55, 62], ["vascular", "MULTI-TISSUE_STRUCTURE", 91, 99], ["vasculitis", "PROBLEM", 35, 45], ["vessels sheathing", "PROBLEM", 55, 72], ["staining", "PROBLEM", 77, 85], ["vascular occlusions", "PROBLEM", 91, 110], ["vasculitis", "OBSERVATION", 35, 45], ["vessels", "ANATOMY", 55, 62], ["vascular", "ANATOMY", 91, 99], ["occlusions", "OBSERVATION", 100, 110]]], ["Follow-up fluorescein angiography performed several months after RVF diagnosis have revealed window defect in the area of the retinitis, vascular occlusions and obliterated macular vessels [84] .", [["vascular", "ANATOMY", 137, 145], ["macular vessels", "ANATOMY", 173, 188], ["fluorescein", "CHEMICAL", 10, 21], ["retinitis", "DISEASE", 126, 135], ["vascular occlusions", "DISEASE", 137, 156], ["fluorescein", "CHEMICAL", 10, 21], ["fluorescein", "SIMPLE_CHEMICAL", 10, 21], ["vascular", "MULTI-TISSUE_STRUCTURE", 137, 145], ["macular vessels", "MULTI-TISSUE_STRUCTURE", 173, 188], ["fluorescein angiography", "TEST", 10, 33], ["RVF diagnosis", "TEST", 65, 78], ["window defect", "PROBLEM", 93, 106], ["the retinitis", "PROBLEM", 122, 135], ["vascular occlusions", "PROBLEM", 137, 156], ["obliterated macular vessels", "PROBLEM", 161, 188], ["window defect", "OBSERVATION", 93, 106], ["retinitis", "OBSERVATION", 126, 135], ["vascular", "ANATOMY", 137, 145], ["occlusions", "OBSERVATION", 146, 156], ["obliterated", "OBSERVATION_MODIFIER", 161, 172], ["macular vessels", "OBSERVATION", 173, 188]]], ["However, ophthalmoscopic and angiographic features of the RVFV associated retinitis are not specific and can be encountered in several viral or bacterial infections (Table 3 ) [85, [87] [88] [89] .", [["RVFV", "DISEASE", 58, 62], ["retinitis", "DISEASE", 74, 83], ["infections", "DISEASE", 154, 164], ["RVFV", "ORGANISM", 58, 62], ["RVFV", "SPECIES", 58, 62], ["ophthalmoscopic", "TEST", 9, 24], ["the RVFV associated retinitis", "PROBLEM", 54, 83], ["several viral or bacterial infections", "PROBLEM", 127, 164], ["RVFV", "OBSERVATION", 58, 62], ["retinitis", "OBSERVATION", 74, 83]]], ["Ocular active lesions resolve spontaneously in 10 to 12 weeks.", [["Ocular", "ANATOMY", 0, 6], ["lesions", "ANATOMY", 14, 21], ["Ocular active lesions", "DISEASE", 0, 21], ["Ocular active lesions", "PATHOLOGICAL_FORMATION", 0, 21], ["Ocular active lesions", "PROBLEM", 0, 21], ["active", "OBSERVATION_MODIFIER", 7, 13], ["lesions", "OBSERVATION", 14, 21]]], ["Macular or paramacular scarring, vascular occlusions and post-infectious optic atrophy associated to the central scarring lead to poor visual acuity outcomes.", [["Macular", "ANATOMY", 0, 7], ["paramacular", "ANATOMY", 11, 22], ["vascular", "ANATOMY", 33, 41], ["optic", "ANATOMY", 73, 78], ["Macular", "DISEASE", 0, 7], ["scarring", "DISEASE", 23, 31], ["vascular occlusions", "DISEASE", 33, 52], ["optic atrophy", "DISEASE", 73, 86], ["Macular", "TISSUE", 0, 7], ["paramacular", "MULTI-TISSUE_STRUCTURE", 11, 22], ["vascular", "MULTI-TISSUE_STRUCTURE", 33, 41], ["optic", "MULTI-TISSUE_STRUCTURE", 73, 78], ["Macular or paramacular scarring", "PROBLEM", 0, 31], ["vascular occlusions", "PROBLEM", 33, 52], ["post-infectious optic atrophy", "PROBLEM", 57, 86], ["the central scarring", "PROBLEM", 101, 121], ["poor visual acuity outcomes", "PROBLEM", 130, 157], ["paramacular", "ANATOMY", 11, 22], ["scarring", "OBSERVATION", 23, 31], ["vascular", "ANATOMY", 33, 41], ["occlusions", "OBSERVATION", 42, 52], ["post-infectious", "OBSERVATION_MODIFIER", 57, 72], ["optic atrophy", "OBSERVATION", 73, 86], ["central", "ANATOMY_MODIFIER", 105, 112], ["scarring", "OBSERVATION", 113, 121], ["poor", "OBSERVATION_MODIFIER", 130, 134], ["visual acuity", "OBSERVATION", 135, 148]]], ["Retinal complications may cause 40-50% of permanent vision loss, and up to 71% of the affected eyes reached the criteria for legal blindness [38, 84, 85] .", [["Retinal", "ANATOMY", 0, 7], ["eyes", "ANATOMY", 95, 99], ["Retinal complications", "DISEASE", 0, 21], ["vision loss", "DISEASE", 52, 63], ["blindness", "DISEASE", 131, 140], ["Retinal", "MULTI-TISSUE_STRUCTURE", 0, 7], ["eyes", "ORGAN", 95, 99], ["Retinal complications", "PROBLEM", 0, 21], ["permanent vision loss", "PROBLEM", 42, 63], ["legal blindness", "PROBLEM", 125, 140], ["complications", "OBSERVATION", 8, 21], ["vision loss", "OBSERVATION", 52, 63]]], ["No chronic anterior uveitis, posterior synechiae, iris nodules, uveitic glaucoma nor cataract were described [38, 84, 85] .", [["posterior synechiae", "ANATOMY", 29, 48], ["iris nodules", "ANATOMY", 50, 62], ["uveitic glaucoma", "ANATOMY", 64, 80], ["uveitis", "DISEASE", 20, 27], ["posterior synechiae", "DISEASE", 29, 48], ["glaucoma", "DISEASE", 72, 80], ["cataract", "DISEASE", 85, 93], ["posterior synechiae", "PATHOLOGICAL_FORMATION", 29, 48], ["iris nodules", "PATHOLOGICAL_FORMATION", 50, 62], ["chronic anterior uveitis", "PROBLEM", 3, 27], ["posterior synechiae", "PROBLEM", 29, 48], ["iris nodules", "PROBLEM", 50, 62], ["uveitic glaucoma", "PROBLEM", 64, 80], ["cataract", "PROBLEM", 85, 93], ["chronic", "OBSERVATION_MODIFIER", 3, 10], ["anterior", "ANATOMY_MODIFIER", 11, 19], ["uveitis", "OBSERVATION", 20, 27], ["posterior", "ANATOMY_MODIFIER", 29, 38], ["synechiae", "OBSERVATION", 39, 48], ["iris", "ANATOMY", 50, 54], ["nodules", "OBSERVATION", 55, 62], ["uveitic glaucoma", "OBSERVATION", 64, 80], ["cataract", "OBSERVATION", 85, 93]]], ["It is not known if the ocular manifestations of the RVF result from direct toxicity of the virus or from an immune response to the infection.", [["ocular", "ANATOMY", 23, 29], ["RVF", "DISEASE", 52, 55], ["toxicity", "DISEASE", 75, 83], ["infection", "DISEASE", 131, 140], ["ocular", "ORGAN", 23, 29], ["the ocular manifestations", "PROBLEM", 19, 44], ["the RVF", "PROBLEM", 48, 55], ["direct toxicity", "PROBLEM", 68, 83], ["the virus", "PROBLEM", 87, 96], ["the infection", "PROBLEM", 127, 140], ["not known", "UNCERTAINTY", 6, 15], ["infection", "OBSERVATION", 131, 140]]], ["Post-mortem examination suggested the presence of focal areas of retinal necrosis and retinal pigment epithelium (RPE) degeneration with round cell inflammatory infiltration and perivascular cuffing but the presence of the virus in the ocular tissues has not been proved.", [["retinal", "ANATOMY", 65, 72], ["retinal pigment epithelium", "ANATOMY", 86, 112], ["RPE", "ANATOMY", 114, 117], ["round cell", "ANATOMY", 137, 147], ["perivascular", "ANATOMY", 178, 190], ["ocular tissues", "ANATOMY", 236, 250], ["retinal necrosis", "DISEASE", 65, 81], ["retinal", "TISSUE", 65, 72], ["retinal pigment epithelium", "TISSUE", 86, 112], ["RPE", "TISSUE", 114, 117], ["round cell", "CELL", 137, 147], ["ocular tissues", "TISSUE", 236, 250], ["Post-mortem examination", "TEST", 0, 23], ["retinal necrosis", "PROBLEM", 65, 81], ["retinal pigment epithelium (RPE) degeneration", "PROBLEM", 86, 131], ["round cell inflammatory infiltration", "PROBLEM", 137, 173], ["perivascular cuffing", "PROBLEM", 178, 198], ["the virus in the ocular tissues", "PROBLEM", 219, 250], ["focal", "OBSERVATION_MODIFIER", 50, 55], ["areas", "OBSERVATION_MODIFIER", 56, 61], ["retinal", "ANATOMY", 65, 72], ["necrosis", "OBSERVATION", 73, 81], ["retinal", "ANATOMY", 86, 93], ["pigment epithelium", "OBSERVATION", 94, 112], ["degeneration", "OBSERVATION_MODIFIER", 119, 131], ["round", "OBSERVATION_MODIFIER", 137, 142], ["cell", "OBSERVATION", 143, 147], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160], ["infiltration", "OBSERVATION", 161, 173], ["perivascular", "ANATOMY_MODIFIER", 178, 190], ["cuffing", "OBSERVATION", 191, 198], ["virus", "OBSERVATION", 223, 228], ["ocular tissues", "ANATOMY", 236, 250]]], ["Most of animal models for RVF do not show any ocular disease [35, 57] .", [["ocular", "ANATOMY", 46, 52], ["RVF", "DISEASE", 26, 29], ["ocular disease", "DISEASE", 46, 60], ["ocular", "ORGAN", 46, 52], ["RVF", "SPECIES", 26, 29], ["RVF", "PROBLEM", 26, 29], ["any ocular disease", "PROBLEM", 42, 60]]], ["In a sheep model quantitative RT-PCR (qRT-PCR) was positive on eye tissues after the viremic phase [90] , but retinal complications of RVF could also be caused by antibodyrelated auto-immune reactions [86] .Congenital and neonatal infectionIn a seroprevalence study, mothers experiencing fetal death or miscarriage had the same RVFV antibody prevalence as those with normal deliveries [91] .", [["eye tissues", "ANATOMY", 63, 74], ["retinal", "ANATOMY", 110, 117], ["fetal", "ANATOMY", 288, 293], ["retinal complications", "DISEASE", 110, 131], ["RVF", "DISEASE", 135, 138], ["Congenital and neonatal infection", "DISEASE", 207, 240], ["fetal death", "DISEASE", 288, 299], ["miscarriage", "DISEASE", 303, 314], ["eye tissues", "TISSUE", 63, 74], ["retinal", "MULTI-TISSUE_STRUCTURE", 110, 117], ["RVF", "ORGANISM", 135, 138], ["mothers", "ORGANISM", 267, 274], ["fetal", "ORGAN", 288, 293], ["RVFV", "ORGANISM", 328, 332], ["RVFV antibody", "PROTEIN", 328, 341], ["sheep", "SPECIES", 5, 10], ["sheep", "SPECIES", 5, 10], ["RVFV", "SPECIES", 328, 332], ["a sheep model quantitative RT-PCR", "TEST", 3, 36], ["qRT", "TEST", 38, 41], ["PCR", "TEST", 42, 45], ["positive on eye tissues", "PROBLEM", 51, 74], ["the viremic phase", "TEST", 81, 98], ["retinal complications", "PROBLEM", 110, 131], ["RVF", "PROBLEM", 135, 138], ["antibodyrelated auto-immune reactions", "PROBLEM", 163, 200], ["Congenital and neonatal infection", "PROBLEM", 207, 240], ["a seroprevalence study", "TEST", 243, 265], ["fetal death", "PROBLEM", 288, 299], ["miscarriage", "PROBLEM", 303, 314], ["eye tissues", "ANATOMY", 63, 74], ["retinal", "ANATOMY", 110, 117], ["complications", "OBSERVATION", 118, 131], ["RVF", "OBSERVATION", 135, 138], ["neonatal", "OBSERVATION_MODIFIER", 222, 230], ["infection", "OBSERVATION", 231, 240]]], ["A retrospective study in Egypt in 1980 found no increase in the risk of abortion in humans [92] .", [["abortion", "DISEASE", 72, 80], ["humans", "ORGANISM", 84, 90], ["humans", "SPECIES", 84, 90], ["humans", "SPECIES", 84, 90], ["A retrospective study", "TEST", 0, 21], ["no", "UNCERTAINTY", 45, 47], ["increase", "OBSERVATION_MODIFIER", 48, 56]]], ["However a recent cross sectional study has demonstrated an association between infection with RVFV and miscarriage in Sudanese pregnant women (54% versus 12% of risk in non-infected pregnant women with p < 0.0001 and OR 7.4 with 95% CI [2.7-20.1] in multiple logistic regression analysis) [93] .", [["infection", "DISEASE", 79, 88], ["RVFV", "DISEASE", 94, 98], ["miscarriage", "DISEASE", 103, 114], ["RVFV", "ORGANISM", 94, 98], ["women", "ORGANISM", 136, 141], ["women", "ORGANISM", 191, 196], ["women", "SPECIES", 136, 141], ["women", "SPECIES", 191, 196], ["RVFV", "SPECIES", 94, 98], ["a recent cross sectional study", "TEST", 8, 38], ["infection", "PROBLEM", 79, 88], ["RVFV", "PROBLEM", 94, 98], ["miscarriage", "PROBLEM", 103, 114], ["CI", "TEST", 233, 235], ["multiple logistic regression analysis", "TEST", 250, 287], ["infection", "OBSERVATION", 79, 88], ["RVFV", "OBSERVATION", 94, 98]]], ["The teratogenic potential of the RVFV is unknown.", [["RVFV", "DISEASE", 33, 37], ["RVFV", "ORGANISM", 33, 37], ["RVFV", "SPECIES", 33, 37], ["the RVFV", "PROBLEM", 29, 37], ["RVFV", "OBSERVATION", 33, 37]]], ["Occasional vertical transmission has been reported, sometimes with fatal outcome in the newborn [94, 95] .", [["vertical transmission", "OBSERVATION", 11, 32]]], ["Few symptomatic infections were described in pregnant women [91] and children under the age of 10 years old [96, 97] .", [["infections", "DISEASE", 16, 26], ["women", "ORGANISM", 54, 59], ["children", "ORGANISM", 69, 77], ["women", "SPECIES", 54, 59], ["children", "SPECIES", 69, 77], ["Few symptomatic infections", "PROBLEM", 0, 26], ["symptomatic", "OBSERVATION_MODIFIER", 4, 15], ["infections", "OBSERVATION", 16, 26]]], ["The question is remaining whether it is the result of a lack of exposure to infected mosquitoes and infected animals, or if there are differences in susceptibility between animals and humans [8] .Infection prevention and control (IPC) measuresImportantly, hemorrhagic complications require high cautious infection control measures, following the CDC guidance on infection control precautions for hemorrhagic viral fevers (HVFs), while waiting for the exclusion of other HVFs such as Ebola virus disease or Crimean-Congo hemorrhagic fever [39, 98] .", [["infected mosquitoes and infected", "DISEASE", 76, 108], ["hemorrhagic", "DISEASE", 256, 267], ["infection", "DISEASE", 304, 313], ["infection", "DISEASE", 362, 371], ["hemorrhagic viral fevers", "DISEASE", 396, 420], ["HVFs", "DISEASE", 422, 426], ["HVFs", "DISEASE", 470, 474], ["Ebola virus disease", "DISEASE", 483, 502], ["Crimean-Congo hemorrhagic fever", "DISEASE", 506, 537], ["humans", "ORGANISM", 184, 190], ["Ebola virus", "ORGANISM", 483, 494], ["Crimean-Congo hemorrhagic fever", "ORGANISM", 506, 537], ["humans", "SPECIES", 184, 190], ["Ebola virus", "SPECIES", 483, 494], ["Congo hemorrhagic fever", "SPECIES", 514, 537], ["humans", "SPECIES", 184, 190], ["Ebola virus", "SPECIES", 483, 494], ["Crimean-Congo hemorrhagic fever", "SPECIES", 506, 537], ["infected mosquitoes", "PROBLEM", 76, 95], ["Infection prevention", "TREATMENT", 196, 216], ["control (IPC)", "TREATMENT", 221, 234], ["hemorrhagic complications", "PROBLEM", 256, 281], ["high cautious infection control measures", "TREATMENT", 290, 330], ["the CDC guidance", "TEST", 342, 358], ["infection control precautions", "TREATMENT", 362, 391], ["hemorrhagic viral fevers", "PROBLEM", 396, 420], ["other HVFs", "PROBLEM", 464, 474], ["Ebola virus disease", "PROBLEM", 483, 502], ["Crimean", "TEST", 506, 513], ["Congo hemorrhagic fever", "PROBLEM", 514, 537], ["infected", "OBSERVATION_MODIFIER", 76, 84], ["mosquitoes", "OBSERVATION", 85, 95], ["infected", "OBSERVATION_MODIFIER", 100, 108], ["hemorrhagic", "OBSERVATION_MODIFIER", 256, 267]]], ["Standard precautions with Personal Protective Equipment (PPE) were reported sufficient to prevent from nosocomial transmission of RVFV during the outbreak in Arabian Peninsula [99] , and must be implemented according the WHO checklist [100] , to care any suspected case regarding the theoretic risk of RVFV transmission through contact with infected blood, tissues, or other body fluids, secretions and excretions.", [["blood", "ANATOMY", 350, 355], ["tissues", "ANATOMY", 357, 364], ["body fluids", "ANATOMY", 375, 386], ["RVFV", "DISEASE", 130, 134], ["RVFV", "DISEASE", 302, 306], ["RVFV", "ORGANISM", 130, 134], ["RVFV", "ORGANISM", 302, 306], ["blood", "ORGANISM_SUBSTANCE", 350, 355], ["tissues", "TISSUE", 357, 364], ["body", "ORGANISM_SUBDIVISION", 375, 379], ["RVFV", "SPECIES", 130, 134], ["RVFV", "SPECIES", 302, 306], ["Standard precautions", "TREATMENT", 0, 20], ["Personal Protective Equipment (PPE)", "TREATMENT", 26, 61], ["infected blood, tissues", "PROBLEM", 341, 364], ["other body fluids", "TEST", 369, 386], ["secretions and excretions", "PROBLEM", 388, 413]]], ["Considering RVF is also mosquito-borne disease [56] , we recommend for all-day preventive measures against vectors using physical (long clothing and bed nets), chemical (topical repellents and insecticide impregnations) barriers in the environment of viremic patients.", [["RVF", "DISEASE", 12, 15], ["mosquito-borne disease", "DISEASE", 24, 46], ["patients", "ORGANISM", 259, 267], ["patients", "SPECIES", 259, 267], ["RVF", "SPECIES", 12, 15], ["RVF", "PROBLEM", 12, 15], ["mosquito-borne disease", "PROBLEM", 24, 46], ["physical (long clothing and bed nets)", "TREATMENT", 121, 158], ["chemical (topical repellents", "TREATMENT", 160, 188], ["insecticide impregnations", "TREATMENT", 193, 218]]], ["Considering the mean length of the viremia, these measures could be reasonably stopped 1 week after the illness onset, but there is no evidence-based cut-off time to allow donation of blood and removal of tissue or organs for transplantation from a RVFV-infected patient.Virologic confirmation of Rift Valley Fever diagnosis Collection of specimensSamples of suspected cases must be collected with PPE and safe handled adhering to BSL-3 precautions.", [["blood", "ANATOMY", 184, 189], ["tissue", "ANATOMY", 205, 211], ["organs", "ANATOMY", 215, 221], ["viremia", "DISEASE", 35, 42], ["illness", "DISEASE", 104, 111], ["RVFV-infected", "DISEASE", 249, 262], ["Rift Valley Fever", "DISEASE", 297, 314], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["tissue", "TISSUE", 205, 211], ["organs", "ORGAN", 215, 221], ["RVFV", "ORGANISM", 249, 253], ["patient", "ORGANISM", 263, 270], ["BSL-3", "GENE_OR_GENE_PRODUCT", 431, 436], ["patient", "SPECIES", 263, 270], ["RVFV", "SPECIES", 249, 253], ["the viremia", "PROBLEM", 31, 42], ["blood and removal of tissue", "TREATMENT", 184, 211], ["transplantation", "TREATMENT", 226, 241], ["Virologic confirmation", "TEST", 271, 293], ["Rift Valley Fever", "PROBLEM", 297, 314], ["Collection of specimensSamples", "TEST", 325, 355], ["suspected cases", "PROBLEM", 359, 374], ["PPE", "TREATMENT", 398, 401], ["BSL", "TEST", 431, 434], ["mean length", "OBSERVATION_MODIFIER", 16, 27], ["viremia", "OBSERVATION", 35, 42], ["no evidence", "UNCERTAINTY", 132, 143], ["infected", "OBSERVATION", 254, 262], ["Rift", "OBSERVATION_MODIFIER", 297, 301]]], ["Specimens must be labelled, packaged in accordance with the guidelines for the transport of dangerous biological goods (triple packaging), stored at 4 \u00b0C and addressed to a reference center.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9], ["triple packaging", "TREATMENT", 120, 136]]], ["If necessary, whole-blood specimens can be dried on blotting paper, stored 30-60 days and transported without refrigeration for retrospective diagnosis confirmation [9] .Diagnostic testingAccording to WHO a confirmed RVF infection relies on (i) detection of RVFV RNA by reverse transcriptasepolymerase chain reaction (RT-PCR) on sera or plasma;Diagnostic testing(ii) IgM and IgG detection by enzyme-linked immunosorbent assay (ELISA).", [["whole-blood specimens", "ANATOMY", 14, 35], ["sera", "ANATOMY", 329, 333], ["plasma", "ANATOMY", 337, 343], ["RVF infection", "DISEASE", 217, 230], ["blood specimens", "ORGANISM_SUBSTANCE", 20, 35], ["RVFV", "ORGANISM", 258, 262], ["sera", "ORGANISM_SUBSTANCE", 329, 333], ["plasma", "ORGANISM_SUBSTANCE", 337, 343], ["IgM", "GENE_OR_GENE_PRODUCT", 367, 370], ["RVFV RNA", "RNA", 258, 266], ["IgM", "PROTEIN", 367, 370], ["IgG", "PROTEIN", 375, 378], ["enzyme", "PROTEIN", 392, 398], ["RVF", "SPECIES", 217, 220], ["RVFV", "SPECIES", 258, 262], ["whole-blood specimens", "TEST", 14, 35], ["retrospective diagnosis confirmation", "TEST", 128, 164], ["RVF infection", "PROBLEM", 217, 230], ["RVFV RNA", "PROBLEM", 258, 266], ["reverse transcriptasepolymerase chain reaction", "PROBLEM", 270, 316], ["RT-PCR", "TEST", 318, 324], ["sera", "TEST", 329, 333], ["Diagnostic testing", "TEST", 344, 362], ["IgM", "TEST", 367, 370], ["IgG detection", "TEST", 375, 388], ["enzyme-linked immunosorbent assay", "TEST", 392, 425], ["infection", "OBSERVATION", 221, 230]]], ["Viral isolation is also an assay for laboratory confirmation of RVFV infection but this assay needs to be done on BSL3 and is less sensitive than detection of viral RNA by RT-PCR.", [["RVFV infection", "DISEASE", 64, 78], ["RVFV", "ORGANISM", 64, 68], ["BSL3", "GENE_OR_GENE_PRODUCT", 114, 118], ["viral RNA", "RNA", 159, 168], ["RVFV", "SPECIES", 64, 68], ["Viral isolation", "PROBLEM", 0, 15], ["an assay", "TEST", 24, 32], ["laboratory confirmation", "TEST", 37, 60], ["RVFV infection", "PROBLEM", 64, 78], ["this assay", "TEST", 83, 93], ["BSL3", "TEST", 114, 118], ["viral RNA", "PROBLEM", 159, 168], ["PCR", "TEST", 175, 178], ["RVFV", "OBSERVATION_MODIFIER", 64, 68], ["infection", "OBSERVATION", 69, 78], ["viral RNA", "OBSERVATION", 159, 168]]], ["Interestingly, RT-PCR for RVFV was reported positive for a prolonged period in urines, semen [74] and whole blood [9] .", [["urines", "ANATOMY", 79, 85], ["semen", "ANATOMY", 87, 92], ["whole blood", "ANATOMY", 102, 113], ["RVFV", "ORGANISM", 26, 30], ["urines", "ORGANISM_SUBSTANCE", 79, 85], ["semen", "ORGANISM_SUBSTANCE", 87, 92], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["RVFV", "SPECIES", 26, 30], ["RT-PCR", "TEST", 15, 21], ["RVFV", "PROBLEM", 26, 30], ["a prolonged period in urines", "PROBLEM", 57, 85], ["semen", "TEST", 87, 92], ["whole blood", "TEST", 102, 113]]], ["The RVFV RNA load in blood usually decreases between days 1 to 4 and may be detectable until day 8 after the onset of symptoms [9] .", [["blood", "ANATOMY", 21, 26], ["RVFV", "ORGANISM", 4, 8], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["RVFV", "SPECIES", 4, 8], ["The RVFV RNA load", "TEST", 0, 17], ["symptoms", "PROBLEM", 118, 126], ["RVFV", "OBSERVATION_MODIFIER", 4, 8], ["RNA load", "OBSERVATION", 9, 17], ["decreases", "OBSERVATION_MODIFIER", 35, 44]]], ["Prolonged and intense viremias were reported during acute encephalitis and hemorrhagic fever.", [["encephalitis", "DISEASE", 58, 70], ["hemorrhagic fever", "DISEASE", 75, 92], ["Prolonged and intense viremias", "PROBLEM", 0, 30], ["acute encephalitis", "PROBLEM", 52, 70], ["hemorrhagic fever", "PROBLEM", 75, 92], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["encephalitis", "OBSERVATION", 58, 70], ["hemorrhagic", "OBSERVATION_MODIFIER", 75, 86], ["fever", "OBSERVATION", 87, 92]]], ["Thus, testing of serial patient specimens collected 24 to 48 h apart may have prognostic value in determining patient outcome.", [["specimens", "ANATOMY", 32, 41], ["patient", "ORGANISM", 24, 31], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 24, 31], ["patient", "SPECIES", 110, 117], ["serial patient specimens", "TEST", 17, 41]]], ["The decrease in viral loads coincides with a rise in RVFV specific IgM and IgG antibodies that may be testing using ELISA.", [["RVFV", "ORGANISM", 53, 57], ["IgM", "GENE_OR_GENE_PRODUCT", 67, 70], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 75, 89], ["IgM", "PROTEIN", 67, 70], ["IgG antibodies", "PROTEIN", 75, 89], ["RVFV", "SPECIES", 53, 57], ["The decrease in viral loads", "PROBLEM", 0, 27], ["a rise in RVFV specific IgM", "PROBLEM", 43, 70], ["IgG antibodies", "TEST", 75, 89], ["ELISA", "TEST", 116, 121], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["viral loads", "OBSERVATION", 16, 27]]], ["The presence of IgM antibodies appears as an early transient response (day 4 to 60) and protective IgG antibodies persist for several years [36] .", [["IgM antibodies", "GENE_OR_GENE_PRODUCT", 16, 30], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 99, 113], ["IgM antibodies", "PROTEIN", 16, 30], ["IgG antibodies", "PROTEIN", 99, 113], ["IgM antibodies", "PROBLEM", 16, 30], ["protective IgG antibodies", "TEST", 88, 113], ["IgM antibodies", "OBSERVATION", 16, 30]]], ["A second convalescent blood sample collected 7-14 days after the first is necessary to confirm the seroconversion making a definitive diagnosis of a recent RVF infection.Diagnostic testingIn case of delayed-onset of encephalitis or ocular complications, imputation to RVFV may be difficult if only IgG are identified in blood at this stage.", [["blood sample", "ANATOMY", 22, 34], ["ocular", "ANATOMY", 232, 238], ["blood", "ANATOMY", 320, 325], ["RVF infection", "DISEASE", 156, 169], ["encephalitis", "DISEASE", 216, 228], ["ocular complications", "DISEASE", 232, 252], ["RVFV", "DISEASE", 268, 272], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["ocular", "ORGAN", 232, 238], ["RVFV", "ORGANISM", 268, 272], ["IgG", "GENE_OR_GENE_PRODUCT", 298, 301], ["blood", "ORGANISM_SUBSTANCE", 320, 325], ["IgG", "PROTEIN", 298, 301], ["RVF", "SPECIES", 156, 159], ["RVFV", "SPECIES", 268, 272], ["A second convalescent blood sample", "TEST", 0, 34], ["the seroconversion", "PROBLEM", 95, 113], ["a recent RVF infection", "PROBLEM", 147, 169], ["Diagnostic testing", "TEST", 170, 188], ["encephalitis", "PROBLEM", 216, 228], ["ocular complications", "PROBLEM", 232, 252], ["imputation to RVFV", "PROBLEM", 254, 272], ["IgG", "PROBLEM", 298, 301], ["RVF", "OBSERVATION_MODIFIER", 156, 159], ["infection", "OBSERVATION", 160, 169], ["encephalitis", "OBSERVATION", 216, 228], ["ocular", "ANATOMY", 232, 238], ["complications", "OBSERVATION", 239, 252]]], ["In human cases with encephalitis, specific IgM and IgG can be detected in CSF [72, 74] .", [["encephalitis", "DISEASE", 20, 32], ["human", "ORGANISM", 3, 8], ["IgM", "GENE_OR_GENE_PRODUCT", 43, 46], ["IgG", "GENE_OR_GENE_PRODUCT", 51, 54], ["CSF", "ORGANISM_SUBSTANCE", 74, 77], ["IgM", "PROTEIN", 43, 46], ["IgG", "PROTEIN", 51, 54], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["encephalitis", "PROBLEM", 20, 32], ["specific IgM", "TEST", 34, 46], ["IgG", "TEST", 51, 54], ["CSF", "TEST", 74, 77], ["encephalitis", "OBSERVATION", 20, 32]]], ["No positive RVFV cultures or RT-PCR have been reported in CSF, or on aqueous or vitreous samples and should be further tested.Treatment of RVF casesManagement of RVF human cases comprises IPC measure implementation and general supportive therapy.", [["aqueous", "ANATOMY", 69, 76], ["vitreous samples", "ANATOMY", 80, 96], ["RVF", "DISEASE", 139, 142], ["RVF", "DISEASE", 162, 165], ["RVFV", "ORGANISM", 12, 16], ["CSF", "ORGANISM_SUBSTANCE", 58, 61], ["aqueous", "ORGANISM_SUBSTANCE", 69, 76], ["vitreous samples", "ORGANISM_SUBSTANCE", 80, 96], ["human", "ORGANISM", 166, 171], ["human", "SPECIES", 166, 171], ["RVFV", "SPECIES", 12, 16], ["human", "SPECIES", 166, 171], ["positive RVFV cultures", "PROBLEM", 3, 25], ["RT-PCR", "TEST", 29, 35], ["CSF", "TEST", 58, 61], ["vitreous samples", "TEST", 80, 96], ["RVF cases", "TREATMENT", 139, 148], ["RVF human cases", "TREATMENT", 162, 177], ["IPC measure implementation", "TREATMENT", 188, 214], ["general supportive therapy", "TREATMENT", 219, 245], ["positive", "OBSERVATION_MODIFIER", 3, 11], ["RVFV", "OBSERVATION", 12, 16], ["RVF", "OBSERVATION", 139, 142]]], ["No specific treatment is currently available.", [["specific treatment", "TREATMENT", 3, 21], ["specific", "OBSERVATION_MODIFIER", 3, 11], ["treatment", "OBSERVATION", 12, 21]]], ["Iatrogenic use of medications such as hepatotoxic analgesics (acetaminophen), aspirin or non-steroid anti-inflammatory drugs, which enhance the risk of hemorrhagic complications, must be avoided in the early stage.", [["acetaminophen", "CHEMICAL", 62, 75], ["aspirin", "CHEMICAL", 78, 85], ["hemorrhagic complications", "DISEASE", 152, 177], ["acetaminophen", "CHEMICAL", 62, 75], ["aspirin", "CHEMICAL", 78, 85], ["acetaminophen", "SIMPLE_CHEMICAL", 62, 75], ["aspirin", "SIMPLE_CHEMICAL", 78, 85], ["medications", "TREATMENT", 18, 29], ["hepatotoxic analgesics", "TREATMENT", 38, 60], ["acetaminophen)", "TREATMENT", 62, 76], ["aspirin", "TREATMENT", 78, 85], ["non-steroid anti-inflammatory drugs", "TREATMENT", 89, 124], ["hemorrhagic complications", "PROBLEM", 152, 177], ["hemorrhagic", "OBSERVATION_MODIFIER", 152, 163], ["complications", "OBSERVATION", 164, 177]]], ["Co-infections or alternative diagnosis with parasitic, bacterial, fungal or viral pathogens must be considered and treated as early as possible to improve the outcome.", [["Co-infections", "DISEASE", 0, 13], ["Co-infections", "PROBLEM", 0, 13], ["parasitic", "PROBLEM", 44, 53], ["bacterial", "PROBLEM", 55, 64], ["fungal", "PROBLEM", 66, 72], ["viral pathogens", "PROBLEM", 76, 91]]], ["Severe patients should be treated empirically with broad spectrum antibacterial drugs and antimalarial molecules according to the local epidemiology.Treatment of RVF casesIn 2000, the Saudi Arabian Ministry of Health evaluated the feasibility of a randomized, placebo-controlled trial using intravenous ribavirin in patients with suspected severe RVF, but no official result was published.", [["intravenous", "ANATOMY", 291, 302], ["RVF", "DISEASE", 162, 165], ["ribavirin", "CHEMICAL", 303, 312], ["RVF", "DISEASE", 347, 350], ["ribavirin", "CHEMICAL", 303, 312], ["patients", "ORGANISM", 7, 15], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 291, 302], ["ribavirin", "SIMPLE_CHEMICAL", 303, 312], ["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 316, 324], ["broad spectrum antibacterial drugs", "TREATMENT", 51, 85], ["antimalarial molecules", "TREATMENT", 90, 112], ["placebo", "TREATMENT", 260, 267], ["intravenous ribavirin", "TREATMENT", 291, 312], ["severe RVF", "PROBLEM", 340, 350], ["severe", "OBSERVATION_MODIFIER", 340, 346], ["RVF", "OBSERVATION", 347, 350]]], ["In a WHO report of the Emerging and Dangerous Pathogens Laboratory Network in 2016, it was briefly mentioned that ribavirin was used without efficacy in Saudi Arabia [101] .", [["ribavirin", "CHEMICAL", 114, 123], ["ribavirin", "CHEMICAL", 114, 123], ["ribavirin", "SIMPLE_CHEMICAL", 114, 123], ["ribavirin", "TREATMENT", 114, 123]]], ["Evidence suggests ribavirin efficacy in animal models [102, 103] , but it failed to prevent from neuropathology in mice infected by RVFV by aerosol exposure [75] .", [["ribavirin", "CHEMICAL", 18, 27], ["neuropathology", "DISEASE", 97, 111], ["RVFV", "DISEASE", 132, 136], ["ribavirin", "CHEMICAL", 18, 27], ["ribavirin", "SIMPLE_CHEMICAL", 18, 27], ["mice", "ORGANISM", 115, 119], ["RVFV", "ORGANISM", 132, 136], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 115, 119], ["RVFV", "SPECIES", 132, 136], ["ribavirin efficacy", "TREATMENT", 18, 36], ["neuropathology", "PROBLEM", 97, 111], ["suggests", "UNCERTAINTY", 9, 17], ["ribavirin efficacy", "OBSERVATION", 18, 36]]], ["Ribavirin is recommended for the treatment and the prophylaxis of hemorrhagic fever due to arenaviruses and bunyaviruses [104] and was successfully used to cure and prevent from Lassa fever [105] .", [["Ribavirin", "CHEMICAL", 0, 9], ["hemorrhagic fever", "DISEASE", 66, 83], ["arenaviruses", "DISEASE", 91, 103], ["Lassa fever", "DISEASE", 178, 189], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["arenaviruses", "ORGANISM", 91, 103], ["Ribavirin", "TREATMENT", 0, 9], ["the treatment", "TREATMENT", 29, 42], ["the prophylaxis", "TREATMENT", 47, 62], ["hemorrhagic fever", "PROBLEM", 66, 83], ["arenaviruses", "PROBLEM", 91, 103], ["bunyaviruses", "TREATMENT", 108, 120], ["Lassa fever", "PROBLEM", 178, 189]]], ["To date, its use is not indicated when RVF diagnosis is confirmed [39, 56] .", [["RVF", "DISEASE", 39, 42], ["RVF diagnosis", "TEST", 39, 52]]], ["Antiviral drugs are under development including favipiravir T-705, 2\u2032-fluoro-2\u2032-deoxycytidine (2\u2032-FdC), and benzavir-2 [106] [107] [108] [109] .", [["favipiravir T-705, 2\u2032-fluoro-2\u2032-deoxycytidine", "CHEMICAL", 48, 93], ["2\u2032-FdC", "CHEMICAL", 95, 101], ["benzavir-2 [106] [107] [108", "CHEMICAL", 108, 135], ["favipiravir T-705", "CHEMICAL", 48, 65], ["2\u2032-fluoro-2\u2032-deoxycytidine", "CHEMICAL", 67, 93], ["2\u2032-FdC", "CHEMICAL", 95, 101], ["benzavir", "CHEMICAL", 108, 116], ["favipiravir T-705, 2\u2032-fluoro-2\u2032-deoxycytidine", "SIMPLE_CHEMICAL", 48, 93], ["2\u2032-FdC", "SIMPLE_CHEMICAL", 95, 101], ["benzavir-2 [106] [107] [108] [109]", "SIMPLE_CHEMICAL", 108, 142], ["Antiviral drugs", "TREATMENT", 0, 15], ["favipiravir T", "TREATMENT", 48, 61], ["fluoro", "TREATMENT", 70, 76], ["deoxycytidine", "TREATMENT", 80, 93]]], ["Molecules targeting viral components, host cellular components or pathways, such as the ubiquitin proteasome system, autophagy system, kinases and oxidative stress responses, have demonstrated in vitro efficacy against RVFV [110] .", [["cellular", "ANATOMY", 43, 51], ["cellular", "CELL", 43, 51], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 88, 97], ["RVFV", "ORGANISM", 219, 223], ["ubiquitin proteasome", "PROTEIN", 88, 108], ["kinases", "PROTEIN", 135, 142], ["RVFV", "SPECIES", 219, 223], ["Molecules targeting viral components", "PROBLEM", 0, 36], ["the ubiquitin proteasome system", "TREATMENT", 84, 115], ["oxidative stress responses", "PROBLEM", 147, 173], ["RVFV", "PROBLEM", 219, 223], ["viral components", "OBSERVATION_MODIFIER", 20, 36], ["host cellular", "OBSERVATION_MODIFIER", 38, 51]]], ["The use of polyclonal immunoglobulins or serum of recovered patients has not been reported.", [["serum", "ANATOMY", 41, 46], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 22, 37], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["patients", "ORGANISM", 60, 68], ["polyclonal immunoglobulins", "PROTEIN", 11, 37], ["patients", "SPECIES", 60, 68], ["polyclonal immunoglobulins", "TREATMENT", 11, 37]]], ["Specific monoclonal neutralizing antibodies could be developed in the coming years [111] .Treatment of RVF casesTo date, liver transplantation has never been attempted in RVFV fulminant hepatitis.", [["liver", "ANATOMY", 121, 126], ["RVF", "DISEASE", 103, 106], ["fulminant hepatitis", "DISEASE", 176, 195], ["liver", "ORGAN", 121, 126], ["RVFV", "ORGANISM", 171, 175], ["monoclonal neutralizing antibodies", "PROTEIN", 9, 43], ["RVFV", "SPECIES", 171, 175], ["Specific monoclonal neutralizing antibodies", "TEST", 0, 43], ["RVF cases", "PROBLEM", 103, 112], ["liver transplantation", "TREATMENT", 121, 142], ["RVFV fulminant hepatitis", "PROBLEM", 171, 195], ["monoclonal", "OBSERVATION_MODIFIER", 9, 19], ["neutralizing antibodies", "OBSERVATION", 20, 43], ["RVF", "OBSERVATION", 103, 106], ["liver", "ANATOMY", 121, 126], ["transplantation", "OBSERVATION", 127, 142], ["RVFV", "OBSERVATION_MODIFIER", 171, 175], ["fulminant", "OBSERVATION_MODIFIER", 176, 185], ["hepatitis", "OBSERVATION", 186, 195]]], ["In case reports of encephalitis, the use of amantadine, rifampicin, and dexamethasone [72] , doubled prednisone doses with a stop in immunosuppressive drugs [74] , and phenytoin [70] were reported but not evaluated precisely.", [["encephalitis", "DISEASE", 19, 31], ["amantadine", "CHEMICAL", 44, 54], ["rifampicin", "CHEMICAL", 56, 66], ["dexamethasone", "CHEMICAL", 72, 85], ["prednisone", "CHEMICAL", 101, 111], ["phenytoin", "CHEMICAL", 168, 177], ["amantadine", "CHEMICAL", 44, 54], ["rifampicin", "CHEMICAL", 56, 66], ["dexamethasone", "CHEMICAL", 72, 85], ["prednisone", "CHEMICAL", 101, 111], ["phenytoin", "CHEMICAL", 168, 177], ["amantadine", "SIMPLE_CHEMICAL", 44, 54], ["rifampicin", "SIMPLE_CHEMICAL", 56, 66], ["dexamethasone", "SIMPLE_CHEMICAL", 72, 85], ["prednisone", "SIMPLE_CHEMICAL", 101, 111], ["phenytoin", "SIMPLE_CHEMICAL", 168, 177], ["encephalitis", "PROBLEM", 19, 31], ["amantadine", "TREATMENT", 44, 54], ["rifampicin", "TREATMENT", 56, 66], ["dexamethasone", "TREATMENT", 72, 85], ["doubled prednisone doses", "TREATMENT", 93, 117], ["immunosuppressive drugs", "TREATMENT", 133, 156], ["phenytoin", "TREATMENT", 168, 177], ["encephalitis", "OBSERVATION", 19, 31]]], ["Early renal substitution therapy in patients with severe acute renal failure improve the prognosis and survival [39, 56, 81] .", [["renal", "ANATOMY", 6, 11], ["renal", "ANATOMY", 63, 68], ["acute renal failure", "DISEASE", 57, 76], ["renal", "ORGAN", 6, 11], ["patients", "ORGANISM", 36, 44], ["renal", "ORGAN", 63, 68], ["patients", "SPECIES", 36, 44], ["Early renal substitution therapy", "TREATMENT", 0, 32], ["severe acute renal failure", "PROBLEM", 50, 76], ["renal", "ANATOMY", 6, 11], ["substitution therapy", "OBSERVATION", 12, 32], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["renal", "ANATOMY", 63, 68], ["failure", "OBSERVATION", 69, 76]]], ["For eye involvement, artificial tear preparations may maintain corneal lubrication and provide temporary comfort for ocular irritation.", [["eye", "ANATOMY", 4, 7], ["tear", "ANATOMY", 32, 36], ["corneal", "ANATOMY", 63, 70], ["ocular", "ANATOMY", 117, 123], ["ocular irritation", "DISEASE", 117, 134], ["eye", "ORGAN", 4, 7], ["corneal", "TISSUE", 63, 70], ["ocular", "ORGANISM_SUBDIVISION", 117, 123], ["eye involvement", "PROBLEM", 4, 19], ["artificial tear preparations", "TREATMENT", 21, 49], ["corneal lubrication", "TREATMENT", 63, 82], ["temporary comfort", "TREATMENT", 95, 112], ["ocular irritation", "PROBLEM", 117, 134], ["ocular", "ANATOMY", 117, 123], ["irritation", "OBSERVATION", 124, 134]]], ["Topical ophthalmic steroids were used in the RVFV anterior segment manifestations [84] .", [["anterior segment", "ANATOMY", 50, 66], ["steroids", "CHEMICAL", 19, 27], ["steroids", "CHEMICAL", 19, 27], ["ophthalmic steroids", "SIMPLE_CHEMICAL", 8, 27], ["RVFV", "SPECIES", 45, 49], ["Topical ophthalmic steroids", "TREATMENT", 0, 27]]], ["Aciclovir was used in eyes lesions of other mosquito-transmitted viral disease notably chikungunya, dengue and West Nile (Table 2 ) [112] .", [["eyes lesions", "ANATOMY", 22, 34], ["Aciclovir", "CHEMICAL", 0, 9], ["viral disease", "DISEASE", 65, 78], ["chikungunya", "DISEASE", 87, 98], ["dengue", "DISEASE", 100, 106], ["Aciclovir", "CHEMICAL", 0, 9], ["Aciclovir", "SIMPLE_CHEMICAL", 0, 9], ["eyes lesions", "PATHOLOGICAL_FORMATION", 22, 34], ["West Nile (Table 2 )", "SPECIES", 111, 131], ["Aciclovir", "TREATMENT", 0, 9], ["eyes lesions", "PROBLEM", 22, 34], ["other mosquito", "PROBLEM", 38, 52], ["transmitted viral disease", "PROBLEM", 53, 78], ["chikungunya", "PROBLEM", 87, 98], ["viral disease", "OBSERVATION", 65, 78]]], ["Other antiviral drugs (e.g. ganciclovir, foscarnet) could be administrated through intravitreal routes.", [["ganciclovir", "CHEMICAL", 28, 39], ["foscarnet", "CHEMICAL", 41, 50], ["ganciclovir", "CHEMICAL", 28, 39], ["foscarnet", "CHEMICAL", 41, 50], ["ganciclovir", "SIMPLE_CHEMICAL", 28, 39], ["foscarnet", "SIMPLE_CHEMICAL", 41, 50], ["Other antiviral drugs", "TREATMENT", 0, 21], ["ganciclovir", "TREATMENT", 28, 39], ["foscarnet", "TREATMENT", 41, 50]]], ["In case of elevated intraocular pressure, antiglaucoma medications could be useful.", [["intraocular", "ANATOMY", 20, 31], ["intraocular", "IMMATERIAL_ANATOMICAL_ENTITY", 20, 31], ["elevated intraocular pressure", "PROBLEM", 11, 40], ["antiglaucoma medications", "TREATMENT", 42, 66], ["elevated", "OBSERVATION_MODIFIER", 11, 19], ["intraocular pressure", "OBSERVATION", 20, 40]]], ["Ocular surgery including cataract removal, retinal hole and detachment repair, vitrectomy, and laser ablation for neovascularization could be additional therapeutics to be evaluated.Algorithm proposal for the management of RVF cases based on their severity and complicationsBased on the clinical and biological scoring system for the prognosis of RVF established by Adam et al. [64] , the CDC definitions of suspected severe RVF cases during the major epidemic in Saudi Arabia in 2000 [42] , the updated guidelines for health workers [39] , and clinical series in literature [19, 40, 43, 45, 47, 61, 63] , we propose an algorithm to help clinicians at the bedside in the classification and referral of patients during a RVF outbreak (Fig. 4) .", [["Ocular", "ANATOMY", 0, 6], ["retinal", "ANATOMY", 43, 50], ["cataract", "DISEASE", 25, 33], ["neovascularization", "DISEASE", 114, 132], ["RVF", "DISEASE", 223, 226], ["RVF", "DISEASE", 347, 350], ["RVF", "DISEASE", 425, 428], ["RVF", "DISEASE", 720, 723], ["Ocular", "ORGAN", 0, 6], ["retinal", "MULTI-TISSUE_STRUCTURE", 43, 50], ["patients", "ORGANISM", 702, 710], ["patients", "SPECIES", 702, 710], ["Ocular surgery", "TREATMENT", 0, 14], ["cataract removal", "TREATMENT", 25, 41], ["retinal hole", "TREATMENT", 43, 55], ["detachment repair", "TREATMENT", 60, 77], ["vitrectomy", "TREATMENT", 79, 89], ["laser ablation", "TREATMENT", 95, 109], ["neovascularization", "PROBLEM", 114, 132], ["the management", "TREATMENT", 205, 219], ["RVF cases", "TREATMENT", 223, 232], ["complications", "PROBLEM", 261, 274], ["RVF", "PROBLEM", 347, 350], ["severe RVF cases", "PROBLEM", 418, 434], ["surgery", "OBSERVATION", 7, 14], ["cataract", "OBSERVATION", 25, 33], ["retinal", "ANATOMY", 43, 50], ["hole", "OBSERVATION_MODIFIER", 51, 55], ["detachment repair", "OBSERVATION", 60, 77], ["vitrectomy", "OBSERVATION", 79, 89], ["neovascularization", "OBSERVATION", 114, 132], ["severe", "OBSERVATION_MODIFIER", 418, 424], ["RVF", "OBSERVATION", 425, 428]]], ["Using the dengue model for case management, we identified clinical and biological warning signs defining complicated cases at risk of severe illness and requiring hospitalization for medical supervision, as we already proposed for chikungunya [113] .", [["dengue", "DISEASE", 10, 16], ["illness", "DISEASE", 141, 148], ["chikungunya", "DISEASE", 231, 242], ["dengue", "SPECIES", 10, 16], ["case management", "TREATMENT", 27, 42], ["severe illness", "PROBLEM", 134, 148], ["chikungunya", "PROBLEM", 231, 242], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["illness", "OBSERVATION", 141, 148]]], ["Severe illness included hemorrhagic fever, neurological disorders or hepatic/ renal failures requiring intensive cares.", [["neurological", "ANATOMY", 43, 55], ["hepatic", "ANATOMY", 69, 76], ["renal", "ANATOMY", 78, 83], ["illness", "DISEASE", 7, 14], ["hemorrhagic fever", "DISEASE", 24, 41], ["neurological disorders", "DISEASE", 43, 65], ["hepatic/ renal failures", "DISEASE", 69, 92], ["hepatic", "ORGAN", 69, 76], ["renal", "ORGAN", 78, 83], ["Severe illness", "PROBLEM", 0, 14], ["hemorrhagic fever", "PROBLEM", 24, 41], ["neurological disorders", "PROBLEM", 43, 65], ["hepatic/ renal failures", "PROBLEM", 69, 92], ["intensive cares", "TREATMENT", 103, 118], ["hemorrhagic", "OBSERVATION_MODIFIER", 24, 35], ["fever", "OBSERVATION", 36, 41], ["hepatic", "ANATOMY", 69, 76], ["renal", "ANATOMY", 78, 83], ["failures", "OBSERVATION", 84, 92]]], ["Ocular signs were classified as complications.", [["Ocular", "ANATOMY", 0, 6], ["Ocular", "ORGAN", 0, 6], ["Ocular signs", "PROBLEM", 0, 12], ["complications", "PROBLEM", 32, 45]]], ["Ophthalmologic examination should be prospectively performed in all confirmed cases to detect early asymptomatic RVFV ocular signs and evaluate their potential ability to predict the occurrence of neuro-ophthalmologic complications.", [["ocular", "ANATOMY", 118, 124], ["RVFV", "SPECIES", 113, 117], ["Ophthalmologic examination", "TEST", 0, 26], ["early asymptomatic RVFV ocular signs", "PROBLEM", 94, 130], ["neuro-ophthalmologic complications", "PROBLEM", 197, 231]]], ["This should at least include visual acuity determination, intra-ocular pressure measurement, slit-lamp biomicroscopy and funduscopy by indirect ophthalmoscopy.", [["intra-ocular", "ANATOMY", 58, 70], ["visual acuity determination", "TEST", 29, 56], ["intra-ocular pressure measurement", "TEST", 58, 91], ["slit-lamp biomicroscopy", "TEST", 93, 116], ["funduscopy", "TEST", 121, 131], ["indirect ophthalmoscopy", "TEST", 135, 158]]], ["In case of RVF signs, a fluorescein angiography should be performed as well as fundus photography if available.", [["fundus", "ANATOMY", 79, 85], ["RVF", "DISEASE", 11, 14], ["fluorescein", "CHEMICAL", 24, 35], ["fluorescein", "CHEMICAL", 24, 35], ["fluorescein", "SIMPLE_CHEMICAL", 24, 35], ["fundus", "MULTI-TISSUE_STRUCTURE", 79, 85], ["RVF signs", "PROBLEM", 11, 20], ["a fluorescein angiography", "TEST", 22, 47], ["fundus photography", "TEST", 79, 97], ["RVF", "OBSERVATION", 11, 14]]], ["Indocyanine Green angiography has not been evaluated yet in FVR ocular manifestation but could possibly bring arguments for a choroidal involvement since a delayed peripapillary choroidal filling in the arteriovenous phase of fluorescein angiography has been described [38, 85] .", [["ocular", "ANATOMY", 64, 70], ["choroidal", "ANATOMY", 126, 135], ["choroidal", "ANATOMY", 178, 187], ["arteriovenous", "ANATOMY", 203, 216], ["Indocyanine Green", "CHEMICAL", 0, 17], ["fluorescein", "CHEMICAL", 226, 237], ["fluorescein", "CHEMICAL", 226, 237], ["Indocyanine", "SIMPLE_CHEMICAL", 0, 11], ["choroidal", "MULTI-TISSUE_STRUCTURE", 126, 135], ["choroidal", "MULTI-TISSUE_STRUCTURE", 178, 187], ["fluorescein", "SIMPLE_CHEMICAL", 226, 237], ["Indocyanine Green angiography", "TEST", 0, 29], ["FVR ocular manifestation", "PROBLEM", 60, 84], ["a choroidal involvement", "PROBLEM", 124, 147], ["a delayed peripapillary choroidal filling", "PROBLEM", 154, 195], ["fluorescein angiography", "TEST", 226, 249], ["choroidal", "ANATOMY", 126, 135], ["peripapillary", "OBSERVATION_MODIFIER", 164, 177], ["choroidal filling", "OBSERVATION", 178, 195], ["arteriovenous phase", "OBSERVATION", 203, 222]]], ["Optic Coherence Tomography (OCT) is a recent technique that is yet to be evaluated in the retinal complications of RVF.", [["retinal", "ANATOMY", 90, 97], ["retinal complications", "DISEASE", 90, 111], ["RVF", "DISEASE", 115, 118], ["retinal", "MULTI-TISSUE_STRUCTURE", 90, 97], ["Optic Coherence Tomography", "TEST", 0, 26], ["a recent technique", "TEST", 36, 54], ["RVF", "PROBLEM", 115, 118], ["retinal", "ANATOMY", 90, 97], ["complications", "OBSERVATION", 98, 111], ["RVF", "OBSERVATION", 115, 118]]], ["OCT could be helpful to describe the retinal lesions and their evolution through time, and could help elucidate the nature of the macular exudate-like lesions described before [114] .", [["retinal lesions", "ANATOMY", 37, 52], ["macular exudate-like lesions", "ANATOMY", 130, 158], ["retinal lesions", "PATHOLOGICAL_FORMATION", 37, 52], ["macular exudate", "PATHOLOGICAL_FORMATION", 130, 145], ["-like lesions", "CANCER", 145, 158], ["OCT", "TEST", 0, 3], ["the retinal lesions", "PROBLEM", 33, 52], ["the macular exudate", "PROBLEM", 126, 145], ["lesions", "PROBLEM", 151, 158], ["retinal", "ANATOMY", 37, 44], ["lesions", "OBSERVATION", 45, 52], ["macular", "ANATOMY", 130, 137], ["exudate", "OBSERVATION", 138, 145], ["lesions", "OBSERVATION", 151, 158]]], ["We recommend to follow-up RVF patients for at least 1 month after the onset of symptoms to monitor for possible delayed neurological and/or ocular complications.", [["neurological", "ANATOMY", 120, 132], ["ocular", "ANATOMY", 140, 146], ["RVF", "DISEASE", 26, 29], ["neurological and/or ocular complications", "DISEASE", 120, 160], ["RVF", "ORGANISM", 26, 29], ["patients", "ORGANISM", 30, 38], ["ocular", "ORGAN", 140, 146], ["patients", "SPECIES", 30, 38], ["symptoms", "PROBLEM", 79, 87], ["delayed neurological and/or ocular complications", "PROBLEM", 112, 160], ["ocular", "ANATOMY", 140, 146], ["complications", "OBSERVATION", 147, 160]]], ["In the lack of adequate medical support, considering the diversity and time course of RVF complications, medical evacuation of confirmed cases may be considered, except if hemorrhages because this presentation is a highly contagious vital emergency.ConclusionRift Valley Fever has emerged and extended outside Africa in the 2000s, leading to the re-description of the human disease.", [["RVF", "DISEASE", 86, 89], ["hemorrhages", "DISEASE", 172, 183], ["Rift Valley Fever", "DISEASE", 259, 276], ["human", "ORGANISM", 368, 373], ["human", "SPECIES", 368, 373], ["human", "SPECIES", 368, 373], ["adequate medical support", "TREATMENT", 15, 39], ["RVF complications", "PROBLEM", 86, 103], ["medical evacuation", "TEST", 105, 123], ["hemorrhages", "PROBLEM", 172, 183], ["Rift Valley Fever", "PROBLEM", 259, 276], ["the human disease", "PROBLEM", 364, 381], ["human disease", "OBSERVATION", 368, 381]]], ["There is a global concern about the risk of RVFV exportation in areas where competent vectors are present including Europe and North America.", [["RVFV", "ORGANISM", 44, 48], ["RVFV", "SPECIES", 44, 48], ["RVFV exportation", "PROBLEM", 44, 60], ["global", "OBSERVATION_MODIFIER", 11, 17], ["RVFV", "OBSERVATION", 44, 48], ["competent vectors", "OBSERVATION", 76, 93]]], ["Economic losses, human morbidity and mortality may be significant during epidemics.", [["human", "ORGANISM", 17, 22], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["Economic losses", "PROBLEM", 0, 15], ["human morbidity", "PROBLEM", 17, 32]]], ["Infection with RVF has a wide clinical spectrum and may result in delayed complications.", [["Infection", "DISEASE", 0, 9], ["RVF", "DISEASE", 15, 18], ["RVF", "SPECIES", 15, 18], ["Infection", "PROBLEM", 0, 9], ["RVF", "PROBLEM", 15, 18], ["delayed complications", "PROBLEM", 66, 87], ["RVF", "OBSERVATION", 15, 18]]], ["There are no commercially licensed vaccines nor antiviral treatment for humans.", [["humans", "ORGANISM", 72, 78], ["humans", "SPECIES", 72, 78], ["humans", "SPECIES", 72, 78], ["commercially licensed vaccines", "TREATMENT", 13, 43], ["antiviral treatment", "TREATMENT", 48, 67], ["no", "UNCERTAINTY", 10, 12], ["antiviral treatment", "OBSERVATION", 48, 67]]], ["Human cases are often detected when the virus has already spread among livestock and people, hence outbreak control is challenging.", [["Human", "ORGANISM", 0, 5], ["people", "ORGANISM", 85, 91], ["Human", "SPECIES", 0, 5], ["people", "SPECIES", 85, 91], ["Human", "SPECIES", 0, 5], ["Human cases", "PROBLEM", 0, 11], ["the virus", "PROBLEM", 36, 45]]], ["Thus, human case surveillance systems for early detection and correct management are essential to reduce global morbidity and mortality.", [["human", "ORGANISM", 6, 11], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11], ["human case surveillance systems", "TEST", 6, 37], ["early detection", "TEST", 42, 57], ["correct management", "TREATMENT", 62, 80], ["global morbidity", "PROBLEM", 105, 121], ["morbidity", "OBSERVATION", 112, 121]]], ["We identified frontiers of knowledge and remaining uncertainties concerning RVF which deserves more interest.", [["RVF", "DISEASE", 76, 79], ["RVF", "PROBLEM", 76, 79]]], ["In particular, therapeutic trials on specific supportive care, antiviral molecules or immunotherapies, should be anticipated to be implemented at the start of future epidemics.", [["therapeutic trials", "TREATMENT", 15, 33], ["specific supportive care", "TREATMENT", 37, 61], ["antiviral molecules", "TREATMENT", 63, 82], ["immunotherapies", "TREATMENT", 86, 101]]]], "PMC7162411": [["IntroductionThe genome of alphaviruses is a positive RNA molecule (gmRNA) of about 9\u201311 kb, which directs viral protein synthesis upon infection (Griffin, 2007).", [["infection", "DISEASE", 135, 144], ["alphaviruses", "ORGANISM", 26, 38], ["gmRNA", "GENE_OR_GENE_PRODUCT", 67, 72], ["positive RNA molecule", "PROTEIN", 44, 65], ["gmRNA", "PROTEIN", 67, 72], ["alphaviruses", "PROBLEM", 26, 38], ["a positive RNA molecule", "PROBLEM", 42, 65], ["viral protein synthesis upon infection", "PROBLEM", 106, 144], ["alphaviruses", "OBSERVATION", 26, 38], ["viral protein synthesis", "OBSERVATION", 106, 129]]], ["The genome contains two cistrons: the first is located in the 5\u2032 two\u2010thirds of the genome and encodes nonstructural proteins (nsPs) that form the viral replication machinery (Jose et al., 2009).", [["nsPs", "GENE_OR_GENE_PRODUCT", 126, 130], ["cistrons", "DNA", 24, 32], ["5\u2032 two\u2010thirds", "DNA", 62, 75], ["nonstructural proteins", "PROTEIN", 102, 124], ["nsPs", "PROTEIN", 126, 130], ["two", "OBSERVATION_MODIFIER", 20, 23], ["cistrons", "OBSERVATION", 24, 32], ["genome", "ANATOMY", 83, 89], ["nonstructural proteins", "OBSERVATION", 102, 124], ["viral replication", "OBSERVATION", 146, 163]]], ["The second open reading frame encodes for the structural proteins that form part of the virus particles, and are synthesized from a subgenomic mRNA (sgmRNA; Strauss and Strauss, 1994).", [["open reading frame", "DNA", 11, 29], ["structural proteins", "PROTEIN", 46, 65], ["subgenomic mRNA", "RNA", 132, 147], ["the structural proteins", "PROBLEM", 42, 65], ["the virus particles", "PROBLEM", 84, 103], ["a subgenomic mRNA", "PROBLEM", 130, 147], ["virus", "OBSERVATION", 88, 93], ["subgenomic mRNA", "OBSERVATION", 132, 147]]], ["Sindbis virus (SINV) is one of the most studied members of alphaviruses and represents a good model to analyse the regulation of protein synthesis in virus\u2010infected cells.", [["virus\u2010infected cells", "ANATOMY", 150, 170], ["Sindbis virus", "ORGANISM", 0, 13], ["SINV", "ORGANISM", 15, 19], ["alphaviruses", "ORGANISM", 59, 71], ["virus\u2010infected cells", "CELL", 150, 170], ["virus\u2010infected cells", "CELL_TYPE", 150, 170], ["Sindbis virus", "SPECIES", 0, 13], ["Sindbis virus", "SPECIES", 0, 13], ["SINV", "SPECIES", 15, 19], ["Sindbis virus", "PROBLEM", 0, 13], ["alphaviruses", "PROBLEM", 59, 71], ["protein synthesis in virus\u2010infected cells", "PROBLEM", 129, 170], ["alphaviruses", "OBSERVATION", 59, 71], ["protein synthesis", "OBSERVATION", 129, 146], ["virus\u2010infected cells", "OBSERVATION", 150, 170]]], ["After virus entry, the genome is delivered to the cytoplasm and is translated to produce nsP1\u20104, which participates in genome replication and transcription (Strauss and Strauss, 1994).", [["cytoplasm", "ANATOMY", 50, 59], ["cytoplasm", "ORGANISM_SUBSTANCE", 50, 59], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 89, 95], ["genome", "CELLULAR_COMPONENT", 119, 125], ["nsP1\u20104", "DNA", 89, 95], ["genome replication", "OBSERVATION", 119, 137]]], ["These nsPs are synthesized from a single AUG initiation codon rendering two precursor polyproteins, which are proteolytically processed by nsP2 (de Groot et al., 1990).", [["nsPs", "GENE_OR_GENE_PRODUCT", 6, 10], ["nsP2", "GENE_OR_GENE_PRODUCT", 139, 143], ["nsPs", "DNA", 6, 10], ["AUG initiation codon", "DNA", 41, 61], ["a single AUG initiation codon", "TREATMENT", 32, 61], ["two precursor polyproteins", "PROBLEM", 72, 98], ["precursor polyproteins", "OBSERVATION", 76, 98]]], ["After initiation at the first AUG initiation codon present in gmRNA, the majority of ribosomes (90\u201395%) translates this template until a stop codon (UGA) is encountered, producing the precursor P123.", [["ribosomes", "ANATOMY", 85, 94], ["ribosomes", "CELLULAR_COMPONENT", 85, 94], ["P123", "GENE_OR_GENE_PRODUCT", 194, 198], ["AUG initiation codon", "DNA", 30, 50], ["gmRNA", "DNA", 62, 67], ["ribosomes", "RNA", 85, 94], ["stop codon", "DNA", 137, 147], ["UGA", "DNA", 149, 152], ["precursor P123", "PROTEIN", 184, 198], ["this template", "TREATMENT", 115, 128], ["a stop codon (UGA", "PROBLEM", 135, 152]]], ["However, in a small proportion of cases, there is readthrough of this stop codon, generating the precursor P1234.", [["stop codon", "DNA", 70, 80], ["precursor P1234", "PROTEIN", 97, 112], ["this stop codon", "TREATMENT", 65, 80]]], ["The four nsPs are generated after proteolytic cleavage of the polyprotein precursors.", [["nsPs", "GENE_OR_GENE_PRODUCT", 9, 13], ["nsPs", "PROTEIN", 9, 13], ["proteolytic cleavage", "TREATMENT", 34, 54], ["the polyprotein precursors", "TREATMENT", 58, 84], ["polyprotein precursors", "OBSERVATION", 62, 84]]], ["Thus, nsP1 is an abundant component of the replicative complex and exhibits its activity either as a mature protein or in the form of precursors P123 or P1234. nsP1 is a palmitoylated protein that participates directly in initiation and elongation of the minus\u2010strand RNA synthesis (Hahn et al., 1989; Wang et al., 1991).", [["nsP1", "CHEMICAL", 160, 164], ["P1234", "CHEMICAL", 153, 158], ["nsP1", "GENE_OR_GENE_PRODUCT", 6, 10], ["P123", "GENE_OR_GENE_PRODUCT", 145, 149], ["P1234", "GENE_OR_GENE_PRODUCT", 153, 158], ["nsP1", "GENE_OR_GENE_PRODUCT", 160, 164], ["nsP1", "PROTEIN", 6, 10], ["replicative complex", "PROTEIN", 43, 62], ["mature protein", "PROTEIN", 101, 115], ["P123", "PROTEIN", 145, 149], ["nsP1", "PROTEIN", 160, 164], ["palmitoylated protein", "PROTEIN", 170, 191], ["minus\u2010strand RNA", "RNA", 255, 271], ["nsP1", "PROBLEM", 6, 10], ["the replicative complex", "PROBLEM", 39, 62], ["nsP1", "PROBLEM", 160, 164], ["a palmitoylated protein", "PROBLEM", 168, 191], ["abundant", "OBSERVATION_MODIFIER", 17, 25], ["component", "OBSERVATION_MODIFIER", 26, 35], ["replicative", "OBSERVATION_MODIFIER", 43, 54], ["complex", "OBSERVATION_MODIFIER", 55, 62], ["palmitoylated protein", "OBSERVATION", 170, 191], ["elongation", "OBSERVATION_MODIFIER", 237, 247]]], ["During this process, nsP1 interacts with nsP4 (Shirako et al., 2000; Fata et al., 2002).", [["nsP1", "GENE_OR_GENE_PRODUCT", 21, 25], ["nsP4", "GENE_OR_GENE_PRODUCT", 41, 45], ["nsP1", "PROTEIN", 21, 25], ["nsP4", "PROTEIN", 41, 45], ["nsP1", "PROBLEM", 21, 25], ["nsP4", "PROBLEM", 41, 45]]], ["Different moieties have been recognized in nsP1.", [["nsP1", "GENE_OR_GENE_PRODUCT", 43, 47], ["nsP1", "PROTEIN", 43, 47]]], ["The N\u2010terminal region exhibits methyltransferase and guanylyltransferase activities involved in capping the viral positive\u2010strand RNAs (Mi et al., 1989; Peranen et al., 1995; Ahola et al., 1997).", [["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 53, 72], ["N\u2010terminal region", "DNA", 4, 21], ["viral positive\u2010strand RNAs", "RNA", 108, 134], ["The N\u2010terminal region", "TREATMENT", 0, 21], ["methyltransferase and guanylyltransferase activities", "TREATMENT", 31, 83], ["methyltransferase", "OBSERVATION", 31, 48]]], ["Association with cellular membranes is promoted by an amphipatic helix located in the middle region of nsP1 (Peranen et al., 1995) that serves to anchor viral replicative complexes to membranes (Salonen et al., 2003).", [["cellular membranes", "ANATOMY", 17, 35], ["middle region", "ANATOMY", 86, 99], ["membranes", "ANATOMY", 184, 193], ["cellular membranes", "CELLULAR_COMPONENT", 17, 35], ["membranes", "CELLULAR_COMPONENT", 184, 193], ["amphipatic helix", "PROTEIN", 54, 70], ["nsP1", "PROTEIN", 103, 107], ["viral replicative complexes", "PROTEIN", 153, 180], ["cellular membranes", "PROBLEM", 17, 35], ["an amphipatic helix", "PROBLEM", 51, 70], ["cellular membranes", "OBSERVATION", 17, 35], ["middle", "ANATOMY_MODIFIER", 86, 92], ["region", "ANATOMY_MODIFIER", 93, 99]]], ["Several domains have also been distinguished in nsP2: an amino\u2010terminal RNA helicase domain, a central protease domain that catalyses all cleavage reactions between the nonstructural proteins and an inactive RNA methyltransferase\u2010like domain (Gomez de Cedron et al., 1999; Russo et al., 2006).", [["nsP2", "GENE_OR_GENE_PRODUCT", 48, 52], ["nsP2", "PROTEIN", 48, 52], ["amino\u2010terminal RNA helicase domain", "PROTEIN", 57, 91], ["central protease domain", "PROTEIN", 95, 118], ["nonstructural proteins", "PROTEIN", 169, 191], ["inactive RNA methyltransferase\u2010like domain", "PROTEIN", 199, 241], ["an amino\u2010terminal RNA helicase domain", "TREATMENT", 54, 91], ["a central protease domain", "TREATMENT", 93, 118], ["all cleavage reactions", "PROBLEM", 134, 156], ["the nonstructural proteins", "PROBLEM", 165, 191], ["nsP2", "OBSERVATION", 48, 52], ["nonstructural proteins", "OBSERVATION", 169, 191]]], ["Apart from its function in viral RNA synthesis, nsP2 is also involved in the interference with cellular transcription and translation.", [["cellular", "ANATOMY", 95, 103], ["nsP2", "GENE_OR_GENE_PRODUCT", 48, 52], ["cellular", "CELL", 95, 103], ["nsP2", "PROTEIN", 48, 52], ["viral RNA synthesis", "PROBLEM", 27, 46], ["nsP2", "PROBLEM", 48, 52], ["cellular transcription", "TREATMENT", 95, 117], ["function", "OBSERVATION_MODIFIER", 15, 23], ["viral RNA synthesis", "OBSERVATION", 27, 46]]], ["Accordingly, nsP2 can antagonize cellular antiviral responses triggered by alphavirus infection (Garmashova et al., 2006; Breakwell et al., 2007).", [["cellular", "ANATOMY", 33, 41], ["nsP2", "CHEMICAL", 13, 17], ["alphavirus infection", "DISEASE", 75, 95], ["nsP2", "GENE_OR_GENE_PRODUCT", 13, 17], ["cellular", "CELL", 33, 41], ["alphavirus", "ORGANISM", 75, 85], ["nsP2", "PROTEIN", 13, 17], ["nsP2", "PROBLEM", 13, 17], ["alphavirus infection", "PROBLEM", 75, 95]]], ["Indeed, a proportion of nsP2 localizes to the nucleus and blocks cellular RNA export to the cytoplasm (Rikkonen et al., 1994; Breakwell et al., 2007).", [["nucleus", "ANATOMY", 46, 53], ["cellular", "ANATOMY", 65, 73], ["cytoplasm", "ANATOMY", 92, 101], ["nsP2", "GENE_OR_GENE_PRODUCT", 24, 28], ["nucleus", "CELLULAR_COMPONENT", 46, 53], ["cellular", "CELL", 65, 73], ["cytoplasm", "ORGANISM_SUBSTANCE", 92, 101], ["nsP2", "PROTEIN", 24, 28], ["nsP2", "PROBLEM", 24, 28], ["nsP2", "OBSERVATION", 24, 28], ["nucleus", "ANATOMY", 46, 53], ["blocks", "OBSERVATION_MODIFIER", 58, 64], ["cellular RNA", "OBSERVATION", 65, 77]]], ["The precise role of nsP3 in virus replication remains poorly understood. nsP3 can be organized into three domains: an amino\u2010terminal macro or X domain (Koonin et al., 1992), a central alphavirus specific region and a carboxyl region with an hypervariable sequence.", [["nsP3", "CHEMICAL", 73, 77], ["amino\u2010terminal", "CHEMICAL", 118, 132], ["carboxyl", "CHEMICAL", 217, 225], ["nsP3", "GENE_OR_GENE_PRODUCT", 20, 24], ["nsP3", "GENE_OR_GENE_PRODUCT", 73, 77], ["nsP3", "PROTEIN", 20, 24], ["nsP3", "PROTEIN", 73, 77], ["amino\u2010terminal macro or X domain", "PROTEIN", 118, 150], ["central alphavirus specific region", "PROTEIN", 176, 210], ["carboxyl region", "PROTEIN", 217, 232], ["nsP3 in virus replication", "TREATMENT", 20, 45], ["nsP3", "PROBLEM", 73, 77], ["a central alphavirus specific region", "PROBLEM", 174, 210], ["a carboxyl region", "TREATMENT", 215, 232], ["an hypervariable sequence", "TEST", 238, 263], ["central", "ANATOMY_MODIFIER", 176, 183], ["alphavirus", "OBSERVATION", 184, 194]]], ["Residues located just after the macro domain of nsP3 play a role in positioning of the P23 cleavage site (Lulla et al., 2012).", [["nsP3", "GENE_OR_GENE_PRODUCT", 48, 52], ["P23", "GENE_OR_GENE_PRODUCT", 87, 90], ["macro domain", "PROTEIN", 32, 44], ["nsP3", "PROTEIN", 48, 52], ["P23 cleavage site", "DNA", 87, 104], ["the macro domain of nsP3", "TREATMENT", 28, 52], ["the P23 cleavage site", "TREATMENT", 83, 104], ["nsP3", "OBSERVATION", 48, 52]]], ["Additionally, the carboxyl terminal region of nsP3 contains several phosphorylation sites (Vihinen et al., 2001). nsP3 blocks the formation of host cellular stress granules (SGs) through the interaction of its carboxy terminal domain with Ras\u2010GTPase activating protein\u2010binding protein (G3BP), leading to the disruption of these granules that are involved in innate antiviral mechanisms (Fros et al., 2012; Panas et al., 2012).", [["cellular stress granules", "ANATOMY", 148, 172], ["SGs", "ANATOMY", 174, 177], ["granules", "ANATOMY", 328, 336], ["nsP3", "CHEMICAL", 114, 118], ["carboxyl", "CHEMICAL", 18, 26], ["carboxy", "CHEMICAL", 210, 217], ["nsP3", "GENE_OR_GENE_PRODUCT", 46, 50], ["nsP3", "GENE_OR_GENE_PRODUCT", 114, 118], ["cellular", "CELL", 148, 156], ["stress granules", "CELLULAR_COMPONENT", 157, 172], ["SGs", "CELLULAR_COMPONENT", 174, 177], ["Ras\u2010GTPase activating protein\u2010binding protein", "GENE_OR_GENE_PRODUCT", 239, 284], ["G3BP", "GENE_OR_GENE_PRODUCT", 286, 290], ["granules", "CELLULAR_COMPONENT", 328, 336], ["carboxyl terminal region", "PROTEIN", 18, 42], ["nsP3", "PROTEIN", 46, 50], ["phosphorylation sites", "PROTEIN", 68, 89], ["nsP3", "PROTEIN", 114, 118], ["carboxy terminal domain", "PROTEIN", 210, 233], ["Ras\u2010GTPase activating protein\u2010binding protein", "PROTEIN", 239, 284], ["G3BP", "PROTEIN", 286, 290], ["the carboxyl terminal region of nsP3", "PROBLEM", 14, 50], ["several phosphorylation sites", "PROBLEM", 60, 89], ["nsP3 blocks", "PROBLEM", 114, 125], ["host cellular stress granules", "PROBLEM", 143, 172], ["its carboxy terminal domain", "PROBLEM", 206, 233], ["Ras\u2010GTPase activating protein\u2010binding protein", "PROBLEM", 239, 284], ["the disruption of these granules", "PROBLEM", 304, 336], ["carboxyl", "OBSERVATION_MODIFIER", 18, 26], ["terminal", "OBSERVATION_MODIFIER", 27, 35], ["nsP3", "OBSERVATION", 46, 50], ["several", "OBSERVATION_MODIFIER", 60, 67], ["phosphorylation sites", "OBSERVATION", 68, 89], ["host cellular", "OBSERVATION", 143, 156], ["stress granules", "OBSERVATION", 157, 172], ["granules", "OBSERVATION", 328, 336]]], ["Finally, nsP4 is an RNA\u2010dependent RNA polymerase that is involved in the synthesis of the different viral RNAs, i.e. gmRNA, sgmRNA and minus\u2010stranded RNA complementary to the genome (Rubach et al., 2009).", [["nsP4", "GENE_OR_GENE_PRODUCT", 9, 13], ["gmRNA", "GENE_OR_GENE_PRODUCT", 117, 122], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 124, 130], ["nsP4", "PROTEIN", 9, 13], ["RNA\u2010dependent RNA polymerase", "RNA", 20, 48], ["viral RNAs", "RNA", 100, 110], ["gmRNA, sgmRNA and minus\u2010stranded RNA", "RNA", 117, 153], ["nsP4", "PROBLEM", 9, 13], ["an RNA\u2010dependent RNA polymerase", "PROBLEM", 17, 48], ["the different viral RNAs", "PROBLEM", 86, 110], ["gmRNA", "PROBLEM", 117, 122], ["sgmRNA", "PROBLEM", 124, 130], ["viral RNAs", "OBSERVATION", 100, 110]]], ["Both P123 + nsP4 and nsP1 + P23 + nsP4 preferentially synthesize the negative strand of viral RNA (Lemm et al., 1994; Shirako and Strauss, 1994).", [["P123", "GENE_OR_GENE_PRODUCT", 5, 9], ["nsP4", "GENE_OR_GENE_PRODUCT", 12, 16], ["nsP1 + P23 + nsP4", "GENE_OR_GENE_PRODUCT", 21, 38], ["P123", "PROTEIN", 5, 9], ["nsP4", "PROTEIN", 12, 16], ["nsP1", "PROTEIN", 21, 25], ["P23", "PROTEIN", 28, 31], ["nsP4", "PROTEIN", 34, 38], ["viral RNA", "RNA", 88, 97], ["P123", "TEST", 5, 9], ["nsP4", "TEST", 12, 16], ["nsP1", "TEST", 21, 25], ["P23", "TEST", 28, 31], ["nsP4", "PROBLEM", 34, 38], ["nsP1 + P23", "OBSERVATION", 21, 31], ["negative strand", "OBSERVATION", 69, 84], ["viral RNA", "OBSERVATION", 88, 97]]], ["The final cleavage event of P23 produces fully mature nsPs and switches the RNA template for synthesis of positive sense genomic and subgenomic RNAs.", [["P23", "GENE_OR_GENE_PRODUCT", 28, 31], ["nsPs", "GENE_OR_GENE_PRODUCT", 54, 58], ["P23", "PROTEIN", 28, 31], ["nsPs", "PROTEIN", 54, 58], ["RNA template", "RNA", 76, 88], ["positive sense genomic and subgenomic RNAs", "RNA", 106, 148], ["P23", "PROBLEM", 28, 31], ["the RNA template", "TREATMENT", 72, 88], ["positive sense genomic and subgenomic RNAs", "PROBLEM", 106, 148], ["positive sense genomic", "OBSERVATION", 106, 128], ["subgenomic RNAs", "OBSERVATION", 133, 148]]], ["The correlation between P23 cleavage and the change from negative to positive sense RNA production is poorly defined.", [["P23", "GENE_OR_GENE_PRODUCT", 24, 27], ["P23", "PROTEIN", 24, 27], ["P23 cleavage", "TREATMENT", 24, 36], ["poorly defined", "OBSERVATION_MODIFIER", 102, 116]]], ["The P23 cleavage site is located at the base of a narrow cleft and is not readily accessible, suggesting a highly regulated cleavage.", [["P23", "GENE_OR_GENE_PRODUCT", 4, 7], ["P23 cleavage site", "DNA", 4, 21], ["The P23 cleavage site", "PROBLEM", 0, 21], ["a narrow cleft", "PROBLEM", 48, 62], ["a highly regulated cleavage", "PROBLEM", 105, 132], ["P23 cleavage", "OBSERVATION", 4, 16], ["site", "OBSERVATION_MODIFIER", 17, 21], ["base", "ANATOMY_MODIFIER", 40, 44], ["narrow", "OBSERVATION_MODIFIER", 50, 56], ["cleft", "OBSERVATION", 57, 62], ["cleavage", "OBSERVATION", 124, 132]]], ["Mutations in nsP2 or nsP3 near this cleavage site may alter viral replication and pathogenicity (Shin et al., 2012).IntroductionMost cytolytic animal viruses induce a profound decrease of cellular protein synthesis in infected cells, particularly during the late phase of infection (Bushell and Sarnow, 2002).", [["cellular", "ANATOMY", 188, 196], ["cells", "ANATOMY", 227, 232], ["infection", "DISEASE", 272, 281], ["nsP2", "GENE_OR_GENE_PRODUCT", 13, 17], ["nsP3", "GENE_OR_GENE_PRODUCT", 21, 25], ["cellular", "CELL", 188, 196], ["cells", "CELL", 227, 232], ["nsP2", "DNA", 13, 17], ["nsP3", "DNA", 21, 25], ["cellular protein", "PROTEIN", 188, 204], ["infected cells", "CELL_TYPE", 218, 232], ["Mutations in nsP2", "PROBLEM", 0, 17], ["nsP3", "PROBLEM", 21, 25], ["this cleavage site", "PROBLEM", 31, 49], ["alter viral replication", "PROBLEM", 54, 77], ["Most cytolytic animal viruses", "PROBLEM", 128, 157], ["cellular protein synthesis in infected cells", "PROBLEM", 188, 232], ["infection", "PROBLEM", 272, 281], ["viral replication", "OBSERVATION", 60, 77], ["viruses", "OBSERVATION", 150, 157], ["profound", "OBSERVATION_MODIFIER", 167, 175], ["decrease", "OBSERVATION_MODIFIER", 176, 184], ["cellular protein synthesis", "OBSERVATION", 188, 214], ["infected cells", "OBSERVATION", 218, 232], ["late phase", "OBSERVATION_MODIFIER", 258, 268], ["infection", "OBSERVATION", 272, 281]]], ["This is the case for SINV, which ablates cellular translation approximately 3 h after virus entry, while the protein\u2010synthesizing machinery is preferentially dedicated to translate the viral sgmRNA (Strauss and Strauss, 1994; Griffin, 2007).", [["cellular", "ANATOMY", 41, 49], ["SINV", "ORGANISM", 21, 25], ["cellular", "CELL", 41, 49], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 191, 197], ["viral sgmRNA", "PROTEIN", 185, 197], ["SINV", "SPECIES", 21, 25], ["SINV", "PROBLEM", 21, 25]]], ["Distinct mechanisms are responsible for the interference of cellular macromolecular synthesis by the different animal viruses.", [["cellular", "ANATOMY", 60, 68], ["cellular", "CELL", 60, 68], ["Distinct mechanisms", "PROBLEM", 0, 19], ["cellular macromolecular synthesis", "PROBLEM", 60, 93], ["the different animal viruses", "PROBLEM", 97, 125], ["cellular", "OBSERVATION_MODIFIER", 60, 68], ["macromolecular synthesis", "OBSERVATION", 69, 93], ["different", "OBSERVATION_MODIFIER", 101, 110], ["animal viruses", "OBSERVATION", 111, 125]]], ["Alphaviruses induce the phosphorylation of eIF2\u03b1 in vertebrate cells, leading to an inhibition of host mRNA translation (McInerney et al., 2005).", [["cells", "ANATOMY", 63, 68], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 43, 48], ["cells", "CELL", 63, 68], ["eIF2\u03b1", "PROTEIN", 43, 48], ["vertebrate cells", "CELL_TYPE", 52, 68], ["Alphaviruses", "TREATMENT", 0, 12], ["the phosphorylation of eIF2\u03b1 in vertebrate cells", "TREATMENT", 20, 68]]], ["However, infection of cells deficient in PKR (protein kinase activated by dsRNA), such as PKR\u2212/\u2212 mouse embryonic fibroblasts (MEFs) by SINV also produces this blockade, despite the fact that no increased eIF2\u03b1 phosphorylation is observed (Gorchakov et al., 2004; Ventoso et al., 2006).", [["cells", "ANATOMY", 22, 27], ["embryonic fibroblasts", "ANATOMY", 103, 124], ["MEFs", "ANATOMY", 126, 130], ["infection", "DISEASE", 9, 18], ["cells", "CELL", 22, 27], ["PKR", "GENE_OR_GENE_PRODUCT", 41, 44], ["protein kinase activated by dsRNA", "GENE_OR_GENE_PRODUCT", 46, 79], ["PKR\u2212", "GENE_OR_GENE_PRODUCT", 90, 94], ["MEFs", "CELL", 126, 130], ["SINV", "ORGANISM", 135, 139], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 204, 209], ["PKR", "PROTEIN", 41, 44], ["protein kinase activated by dsRNA", "PROTEIN", 46, 79], ["PKR\u2212/\u2212 mouse embryonic fibroblasts", "CELL_LINE", 90, 124], ["MEFs", "CELL_TYPE", 126, 130], ["eIF2\u03b1", "PROTEIN", 204, 209], ["mouse", "SPECIES", 97, 102], ["mouse", "SPECIES", 97, 102], ["SINV", "SPECIES", 135, 139], ["infection of cells deficient", "PROBLEM", 9, 37], ["PKR", "TEST", 41, 44], ["protein kinase", "TEST", 46, 60], ["dsRNA", "PROBLEM", 74, 79], ["mouse embryonic fibroblasts", "PROBLEM", 97, 124], ["this blockade", "TREATMENT", 154, 167], ["increased eIF2\u03b1 phosphorylation", "PROBLEM", 194, 225], ["infection", "OBSERVATION", 9, 18], ["cells deficient", "OBSERVATION", 22, 37], ["embryonic fibroblasts", "OBSERVATION", 103, 124]]], ["These observations suggest that SINV employs additional mechanisms, separate to eIF2\u03b1 phosphorylation, to interfere with cellular protein synthesis.", [["cellular", "ANATOMY", 121, 129], ["SINV", "ORGANISM", 32, 36], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 80, 85], ["cellular", "CELL", 121, 129], ["eIF2\u03b1", "PROTEIN", 80, 85], ["SINV", "SPECIES", 32, 36], ["eIF2\u03b1 phosphorylation", "TREATMENT", 80, 101], ["cellular protein synthesis", "TREATMENT", 121, 147], ["protein synthesis", "OBSERVATION", 130, 147]]], ["For example, the imbalance of ionic concentrations in the cytoplasm of infected cells, or the release of cellular proteins from the nucleus to the cytoplasm have been implicated as responsible for this inhibition (Garry et al., 1979; Garry, 1994; McInerney et al., 2005).", [["cytoplasm", "ANATOMY", 58, 67], ["cells", "ANATOMY", 80, 85], ["cellular", "ANATOMY", 105, 113], ["nucleus", "ANATOMY", 132, 139], ["cytoplasm", "ANATOMY", 147, 156], ["cytoplasm", "ORGANISM_SUBSTANCE", 58, 67], ["cells", "CELL", 80, 85], ["cellular", "CELL", 105, 113], ["nucleus", "CELLULAR_COMPONENT", 132, 139], ["cytoplasm", "ORGANISM_SUBSTANCE", 147, 156], ["infected cells", "CELL_TYPE", 71, 85], ["cellular proteins", "PROTEIN", 105, 122], ["ionic concentrations", "PROBLEM", 30, 50], ["infected cells", "PROBLEM", 71, 85], ["cellular proteins", "PROBLEM", 105, 122], ["ionic concentrations", "OBSERVATION_MODIFIER", 30, 50], ["cytoplasm", "OBSERVATION_MODIFIER", 58, 67], ["infected cells", "OBSERVATION", 71, 85], ["cellular proteins", "OBSERVATION", 105, 122], ["nucleus", "ANATOMY_MODIFIER", 132, 139]]], ["Analysis of a number of alphavirus nsP variants suggest that nsP2 is chiefly responsible for the inhibition of cellular macromolecular synthesis after viral infection (Gorchakov et al., 2004; Garmashova et al., 2006; Frolov et al., 2009).", [["cellular", "ANATOMY", 111, 119], ["viral infection", "DISEASE", 151, 166], ["alphavirus", "ORGANISM", 24, 34], ["nsP", "GENE_OR_GENE_PRODUCT", 35, 38], ["nsP2", "GENE_OR_GENE_PRODUCT", 61, 65], ["cellular", "CELL", 111, 119], ["alphavirus nsP variants", "PROTEIN", 24, 47], ["nsP2", "PROTEIN", 61, 65], ["alphavirus nsP variants", "PROBLEM", 24, 47], ["nsP2", "PROBLEM", 61, 65], ["cellular macromolecular synthesis", "PROBLEM", 111, 144], ["viral infection", "PROBLEM", 151, 166], ["alphavirus nsP variants", "OBSERVATION", 24, 47], ["nsP2", "OBSERVATION", 61, 65], ["macromolecular synthesis", "OBSERVATION", 120, 144]]], ["Accordingly, SINV with a single nsP2 point mutation at proline 726 exhibits defects in host translational shut\u2010off (Frolov et al., 1999).", [["proline 726", "CHEMICAL", 55, 66], ["proline", "CHEMICAL", 55, 62], ["SINV", "ORGANISM", 13, 17], ["nsP2", "GENE_OR_GENE_PRODUCT", 32, 36], ["proline", "AMINO_ACID", 55, 62], ["726", "AMINO_ACID", 63, 66], ["SINV", "SPECIES", 13, 17], ["SINV", "TREATMENT", 13, 17], ["a single nsP2 point mutation at proline", "TREATMENT", 23, 62], ["defects", "PROBLEM", 76, 83]]], ["The possibility that the translational efficiency and the quantity of subgenomic mRNA play a role in the inhibition of host protein synthesis has also been proposed (Patel et al., 2013).", [["subgenomic mRNA", "RNA", 70, 85], ["the translational efficiency", "PROBLEM", 21, 49], ["subgenomic mRNA", "PROBLEM", 70, 85], ["host protein synthesis", "TREATMENT", 119, 141], ["translational efficiency", "OBSERVATION", 25, 49], ["subgenomic mRNA", "OBSERVATION", 70, 85]]], ["Regardless, the cellular shut\u2010off is efficiently induced by replicons lacking the coding region for the viral structural proteins (Frolov and Schlesinger, 1994; Sanz et al., 2007).", [["cellular", "ANATOMY", 16, 24], ["cellular", "CELL", 16, 24], ["viral structural proteins", "PROTEIN", 104, 129], ["the cellular shut\u2010off", "PROBLEM", 12, 33], ["cellular shut\u2010off", "OBSERVATION", 16, 33]]], ["These observations are consistent with the concept that nsPs participate and are necessary to trigger shut\u2010off of host protein synthesis.", [["nsPs", "GENE_OR_GENE_PRODUCT", 56, 60], ["nsPs", "PROTEIN", 56, 60], ["host protein synthesis", "TREATMENT", 114, 136], ["consistent with", "UNCERTAINTY", 23, 38]]], ["In the present work, we have analysed the expression of nsPs and their potential relationship with the inhibition of cellular mRNA translation.", [["cellular", "ANATOMY", 117, 125], ["nsPs", "GENE_OR_GENE_PRODUCT", 56, 60], ["cellular", "CELL", 117, 125], ["nsPs", "PROTEIN", 56, 60], ["cellular mRNA", "RNA", 117, 130], ["cellular mRNA translation", "PROBLEM", 117, 142], ["cellular mRNA", "OBSERVATION", 117, 130]]], ["In addition, viral RNA replication and the redistribution of nuclear proteins to the cytoplasm have been examined under restrictive conditions.", [["nuclear", "ANATOMY", 61, 68], ["cytoplasm", "ANATOMY", 85, 94], ["nuclear", "CELLULAR_COMPONENT", 61, 68], ["cytoplasm", "ORGANISM_SUBSTANCE", 85, 94], ["nuclear proteins", "PROTEIN", 61, 77], ["viral RNA replication", "TREATMENT", 13, 34], ["nuclear proteins", "PROBLEM", 61, 77], ["viral RNA replication", "OBSERVATION", 13, 34], ["redistribution", "OBSERVATION_MODIFIER", 43, 57], ["nuclear proteins", "OBSERVATION", 61, 77], ["restrictive conditions", "OBSERVATION", 120, 142]]], ["Our findings suggest an association among these three phenomena: the blockade of host translation, the level of viral RNA replication and the redistribution of nuclear proteins to the cytoplasm.Individual expression of SINV nsPs in BHK\u2010T7 cells ::: ResultsPrevious work demonstrated that replicons expressing only SINV nsPs have the ability to interfere with host translation (Frolov and Schlesinger, 1994; Sanz et al., 2007).", [["nuclear", "ANATOMY", 160, 167], ["cytoplasm", "ANATOMY", 184, 193], ["BHK\u2010T7 cells", "ANATOMY", 232, 244], ["nuclear", "CELLULAR_COMPONENT", 160, 167], ["cytoplasm", "ORGANISM_SUBSTANCE", 184, 193], ["SINV", "ORGANISM", 219, 223], ["BHK\u2010T7 cells", "CELL", 232, 244], ["SINV", "ORGANISM", 314, 318], ["nsPs", "GENE_OR_GENE_PRODUCT", 319, 323], ["nuclear proteins", "PROTEIN", 160, 176], ["SINV nsPs", "PROTEIN", 219, 228], ["BHK\u2010T7 cells", "CELL_LINE", 232, 244], ["SINV nsPs", "PROTEIN", 314, 323], ["SINV", "SPECIES", 219, 223], ["BHK", "SPECIES", 232, 235], ["SINV", "SPECIES", 314, 318], ["host translation", "TREATMENT", 81, 97], ["viral RNA replication", "TREATMENT", 112, 133], ["viral RNA replication", "OBSERVATION", 112, 133], ["redistribution", "OBSERVATION_MODIFIER", 142, 156], ["SINV nsPs", "OBSERVATION", 219, 228]]], ["Moreover, SINV bearing mutations in nsP2 are defective in blocking cellular protein synthesis (Frolov et al., 1999).", [["cellular", "ANATOMY", 67, 75], ["SINV", "ORGANISM", 10, 14], ["nsP2", "GENE_OR_GENE_PRODUCT", 36, 40], ["cellular", "CELL", 67, 75], ["nsP2", "DNA", 36, 40], ["SINV", "SPECIES", 10, 14], ["SINV bearing mutations in nsP2", "PROBLEM", 10, 40], ["defective in blocking cellular protein synthesis", "PROBLEM", 45, 93], ["protein synthesis", "OBSERVATION", 76, 93]]], ["Thus, we tested the activity of the individual expression of nsP1, nsP2 and nsP3, and expression of nsP1\u20104, on the endogenous translation of cellular mRNAs.", [["cellular", "ANATOMY", 141, 149], ["nsP1", "GENE_OR_GENE_PRODUCT", 61, 65], ["nsP2", "GENE_OR_GENE_PRODUCT", 67, 71], ["nsP3", "GENE_OR_GENE_PRODUCT", 76, 80], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 100, 106], ["cellular", "CELL", 141, 149], ["nsP1", "PROTEIN", 61, 65], ["nsP2", "PROTEIN", 67, 71], ["nsP3", "PROTEIN", 76, 80], ["nsP1\u20104", "PROTEIN", 100, 106], ["cellular mRNAs", "RNA", 141, 155], ["nsP1", "PROBLEM", 61, 65], ["nsP2", "TEST", 67, 71], ["nsP3", "PROBLEM", 76, 80], ["nsP1", "TEST", 100, 104], ["cellular mRNAs", "PROBLEM", 141, 155], ["endogenous translation", "OBSERVATION", 115, 137], ["cellular mRNAs", "OBSERVATION", 141, 155]]], ["In order to achieve high\u2010level synthesis of nsPs, we used BHK\u2010T7 cells that constitutively express the T7 RNA polymerase.", [["BHK\u2010T7 cells", "ANATOMY", 58, 70], ["nsPs", "SIMPLE_CHEMICAL", 44, 48], ["BHK\u2010T7 cells", "CELL", 58, 70], ["nsPs", "PROTEIN", 44, 48], ["BHK\u2010T7 cells", "CELL_LINE", 58, 70], ["T7 RNA polymerase", "PROTEIN", 103, 120], ["high\u2010level synthesis of nsPs", "PROBLEM", 20, 48], ["BHK\u2010T7 cells", "TREATMENT", 58, 70], ["T7", "ANATOMY", 103, 105]]], ["This system has been employed successfully to express the precursors of Semliki Forest virus (SFV) nsPs (Spuul et al., 2011).", [["Semliki Forest virus", "ORGANISM", 72, 92], ["SFV", "ORGANISM", 94, 97], ["Semliki Forest virus", "SPECIES", 72, 92], ["SFV", "SPECIES", 94, 97], ["Semliki Forest virus", "TREATMENT", 72, 92]]], ["BHK\u2010T7 cells were transfected with pTM1 plasmids containing the coding region for SINV nsPs downstream of the IRES element of encephalomyocarditis virus EMCV(IRES).", [["BHK\u2010T7 cells", "ANATOMY", 0, 12], ["plasmids", "ANATOMY", 40, 48], ["BHK\u2010T7 cells", "CELL", 0, 12], ["pTM1", "GENE_OR_GENE_PRODUCT", 35, 39], ["SINV", "ORGANISM", 82, 86], ["nsPs", "GENE_OR_GENE_PRODUCT", 87, 91], ["encephalomyocarditis virus EMCV", "ORGANISM", 126, 157], ["BHK\u2010T7 cells", "CELL_LINE", 0, 12], ["pTM1 plasmids", "DNA", 35, 48], ["coding region", "DNA", 64, 77], ["SINV nsPs downstream", "DNA", 82, 102], ["IRES element", "DNA", 110, 122], ["IRES", "DNA", 158, 162], ["encephalomyocarditis virus EMCV", "SPECIES", 126, 157], ["BHK", "SPECIES", 0, 3], ["SINV", "SPECIES", 82, 86], ["encephalomyocarditis virus EMCV", "SPECIES", 126, 157], ["BHK\u2010T7 cells", "PROBLEM", 0, 12], ["pTM1 plasmids", "TREATMENT", 35, 48], ["SINV nsPs", "TREATMENT", 82, 91], ["encephalomyocarditis virus EMCV", "TREATMENT", 126, 157], ["T7 cells", "OBSERVATION", 4, 12], ["SINV nsPs", "OBSERVATION", 82, 91], ["encephalomyocarditis virus EMCV", "OBSERVATION", 126, 157]]], ["As shown in Fig. 1A, cells transfected with pTM1\u2010nsP1, pTM1\u2010nsP2 or pTM1\u2010nsP3 synthesized a new product that may correspond to the individual viral proteins.", [["cells", "ANATOMY", 21, 26], ["cells", "CELL", 21, 26], ["pTM1\u2010nsP1", "GENE_OR_GENE_PRODUCT", 44, 53], ["pTM1\u2010nsP2", "GENE_OR_GENE_PRODUCT", 55, 64], ["pTM1\u2010nsP3", "GENE_OR_GENE_PRODUCT", 68, 77], ["pTM1\u2010nsP1", "PROTEIN", 44, 53], ["pTM1\u2010nsP2", "PROTEIN", 55, 64], ["pTM1\u2010nsP3", "PROTEIN", 68, 77], ["viral proteins", "PROTEIN", 142, 156], ["pTM1\u2010nsP1", "TEST", 44, 53], ["pTM1\u2010nsP2", "TEST", 55, 64], ["the individual viral proteins", "PROBLEM", 127, 156], ["Fig", "OBSERVATION", 12, 15], ["may correspond to", "UNCERTAINTY", 109, 126]]], ["Both nsP1 and nsP3 were clearly detectable at 8 and 18 hpt, whereas nsP2 was synthesized at lower levels.", [["nsP1", "GENE_OR_GENE_PRODUCT", 5, 9], ["nsP3", "GENE_OR_GENE_PRODUCT", 14, 18], ["nsP2", "GENE_OR_GENE_PRODUCT", 68, 72], ["nsP1", "PROTEIN", 5, 9], ["nsP3", "PROTEIN", 14, 18], ["nsP2", "PROTEIN", 68, 72], ["Both nsP1 and nsP3", "TEST", 0, 18], ["nsP2", "TEST", 68, 72], ["nsP1", "OBSERVATION", 5, 9], ["nsP3", "OBSERVATION", 14, 18]]], ["However, the synthesis of new proteins was not evident by radioactive labelling after transfection of BHK\u2010T7 cells with pTM1\u2010nsP1\u20104.", [["BHK\u2010T7 cells", "ANATOMY", 102, 114], ["BHK\u2010T7 cells", "CELL", 102, 114], ["BHK\u2010T7 cells", "CELL_LINE", 102, 114], ["pTM1", "PROTEIN", 120, 124], ["new proteins", "PROBLEM", 26, 38], ["BHK", "TEST", 102, 105], ["not evident", "UNCERTAINTY", 43, 54]]], ["We employed poliovirus 2A protease (PV 2Apro) as a positive control as it is a viral protein that profoundly inhibits cellular translation, while the expression of PV 2C was employed as a negative control as it is a viral protein that does not directly affect cellular protein synthesis (Redondo et al., 2011).", [["cellular", "ANATOMY", 118, 126], ["cellular", "ANATOMY", 260, 268], ["poliovirus 2A", "ORGANISM", 12, 25], ["PV 2Apro", "GENE_OR_GENE_PRODUCT", 36, 44], ["cellular", "CELL", 118, 126], ["PV 2C", "GENE_OR_GENE_PRODUCT", 164, 169], ["cellular", "CELL", 260, 268], ["poliovirus 2A protease", "PROTEIN", 12, 34], ["PV 2Apro", "PROTEIN", 36, 44], ["viral protein", "PROTEIN", 79, 92], ["PV 2C", "PROTEIN", 164, 169], ["viral protein", "PROTEIN", 216, 229], ["poliovirus 2A", "SPECIES", 12, 25], ["PV", "SPECIES", 36, 38], ["PV", "SPECIES", 164, 166], ["poliovirus 2A protease", "TREATMENT", 12, 34], ["PV 2Apro)", "TREATMENT", 36, 45], ["a positive control", "TREATMENT", 49, 67], ["a viral protein", "PROBLEM", 77, 92], ["PV 2C", "TREATMENT", 164, 169], ["a viral protein", "PROBLEM", 214, 229]]], ["Densitometric analysis of cellular actin revealed that PV 2Apro inhibited its synthesis by more than 90% at 8 hpt, suggesting that transfection of BHK\u2010T7 cells was very efficient (Fig. 1A and B).", [["cellular", "ANATOMY", 26, 34], ["BHK\u2010T7 cells", "ANATOMY", 147, 159], ["2Apro", "CHEMICAL", 58, 63], ["cellular actin", "GENE_OR_GENE_PRODUCT", 26, 40], ["PV 2Apro", "SIMPLE_CHEMICAL", 55, 63], ["BHK\u2010T7 cells", "CELL", 147, 159], ["B", "GENE_OR_GENE_PRODUCT", 192, 193], ["cellular actin", "PROTEIN", 26, 40], ["BHK\u2010T7 cells", "CELL_LINE", 147, 159], ["PV", "SPECIES", 55, 57], ["Densitometric analysis", "TEST", 0, 22], ["cellular actin", "TEST", 26, 40], ["PV 2Apro", "TEST", 55, 63], ["transfection of BHK\u2010T7 cells", "PROBLEM", 131, 159], ["cellular actin", "OBSERVATION", 26, 40]]], ["In contrast, inhibition of cellular actin synthesis was 39% by expression of PV 2C.", [["cellular", "ANATOMY", 27, 35], ["cellular", "CELL", 27, 35], ["actin", "GENE_OR_GENE_PRODUCT", 36, 41], ["PV 2C", "GENE_OR_GENE_PRODUCT", 77, 82], ["actin", "PROTEIN", 36, 41], ["PV 2C", "PROTEIN", 77, 82], ["cellular actin synthesis", "TEST", 27, 51], ["PV 2C", "OBSERVATION", 77, 82]]], ["This partial blockade of cellular translation by PV 2C at 8 hpt may be due to the efficient transcription of this plasmid followed by translation of the corresponding mRNA.", [["cellular", "ANATOMY", 25, 33], ["plasmid", "ANATOMY", 114, 121], ["cellular", "CELL", 25, 33], ["PV 2C", "GENE_OR_GENE_PRODUCT", 49, 54], ["PV 2C", "PROTEIN", 49, 54], ["plasmid", "DNA", 114, 121], ["mRNA", "RNA", 167, 171], ["This partial blockade of cellular translation", "TREATMENT", 0, 45], ["this plasmid", "TREATMENT", 109, 121]]], ["Additionally, BHK cells expressing nsP2, nsP3 or nsP1\u20104 exhibited an inhibition of actin synthesis similar to that observed with PV 2C (34, 48 and 42%, respectively) at 8 hpt (Fig. 1A and B).", [["BHK cells", "ANATOMY", 14, 23], ["BHK cells", "CELL", 14, 23], ["nsP2", "GENE_OR_GENE_PRODUCT", 35, 39], ["nsP3", "GENE_OR_GENE_PRODUCT", 41, 45], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 49, 55], ["actin", "GENE_OR_GENE_PRODUCT", 83, 88], ["B", "GENE_OR_GENE_PRODUCT", 188, 189], ["BHK cells", "CELL_LINE", 14, 23], ["nsP2", "PROTEIN", 35, 39], ["nsP3", "PROTEIN", 41, 45], ["nsP1\u20104", "PROTEIN", 49, 55], ["actin", "PROTEIN", 83, 88], ["PV", "SPECIES", 129, 131], ["BHK cells", "TEST", 14, 23], ["nsP2", "PROBLEM", 35, 39], ["nsP3", "TEST", 41, 45], ["nsP1", "TEST", 49, 53], ["actin synthesis", "PROBLEM", 83, 98], ["PV 2C", "TEST", 129, 134], ["BHK cells", "OBSERVATION", 14, 23], ["actin synthesis", "OBSERVATION", 83, 98]]], ["Expression of nsP1, which is very efficient at this time, provoked a 72% decrease in actin synthesis.", [["nsP1", "GENE_OR_GENE_PRODUCT", 14, 18], ["actin", "GENE_OR_GENE_PRODUCT", 85, 90], ["nsP1", "PROTEIN", 14, 18], ["actin", "PROTEIN", 85, 90], ["nsP1", "PROBLEM", 14, 18], ["a 72% decrease in actin synthesis", "PROBLEM", 67, 100], ["nsP1", "OBSERVATION", 14, 18], ["actin synthesis", "OBSERVATION", 85, 100]]], ["Strikingly, when the synthesis of cellular actin was measured at 18 hpt, PV 2Apro still blocked its production by 95%, whereas PV 2C showed no inhibition (3%) at this time.", [["cellular", "ANATOMY", 34, 42], ["2Apro", "CHEMICAL", 76, 81], ["cellular", "CELL", 34, 42], ["actin", "GENE_OR_GENE_PRODUCT", 43, 48], ["cellular actin", "PROTEIN", 34, 48], ["PV", "SPECIES", 73, 75], ["PV 2C", "TEST", 127, 132], ["inhibition", "PROBLEM", 143, 153]]], ["Reduced blockade of cellular protein synthesis was also observed with the SINV nsPs, including protein nsP1, which caused an inhibition of 24% at this time.", [["cellular", "ANATOMY", 20, 28], ["cellular", "CELL", 20, 28], ["SINV", "ORGANISM", 74, 78], ["nsPs", "GENE_OR_GENE_PRODUCT", 79, 83], ["nsP1", "GENE_OR_GENE_PRODUCT", 103, 107], ["SINV nsPs", "PROTEIN", 74, 83], ["protein nsP1", "PROTEIN", 95, 107], ["SINV", "SPECIES", 74, 78], ["Reduced blockade of cellular protein synthesis", "PROBLEM", 0, 46], ["the SINV nsPs", "TEST", 70, 83], ["protein nsP1", "TEST", 95, 107], ["an inhibition", "TEST", 122, 135], ["blockade", "OBSERVATION", 8, 16], ["cellular protein synthesis", "OBSERVATION", 20, 46]]], ["Collectively, these results show that individual expression of SINV nsPs does not abrogate cellular translation to the extent shown by a genuine inducer of the shut\u2010off of host translation, PV 2Apro.", [["cellular", "ANATOMY", 91, 99], ["SINV", "ORGANISM", 63, 67], ["nsPs", "GENE_OR_GENE_PRODUCT", 68, 72], ["cellular", "CELL", 91, 99], ["PV 2Apro", "GENE_OR_GENE_PRODUCT", 190, 198], ["SINV nsPs", "PROTEIN", 63, 72], ["PV 2Apro", "PROTEIN", 190, 198], ["SINV", "SPECIES", 63, 67], ["SINV nsPs", "PROBLEM", 63, 72], ["PV 2Apro", "TREATMENT", 190, 198]]], ["The partial inhibition detected at 8 hpt by SINV nsPs might be due to the high efficiency of transcription and translation of this system, which decreases after prolonged incubation (18 hpt), rather than to the activity of the SINV proteins on the translational machinery.", [["SINV", "ORGANISM", 44, 48], ["SINV", "ORGANISM", 227, 231], ["SINV nsPs", "PROTEIN", 44, 53], ["SINV proteins", "PROTEIN", 227, 240], ["SINV", "SPECIES", 44, 48], ["SINV", "SPECIES", 227, 231], ["The partial inhibition", "PROBLEM", 0, 22], ["SINV nsPs", "TEST", 44, 53], ["the high efficiency of transcription", "PROBLEM", 70, 106], ["prolonged incubation", "TREATMENT", 161, 181]]], ["If one individual nsP was responsible for the inhibition of cellular protein synthesis, we would expect that after prolonged synthesis (18 hpt), this inhibition would be cumulative, but rather, we observed that the blockade of cellular translation declines with time.Individual expression of SINV nsPs in BHK\u2010T7 cells ::: ResultsTo further show that the protein species observed in Fig. 1A corresponded to the translation of mRNAs bearing the EMCV IRES, and also to assess whether nsP1\u20104 is expressed from the corresponding plasmid, we took advantage of the ability of PV 2Apro to enhance picornavirus IRES\u2010driven translation (Castello et al., 2011).", [["cellular", "ANATOMY", 60, 68], ["cellular", "ANATOMY", 227, 235], ["BHK", "ANATOMY", 305, 308], ["T7 cells", "ANATOMY", 309, 317], ["plasmid", "ANATOMY", 524, 531], ["nsP", "GENE_OR_GENE_PRODUCT", 18, 21], ["cellular", "CELL", 60, 68], ["cellular", "CELL", 227, 235], ["SINV", "ORGANISM", 292, 296], ["BHK", "CELL", 305, 308], ["T7 cells", "CELL", 309, 317], ["1A", "GENE_OR_GENE_PRODUCT", 387, 389], ["EMCV", "ORGANISM", 443, 447], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 481, 487], ["PV 2Apro", "GENE_OR_GENE_PRODUCT", 569, 577], ["nsP", "DNA", 18, 21], ["SINV nsPs", "PROTEIN", 292, 301], ["BHK", "CELL_LINE", 305, 308], ["T7 cells", "CELL_LINE", 309, 317], ["mRNAs", "RNA", 425, 430], ["EMCV IRES", "DNA", 443, 452], ["nsP1\u20104", "DNA", 481, 487], ["PV 2Apro", "PROTEIN", 569, 577], ["picornavirus IRES", "DNA", 589, 606], ["SINV", "SPECIES", 292, 296], ["BHK", "SPECIES", 305, 308], ["EMCV", "SPECIES", 443, 447], ["PV", "SPECIES", 569, 571], ["cellular protein synthesis", "PROBLEM", 60, 86], ["prolonged synthesis (18 hpt", "TREATMENT", 115, 142], ["cellular translation", "PROBLEM", 227, 247], ["the protein species", "PROBLEM", 350, 369], ["nsP1", "TEST", 481, 485], ["PV 2Apro", "TREATMENT", 569, 577], ["picornavirus IRES", "TREATMENT", 589, 606], ["cellular translation", "OBSERVATION", 227, 247], ["SINV nsPs", "OBSERVATION", 292, 301]]], ["In addition, expression of PV 2Apro decreases endogenous cellular protein synthesis resulting in a more prominent and clear synthesis of proteins from pTM1 in this system, thus facilitating their detection.", [["cellular", "ANATOMY", 57, 65], ["PV 2Apro", "GENE_OR_GENE_PRODUCT", 27, 35], ["cellular", "CELL", 57, 65], ["pTM1", "GENE_OR_GENE_PRODUCT", 151, 155], ["PV 2Apro", "PROTEIN", 27, 35], ["pTM1", "PROTEIN", 151, 155], ["PV", "SPECIES", 27, 29], ["PV 2Apro", "PROBLEM", 27, 35], ["endogenous cellular protein synthesis", "PROBLEM", 46, 83], ["their detection", "TEST", 190, 205], ["cellular protein synthesis", "OBSERVATION", 57, 83], ["more prominent", "OBSERVATION_MODIFIER", 99, 113], ["clear", "OBSERVATION_MODIFIER", 118, 123], ["synthesis", "OBSERVATION", 124, 133]]], ["Strikingly, transfection of pTM1\u2010nsP1\u20104 in cells previously transfected with pTM1\u20102A resulted in the appearance of protein species that corresponded to precursor and mature nsPs (Supporting Information http://onlinelibrary.wiley.com/doi/10.1111/cmi.12381/suppinfo).", [["cells", "ANATOMY", 43, 48], ["pTM1\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 28, 39], ["cells", "CELL", 43, 48], ["pTM1\u20102A", "GENE_OR_GENE_PRODUCT", 77, 84], ["pTM1\u2010nsP1\u20104", "PROTEIN", 28, 39], ["pTM1\u20102A", "PROTEIN", 77, 84], ["pTM1\u2010nsP1", "TEST", 28, 37], ["protein species", "PROBLEM", 115, 130], ["protein species", "OBSERVATION", 115, 130]]], ["Moreover, the synthesis of nsP1, nsP2 and nsP3 was more clearly distinguished when PV 2Apro was present.", [["nsP1", "GENE_OR_GENE_PRODUCT", 27, 31], ["nsP2", "GENE_OR_GENE_PRODUCT", 33, 37], ["nsP3", "GENE_OR_GENE_PRODUCT", 42, 46], ["nsP1", "PROTEIN", 27, 31], ["nsP2", "PROTEIN", 33, 37], ["nsP3", "PROTEIN", 42, 46], ["PV", "SPECIES", 83, 85], ["nsP1", "PROBLEM", 27, 31], ["nsP2", "PROBLEM", 33, 37], ["nsP3", "PROBLEM", 42, 46]]], ["Consistent with these results obtained in cultured cells, in vitro transcription/translation of the corresponding plasmids in rabbit reticulocyte lysates rendered proteins with the expected molecular mass (Supporting Information http://onlinelibrary.wiley.com/doi/10.1111/cmi.12381/suppinfo).", [["cells", "ANATOMY", 51, 56], ["plasmids", "ANATOMY", 114, 122], ["reticulocyte lysates", "ANATOMY", 133, 153], ["cells", "CELL", 51, 56], ["rabbit", "ORGANISM", 126, 132], ["reticulocyte lysates", "ORGANISM_SUBSTANCE", 133, 153], ["cultured cells", "CELL_LINE", 42, 56], ["plasmids", "DNA", 114, 122], ["rabbit", "SPECIES", 126, 132], ["rabbit", "SPECIES", 126, 132], ["the corresponding plasmids", "TREATMENT", 96, 122], ["rabbit reticulocyte lysates", "TEST", 126, 153], ["the expected molecular mass", "PROBLEM", 177, 204], ["rabbit reticulocyte lysates", "OBSERVATION", 126, 153], ["mass", "OBSERVATION", 200, 204]]], ["In the case of nsP1\u20104 mRNA, different products were produced because of the proteolytic processing of the polyprotein, rendering a variety of proteolytic precursors and mature proteins.Individual expression of SINV nsPs in BHK\u2010T7 cells ::: ResultsTo further assess if these proteins corresponded to genuine SINV nsPs, we analysed their expression by immunoblotting using polyclonal antibodies to nsP1, nsP2 and nsP4.", [["BHK", "ANATOMY", 223, 226], ["T7 cells", "ANATOMY", 227, 235], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 15, 21], ["SINV", "ORGANISM", 210, 214], ["BHK", "CELL", 223, 226], ["T7 cells", "CELL", 227, 235], ["SINV", "ORGANISM", 307, 311], ["nsPs", "GENE_OR_GENE_PRODUCT", 312, 316], ["nsP1", "GENE_OR_GENE_PRODUCT", 396, 400], ["nsP2", "GENE_OR_GENE_PRODUCT", 402, 406], ["nsP4", "GENE_OR_GENE_PRODUCT", 411, 415], ["nsP1\u20104 mRNA", "RNA", 15, 26], ["proteolytic precursors", "PROTEIN", 142, 164], ["mature proteins", "PROTEIN", 169, 184], ["SINV nsPs", "PROTEIN", 210, 219], ["BHK", "CELL_LINE", 223, 226], ["T7 cells", "CELL_LINE", 227, 235], ["SINV nsPs", "PROTEIN", 307, 316], ["polyclonal antibodies", "PROTEIN", 371, 392], ["nsP1", "PROTEIN", 396, 400], ["nsP2", "PROTEIN", 402, 406], ["nsP4", "PROTEIN", 411, 415], ["SINV", "SPECIES", 210, 214], ["BHK", "SPECIES", 223, 226], ["SINV", "SPECIES", 307, 311], ["nsP1\u20104 mRNA", "TREATMENT", 15, 26], ["different products", "TREATMENT", 28, 46], ["the proteolytic processing of the polyprotein", "PROBLEM", 72, 117], ["proteolytic precursors", "TREATMENT", 142, 164], ["mature proteins", "PROBLEM", 169, 184], ["these proteins", "PROBLEM", 268, 282], ["genuine SINV nsPs", "PROBLEM", 299, 316], ["immunoblotting", "TEST", 350, 364], ["polyclonal antibodies", "TEST", 371, 392], ["nsP1", "PROBLEM", 396, 400], ["nsP2", "PROBLEM", 402, 406], ["nsP4", "PROBLEM", 411, 415], ["SINV nsPs", "OBSERVATION", 210, 219], ["SINV nsPs", "OBSERVATION", 307, 316]]], ["Additionally, we compared the levels of production of these proteins in BHK\u2010T7 cells with those produced in SINV\u2010infected cells.", [["BHK\u2010T7 cells", "ANATOMY", 72, 84], ["cells", "ANATOMY", 122, 127], ["BHK\u2010T7 cells", "CELL", 72, 84], ["SINV", "ORGANISM", 108, 112], ["cells", "CELL", 122, 127], ["BHK\u2010T7 cells", "CELL_LINE", 72, 84], ["SINV\u2010infected cells", "CELL_LINE", 108, 127], ["BHK", "SPECIES", 72, 75], ["SINV", "SPECIES", 108, 112], ["these proteins in BHK\u2010T7 cells", "PROBLEM", 54, 84], ["SINV\u2010infected cells", "PROBLEM", 108, 127], ["T7", "ANATOMY", 76, 78], ["SINV\u2010infected cells", "OBSERVATION", 108, 127]]], ["As these proteins were recognized by the specific antibodies and migrated similarly as in infected cells (Fig. 1C), we can conclude that genuine nsP1, nsP2 and nsP4 are being synthesized using the T7\u2010expressing system.", [["cells", "ANATOMY", 99, 104], ["cells", "CELL", 99, 104], ["Fig. 1C", "CELL", 106, 113], ["nsP1", "GENE_OR_GENE_PRODUCT", 145, 149], ["nsP2", "GENE_OR_GENE_PRODUCT", 151, 155], ["nsP4", "GENE_OR_GENE_PRODUCT", 160, 164], ["specific antibodies", "PROTEIN", 41, 60], ["infected cells", "CELL_TYPE", 90, 104], ["nsP1", "PROTEIN", 145, 149], ["nsP2", "PROTEIN", 151, 155], ["nsP4", "PROTEIN", 160, 164], ["genuine nsP1", "PROBLEM", 137, 149], ["nsP2", "PROBLEM", 151, 155], ["nsP4", "PROBLEM", 160, 164], ["the T7\u2010expressing system", "TREATMENT", 193, 217], ["infected cells", "OBSERVATION", 90, 104]]], ["Moreover, nsP1 or nsP2 were produced at higher levels at 8 hpt when compared with that observed during virus infection at 8 hpi.", [["infection", "DISEASE", 109, 118], ["nsP1", "GENE_OR_GENE_PRODUCT", 10, 14], ["nsP2", "GENE_OR_GENE_PRODUCT", 18, 22], ["nsP1", "PROTEIN", 10, 14], ["nsP2", "PROTEIN", 18, 22], ["nsP1", "PROBLEM", 10, 14], ["nsP2", "PROBLEM", 18, 22], ["virus infection", "PROBLEM", 103, 118]]], ["Further, as shown in the labelling experiments (Fig. 1A), the level of nsP3 synthesis should be much greater in this system relative to infected cells, where nsPs cannot be directly detected by radioactive labelling.Functionality of nsP1\u20104 determined by complementation of a defective SINV replicon ::: ResultsIn order to assess whether the nsPs synthesized after plasmid transfection of pTM1\u2010nsP1\u20104 were active and functional in viral RNA replication, we performed a complementation assay with a SINV replicon that lacks the majority of the nsP\u2010coding region.", [["cells", "ANATOMY", 145, 150], ["nsP3", "GENE_OR_GENE_PRODUCT", 71, 75], ["cells", "CELL", 145, 150], ["nsPs", "GENE_OR_GENE_PRODUCT", 158, 162], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 233, 239], ["SINV", "ORGANISM", 285, 289], ["nsPs", "GENE_OR_GENE_PRODUCT", 341, 345], ["pTM1\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 388, 399], ["SINV", "ORGANISM", 497, 501], ["nsP3", "PROTEIN", 71, 75], ["infected cells", "CELL_TYPE", 136, 150], ["nsPs", "PROTEIN", 158, 162], ["nsP1\u20104", "PROTEIN", 233, 239], ["nsPs", "DNA", 341, 345], ["pTM1\u2010nsP1\u20104", "DNA", 388, 399], ["nsP\u2010coding region", "DNA", 542, 559], ["SINV", "SPECIES", 285, 289], ["SINV", "SPECIES", 497, 501], ["nsP3 synthesis", "PROBLEM", 71, 85], ["infected cells", "PROBLEM", 136, 150], ["nsPs", "PROBLEM", 158, 162], ["the nsPs", "PROBLEM", 337, 345], ["plasmid transfection", "TREATMENT", 364, 384], ["pTM1\u2010nsP1", "TEST", 388, 397], ["a complementation assay", "TEST", 466, 489], ["a SINV replicon", "TREATMENT", 495, 510], ["nsP3 synthesis", "OBSERVATION", 71, 85], ["infected cells", "OBSERVATION", 136, 150], ["radioactive labelling", "OBSERVATION", 194, 215], ["SINV replicon", "OBSERVATION", 285, 298], ["SINV replicon", "OBSERVATION", 497, 510]]], ["This plasmid contains luciferase (luc) as a reporter placed after the coding region of the capsid protein (C) (see scheme of rep C+luc(\u0394nsPs) in Fig. 2A).", [["plasmid", "ANATOMY", 5, 12], ["luciferase", "GENE_OR_GENE_PRODUCT", 22, 32], ["luc", "GENE_OR_GENE_PRODUCT", 34, 37], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 125, 134], ["plasmid", "DNA", 5, 12], ["luciferase", "PROTEIN", 22, 32], ["luc", "DNA", 34, 37], ["capsid protein", "PROTEIN", 91, 105], ["C", "PROTEIN", 107, 108], ["rep C+luc", "PROTEIN", 125, 134], ["\u0394nsPs", "PROTEIN", 135, 140], ["This plasmid", "TREATMENT", 0, 12], ["a reporter", "TREATMENT", 42, 52], ["rep C+luc(\u0394nsPs)", "TREATMENT", 125, 141], ["luciferase", "OBSERVATION_MODIFIER", 22, 32], ["capsid protein", "ANATOMY", 91, 105]]], ["Two different complementation approaches were used: in the first approach, two plasmids (pT7\u2010rep C+luc(\u0394nsPs) and pTM1\u2010nsP1\u20104) were co\u2010transfected; in the second approach, we co\u2010transfected two RNAs obtained by in vitro transcription of the plasmids, rep C+luc(\u0394nsPs) and EMCV(IRES)\u2010nsP1\u20104.", [["plasmids", "ANATOMY", 79, 87], ["plasmids", "ANATOMY", 241, 249], ["pT7\u2010rep C+luc", "GENE_OR_GENE_PRODUCT", 89, 102], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 251, 260], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 261, 266], ["plasmids", "DNA", 79, 87], ["pT7\u2010rep C+luc", "DNA", 89, 102], ["\u0394nsPs", "DNA", 103, 108], ["pTM1", "DNA", 114, 118], ["plasmids", "DNA", 241, 249], ["rep C+luc", "DNA", 251, 260], ["\u0394nsPs", "DNA", 261, 266], ["EMCV", "DNA", 272, 276], ["IRES", "DNA", 277, 281], ["EMCV", "SPECIES", 272, 276], ["two plasmids (pT7\u2010rep C+luc(\u0394nsPs)", "TREATMENT", 75, 109], ["the plasmids", "TREATMENT", 237, 249], ["rep C+luc(\u0394nsPs)", "TREATMENT", 251, 267], ["EMCV(IRES", "TREATMENT", 272, 281]]], ["Viral RNA replication can be complemented in trans in BHK\u2010T7 cells transfected with plasmids encoding SFV nsPs (Spuul et al., 2011); however, in that study, transfections of DNA plasmids or RNA replicons were not compared.", [["BHK\u2010T7 cells", "ANATOMY", 54, 66], ["plasmids", "ANATOMY", 84, 92], ["plasmids", "ANATOMY", 178, 186], ["BHK\u2010T7 cells", "CELL", 54, 66], ["SFV", "ORGANISM", 102, 105], ["DNA", "CELLULAR_COMPONENT", 174, 177], ["BHK\u2010T7 cells", "CELL_LINE", 54, 66], ["plasmids", "DNA", 84, 92], ["DNA plasmids", "DNA", 174, 186], ["RNA replicons", "DNA", 190, 203], ["BHK", "SPECIES", 54, 57], ["SFV", "SPECIES", 102, 105], ["Viral RNA replication", "PROBLEM", 0, 21], ["that study", "TEST", 145, 155], ["DNA plasmids", "TREATMENT", 174, 186], ["RNA replicons", "TREATMENT", 190, 203], ["RNA replication", "OBSERVATION", 6, 21], ["T7", "ANATOMY", 58, 60], ["SFV", "OBSERVATION_MODIFIER", 102, 105]]], ["Transfection of DNA plasmid pT7\u2010rep C+luc(\u0394nsPs) alone produced virtually no luc activity, whereas co\u2010transfection with pTM1\u2010nsP1\u20104 induced significant luc synthesis (Fig. 2B).", [["DNA", "CELLULAR_COMPONENT", 16, 19], ["pT7\u2010rep C+luc(\u0394nsPs)", "GENE_OR_GENE_PRODUCT", 28, 48], ["luc", "GENE_OR_GENE_PRODUCT", 152, 155], ["DNA plasmid pT7\u2010rep C+luc(\u0394nsPs)", "DNA", 16, 48], ["pTM1\u2010nsP1\u20104", "DNA", 120, 131], ["luc", "DNA", 152, 155], ["DNA plasmid", "TREATMENT", 16, 27], ["luc activity", "PROBLEM", 77, 89], ["pTM1", "TEST", 120, 124], ["significant luc synthesis", "PROBLEM", 140, 165], ["no", "UNCERTAINTY", 74, 76], ["luc activity", "OBSERVATION", 77, 89], ["significant", "OBSERVATION_MODIFIER", 140, 151], ["luc synthesis", "OBSERVATION", 152, 165]]], ["Presumably, in these cells, the T7 RNA polymerase synthesizes mRNAs EMCV(IRES)\u2010nsP1\u20104 and rep C+luc(\u0394nsPs) and the complementation occurs (as indicated in Fig. 2A).", [["cells", "ANATOMY", 21, 26], ["cells", "CELL", 21, 26], ["\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 78, 85], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 90, 99], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 100, 105], ["T7 RNA polymerase", "PROTEIN", 32, 49], ["mRNAs", "RNA", 62, 67], ["EMCV(IRES)\u2010nsP1\u20104", "DNA", 68, 85], ["rep C+luc", "DNA", 90, 99], ["\u0394nsPs", "DNA", 100, 105], ["the T7 RNA polymerase", "TEST", 28, 49], ["mRNAs EMCV", "TEST", 62, 72], ["IRES", "TEST", 73, 77], ["\u2010nsP1", "TEST", 78, 83], ["rep C+luc", "TEST", 90, 99], ["T7", "ANATOMY", 32, 34]]], ["Notably, co\u2010transfection of these mRNAs previously obtained by in vitro transcription led to a much greater production of luc (Fig. 2B).", [["luc (Fig. 2B", "GENE_OR_GENE_PRODUCT", 122, 134], ["mRNAs", "RNA", 34, 39], ["luc", "DNA", 122, 125], ["these mRNAs", "PROBLEM", 28, 39]]], ["This result is of interest as it indicates that the mRNA EMCV(IRES)\u2010nsP1\u20104 synthesized produces precursor and mature proteins that are active in SINV RNA replication and the subsequent transcription of the sgmRNA.", [["\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 67, 74], ["SINV", "ORGANISM", 145, 149], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 206, 212], ["mRNA EMCV(IRES)\u2010nsP1\u20104", "DNA", 52, 74], ["precursor and mature proteins", "PROTEIN", 96, 125], ["sgmRNA", "PROTEIN", 206, 212], ["SINV", "SPECIES", 145, 149], ["the mRNA EMCV(IRES)\u2010nsP1", "TEST", 48, 72], ["mature proteins", "PROBLEM", 110, 125], ["SINV RNA replication", "TREATMENT", 145, 165], ["the sgmRNA", "TREATMENT", 202, 212], ["active", "OBSERVATION_MODIFIER", 135, 141]]], ["Further, it indicates that complementation of the defective replicon rep C+luc(\u0394nsPs) is approximately 10\u201315\u2010fold more efficient when transcribed RNAs are transfected relative to plasmid transfection.", [["plasmid", "ANATOMY", 179, 186], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 69, 78], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 79, 84], ["defective replicon rep C+luc", "DNA", 50, 78], ["\u0394nsPs", "DNA", 79, 84], ["transcribed RNAs", "RNA", 134, 150], ["the defective replicon rep C+luc(\u0394nsPs)", "TREATMENT", 46, 85], ["plasmid transfection", "TREATMENT", 179, 199], ["plasmid transfection", "OBSERVATION", 179, 199]]], ["Of note, a low level of luc synthesis occurred when capped RNA rep C+luc(\u0394nsPs) was transfected alone (Fig. 2B).", [["luc", "GENE_OR_GENE_PRODUCT", 24, 27], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 63, 72], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 73, 78], ["luc", "DNA", 24, 27], ["capped RNA rep C+luc", "DNA", 52, 72], ["\u0394nsPs", "DNA", 73, 78], ["a low level of luc synthesis", "PROBLEM", 9, 37]]], ["This activity may correspond to the inefficient translation of the second cistron (C+luc) present in this RNA, perhaps after ribosome reinitiation on this cistron.", [["ribosome", "ANATOMY", 125, 133], ["C+luc", "GENE_OR_GENE_PRODUCT", 83, 88], ["ribosome", "CELLULAR_COMPONENT", 125, 133], ["cistron", "DNA", 74, 81], ["C+luc", "DNA", 83, 88], ["cistron", "DNA", 155, 162], ["the second cistron", "TREATMENT", 63, 81], ["ribosome reinitiation", "TREATMENT", 125, 146], ["this cistron", "TREATMENT", 150, 162]]], ["In addition, we measured luc activity from cells co\u2010transfected with rep C+luc(\u0394nsPs) and a non\u2010defective replicon, rep\u201026S, which gives rise to all functional nsPs.", [["cells", "ANATOMY", 43, 48], ["luc", "GENE_OR_GENE_PRODUCT", 25, 28], ["cells", "CELL", 43, 48], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 69, 78], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 79, 84], ["rep\u201026S", "GENE_OR_GENE_PRODUCT", 116, 123], ["luc", "DNA", 25, 28], ["rep C+luc", "DNA", 69, 78], ["\u0394nsPs", "DNA", 79, 84], ["non\u2010defective replicon", "DNA", 92, 114], ["rep", "DNA", 116, 119], ["26S", "DNA", 120, 123], ["nsPs", "DNA", 160, 164], ["rep C+luc(\u0394nsPs", "TREATMENT", 69, 84], ["a non\u2010defective replicon", "TREATMENT", 90, 114], ["luc activity", "OBSERVATION", 25, 37], ["functional nsPs", "OBSERVATION", 149, 164]]], ["In this way, the effectiveness of complementation of EMCV(IRES)\u2010nsP1\u20104 RNA was compared with that obtained with the replicon rep\u201026S.", [["EMCV", "ORGANISM", 53, 57], ["rep\u201026S", "GENE_OR_GENE_PRODUCT", 125, 132], ["EMCV(IRES)\u2010nsP1\u20104 RNA", "RNA", 53, 74], ["replicon rep\u201026S", "DNA", 116, 132], ["EMCV", "SPECIES", 53, 57], ["EMCV(IRES", "TREATMENT", 53, 62]]], ["Complementation in trans by nsPs derived from EMCV(IRES)\u2010nsP1\u20104 is similar to that obtained with rep\u201026S (Fig. 2B).", [["EMCV", "ORGANISM", 46, 50], ["rep\u201026S", "GENE_OR_GENE_PRODUCT", 97, 104], ["nsPs", "PROTEIN", 28, 32], ["EMCV(IRES)\u2010nsP1\u20104", "DNA", 46, 63], ["rep", "DNA", 97, 100], ["26S", "DNA", 101, 104], ["EMCV", "SPECIES", 46, 50], ["EMCV(IRES)\u2010nsP1", "TEST", 46, 61], ["rep", "TEST", 97, 100]]], ["This suggests that the proteins synthesized from EMCV(IRES)\u2010nsP1\u20104 mRNA are as functional as those derived from the replicon rep\u201026S.", [["EMCV", "ORGANISM", 49, 53], ["P1\u20104", "GENE_OR_GENE_PRODUCT", 62, 66], ["rep\u201026S", "GENE_OR_GENE_PRODUCT", 125, 132], ["EMCV(IRES)\u2010nsP1\u20104 mRNA", "RNA", 49, 71], ["replicon rep\u201026S", "DNA", 116, 132], ["the proteins synthesized", "PROBLEM", 19, 43], ["EMCV(IRES)\u2010nsP1", "TREATMENT", 49, 64]]], ["Both types of complementation in trans yield up to 90% less luc activity than rep C+luc (Fig. 2B).Functionality of nsP1\u20104 determined by complementation of a defective SINV replicon ::: ResultsAs the expression of nsPs had little effect on cellular translation (Fig. 1), we wondered whether the expression of these proteins together with the replication of a viral RNA upon complementation could induce an inhibition of cellular protein synthesis.", [["cellular", "ANATOMY", 239, 247], ["cellular", "ANATOMY", 419, 427], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 115, 121], ["SINV", "ORGANISM", 167, 171], ["nsPs", "GENE_OR_GENE_PRODUCT", 213, 217], ["cellular", "CELL", 239, 247], ["cellular", "CELL", 419, 427], ["rep C+luc", "DNA", 78, 87], ["nsP1\u20104", "PROTEIN", 115, 121], ["nsPs", "PROTEIN", 213, 217], ["viral RNA", "RNA", 358, 367], ["SINV", "SPECIES", 167, 171], ["nsPs", "PROBLEM", 213, 217], ["these proteins", "PROBLEM", 308, 322], ["a viral RNA upon complementation", "PROBLEM", 356, 388], ["cellular protein synthesis", "PROBLEM", 419, 445], ["complementation", "OBSERVATION", 14, 29], ["SINV replicon", "OBSERVATION", 167, 180], ["little effect", "OBSERVATION_MODIFIER", 222, 235], ["viral RNA", "OBSERVATION", 358, 367], ["cellular protein synthesis", "OBSERVATION", 419, 445]]], ["To this end, we examined protein synthesis in BHK cells with nsPs complementing rep C+luc(\u0394nsPs) (Fig. 2C).", [["BHK cells", "ANATOMY", 46, 55], ["BHK cells", "CELL", 46, 55], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 80, 89], ["BHK cells", "CELL_LINE", 46, 55], ["nsPs", "PROTEIN", 61, 65], ["rep C+luc", "DNA", 80, 89], ["\u0394nsPs", "DNA", 90, 95], ["protein synthesis in BHK cells", "TREATMENT", 25, 55], ["nsPs", "TEST", 61, 65]]], ["BHK cells were transfected with EMCV(IRES)\u2010nsP1\u20104 mRNA, with rep C+luc(\u0394nsPs) or with both combined.", [["BHK cells", "ANATOMY", 0, 9], ["BHK cells", "CELL", 0, 9], ["EMCV", "ORGANISM", 32, 36], ["\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 42, 49], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 61, 70], ["BHK cells", "CELL_LINE", 0, 9], ["EMCV(IRES)\u2010nsP1\u20104 mRNA", "RNA", 32, 54], ["rep C+luc", "DNA", 61, 70], ["BHK", "SPECIES", 0, 3], ["EMCV", "SPECIES", 32, 36], ["BHK cells", "PROBLEM", 0, 9], ["EMCV", "TEST", 32, 36], ["IRES", "TEST", 37, 41], ["\u2010nsP1", "TEST", 42, 47], ["mRNA", "TEST", 50, 54], ["rep C+luc", "TEST", 61, 70]]], ["As controls for this assay, we used rep C+luc and rep\u201026S, which renders a minimal sgmRNA with the 5\u2032UTR sequence but without the sequence for structural proteins.", [["rep C+luc", "GENE_OR_GENE_PRODUCT", 36, 45], ["rep\u201026S", "GENE_OR_GENE_PRODUCT", 50, 57], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 83, 89], ["rep C+luc", "DNA", 36, 45], ["rep\u201026S", "DNA", 50, 57], ["minimal sgmRNA", "DNA", 75, 89], ["5\u2032UTR sequence", "DNA", 99, 113], ["structural proteins", "PROTEIN", 143, 162], ["this assay", "TEST", 16, 26], ["rep C+luc", "TEST", 36, 45], ["a minimal sgmRNA", "PROBLEM", 73, 89], ["the 5\u2032UTR sequence", "TEST", 95, 113], ["the sequence", "TEST", 126, 138], ["structural proteins", "PROBLEM", 143, 162]]], ["At 7 hpt, cells were labelled with [35S]Met/Cys for 30 min.", [["cells", "ANATOMY", 10, 15], ["[35S]Met", "CHEMICAL", 35, 43], ["[35S]Met", "CHEMICAL", 35, 43], ["Cys", "CHEMICAL", 44, 47], ["cells", "CELL", 10, 15], ["[35S]Met", "SIMPLE_CHEMICAL", 35, 43], ["Cys", "AMINO_ACID", 44, 47]]], ["As expected, a strong inhibition of cellular translation was observed in cells transfected with rep C+luc or rep\u201026S, whereas cellular protein synthesis persisted in cells transfected with EMCV(IRES)\u2010nsP1\u20104 or with rep C+luc(\u0394nsPs) (Fig. 2C and D).", [["cellular", "ANATOMY", 36, 44], ["cells", "ANATOMY", 73, 78], ["cellular", "ANATOMY", 126, 134], ["cells", "ANATOMY", 166, 171], ["cellular", "CELL", 36, 44], ["cells", "CELL", 73, 78], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 96, 105], ["rep\u201026S", "GENE_OR_GENE_PRODUCT", 109, 116], ["cellular", "CELL", 126, 134], ["cells", "CELL", 166, 171], ["EMCV", "ORGANISM", 189, 193], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 215, 224], ["rep C", "DNA", 96, 101], ["luc", "DNA", 102, 105], ["rep", "DNA", 109, 112], ["26S", "DNA", 113, 116], ["EMCV(IRES)\u2010nsP1\u20104", "DNA", 189, 206], ["rep C+luc", "DNA", 215, 224], ["\u0394nsPs", "DNA", 225, 230], ["EMCV", "SPECIES", 189, 193], ["a strong inhibition of cellular translation", "PROBLEM", 13, 56], ["cellular protein synthesis", "TEST", 126, 152], ["EMCV(IRES", "TREATMENT", 189, 198], ["\u2010nsP1", "TEST", 199, 204], ["rep C+luc(\u0394nsPs", "TREATMENT", 215, 230]]], ["Interestingly, protein synthesis also continued unabated in cells co\u2010transfected with EMCV(IRES)\u2010nsP1\u20104 and rep C+luc(\u0394nsPs).", [["cells", "ANATOMY", 60, 65], ["cells", "CELL", 60, 65], ["EMCV", "ORGANISM", 86, 90], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 108, 117], ["IRES", "DNA", 91, 95], ["rep C+luc", "DNA", 108, 117], ["\u0394nsPs", "DNA", 118, 123], ["EMCV", "SPECIES", 86, 90], ["protein synthesis", "TEST", 15, 32], ["EMCV(IRES", "TREATMENT", 86, 95], ["\u2010nsP1", "TEST", 96, 101], ["rep C+luc", "TEST", 108, 117]]], ["This result suggests that the replication of this defective SINV replicon after complementation with nsPs is not sufficient to abrogate cellular translation.Functionality of nsP1\u20104 determined by complementation of a defective SINV replicon ::: ResultsIn a parallel experiment, the synthesis of viral RNA was studied in cells transfected with the different RNAs described above.", [["cellular", "ANATOMY", 136, 144], ["cells", "ANATOMY", 319, 324], ["SINV replicon", "ORGANISM", 60, 73], ["nsPs", "GENE_OR_GENE_PRODUCT", 101, 105], ["cellular", "CELL", 136, 144], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 174, 180], ["SINV", "ORGANISM", 226, 230], ["cells", "CELL", 319, 324], ["nsPs", "PROTEIN", 101, 105], ["nsP1\u20104", "PROTEIN", 174, 180], ["viral RNA", "RNA", 294, 303], ["SINV", "SPECIES", 60, 64], ["SINV", "SPECIES", 226, 230], ["this defective SINV replicon", "TREATMENT", 45, 73], ["the synthesis of viral RNA", "PROBLEM", 277, 303], ["SINV replicon", "OBSERVATION", 226, 239], ["viral RNA", "OBSERVATION", 294, 303]]], ["To do this, transfected cells were incubated with [3H]Uridine from 3 to 7 hpt in the presence of 2.5 \u03bcg ml\u22121 actinomycin D. Results showed that cells transfected with rep C+luc or rep\u201026S synthesized genomic or subgenomic RNAs (Fig. 2E).", [["cells", "ANATOMY", 24, 29], ["cells", "ANATOMY", 144, 149], ["[3H]Uridine", "CHEMICAL", 50, 61], ["actinomycin", "CHEMICAL", 109, 120], ["[3H]Uridine", "CHEMICAL", 50, 61], ["actinomycin", "CHEMICAL", 109, 120], ["cells", "CELL", 24, 29], ["[3H]Uridine", "SIMPLE_CHEMICAL", 50, 61], ["cells", "CELL", 144, 149], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 167, 176], ["rep\u201026S", "GENE_OR_GENE_PRODUCT", 180, 187], ["transfected cells", "CELL_LINE", 12, 29], ["rep C+luc or rep\u201026S synthesized genomic", "DNA", 167, 207], ["subgenomic RNAs", "RNA", 211, 226], ["Uridine", "TREATMENT", 54, 61], ["rep C", "TEST", 167, 172], ["luc", "PROBLEM", 173, 176], ["rep\u201026S synthesized genomic or subgenomic RNAs", "PROBLEM", 180, 226], ["subgenomic RNAs", "OBSERVATION", 211, 226]]], ["In contrast, no viral RNAs were detected in cells co\u2010transfected with EMCV(IRES)\u2010nsP1\u20104 and rep C+luc(\u0394nsPs), suggesting that although complementation can be demonstrated through measurement of luc activity, the production of RNA is below the threshold of detection.", [["cells", "ANATOMY", 44, 49], ["cells", "CELL", 44, 49], ["EMCV", "ORGANISM", 70, 74], ["\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 80, 87], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 92, 101], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 102, 107], ["luc", "GENE_OR_GENE_PRODUCT", 194, 197], ["viral RNAs", "RNA", 16, 26], ["EMCV(IRES)\u2010nsP1\u20104", "DNA", 70, 87], ["rep C+luc", "DNA", 92, 101], ["\u0394nsPs", "DNA", 102, 107], ["luc", "DNA", 194, 197], ["EMCV", "SPECIES", 70, 74], ["viral RNAs", "PROBLEM", 16, 26], ["EMCV", "TEST", 70, 74], ["IRES", "TEST", 75, 79], ["\u2010nsP1", "TEST", 80, 85], ["rep C+luc", "TEST", 92, 101], ["the production of RNA", "PROBLEM", 208, 229], ["no", "UNCERTAINTY", 13, 15], ["viral RNAs", "OBSERVATION", 16, 26], ["luc activity", "OBSERVATION", 194, 206]]], ["Nevertheless, the synthesis of C protein can be observed by immunoblotting in co\u2010transfected cells (Fig. 2F), although the level of this protein is approximately 100\u2010fold lower relative to cells transfected with rep C+luc.", [["cells", "ANATOMY", 93, 98], ["cells", "ANATOMY", 189, 194], ["C", "GENE_OR_GENE_PRODUCT", 31, 32], ["cells", "CELL", 93, 98], ["Fig. 2F", "CELL", 100, 107], ["cells", "CELL", 189, 194], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 212, 221], ["C protein", "PROTEIN", 31, 40], ["co\u2010transfected cells", "CELL_LINE", 78, 98], ["rep C+luc", "DNA", 212, 221], ["the synthesis of C protein", "PROBLEM", 14, 40], ["this protein", "TEST", 132, 144], ["rep C+luc", "TREATMENT", 212, 221]]], ["In conclusion, this low RNA replication rate has no consequences for the blockade of host translation.Release of nuclear proteins in SINV\u2010replicating cells ::: ResultsInfection of mammalian cells by a variety of animal viruses induces the formation of SGs containing some nuclear proteins that are released to the cytoplasm (Valiente\u2010Echeverria et al., 2012).", [["nuclear", "ANATOMY", 113, 120], ["cells", "ANATOMY", 150, 155], ["mammalian cells", "ANATOMY", 180, 195], ["SGs", "ANATOMY", 252, 255], ["nuclear", "ANATOMY", 272, 279], ["cytoplasm", "ANATOMY", 314, 323], ["nuclear", "CELLULAR_COMPONENT", 113, 120], ["SINV", "ORGANISM", 133, 137], ["cells", "CELL", 150, 155], ["mammalian cells", "CELL", 180, 195], ["SGs", "GENE_OR_GENE_PRODUCT", 252, 255], ["nuclear", "CELLULAR_COMPONENT", 272, 279], ["cytoplasm", "ORGANISM_SUBSTANCE", 314, 323], ["nuclear proteins", "PROTEIN", 113, 129], ["SINV\u2010replicating cells", "CELL_LINE", 133, 155], ["mammalian cells", "CELL_TYPE", 180, 195], ["SGs", "PROTEIN", 252, 255], ["nuclear proteins", "PROTEIN", 272, 288], ["SINV", "SPECIES", 133, 137], ["this low RNA replication rate", "PROBLEM", 15, 44], ["mammalian cells", "PROBLEM", 180, 195], ["animal viruses", "PROBLEM", 212, 226], ["SGs", "PROBLEM", 252, 255], ["some nuclear proteins", "PROBLEM", 267, 288], ["mammalian cells", "OBSERVATION", 180, 195], ["animal viruses", "OBSERVATION", 212, 226], ["nuclear proteins", "OBSERVATION", 272, 288]]], ["Alphavirus infection elicits the release of T\u2010cell intracellular antigen (TIA\u20101) from the nucleus to the cytoplasm, giving rise to the transient accumulation of SGs (Panas et al., 2012; Garcia\u2010Moreno et al., 2013).", [["intracellular", "ANATOMY", 51, 64], ["nucleus", "ANATOMY", 90, 97], ["cytoplasm", "ANATOMY", 105, 114], ["infection", "DISEASE", 11, 20], ["T\u2010cell intracellular antigen", "GENE_OR_GENE_PRODUCT", 44, 72], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 74, 79], ["nucleus", "CELLULAR_COMPONENT", 90, 97], ["cytoplasm", "ORGANISM_SUBSTANCE", 105, 114], ["SGs", "CELLULAR_COMPONENT", 161, 164], ["T\u2010cell intracellular antigen", "PROTEIN", 44, 72], ["TIA\u20101", "PROTEIN", 74, 79], ["Alphavirus infection", "PROBLEM", 0, 20], ["T\u2010cell intracellular antigen", "PROBLEM", 44, 72], ["infection", "OBSERVATION", 11, 20], ["nucleus", "ANATOMY", 90, 97], ["transient", "OBSERVATION_MODIFIER", 135, 144], ["accumulation", "OBSERVATION_MODIFIER", 145, 157]]], ["Interestingly, the release of some nuclear proteins by SFV infection, such as TIA\u20101, has been involved in the shut\u2010off of host translation (McInerney et al., 2005).", [["nuclear", "ANATOMY", 35, 42], ["infection", "DISEASE", 59, 68], ["nuclear", "CELLULAR_COMPONENT", 35, 42], ["SFV", "ORGANISM", 55, 58], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 78, 83], ["nuclear proteins", "PROTEIN", 35, 51], ["TIA\u20101", "PROTEIN", 78, 83], ["SFV", "SPECIES", 55, 58], ["some nuclear proteins", "PROBLEM", 30, 51], ["SFV infection", "PROBLEM", 55, 68], ["some", "OBSERVATION_MODIFIER", 30, 34], ["nuclear proteins", "OBSERVATION", 35, 51], ["SFV", "OBSERVATION_MODIFIER", 55, 58], ["infection", "OBSERVATION", 59, 68]]], ["In addition to TIA\u20101, other nuclear proteins appear in the cytoplasm after SINV infection, including hnRNP K, hnRNP A1 and HuR proteins (Burnham et al., 2007; Lin et al., 2009; Gui et al., 2010; Dickson et al., 2012).", [["nuclear", "ANATOMY", 28, 35], ["cytoplasm", "ANATOMY", 59, 68], ["infection", "DISEASE", 80, 89], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 15, 20], ["nuclear", "CELLULAR_COMPONENT", 28, 35], ["cytoplasm", "ORGANISM_SUBSTANCE", 59, 68], ["SINV", "ORGANISM", 75, 79], ["hnRNP K", "GENE_OR_GENE_PRODUCT", 101, 108], ["hnRNP A1", "GENE_OR_GENE_PRODUCT", 110, 118], ["HuR", "GENE_OR_GENE_PRODUCT", 123, 126], ["TIA\u20101", "PROTEIN", 15, 20], ["nuclear proteins", "PROTEIN", 28, 44], ["hnRNP K", "PROTEIN", 101, 108], ["hnRNP A1", "PROTEIN", 110, 118], ["HuR proteins", "PROTEIN", 123, 135], ["SINV", "SPECIES", 75, 79], ["TIA\u20101", "TREATMENT", 15, 20], ["other nuclear proteins", "PROBLEM", 22, 44], ["SINV infection", "PROBLEM", 75, 89], ["hnRNP K", "TEST", 101, 108], ["HuR proteins", "TEST", 123, 135], ["SINV infection", "OBSERVATION", 75, 89]]], ["Thus, initially, we decided to examine if two nuclear proteins, TIA\u20101 and polypyrimidine tract\u2010binding protein (PTB), changed their cellular distribution in SINV\u2010infected BHK cells and in cells transfected with the SINV replicon.", [["nuclear", "ANATOMY", 46, 53], ["cellular", "ANATOMY", 132, 140], ["BHK cells", "ANATOMY", 171, 180], ["cells", "ANATOMY", 188, 193], ["polypyrimidine", "CHEMICAL", 74, 88], ["nuclear", "CELLULAR_COMPONENT", 46, 53], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 64, 69], ["polypyrimidine tract\u2010binding protein", "GENE_OR_GENE_PRODUCT", 74, 110], ["PTB", "GENE_OR_GENE_PRODUCT", 112, 115], ["cellular", "CELL", 132, 140], ["SINV", "ORGANISM", 157, 161], ["BHK cells", "CELL", 171, 180], ["cells", "CELL", 188, 193], ["SINV replicon", "ORGANISM", 215, 228], ["nuclear proteins", "PROTEIN", 46, 62], ["TIA\u20101", "PROTEIN", 64, 69], ["polypyrimidine tract\u2010binding protein", "PROTEIN", 74, 110], ["PTB", "PROTEIN", 112, 115], ["SINV\u2010infected BHK cells", "CELL_LINE", 157, 180], ["SINV", "SPECIES", 157, 161], ["SINV", "SPECIES", 215, 219], ["two nuclear proteins", "PROBLEM", 42, 62], ["TIA\u20101", "TEST", 64, 69], ["polypyrimidine tract\u2010binding protein (PTB)", "PROBLEM", 74, 116], ["SINV\u2010infected BHK cells", "PROBLEM", 157, 180], ["the SINV replicon", "TREATMENT", 211, 228], ["cellular distribution", "OBSERVATION", 132, 153], ["SINV\u2010infected BHK cells", "OBSERVATION", 157, 180], ["SINV replicon", "OBSERVATION", 215, 228]]], ["Polypyrimidine tract\u2010binding protein is a ubiquitous RNA\u2010binding protein that is involved in a number of diverse cellular functions including splicing regulation, polyadenylation and viral mRNA translation (Sawicka et al., 2008).", [["cellular", "ANATOMY", 113, 121], ["Polypyrimidine", "CHEMICAL", 0, 14], ["Polypyrimidine", "CHEMICAL", 0, 14], ["Polypyrimidine tract\u2010binding protein", "GENE_OR_GENE_PRODUCT", 0, 36], ["cellular", "CELL", 113, 121], ["Polypyrimidine tract\u2010binding protein", "PROTEIN", 0, 36], ["ubiquitous RNA\u2010binding protein", "PROTEIN", 42, 72], ["viral mRNA", "RNA", 183, 193], ["Polypyrimidine tract\u2010binding protein", "PROBLEM", 0, 36], ["a ubiquitous RNA\u2010binding protein", "PROBLEM", 40, 72], ["splicing regulation", "TREATMENT", 142, 161], ["polyadenylation", "TREATMENT", 163, 178], ["viral mRNA translation", "PROBLEM", 183, 205], ["diverse", "OBSERVATION_MODIFIER", 105, 112], ["cellular functions", "OBSERVATION", 113, 131], ["viral mRNA", "OBSERVATION", 183, 193]]], ["This protein is released from the nucleus to the cytoplasm in picornavirus and coronavirus\u2010infected cells (Back et al., 2002; Borghese and Michiels, 2011; Sola et al., 2011); to our knowledge, redistribution of PTB has not been examined in alphavirus\u2010infected cells.", [["nucleus", "ANATOMY", 34, 41], ["cytoplasm", "ANATOMY", 49, 58], ["cells", "ANATOMY", 100, 105], ["cells", "ANATOMY", 260, 265], ["PTB", "DISEASE", 211, 214], ["nucleus", "CELLULAR_COMPONENT", 34, 41], ["cytoplasm", "ORGANISM_SUBSTANCE", 49, 58], ["picornavirus", "ORGANISM", 62, 74], ["coronavirus\u2010infected cells", "CELL", 79, 105], ["PTB", "GENE_OR_GENE_PRODUCT", 211, 214], ["alphavirus\u2010infected cells", "CELL", 240, 265], ["picornavirus and coronavirus\u2010infected cells", "CELL_TYPE", 62, 105], ["PTB", "PROTEIN", 211, 214], ["alphavirus\u2010infected cells", "CELL_LINE", 240, 265], ["This protein", "TEST", 0, 12], ["picornavirus", "PROBLEM", 62, 74], ["coronavirus\u2010infected cells", "PROBLEM", 79, 105], ["PTB", "PROBLEM", 211, 214], ["nucleus", "ANATOMY", 34, 41], ["cytoplasm", "OBSERVATION_MODIFIER", 49, 58], ["picornavirus", "OBSERVATION", 62, 74], ["coronavirus\u2010infected cells", "OBSERVATION", 79, 105], ["PTB", "OBSERVATION", 211, 214]]], ["To this end, BHK cells were infected with SINV or transfected with replicon rep C+luc and at 5 or 7 hpt, respectively, the subcellular distribution of TIA\u20101 and PTB was analysed by confocal microscopy (Fig. 3).", [["BHK cells", "ANATOMY", 13, 22], ["subcellular", "ANATOMY", 123, 134], ["TIA", "DISEASE", 151, 154], ["BHK cells", "CELL", 13, 22], ["SINV", "ORGANISM", 42, 46], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 76, 85], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 151, 156], ["PTB", "GENE_OR_GENE_PRODUCT", 161, 164], ["BHK cells", "CELL_LINE", 13, 22], ["replicon rep C", "DNA", 67, 81], ["luc", "DNA", 82, 85], ["TIA\u20101", "PROTEIN", 151, 156], ["PTB", "PROTEIN", 161, 164], ["BHK", "SPECIES", 13, 16], ["SINV", "SPECIES", 42, 46], ["BHK cells", "PROBLEM", 13, 22], ["SINV", "PROBLEM", 42, 46], ["replicon rep", "TREATMENT", 67, 79], ["TIA", "PROBLEM", 151, 154], ["PTB", "PROBLEM", 161, 164], ["confocal microscopy", "TEST", 181, 200], ["TIA", "OBSERVATION", 151, 154]]], ["Clearly, these proteins have a preferential nuclear localization in uninfected BHK cells, whereas they were released from nucleus to cytoplasm both in infected and in transfected cells.", [["nuclear", "ANATOMY", 44, 51], ["BHK cells", "ANATOMY", 79, 88], ["nucleus", "ANATOMY", 122, 129], ["cytoplasm", "ANATOMY", 133, 142], ["cells", "ANATOMY", 179, 184], ["nuclear", "CELLULAR_COMPONENT", 44, 51], ["BHK cells", "CELL", 79, 88], ["nucleus", "CELLULAR_COMPONENT", 122, 129], ["cytoplasm", "ORGANISM_SUBSTANCE", 133, 142], ["cells", "CELL", 179, 184], ["uninfected BHK cells", "CELL_LINE", 68, 88], ["transfected cells", "CELL_LINE", 167, 184], ["uninfected BHK cells", "PROBLEM", 68, 88], ["preferential", "OBSERVATION_MODIFIER", 31, 43], ["nuclear localization", "OBSERVATION", 44, 64], ["uninfected BHK cells", "OBSERVATION", 68, 88], ["cytoplasm", "OBSERVATION_MODIFIER", 133, 142], ["infected", "OBSERVATION_MODIFIER", 151, 159], ["transfected cells", "OBSERVATION", 167, 184]]], ["Densitometric analysis of the TIA\u20101 signal indicated that in uninfected cells, approximately 55\u201360% of the total amount of TIA\u20101was present in the nucleus.", [["cells", "ANATOMY", 72, 77], ["nucleus", "ANATOMY", 147, 154], ["TIA", "DISEASE", 123, 126], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 30, 35], ["cells", "CELL", 72, 77], ["TIA\u20101was", "GENE_OR_GENE_PRODUCT", 123, 131], ["nucleus", "CELLULAR_COMPONENT", 147, 154], ["TIA\u20101", "PROTEIN", 30, 35], ["uninfected cells", "CELL_TYPE", 61, 77], ["TIA", "PROTEIN", 123, 126], ["1was", "PROTEIN", 127, 131], ["Densitometric analysis", "TEST", 0, 22], ["the TIA\u20101 signal", "TEST", 26, 42], ["uninfected cells", "PROBLEM", 61, 77], ["TIA", "PROBLEM", 123, 126], ["uninfected cells", "OBSERVATION", 61, 77], ["total", "OBSERVATION_MODIFIER", 107, 112], ["amount", "OBSERVATION_MODIFIER", 113, 119], ["TIA", "OBSERVATION", 123, 126], ["nucleus", "ANATOMY", 147, 154]]], ["However, both in infected cells and in cells transfected with rep C+luc TIA\u20101 accumulated over 82\u201390% in the cytoplasm (Fig. 3A).", [["cells", "ANATOMY", 26, 31], ["cells", "ANATOMY", 39, 44], ["cytoplasm", "ANATOMY", 109, 118], ["cells", "CELL", 26, 31], ["cells", "CELL", 39, 44], ["rep C+luc TIA\u20101", "GENE_OR_GENE_PRODUCT", 62, 77], ["cytoplasm", "ORGANISM_SUBSTANCE", 109, 118], ["infected cells", "CELL_TYPE", 17, 31], ["rep C+luc TIA\u20101", "DNA", 62, 77], ["infected cells", "PROBLEM", 17, 31], ["rep C", "TEST", 62, 67], ["luc TIA\u2010", "TEST", 68, 76], ["infected cells", "OBSERVATION", 17, 31]]], ["Similar results were obtained whit PTB that exhibited a nuclear level of 75\u201380% in mock\u2010infected BHK cells, whereas this amount was reduced to 11\u201315% in infected cells and 11\u201318% in rep C+luc\u2010transfected cells (Fig. 3B).", [["nuclear", "ANATOMY", 56, 63], ["BHK cells", "ANATOMY", 97, 106], ["cells", "ANATOMY", 162, 167], ["rep C+luc\u2010transfected cells", "ANATOMY", 182, 209], ["PTB", "GENE_OR_GENE_PRODUCT", 35, 38], ["BHK cells", "CELL", 97, 106], ["cells", "CELL", 162, 167], ["PTB", "PROTEIN", 35, 38], ["mock\u2010infected BHK cells", "CELL_LINE", 83, 106], ["infected cells", "CELL_TYPE", 153, 167], ["rep C+luc\u2010transfected cells", "CELL_LINE", 182, 209], ["whit PTB", "TEST", 30, 38], ["a nuclear level", "TEST", 54, 69], ["infected cells", "TEST", 153, 167], ["rep C", "TEST", 182, 187], ["luc\u2010transfected cells", "PROBLEM", 188, 209], ["BHK cells", "OBSERVATION", 97, 106], ["infected cells", "OBSERVATION", 153, 167], ["luc\u2010transfected cells", "OBSERVATION", 188, 209]]], ["Therefore, there is a correlation between SINV replication and the release of proteins from nucleus to cytoplasm.", [["nucleus", "ANATOMY", 92, 99], ["cytoplasm", "ANATOMY", 103, 112], ["SINV", "ORGANISM", 42, 46], ["nucleus", "CELLULAR_COMPONENT", 92, 99], ["cytoplasm", "ORGANISM_SUBSTANCE", 103, 112], ["SINV", "SPECIES", 42, 46], ["SINV replication", "TREATMENT", 42, 58]]], ["Next, we wished to examine the release of nuclear proteins in cells co\u2010transfected with rep C+luc (\u0394nsPs) and EMCV(IRES)\u2010nsP1\u20104 compared with cells transfected with rep C+luc (Figs 4A and B).", [["nuclear", "ANATOMY", 42, 49], ["cells", "ANATOMY", 62, 67], ["cells", "ANATOMY", 142, 147], ["nuclear", "CELLULAR_COMPONENT", 42, 49], ["cells", "CELL", 62, 67], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 88, 97], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 99, 104], ["EMCV", "ORGANISM", 110, 114], ["cells", "CELL", 142, 147], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 165, 174], ["Figs 4A", "GENE_OR_GENE_PRODUCT", 176, 183], ["B", "GENE_OR_GENE_PRODUCT", 188, 189], ["nuclear proteins", "PROTEIN", 42, 58], ["rep C+luc (\u0394nsPs) and EMCV(IRES)\u2010nsP1\u20104", "DNA", 88, 127], ["rep C+luc", "DNA", 165, 174], ["EMCV", "SPECIES", 110, 114], ["nuclear proteins in cells", "PROBLEM", 42, 67], ["rep C+luc (\u0394nsPs", "TREATMENT", 88, 104], ["EMCV(IRES", "TREATMENT", 110, 119]]], ["As shown above, although inefficiently, viral replication can be induced by trans\u2010complementation.", [["viral replication", "PROBLEM", 40, 57]]], ["The presence of luc tested with specific antibodies indicates SINV RNA replication, transcription of the sgmRNA C+luc and subsequent translation to produce luc in transfected cells.", [["cells", "ANATOMY", 175, 180], ["luc", "GENE_OR_GENE_PRODUCT", 16, 19], ["SINV", "ORGANISM", 62, 66], ["sgmRNA C+luc", "GENE_OR_GENE_PRODUCT", 105, 117], ["luc", "GENE_OR_GENE_PRODUCT", 156, 159], ["cells", "CELL", 175, 180], ["luc", "DNA", 16, 19], ["sgmRNA C+luc", "DNA", 105, 117], ["luc", "DNA", 156, 159], ["transfected cells", "CELL_LINE", 163, 180], ["SINV", "SPECIES", 62, 66], ["luc", "PROBLEM", 16, 19], ["specific antibodies", "TEST", 32, 51], ["SINV RNA replication", "TREATMENT", 62, 82], ["luc", "PROBLEM", 114, 117], ["luc in transfected cells", "PROBLEM", 156, 180], ["luc", "OBSERVATION", 16, 19], ["transfected cells", "OBSERVATION", 163, 180]]], ["In cells transfected with rep C+luc, a clear re\u2010localization of TIA\u20101 to the cytoplasm was observed in cells synthesizing luc whereas it largely remained nuclear in cells co\u2010transfected with rep C+luc (\u0394nsPs) and EMCV(IRES)\u2010nsP1\u20104, even in cells with conspicuous luc production (Fig. 4A).", [["cells", "ANATOMY", 3, 8], ["cytoplasm", "ANATOMY", 77, 86], ["cells", "ANATOMY", 103, 108], ["nuclear", "ANATOMY", 154, 161], ["cells", "ANATOMY", 165, 170], ["cells", "ANATOMY", 240, 245], ["cells", "CELL", 3, 8], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 26, 35], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 64, 69], ["cytoplasm", "ORGANISM_SUBSTANCE", 77, 86], ["cells", "CELL", 103, 108], ["luc", "GENE_OR_GENE_PRODUCT", 122, 125], ["cells", "CELL", 165, 170], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 191, 200], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 202, 207], ["EMCV(IRES)\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 213, 230], ["cells", "CELL", 240, 245], ["luc", "GENE_OR_GENE_PRODUCT", 263, 266], ["rep C+luc", "DNA", 26, 35], ["TIA\u20101", "PROTEIN", 64, 69], ["luc", "DNA", 122, 125], ["rep C+luc", "DNA", 191, 200], ["\u0394nsPs", "DNA", 202, 207], ["EMCV(IRES)\u2010nsP1\u20104", "DNA", 213, 230], ["EMCV", "SPECIES", 213, 217], ["the cytoplasm", "PROBLEM", 73, 86], ["EMCV(IRES", "TREATMENT", 213, 222], ["conspicuous", "OBSERVATION_MODIFIER", 251, 262], ["luc production", "OBSERVATION", 263, 277]]], ["Thus, in rep C+luc\u2010transfected cells, the nuclear signal for TIA\u20101 related to mock\u2010transfected cells drops by 74\u201380% and in cells co\u2010transfected with rep C+luc (\u0394nsPs) and EMCV(IRES)\u2010nsP1\u20104 diminishes only by 2\u20136%.", [["cells", "ANATOMY", 31, 36], ["nuclear", "ANATOMY", 42, 49], ["cells", "ANATOMY", 95, 100], ["cells", "ANATOMY", 124, 129], ["TIA", "DISEASE", 61, 64], ["rep C", "GENE_OR_GENE_PRODUCT", 9, 14], ["cells", "CELL", 31, 36], ["nuclear", "CELLULAR_COMPONENT", 42, 49], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 61, 66], ["cells", "CELL", 95, 100], ["cells", "CELL", 124, 129], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 150, 159], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 161, 166], ["rep C+luc\u2010transfected cells", "CELL_LINE", 9, 36], ["TIA\u20101", "PROTEIN", 61, 66], ["mock\u2010transfected cells", "CELL_LINE", 78, 100], ["rep C+luc", "DNA", 150, 159], ["\u0394nsPs", "DNA", 161, 166], ["IRES", "DNA", 177, 181], ["EMCV", "SPECIES", 172, 176], ["luc\u2010transfected cells", "PROBLEM", 15, 36], ["TIA", "PROBLEM", 61, 64], ["mock\u2010transfected cells", "PROBLEM", 78, 100], ["rep C+luc (\u0394nsPs", "TREATMENT", 150, 166], ["EMCV(IRES", "TREATMENT", 172, 181]]], ["Similar results were obtained with PTB (Fig. 4B).", [["PTB", "PROTEIN", 35, 38]]], ["The immunofluorescence signal associated to PTB into the nucleus of cells transfected with rep C+luc drops by 70\u201375% as compared to mock\u2010transfected cells, but in cells co\u2010transfected with rep C+luc (\u0394nsPs) plus EMCV(IRES)\u2010nsP1\u20104 decreases only by 1\u20134%.", [["nucleus", "ANATOMY", 57, 64], ["cells", "ANATOMY", 68, 73], ["cells", "ANATOMY", 149, 154], ["cells", "ANATOMY", 163, 168], ["PTB", "GENE_OR_GENE_PRODUCT", 44, 47], ["nucleus", "CELLULAR_COMPONENT", 57, 64], ["cells", "CELL", 68, 73], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 91, 100], ["cells", "CELL", 149, 154], ["cells", "CELL", 163, 168], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 189, 198], ["PTB", "PROTEIN", 44, 47], ["rep C", "DNA", 91, 96], ["mock\u2010transfected cells", "CELL_LINE", 132, 154], ["rep C+luc", "DNA", 189, 198], ["\u0394nsPs", "DNA", 200, 205], ["IRES", "DNA", 217, 221], ["EMCV", "SPECIES", 212, 216], ["The immunofluorescence signal", "TEST", 0, 29], ["PTB", "PROBLEM", 44, 47], ["rep C", "TEST", 91, 96], ["rep C+luc (\u0394nsPs)", "TREATMENT", 189, 206], ["EMCV(IRES", "TREATMENT", 212, 221], ["\u2010nsP1", "TEST", 222, 227], ["nucleus", "ANATOMY", 57, 64]]], ["These observations are consistent with the idea that a correlation exists between the level of viral RNA replication, the redistribution of nucleocytoplasmic shuttling proteins as TIA\u20101 or PTB to the cytoplasm and the inhibition of cellular protein synthesis.Release of nuclear proteins in SINV\u2010replicating cells ::: ResultsTo analyse the contribution of nsPs to the potential release of PTB to the cytoplasm, we also tested BHK\u2010T7 cells transfected with plasmids pTM1\u2010nsP1\u20104 or pTM1\u2010nsP2.", [["nucleocytoplasmic", "ANATOMY", 140, 157], ["cytoplasm", "ANATOMY", 200, 209], ["cellular", "ANATOMY", 232, 240], ["nuclear", "ANATOMY", 270, 277], ["cells", "ANATOMY", 307, 312], ["cytoplasm", "ANATOMY", 399, 408], ["BHK\u2010T7 cells", "ANATOMY", 425, 437], ["plasmids", "ANATOMY", 455, 463], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 180, 185], ["PTB", "GENE_OR_GENE_PRODUCT", 189, 192], ["cytoplasm", "ORGANISM_SUBSTANCE", 200, 209], ["cellular", "CELL", 232, 240], ["nuclear", "CELLULAR_COMPONENT", 270, 277], ["SINV", "ORGANISM", 290, 294], ["cells", "CELL", 307, 312], ["PTB", "GENE_OR_GENE_PRODUCT", 388, 391], ["cytoplasm", "ORGANISM_SUBSTANCE", 399, 408], ["BHK\u2010T7 cells", "CELL", 425, 437], ["pTM1\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 464, 475], ["pTM1\u2010nsP2", "GENE_OR_GENE_PRODUCT", 479, 488], ["nucleocytoplasmic shuttling proteins", "PROTEIN", 140, 176], ["TIA\u20101", "PROTEIN", 180, 185], ["PTB", "PROTEIN", 189, 192], ["nuclear proteins", "PROTEIN", 270, 286], ["SINV\u2010replicating cells", "CELL_LINE", 290, 312], ["nsPs", "PROTEIN", 355, 359], ["PTB", "PROTEIN", 388, 391], ["BHK\u2010T7 cells", "CELL_LINE", 425, 437], ["plasmids pTM1\u2010nsP1\u20104", "DNA", 455, 475], ["pTM1\u2010nsP2", "DNA", 479, 488], ["SINV", "SPECIES", 290, 294], ["viral RNA replication", "TREATMENT", 95, 116], ["nucleocytoplasmic shuttling proteins", "PROBLEM", 140, 176], ["PTB", "PROBLEM", 189, 192], ["cellular protein synthesis", "PROBLEM", 232, 258], ["plasmids pTM1", "TREATMENT", 455, 468], ["consistent with", "UNCERTAINTY", 23, 38], ["viral RNA replication", "OBSERVATION", 95, 116], ["nucleocytoplasmic shuttling", "OBSERVATION", 140, 167], ["cellular protein synthesis", "OBSERVATION", 232, 258]]], ["The pTM1\u2010BHK\u2010T7 system allows the expression of higher levels of nsPs, compared with transfection of EMCV(IRES)\u2010nsP1\u20104 mRNA.", [["pTM1", "GENE_OR_GENE_PRODUCT", 4, 8], ["nsPs", "GENE_OR_GENE_PRODUCT", 65, 69], ["EMCV", "ORGANISM", 101, 105], ["\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 111, 118], ["pTM1", "PROTEIN", 4, 8], ["nsPs", "PROTEIN", 65, 69], ["EMCV(IRES)\u2010nsP1\u20104 mRNA", "RNA", 101, 123], ["EMCV", "SPECIES", 101, 105], ["The pTM1\u2010BHK\u2010T7 system", "TEST", 0, 22], ["higher levels of nsPs", "PROBLEM", 48, 69]]], ["Thus, the location of PTB at 18 hpt was assessed in BHK\u2010T7 cells transfected with pTM1\u2010nsP1\u20104 or pTM1\u2010nsP2, using anti\u2010nsP1 or anti\u2010nsP2 antibodies to detect the corresponding proteins in transfected cells.", [["BHK\u2010T7 cells", "ANATOMY", 52, 64], ["cells", "ANATOMY", 200, 205], ["PTB", "DISEASE", 22, 25], ["PTB", "GENE_OR_GENE_PRODUCT", 22, 25], ["BHK\u2010T7 cells", "CELL", 52, 64], ["pTM1\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 82, 93], ["pTM1\u2010nsP2", "GENE_OR_GENE_PRODUCT", 97, 106], ["anti\u2010nsP1", "GENE_OR_GENE_PRODUCT", 114, 123], ["anti\u2010nsP2", "GENE_OR_GENE_PRODUCT", 127, 136], ["cells", "CELL", 200, 205], ["PTB", "PROTEIN", 22, 25], ["BHK\u2010T7 cells", "CELL_LINE", 52, 64], ["pTM1\u2010nsP1", "PROTEIN", 82, 91], ["pTM1\u2010nsP2", "PROTEIN", 97, 106], ["anti\u2010nsP1", "PROTEIN", 114, 123], ["anti\u2010nsP2 antibodies", "PROTEIN", 127, 147], ["transfected cells", "CELL_LINE", 188, 205], ["BHK\u2010T7", "SPECIES", 52, 58], ["PTB", "PROBLEM", 22, 25], ["pTM1\u2010nsP1", "TEST", 82, 91], ["pTM1\u2010nsP2", "TREATMENT", 97, 106], ["anti\u2010nsP1", "TREATMENT", 114, 123], ["anti\u2010nsP2 antibodies", "TEST", 127, 147], ["the corresponding proteins in transfected cells", "PROBLEM", 158, 205], ["transfected cells", "OBSERVATION", 188, 205]]], ["Notably, PTB exhibited a normal nuclear location in cells expressing nsP2 or nsP1\u20104 (Supporting Information http://onlinelibrary.wiley.com/doi/10.1111/cmi.12381/suppinfo), indicating that expression of SINV nsPs does not affect the redistribution of PTB between nucleus and cytoplasm.", [["nuclear", "ANATOMY", 32, 39], ["cells", "ANATOMY", 52, 57], ["nucleus", "ANATOMY", 262, 269], ["cytoplasm", "ANATOMY", 274, 283], ["PTB", "GENE_OR_GENE_PRODUCT", 9, 12], ["nuclear", "CELLULAR_COMPONENT", 32, 39], ["cells", "CELL", 52, 57], ["nsP2", "GENE_OR_GENE_PRODUCT", 69, 73], ["SINV", "ORGANISM", 202, 206], ["nsPs", "GENE_OR_GENE_PRODUCT", 207, 211], ["PTB", "GENE_OR_GENE_PRODUCT", 250, 253], ["nucleus", "CELLULAR_COMPONENT", 262, 269], ["cytoplasm", "ORGANISM_SUBSTANCE", 274, 283], ["PTB", "PROTEIN", 9, 12], ["nsP2", "PROTEIN", 69, 73], ["nsP1\u20104", "PROTEIN", 77, 83], ["SINV nsPs", "PROTEIN", 202, 211], ["PTB", "PROTEIN", 250, 253], ["SINV", "SPECIES", 202, 206], ["PTB", "PROBLEM", 9, 12], ["SINV nsPs", "PROBLEM", 202, 211], ["the redistribution of PTB between nucleus and cytoplasm", "PROBLEM", 228, 283], ["normal", "OBSERVATION", 25, 31], ["SINV nsPs", "OBSERVATION", 202, 211], ["redistribution", "OBSERVATION", 232, 246], ["PTB", "OBSERVATION", 250, 253], ["nucleus", "ANATOMY", 262, 269]]], ["These results are consistent with the findings reported in Fig. 1, demonstrating that these proteins do not block cellular protein synthesis at 18 hpt.Protein synthesis and release of nuclear proteins in cells transfected with the defective variant SINV nsP2 (P726G) ::: ResultsAs the SINV variant with a point mutation in nsP2 (P726G) is defective in the shut\u2010off of host protein synthesis (Frolov et al., 1999; Sanz et al., 2007), we used this to test the potential parallelism between the ablation of host translation and the release of nuclear proteins.", [["cellular", "ANATOMY", 114, 122], ["nuclear", "ANATOMY", 184, 191], ["cells", "ANATOMY", 204, 209], ["nuclear", "ANATOMY", 540, 547], ["cellular", "CELL", 114, 122], ["nuclear", "CELLULAR_COMPONENT", 184, 191], ["cells", "CELL", 204, 209], ["SINV", "ORGANISM", 285, 289], ["nsP2 (P726G)", "GENE_OR_GENE_PRODUCT", 323, 335], ["nuclear", "CELLULAR_COMPONENT", 540, 547], ["nuclear proteins", "PROTEIN", 184, 200], ["SINV nsP2", "PROTEIN", 249, 258], ["nsP2 (P726G)", "DNA", 323, 335], ["nuclear proteins", "PROTEIN", 540, 556], ["SINV", "SPECIES", 285, 289], ["these proteins", "TEST", 86, 100], ["cellular protein synthesis", "PROBLEM", 114, 140], ["Protein synthesis", "TEST", 151, 168], ["nuclear proteins", "TEST", 184, 200], ["a point mutation in nsP2", "PROBLEM", 303, 327], ["the ablation", "TREATMENT", 488, 500], ["host translation", "TREATMENT", 504, 520], ["nuclear proteins", "PROBLEM", 540, 556], ["consistent with", "UNCERTAINTY", 18, 33], ["protein synthesis", "OBSERVATION", 123, 140], ["SINV variant", "OBSERVATION", 285, 297]]], ["Initially, BHK cells were transfected with in vitro synthesized gmRNAs SINV wild type (wt) or SINV nsP2 (P726G), and protein synthesis was analysed by radioactive labelling.", [["BHK cells", "ANATOMY", 11, 20], ["BHK cells", "CELL", 11, 20], ["gmRNAs SINV wild type (wt)", "ORGANISM", 64, 90], ["SINV", "ORGANISM", 94, 98], ["nsP2", "GENE_OR_GENE_PRODUCT", 99, 103], ["BHK cells", "CELL_LINE", 11, 20], ["SINV nsP2", "PROTEIN", 94, 103], ["BHK", "SPECIES", 11, 14], ["SINV", "SPECIES", 94, 98], ["BHK cells", "PROBLEM", 11, 20], ["SINV nsP2", "TEST", 94, 103], ["protein synthesis", "TEST", 117, 134], ["BHK cells", "OBSERVATION", 11, 20]]], ["Whereas transfection of cells with SINV wt gmRNA profoundly arrested cellular protein synthesis at 8 hpt, transfection of the variant P726G resulted in a partial inhibition of protein synthesis (Fig. 5A), estimated at 33% by densitometric analysis (Fig. 5B).", [["cells", "ANATOMY", 24, 29], ["cellular", "ANATOMY", 69, 77], ["cells", "CELL", 24, 29], ["SINV wt gmRNA", "ORGANISM", 35, 48], ["cellular", "CELL", 69, 77], ["SINV wt gmRNA", "DNA", 35, 48], ["P726G", "DNA", 134, 139], ["SINV", "SPECIES", 35, 39], ["SINV wt gmRNA", "TEST", 35, 48], ["profoundly arrested cellular protein synthesis", "PROBLEM", 49, 95], ["a partial inhibition of protein synthesis", "PROBLEM", 152, 193], ["densitometric analysis", "TEST", 225, 247], ["protein synthesis", "OBSERVATION", 78, 95]]], ["Thus, this SINV variant was not entirely defective in its ability to interfere with cellular protein synthesis.", [["cellular", "ANATOMY", 84, 92], ["SINV", "ORGANISM", 11, 15], ["cellular", "CELL", 84, 92], ["SINV", "SPECIES", 11, 15], ["this SINV variant", "PROBLEM", 6, 23], ["cellular protein synthesis", "PROBLEM", 84, 110], ["protein synthesis", "OBSERVATION", 93, 110]]], ["Next, the synthesis of viral RNAs was assayed by [3H]Uridine incorporation in the presence of 2.5 \u03bcg ml\u22121 actinomycin D from 3 to 8 hpt.", [["[3H]Uridine", "CHEMICAL", 49, 60], ["actinomycin D", "CHEMICAL", 106, 119], ["[3H]Uridine", "CHEMICAL", 49, 60], ["actinomycin D", "CHEMICAL", 106, 119], ["[3H]Uridine", "SIMPLE_CHEMICAL", 49, 60], ["actinomycin D", "SIMPLE_CHEMICAL", 106, 119], ["viral RNAs", "RNA", 23, 33], ["viral RNAs", "TREATMENT", 23, 33], ["Uridine incorporation", "TREATMENT", 53, 74], ["2.5 \u03bcg ml\u22121 actinomycin D", "TREATMENT", 94, 119]]], ["Compared with SINV wt, there was a significant reduction in the synthesis of viral RNAs, such that the amount of gmRNA SINV (P726G) was 4% of control, while the amount of sgmRNA was approximately 10% compared with control (Fig. 5C and D).", [["SINV", "ORGANISM", 14, 18], ["gmRNA SINV", "ORGANISM", 113, 123], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 171, 177], ["viral RNAs", "RNA", 77, 87], ["gmRNA SINV", "PROTEIN", 113, 123], ["sgmRNA", "PROTEIN", 171, 177], ["SINV", "SPECIES", 14, 18], ["SINV", "SPECIES", 119, 123], ["SINV wt", "TEST", 14, 21], ["a significant reduction", "PROBLEM", 33, 56], ["the synthesis of viral RNAs", "PROBLEM", 60, 87], ["sgmRNA", "TEST", 171, 177], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["reduction", "OBSERVATION_MODIFIER", 47, 56], ["viral RNAs", "OBSERVATION", 77, 87], ["amount", "OBSERVATION_MODIFIER", 103, 109], ["amount", "OBSERVATION_MODIFIER", 161, 167]]], ["Curiously, production of nsP1 measured by immunoblot was 47% compared with control cells transfected with SINV wt gmRNA (Fig. 5E and F), whereas the synthesis of C at 4 and 8 hpt was 83% and 75% of control respectively (Fig. 5A and B).", [["cells", "ANATOMY", 83, 88], ["nsP1", "GENE_OR_GENE_PRODUCT", 25, 29], ["cells", "CELL", 83, 88], ["SINV", "ORGANISM", 106, 110], ["nsP1", "PROTEIN", 25, 29], ["SINV wt gmRNA", "PROTEIN", 106, 119], ["SINV", "SPECIES", 106, 110], ["nsP1", "PROBLEM", 25, 29], ["immunoblot", "TEST", 42, 52], ["SINV wt gmRNA", "TEST", 106, 119], ["the synthesis of C", "TEST", 145, 163], ["hpt", "TEST", 175, 178]]], ["Therefore, it appears that there is no correlation between the synthesis of viral mRNAs and the quantity of viral proteins synthesized.", [["viral mRNAs", "RNA", 76, 87], ["viral proteins", "PROTEIN", 108, 122], ["viral mRNAs", "PROBLEM", 76, 87], ["viral proteins synthesized", "PROBLEM", 108, 134], ["viral mRNAs", "OBSERVATION", 76, 87], ["viral proteins synthesized", "OBSERVATION", 108, 134]]], ["In conclusion, the major defect exhibited by this SINV variant is in the synthesis of viral RNAs, whereas viral proteins are still synthesized, although to a lower extent.", [["SINV", "ORGANISM", 50, 54], ["viral RNAs", "RNA", 86, 96], ["viral proteins", "PROTEIN", 106, 120], ["SINV", "SPECIES", 50, 54], ["the major defect", "PROBLEM", 15, 31], ["this SINV variant", "PROBLEM", 45, 62], ["viral RNAs", "PROBLEM", 86, 96], ["viral proteins", "PROBLEM", 106, 120], ["major", "OBSERVATION_MODIFIER", 19, 24], ["defect", "OBSERVATION", 25, 31], ["SINV variant", "OBSERVATION", 50, 62], ["viral RNAs", "OBSERVATION", 86, 96], ["viral proteins", "OBSERVATION", 106, 120], ["lower extent", "OBSERVATION_MODIFIER", 158, 170]]], ["Our next aim was to analyse the release of nuclear proteins to the cytoplasm in cells transfected with gmRNA from SINV wt or SINV nsP2 (P726G) (Fig. 6A and B).", [["nuclear", "ANATOMY", 43, 50], ["cytoplasm", "ANATOMY", 67, 76], ["cells", "ANATOMY", 80, 85], ["nuclear", "CELLULAR_COMPONENT", 43, 50], ["cytoplasm", "ORGANISM_SUBSTANCE", 67, 76], ["cells", "CELL", 80, 85], ["gmRNA", "GENE_OR_GENE_PRODUCT", 103, 108], ["SINV wt", "ORGANISM", 114, 121], ["SINV nsP2", "ORGANISM", 125, 134], ["B", "GENE_OR_GENE_PRODUCT", 156, 157], ["nuclear proteins", "PROTEIN", 43, 59], ["gmRNA", "PROTEIN", 103, 108], ["SINV nsP2", "PROTEIN", 125, 134], ["SINV", "SPECIES", 114, 118], ["SINV nsP2 (P726G)", "SPECIES", 125, 142], ["gmRNA", "TEST", 103, 108], ["SINV wt", "TEST", 114, 121], ["SINV nsP2", "TEST", 125, 134]]], ["Sindbis virus\u2010replicating cells were detected by immunofluorescence of proteins C and nsP1.", [["virus\u2010replicating cells", "ANATOMY", 8, 31], ["Sindbis", "ORGANISM", 0, 7], ["virus\u2010replicating cells", "CELL", 8, 31], ["C", "GENE_OR_GENE_PRODUCT", 80, 81], ["nsP1", "GENE_OR_GENE_PRODUCT", 86, 90], ["Sindbis virus\u2010replicating cells", "CELL_LINE", 0, 31], ["C", "PROTEIN", 80, 81], ["nsP1", "PROTEIN", 86, 90], ["Sindbis", "SPECIES", 0, 7], ["Sindbis virus\u2010replicating cells", "TREATMENT", 0, 31], ["nsP1", "PROBLEM", 86, 90]]], ["The redistribution of TIA\u20101, PTB and additionally redox factor\u20101 (Ref\u20101) was examined.", [["TIA", "DISEASE", 22, 25], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 22, 27], ["PTB", "GENE_OR_GENE_PRODUCT", 29, 32], ["Ref\u20101", "GENE_OR_GENE_PRODUCT", 66, 71], ["TIA\u20101", "PROTEIN", 22, 27], ["PTB", "PROTEIN", 29, 32], ["redox factor\u20101", "PROTEIN", 50, 64], ["Ref\u20101", "PROTEIN", 66, 71], ["TIA", "PROBLEM", 22, 25], ["PTB", "PROBLEM", 29, 32], ["redistribution", "OBSERVATION_MODIFIER", 4, 18], ["TIA", "OBSERVATION", 22, 25]]], ["Of note, SINV wt induced the release of both TIA\u20101 and PTB to the cytoplasm at 7 hpt to a similar extent as with the replicon rep C+luc described above, although with more variability between individual cells.", [["cytoplasm", "ANATOMY", 66, 75], ["cells", "ANATOMY", 203, 208], ["SINV wt", "ORGANISM", 9, 16], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 45, 50], ["PTB", "GENE_OR_GENE_PRODUCT", 55, 58], ["cytoplasm", "ORGANISM_SUBSTANCE", 66, 75], ["rep C", "GENE_OR_GENE_PRODUCT", 126, 131], ["cells", "CELL", 203, 208], ["TIA\u20101", "PROTEIN", 45, 50], ["PTB", "PROTEIN", 55, 58], ["replicon rep C", "DNA", 117, 131], ["luc", "DNA", 132, 135], ["SINV", "SPECIES", 9, 13], ["both TIA\u20101", "TREATMENT", 40, 50]]], ["This may be due to different viral replication levels in the different cells as a consequence of secondary infections propitiated by viruses produced in the transfected cells (Fig. 6A).", [["cells", "ANATOMY", 71, 76], ["cells", "ANATOMY", 169, 174], ["infections", "DISEASE", 107, 117], ["cells", "CELL", 71, 76], ["cells", "CELL", 169, 174], ["Fig. 6A", "CELL", 176, 183], ["transfected cells", "CELL_LINE", 157, 174], ["different viral replication levels", "PROBLEM", 19, 53], ["secondary infections", "PROBLEM", 97, 117], ["viruses", "PROBLEM", 133, 140], ["may be due to", "UNCERTAINTY", 5, 18], ["different", "OBSERVATION_MODIFIER", 19, 28], ["viral replication", "OBSERVATION", 29, 46], ["different cells", "OBSERVATION_MODIFIER", 61, 76], ["secondary", "OBSERVATION_MODIFIER", 97, 106], ["infections", "OBSERVATION", 107, 117], ["transfected cells", "OBSERVATION", 157, 174]]], ["In contrast, Ref\u20101 preserved its nuclear localization by about 90\u201396% in cells that produced nsP1 as related to uninfected cells, indicating that clearly not all nuclear proteins are redistributed to the cytoplasm in SINV\u2010replicating cells.", [["nuclear", "ANATOMY", 33, 40], ["cells", "ANATOMY", 73, 78], ["cells", "ANATOMY", 123, 128], ["nuclear", "ANATOMY", 162, 169], ["cytoplasm", "ANATOMY", 204, 213], ["cells", "ANATOMY", 234, 239], ["Ref\u20101", "GENE_OR_GENE_PRODUCT", 13, 18], ["nuclear", "CELLULAR_COMPONENT", 33, 40], ["cells", "CELL", 73, 78], ["nsP1", "GENE_OR_GENE_PRODUCT", 93, 97], ["cells", "CELL", 123, 128], ["nuclear", "CELLULAR_COMPONENT", 162, 169], ["cytoplasm", "ORGANISM_SUBSTANCE", 204, 213], ["SINV", "ORGANISM", 217, 221], ["cells", "CELL", 234, 239], ["Ref\u20101", "PROTEIN", 13, 18], ["nsP1", "PROTEIN", 93, 97], ["uninfected cells", "CELL_TYPE", 112, 128], ["nuclear proteins", "PROTEIN", 162, 178], ["SINV\u2010replicating cells", "CELL_LINE", 217, 239], ["SINV", "SPECIES", 217, 221], ["nsP1", "PROBLEM", 93, 97], ["uninfected cells", "PROBLEM", 112, 128], ["all nuclear proteins", "PROBLEM", 158, 178], ["uninfected cells", "OBSERVATION", 112, 128], ["proteins", "OBSERVATION", 170, 178], ["cytoplasm", "OBSERVATION_MODIFIER", 204, 213], ["replicating cells", "OBSERVATION", 222, 239]]], ["Interestingly, the SINV nsP2 variant (P726G) had little effect on the redistribution of nuclear proteins TIA\u20101, PTB and Ref\u20101 (Fig. 6B).", [["nuclear", "ANATOMY", 88, 95], ["SINV", "ORGANISM", 19, 23], ["nsP2", "GENE_OR_GENE_PRODUCT", 24, 28], ["nuclear", "CELLULAR_COMPONENT", 88, 95], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 105, 110], ["PTB", "GENE_OR_GENE_PRODUCT", 112, 115], ["Ref\u20101", "GENE_OR_GENE_PRODUCT", 120, 125], ["SINV nsP2 variant", "PROTEIN", 19, 36], ["nuclear proteins", "PROTEIN", 88, 104], ["TIA", "PROTEIN", 105, 108], ["\u20101", "PROTEIN", 108, 110], ["PTB", "PROTEIN", 112, 115], ["Ref\u20101", "PROTEIN", 120, 125], ["Fig. 6B", "PROTEIN", 127, 134], ["SINV", "SPECIES", 19, 23], ["the SINV nsP2 variant", "PROBLEM", 15, 36], ["nuclear proteins TIA", "PROBLEM", 88, 108], ["PTB", "PROBLEM", 112, 115], ["SINV", "OBSERVATION", 19, 23], ["nsP2 variant", "OBSERVATION", 24, 36], ["redistribution", "OBSERVATION_MODIFIER", 70, 84]]], ["Thus, the signal of TIA\u20101 at the nucleus of these cells reaches 88\u201393% of that of uninfected cells and similar values were obtained for PTB (86\u201393%) and Ref\u20101 (91\u201396%).", [["nucleus", "ANATOMY", 33, 40], ["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 93, 98], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 20, 25], ["nucleus", "CELLULAR_COMPONENT", 33, 40], ["cells", "CELL", 50, 55], ["cells", "CELL", 93, 98], ["PTB", "GENE_OR_GENE_PRODUCT", 136, 139], ["TIA\u20101", "PROTEIN", 20, 25], ["uninfected cells", "CELL_TYPE", 82, 98], ["PTB", "PROTEIN", 136, 139], ["these cells", "TEST", 44, 55], ["PTB", "TEST", 136, 139], ["Ref\u20101", "TEST", 153, 158], ["nucleus", "ANATOMY_MODIFIER", 33, 40], ["uninfected cells", "OBSERVATION", 82, 98]]], ["Transfected cells were also evaluated at 24 hpt (Supporting Information http://onlinelibrary.wiley.com/doi/10.1111/cmi.12381/suppinfo).", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17]]], ["At this time, cells transfected with gmRNA from SINV wt showed clear signs of an infection\u2010associated cytopathic response.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["gmRNA", "GENE_OR_GENE_PRODUCT", 37, 42], ["SINV", "ORGANISM", 48, 52], ["gmRNA", "PROTEIN", 37, 42], ["SINV", "SPECIES", 48, 52], ["gmRNA", "TEST", 37, 42], ["SINV wt", "TEST", 48, 55], ["an infection\u2010associated cytopathic response", "PROBLEM", 78, 121], ["cytopathic response", "OBSERVATION", 102, 121]]], ["This was not apparent in SINV nsP2 (P726G) transfected cells, which did not show changes in the pattern of distribution of TIA\u20101 or PTB.", [["cells", "ANATOMY", 55, 60], ["TIA", "DISEASE", 123, 126], ["SINV", "ORGANISM", 25, 29], ["nsP2", "GENE_OR_GENE_PRODUCT", 30, 34], ["cells", "CELL", 55, 60], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 123, 128], ["PTB", "GENE_OR_GENE_PRODUCT", 132, 135], ["SINV nsP2 (P726G) transfected cells", "CELL_LINE", 25, 60], ["TIA", "PROTEIN", 123, 126], ["PTB", "PROTEIN", 132, 135], ["SINV", "SPECIES", 25, 29], ["transfected cells", "TEST", 43, 60], ["TIA", "PROBLEM", 123, 126], ["PTB", "PROBLEM", 132, 135], ["not apparent", "UNCERTAINTY", 9, 21], ["TIA", "OBSERVATION", 123, 126]]], ["Therefore, in SINV nsP2 (P726G)\u2010replicating BHK cells, a correlation exists between the inhibition of viral RNA replication and the release of nuclear proteins, in addition to the failure to completely block cellular mRNA translation.Action of inhibitors of RNA synthesis ::: ResultsAs the above observations suggested a correlation between the shut\u2010off of host protein translation, the level of viral RNA replication and the release of some nuclear proteins to the cytoplasm, we next examined the effect of inhibiting viral RNA replication.", [["BHK cells", "ANATOMY", 44, 53], ["nuclear", "ANATOMY", 143, 150], ["cellular", "ANATOMY", 208, 216], ["nuclear", "ANATOMY", 442, 449], ["cytoplasm", "ANATOMY", 466, 475], ["SINV", "ORGANISM", 14, 18], ["nsP2", "GENE_OR_GENE_PRODUCT", 19, 23], ["BHK cells", "CELL", 44, 53], ["nuclear", "CELLULAR_COMPONENT", 143, 150], ["cellular", "CELL", 208, 216], ["nuclear", "CELLULAR_COMPONENT", 442, 449], ["cytoplasm", "ORGANISM_SUBSTANCE", 466, 475], ["SINV nsP2 (P726G)\u2010replicating BHK cells", "CELL_LINE", 14, 53], ["nuclear proteins", "PROTEIN", 143, 159], ["cellular mRNA", "RNA", 208, 221], ["nuclear proteins", "PROTEIN", 442, 458], ["SINV", "SPECIES", 14, 18], ["BHK cells", "PROBLEM", 44, 53], ["viral RNA replication", "TREATMENT", 102, 123], ["nuclear proteins", "PROBLEM", 143, 159], ["the failure to completely block cellular mRNA translation", "PROBLEM", 176, 233], ["host protein translation", "TREATMENT", 357, 381], ["viral RNA replication", "TREATMENT", 396, 417], ["viral RNA replication", "TREATMENT", 519, 540], ["BHK cells", "OBSERVATION", 44, 53], ["viral RNA replication", "OBSERVATION", 102, 123], ["failure", "OBSERVATION", 180, 187], ["cellular mRNA", "OBSERVATION", 208, 221], ["viral RNA replication", "OBSERVATION", 396, 417]]], ["To this end, two nucleoside analogues, 6\u2010aza\u2010uridine and ribavirin, which interfere with the metabolism of nucleosides and nucleotides and have detrimental effects on both cellular and viral RNA synthesis, were employed to inhibit viral replication (Carrasco and Vazquez, 1984; Vignuzzi et al., 2005).", [["cellular", "ANATOMY", 172, 180], ["nucleoside", "CHEMICAL", 17, 27], ["6\u2010aza\u2010uridine", "CHEMICAL", 39, 52], ["ribavirin", "CHEMICAL", 57, 66], ["nucleosides", "CHEMICAL", 107, 118], ["nucleoside", "CHEMICAL", 17, 27], ["6\u2010aza\u2010uridine", "CHEMICAL", 39, 52], ["ribavirin", "CHEMICAL", 57, 66], ["nucleosides", "CHEMICAL", 107, 118], ["nucleotides", "CHEMICAL", 123, 134], ["nucleoside analogues", "SIMPLE_CHEMICAL", 17, 37], ["6\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 39, 52], ["ribavirin", "SIMPLE_CHEMICAL", 57, 66], ["nucleosides", "SIMPLE_CHEMICAL", 107, 118], ["cellular", "CELL", 172, 180], ["two nucleoside analogues", "TREATMENT", 13, 37], ["6\u2010aza\u2010uridine", "TREATMENT", 39, 52], ["ribavirin", "TREATMENT", 57, 66], ["the metabolism of nucleosides", "TREATMENT", 89, 118], ["nucleotides", "TREATMENT", 123, 134], ["detrimental effects", "PROBLEM", 144, 163], ["viral RNA synthesis", "TREATMENT", 185, 204], ["viral RNA synthesis", "OBSERVATION", 185, 204]]], ["BHK cells were infected with SINV for 1 h to allow virus entry, and then the medium was exchanged with addition of inhibitors.", [["BHK cells", "ANATOMY", 0, 9], ["BHK cells", "CELL", 0, 9], ["SINV", "ORGANISM", 29, 33], ["BHK cells", "CELL_LINE", 0, 9], ["BHK", "SPECIES", 0, 3], ["SINV", "SPECIES", 29, 33], ["BHK cells", "PROBLEM", 0, 9], ["SINV", "TREATMENT", 29, 33], ["virus entry", "TEST", 51, 62], ["inhibitors", "TREATMENT", 115, 125]]], ["This protocol avoids the potential inhibitory effects of nucleoside analogues on virus attachment and entry.", [["nucleoside", "CHEMICAL", 57, 67], ["nucleoside", "CHEMICAL", 57, 67], ["nucleoside analogues", "SIMPLE_CHEMICAL", 57, 77], ["This protocol", "TREATMENT", 0, 13], ["nucleoside analogues", "TREATMENT", 57, 77], ["virus attachment", "TREATMENT", 81, 97]]], ["Protein synthesis was estimated at 5 hpi.", [["Protein synthesis", "TEST", 0, 17]]], ["As observed in Fig. 7A, increasing concentrations of 6\u2010aza\u2010uridine and ribavirin led to a partial decline of protein synthesis in uninfected BHK cells.", [["BHK cells", "ANATOMY", 141, 150], ["6\u2010aza\u2010uridine", "CHEMICAL", 53, 66], ["ribavirin", "CHEMICAL", 71, 80], ["6\u2010aza\u2010uridine", "CHEMICAL", 53, 66], ["ribavirin", "CHEMICAL", 71, 80], ["7A", "GENE_OR_GENE_PRODUCT", 20, 22], ["6\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 53, 66], ["ribavirin", "SIMPLE_CHEMICAL", 71, 80], ["BHK cells", "CELL", 141, 150], ["uninfected BHK cells", "CELL_LINE", 130, 150], ["BHK", "SPECIES", 141, 144], ["6\u2010aza\u2010uridine", "TREATMENT", 53, 66], ["ribavirin", "TREATMENT", 71, 80], ["a partial decline of protein synthesis", "PROBLEM", 88, 126], ["uninfected BHK cells", "PROBLEM", 130, 150], ["protein synthesis", "OBSERVATION", 109, 126], ["uninfected BHK cells", "OBSERVATION", 130, 150]]], ["Densitometric measurements indicated that cellular actin represented 60% of control at 0.5 mM 6\u2010aza\u2010uridine and 74% at 0.2 mM ribavirin (Fig. 7B).", [["cellular", "ANATOMY", 42, 50], ["\u2010aza\u2010uridine", "CHEMICAL", 95, 107], ["ribavirin", "CHEMICAL", 126, 135], ["\u2010aza\u2010uridine", "CHEMICAL", 95, 107], ["ribavirin", "CHEMICAL", 126, 135], ["cellular", "CELL", 42, 50], ["actin", "GENE_OR_GENE_PRODUCT", 51, 56], ["actin", "PROTEIN", 51, 56], ["Densitometric measurements", "TEST", 0, 26], ["cellular actin", "TEST", 42, 56], ["\u2010aza\u2010uridine", "TREATMENT", 95, 107], ["mM ribavirin", "TREATMENT", 123, 135], ["cellular", "OBSERVATION_MODIFIER", 42, 50], ["actin", "OBSERVATION_MODIFIER", 51, 56]]], ["Under these conditions, SINV infection does not intensify the inhibition of actin synthesis.", [["infection", "DISEASE", 29, 38], ["SINV", "ORGANISM", 24, 28], ["actin", "GENE_OR_GENE_PRODUCT", 76, 81], ["actin", "PROTEIN", 76, 81], ["SINV", "SPECIES", 24, 28], ["SINV infection", "PROBLEM", 24, 38], ["actin synthesis", "TREATMENT", 76, 91], ["SINV infection", "OBSERVATION", 24, 38], ["actin synthesis", "OBSERVATION", 76, 91]]], ["In SINV\u2010infected BHK cells, actin synthesis was blocked by 97% in the absence of inhibitors.", [["BHK cells", "ANATOMY", 17, 26], ["SINV", "ORGANISM", 3, 7], ["BHK cells", "CELL", 17, 26], ["actin", "GENE_OR_GENE_PRODUCT", 28, 33], ["SINV\u2010infected BHK cells", "CELL_LINE", 3, 26], ["actin", "PROTEIN", 28, 33], ["SINV", "SPECIES", 3, 7], ["BHK", "SPECIES", 17, 20], ["actin synthesis", "TREATMENT", 28, 43], ["inhibitors", "TREATMENT", 81, 91], ["BHK cells", "OBSERVATION", 17, 26]]], ["Conversely, the decrease of actin synthesis was 8% in SINV\u2010infected cells, relative to uninfected BHK cells, in the presence of 0.5 mM 6\u2010aza\u2010uridine, whereas the blockade of actin synthesis was 18% in SINV\u2010infected cells incubated with 0.2 mM ribavirin (Fig. 7A and B).", [["cells", "ANATOMY", 68, 73], ["BHK cells", "ANATOMY", 98, 107], ["cells", "ANATOMY", 215, 220], ["6\u2010aza\u2010uridine", "CHEMICAL", 135, 148], ["ribavirin", "CHEMICAL", 243, 252], ["6\u2010aza\u2010uridine", "CHEMICAL", 135, 148], ["ribavirin", "CHEMICAL", 243, 252], ["actin", "GENE_OR_GENE_PRODUCT", 28, 33], ["SINV", "ORGANISM", 54, 58], ["cells", "CELL", 68, 73], ["BHK cells", "CELL", 98, 107], ["6\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 135, 148], ["actin", "GENE_OR_GENE_PRODUCT", 174, 179], ["SINV", "ORGANISM", 201, 205], ["cells", "CELL", 215, 220], ["ribavirin", "SIMPLE_CHEMICAL", 243, 252], ["B", "GENE_OR_GENE_PRODUCT", 266, 267], ["actin", "PROTEIN", 28, 33], ["SINV\u2010infected cells", "CELL_LINE", 54, 73], ["uninfected BHK cells", "CELL_LINE", 87, 107], ["actin", "PROTEIN", 174, 179], ["SINV\u2010infected cells", "CELL_LINE", 201, 220], ["SINV", "SPECIES", 54, 58], ["SINV", "SPECIES", 201, 205], ["actin synthesis", "TEST", 28, 43], ["SINV\u2010infected cells", "PROBLEM", 54, 73], ["uninfected BHK cells", "PROBLEM", 87, 107], ["0.5 mM 6\u2010aza\u2010uridine", "TREATMENT", 128, 148], ["actin synthesis", "TEST", 174, 189], ["0.2 mM ribavirin (Fig", "TREATMENT", 236, 257], ["decrease", "OBSERVATION_MODIFIER", 16, 24], ["uninfected BHK cells", "OBSERVATION", 87, 107]]], ["As a control, we also tested the inhibitory effect of actinomycin D that potently blocks cellular RNA synthesis but has almost no effect on the synthesis of SINV RNAs.", [["cellular", "ANATOMY", 89, 97], ["actinomycin D", "CHEMICAL", 54, 67], ["actinomycin D", "CHEMICAL", 54, 67], ["actinomycin D", "SIMPLE_CHEMICAL", 54, 67], ["cellular", "CELL", 89, 97], ["SINV", "ORGANISM", 157, 161], ["SINV RNAs", "RNA", 157, 166], ["SINV", "SPECIES", 157, 161], ["actinomycin D", "TREATMENT", 54, 67], ["potently blocks cellular RNA synthesis", "PROBLEM", 73, 111], ["the synthesis of SINV RNAs", "PROBLEM", 140, 166], ["RNA synthesis", "OBSERVATION", 98, 111], ["SINV RNAs", "OBSERVATION", 157, 166]]], ["As expected, actinomycin D treatment from 0 to 5 hpi had little effect on protein synthesis both in infected and uninfected cells (Fig. 7A).Action of inhibitors of RNA synthesis ::: ResultsTo measure the effects of the inhibitors on cellular and viral RNA synthesis, [3H]Uridine incorporation was performed from 3 to 5 hpi, and RNA was extracted and separated in agarose gels.", [["cells", "ANATOMY", 124, 129], ["cellular", "ANATOMY", 233, 241], ["actinomycin D", "CHEMICAL", 13, 26], ["[3H]", "CHEMICAL", 267, 271], ["Uridine", "CHEMICAL", 271, 278], ["actinomycin D", "CHEMICAL", 13, 26], ["[3H]Uridine", "CHEMICAL", 267, 278], ["actinomycin D", "SIMPLE_CHEMICAL", 13, 26], ["cells", "CELL", 124, 129], ["cellular", "CELL", 233, 241], ["[3H]Uridine", "SIMPLE_CHEMICAL", 267, 278], ["agarose", "SIMPLE_CHEMICAL", 363, 370], ["uninfected cells", "CELL_TYPE", 113, 129], ["actinomycin D treatment", "TREATMENT", 13, 36], ["protein synthesis", "PROBLEM", 74, 91], ["the inhibitors", "TREATMENT", 215, 229], ["cellular and viral RNA synthesis", "TREATMENT", 233, 265], ["Uridine incorporation", "TREATMENT", 271, 292], ["RNA", "TREATMENT", 328, 331], ["infected", "OBSERVATION_MODIFIER", 100, 108], ["uninfected cells", "OBSERVATION", 113, 129]]], ["Both nucleoside analogues potently inhibited cellular and viral RNA synthesis (Fig. 7C); transcription of sgmRNA was inhibited by approximately 90% with 0.5 mM 6\u2010aza\u2010uridine and 98% with 0.2 mM ribavirin, although these data are approximations because cellular mRNA (as 28S rRNA), overlap with the viral mRNAs in gels.", [["cellular", "ANATOMY", 45, 53], ["cellular", "ANATOMY", 252, 260], ["nucleoside", "CHEMICAL", 5, 15], ["\u2010aza\u2010uridine", "CHEMICAL", 161, 173], ["ribavirin", "CHEMICAL", 194, 203], ["nucleoside", "CHEMICAL", 5, 15], ["\u2010aza\u2010uridine", "CHEMICAL", 161, 173], ["ribavirin", "CHEMICAL", 194, 203], ["nucleoside analogues", "SIMPLE_CHEMICAL", 5, 25], ["cellular", "CELL", 45, 53], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 106, 112], ["\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 161, 173], ["ribavirin", "SIMPLE_CHEMICAL", 194, 203], ["cellular", "CELL", 252, 260], ["28S", "GENE_OR_GENE_PRODUCT", 270, 273], ["rRNA", "CELLULAR_COMPONENT", 274, 278], ["sgmRNA", "PROTEIN", 106, 112], ["cellular mRNA", "RNA", 252, 265], ["28S rRNA", "RNA", 270, 278], ["viral mRNAs", "RNA", 298, 309], ["Both nucleoside analogues", "TREATMENT", 0, 25], ["viral RNA synthesis", "TREATMENT", 58, 77], ["\u2010aza\u2010uridine", "TREATMENT", 161, 173], ["0.2 mM ribavirin", "TREATMENT", 187, 203], ["these data", "TEST", 214, 224], ["cellular mRNA", "PROBLEM", 252, 265], ["28S rRNA", "TEST", 270, 278], ["the viral mRNAs in gels", "PROBLEM", 294, 317], ["nucleoside analogues", "OBSERVATION", 5, 25], ["viral RNA synthesis", "OBSERVATION", 58, 77], ["viral mRNAs", "OBSERVATION", 298, 309]]], ["Predictably, actinomycin D inhibited cellular RNA synthesis only (Fig. 7C).", [["cellular", "ANATOMY", 37, 45], ["actinomycin D", "CHEMICAL", 13, 26], ["actinomycin D", "CHEMICAL", 13, 26], ["actinomycin D", "SIMPLE_CHEMICAL", 13, 26], ["cellular", "CELL", 37, 45], ["actinomycin D", "TREATMENT", 13, 26], ["cellular RNA synthesis", "TREATMENT", 37, 59], ["cellular RNA synthesis", "OBSERVATION", 37, 59]]], ["Additionally, the production of nsPs and sPs were measured in treated and untreated infected cells by immunoblotting.", [["cells", "ANATOMY", 93, 98], ["nsPs", "GENE_OR_GENE_PRODUCT", 32, 36], ["sPs", "GENE_OR_GENE_PRODUCT", 41, 44], ["cells", "CELL", 93, 98], ["nsPs", "PROTEIN", 32, 36], ["sPs", "PROTEIN", 41, 44], ["sPs", "TEST", 41, 44], ["untreated infected cells", "PROBLEM", 74, 98], ["immunoblotting", "TEST", 102, 116], ["infected cells", "OBSERVATION", 84, 98]]], ["As noted previously, and also in several reports, there was no correlation between the level of mRNA and the production of viral proteins (Fig. 7C and D).", [["D", "GENE_OR_GENE_PRODUCT", 151, 152], ["mRNA", "RNA", 96, 100], ["viral proteins", "PROTEIN", 123, 137], ["Fig. 7C and D", "PROTEIN", 139, 152], ["viral proteins", "PROBLEM", 123, 137]]], ["Accordingly, the production of nsP2 in ribavirin\u2010treated cells decreased proportionately less than the production of gmRNA.", [["cells", "ANATOMY", 57, 62], ["nsP2", "GENE_OR_GENE_PRODUCT", 31, 35], ["ribavirin\u2010treated cells", "CELL", 39, 62], ["gmRNA", "GENE_OR_GENE_PRODUCT", 117, 122], ["nsP2", "PROTEIN", 31, 35], ["ribavirin\u2010treated cells", "CELL_LINE", 39, 62], ["gmRNA", "PROTEIN", 117, 122], ["nsP2 in ribavirin\u2010treated cells", "PROBLEM", 31, 62], ["nsP2", "OBSERVATION", 31, 35]]], ["Similarly, in ribavirin\u2010treated cells, synthesis of C and E1 glycoproteins decreased less than synthesis of sgmRNA (Fig. 7C and D).", [["cells", "ANATOMY", 32, 37], ["cells", "CELL", 32, 37], ["C", "GENE_OR_GENE_PRODUCT", 52, 53], ["E1 glycoproteins", "GENE_OR_GENE_PRODUCT", 58, 74], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 108, 114], ["ribavirin\u2010treated cells", "CELL_LINE", 14, 37], ["C and E1 glycoproteins", "PROTEIN", 52, 74], ["sgmRNA", "PROTEIN", 108, 114], ["ribavirin\u2010treated cells", "PROBLEM", 14, 37], ["synthesis of C and E1 glycoproteins", "PROBLEM", 39, 74], ["sgmRNA", "TEST", 108, 114], ["ribavirin\u2010treated cells", "OBSERVATION", 14, 37]]], ["Comparable results were obtained in 6\u2010aza\u2010uridine\u2010treated cells.Action of inhibitors of RNA synthesis ::: ResultsFinally, the release of TIA\u20101 and PTB was analysed in SINV\u2010infected BHK cells treated with nucleoside analogues.", [["cells", "ANATOMY", 58, 63], ["BHK cells", "ANATOMY", 181, 190], ["nucleoside", "CHEMICAL", 204, 214], ["nucleoside", "CHEMICAL", 204, 214], ["6\u2010aza\u2010uridine\u2010treated cells", "CELL", 36, 63], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 137, 142], ["PTB", "GENE_OR_GENE_PRODUCT", 147, 150], ["SINV", "ORGANISM", 167, 171], ["BHK cells", "CELL", 181, 190], ["nucleoside analogues", "SIMPLE_CHEMICAL", 204, 224], ["6\u2010aza\u2010uridine\u2010treated cells", "CELL_LINE", 36, 63], ["TIA\u20101", "PROTEIN", 137, 142], ["PTB", "PROTEIN", 147, 150], ["SINV\u2010infected BHK cells", "CELL_LINE", 167, 190], ["SINV", "SPECIES", 167, 171], ["TIA\u20101", "TREATMENT", 137, 142], ["PTB", "PROBLEM", 147, 150], ["SINV\u2010infected BHK cells", "TREATMENT", 167, 190], ["nucleoside analogues", "TREATMENT", 204, 224], ["PTB", "OBSERVATION", 147, 150], ["BHK cells", "OBSERVATION", 181, 190]]], ["Whereas treatment of control\u2010uninfected BHK cells with these compounds had no effect in the redistribution of PTB or TIA\u20101, both inhibitors blocked the release of PTB to the cytoplasm in SINV\u2010infected cells (Fig. 8).", [["BHK cells", "ANATOMY", 40, 49], ["cytoplasm", "ANATOMY", 174, 183], ["cells", "ANATOMY", 201, 206], ["TIA", "DISEASE", 117, 120], ["BHK cells", "CELL", 40, 49], ["PTB", "GENE_OR_GENE_PRODUCT", 110, 113], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 117, 122], ["PTB", "GENE_OR_GENE_PRODUCT", 163, 166], ["cytoplasm", "ORGANISM_SUBSTANCE", 174, 183], ["SINV", "ORGANISM", 187, 191], ["cells", "CELL", 201, 206], ["control\u2010uninfected BHK cells", "CELL_LINE", 21, 49], ["PTB", "PROTEIN", 110, 113], ["PTB", "PROTEIN", 163, 166], ["SINV\u2010infected cells", "CELL_LINE", 187, 206], ["BHK", "SPECIES", 40, 43], ["SINV", "SPECIES", 187, 191], ["control\u2010uninfected BHK cells", "PROBLEM", 21, 49], ["these compounds", "PROBLEM", 55, 70], ["PTB", "PROBLEM", 110, 113], ["TIA", "PROBLEM", 117, 120], ["both inhibitors", "TREATMENT", 124, 139], ["PTB", "PROBLEM", 163, 166], ["BHK cells", "OBSERVATION", 40, 49], ["PTB", "OBSERVATION", 110, 113], ["infected cells", "OBSERVATION", 192, 206]]], ["The nuclear signal of PTB in infected cells treated with 6\u2010aza\u2010uridine varies between 63% and 72% of total signal, while it ranged between 11% and 16% in infected untreated cells.", [["nuclear", "ANATOMY", 4, 11], ["cells", "ANATOMY", 38, 43], ["cells", "ANATOMY", 173, 178], ["\u2010aza\u2010uridine", "CHEMICAL", 58, 70], ["6\u2010aza\u2010uridine", "CHEMICAL", 57, 70], ["nuclear", "CELLULAR_COMPONENT", 4, 11], ["PTB", "GENE_OR_GENE_PRODUCT", 22, 25], ["cells", "CELL", 38, 43], ["6\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 57, 70], ["cells", "CELL", 173, 178], ["PTB", "PROTEIN", 22, 25], ["infected cells", "CELL_TYPE", 29, 43], ["infected untreated cells", "CELL_TYPE", 154, 178], ["PTB in infected cells", "PROBLEM", 22, 43], ["6\u2010aza\u2010uridine", "TREATMENT", 57, 70], ["total signal", "TEST", 101, 113], ["infected untreated cells", "PROBLEM", 154, 178], ["PTB", "OBSERVATION", 22, 25], ["infected cells", "OBSERVATION", 29, 43], ["untreated cells", "OBSERVATION", 163, 178]]], ["Similarly, ribavirin treatment led to PTB retention in the nucleus (65\u201372% of total signal).", [["nucleus", "ANATOMY", 59, 66], ["ribavirin", "CHEMICAL", 11, 20], ["PTB retention", "DISEASE", 38, 51], ["ribavirin", "CHEMICAL", 11, 20], ["ribavirin", "SIMPLE_CHEMICAL", 11, 20], ["PTB", "GENE_OR_GENE_PRODUCT", 38, 41], ["nucleus", "CELLULAR_COMPONENT", 59, 66], ["PTB", "PROTEIN", 38, 41], ["ribavirin treatment", "TREATMENT", 11, 30], ["PTB retention in the nucleus", "PROBLEM", 38, 66], ["total signal", "TEST", 78, 90], ["ribavirin", "OBSERVATION", 11, 20], ["PTB retention", "OBSERVATION", 38, 51], ["nucleus", "ANATOMY", 59, 66]]], ["Moreover, treatment with nucleoside analogues also reduced the accumulation of TIA\u20101 in the cytoplasm of infected cells (Supporting Information http://onlinelibrary.wiley.com/doi/10.1111/cmi.12381/suppinfo).", [["cytoplasm", "ANATOMY", 92, 101], ["cells", "ANATOMY", 114, 119], ["nucleoside", "CHEMICAL", 25, 35], ["TIA", "DISEASE", 79, 82], ["nucleoside", "CHEMICAL", 25, 35], ["nucleoside analogues", "SIMPLE_CHEMICAL", 25, 45], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 79, 84], ["cytoplasm", "ORGANISM_SUBSTANCE", 92, 101], ["cells", "CELL", 114, 119], ["TIA\u20101", "PROTEIN", 79, 84], ["infected cells", "CELL_TYPE", 105, 119], ["nucleoside analogues", "TREATMENT", 25, 45], ["TIA", "PROBLEM", 79, 82], ["infected cells", "PROBLEM", 105, 119], ["TIA", "OBSERVATION", 79, 82], ["infected cells", "OBSERVATION", 105, 119]]], ["Thus, in agreement with previous results, these findings indicate that the shut\u2010off of host translation after SINV infection is restricted when viral RNA synthesis is blocked and nuclear proteins are not released to the cytoplasm.Inhibition of cellular protein synthesis in PKR\u2212/\u2212MEFs::: ResultsAn important contributing factor to the arrest of host mRNA translation is the activation of PKR after SINV infection of mammalian cells (Ventoso et al., 2006; Garcia\u2010Moreno et al., 2013).", [["nuclear", "ANATOMY", 179, 186], ["cytoplasm", "ANATOMY", 220, 229], ["cellular", "ANATOMY", 244, 252], ["PKR\u2212/\u2212MEFs", "ANATOMY", 274, 284], ["cells", "ANATOMY", 426, 431], ["infection", "DISEASE", 115, 124], ["infection", "DISEASE", 403, 412], ["SINV", "ORGANISM", 110, 114], ["nuclear", "CELLULAR_COMPONENT", 179, 186], ["cytoplasm", "ORGANISM_SUBSTANCE", 220, 229], ["cellular", "CELL", 244, 252], ["PKR", "GENE_OR_GENE_PRODUCT", 274, 277], ["PKR", "GENE_OR_GENE_PRODUCT", 388, 391], ["SINV", "ORGANISM", 398, 402], ["mammalian cells", "CELL", 416, 431], ["nuclear proteins", "PROTEIN", 179, 195], ["PKR", "PROTEIN", 274, 277], ["PKR", "PROTEIN", 388, 391], ["mammalian cells", "CELL_TYPE", 416, 431], ["SINV", "SPECIES", 110, 114], ["SINV", "SPECIES", 398, 402], ["host translation", "TREATMENT", 87, 103], ["SINV infection", "PROBLEM", 110, 124], ["viral RNA synthesis", "PROBLEM", 144, 163], ["nuclear proteins", "TEST", 179, 195], ["cellular protein synthesis", "TEST", 244, 270], ["the arrest", "PROBLEM", 331, 341], ["PKR", "PROBLEM", 388, 391], ["SINV infection of mammalian cells", "PROBLEM", 398, 431], ["cellular protein synthesis", "OBSERVATION", 244, 270]]], ["This activation leads to the phosphorylation of eIF2\u03b1, blocking cellular but not viral mRNA translation.", [["cellular", "ANATOMY", 64, 72], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 48, 53], ["cellular", "CELL", 64, 72], ["eIF2\u03b1", "PROTEIN", 48, 53], ["viral mRNA", "RNA", 81, 91], ["viral mRNA translation", "PROBLEM", 81, 103], ["not", "UNCERTAINTY", 77, 80], ["viral mRNA", "OBSERVATION", 81, 91]]], ["Thus, it was important to analyse whether the nucleoside analogues prevented eIF2\u03b1 phosphorylation, and whether this was the principal reason for the lack of shut\u2010off of host translation observed in BHK cells.", [["BHK cells", "ANATOMY", 199, 208], ["nucleoside", "CHEMICAL", 46, 56], ["nucleoside", "CHEMICAL", 46, 56], ["nucleoside analogues", "SIMPLE_CHEMICAL", 46, 66], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 77, 82], ["BHK cells", "CELL", 199, 208], ["eIF2\u03b1", "PROTEIN", 77, 82], ["BHK cells", "CELL_LINE", 199, 208], ["the nucleoside analogues", "TREATMENT", 42, 66], ["eIF2\u03b1 phosphorylation", "TREATMENT", 77, 98], ["host translation", "PROBLEM", 170, 186], ["BHK cells", "PROBLEM", 199, 208], ["BHK cells", "OBSERVATION", 199, 208]]], ["To this end, phosphorylation of eIF2\u03b1 and the inhibition of cellular protein synthesis were examined in BHK cells treated with 0.5 mM 6\u2010aza\u2010uridine or 0.2 mM ribavirin (Fig. 9A and B).", [["cellular", "ANATOMY", 60, 68], ["BHK cells", "ANATOMY", 104, 113], ["6\u2010aza\u2010uridine", "CHEMICAL", 134, 147], ["ribavirin", "CHEMICAL", 158, 167], ["6\u2010aza\u2010uridine", "CHEMICAL", 134, 147], ["ribavirin", "CHEMICAL", 158, 167], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 32, 37], ["cellular", "CELL", 60, 68], ["BHK cells", "CELL", 104, 113], ["\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 135, 147], ["ribavirin", "SIMPLE_CHEMICAL", 158, 167], ["B", "GENE_OR_GENE_PRODUCT", 181, 182], ["eIF2\u03b1", "PROTEIN", 32, 37], ["BHK cells", "CELL_LINE", 104, 113], ["phosphorylation of eIF2", "TREATMENT", 13, 36], ["cellular protein synthesis", "TREATMENT", 60, 86], ["\u2010aza\u2010uridine", "TREATMENT", 135, 147], ["0.2 mM ribavirin", "TREATMENT", 151, 167]]], ["As anticipated, SINV infection of BHK cells induced eIF2\u03b1 phosphorylation (Fig. 9A, lower panel).", [["BHK cells", "ANATOMY", 34, 43], ["infection", "DISEASE", 21, 30], ["SINV", "ORGANISM", 16, 20], ["BHK cells", "CELL", 34, 43], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 52, 57], ["BHK cells", "CELL_LINE", 34, 43], ["eIF2\u03b1", "PROTEIN", 52, 57], ["SINV", "SPECIES", 16, 20], ["BHK", "SPECIES", 34, 37], ["SINV infection of BHK cells", "PROBLEM", 16, 43], ["eIF2\u03b1 phosphorylation", "TREATMENT", 52, 73]]], ["Interestingly, ribavirin largely prevented eIF2\u03b1 phosphorylation, whereas this prevention was only partial in 6\u2010aza\u2010uridine\u2010treated cells (Fig. 9A, lower panel).", [["6\u2010aza\u2010uridine\u2010treated cells", "ANATOMY", 110, 137], ["ribavirin", "CHEMICAL", 15, 24], ["ribavirin", "CHEMICAL", 15, 24], ["ribavirin", "SIMPLE_CHEMICAL", 15, 24], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 43, 48], ["cells", "CELL", 132, 137], ["eIF2\u03b1", "PROTEIN", 43, 48], ["6\u2010aza\u2010uridine\u2010treated cells", "CELL_LINE", 110, 137], ["ribavirin", "TREATMENT", 15, 24], ["eIF2\u03b1 phosphorylation", "TREATMENT", 43, 64], ["ribavirin", "OBSERVATION", 15, 24]]], ["We reasoned that the prevention of the shut\u2010off of host translation by the nucleoside analogues in BHK cells may be due to their interference with eIF2\u03b1 phosphorylation.", [["BHK cells", "ANATOMY", 99, 108], ["nucleoside", "CHEMICAL", 75, 85], ["nucleoside", "CHEMICAL", 75, 85], ["nucleoside analogues", "SIMPLE_CHEMICAL", 75, 95], ["BHK cells", "CELL", 99, 108], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 147, 152], ["BHK cells", "CELL_LINE", 99, 108], ["eIF2\u03b1", "PROTEIN", 147, 152], ["host translation", "TREATMENT", 51, 67], ["the nucleoside analogues in BHK cells", "TREATMENT", 71, 108], ["eIF2\u03b1 phosphorylation", "TREATMENT", 147, 168]]], ["To test this, we used PKR\u2212/\u2212 MEFs that do not undergo eIF2 inactivation following SINV infection (Ventoso et al., 2006).", [["PKR\u2212/\u2212 MEFs", "ANATOMY", 22, 33], ["SINV infection", "DISEASE", 82, 96], ["PKR", "GENE_OR_GENE_PRODUCT", 22, 25], ["eIF2", "GENE_OR_GENE_PRODUCT", 54, 58], ["SINV", "ORGANISM", 82, 86], ["PKR", "PROTEIN", 22, 25], ["eIF2", "PROTEIN", 54, 58], ["SINV", "SPECIES", 82, 86], ["PKR\u2212/\u2212 MEFs", "TREATMENT", 22, 33], ["eIF2 inactivation", "TREATMENT", 54, 71], ["SINV infection", "PROBLEM", 82, 96]]], ["Indeed, no phosphorylation of the eIF2 \u03b1 subunit was evident in SINV\u2010infected PKR\u2212/\u2212 MEFs (Fig. 9C, lower panel).", [["PKR\u2212/\u2212 MEFs", "ANATOMY", 78, 89], ["eIF2 \u03b1", "GENE_OR_GENE_PRODUCT", 34, 40], ["SINV", "ORGANISM", 64, 68], ["PKR", "GENE_OR_GENE_PRODUCT", 78, 81], ["eIF2 \u03b1 subunit", "PROTEIN", 34, 48], ["PKR", "PROTEIN", 78, 81], ["\u2212 MEFs", "CELL_LINE", 83, 89], ["SINV", "SPECIES", 64, 68], ["phosphorylation", "TREATMENT", 11, 26], ["the eIF2 \u03b1 subunit", "TREATMENT", 30, 48], ["MEFs", "TEST", 85, 89], ["lower panel", "TEST", 100, 111], ["no", "UNCERTAINTY", 8, 10]]], ["Similar to previous results, inhibition of protein synthesis by 0.5 mM 6\u2010aza\u2010uridine or 0.2 mM ribavirin was 33% and 46%, respectively, in uninfected cells (Fig. 9C and D).", [["cells", "ANATOMY", 150, 155], ["6\u2010aza\u2010uridine", "CHEMICAL", 71, 84], ["ribavirin", "CHEMICAL", 95, 104], ["6\u2010aza\u2010uridine", "CHEMICAL", 71, 84], ["ribavirin", "CHEMICAL", 95, 104], ["6\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 71, 84], ["ribavirin", "SIMPLE_CHEMICAL", 95, 104], ["cells", "CELL", 150, 155], ["uninfected cells", "CELL_TYPE", 139, 155], ["inhibition of protein synthesis", "TREATMENT", 29, 60], ["\u2010aza\u2010uridine", "TREATMENT", 72, 84], ["0.2 mM ribavirin", "TREATMENT", 88, 104], ["uninfected cells", "OBSERVATION", 139, 155]]], ["Notably, treatment with the nucleoside analogues prevented the inhibition of cellular protein synthesis by SINV infection even when no phosphorylation of eIF2\u03b1 took place; in the presence of 0.5 mM 6\u2010aza\u2010uridine, SINV infection inhibited actin synthesis by 3%, related to 6\u2010aza\u2010uridine\u2010treated uninfected cells, whereas this inhibition was 10% with ribavirin.", [["cellular", "ANATOMY", 77, 85], ["cells", "ANATOMY", 305, 310], ["nucleoside", "CHEMICAL", 28, 38], ["SINV infection", "DISEASE", 107, 121], ["6\u2010aza\u2010uridine", "CHEMICAL", 198, 211], ["infection", "DISEASE", 218, 227], ["ribavirin", "CHEMICAL", 349, 358], ["nucleoside", "CHEMICAL", 28, 38], ["\u2010aza\u2010uridine", "CHEMICAL", 199, 211], ["ribavirin", "CHEMICAL", 349, 358], ["nucleoside analogues", "SIMPLE_CHEMICAL", 28, 48], ["cellular", "CELL", 77, 85], ["SINV", "ORGANISM", 107, 111], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 154, 159], ["6\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 198, 211], ["SINV", "ORGANISM", 213, 217], ["actin", "GENE_OR_GENE_PRODUCT", 238, 243], ["cells", "CELL", 305, 310], ["ribavirin", "SIMPLE_CHEMICAL", 349, 358], ["eIF2\u03b1", "PROTEIN", 154, 159], ["actin", "PROTEIN", 238, 243], ["6\u2010aza\u2010uridine\u2010treated uninfected cells", "CELL_LINE", 272, 310], ["SINV", "SPECIES", 107, 111], ["SINV", "SPECIES", 213, 217], ["treatment", "TREATMENT", 9, 18], ["the nucleoside analogues", "TREATMENT", 24, 48], ["cellular protein synthesis", "TREATMENT", 77, 103], ["SINV infection", "PROBLEM", 107, 121], ["phosphorylation of eIF2", "TREATMENT", 135, 158], ["0.5 mM 6\u2010aza\u2010uridine", "TREATMENT", 191, 211], ["SINV infection", "PROBLEM", 213, 227], ["actin synthesis", "TREATMENT", 238, 253], ["6\u2010aza\u2010uridine\u2010treated uninfected cells", "TREATMENT", 272, 310], ["ribavirin", "TREATMENT", 349, 358], ["infection", "OBSERVATION", 218, 227], ["uninfected cells", "OBSERVATION", 294, 310]]], ["In contrast, the decrease in actin synthesis was 95% in untreated PKR\u2212/\u2212 MEFs after SINV infection related to untreated and uninfected cells (Fig. 9C and D).Inhibition of cellular protein synthesis in PKR\u2212/\u2212MEFs::: ResultsNext, we assessed the location of PTB in PKR\u2212/\u2212 MEFs infected with SINV.", [["PKR\u2212/\u2212 MEFs", "ANATOMY", 66, 77], ["cells", "ANATOMY", 135, 140], ["cellular", "ANATOMY", 171, 179], ["PKR\u2212/\u2212MEFs", "ANATOMY", 201, 211], ["PKR\u2212/\u2212 MEFs", "ANATOMY", 263, 274], ["SINV infection", "DISEASE", 84, 98], ["actin", "GENE_OR_GENE_PRODUCT", 29, 34], ["PKR", "GENE_OR_GENE_PRODUCT", 66, 69], ["SINV", "ORGANISM", 84, 88], ["cells", "CELL", 135, 140], ["cellular", "CELL", 171, 179], ["PKR", "GENE_OR_GENE_PRODUCT", 201, 204], ["PTB", "GENE_OR_GENE_PRODUCT", 256, 259], ["PKR", "GENE_OR_GENE_PRODUCT", 263, 266], ["SINV", "ORGANISM", 289, 293], ["actin", "PROTEIN", 29, 34], ["PKR", "PROTEIN", 66, 69], ["uninfected cells", "CELL_TYPE", 124, 140], ["PKR", "PROTEIN", 201, 204], ["PTB", "PROTEIN", 256, 259], ["PKR", "PROTEIN", 263, 266], ["SINV", "SPECIES", 84, 88], ["SINV", "SPECIES", 289, 293], ["the decrease in actin synthesis", "PROBLEM", 13, 44], ["MEFs", "PROBLEM", 73, 77], ["SINV infection", "PROBLEM", 84, 98], ["untreated and uninfected cells", "PROBLEM", 110, 140], ["cellular protein synthesis", "TEST", 171, 197], ["PTB", "PROBLEM", 256, 259], ["MEFs", "PROBLEM", 270, 274], ["SINV", "TREATMENT", 289, 293], ["decrease", "OBSERVATION_MODIFIER", 17, 25], ["SINV infection", "OBSERVATION", 84, 98], ["uninfected cells", "OBSERVATION", 124, 140], ["cellular protein synthesis", "OBSERVATION", 171, 197], ["PTB", "OBSERVATION", 256, 259]]], ["Consistent with the results obtained in BHK cells, a potent release of PTB occurred in PKR\u2212/\u2212 MEFs infected with SINV containing less than 15% of PTB in the nucleus of infected cells.", [["BHK cells", "ANATOMY", 40, 49], ["PKR\u2212/\u2212 MEFs", "ANATOMY", 87, 98], ["nucleus", "ANATOMY", 157, 164], ["cells", "ANATOMY", 177, 182], ["PTB", "DISEASE", 71, 74], ["BHK cells", "CELL", 40, 49], ["PTB", "GENE_OR_GENE_PRODUCT", 71, 74], ["PKR", "GENE_OR_GENE_PRODUCT", 87, 90], ["SINV", "ORGANISM", 113, 117], ["PTB", "GENE_OR_GENE_PRODUCT", 146, 149], ["nucleus", "CELLULAR_COMPONENT", 157, 164], ["cells", "CELL", 177, 182], ["BHK cells", "CELL_LINE", 40, 49], ["PTB", "PROTEIN", 71, 74], ["PKR", "PROTEIN", 87, 90], ["PTB", "PROTEIN", 146, 149], ["infected cells", "CELL_TYPE", 168, 182], ["BHK", "SPECIES", 40, 43], ["SINV", "SPECIES", 113, 117], ["PTB", "PROBLEM", 71, 74], ["PKR", "TEST", 87, 90], ["MEFs", "PROBLEM", 94, 98], ["SINV", "TREATMENT", 113, 117], ["PTB", "TREATMENT", 146, 149], ["infected cells", "PROBLEM", 168, 182], ["nucleus", "ANATOMY", 157, 164], ["infected cells", "OBSERVATION", 168, 182]]], ["However, in infected cells treated with nucleoside analogues around 68\u201372% of PTB remained into the nucleus (Fig. 9E).", [["cells", "ANATOMY", 21, 26], ["nucleus", "ANATOMY", 100, 107], ["nucleoside", "CHEMICAL", 40, 50], ["nucleoside", "CHEMICAL", 40, 50], ["cells", "CELL", 21, 26], ["nucleoside analogues", "SIMPLE_CHEMICAL", 40, 60], ["PTB", "GENE_OR_GENE_PRODUCT", 78, 81], ["nucleus", "CELLULAR_COMPONENT", 100, 107], ["infected cells", "CELL_TYPE", 12, 26], ["PTB", "PROTEIN", 78, 81], ["infected cells", "PROBLEM", 12, 26], ["nucleoside analogues", "TREATMENT", 40, 60], ["PTB", "PROBLEM", 78, 81], ["infected cells", "OBSERVATION", 12, 26], ["nucleus", "ANATOMY", 100, 107]]], ["Thus, the inability of SINV to induce shut\u2010off in the presence of 6\u2010aza\u2010uridine or ribavirin is not related to the prevention of eIF2\u03b1 phosphorylation.Inhibition of cellular protein synthesis in PKR\u2212/\u2212MEFs::: ResultsFinally, we tested shut\u2010off of host translation in PKR\u2212/\u2212 MEFs infected with the SINV nsP2 variant (P726G).", [["cellular", "ANATOMY", 165, 173], ["PKR\u2212/\u2212MEFs", "ANATOMY", 195, 205], ["PKR\u2212/\u2212 MEFs", "ANATOMY", 267, 278], ["6\u2010aza\u2010uridine", "CHEMICAL", 66, 79], ["ribavirin", "CHEMICAL", 83, 92], ["6\u2010aza\u2010uridine", "CHEMICAL", 66, 79], ["ribavirin", "CHEMICAL", 83, 92], ["SINV", "ORGANISM", 23, 27], ["6\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 66, 79], ["ribavirin", "SIMPLE_CHEMICAL", 83, 92], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 129, 134], ["cellular", "CELL", 165, 173], ["PKR", "GENE_OR_GENE_PRODUCT", 195, 198], ["PKR", "GENE_OR_GENE_PRODUCT", 267, 270], ["SINV", "ORGANISM", 297, 301], ["nsP2", "GENE_OR_GENE_PRODUCT", 302, 306], ["eIF2\u03b1", "PROTEIN", 129, 134], ["PKR", "PROTEIN", 195, 198], ["PKR", "PROTEIN", 267, 270], ["SINV nsP2 variant", "PROTEIN", 297, 314], ["SINV", "SPECIES", 23, 27], ["SINV nsP2", "SPECIES", 297, 306], ["SINV", "TREATMENT", 23, 27], ["6\u2010aza\u2010uridine", "TREATMENT", 66, 79], ["ribavirin", "TREATMENT", 83, 92], ["eIF2\u03b1 phosphorylation", "TREATMENT", 129, 150], ["cellular protein synthesis", "TEST", 165, 191], ["PKR", "TEST", 267, 270], ["MEFs", "PROBLEM", 274, 278], ["cellular protein synthesis", "OBSERVATION", 165, 191]]], ["Cells were transfected with in vitro synthesized gmRNAs from SINV wt or SINV nsP2 (P726G) and protein synthesis was estimated at 4 and 8 hpt.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["gmRNAs", "GENE_OR_GENE_PRODUCT", 49, 55], ["SINV wt", "ORGANISM", 61, 68], ["SINV", "ORGANISM", 72, 76], ["nsP2", "GENE_OR_GENE_PRODUCT", 77, 81], ["in vitro synthesized gmRNAs", "PROTEIN", 28, 55], ["SINV nsP2", "PROTEIN", 72, 81], ["SINV", "SPECIES", 61, 65], ["SINV", "SPECIES", 72, 76], ["SINV wt", "TEST", 61, 68], ["SINV nsP2", "TEST", 72, 81], ["protein synthesis", "TEST", 94, 111]]], ["Compared with SINV wt, virtually no inhibition of cellular translation was observed in PKR\u2212/\u2212 MEFs after infection with the SINV variant (Fig. 10A and B), suggesting that the partial inhibition observed in BHK cells (Fig. 5A) may be due to the presence of PKR in these cells.", [["cellular", "ANATOMY", 50, 58], ["PKR\u2212/\u2212 MEFs", "ANATOMY", 87, 98], ["BHK cells", "ANATOMY", 206, 215], ["cells", "ANATOMY", 269, 274], ["infection", "DISEASE", 105, 114], ["SINV wt", "ORGANISM", 14, 21], ["cellular", "CELL", 50, 58], ["PKR", "GENE_OR_GENE_PRODUCT", 87, 90], ["SINV", "ORGANISM", 124, 128], ["B", "GENE_OR_GENE_PRODUCT", 151, 152], ["BHK cells", "CELL", 206, 215], ["Fig. 5A", "CELL", 217, 224], ["PKR", "GENE_OR_GENE_PRODUCT", 256, 259], ["cells", "CELL", 269, 274], ["PKR", "PROTEIN", 87, 90], ["BHK cells", "CELL_LINE", 206, 215], ["PKR", "PROTEIN", 256, 259], ["SINV", "SPECIES", 14, 18], ["SINV", "SPECIES", 124, 128], ["SINV wt", "TEST", 14, 21], ["PKR", "TEST", 87, 90], ["MEFs", "PROBLEM", 94, 98], ["infection", "PROBLEM", 105, 114], ["the SINV variant", "PROBLEM", 120, 136], ["the partial inhibition", "PROBLEM", 171, 193], ["BHK cells", "PROBLEM", 206, 215], ["PKR in these cells", "PROBLEM", 256, 274], ["infection", "OBSERVATION", 105, 114], ["partial inhibition", "OBSERVATION", 175, 193], ["BHK cells", "OBSERVATION", 206, 215], ["PKR", "OBSERVATION", 256, 259]]], ["Further, in agreement with the results obtained in BHK cells, TIA\u20101 and PTB accumulated in the cytoplasm of SINV wt gmRNA\u2010transfected cells, and their nuclear location was unchanged after transfection of SINV nsP2 (P726G) (Fig. 10C).", [["BHK cells", "ANATOMY", 51, 60], ["cytoplasm", "ANATOMY", 95, 104], ["cells", "ANATOMY", 134, 139], ["nuclear", "ANATOMY", 151, 158], ["BHK cells", "CELL", 51, 60], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 62, 67], ["PTB", "GENE_OR_GENE_PRODUCT", 72, 75], ["cytoplasm", "ORGANISM_SUBSTANCE", 95, 104], ["SINV", "ORGANISM", 108, 112], ["gmRNA", "GENE_OR_GENE_PRODUCT", 116, 121], ["cells", "CELL", 134, 139], ["nuclear", "CELLULAR_COMPONENT", 151, 158], ["SINV", "ORGANISM", 204, 208], ["nsP2", "GENE_OR_GENE_PRODUCT", 209, 213], ["BHK cells", "CELL_LINE", 51, 60], ["TIA\u20101", "PROTEIN", 62, 67], ["PTB", "PROTEIN", 72, 75], ["SINV wt gmRNA\u2010transfected cells", "CELL_LINE", 108, 139], ["SINV nsP2", "PROTEIN", 204, 213], ["BHK", "SPECIES", 51, 54], ["SINV", "SPECIES", 108, 112], ["SINV nsP2 (P726G)", "SPECIES", 204, 221], ["TIA\u20101", "TEST", 62, 67], ["PTB", "PROBLEM", 72, 75], ["transfected cells", "PROBLEM", 122, 139], ["SINV nsP2", "TREATMENT", 204, 213], ["transfected cells", "OBSERVATION", 122, 139], ["unchanged", "OBSERVATION_MODIFIER", 172, 181]]], ["Taken together, these results support an association between the shut\u2010off of host translation and the exit of nuclear proteins to the cytoplasm.", [["nuclear", "ANATOMY", 110, 117], ["cytoplasm", "ANATOMY", 134, 143], ["nuclear", "CELLULAR_COMPONENT", 110, 117], ["cytoplasm", "ORGANISM_SUBSTANCE", 134, 143], ["nuclear proteins", "PROTEIN", 110, 126], ["host translation", "TREATMENT", 77, 93]]], ["Additionally, the prevention of SINV\u2010induced cellular protein synthesis blockade by nucleoside analogues or the SINV variant nsP2 (P726G), is more clearly observed in PKR\u2010defective cells.DiscussionInfection of mammalian cells with a number of animal viruses leads to a profound inhibition of cellular macromolecular synthesis, blocking innate antiviral responses.", [["cellular", "ANATOMY", 45, 53], ["cells", "ANATOMY", 181, 186], ["cells", "ANATOMY", 220, 225], ["cellular", "ANATOMY", 292, 300], ["nucleoside", "CHEMICAL", 84, 94], ["nucleoside", "CHEMICAL", 84, 94], ["SINV", "ORGANISM", 32, 36], ["cellular", "CELL", 45, 53], ["nucleoside analogues", "SIMPLE_CHEMICAL", 84, 104], ["nsP2", "GENE_OR_GENE_PRODUCT", 125, 129], ["PKR", "GENE_OR_GENE_PRODUCT", 167, 170], ["cells", "CELL", 181, 186], ["mammalian cells", "CELL", 210, 225], ["cellular", "CELL", 292, 300], ["P726G", "PROTEIN", 131, 136], ["PKR", "PROTEIN", 167, 170], ["defective cells", "CELL_TYPE", 171, 186], ["mammalian cells", "CELL_TYPE", 210, 225], ["SINV", "SPECIES", 32, 36], ["SINV\u2010induced cellular protein synthesis blockade", "TREATMENT", 32, 80], ["nucleoside analogues", "TREATMENT", 84, 104], ["the SINV variant nsP2", "PROBLEM", 108, 129], ["defective cells", "PROBLEM", 171, 186], ["mammalian cells", "PROBLEM", 210, 225], ["animal viruses", "PROBLEM", 243, 257], ["cellular macromolecular synthesis", "PROBLEM", 292, 325], ["defective cells", "OBSERVATION", 171, 186], ["mammalian cells", "OBSERVATION", 210, 225], ["viruses", "OBSERVATION", 250, 257], ["cellular macromolecular synthesis", "OBSERVATION", 292, 325]]], ["Alphavirus replicons encoding solely nsPs interfere with cellular translation to a degree similar to that observed with non\u2010defective viruses (Frolov and Schlesinger, 1994; Sanz et al., 2007).", [["cellular", "ANATOMY", 57, 65], ["nsPs", "GENE_OR_GENE_PRODUCT", 37, 41], ["cellular", "CELL", 57, 65], ["Alphavirus replicons", "DNA", 0, 20], ["nsPs", "PROTEIN", 37, 41], ["Alphavirus replicons", "TREATMENT", 0, 20], ["cellular translation", "TREATMENT", 57, 77]]], ["Several observations point to nsP2 as the mediator of these inhibitory effects (Frolov et al., 1999; Gorchakov et al., 2004; 2005; Garmashova et al., 2006).", [["nsP2", "GENE_OR_GENE_PRODUCT", 30, 34], ["nsP2", "PROTEIN", 30, 34], ["nsP2", "TREATMENT", 30, 34]]], ["However, a mutant in the 5\u2032UTR sequence of sgmRNA of SINV that expresses more nsPs than wt virus is defective in the shut\u2010off of host mRNA translation (Patel et al., 2013).", [["sgmRNA", "GENE_OR_GENE_PRODUCT", 43, 49], ["SINV", "ORGANISM", 53, 57], ["nsPs", "GENE_OR_GENE_PRODUCT", 78, 82], ["wt virus", "ORGANISM", 88, 96], ["5\u2032UTR sequence", "DNA", 25, 39], ["sgmRNA", "PROTEIN", 43, 49], ["nsPs", "PROTEIN", 78, 82], ["SINV", "SPECIES", 53, 57], ["a mutant in the 5\u2032UTR sequence", "PROBLEM", 9, 39], ["sgmRNA of SINV", "PROBLEM", 43, 57]]], ["We have analysed the inhibition of cellular mRNA translation mediated by individual nsPs and nsP1\u20104.", [["cellular", "ANATOMY", 35, 43], ["cellular", "CELL", 35, 43], ["nsPs", "GENE_OR_GENE_PRODUCT", 84, 88], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 93, 99], ["cellular mRNA", "RNA", 35, 48], ["nsPs", "PROTEIN", 84, 88], ["nsP1\u20104", "PROTEIN", 93, 99], ["cellular mRNA translation", "TREATMENT", 35, 60], ["cellular mRNA", "OBSERVATION", 35, 48]]], ["We found that individual expression of nsP1, nsP2 and nsP3 or nsP1\u20104 has little effect on cellular protein synthesis.", [["cellular", "ANATOMY", 90, 98], ["nsP1", "GENE_OR_GENE_PRODUCT", 39, 43], ["nsP2", "GENE_OR_GENE_PRODUCT", 45, 49], ["nsP3", "GENE_OR_GENE_PRODUCT", 54, 58], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 62, 68], ["cellular", "CELL", 90, 98], ["nsP1", "PROTEIN", 39, 43], ["nsP2", "PROTEIN", 45, 49], ["nsP3", "PROTEIN", 54, 58], ["nsP1\u20104", "PROTEIN", 62, 68], ["nsP1", "PROBLEM", 39, 43], ["nsP2", "TEST", 45, 49], ["nsP3", "TEST", 54, 58], ["nsP1", "TEST", 62, 66], ["cellular protein synthesis", "PROBLEM", 90, 116], ["cellular protein synthesis", "OBSERVATION", 90, 116]]], ["In the case of nsP1\u20104, not only mature nsPs are synthesized, but also their precursors, which is more akin to the situation observed in SINV\u2010infected cells.", [["cells", "ANATOMY", 150, 155], ["nsP1\u20104", "GENE_OR_GENE_PRODUCT", 15, 21], ["nsPs", "GENE_OR_GENE_PRODUCT", 39, 43], ["SINV", "ORGANISM", 136, 140], ["cells", "CELL", 150, 155], ["nsP1\u20104", "PROTEIN", 15, 21], ["nsPs", "PROTEIN", 39, 43], ["SINV\u2010infected cells", "CELL_LINE", 136, 155], ["SINV", "SPECIES", 136, 140], ["nsP1", "TEST", 15, 19], ["SINV\u2010infected cells", "PROBLEM", 136, 155], ["SINV\u2010infected cells", "OBSERVATION", 136, 155]]], ["As a control, we tested the expression of PV 2Apro that induces a profound arrest in cellular mRNA translation upon cleavage of eIF4G (Castello et al., 2011), in clear contrast to SINV nsPs.", [["cellular", "ANATOMY", 85, 93], ["PV 2Apro", "GENE_OR_GENE_PRODUCT", 42, 50], ["cellular", "CELL", 85, 93], ["eIF4G", "GENE_OR_GENE_PRODUCT", 128, 133], ["SINV", "ORGANISM", 180, 184], ["PV 2Apro", "PROTEIN", 42, 50], ["cellular mRNA", "RNA", 85, 98], ["eIF4G", "PROTEIN", 128, 133], ["SINV nsPs", "PROTEIN", 180, 189], ["PV", "SPECIES", 42, 44], ["SINV", "SPECIES", 180, 184], ["PV 2Apro", "TREATMENT", 42, 50], ["a profound arrest", "PROBLEM", 64, 81], ["cellular mRNA translation", "PROBLEM", 85, 110], ["profound", "OBSERVATION_MODIFIER", 66, 74], ["arrest", "OBSERVATION", 75, 81], ["cellular mRNA", "OBSERVATION", 85, 98], ["SINV nsPs", "OBSERVATION", 180, 189]]], ["Additionally, PV 2Apro substantially modifies the shuttling of proteins between nucleus and cytoplasm, after cleavage of several nuPs (Park et al., 2008; 2010; Castello et al., 2009; Alvarez et al., 2011; 2013).", [["nucleus", "ANATOMY", 80, 87], ["cytoplasm", "ANATOMY", 92, 101], ["2Apro", "CHEMICAL", 17, 22], ["PV 2Apro", "GENE_OR_GENE_PRODUCT", 14, 22], ["nucleus", "CELLULAR_COMPONENT", 80, 87], ["cytoplasm", "ORGANISM_SUBSTANCE", 92, 101], ["nuPs", "GENE_OR_GENE_PRODUCT", 129, 133], ["PV 2Apro", "PROTEIN", 14, 22], ["PV", "SPECIES", 14, 16], ["PV 2Apro", "TREATMENT", 14, 22], ["nucleus", "ANATOMY", 80, 87], ["cytoplasm", "OBSERVATION_MODIFIER", 92, 101]]], ["In contrast, SINV nsPs did not elicit the release of nuclear proteins TIA\u20101 and PTB.DiscussionOur results are consistent with the idea that inhibition of host translation in alphavirus\u2010infected mammalian cells requires a high level of viral RNA replication.", [["nuclear", "ANATOMY", 53, 60], ["alphavirus\u2010infected mammalian cells", "ANATOMY", 174, 209], ["TIA", "DISEASE", 70, 73], ["SINV", "ORGANISM", 13, 17], ["nuclear", "CELLULAR_COMPONENT", 53, 60], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 70, 75], ["PTB", "GENE_OR_GENE_PRODUCT", 80, 83], ["alphavirus\u2010infected mammalian cells", "CELL", 174, 209], ["SINV nsPs", "PROTEIN", 13, 22], ["nuclear proteins", "PROTEIN", 53, 69], ["TIA\u20101", "PROTEIN", 70, 75], ["PTB", "PROTEIN", 80, 83], ["alphavirus\u2010infected mammalian cells", "CELL_TYPE", 174, 209], ["SINV", "SPECIES", 13, 17], ["nuclear proteins TIA", "PROBLEM", 53, 73], ["PTB", "PROBLEM", 80, 83], ["host translation", "TREATMENT", 154, 170], ["alphavirus\u2010infected mammalian cells", "PROBLEM", 174, 209], ["viral RNA replication", "TREATMENT", 235, 256], ["consistent with", "UNCERTAINTY", 110, 125], ["mammalian cells", "OBSERVATION", 194, 209], ["viral RNA replication", "OBSERVATION", 235, 256]]], ["Indeed, in cells co\u2010transfected with rep C+luc(\u0394nsPs) and EMCV(IRES)\u2010nsP1\u20104 mRNA, there is low\u2010level RNA replication, no release of nuclear proteins and the synthesis of cellular proteins is not blocked.", [["cells", "ANATOMY", 11, 16], ["nuclear", "ANATOMY", 132, 139], ["cellular", "ANATOMY", 170, 178], ["cells", "CELL", 11, 16], ["rep C+luc", "GENE_OR_GENE_PRODUCT", 37, 46], ["\u0394nsPs", "GENE_OR_GENE_PRODUCT", 47, 52], ["EMCV(IRES)\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 58, 75], ["nuclear", "CELLULAR_COMPONENT", 132, 139], ["cellular", "CELL", 170, 178], ["rep C+luc(\u0394nsPs) and EMCV(IRES)\u2010nsP1\u20104 mRNA", "RNA", 37, 80], ["nuclear proteins", "PROTEIN", 132, 148], ["cellular proteins", "PROTEIN", 170, 187], ["EMCV", "SPECIES", 58, 62], ["rep C+luc(\u0394nsPs)", "TREATMENT", 37, 53], ["EMCV(IRES", "TREATMENT", 58, 67], ["low\u2010level RNA replication", "PROBLEM", 91, 116], ["nuclear proteins", "TEST", 132, 148], ["the synthesis of cellular proteins", "TEST", 153, 187], ["RNA replication", "OBSERVATION", 101, 116], ["no", "UNCERTAINTY", 118, 120], ["cellular proteins", "OBSERVATION", 170, 187]]], ["A similar situation arises for the variant SINV nsP2 (P726G), which has little effect on cellular mRNA translation, particularly in PKR\u2212/\u2212 MEFs, concomitant with a low level of viral RNA replication.", [["cellular", "ANATOMY", 89, 97], ["PKR\u2212/\u2212 MEFs", "ANATOMY", 132, 143], ["SINV", "ORGANISM", 43, 47], ["nsP2", "GENE_OR_GENE_PRODUCT", 48, 52], ["P726G", "AMINO_ACID", 54, 59], ["cellular", "CELL", 89, 97], ["PKR", "GENE_OR_GENE_PRODUCT", 132, 135], ["SINV nsP2", "PROTEIN", 43, 52], ["cellular mRNA", "RNA", 89, 102], ["PKR\u2212/\u2212 MEFs", "CELL_LINE", 132, 143], ["the variant SINV nsP2", "PROBLEM", 31, 52], ["cellular mRNA translation", "PROBLEM", 89, 114], ["PKR", "TEST", 132, 135], ["MEFs", "PROBLEM", 139, 143], ["viral RNA replication", "TREATMENT", 177, 198], ["cellular mRNA translation", "OBSERVATION", 89, 114], ["viral RNA replication", "OBSERVATION", 177, 198]]], ["Analogous to SINV nsP2 (P726G), two variants of SFV with point mutations in nsP2 that severely reduce the levels of viral RNA accumulation, were also unable to induce shut\u2010off (Tamm et al., 2008).", [["SINV", "ORGANISM", 13, 17], ["nsP2", "GENE_OR_GENE_PRODUCT", 18, 22], ["SFV", "ORGANISM", 48, 51], ["nsP2", "GENE_OR_GENE_PRODUCT", 76, 80], ["SINV nsP2", "PROTEIN", 13, 22], ["nsP2", "DNA", 76, 80], ["SINV", "SPECIES", 13, 17], ["SFV", "SPECIES", 48, 51], ["Analogous to SINV nsP2", "PROBLEM", 0, 22], ["two variants of SFV", "PROBLEM", 32, 51], ["point mutations in nsP2", "PROBLEM", 57, 80], ["viral RNA accumulation", "PROBLEM", 116, 138], ["SFV", "ANATOMY", 48, 51], ["viral RNA accumulation", "OBSERVATION", 116, 138]]], ["Notably, this inhibition of host protein synthesis is prevented with nucleoside analogues that diminish viral RNA synthesis.", [["nucleoside", "CHEMICAL", 69, 79], ["nucleoside", "CHEMICAL", 69, 79], ["nucleoside analogues", "SIMPLE_CHEMICAL", 69, 89], ["viral RNA", "RNA", 104, 113], ["host protein synthesis", "TREATMENT", 28, 50], ["nucleoside analogues", "TREATMENT", 69, 89], ["viral RNA synthesis", "PROBLEM", 104, 123]]], ["These nucleoside analogues inhibit cellular transcription to a similar extent as actinomycin D, but additionally block viral transcription.", [["cellular", "ANATOMY", 35, 43], ["nucleoside", "CHEMICAL", 6, 16], ["actinomycin D", "CHEMICAL", 81, 94], ["nucleoside", "CHEMICAL", 6, 16], ["actinomycin D", "CHEMICAL", 81, 94], ["nucleoside analogues", "SIMPLE_CHEMICAL", 6, 26], ["cellular", "CELL", 35, 43], ["actinomycin D", "SIMPLE_CHEMICAL", 81, 94], ["These nucleoside analogues", "TREATMENT", 0, 26], ["cellular transcription", "TREATMENT", 35, 57], ["actinomycin D", "TREATMENT", 81, 94], ["additionally block viral transcription", "PROBLEM", 100, 138], ["viral transcription", "OBSERVATION", 119, 138]]], ["Actinomycin D treatment does not impede the process of cellular shut\u2010off in SINV\u2010infected cells, whereas 6\u2010aza\u2010uridine or ribavirin prevents this.", [["cellular", "ANATOMY", 55, 63], ["cells", "ANATOMY", 90, 95], ["Actinomycin D", "CHEMICAL", 0, 13], ["\u2010aza\u2010uridine", "CHEMICAL", 106, 118], ["ribavirin", "CHEMICAL", 122, 131], ["Actinomycin D", "CHEMICAL", 0, 13], ["\u2010aza\u2010uridine", "CHEMICAL", 106, 118], ["ribavirin", "CHEMICAL", 122, 131], ["Actinomycin D", "SIMPLE_CHEMICAL", 0, 13], ["cellular", "CELL", 55, 63], ["SINV", "ORGANISM", 76, 80], ["cells", "CELL", 90, 95], ["\u2010aza\u2010uridine", "SIMPLE_CHEMICAL", 106, 118], ["ribavirin", "SIMPLE_CHEMICAL", 122, 131], ["SINV\u2010infected cells", "CELL_LINE", 76, 95], ["SINV", "SPECIES", 76, 80], ["Actinomycin D treatment", "TREATMENT", 0, 23], ["SINV\u2010infected cells", "PROBLEM", 76, 95], ["\u2010aza\u2010uridine", "TREATMENT", 106, 118], ["ribavirin", "TREATMENT", 122, 131]]], ["Further support for this notion stems from the observation that SINV infection of mosquito cells, which results in low levels of viral RNA replication, does not abolish protein synthesis (Kim et al., 2004).", [["cells", "ANATOMY", 91, 96], ["infection", "DISEASE", 69, 78], ["SINV", "ORGANISM", 64, 68], ["mosquito cells", "CELL", 82, 96], ["mosquito cells", "CELL_TYPE", 82, 96], ["SINV", "SPECIES", 64, 68], ["Further support", "TREATMENT", 0, 15], ["this notion stems", "PROBLEM", 20, 37], ["the observation", "TEST", 43, 58], ["SINV infection of mosquito cells", "PROBLEM", 64, 96], ["viral RNA replication", "TREATMENT", 129, 150], ["low levels", "OBSERVATION_MODIFIER", 115, 125], ["viral RNA replication", "OBSERVATION", 129, 150]]], ["In conclusion, for the shut\u2010off of host mRNA translation to take place, synthesis of SINV nsPs is not sufficient and viral RNA replication is necessary.", [["SINV", "ORGANISM", 85, 89], ["nsPs", "GENE_OR_GENE_PRODUCT", 90, 94], ["SINV nsPs", "PROTEIN", 85, 94], ["SINV", "SPECIES", 85, 89], ["host mRNA translation", "TREATMENT", 35, 56], ["SINV nsPs", "PROBLEM", 85, 94], ["viral RNA replication", "TREATMENT", 117, 138]]], ["This replication should have to take place at normal levels, because no inhibition of host translation occurs when viral RNA replication is compromised.", [["inhibition of host translation", "PROBLEM", 72, 102], ["viral RNA replication", "PROBLEM", 115, 136]]], ["Notably, shut\u2010off of cellular protein synthesis coincides with release of nuclear proteins to the cytoplasm and efficient viral RNA replication.", [["cellular", "ANATOMY", 21, 29], ["nuclear", "ANATOMY", 74, 81], ["cytoplasm", "ANATOMY", 98, 107], ["cellular", "CELL", 21, 29], ["nuclear", "CELLULAR_COMPONENT", 74, 81], ["cytoplasm", "ORGANISM_SUBSTANCE", 98, 107], ["nuclear proteins", "PROTEIN", 74, 90], ["cellular protein synthesis", "PROBLEM", 21, 47], ["nuclear proteins", "PROBLEM", 74, 90], ["the cytoplasm", "PROBLEM", 94, 107], ["efficient viral RNA replication", "TREATMENT", 112, 143], ["cellular protein synthesis", "OBSERVATION", 21, 47], ["viral RNA replication", "OBSERVATION", 122, 143]]], ["This viral replication might trigger a cellular response that obstructs the shuttling of proteins between nucleus and cytoplasm.", [["cellular", "ANATOMY", 39, 47], ["nucleus", "ANATOMY", 106, 113], ["cytoplasm", "ANATOMY", 118, 127], ["cellular", "CELL", 39, 47], ["nucleus", "CELLULAR_COMPONENT", 106, 113], ["cytoplasm", "ORGANISM_SUBSTANCE", 118, 127], ["This viral replication", "TREATMENT", 0, 22], ["cellular response", "OBSERVATION", 39, 56], ["nucleus", "ANATOMY", 106, 113], ["cytoplasm", "OBSERVATION_MODIFIER", 118, 127]]], ["Therefore, it could be possible that one or more nuclear proteins are inhibitory for cellular translation when they are present in the cytoplasm.", [["nuclear", "ANATOMY", 49, 56], ["cellular", "ANATOMY", 85, 93], ["cytoplasm", "ANATOMY", 135, 144], ["nuclear", "CELLULAR_COMPONENT", 49, 56], ["cellular", "CELL", 85, 93], ["cytoplasm", "ORGANISM_SUBSTANCE", 135, 144], ["nuclear proteins", "PROTEIN", 49, 65], ["cellular translation", "TREATMENT", 85, 105], ["could be possible", "UNCERTAINTY", 14, 31]]], ["Of note, a number of nuclear proteins are released to the cytoplasm in various animal viruses studied (Li and Nagy, 2011).", [["nuclear", "ANATOMY", 21, 28], ["cytoplasm", "ANATOMY", 58, 67], ["nuclear", "CELLULAR_COMPONENT", 21, 28], ["cytoplasm", "ORGANISM_SUBSTANCE", 58, 67], ["nuclear proteins", "PROTEIN", 21, 37], ["nuclear proteins", "PROBLEM", 21, 37], ["viruses", "OBSERVATION", 86, 93]]], ["In the case of SINV, hnRNP K protein can be found enriched in membranous fractions containing SINV replication complexes, interacting with sgmRNA (Burnham et al., 2007).", [["membranous fractions", "ANATOMY", 62, 82], ["SINV", "ORGANISM", 15, 19], ["hnRNP K", "GENE_OR_GENE_PRODUCT", 21, 28], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 139, 145], ["hnRNP K protein", "PROTEIN", 21, 36], ["SINV replication complexes", "PROTEIN", 94, 120], ["sgmRNA", "PROTEIN", 139, 145], ["SINV", "SPECIES", 15, 19], ["SINV", "SPECIES", 94, 98], ["SINV", "PROBLEM", 15, 19], ["hnRNP K protein", "TEST", 21, 36], ["membranous fractions", "PROBLEM", 62, 82], ["membranous fractions", "OBSERVATION", 62, 82], ["SINV replication", "OBSERVATION", 94, 110]]], ["Also, hnRNP A1 can bind to the 5\u2032\u2010UTR of SINV genomic RNA and facilitates translation (Lin et al., 2009; Gui et al., 2010).", [["hnRNP A1", "GENE_OR_GENE_PRODUCT", 6, 14], ["hnRNP A1", "PROTEIN", 6, 14], ["5\u2032\u2010UTR", "DNA", 31, 37], ["SINV genomic RNA", "RNA", 41, 57], ["SINV", "SPECIES", 41, 45], ["SINV genomic RNA", "TREATMENT", 41, 57]]], ["HuR protein also relocalizes to the cytoplasm after alphavirus infection (Dickson et al., 2012) and interacts with a U\u2010rich element in the 3\u2032\u2010UTR of SINV transcripts, mediating viral RNA stabilization (Garneau et al., 2008; Sokoloski et al., 2010).", [["cytoplasm", "ANATOMY", 36, 45], ["alphavirus infection", "DISEASE", 52, 72], ["HuR", "GENE_OR_GENE_PRODUCT", 0, 3], ["cytoplasm", "ORGANISM_SUBSTANCE", 36, 45], ["SINV", "ORGANISM", 149, 153], ["HuR protein", "PROTEIN", 0, 11], ["U\u2010rich element", "DNA", 117, 131], ["3\u2032\u2010UTR", "DNA", 139, 145], ["SINV transcripts", "RNA", 149, 165], ["SINV", "SPECIES", 149, 153], ["HuR protein", "TEST", 0, 11], ["alphavirus infection", "PROBLEM", 52, 72], ["SINV transcripts", "TREATMENT", 149, 165], ["viral RNA stabilization", "TREATMENT", 177, 200], ["alphavirus", "OBSERVATION_MODIFIER", 52, 62], ["infection", "OBSERVATION", 63, 72], ["viral RNA stabilization", "OBSERVATION", 177, 200]]], ["Recently, it was proposed that the 3\u2032\u2010UTR of SINV serves as a sponge for HuR contributing to disrupt cellular posttranscriptional control (Barnhart et al., 2013).", [["cellular", "ANATOMY", 101, 109], ["SINV", "ORGANISM", 45, 49], ["HuR", "GENE_OR_GENE_PRODUCT", 73, 76], ["cellular", "CELL", 101, 109], ["3\u2032\u2010UTR", "DNA", 35, 41], ["HuR", "PROTEIN", 73, 76], ["SINV", "SPECIES", 45, 49], ["SINV serves", "TREATMENT", 45, 56], ["a sponge", "TREATMENT", 60, 68], ["HuR", "PROBLEM", 73, 76], ["disrupt cellular posttranscriptional control", "TREATMENT", 93, 137]]], ["In addition, PTB interacts with coronavirus RNAs and negatively affects the production of viral RNA (Sola et al., 2011).", [["PTB", "GENE_OR_GENE_PRODUCT", 13, 16], ["coronavirus", "ORGANISM", 32, 43], ["PTB", "PROTEIN", 13, 16], ["coronavirus RNAs", "RNA", 32, 48], ["viral RNA", "RNA", 90, 99], ["coronavirus RNAs", "PROBLEM", 32, 48], ["viral RNA", "OBSERVATION", 90, 99]]], ["Also, several hnRNPs and other nuclear proteins have been located in the antiviral granules formed as an innate host response to combat poxvirus infection (Rozelle et al., 2014).", [["nuclear", "ANATOMY", 31, 38], ["granules", "ANATOMY", 83, 91], ["poxvirus infection", "DISEASE", 136, 154], ["hnRNPs", "GENE_OR_GENE_PRODUCT", 14, 20], ["nuclear", "CELLULAR_COMPONENT", 31, 38], ["granules", "CELLULAR_COMPONENT", 83, 91], ["poxvirus", "ORGANISM", 136, 144], ["hnRNPs", "PROTEIN", 14, 20], ["nuclear proteins", "PROTEIN", 31, 47], ["several hnRNPs and other nuclear proteins", "PROBLEM", 6, 47], ["the antiviral granules", "PROBLEM", 69, 91], ["poxvirus infection", "PROBLEM", 136, 154], ["several", "OBSERVATION_MODIFIER", 6, 13], ["hnRNPs", "OBSERVATION", 14, 20], ["antiviral granules", "OBSERVATION", 73, 91]]], ["When MEFs defective in TIA\u20101 are infected with SFV, the shut\u2010off of host translation was significantly delayed as compared with control MEFs (McInerney et al., 2005).", [["MEFs", "ANATOMY", 5, 9], ["MEFs", "ANATOMY", 136, 140], ["MEFs", "CELL", 5, 9], ["TIA\u20101", "GENE_OR_GENE_PRODUCT", 23, 28], ["SFV", "ORGANISM", 47, 50], ["MEFs", "CELL", 136, 140], ["TIA\u20101", "PROTEIN", 23, 28], ["SFV", "SPECIES", 47, 50], ["MEFs defective in TIA\u20101", "PROBLEM", 5, 28], ["SFV", "PROBLEM", 47, 50], ["infected", "OBSERVATION", 33, 41]]], ["Undoubtedly, there are a large number of shuttling proteins that could be involved in the inhibition of cellular translation that remain to be studied.DiscussionThe replication of viral genomes in the cytoplasm of infected cells is associated with profound rearrangements of cellular membranes.", [["cellular", "ANATOMY", 104, 112], ["cytoplasm", "ANATOMY", 201, 210], ["cells", "ANATOMY", 223, 228], ["cellular membranes", "ANATOMY", 275, 293], ["cellular", "CELL", 104, 112], ["cytoplasm", "ORGANISM_SUBSTANCE", 201, 210], ["cells", "CELL", 223, 228], ["cellular membranes", "CELLULAR_COMPONENT", 275, 293], ["shuttling proteins", "PROTEIN", 41, 59], ["viral genomes", "DNA", 180, 193], ["infected cells", "CELL_TYPE", 214, 228], ["cellular translation", "TREATMENT", 104, 124], ["viral genomes", "PROBLEM", 180, 193], ["infected cells", "PROBLEM", 214, 228], ["profound rearrangements of cellular membranes", "PROBLEM", 248, 293], ["large", "OBSERVATION_MODIFIER", 25, 30], ["shuttling proteins", "OBSERVATION", 41, 59], ["viral genomes", "OBSERVATION", 180, 193], ["infected cells", "OBSERVATION", 214, 228], ["cellular membranes", "OBSERVATION", 275, 293]]], ["There are several possible explanations that might account for the connection between inhibition of host translation, viral RNA replication and the redistribution of nuclear proteins to the cytoplasm.", [["nuclear", "ANATOMY", 166, 173], ["cytoplasm", "ANATOMY", 190, 199], ["nuclear", "CELLULAR_COMPONENT", 166, 173], ["cytoplasm", "ORGANISM_SUBSTANCE", 190, 199], ["nuclear proteins", "PROTEIN", 166, 182], ["host translation", "TREATMENT", 100, 116], ["viral RNA replication", "TREATMENT", 118, 139], ["redistribution", "OBSERVATION_MODIFIER", 148, 162]]], ["One such possibility is that the appearance of large quantities of viral sequences in the cytoplasm induces a redistribution of nuclear proteins (Barnhart et al., 2013).", [["cytoplasm", "ANATOMY", 90, 99], ["nuclear", "ANATOMY", 128, 135], ["cytoplasm", "ORGANISM_SUBSTANCE", 90, 99], ["nuclear", "CELLULAR_COMPONENT", 128, 135], ["viral sequences", "DNA", 67, 82], ["nuclear proteins", "PROTEIN", 128, 144], ["viral sequences", "PROBLEM", 67, 82], ["large", "OBSERVATION_MODIFIER", 47, 52], ["quantities", "OBSERVATION_MODIFIER", 53, 63], ["viral", "OBSERVATION", 67, 72], ["redistribution", "OBSERVATION_MODIFIER", 110, 124], ["nuclear proteins", "OBSERVATION", 128, 144]]], ["Another possibility is that viral RNA replication itself induces this release, as this phenomenon is coupled to the rearrangement of intracellular membranes (Kujala et al., 2001; Miller and Krijnse\u2010Locker, 2008).", [["intracellular membranes", "ANATOMY", 133, 156], ["intracellular membranes", "CELLULAR_COMPONENT", 133, 156], ["viral RNA replication", "PROBLEM", 28, 49], ["this phenomenon", "PROBLEM", 82, 97], ["viral RNA replication", "OBSERVATION", 28, 49], ["intracellular membranes", "ANATOMY", 133, 156]]], ["This rearrangement can distort the shuttling of proteins between the nucleus and the cytoplasm.", [["nucleus", "ANATOMY", 69, 76], ["cytoplasm", "ANATOMY", 85, 94], ["nucleus", "CELLULAR_COMPONENT", 69, 76], ["cytoplasm", "ORGANISM_SUBSTANCE", 85, 94], ["nucleus", "ANATOMY", 69, 76], ["cytoplasm", "OBSERVATION_MODIFIER", 85, 94]]], ["In the case of alphaviruses, the replication complexes are associated with newly formed membranous structures named spherules (Kujala et al., 2001; Spuul et al., 2011).", [["membranous structures", "ANATOMY", 88, 109], ["spherules", "ANATOMY", 116, 125], ["membranous structures", "TISSUE", 88, 109], ["spherules", "CELLULAR_COMPONENT", 116, 125], ["replication complexes", "PROTEIN", 33, 54], ["alphaviruses", "PROBLEM", 15, 27], ["newly formed membranous structures", "PROBLEM", 75, 109], ["alphaviruses", "OBSERVATION", 15, 27], ["membranous", "OBSERVATION", 88, 98], ["spherules", "OBSERVATION_MODIFIER", 116, 125]]], ["These spherules are connected to the cytoplasm by a narrow neck, through which the synthesized viral RNAs can be delivered.", [["spherules", "ANATOMY", 6, 15], ["cytoplasm", "ANATOMY", 37, 46], ["neck", "ANATOMY", 59, 63], ["spherules", "CELLULAR_COMPONENT", 6, 15], ["cytoplasm", "ORGANISM_SUBSTANCE", 37, 46], ["neck", "ORGAN", 59, 63], ["viral RNAs", "RNA", 95, 105], ["a narrow neck", "PROBLEM", 50, 63], ["the synthesized viral RNAs", "TREATMENT", 79, 105], ["spherules", "OBSERVATION", 6, 15], ["cytoplasm", "OBSERVATION_MODIFIER", 37, 46], ["narrow", "OBSERVATION_MODIFIER", 52, 58], ["neck", "ANATOMY", 59, 63], ["viral RNAs", "OBSERVATION", 95, 105]]], ["Expression of SFV nsPs in the absence of RNA replication does not induce formation of these structures.", [["SFV", "ORGANISM", 14, 17], ["nsPs", "GENE_OR_GENE_PRODUCT", 18, 22], ["SFV nsPs", "PROTEIN", 14, 22], ["SFV", "SPECIES", 14, 17], ["SFV nsPs", "PROBLEM", 14, 22], ["RNA replication", "PROBLEM", 41, 56], ["SFV nsPs", "OBSERVATION", 14, 22], ["RNA replication", "OBSERVATION", 41, 56]]], ["Indeed, the size of these spherules is dependent on the length of the replicative viral RNA (Kallio et al., 2013).", [["spherules", "ANATOMY", 26, 35], ["replicative viral RNA", "RNA", 70, 91], ["these spherules", "PROBLEM", 20, 35], ["size", "OBSERVATION_MODIFIER", 12, 16], ["spherules", "OBSERVATION", 26, 35], ["dependent", "OBSERVATION_MODIFIER", 39, 48], ["length", "OBSERVATION_MODIFIER", 56, 62], ["replicative", "OBSERVATION_MODIFIER", 70, 81], ["viral RNA", "OBSERVATION", 82, 91]]], ["If the shut\u2010off of cellular protein synthesis is due to the increase of nuclear proteins in the cytoplasm, a number of new questions arise: (i) which nuclear proteins are able to block cellular mRNA translation?; (ii) why is this inhibition selective for cellular versus viral mRNA?; (iii) what is the molecular mechanism that triggers the release of nuclear proteins?; and (iv) is the presence of a specific viral RNA sequence responsible for this inhibition?", [["cellular", "ANATOMY", 19, 27], ["nuclear", "ANATOMY", 72, 79], ["cytoplasm", "ANATOMY", 96, 105], ["nuclear", "ANATOMY", 150, 157], ["cellular", "ANATOMY", 185, 193], ["cellular", "ANATOMY", 255, 263], ["nuclear", "ANATOMY", 351, 358], ["cellular", "CELL", 19, 27], ["nuclear", "CELLULAR_COMPONENT", 72, 79], ["cytoplasm", "ORGANISM_SUBSTANCE", 96, 105], ["nuclear", "CELLULAR_COMPONENT", 150, 157], ["cellular", "CELL", 185, 193], ["cellular", "CELL", 255, 263], ["nuclear", "CELLULAR_COMPONENT", 351, 358], ["nuclear proteins", "PROTEIN", 72, 88], ["nuclear proteins", "PROTEIN", 150, 166], ["cellular mRNA", "RNA", 185, 198], ["viral mRNA", "RNA", 271, 281], ["nuclear proteins", "PROTEIN", 351, 367], ["viral RNA sequence", "DNA", 409, 427], ["cellular protein synthesis", "PROBLEM", 19, 45], ["the increase of nuclear proteins in the cytoplasm", "PROBLEM", 56, 105], ["cellular versus viral mRNA", "PROBLEM", 255, 281], ["a specific viral RNA sequence", "PROBLEM", 398, 427], ["this inhibition", "PROBLEM", 444, 459]]], ["Although the inhibition of host mRNA translation can take place by redundant mechanisms, such as redistribution of nuclear proteins, modification of eIFs, ionic imbalance or mRNA competition, it is possible that one of the most important factors to explain this event is the re\u2010localization of nuclear proteins.", [["nuclear", "ANATOMY", 115, 122], ["nuclear", "ANATOMY", 294, 301], ["nuclear", "CELLULAR_COMPONENT", 115, 122], ["eIFs", "GENE_OR_GENE_PRODUCT", 149, 153], ["nuclear", "CELLULAR_COMPONENT", 294, 301], ["nuclear proteins", "PROTEIN", 115, 131], ["eIFs", "PROTEIN", 149, 153], ["nuclear proteins", "PROTEIN", 294, 310], ["host mRNA translation", "TREATMENT", 27, 48], ["nuclear proteins", "PROBLEM", 115, 131], ["eIFs", "TREATMENT", 149, 153], ["ionic imbalance", "PROBLEM", 155, 170], ["mRNA competition", "PROBLEM", 174, 190], ["nuclear proteins", "PROBLEM", 294, 310], ["nuclear proteins", "OBSERVATION", 115, 131]]], ["Future work along this line will provide insight into the molecular mechanisms employed by alphaviruses and other animal viruses to interfere with cellular functions and with innate antiviral responses.Cell lines and viruses ::: Experimental proceduresBaby hamster kidney (BHK\u201021, and clone BSR\u2010T7/5 designated as BHK\u2010T7) cells (Buchholz et al., 1999) or MEFs derived from PKR\u2212/\u2212 mice (Yang et al., 1995) were used to perform the experiments.", [["cellular", "ANATOMY", 147, 155], ["Cell lines", "ANATOMY", 202, 212], ["kidney", "ANATOMY", 265, 271], ["BHK\u201021", "ANATOMY", 273, 279], ["BHK\u2010T7) cells", "ANATOMY", 314, 327], ["MEFs", "ANATOMY", 355, 359], ["cellular", "CELL", 147, 155], ["Cell lines", "CELL", 202, 212], ["hamster", "ORGANISM", 257, 264], ["kidney", "ORGAN", 265, 271], ["BHK\u201021", "CELL", 273, 279], ["clone", "CELL", 285, 290], ["BHK\u2010T7", "CELL", 314, 320], ["cells", "CELL", 322, 327], ["MEFs", "CELL", 355, 359], ["PKR", "GENE_OR_GENE_PRODUCT", 373, 376], ["BHK\u201021", "CELL_LINE", 273, 279], ["clone BSR", "CELL_LINE", 285, 294], ["T7", "DNA", 295, 297], ["BHK\u2010T7) cells", "CELL_LINE", 314, 327], ["PKR", "PROTEIN", 373, 376], ["hamster", "SPECIES", 257, 264], ["mice", "SPECIES", 380, 384], ["hamster", "SPECIES", 257, 264], ["this line", "TREATMENT", 18, 27], ["alphaviruses", "PROBLEM", 91, 103], ["Experimental procedures", "TREATMENT", 229, 252], ["T7", "TEST", 295, 297], ["MEFs", "PROBLEM", 355, 359], ["viruses", "OBSERVATION", 217, 224], ["kidney", "ANATOMY", 265, 271]]], ["Sindbis virus stock was prepared from a pT7 SVwt infective cDNA clone (where wt is wild type; Sanz and Carrasco, 2001).", [["Sindbis virus", "ORGANISM", 0, 13], ["pT7 SVwt infective cDNA clone", "DNA", 40, 69], ["Sindbis virus", "SPECIES", 0, 13], ["Sindbis virus", "SPECIES", 0, 13], ["Sindbis virus stock", "TREATMENT", 0, 19], ["a pT7 SVwt infective cDNA clone", "PROBLEM", 38, 69]]], ["Viral infections were carried out in Dulbecco's modified Eagle's medium (DMEM) without serum for 60 min to permit virus attachment.", [["serum", "ANATOMY", 87, 92], ["Viral infections", "DISEASE", 0, 16], ["Viral", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["Viral infections", "PROBLEM", 0, 16], ["serum", "TEST", 87, 92], ["infections", "OBSERVATION", 6, 16]]], ["This medium was then removed and infection continued in DMEM with 10% fetal calf serum.Plasmids and recombinant DNA procedures ::: Experimental procedurespT7 SVwt was used as the parental plasmid for all constructs. pT7\u2010rep C+Luc, pT7\u2010rep C+luc(\u0394nsPs) and pT7\u2010rep\u201026S (Sanz et al., 2007), pTM1\u20102A (Ventoso et al., 1998) and pTM1\u20102C (Aldabe et al., 1996) have been described.", [["fetal calf serum", "ANATOMY", 70, 86], ["plasmid", "ANATOMY", 188, 195], ["infection", "DISEASE", 33, 42], ["fetal calf", "ORGANISM_SUBSTANCE", 70, 80], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["pT7\u2010rep C", "GENE_OR_GENE_PRODUCT", 216, 225], ["pT7\u2010rep C+luc", "GENE_OR_GENE_PRODUCT", 231, 244], ["procedurespT7 SVwt", "DNA", 144, 162], ["parental plasmid", "DNA", 179, 195], ["pT7\u2010rep C", "PROTEIN", 216, 225], ["Luc", "PROTEIN", 226, 229], ["pT7\u2010rep C+luc", "PROTEIN", 231, 244], ["\u0394nsPs", "PROTEIN", 245, 250], ["calf", "SPECIES", 76, 80], ["infection", "PROBLEM", 33, 42], ["10% fetal calf serum", "TEST", 66, 86], ["Experimental procedurespT7 SVwt", "TREATMENT", 131, 162], ["the parental plasmid", "TREATMENT", 175, 195], ["infection", "OBSERVATION", 33, 42], ["calf", "ANATOMY", 76, 80]]], ["Plasmids pTM1\u2010nsP1, pTM1\u2010nsP2 and pTM1\u2010nsP3 were constructed by inserting the corresponding polymerase chain reaction (PCR)\u2010generated nsP sequences into the pTM1 plasmid.", [["plasmid", "ANATOMY", 162, 169], ["pTM1\u2010nsP1", "GENE_OR_GENE_PRODUCT", 9, 18], ["pTM1\u2010nsP2", "GENE_OR_GENE_PRODUCT", 20, 29], ["pTM1\u2010nsP3", "GENE_OR_GENE_PRODUCT", 34, 43], ["pTM1", "GENE_OR_GENE_PRODUCT", 157, 161], ["pTM1\u2010nsP1", "DNA", 9, 18], ["pTM1\u2010nsP2", "DNA", 20, 29], ["pTM1\u2010nsP3", "DNA", 34, 43], ["nsP sequences", "DNA", 134, 147], ["pTM1 plasmid", "DNA", 157, 169], ["Plasmids pTM1\u2010nsP1", "TREATMENT", 0, 18], ["pTM1\u2010nsP2", "TEST", 20, 29], ["pTM1\u2010nsP3", "TREATMENT", 34, 43], ["PCR", "TEST", 119, 122], ["the pTM1 plasmid", "TREATMENT", 153, 169]]], ["Thus, the nsP1 PCR product was digested with Nco I and Bam HI, the nsP2 PCR product was partially digested with Nco I and completely with Bam HI, and the nsP3 PCR product was partially digested with Nco I and completely with Xba I. Digested products were cloned into the corresponding sites of pTM1. pTM1\u2010nsP1\u20104 was constructed by inserting the Eco 47III/Xho I fragment obtained from pT7\u2010rep\u201026S into the corresponding sites of pTM1\u2010nsP1.Oligonucleotides ::: Experimental proceduresOligonucleotides for PCR amplification were 5\u2032Nco\u2010nsp1 cgcgcgccatggagaagccagtagtaaac; 3\u2032Bam\u2010nsp1 gctgagggatcctatgctccgatgtccgcctg; 5\u2032Nco\u2010nsp2 gcgcgcccatggcattagttgaaaccccg; 3\u2032Bam\u2010nsp2 ctgcagggatccttaggctccaactccatctcttg; 5\u2032Nco\u2010nsp3 cgcgcgccatggcgccgtcataccgcacc; 3\u2032Xba\u2010nsp3 ctgcagtcttagattatcagtattcagtcctcctgc.", [["nsP1", "GENE_OR_GENE_PRODUCT", 10, 14], ["Nco I", "GENE_OR_GENE_PRODUCT", 45, 50], ["Bam HI", "GENE_OR_GENE_PRODUCT", 55, 61], ["nsP2", "GENE_OR_GENE_PRODUCT", 67, 71], ["Nco I", "GENE_OR_GENE_PRODUCT", 112, 117], ["Bam HI", "GENE_OR_GENE_PRODUCT", 138, 144], ["nsP3", "GENE_OR_GENE_PRODUCT", 154, 158], ["Nco I", "GENE_OR_GENE_PRODUCT", 199, 204], ["Xba", "GENE_OR_GENE_PRODUCT", 225, 228], ["pTM1", "GENE_OR_GENE_PRODUCT", 294, 298], ["pTM1\u2010nsP1\u20104", "GENE_OR_GENE_PRODUCT", 300, 311], ["Eco 47III", "GENE_OR_GENE_PRODUCT", 345, 354], ["Xho I", "GENE_OR_GENE_PRODUCT", 355, 360], ["pT7\u2010rep\u201026S", "GENE_OR_GENE_PRODUCT", 384, 395], ["pTM1\u2010nsP1", "GENE_OR_GENE_PRODUCT", 428, 437], ["nsP1 PCR product", "PROTEIN", 10, 26], ["Nco I", "PROTEIN", 45, 50], ["nsP2 PCR product", "PROTEIN", 67, 83], ["Nco I", "PROTEIN", 112, 117], ["Bam HI", "DNA", 138, 144], ["nsP3 PCR product", "PROTEIN", 154, 170], ["Nco I", "PROTEIN", 199, 204], ["Xba I. Digested products", "PROTEIN", 225, 249], ["pTM1", "DNA", 294, 298], ["pTM1\u2010nsP1\u20104", "DNA", 300, 311], ["Eco 47III/Xho I fragment", "DNA", 345, 369], ["pT7\u2010rep\u201026S", "DNA", 384, 395], ["pTM1\u2010nsP1", "DNA", 428, 437], ["Nco\u2010nsp3 cgcgcgccatggcgccgtcataccgcacc; 3\u2032Xba\u2010nsp3 ctgcagtcttagattatcagtattcagtcctcctgc", "PROTEIN", 705, 792], ["the nsP1 PCR", "TEST", 6, 18], ["the nsP2 PCR", "TEST", 63, 75], ["Bam HI", "TREATMENT", 138, 144], ["the nsP3 PCR", "TEST", 150, 162], ["Xba I. Digested products", "TREATMENT", 225, 249], ["the Eco 47III/Xho I fragment", "TREATMENT", 341, 369], ["Experimental proceduresOligonucleotides", "TREATMENT", 459, 498], ["PCR amplification", "TREATMENT", 503, 520], ["Nco\u2010nsp1 cgcgcgccatggagaagccagtagtaaac", "TREATMENT", 528, 566], ["Nco\u2010nsp2 gcgcgcccatggcattagttgaaaccccg", "TREATMENT", 615, 653], ["Nco\u2010nsp3 cgcgcgccatggcgccgtcataccgcacc", "TREATMENT", 705, 743]]]], "c67af56a3a797e645b80a1d9fcd4a6e923c48cdd": [["IntroductionTo date, SARS-CoV-2 has infected several millions and COVID-19 has killed hundreds of thousands around the globe.", [["SARS", "DISEASE", 21, 25], ["SARS-CoV-2", "ORGANISM", 21, 31], ["SARS-CoV", "SPECIES", 21, 29], ["COVID", "TEST", 66, 71], ["infected", "OBSERVATION_MODIFIER", 36, 44], ["several", "OBSERVATION_MODIFIER", 45, 52], ["millions", "OBSERVATION", 53, 61], ["globe", "ANATOMY", 119, 124]]], ["Its long incubation time calls for fast, accurate, and reliable techniques for early disease diagnosis to successfully fight the spread [29] .", [["early disease diagnosis", "PROBLEM", 79, 102]]], ["The standard genetic test (RT-PCR), suffers from a processing time of up to 2 days [33] , several publications reported sensitivity as low as 70% [2, 25] and a recent meta-analysis estimated the false negative rate to be at least 20% over the course of the infection [26] .", [["infection", "DISEASE", 257, 266], ["The standard genetic test", "TEST", 0, 25], ["(RT-PCR", "TREATMENT", 26, 33], ["sensitivity", "TEST", 120, 131], ["a recent meta-analysis", "TEST", 158, 180], ["the infection", "PROBLEM", 253, 266], ["false negative", "OBSERVATION", 195, 209], ["infection", "OBSERVATION", 257, 266]]], ["Medical imaging has great potential to complement the diagnostic process as a fast assessment tool that guides further PCR-testing, especially in triage situations [16] .", [["Medical imaging", "TEST", 0, 15], ["a fast assessment tool", "TEST", 76, 98], ["further PCR", "TEST", 111, 122]]], ["Currently, CT scans are the gold standard for pneumonia [8] and are considered relatively reliable for COVID-19 diagnosis [2, 5, 18] , although a significant amount of patients exhibit normal CT scans [52] .", [["pneumonia", "DISEASE", 46, 55], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["CT scans", "TEST", 11, 19], ["pneumonia", "PROBLEM", 46, 55], ["COVID", "TEST", 103, 108], ["pneumonia", "OBSERVATION", 46, 55], ["significant", "OBSERVATION_MODIFIER", 146, 157], ["amount", "OBSERVATION_MODIFIER", 158, 164]]], ["However, performing CT is expensive and highly irradiating, posing risks of infection for patients and staff, requires extensive sterilization [34] , and is reserved for developed countries; there are only \u223c30k CT scanner globally [13] .", [["infection", "DISEASE", 76, 85], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["performing CT", "TEST", 9, 22], ["infection", "PROBLEM", 76, 85], ["extensive sterilization", "TREATMENT", 119, 142], ["infection", "OBSERVATION", 76, 85]]], ["Chest X-ray (CXR) scans are still the first line examination, despite some reports of low specificity and sensitivity for COVID-19 (for example, Weinstock et al. [51] found 89% normal CXR in 493 COVID-19 patients).", [["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["Chest X-ray", "TEST", 0, 11], ["CXR) scans", "TEST", 13, 23], ["the first line examination", "TEST", 34, 60], ["low specificity", "PROBLEM", 86, 101], ["COVID", "TEST", 122, 127], ["CXR", "TEST", 184, 187], ["COVID", "TEST", 195, 200]]], ["Ultrasound (US), by contrast, is a cheap, safe, non-invasive and repeatable technique that can be performed with portable devices at patient bedside and is ubiquitously available around the globe.", [["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["Ultrasound (US)", "TEST", 0, 15], ["repeatable technique", "TEST", 65, 85], ["portable devices at patient bedside", "TEST", 113, 148], ["globe", "ANATOMY", 190, 195]]], ["Over the last two decades, ultrasound became an established tool to diagnose pulmonary diseases [14, 30, 36] , has been forecast to replace radiographic techniques [9] , was demonstrated to be superior to CXR for pulmonary diseases [15, 38] , and started to replace X-Ray as first-line examination [1, 10] .IntroductionIn the COVID-19 outbreak, a growing body of evidence for disease-specific patterns in US (e.g. B-lines and subpleural consolidations) has led to advocacy for an amplified role of US from the research community [11, 27, 44, 46] and radiologists reported great agreement between US and CT findings for COVID-19 infections [19, 37] .", [["pulmonary", "ANATOMY", 77, 86], ["pulmonary", "ANATOMY", 213, 222], ["subpleural", "ANATOMY", 426, 436], ["pulmonary diseases", "DISEASE", 77, 95], ["pulmonary diseases", "DISEASE", 213, 231], ["infections", "DISEASE", 628, 638], ["pulmonary", "ORGAN", 77, 86], ["pulmonary", "ORGAN", 213, 222], ["B-lines", "CELL", 414, 421], ["subpleural", "MULTI-TISSUE_STRUCTURE", 426, 436], ["ultrasound", "TEST", 27, 37], ["diagnose pulmonary diseases", "PROBLEM", 68, 95], ["radiographic techniques", "TEST", 140, 163], ["CXR", "TEST", 205, 208], ["pulmonary diseases", "PROBLEM", 213, 231], ["first-line examination", "TEST", 275, 297], ["disease", "PROBLEM", 376, 383], ["US", "TEST", 405, 407], ["B-lines", "TREATMENT", 414, 421], ["subpleural consolidations", "PROBLEM", 426, 451], ["US", "TEST", 596, 598], ["CT findings", "TEST", 603, 614], ["COVID", "TEST", 619, 624], ["pulmonary", "ANATOMY", 77, 86], ["diseases", "OBSERVATION", 87, 95], ["pulmonary", "ANATOMY", 213, 222], ["diseases", "OBSERVATION", 223, 231], ["evidence for", "UNCERTAINTY", 363, 375], ["disease", "OBSERVATION", 376, 383], ["subpleural", "ANATOMY", 426, 436], ["consolidations", "OBSERVATION", 437, 451]]], ["Moreover, in triage situations or in third-world countries, where CT, PCR and CXR are not available, US was demonstrated to be a valuable patient stratification technique for pneumonia [3, 17] .", [["pneumonia", "DISEASE", 175, 184], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["CT", "TEST", 66, 68], ["PCR", "TEST", 70, 73], ["CXR", "TEST", 78, 81], ["US", "TEST", 101, 103], ["pneumonia", "PROBLEM", 175, 184], ["pneumonia", "OBSERVATION", 175, 184]]], ["This gives US, in contrast to other imaging techniques, the potential to become a globally applicable first-line examination method [45] .", [["other imaging techniques", "TEST", 30, 54]]], ["However, the relevant pattern are hard to discern for humans [35, 47] , calling into play medical image analysis based on machine learning technique as a decision support tool for physicians.", [["humans", "ORGANISM", 54, 60], ["humans", "SPECIES", 54, 60], ["humans", "SPECIES", 54, 60]]], ["Here, we provide the first study of automatic lung ultrasound analysis for differential diagnosis of bacterial and viral pneumonia; aiming to develop a medical decision support tool.IntroductionRelated work.", [["lung", "ANATOMY", 46, 50], ["bacterial and viral pneumonia", "DISEASE", 101, 130], ["lung", "ORGAN", 46, 50], ["the first study", "TEST", 17, 32], ["automatic lung ultrasound analysis", "TEST", 36, 70], ["bacterial and viral pneumonia", "PROBLEM", 101, 130], ["lung", "ANATOMY", 46, 50], ["bacterial", "OBSERVATION_MODIFIER", 101, 110], ["viral", "OBSERVATION_MODIFIER", 115, 120], ["pneumonia", "OBSERVATION", 121, 130]]], ["Literature on exploiting medical image analysis and computer vision techniques to classify or segment CT or CXR data of COVID-19 patients recently exploded (for reviews, see Shi et al. [42] , Ulhaq et al. [48] , for a list of public data sources see Kalkreuth and Kaufmann [24] ).", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["medical image analysis", "TEST", 25, 47], ["computer vision techniques", "TEST", 52, 78], ["segment CT", "TEST", 94, 104], ["CXR data", "TEST", 108, 116], ["COVID", "TEST", 120, 125]]], ["For example, in an early study, Butt et al. [12] reported a sensitivity of 98% (specificity 92%) in a binary classification on CT scans from 110 COVID-19 patients, while Mei et al. [33] very recently achieved equal sensitivity (but lower specificity) compared to senior radiologists in detecting COVID-19 from CT and clinical information of 279 patients.", [["patients", "ORGANISM", 154, 162], ["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 345, 353], ["an early study", "TEST", 16, 30], ["a sensitivity", "TEST", 58, 71], ["specificity", "TEST", 80, 91], ["CT scans", "TEST", 127, 135], ["COVID", "TEST", 145, 150], ["COVID", "TEST", 296, 301], ["CT", "TEST", 310, 312]]], ["US instead has been neglected heavily by the ML community [6] ; only the Italian COVID-19 Lung Ultrasound (ICLUS) project has proposed a deep learning approach for a severity assessment of COVID-19 from ultrasound data [39] .", [["Lung", "ANATOMY", 90, 94], ["US", "TEST", 0, 2], ["the Italian COVID", "TEST", 69, 86], ["Lung Ultrasound", "TEST", 90, 105], ["a deep learning approach", "TREATMENT", 135, 159], ["a severity assessment", "TEST", 164, 185], ["COVID", "TEST", 189, 194], ["ultrasound data", "TEST", 203, 218], ["Lung", "ANATOMY", 90, 94]]], ["The work convincingly predicts disease severity and segments COVID-19 specific patterns, building up on their previous work on localizing B-lines [49] .", [["B-lines", "ANATOMY", 138, 145], ["B-lines", "CELL", 138, 145], ["B-lines", "CELL_LINE", 138, 145], ["disease severity", "PROBLEM", 31, 47], ["segments COVID", "TEST", 52, 66], ["localizing B-lines", "TREATMENT", 127, 145]]], ["The paper claims to release a dataset of annotated COVID-19 cases, but to date, no annotations are available.", [["COVID", "DNA", 51, 56], ["annotated COVID", "TEST", 41, 56]]], ["While this effort is highly relevant for disease monitoring, it is not directly applicable for first-line diagnosis, where the main problem lies in distinguishing COVID-19 from other pneumonia.", [["pneumonia", "DISEASE", 183, 192], ["disease monitoring", "TEST", 41, 59], ["COVID", "TEST", 163, 168], ["other pneumonia", "PROBLEM", 177, 192], ["main", "OBSERVATION_MODIFIER", 127, 131], ["pneumonia", "OBSERVATION", 183, 192]]], ["We aim to close this gap with our approach to classify COVID-19, healthy, and pneumonia point-of-care ultrasound (POCUS) images.IntroductionOur contributions.", [["pneumonia", "DISEASE", 78, 87], ["COVID", "TEST", 55, 60], ["pneumonia point", "TEST", 78, 93], ["ultrasound", "TEST", 102, 112], ["POCUS) images", "TEST", 114, 127], ["pneumonia", "OBSERVATION", 78, 87]]], ["We provide the largest publicly-available dataset of lung US recordings consisting of 106 videos.", [["lung", "ANATOMY", 53, 57], ["lung", "ORGAN", 53, 57], ["lung US recordings", "TEST", 53, 71], ["lung", "ANATOMY", 53, 57]]], ["This dataset is heterogeneous and mostly from public sources, but was curated manually and approved by a medical doctor.", [["heterogeneous", "OBSERVATION_MODIFIER", 16, 29]]], ["We further take a first step towards a tool for differential diagnosis of pulmonary diseases, here especially focused on bacterial and viral pneumonia such as COVID-19.", [["pulmonary", "ANATOMY", 74, 83], ["pulmonary diseases", "DISEASE", 74, 92], ["pneumonia", "DISEASE", 141, 150], ["pulmonary", "ORGAN", 74, 83], ["pulmonary diseases", "PROBLEM", 74, 92], ["bacterial and viral pneumonia", "PROBLEM", 121, 150], ["COVID", "TEST", 159, 164], ["pulmonary", "ANATOMY", 74, 83], ["diseases", "OBSERVATION", 84, 92], ["viral", "OBSERVATION_MODIFIER", 135, 140], ["pneumonia", "OBSERVATION", 141, 150]]], ["Without deprivation of novelty, we here demonstrate that competitive performance can be achieved from raw US recordings, thereby challenging the current focus on irradiating imagining techniques.", [["raw US recordings", "TEST", 102, 119], ["irradiating imagining techniques", "TREATMENT", 162, 194]]], ["Moreover, we employ explainability techniques such as class activation maps or uncertainty estimates and present a roadmap towards an automatic detection system that can segment and highlight relevant spatio-temporal patterns.", [["class activation maps", "TREATMENT", 54, 75], ["an automatic detection system", "TEST", 131, 160], ["temporal", "ANATOMY_MODIFIER", 208, 216]]], ["Such a system could not only lead to superior diagnostic performance, as was partially shown for CT [33] , but can also reduce the time doctors require to make a diagnosis [41] .", [["CT", "TEST", 97, 99]]], ["Our approach is of evident need because physicians must be trained thoroughly to reliably differentiate COVID-19 from pneumonia [35] , making it necessary to use powerful deep learning to develop a system that can complement the work of physicians in a timely manner.A lung ultrasound dataset for COVID-19 detectionWe provide the to-date largest pre-processed and publicly available lung POCUS dataset 1 , comprising samples of COVID-19 patients, pneumonia-infected lungs and healthy patients.", [["lung", "ANATOMY", 269, 273], ["lung", "ANATOMY", 383, 387], ["samples", "ANATOMY", 417, 424], ["lungs", "ANATOMY", 466, 471], ["pneumonia", "DISEASE", 118, 127], ["pneumonia-infected lungs", "DISEASE", 447, 471], ["lung", "ORGAN", 269, 273], ["lung", "ORGAN", 383, 387], ["patients", "ORGANISM", 437, 445], ["lungs", "ORGAN", 466, 471], ["patients", "ORGANISM", 484, 492], ["COVID-19", "DNA", 297, 305], ["patients", "SPECIES", 437, 445], ["patients", "SPECIES", 484, 492], ["COVID", "TEST", 104, 109], ["pneumonia", "PROBLEM", 118, 127], ["A lung ultrasound dataset", "TEST", 267, 292], ["COVID", "TEST", 297, 302], ["COVID", "TEST", 428, 433], ["pneumonia", "PROBLEM", 447, 456], ["pneumonia", "OBSERVATION", 118, 127], ["lung", "ANATOMY", 269, 273], ["lung", "ANATOMY", 383, 387], ["pneumonia", "OBSERVATION", 447, 456], ["infected", "OBSERVATION", 457, 465], ["lungs", "ANATOMY", 466, 471]]], ["As shown in Table 1 , we collected and gathered 139 recordings (106 videos + 33 images) recorded with either convex or linear probes, where the latter is a higher frequency probe yielding more superficial images.", [["videos + 33 images", "TEST", 68, 86]]], ["3 Differential diagnosis of COVID-19 with lung ultrasound 3.1 Experimental setup Data processing.", [["lung", "ANATOMY", 42, 46], ["lung", "ORGAN", 42, 46], ["COVID-19", "DNA", 28, 36], ["COVID", "TEST", 28, 33], ["lung ultrasound", "TEST", 42, 57], ["lung", "ANATOMY", 42, 46]]], ["All experiments are conducted on data recorded with convex ultrasound probes, the standard probe for lung assessment that allows to see deeply into the lung [31] .", [["lung", "ANATOMY", 101, 105], ["lung", "ANATOMY", 152, 156], ["lung", "ORGAN", 101, 105], ["lung", "ORGAN", 152, 156], ["convex ultrasound probes", "TEST", 52, 76], ["the standard probe", "TREATMENT", 78, 96], ["lung assessment", "TEST", 101, 116], ["lung", "ANATOMY", 101, 105], ["lung", "ANATOMY", 152, 156]]], ["We manually processed all convex ultrasound recordings and split them into images at a frame rate of 3Hz (with maximal 30 frames per video), leading to a database of 693 COVID-19, 377 bacterial pneumonia, and 295 healthy control images.", [["pneumonia", "DISEASE", 194, 203], ["all convex ultrasound recordings", "TEST", 22, 54], ["a frame rate", "TEST", 85, 97], ["a database", "TEST", 152, 162], ["COVID", "TEST", 170, 175], ["bacterial pneumonia", "PROBLEM", 184, 203], ["healthy control images", "TEST", 213, 235], ["bacterial", "OBSERVATION_MODIFIER", 184, 193], ["pneumonia", "OBSERVATION", 194, 203]]], ["All images were cropped to a quadratic window excluding measure bars and texts and artifacts on the borders before they were resized to 224 \u00d7 224 pixels.", [["All images", "TEST", 0, 10], ["a quadratic window", "TEST", 27, 45]]], ["Apart from the independent test data, all reported results were obtained in a 5-fold stratified cross validation.", [["the independent test data", "TEST", 11, 36]]], ["It was ensured that the frames of a single video are present within a single fold only, and that the number of samples per class is similar in all folds.", [["a single video", "TEST", 34, 48]]], ["All models were trained to classify images as COVID-19, pneumonia, healthy, or uninformative.", [["pneumonia", "DISEASE", 56, 65], ["images", "TEST", 36, 42], ["COVID", "TEST", 46, 51], ["pneumonia", "PROBLEM", 56, 65], ["pneumonia", "OBSERVATION", 56, 65]]], ["The latter consists of ImageNet pictures as well as neck ultraosund data; we added these picture for the purpose of detecting out-of-distribution data (thus making the model more robust).", [["neck", "ANATOMY", 52, 56], ["ImageNet pictures", "TEST", 23, 40], ["neck ultraosund data", "TEST", 52, 72], ["neck", "ANATOMY", 52, 56]]], ["In this paper, we present all results omitting the uninformative class, as it is not relevant for the analysis of differential diagnosis performance and would bias the results (please refer to appendix A.4.1 for results including uninformative data).", [["uninformative data", "TEST", 230, 248]]], ["Furthermore, we use data augmentation techniques (horizontal and vertical flips, rotations up to 10 \u2022 and translations of up to 10%) to diversify the dataset and prevent overfitting.A lung ultrasound dataset for COVID-19 detectionFrame-based models.", [["lung", "ANATOMY", 184, 188], ["lung", "ORGAN", 184, 188], ["COVID-19 detectionFrame", "DNA", 212, 235], ["data augmentation techniques", "TREATMENT", 20, 48], ["horizontal and vertical flips", "TREATMENT", 50, 79], ["overfitting", "PROBLEM", 170, 181], ["A lung ultrasound dataset", "TEST", 182, 207], ["COVID", "TEST", 212, 217], ["overfitting", "OBSERVATION", 170, 181], ["lung", "ANATOMY", 184, 188]]], ["Our backbone neural architecture is a VGG-16 [43] that is compared to NasNET Mobile, a light-weight alternative [55] that uses less than 1 /3 of the parameters of VGG and was optimized for applications on portable devices.", [["neural", "ANATOMY", 13, 19], ["VGG-16", "CHEMICAL", 38, 44], ["VGG", "SIMPLE_CHEMICAL", 163, 166], ["a VGG", "TEST", 36, 41], ["portable devices", "TEST", 205, 221], ["backbone", "ANATOMY_MODIFIER", 4, 12], ["neural architecture", "ANATOMY", 13, 32]]], ["Both models are pre-trained on Imagenet and fine-tuned on the frames sampled from the videos.", [["Imagenet", "TREATMENT", 31, 39]]], ["Specifically, we use two variants of VGG-16 that we name VGG and VGG-CAM.", [["VGG", "GENE_OR_GENE_PRODUCT", 57, 60], ["VGG-CAM", "GENE_OR_GENE_PRODUCT", 65, 72], ["VGG-16", "DNA", 37, 43], ["VGG", "PROTEIN", 57, 60], ["VGG", "PROTEIN", 65, 68], ["VGG", "TEST", 37, 40]]], ["VGG-CAM has a single dense layer following the convolutions, thus enabling the usage of plain CAMs, class activation maps [53] , whereas VGG has an additional dense layer with ReLU activation and batch normalization.A lung ultrasound dataset for COVID-19 detectionConsidering the recent work of Roy et al. [39] on lung US segmentation and severity prediction for COVID-19, we investigated whether a segmentation-targeted network can also add value to the prediction in differential diagnosis.", [["lung", "ANATOMY", 218, 222], ["lung", "ANATOMY", 314, 318], ["VGG", "CHEMICAL", 0, 3], ["CAM", "MULTI-TISSUE_STRUCTURE", 4, 7], ["VGG", "SIMPLE_CHEMICAL", 137, 140], ["lung", "ORGAN", 218, 222], ["lung", "ORGAN", 314, 318], ["VGG", "PROTEIN", 0, 3], ["plain CAMs", "PROTEIN", 88, 98], ["VGG", "PROTEIN", 137, 140], ["COVID-19", "DNA", 246, 254], ["COVID-19", "DNA", 363, 371], ["plain CAMs", "TREATMENT", 88, 98], ["class activation maps", "TEST", 100, 121], ["ReLU activation", "TREATMENT", 176, 191], ["A lung ultrasound dataset", "TEST", 216, 241], ["COVID", "TEST", 246, 251], ["lung US segmentation", "TEST", 314, 334], ["severity prediction", "TEST", 339, 358], ["COVID", "TEST", 363, 368], ["dense", "OBSERVATION_MODIFIER", 21, 26], ["layer", "OBSERVATION_MODIFIER", 27, 32], ["dense", "OBSERVATION_MODIFIER", 159, 164], ["layer", "OBSERVATION_MODIFIER", 165, 170], ["lung", "ANATOMY", 218, 222], ["lung", "ANATOMY", 314, 318]]], ["We implemented two approaches building upon the pre-trained model of Roy et al. [39] , an ensemble of three separate U-Net-based models (U-Net, U-Net++, and DeepLabv3+, with a total of \u223c 19.5M parameters).", [["U", "TEST", 137, 138], ["U", "TEST", 144, 145], ["DeepLabv3", "TEST", 157, 166]]], ["First, VGG-Segment is identical to VGG, however instead of training on the raw US data, we train on the segmented images from the ensemble (see example in Appendix A.2).", [["VGG", "GENE_OR_GENE_PRODUCT", 7, 10], ["VGG", "CANCER", 35, 38], ["VGG", "PROTEIN", 7, 10], ["VGG", "DNA", 35, 38], ["the raw US data", "TEST", 71, 86], ["the segmented images", "TEST", 100, 120], ["Segment", "ANATOMY_MODIFIER", 11, 18], ["VGG", "OBSERVATION", 35, 38]]], ["Secondly, in Segment-Enc the bottleneck layer of each of the three models is used as a feature encoding of the images, resulting in 560 filter maps that are fed through two dense layers of size 512 and 256 respectively.", [["the images", "TEST", 107, 117], ["560 filter maps", "TREATMENT", 132, 147], ["Segment", "ANATOMY_MODIFIER", 13, 20], ["bottleneck", "OBSERVATION_MODIFIER", 29, 39], ["layer", "OBSERVATION_MODIFIER", 40, 45], ["560 filter", "OBSERVATION", 132, 142], ["two", "OBSERVATION_MODIFIER", 169, 172], ["dense", "OBSERVATION_MODIFIER", 173, 178], ["layers", "OBSERVATION_MODIFIER", 179, 185], ["size", "OBSERVATION_MODIFIER", 189, 193]]], ["Both settings are compared to the other models that directly utilize the raw images.", [["the raw images", "TEST", 69, 83]]], ["For more details on the architectures and the training procedure, please refer to appendix A.1.A lung ultrasound dataset for COVID-19 detectionVideo-based model.", [["lung", "ANATOMY", 97, 101], ["lung", "ORGAN", 97, 101], ["the training procedure", "TREATMENT", 42, 64], ["A lung ultrasound dataset", "TEST", 95, 120], ["COVID", "TEST", 125, 130], ["appendix", "ANATOMY", 82, 90], ["lung", "ANATOMY", 97, 101]]], ["In comparison to a na\u00efve, frame-based video classifier (obtained by averaging scores of all frames), we also investigate Models Genesis, a generic model for 3D medical image analysis pretrained on lung CT scans [54] .", [["lung", "ANATOMY", 197, 201], ["lung", "ORGAN", 197, 201], ["na\u00efve, frame", "DNA", 19, 31], ["3D medical image analysis", "TEST", 157, 182], ["lung CT scans", "TEST", 197, 210], ["lung", "ANATOMY", 197, 201]]], ["5-fold cross validation is performed using the same split as for frame-based classifiers.", [["fold cross validation", "TEST", 2, 23], ["frame-based classifiers", "TREATMENT", 65, 88]]], ["Individual images were excluded, leaving aside 86 videos (from which 10 were excluded due to too many frames with artifacts such as moving pointers) which were split into 292 video chunks.", [["Individual images", "TEST", 0, 17]]], ["Table 2 shows a detailed comparison of the three best models in terms of recall, precision, specificity and F1-scores, as well as MCC.", [["MCC", "CANCER", 130, 133]]], ["Overall, both VGG and VGG-CAM achieve promising performance with an accuracy of 90 \u00b1 2% and 90 \u00b1 5% respectively on a 5-fold CV of 1,365 frames.", [["CAM", "MULTI-TISSUE_STRUCTURE", 26, 29], ["an accuracy", "TEST", 65, 76]]], ["Concerning per-class prediction accuracies, it is evident that bacterial pneumonia infections are distinguished best, with recall, precision, and specificity above 0.93 for VGG and VGG-CAM, indicating the models' ability to recognize strong irregularities in lung images.", [["lung", "ANATOMY", 259, 263], ["pneumonia", "DISEASE", 73, 82], ["infections", "DISEASE", 83, 93], ["CAM", "MULTI-TISSUE_STRUCTURE", 185, 188], ["lung", "ORGAN", 259, 263], ["bacterial pneumonia infections", "PROBLEM", 63, 93], ["specificity", "TEST", 146, 157], ["VGG", "TEST", 173, 176], ["strong irregularities in lung images", "PROBLEM", 234, 270], ["bacterial", "OBSERVATION_MODIFIER", 63, 72], ["pneumonia", "OBSERVATION", 73, 82], ["strong", "OBSERVATION_MODIFIER", 234, 240], ["irregularities", "OBSERVATION", 241, 255], ["lung", "ANATOMY", 259, 263]]], ["Although VGG slightly outperforms VGG-CAM, we explored the latter more in detail, due to its higher sensitivity for COVID-19 and its better performance when taking into account the class activation maps.", [["VGG", "SIMPLE_CHEMICAL", 9, 12], ["VGG", "PROTEIN", 34, 37], ["COVID", "TEST", 116, 121]]], ["Figure 2a visualizes the results of the VGG-CAM model for each binary detection task as a ROC curve, showing ROC-AUC scores of 0.94 and above for COVID-19 and the other two classes, while depicting the point where the accuracy is maximal for each class.", [["the VGG", "TEST", 36, 43], ["each binary detection task", "TEST", 58, 84], ["a ROC curve", "TEST", 88, 99], ["ROC", "TEST", 109, 112], ["AUC scores", "TEST", 113, 123], ["COVID", "TEST", 146, 151]]], ["The false positive rate at the maximal-accuracy point is larger for COVID-19 than for pneumonia and healthy patients.", [["pneumonia", "DISEASE", 86, 95], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["The false positive rate", "PROBLEM", 0, 23], ["COVID", "TEST", 68, 73], ["pneumonia", "PROBLEM", 86, 95], ["false", "OBSERVATION", 4, 9], ["positive rate", "OBSERVATION", 10, 23], ["larger", "OBSERVATION_MODIFIER", 57, 63], ["pneumonia", "OBSERVATION", 86, 95]]], ["In a clinical setting, where false positives are less problematic than false negatives, this property is highly desirable.", [["false positives", "TEST", 29, 44], ["less problematic", "OBSERVATION_MODIFIER", 49, 65]]], ["Since the data is imbalanced, we also plot the precision-recall curve in Figure 2b , which confirms that pneumonia is the class that is predicted most easily.", [["pneumonia", "DISEASE", 105, 114], ["pneumonia", "PROBLEM", 105, 114], ["pneumonia", "OBSERVATION", 105, 114]]], ["In addition, the confusion matrices in Figure 2c and Figure 2d further detail the predictions of VGG-CAM; we observe that the high sensitivity for COVID-19 (0.93, 642 out of 693 frames) comes at a cost of 22% false positives from the healthy class.", [["confusion", "DISEASE", 17, 26], ["CAM", "MULTI-TISSUE_STRUCTURE", 101, 104], ["VGG", "PROTEIN", 97, 100], ["the confusion matrices", "PROBLEM", 13, 35], ["COVID", "TEST", 147, 152]]], ["For further results including the ROC-and precision-recall curves of all three models see Appendix A.4.Frame-based experimentsAblation study with segmentation models.", [["the ROC", "TEST", 30, 37], ["precision", "TEST", 42, 51], ["Ablation study", "TEST", 126, 140], ["segmentation models", "TEST", 146, 165], ["Appendix", "ANATOMY", 90, 98]]], ["Lung US recordings are noisy and operator-dependent, posing difficulties for the classification of raw data.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["Lung US recordings", "TEST", 0, 18]]], ["Hence, we compare VGG and VGG-CAM to VGG-Segment where all frames are segmented (i.e. classified on a pixel level into pathological patterns) with the model from Roy et al. [39] ; see Appendix A.1) for an example input.", [["VGG", "CANCER", 18, 21], ["CAM", "MULTI-TISSUE_STRUCTURE", 30, 33], ["VGG", "DNA", 18, 21], ["VGG", "PROTEIN", 26, 29], ["VGG", "DNA", 37, 40], ["VGG", "TEST", 18, 21], ["VGG", "TEST", 26, 29], ["Segment", "ANATOMY_MODIFIER", 41, 48]]], ["The relevant rows in Table 2 exhibit mixed results: while training on segmented images improves most relevant performance metrics slightly (higher accuracy, COVID-19 sensitivity, and MCC scores), balanced accuracy is inferior compared to VGG.", [["VGG", "PROTEIN", 238, 241], ["segmented images", "TEST", 70, 86], ["accuracy", "TEST", 147, 155], ["COVID", "TEST", 157, 162], ["sensitivity", "TEST", 166, 177], ["MCC scores", "TEST", 183, 193], ["inferior", "OBSERVATION_MODIFIER", 217, 225]]], ["Since this small increase in predictive performance comes at the cost of a large increase in model size (due to the ensemble of three independent models; selecting only one of the models resulted in inferior performance), we considered Segment-Enc, i.e. a dense model classifying the 560-dimensional encoding produced by the pre-trained segmentation models.", [["Segment-Enc", "DNA", 236, 247], ["this small increase in predictive performance", "PROBLEM", 6, 51], ["a large increase in model size", "PROBLEM", 73, 103], ["small", "OBSERVATION_MODIFIER", 11, 16], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["large", "OBSERVATION_MODIFIER", 75, 80], ["increase", "OBSERVATION_MODIFIER", 81, 89], ["model", "OBSERVATION_MODIFIER", 93, 98], ["size", "OBSERVATION_MODIFIER", 99, 103], ["dense", "OBSERVATION_MODIFIER", 256, 261]]], ["Segment-Enc achieved comparable performance for most metrics, apart from lower scores for pneumonia detection.", [["pneumonia", "DISEASE", 90, 99], ["Enc", "DNA", 8, 11], ["pneumonia detection", "PROBLEM", 90, 109], ["pneumonia", "OBSERVATION", 90, 99]]], ["Since the difference in performance is only marginal, and the architectures of VGG-Segment and Segment-Enc prohibit the computation of class activation maps, we prefer to focus on the analysis of VGG-CAM in the following.Frame-based experimentsAblation study on other architectures.", [["VGG-CAM", "GENE_OR_GENE_PRODUCT", 196, 203], ["VGG", "PROTEIN", 79, 82], ["Enc", "DNA", 103, 106], ["VGG", "PROTEIN", 196, 199], ["class activation maps", "TREATMENT", 135, 156], ["the analysis", "TEST", 180, 192], ["VGG", "TEST", 196, 199], ["Ablation study", "TEST", 244, 258], ["marginal", "OBSERVATION_MODIFIER", 44, 52], ["Segment", "ANATOMY_MODIFIER", 83, 90], ["Segment", "ANATOMY_MODIFIER", 95, 102]]], ["Initially, we had tested further models proposed for medical image analysis, such as COVID-Net (previously used for the classification of X-Ray images [50] ), and an architecture following [28] based on a Res-Net [22] , but we observed that the experiments on our data resulted in significantly worse results.", [["Res", "CHEMICAL", 205, 208], ["COVID", "PROTEIN", 85, 90], ["medical image analysis", "TEST", 53, 75], ["our data", "TEST", 260, 268]]], ["Last, we tested several smaller networks such as MobileNet [23] as an additional ablation study, with NASNetMobile [55] performing best.", [["an additional ablation study", "TEST", 67, 95], ["smaller", "OBSERVATION_MODIFIER", 24, 31]]], ["As most ultrasound devices are portable and real-time inference on the devices is technically feasible, resource-efficient networks are highly relevant and could supersede web-based inference.", [["networks", "MULTI-TISSUE_STRUCTURE", 123, 131], ["most ultrasound devices", "TEST", 3, 26], ["portable", "TEST", 31, 39], ["the devices", "TREATMENT", 67, 78]]], ["Due to low precision and recall on healthy data, our fine-tuned NASNetMobile is less performant than VGG-CAM, Table 3 : Video classification results.", [["Video classification", "TEST", 120, 140]]], ["The frame-based model VGG-CAM outperforms the 3D CNN Models Genesis, showing high accuracy (94%), recall, precision for COVID-19 and pneumonia detection. but also requires less than a third of the parameters, thus providing a first step towards real-time on-device inference.Video-based experimentsTo investigate the need for a model with the ability to detect spatiotemporal patterns in lung US, we explored Models Genesis, a pretrained 3D-CNN designed for 3D medical image analysis [54] .", [["lung", "ANATOMY", 388, 392], ["pneumonia", "DISEASE", 133, 142], ["lung", "ORGAN", 388, 392], ["VGG", "DNA", 22, 25], ["CAM", "DNA", 26, 29], ["pretrained 3D-CNN", "DNA", 427, 444], ["COVID", "TEST", 120, 125], ["pneumonia detection", "PROBLEM", 133, 152], ["lung US", "TEST", 388, 395], ["3D medical image analysis", "TEST", 458, 483], ["high", "OBSERVATION_MODIFIER", 77, 81], ["pneumonia", "OBSERVATION", 133, 142], ["lung", "ANATOMY", 388, 392]]], ["Table 3 contrasts the frame-based performance of VGG-CAM model to Model Genesis.", [["CAM", "MULTI-TISSUE_STRUCTURE", 53, 56], ["VGG", "PROTEIN", 49, 52], ["VGG", "TREATMENT", 49, 52]]], ["The video classifier is outperformed by VGG-CAM, with a video accuracy of 94% compared to 87%.", [["VGG", "PROTEIN", 40, 43], ["a video accuracy", "TEST", 54, 70]]], ["Note that all videos of pneumonia-infections are classified correctly, while especially Model Genesis struggles with the prediction of healthy patients.", [["pneumonia", "DISEASE", 24, 33], ["infections", "DISEASE", 34, 44], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["pneumonia", "PROBLEM", 24, 33], ["infections", "PROBLEM", 34, 44], ["pneumonia", "OBSERVATION", 24, 33], ["infections", "OBSERVATION", 34, 44]]], ["Considering that only 292 video-chunks were available for training Model Genesis, while 1356 images are used to train VGG-CAM, even extended through data augmentation techniques, it is likely that video-based classification may improve with increasing data availability.Evaluation on independent test dataVery recently, the ICLUS initiative released 60 COVID-19 lung US recordings from Italian patients 2 [39] .", [["lung", "ANATOMY", 362, 366], ["CAM", "MULTI-TISSUE_STRUCTURE", 122, 125], ["lung", "ORGAN", 362, 366], ["patients", "ORGANISM", 394, 402], ["VGG", "DNA", 118, 121], ["patients", "SPECIES", 394, 402], ["augmentation techniques", "TREATMENT", 154, 177], ["Evaluation", "TEST", 270, 280], ["independent test dataVery", "TEST", 284, 309], ["COVID", "TEST", 353, 358], ["lung US recordings", "TEST", 362, 380], ["lung", "ANATOMY", 362, 366]]], ["The data is not annotated, but was initially assumed to contain only COVID-19 videos, based on its general description.", [["COVID", "DNA", 69, 74], ["COVID", "TEST", 69, 74]]], ["We evaluated the performance of the VGG-CAM model on all 40 convex probes from ICLUS, alongside 24 recordings from healthy controls (6 viewpoints each) and 2 videos from public sources (healthy), jointly comprising an independent test dataset of 66 videos.Evaluation on independent test dataWe predicted all frames as an average of the five VGG-CAM models trained in cross-validation.", [["CAM", "MULTI-TISSUE_STRUCTURE", 345, 348], ["VGG", "DNA", 36, 39], ["VGG", "DNA", 341, 344], ["the VGG", "TEST", 32, 39], ["an independent test dataset", "TEST", 215, 242], ["Evaluation on independent test dataWe", "TEST", 256, 293]]], ["The model achieves a frame-prediction accuracy of 83.3%, divided into 89.5% for healthy-patient data and 74% for COVID-19 videos.", [["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["prediction accuracy", "TEST", 27, 46], ["COVID", "TEST", 113, 118]]], ["Furthermore, averaging the class probabilities over all frames, VGG-CAM achieves a video classification accuracy of 92.2% and 77.5%, respectively.", [["VGG", "DNA", 64, 67], ["a video classification accuracy", "TEST", 81, 112]]], ["Notably, the four healthy patients are all classified correctly if summarized across viewpoints.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["Combining both datasets, the sensitivity of detecting COVID-19 corresponds to the accuracy (0.775) with a precision score of 0.94 (no video was classified as bacterial pneumonia).Evaluation on independent test dataEvaluation by domain experts.", [["pneumonia", "DISEASE", 168, 177], ["COVID-19", "DNA", 54, 62], ["COVID", "TEST", 54, 59], ["the accuracy", "TEST", 78, 90], ["a precision score", "TEST", 104, 121], ["bacterial pneumonia", "PROBLEM", 158, 177], ["Evaluation", "TEST", 179, 189], ["independent test dataEvaluation", "TEST", 193, 224], ["bacterial", "OBSERVATION_MODIFIER", 158, 167], ["pneumonia", "OBSERVATION", 168, 177]]], ["We further investigated the comparably low sensitivity on the COVID-19 data (ICLUS) with the help of two medical experts.", [["the COVID", "TEST", 58, 67]]], ["When asked for their unbiased diagnosis of the incorrectly-predicted videos, they independently reported for 6 out of 9 videos that no disease-specific patterns can be observed (\"A-lines, normal lung\").", [["lung", "ANATOMY", 195, 199], ["A-lines", "CELL", 179, 186], ["lung", "ORGAN", 195, 199], ["disease", "PROBLEM", 135, 142], ["lung", "ANATOMY", 195, 199]]], ["In addition, the dataset may contain further healthy-patient data which was incorrectly predicted as COVID-19.", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["COVID", "TEST", 101, 106]]], ["At this point, we can safely conclude that test data performance is highly promising, in particular considering the high accuracy for healthy patients, but requires further validation with independent and labeled data..1 Class activation mapsClass activation mapping (CAM) are a popular technique for model explainability that exploits global average pooling and allows to compute class-specific heatmaps that indicate the discriminative regions of the image that caused the particular class activity of interest [53] .", [["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["test data performance", "TEST", 43, 64], ["a popular technique", "TREATMENT", 277, 296], ["global average pooling", "PROBLEM", 336, 358], ["specific heatmaps", "PROBLEM", 387, 404]]], ["For healthcare applications, CAMs, or their generalization Grad-CAMs [40] , can provide valuable decision support by unravelling whether a model's prediction was based on visible pathological patterns.", [["CAMs", "PROTEIN", 29, 33], ["a model's prediction", "PROBLEM", 137, 157]]], ["Moreover, CAMs can guide doctors and point to informative patterns, especially relevant in time-sensitive (triage) or knowledge-sensitive (third-world countries) situations.", [["CAMs", "PROTEIN", 10, 14]]], ["Figure 3 shows representative CAMs in the three rightmost panels.", [["CAMs", "PROTEIN", 30, 34]]], ["They highlight the most frequent US pattern for the three classes, COVID-19 (vertical B-lines), bacterial pneumonia (consolidations), and healthy (horizontal A-line).", [["pneumonia", "DISEASE", 106, 115], ["B-lines", "CELL", 86, 93], ["COVID", "TEST", 67, 72], ["vertical B-lines", "TREATMENT", 77, 93], ["bacterial pneumonia (consolidations", "PROBLEM", 96, 131], ["healthy (horizontal A-line", "TREATMENT", 138, 164], ["bacterial", "OBSERVATION_MODIFIER", 96, 105], ["pneumonia", "OBSERVATION", 106, 115], ["consolidations", "OBSERVATION", 117, 131]]], ["For a more quantitative estimate, we computed the points of maximal activation of the CAMs for each class (abbreviated as C, P, and H) and all samples of the dataset (see Figure 3 left).", [["CAMs", "PROTEIN", 86, 90], ["the dataset", "TEST", 154, 165]]], ["While, in general, the heatmaps are fairly distributed across the probe, pneumonia related features were rather found in the center and bottom part, especially compared to COVID-19 and healthy patterns 3 .", [["pneumonia", "DISEASE", 73, 82], ["pneumonia", "PROBLEM", 73, 82], ["COVID", "TEST", 172, 177], ["pneumonia", "OBSERVATION", 73, 82], ["bottom", "OBSERVATION_MODIFIER", 136, 142]]], ["Please refer to Appendix A.5 for a density plot.", [["a density plot", "TEST", 33, 47], ["Appendix", "ANATOMY", 16, 24], ["density", "OBSERVATION", 35, 42]]], ["To assess to what extent the differences between the individual distributions are significant, we employed maximum mean discrepancy (MMD), a metric between statistical distributions [21] that enables the comparison of distributions via kernels, i.e. generic similarity functions.", [["significant", "OBSERVATION_MODIFIER", 82, 93]]], ["Given two coordinates x, y \u2208 R 2 and a smoothing parameter \u03c3 \u2208 R, we use a Gaussian kernel k(x, y) := exp(\u2212 x\u2212y 2 /\u03c3 2 ) to assess the dissimilarity between x and y.", [["a smoothing parameter", "TEST", 37, 58], ["a Gaussian kernel k", "TEST", 73, 92], ["exp", "TEST", 102, 105]]], ["Following Gretton et al. [21] , we set \u03c3 to the median distance in the aggregated samples (i.e. all samples, without considering labels).", [["samples", "ANATOMY", 82, 89], ["samples", "ANATOMY", 100, 107], ["all samples", "TEST", 96, 107]]], ["We then calculate MMD values for the distance between the three classes, i.e. MMD(C, P) \u2248 0.0051, MMD(C, H) \u2248 0.0061, and MMD(P, H) \u2248 0.0065.", [["MMD", "DISEASE", 18, 21], ["MMD", "DISEASE", 78, 81], ["MMD", "DISEASE", 98, 101], ["MMD", "DISEASE", 122, 125], ["MMD values", "TEST", 18, 28], ["MMD", "TEST", 98, 101]]], ["Repeating this calculation for 5000 bootstrap samples per class (see Figure 9 for the resulting histograms), we find that the observe achieved significance levels of the intra-class MMD values of well below an \u03b1 = 0.05 significance level.Results.Expert validation of CAMs for Human-in-the-loop settings.", [["Human", "ORGANISM", 276, 281], ["CAMs", "PROTEIN", 267, 271], ["Human", "SPECIES", 276, 281], ["the resulting histograms", "TEST", 82, 106], ["the intra-class MMD values", "TEST", 166, 192]]], ["A potential application of our framework is a human-in-the-loop (HITL) setting with CAMs as a core component of the decision support tool that highlights pulmonary biomarkers and guides the decision makers.", [["pulmonary", "ANATOMY", 154, 163], ["human", "ORGANISM", 46, 51], ["pulmonary", "ORGAN", 154, 163], ["CAMs", "PROTEIN", 84, 88], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["pulmonary", "ANATOMY", 154, 163]]], ["Since the performance of qualitative methods like CAMs can only be validated with the help of doctors, we conducted a blind-folded study with two medical experts experienced in the diagnostic process with ultrasound recordings.", [["CAMs", "PROTEIN", 50, 54], ["a blind-folded study", "TEST", 116, 136], ["ultrasound recordings", "TEST", 205, 226]]], ["The experts were shown 50 videos (14 COVID-19, 21 pneumonia, 14 regular) comprising all non-proprietary video data which was correctly classified by the model.", [["pneumonia", "DISEASE", 50, 59], ["COVID", "TEST", 37, 42], ["pneumonia", "PROBLEM", 50, 59], ["all non-proprietary video data", "TEST", 84, 114], ["pneumonia", "OBSERVATION", 50, 59]]], ["The class activation map for the respective class was computed two times, first with an average of all five models that were trained, and second only with the model that did not see any frame of the video during training (called train-and test-CAMs in the following).", [["CAMs", "PROTEIN", 244, 248], ["test", "TEST", 239, 243]]], ["Both experts were asked to compare both activation maps for all 50 videos, and to score them on a scale of \u22123 (\"the heatmap is only distracting\") to 3 (\"the heatmap is very helpful for diagnosis\").Results.First, the CAMs were overall perceived useful and the train and test CAMs were assigned a higher average score of 0.45 and 0.81 respectively.", [["CAMs", "PROTEIN", 216, 220], ["test CAMs", "TEST", 269, 278]]], ["Second, disagreeing in only 8% of the cases, both experts independently decided for the test-CAM with a probability of 56%.", [["CAM", "MULTI-TISSUE_STRUCTURE", 93, 96], ["the test", "TEST", 84, 92]]], ["Hence, the test-CAMs are not inferior to the train-CAMs, however non-significant in a Wilcoxon signed-rank test.", [["the test", "TEST", 7, 15], ["rank test", "TEST", 102, 111]]], ["However, trainand test-CAM both scored best for videos of bacterial pneumonia, lacking performance for videos of healthy and COVID-19 patients.", [["pneumonia", "DISEASE", 68, 77], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["trainand test", "TEST", 9, 22], ["bacterial pneumonia", "PROBLEM", 58, 77], ["bacterial", "OBSERVATION_MODIFIER", 58, 67], ["pneumonia", "OBSERVATION", 68, 77]]], ["Specifically, test-CAM received an average score of 0.81, divided into \u22120.25 for COVID-19, 2.05 for pneumonia, and 0 for healthy patients.", [["pneumonia", "DISEASE", 100, 109], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["test", "TEST", 14, 18], ["an average score", "TEST", 32, 48], ["COVID", "TEST", 81, 86], ["pneumonia", "PROBLEM", 100, 109], ["pneumonia", "OBSERVATION", 100, 109]]], ["Figure 4 shows the average ratio of pattern that were correctly highlighted by the CAM model, where the patterns listed by the more senior expert are taken as the ground truth for each video.", [["CAM", "MULTI-TISSUE_STRUCTURE", 83, 86]]], ["Interestingly, the high performance of our model in classifying videos of bacterial pneumonia is probably explained by the model's ability to detect consolidated areas, where 17 out of 18 are correctly classified.", [["pneumonia", "DISEASE", 84, 93], ["bacterial pneumonia", "PROBLEM", 74, 93], ["consolidated areas", "PROBLEM", 149, 167], ["high", "OBSERVATION_MODIFIER", 19, 23], ["bacterial", "OBSERVATION_MODIFIER", 74, 83], ["pneumonia", "OBSERVATION", 84, 93], ["probably explained", "UNCERTAINTY", 97, 115], ["consolidated", "OBSERVATION_MODIFIER", 149, 161], ["areas", "OBSERVATION", 162, 167]]], ["Moreover, A-lines are highlighted in \u223c 60% of the normal lung recordings.", [["lung", "ANATOMY", 57, 61], ["lung", "ORGAN", 57, 61], ["A-lines", "TREATMENT", 10, 17], ["normal", "OBSERVATION", 50, 56], ["lung", "ANATOMY", 57, 61]]], ["Problematically, in 13 videos mostly fat, muscles or skin is highlighted, which has to be studied and improved in future work.Confidence estimatesThe ability to quantify states of high uncertainty is of crucial importance for medical image analysis and computer vision applications in healthcare.", [["fat", "ANATOMY", 37, 40], ["muscles", "ANATOMY", 42, 49], ["skin", "ANATOMY", 53, 57], ["fat", "TISSUE", 37, 40], ["muscles", "ORGAN", 42, 49], ["skin", "ORGAN", 53, 57], ["medical image analysis", "TEST", 226, 248], ["muscles", "ANATOMY", 42, 49], ["skin", "ANATOMY", 53, 57]]], ["We assessed this via independent measures of epistemic (model) uncertainty (by drawing Monte Carlo samples from the approximate predictive posterior [20] ) and aleatoric (data) uncertainty (by means of test time data augmentation [4] ).", [["epistemic (model)", "TREATMENT", 45, 62]]], ["The sample standard deviation of 10 forward passes is interpreted as inverse, empirical confidence score \u2208 [0, 1] (for details see appendix).", [["empirical confidence score", "TEST", 78, 104], ["appendix", "ANATOMY", 131, 139]]], ["The epistemic confidence estimate was found to be highly correlated with the correctness of the predictions (\u03c1 = 0.41, p < 4e\u2212124, mean confidence of 0.75 and 0.26 for correct and wrong predictions), while the aleatoric confidence was found correlated to a lesser extent (\u03c1 = 0.29, p < 6e\u221235, mean confidence of 0.88 and 0.73, respectively).", [["mean confidence", "TEST", 131, 146], ["mean confidence", "TEST", 293, 308], ["lesser", "OBSERVATION_MODIFIER", 257, 263], ["extent", "OBSERVATION_MODIFIER", 264, 270]]], ["Across the entire dataset, both scores are highly correlated (\u03c1 = 0.52), suggesting to exploit them jointly to detect and remove predictions of low confidence in a possible application.DiscussionUltrasound as an established diagnosis tool that is both safe and highly available constitutes a method with potentially huge impact that has nevertheless been neglected by the machine learning community.", [["DiscussionUltrasound", "TEST", 185, 205]]], ["This work presents methods and analyses that pave the way towards computer vision-assisted differential diagnosis of COVID-19 from US, providing an extensive analysis of (interpretable) methods that are relevant not only in the context of COVID-19, but in general for the diagnosis of viral and bacterial pneumonia.DiscussionWe provide strong evidence that automatic detection of COVID-19 is a promising future endeavour and competitive compared to CT and CXR based models, with a sensitivity of 98% and a specificity of 91% for COVID-19, achieved on our dataset of 106 lung US videos.", [["lung", "ANATOMY", 570, 574], ["viral and bacterial pneumonia", "DISEASE", 285, 314], ["COVID-19", "CELL", 117, 125], ["lung", "ORGAN", 570, 574], ["COVID-19", "DNA", 380, 388], ["COVID", "TEST", 117, 122], ["an extensive analysis", "TEST", 145, 166], ["COVID", "TEST", 239, 244], ["viral and bacterial pneumonia", "PROBLEM", 285, 314], ["COVID", "TEST", 380, 385], ["CT", "TEST", 449, 451], ["CXR based models", "TEST", 456, 472], ["a sensitivity", "TEST", 479, 492], ["a specificity", "TEST", 504, 517], ["COVID", "TEST", 529, 534], ["viral", "OBSERVATION", 285, 290], ["bacterial", "OBSERVATION_MODIFIER", 295, 304], ["pneumonia", "OBSERVATION", 305, 314], ["lung", "ANATOMY", 570, 574]]], ["In comparison, sensitivity up to 98% and specificity up to 92% was reported for CT [12, 33] .", [["sensitivity", "TEST", 15, 26], ["specificity", "TEST", 41, 52], ["CT", "TEST", 80, 82]]], ["We verified our results with independent test data, studied model uncertainty and concluded a significant ability of our model to recognize low-confidence situations.", [["independent test data", "TEST", 29, 50]]], ["We combined our approach with the only available related work, lung US segmentation models from Roy et al. [39] , and found mild performance improvement in most metrics.", [["lung", "ANATOMY", 63, 67], ["lung", "ORGAN", 63, 67], ["mild performance", "PROBLEM", 124, 140], ["lung", "ANATOMY", 63, 67], ["mild", "OBSERVATION_MODIFIER", 124, 128], ["performance", "OBSERVATION_MODIFIER", 129, 140], ["improvement", "OBSERVATION_MODIFIER", 141, 152], ["most metrics", "OBSERVATION_MODIFIER", 156, 168]]], ["It however remains unclear whether this gain can be attributed to the segmentation itself or is a side-effect of the increased parametrization.", [["the increased parametrization", "TREATMENT", 113, 142], ["segmentation", "OBSERVATION", 70, 82], ["side-effect", "OBSERVATION_MODIFIER", 98, 109], ["increased", "OBSERVATION_MODIFIER", 117, 126], ["parametrization", "OBSERVATION", 127, 142]]], ["Certainly, there are many approaches yet to be explored in order to improve on the results presented here, including further work on video classification, but also exploiting the higher availability of CT or X-ray scans with transfer learning or adapting generative models to complement the scarce data about COVID-19 as proposed in [32] .", [["COVID-19", "DNA", 309, 317], ["video classification", "TEST", 133, 153], ["CT or X-ray scans", "TEST", 202, 219], ["COVID", "TEST", 309, 314]]], ["Furthermore, we investigated the value of interpretable methods in a quantitative manner with the implementation and validation of class activation mapping in a study involving medical experts.", [["class activation mapping", "TREATMENT", 131, 155], ["a study", "TEST", 159, 166]]], ["While the analysis provides excellent evidence for the successful detection of pathological patterns like consolidations, A-lines and effusion, it reveals problems in the model's \"focal point\" (e.g. missing B-lines and sometimes highlighting muscles instead of the lung) which should be further addressed using ultrasound segmentation techniques [49] .DiscussionOur published database is constantly updated and verified by medical experts researchers are invited to contribute to our initiative.", [["B-lines", "ANATOMY", 207, 214], ["muscles", "ANATOMY", 242, 249], ["lung", "ANATOMY", 265, 269], ["A-lines", "DISEASE", 122, 129], ["effusion", "DISEASE", 134, 142], ["B-lines", "CELL", 207, 214], ["muscles", "ORGAN", 242, 249], ["lung", "ORGAN", 265, 269], ["the analysis", "TEST", 6, 18], ["pathological patterns", "PROBLEM", 79, 100], ["consolidations", "PROBLEM", 106, 120], ["A-lines", "TREATMENT", 122, 129], ["effusion", "PROBLEM", 134, 142], ["B-lines", "TREATMENT", 207, 214], ["ultrasound segmentation techniques", "TEST", 311, 345], ["consolidations", "OBSERVATION", 106, 120], ["effusion", "OBSERVATION", 134, 142], ["focal", "OBSERVATION_MODIFIER", 180, 185], ["muscles", "ANATOMY", 242, 249], ["lung", "ANATOMY", 265, 269]]], ["We started to collaborate with radiologists and an intensive care unit and are currently designing a controlled, clinical study to investigate the predictive power of US for automatic detection of COVID-19, especially in comparison to CT and CXR.", [["CXR", "PROTEIN", 242, 245], ["clinical study", "TEST", 113, 127], ["automatic detection", "TEST", 174, 193], ["COVID", "TEST", 197, 202], ["CT", "TEST", 235, 237], ["CXR", "TEST", 242, 245]]], ["As a preliminary demonstration, we have built a web service (link not anonymized) where users can screen ultrasound images, querying our averaged prediction model.", [["ultrasound images", "TEST", 105, 122]]], ["We aim to extend the functionality of the website in the future to offer interpretable video inference, aiming for an accessible and validated tool that enables medical doctors to draw inference from their US images with unprecedented ease, convenience and speed.A.1 Model architectures and hyperparameterAs a base, we use the convolutional part of the established VGG-16 [43] , pre-trained on Imagenet.", [["VGG-16", "CHEMICAL", 365, 371], ["VGG", "DNA", 365, 368], ["their US images", "TEST", 200, 215], ["architectures", "OBSERVATION_MODIFIER", 273, 286], ["base", "ANATOMY_MODIFIER", 310, 314]]], ["The model we call VGG is followed by one hidden layer of 64 neurons with ReLU activation, dropout of 0.5, batch normalization and the output layer with softmax activation.", [["neurons", "ANATOMY", 60, 67], ["neurons", "CELL", 60, 67], ["VGG", "PROTEIN", 18, 21], ["dropout", "TEST", 90, 97], ["softmax activation", "PROBLEM", 152, 170]]], ["The CAMs for this model were computed with Grad-CAM [40] .", [["CAMs", "PROTEIN", 4, 8]]], ["To compare Grad-CAMs with regular CAMs [53] , we also tested VGG-CAM, a CAM-compatible VGG with a single dense layer following the global average pooling after the last convolutional layer.", [["VGG-CAM", "SIMPLE_CHEMICAL", 61, 68], ["CAM", "MULTI-TISSUE_STRUCTURE", 72, 75], ["VGG", "CANCER", 87, 90], ["Grad-CAMs", "PROTEIN", 11, 20], ["VGG", "PROTEIN", 61, 64], ["a CAM", "TEST", 70, 75], ["VGG", "PROBLEM", 87, 90], ["a single dense layer", "PROBLEM", 96, 116], ["the global average pooling", "PROBLEM", 127, 153], ["dense", "OBSERVATION_MODIFIER", 105, 110], ["layer", "OBSERVATION_MODIFIER", 111, 116], ["global", "OBSERVATION_MODIFIER", 131, 137], ["average", "OBSERVATION_MODIFIER", 138, 145], ["pooling", "OBSERVATION", 146, 153]]], ["The model is trained with a cross entropy loss function on the softmax outputs, and optimized with Adam with an initial learning rate of 1e\u22124.", [["a cross entropy loss function", "PROBLEM", 26, 55], ["the softmax outputs", "TEST", 59, 78]]], ["All models were implemented in TensorFlow and trained for 40 epochs with a batch size of 8 and early stopping was enabled.A.1 Model architectures and hyperparameterA.2 Pretrained segmentation models Figure 5 gives an example for the segmented ultrasound image with the model from Roy et al. [39] .", [["hyperparameterA.2", "CHEMICAL", 150, 167], ["a batch size", "TREATMENT", 73, 85], ["the segmented ultrasound image", "TEST", 229, 259], ["architectures", "OBSERVATION_MODIFIER", 132, 145]]], ["In our work the segmented image serves as input to the VGG-Segment model.", [["VGG", "PROTEIN", 55, 58], ["Segment model", "ANATOMY_MODIFIER", 59, 72]]], ["Left side shows the raw US recording and the right side shows the segmentation method from Roy et al. [39] highlighting the B-line.", [["B-line", "ANATOMY", 124, 130], ["B-line", "CELL", 124, 130], ["B-line", "CELL_LINE", 124, 130], ["the raw US recording", "TEST", 16, 36], ["the B-line", "TREATMENT", 120, 130], ["right", "ANATOMY_MODIFIER", 45, 50]]], ["The images shown on the right were used as input for the VGG-Segment model.A.3 Uncertainty estimationFor both aleatoric and epistemic uncertainty, the confidence estimate c i of sample i is computed by scaling the sample's standard deviation to \u2208 [0, 1] and interpreting it as an inverse precision:A.3 Uncertainty estimationwhere \u03c3 i,j is the sample standard deviation of the ten class probabilities of the winning class j, \u03c3 min is the minimal standard deviation (0, i.e. all probabilities for the winning class are identical) and \u03c3 max is the maximal standard deviation, i.e. 0.5.", [["VGG", "PROTEIN", 57, 60], ["The images", "TEST", 0, 10], ["the VGG-Segment model", "TREATMENT", 53, 74], ["right", "ANATOMY_MODIFIER", 24, 29], ["Segment model", "ANATOMY_MODIFIER", 61, 74], ["minimal", "OBSERVATION_MODIFIER", 437, 444], ["standard deviation", "OBSERVATION", 445, 463], ["maximal", "OBSERVATION_MODIFIER", 545, 552], ["standard deviation", "OBSERVATION", 553, 571]]], ["Practically, for epistemic uncertainty, dropout was set to 0.5 across the VGG model and for aleatoric uncertainty the same transformations as during training are employed.A.4 ResultsRe-formulating the classification as a binary task, the ROC-curve and precision-recall curves can be computed for each class.", [["ResultsRe", "PROTEIN", 175, 184], ["epistemic uncertainty", "PROBLEM", 17, 38], ["dropout", "PROBLEM", 40, 47], ["aleatoric uncertainty", "PROBLEM", 92, 113], ["the ROC", "TEST", 234, 241]]], ["While pneumonia is distinguished well by all models, NASNet has difficulties with the correct classification of normal lung images.", [["lung", "ANATOMY", 119, 123], ["pneumonia", "DISEASE", 6, 15], ["lung", "ORGAN", 119, 123], ["pneumonia", "PROBLEM", 6, 15], ["pneumonia", "OBSERVATION", 6, 15], ["normal", "OBSERVATION", 112, 118], ["lung", "ANATOMY", 119, 123]]], ["Figure 7a and Figure 7b show that COVID-19 is predicted better than healthy lung images, but not as distinct as pneumonia infections.", [["lung", "ANATOMY", 76, 80], ["pneumonia", "DISEASE", 112, 121], ["infections", "DISEASE", 122, 132], ["lung", "ORGAN", 76, 80], ["COVID-19", "DNA", 34, 42], ["Figure 7b", "TEST", 14, 23], ["COVID", "TEST", 34, 39], ["pneumonia infections", "PROBLEM", 112, 132], ["lung", "ANATOMY", 76, 80], ["pneumonia", "OBSERVATION", 112, 121]]], ["Furthermore, in addition to the normalized confusion matrices we provide the absolute values here in Figure 7c (referring to VGG-CAM).", [["confusion", "DISEASE", 43, 52], ["VGG", "PROTEIN", 125, 128], ["the normalized confusion matrices", "PROBLEM", 28, 61]]], ["Note that most of our data shows COVID-19 infected lungs, despite the novelty of the disease.", [["lungs", "ANATOMY", 51, 56], ["lungs", "ORGAN", 51, 56], ["our data", "TEST", 18, 26], ["COVID", "TEST", 33, 38], ["19 infected lungs", "PROBLEM", 39, 56], ["the disease", "PROBLEM", 81, 92], ["infected", "OBSERVATION", 42, 50], ["lungs", "ANATOMY", 51, 56], ["disease", "OBSERVATION", 85, 92]]], ["Problematically, healthy and COVID-19 patients are confused in 100 images, whereas bacterial pneumonia is predicted rather reliably.A.4.1 Uninformative classAlthough the main task is defined as differentiating COVID-19, bacterial pneumonia and healthy, we trained the model actually with a fourth \"uninformative\" class in order to identify out-of-distribution samples.", [["samples", "ANATOMY", 360, 367], ["pneumonia", "DISEASE", 93, 102], ["pneumonia", "DISEASE", 230, 239], ["patients", "ORGANISM", 38, 46], ["COVID-19", "CELL", 210, 218], ["patients", "SPECIES", 38, 46], ["confused", "PROBLEM", 51, 59], ["bacterial pneumonia", "PROBLEM", 83, 102], ["COVID", "TEST", 210, 215], ["bacterial pneumonia", "PROBLEM", 220, 239], ["bacterial", "OBSERVATION_MODIFIER", 83, 92], ["pneumonia", "OBSERVATION", 93, 102], ["main", "OBSERVATION_MODIFIER", 170, 174], ["bacterial", "OBSERVATION_MODIFIER", 220, 229], ["pneumonia", "OBSERVATION", 230, 239]]], ["This concerns both entirely different pictures (no ultrasound), as well as ultrasound images not showing the lung.", [["lung", "ANATOMY", 109, 113], ["lung", "ORGAN", 109, 113], ["ultrasound", "TEST", 51, 61], ["ultrasound images", "TEST", 75, 92], ["lung", "ANATOMY", 109, 113]]], ["Thus, we added 200 images from Tiny ImageNet (one per class taken from the test set) together with 200 neck ultrasound scans taken from the Kaggle ultrasound nerve segmentation challenge.", [["nerve", "ANATOMY", 158, 163], ["200 neck ultrasound scans", "TEST", 99, 124], ["the Kaggle ultrasound nerve segmentation challenge", "TEST", 136, 186], ["nerve", "ANATOMY", 158, 163]]], ["Note that the latter is data recorded with linear ultrasound probes, leading to very different ultrasound images.A.5 Class activation mapsIn addition to the scatter plot in Figure 3 we present the corresponding density plot in Figure 8 , showing the area of the ultrasound image where the class activation is maximal for each class.", [["linear ultrasound probes", "TEST", 43, 67], ["very different ultrasound images", "TEST", 80, 112], ["the scatter plot", "TEST", 153, 169], ["the ultrasound image", "TEST", 258, 278], ["density", "OBSERVATION", 211, 218]]], ["It can be observed that the activation on healthy and COVID-19 videos is located further in the upper part of the image, where usually only muscles and skin are observed.", [["muscles", "ANATOMY", 140, 147], ["skin", "ANATOMY", 152, 156], ["upper", "ORGANISM_SUBDIVISION", 96, 101], ["muscles", "ORGAN", 140, 147], ["skin", "ORGAN", 152, 156], ["upper", "ANATOMY_MODIFIER", 96, 101], ["muscles", "ANATOMY", 140, 147], ["skin", "ANATOMY", 152, 156]]], ["Note that with respect to the pleural line, we only consider the opinion of expert 2 since expert 1 did not mention it.", [["pleural line", "ANATOMY", 30, 42], ["pleural line", "CELL", 30, 42], ["the pleural line", "TREATMENT", 26, 42], ["pleural", "ANATOMY", 30, 37], ["line", "OBSERVATION", 38, 42]]], ["With the exception of consolidations, the difference in responses is quite large, which is however unsurprising for such a qualitative task.", [["consolidations", "PROBLEM", 22, 36], ["consolidations", "OBSERVATION", 22, 36], ["difference", "OBSERVATION_MODIFIER", 42, 52], ["quite", "OBSERVATION_MODIFIER", 69, 74], ["large", "OBSERVATION_MODIFIER", 75, 80]]], ["Besides the patterns that were already named in Figure 4 , the heatmaps also correctly highlighted air bronchograms (2 cases according to expert 1) and a pleural effusion in 1 out of 7 cases. e. the ones we obtain by looking at the labels, is indicated as a dashed line in each histogram.", [["pleural effusion", "ANATOMY", 154, 170], ["pleural effusion", "DISEASE", 154, 170], ["pleural effusion", "CANCER", 154, 170], ["air bronchograms", "PROBLEM", 99, 115], ["a pleural effusion", "PROBLEM", 152, 170], ["a dashed line", "TREATMENT", 256, 269], ["each histogram", "TEST", 273, 287], ["air bronchograms", "OBSERVATION", 99, 115], ["pleural", "ANATOMY", 154, 161], ["effusion", "OBSERVATION", 162, 170]]], ["We observe that these values are highly infrequent under the null distribution, indicating that the differences betwee the three classes are significant.", [["these values", "TEST", 16, 28], ["null distribution", "OBSERVATION", 61, 78], ["significant", "OBSERVATION_MODIFIER", 141, 152]]], ["Notably, the statistical distance between patients suffering from bacterial pneumonia and healthy patients (rightmost histogram) achieves a slightly lower empirical significance of \u2248 0.04.", [["pneumonia", "DISEASE", 76, 85], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 98, 106], ["bacterial pneumonia", "PROBLEM", 66, 85], ["rightmost histogram", "TEST", 108, 127], ["a slightly lower empirical significance", "PROBLEM", 138, 177], ["bacterial", "OBSERVATION_MODIFIER", 66, 75], ["pneumonia", "OBSERVATION", 76, 85]]], ["We speculate that this might be related to other pre-existing conditions in healthy patients that are not pertinent to this study, though.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["this study", "TEST", 119, 129]]]], "PMC7220575": [["IntroductionA novel coronavirus named SARS-CoV-2 of a zoonotic origin emerged in the beginning of this year and the disease called Coronavirus Disease 2019 (COVID-19) started spreading worldwide.", [["Coronavirus Disease", "DISEASE", 131, 150], ["COVID-19", "CHEMICAL", 157, 165], ["coronavirus", "ORGANISM", 20, 31], ["SARS-CoV-2", "ORGANISM", 38, 48], ["coronavirus", "SPECIES", 20, 31], ["SARS-CoV", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 38, 46], ["IntroductionA novel coronavirus", "PROBLEM", 0, 31], ["CoV", "TEST", 43, 46], ["the disease", "PROBLEM", 112, 123], ["Coronavirus Disease", "PROBLEM", 131, 150], ["COVID", "TEST", 157, 162], ["disease", "OBSERVATION", 116, 123]]], ["Next, a large number of cases started to appear in northern Italy.", [["large", "OBSERVATION_MODIFIER", 8, 13]]], ["The WHO classified COVID-19 a pandemic on March 11.", [["COVID", "TEST", 19, 24]]], ["The pressure on health care systems is very high in all countries affected and increasing numbers of infected health care staff are being reported.", [["pressure", "OBSERVATION_MODIFIER", 4, 12], ["very", "OBSERVATION_MODIFIER", 39, 43], ["high", "OBSERVATION", 44, 48], ["increasing", "OBSERVATION_MODIFIER", 79, 89], ["numbers", "OBSERVATION_MODIFIER", 90, 97], ["infected", "OBSERVATION_MODIFIER", 101, 109]]], ["This is likely to impact greatly on the HCT and CAR T activity in Europe as in many other parts of the world throughout 2020, and potentially beyond.IntroductionEarly in the outbreak, the Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT) started working on guidelines to support transplant centers in developing strategies for management based on existing experience.", [["Blood", "ANATOMY", 257, 262], ["Marrow", "ANATOMY", 267, 273], ["HCT", "CANCER", 40, 43], ["CAR T", "GENE_OR_GENE_PRODUCT", 48, 53], ["Blood", "ORGANISM_SUBSTANCE", 257, 262], ["Marrow", "TISSUE", 267, 273], ["the HCT", "TEST", 36, 43], ["Blood and Marrow Transplantation", "TREATMENT", 257, 289], ["transplant centers", "TREATMENT", 338, 356], ["management", "TREATMENT", 386, 396], ["likely to", "UNCERTAINTY", 8, 17], ["Infectious", "OBSERVATION_MODIFIER", 188, 198], ["Marrow", "ANATOMY", 267, 273]]], ["This work was performed in collaboration with the infectious diseases group of American Society of Transplantation and Cellular Therapy.", [["infectious diseases", "DISEASE", 50, 69], ["Transplantation", "TREATMENT", 99, 114], ["Cellular Therapy", "TREATMENT", 119, 135], ["infectious", "OBSERVATION_MODIFIER", 50, 60], ["Cellular Therapy", "OBSERVATION", 119, 135]]], ["In addition, the IDWP started collecting patient reports through the mechanism of the EBMT registry to rapidly collect information about outcome of autologous and allogeneic HCT patients developing COVID-19.", [["patient", "ORGANISM", 41, 48], ["patients", "ORGANISM", 178, 186], ["patient", "SPECIES", 41, 48], ["patients", "SPECIES", 178, 186], ["the IDWP", "TREATMENT", 13, 21], ["autologous and allogeneic HCT", "TREATMENT", 148, 177], ["COVID", "TEST", 198, 203]]], ["The EBMT has also started educational activities directed to physicians, patients, and care givers through webinars.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81]]], ["Five weekly updates of the recommendations have now been distributed and the current status is summarized in this paper.COVID-19The infection has spread very rapidly in the population of several countries.", [["COVID-19", "CHEMICAL", 120, 128], ["infection", "DISEASE", 132, 141], ["COVID", "TEST", 120, 125], ["The infection", "PROBLEM", 128, 141], ["infection", "OBSERVATION", 132, 141], ["spread", "OBSERVATION_MODIFIER", 146, 152], ["very", "OBSERVATION_MODIFIER", 153, 157], ["rapidly", "OBSERVATION_MODIFIER", 158, 165]]], ["The time from exposure to symptom development is between 2 and 14 days (median 5 days).", [["symptom", "PROBLEM", 26, 33]]], ["Symptoms vary from no or very mild symptoms of an upper respiratory infection to very severe resulting in the need for intensive care and death from Acute Respiratory Distress Syndrome (ARDS).", [["respiratory", "ANATOMY", 56, 67], ["respiratory infection", "DISEASE", 56, 77], ["death", "DISEASE", 138, 143], ["Acute Respiratory Distress Syndrome", "DISEASE", 149, 184], ["ARDS", "DISEASE", 186, 190], ["Symptoms", "PROBLEM", 0, 8], ["very mild symptoms", "PROBLEM", 25, 43], ["an upper respiratory infection", "PROBLEM", 47, 77], ["intensive care", "TREATMENT", 119, 133], ["death", "PROBLEM", 138, 143], ["Acute Respiratory Distress Syndrome", "PROBLEM", 149, 184], ["ARDS", "PROBLEM", 186, 190], ["upper", "ANATOMY_MODIFIER", 50, 55], ["respiratory", "ANATOMY", 56, 67], ["infection", "OBSERVATION", 68, 77], ["Acute", "OBSERVATION_MODIFIER", 149, 154], ["Respiratory Distress", "OBSERVATION", 155, 175]]], ["It is becoming increasingly clear that asymptomatic or very mildly symptomatic individuals are important for the rapid spread of the infection in the population.", [["infection", "DISEASE", 133, 142], ["asymptomatic", "PROBLEM", 39, 51], ["very mildly symptomatic individuals", "PROBLEM", 55, 90], ["the infection", "PROBLEM", 129, 142], ["increasingly", "OBSERVATION_MODIFIER", 15, 27], ["clear", "OBSERVATION", 28, 33], ["very", "OBSERVATION_MODIFIER", 55, 59], ["mildly", "OBSERVATION_MODIFIER", 60, 66], ["symptomatic", "OBSERVATION", 67, 78], ["infection", "OBSERVATION", 133, 142]]], ["The risks both for infections and for severe disease seem to be lower in children.", [["infections", "DISEASE", 19, 29], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["infections", "PROBLEM", 19, 29], ["severe disease", "PROBLEM", 38, 52]]], ["Increasing age and the presence of comorbidities, such as hypertension, cardiovascular disease, diabetes, and pulmonary disease, are reported risk factors for severe disease and mortality [1\u20136].", [["cardiovascular", "ANATOMY", 72, 86], ["pulmonary", "ANATOMY", 110, 119], ["hypertension", "DISEASE", 58, 70], ["cardiovascular disease", "DISEASE", 72, 94], ["diabetes", "DISEASE", 96, 104], ["pulmonary disease", "DISEASE", 110, 127], ["pulmonary", "ORGAN", 110, 119], ["comorbidities", "PROBLEM", 35, 48], ["hypertension", "PROBLEM", 58, 70], ["cardiovascular disease", "PROBLEM", 72, 94], ["diabetes", "PROBLEM", 96, 104], ["pulmonary disease", "PROBLEM", 110, 127], ["severe disease", "PROBLEM", 159, 173], ["comorbidities", "OBSERVATION", 35, 48], ["hypertension", "OBSERVATION", 58, 70], ["cardiovascular disease", "OBSERVATION", 72, 94], ["diabetes", "OBSERVATION", 96, 104], ["pulmonary", "ANATOMY", 110, 119], ["disease", "OBSERVATION", 120, 127]]], ["Patients, who develop more severe symptoms including respiratory failure, often progress during the 2nd week after the start of symptoms and it is believed that this is to a great extent due to an immune reaction in the lower airways.", [["respiratory", "ANATOMY", 53, 64], ["lower airways", "ANATOMY", 220, 233], ["respiratory failure", "DISEASE", 53, 72], ["Patients", "ORGANISM", 0, 8], ["lower airways", "MULTI-TISSUE_STRUCTURE", 220, 233], ["Patients", "SPECIES", 0, 8], ["more severe symptoms", "PROBLEM", 22, 42], ["respiratory failure", "PROBLEM", 53, 72], ["symptoms", "PROBLEM", 128, 136], ["an immune reaction in the lower airways", "PROBLEM", 194, 233], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["respiratory failure", "OBSERVATION", 53, 72], ["immune reaction", "OBSERVATION", 197, 212], ["lower", "ANATOMY_MODIFIER", 220, 225], ["airways", "ANATOMY", 226, 233]]], ["Whether patients, who are immunosuppressed develop a different form of disease is currently unclear although some preliminary information from early cases indicate that such can be the case.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["immunosuppressed", "PROBLEM", 26, 42], ["disease", "PROBLEM", 71, 78], ["disease", "OBSERVATION", 71, 78]]], ["Health care workers are also at risk for contracting COVID-19 [7].Staff ::: Prevention policies and proceduresStaff with any symptoms of infection should stay at home.", [["infection", "DISEASE", 137, 146], ["COVID-19", "CHEMICAL", 53, 61], ["contracting COVID", "TEST", 41, 58], ["any symptoms of infection", "PROBLEM", 121, 146], ["infection", "OBSERVATION", 137, 146]]], ["Testing for SARS-CoV-2 is strongly recommended since symptoms can be uncharacteristic and very mild.", [["SARS", "DISEASE", 12, 16], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 12, 22], ["SARS-CoV", "SPECIES", 12, 20], ["Testing", "TEST", 0, 7], ["SARS", "PROBLEM", 12, 16], ["CoV", "TEST", 17, 20], ["symptoms", "PROBLEM", 53, 61], ["mild", "OBSERVATION_MODIFIER", 95, 99]]], ["Return to work by staff, who have recovered from COVID-19 should follow national guidelines, usually requiring the resolution of symptoms and two negative PCR results.Staff ::: Prevention policies and proceduresTraining of staff in proper procedures, including caring for those with suspected or confirmed infection, ensuring adequate access to personal protection equipment and planning for possible staff shortage are critical.", [["infection", "DISEASE", 306, 315], ["symptoms", "PROBLEM", 129, 137], ["infection", "PROBLEM", 306, 315], ["personal protection equipment", "TREATMENT", 345, 374], ["infection", "OBSERVATION", 306, 315]]], ["Personal protective equipment especially masks are important to limit the spread and to reduce the risk for health care workers to become infected.", [["Personal protective equipment", "TREATMENT", 0, 29], ["health care workers", "TREATMENT", 108, 127], ["infected", "PROBLEM", 138, 146], ["infected", "OBSERVATION", 138, 146]]], ["Surgical masks protect mainly for transmission of the virus from an infected individual while certain masks of the FFP2/3 class (those with an exhalation valve) protect the wearer of the mask but may not prevent from transmitting the virus.", [["Surgical masks", "TREATMENT", 0, 14], ["the virus", "PROBLEM", 50, 59], ["an exhalation valve", "TREATMENT", 140, 159], ["the mask", "TREATMENT", 183, 191], ["the virus", "PROBLEM", 230, 239], ["infected", "OBSERVATION", 68, 76], ["exhalation valve", "OBSERVATION", 143, 159]]], ["An FFP2/3 mask without exhalation valve also prevents from transmitting and is an alternative.", [["An FFP2/3 mask", "TREATMENT", 0, 14], ["exhalation valve", "TREATMENT", 23, 39], ["exhalation valve", "OBSERVATION", 23, 39]]], ["Thus, correct selection of the mask and correct use are crucial.", [["the mask", "TREATMENT", 27, 35]]], ["Regular team briefings and opportunities to talk to prevent carer fatigue should be in place.Outpatient visits and visitors ::: Prevention policies and proceduresOutpatient visits should be as much as possible either deferred or substituted with telemedicine visits if deemed appropriate and feasible.", [["fatigue", "DISEASE", 66, 73], ["carer fatigue", "PROBLEM", 60, 73]]], ["Staff should preferably be dedicated to a COVID-19 free transplant unit and not used interchangeably to care for COVID-19 positive patients although in centers with a large number of COVID-19 positive patients, it is recognized that this will not be feasible.", [["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 201, 209], ["a COVID-19 free transplant unit", "TREATMENT", 40, 71], ["COVID", "TEST", 113, 118], ["COVID", "TEST", 183, 188], ["large", "OBSERVATION_MODIFIER", 167, 172]]], ["It is critical that proper protective equipment is used as recommended by national and international competent authorities.Outpatient visits and visitors ::: Prevention policies and proceduresNo visitors should be allowed in transplant units.", [["proper protective equipment", "TREATMENT", 20, 47]]], ["There might be exceptions for parents to transplanted children; testing for SAR-CoV-2 should then be considered before entering the ward.", [["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62], ["testing", "TEST", 64, 71], ["SAR", "TEST", 76, 79], ["CoV", "TEST", 80, 83]]], ["Repeated testing might then be necessary.", [["Repeated testing", "TEST", 0, 16]]], ["This will bring its own set of challenges when attempting to have end of life conversations with families who will not be present in person.", [["person", "SPECIES", 133, 139]]], ["New ways of working and communicating with patients and families need to be identified, such as a daily telephone round of the next of kin to update on progress and transmit the patient\u2019s wishes.Patients after HCT ::: Prevention policies and proceduresConsiderations in HCT and CAR T-cell recipients still being regarded as immunosuppressed or having significant organ dysfunction.", [["T-cell", "ANATOMY", 282, 288], ["organ", "ANATOMY", 363, 368], ["organ dysfunction", "DISEASE", 363, 380], ["patients", "ORGANISM", 43, 51], ["patient", "ORGANISM", 178, 185], ["Patients", "ORGANISM", 195, 203], ["CAR T-cell", "CELL", 278, 288], ["organ", "ORGAN", 363, 368], ["patients", "SPECIES", 43, 51], ["patient", "SPECIES", 178, 185], ["Patients", "SPECIES", 195, 203], ["HCT", "TEST", 210, 213], ["HCT", "TEST", 270, 273], ["CAR T-cell recipients", "TREATMENT", 278, 299], ["significant organ dysfunction", "PROBLEM", 351, 380], ["organ", "ANATOMY", 363, 368], ["dysfunction", "OBSERVATION", 369, 380]]], ["They should limit their risk of exposure to infected individuals as much as possible and strictly adhere to prevention practices such as hand hygiene and social distancing.", [["hand", "ANATOMY", 137, 141], ["hand", "ORGANISM_SUBDIVISION", 137, 141], ["prevention practices", "TREATMENT", 108, 128], ["infected", "OBSERVATION", 44, 52]]], ["Stem cell transplant patients should refrain from travel and if travel is deemed absolutely necessary, travel by private car instead of any public transportations system including train, bus, or plane is recommended if feasible.Patients after HCT ::: Prevention policies and proceduresPhysical and social isolation although a usual practice for many transplant patients will now extend further and for a longer period of time and local services and practices need to be explored by the nursing staff to ensure that patients have adequate provision to be cared for at home.Patients after HCT ::: Prevention policies and proceduresAll patients, including those without symptoms, should be triaged and tested before entering the transplant ward.", [["Stem cell", "ANATOMY", 0, 9], ["Stem cell", "CELL", 0, 9], ["patients", "ORGANISM", 21, 29], ["Patients", "ORGANISM", 228, 236], ["patients", "ORGANISM", 361, 369], ["patients", "ORGANISM", 515, 523], ["Patients", "ORGANISM", 572, 580], ["patients", "ORGANISM", 633, 641], ["patients", "SPECIES", 21, 29], ["Patients", "SPECIES", 228, 236], ["patients", "SPECIES", 361, 369], ["patients", "SPECIES", 515, 523], ["Patients", "SPECIES", 572, 580], ["patients", "SPECIES", 633, 641], ["Stem cell transplant", "TREATMENT", 0, 20], ["HCT", "TEST", 243, 246], ["many transplant patients", "TREATMENT", 345, 369], ["HCT", "TEST", 587, 590], ["symptoms", "PROBLEM", 667, 675], ["cell transplant", "OBSERVATION", 5, 20]]], ["Adequate space for symptomatic patients while awaiting the results of COVID-19 testing should be allocated preferably separate from the transplant unit.Patients after HCT ::: Prevention policies and proceduresPatients planned to be admitted for a transplant or to undergo CAR T-cell therapy should try to minimize the risk by home isolation 14 days before the start of the transplant conditioning.", [["T-cell", "ANATOMY", 276, 282], ["patients", "ORGANISM", 31, 39], ["Patients", "ORGANISM", 152, 160], ["Patients", "ORGANISM", 209, 217], ["CAR T-cell", "CELL", 272, 282], ["patients", "SPECIES", 31, 39], ["Patients", "SPECIES", 152, 160], ["Patients", "SPECIES", 209, 217], ["COVID", "TEST", 70, 75], ["HCT", "TEST", 167, 170], ["a transplant", "TREATMENT", 245, 257], ["CAR T-cell therapy", "TREATMENT", 272, 290], ["home isolation", "TREATMENT", 326, 340], ["the transplant conditioning", "TREATMENT", 369, 396], ["symptomatic", "OBSERVATION_MODIFIER", 19, 30], ["transplant", "OBSERVATION", 373, 383]]], ["Unnecessary clinic visits should be avoided.Transplant candidates ::: Prevention policies and proceduresIt is recognized that patients might suffer harm if necessary transplant and other treatment procedures are delayed due to COVID-19.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["transplant", "TREATMENT", 166, 176], ["other treatment procedures", "TREATMENT", 181, 207], ["COVID", "TEST", 227, 232]]], ["It is not possible to give clear guidelines regarding which procedures should be delayed since the situation is highly variable between transplant centers.", [["not possible", "UNCERTAINTY", 6, 18]]], ["Before starting the transplant procedure, availability of adequately trained staff, ICU beds, ventilators, as well as availability of the stem cell product should be ensured.", [["stem cell", "ANATOMY", 138, 147], ["stem cell", "CELL", 138, 147], ["the transplant procedure", "TREATMENT", 16, 40], ["ICU beds", "TREATMENT", 84, 92], ["ventilators", "TREATMENT", 94, 105], ["the stem cell product", "TREATMENT", 134, 155], ["stem cell", "OBSERVATION", 138, 147]]], ["In general, however, non-urgent transplants should be deferred as much as possible, especially for non-malignant disorders.", [["non-malignant", "ANATOMY", 99, 112], ["non-urgent transplants", "TREATMENT", 21, 43], ["non-malignant disorders", "PROBLEM", 99, 122]]], ["For those that will have delays in treatment, signposting to appropriate local advice and support groups is of paramount importance.Transplant candidates ::: Prevention policies and proceduresAll patients should be tested for SARS-CoV-2 and the test results should be negative before start of the conditioning regardless of whether upper respiratory symptoms are present.Transplant candidates ::: Prevention policies and proceduresA difficult question based on lack of data is deferral of transplant candidates if they become infected with COVID-19.", [["respiratory", "ANATOMY", 338, 349], ["SARS", "DISEASE", 226, 230], ["COVID-19", "CHEMICAL", 540, 548], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["SARS-CoV", "SPECIES", 226, 234], ["treatment", "TREATMENT", 35, 44], ["SARS", "PROBLEM", 226, 230], ["CoV", "TEST", 231, 234], ["the test", "TEST", 241, 249], ["the conditioning", "TREATMENT", 293, 309], ["upper respiratory symptoms", "PROBLEM", 332, 358], ["transplant candidates", "TREATMENT", 489, 510], ["COVID", "TEST", 540, 545], ["upper", "ANATOMY_MODIFIER", 332, 337], ["respiratory", "ANATOMY", 338, 349], ["symptoms", "OBSERVATION", 350, 358]]], ["At the point of consent for transplant discussions around advanced care planning should be initiated and include the scenario of becoming positive during the transplant process and what steps and actions the patient and treating team wish to take, with early conversations and plans put in place as soon as there is a suspicion that the patient may be COVID-19 positive.", [["patient", "ORGANISM", 208, 215], ["patient", "ORGANISM", 337, 344], ["patient", "SPECIES", 208, 215], ["patient", "SPECIES", 337, 344], ["transplant discussions", "TREATMENT", 28, 50], ["advanced care planning", "TREATMENT", 58, 80], ["the transplant process", "TREATMENT", 154, 176], ["COVID", "TEST", 352, 357], ["positive", "OBSERVATION", 138, 146]]], ["The decision has to be made based on individual considerations taking into account the risk of the patient associated with on one hand the delay of the procedure and on the other proceeding with conditioning.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["the procedure", "TREATMENT", 148, 161]]], ["In general, however, if a transplant candidate is diagnosed with COVID-19 a deferral of at least 3 months is advisable, in accordance with ECDC recommendations.", [["COVID", "TEST", 65, 70]]], ["However, this is not always possible due to the risk for progression of the underlying disease.", [["the underlying disease", "PROBLEM", 72, 94], ["not always possible", "UNCERTAINTY", 17, 36], ["disease", "OBSERVATION", 87, 94]]], ["This might be particularly pertinent for patients waiting for CAR T-cell therapy since this is frequently performed on patients refractory for other therapies and therefore being at a very high risk for progress of the underlying disease Therefore, in patients with high risk disease, stem cell transplantation should be deferred until the patient is asymptomatic and has two negative virus PCR swabs taken at least 24 h apart.", [["T-cell", "ANATOMY", 66, 72], ["stem cell", "ANATOMY", 285, 294], ["patients", "ORGANISM", 41, 49], ["CAR T-cell", "CELL", 62, 72], ["patients", "ORGANISM", 119, 127], ["patients", "ORGANISM", 252, 260], ["stem cell", "CELL", 285, 294], ["patient", "ORGANISM", 340, 347], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 252, 260], ["patient", "SPECIES", 340, 347], ["CAR T-cell therapy", "TREATMENT", 62, 80], ["other therapies", "TREATMENT", 143, 158], ["the underlying disease", "PROBLEM", 215, 237], ["high risk disease", "PROBLEM", 266, 283], ["stem cell transplantation", "TREATMENT", 285, 310], ["asymptomatic", "PROBLEM", 351, 363], ["virus PCR swabs", "TEST", 385, 400], ["disease", "OBSERVATION", 230, 237], ["stem cell transplantation", "OBSERVATION", 285, 310]]], ["Deferral of 14 days is a minimum but should preferably be 21 days and a new PCR is recommended before the start of conditioning.", [["a new PCR", "TEST", 70, 79]]], ["In patients with low-risk disease a 3-month HCT deferral is recommended.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["low-risk disease", "PROBLEM", 17, 33], ["HCT deferral", "TEST", 44, 56]]], ["Individual considerations have to be made for CAR T-cell patients.Transplant candidates ::: Prevention policies and proceduresIn case of close contact with a person diagnosed with COVID-19 any transplant procedures (PBSC mobilization, BM harvest, and conditioning) shall not be performed within at least 14, and preferably 21, days from the last contact.", [["T-cell", "ANATOMY", 50, 56], ["PBSC", "ANATOMY", 216, 220], ["BM", "ANATOMY", 235, 237], ["COVID", "DISEASE", 180, 185], ["CAR T-cell", "CELL", 46, 56], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["person", "SPECIES", 158, 164], ["COVID", "TREATMENT", 180, 185], ["any transplant procedures", "TREATMENT", 189, 214], ["PBSC mobilization", "TREATMENT", 216, 233], ["BM harvest", "TREATMENT", 235, 245]]], ["Patient should be closely monitored for the presence of COVID-19, with confirmed PCR negativity before any transplant procedure is undertaken.Donor considerations ::: Prevention policies and proceduresAccess to a stem cell donor might be restricted either due to the donor becoming infected, logistical reasons at the harvest centers in the middle of a strained health care system, or travel restrictions across international borders.", [["stem cell", "ANATOMY", 213, 222], ["Patient", "ORGANISM", 0, 7], ["stem cell", "CELL", 213, 222], ["Patient", "SPECIES", 0, 7], ["COVID", "TEST", 56, 61], ["PCR", "TEST", 81, 84], ["any transplant procedure", "TREATMENT", 103, 127], ["a stem cell donor", "TREATMENT", 211, 228], ["infected", "PROBLEM", 282, 290], ["the harvest centers", "TREATMENT", 314, 333], ["stem cell", "OBSERVATION", 213, 222], ["infected", "OBSERVATION", 282, 290], ["middle", "ANATOMY_MODIFIER", 341, 347]]], ["It is therefore strongly recommended to have secured stem cell product access by freezing the product before start of conditioning, and, in situations when this is not possible, to have an alternative donor as a back-up.", [["stem cell", "ANATOMY", 53, 62], ["stem cell", "CELL", 53, 62], ["secured stem cell product access", "TREATMENT", 45, 77], ["an alternative donor", "TREATMENT", 186, 206], ["stem cell", "OBSERVATION", 53, 62]]], ["Peripheral blood should be preferentially used unless there is a strong indication for bone marrow.Donor considerations ::: Prevention policies and proceduresSARS-CoV and MERS-CoV have been detected in blood, although there have not been any reports of transmission from donor to recipient either in transfusion of blood products or cellular therapies [8].", [["Peripheral blood", "ANATOMY", 0, 16], ["bone marrow", "ANATOMY", 87, 98], ["blood", "ANATOMY", 202, 207], ["blood", "ANATOMY", 315, 320], ["cellular", "ANATOMY", 333, 341], ["Peripheral blood", "ORGANISM_SUBSTANCE", 0, 16], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 87, 98], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 171, 179], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["blood", "ORGANISM_SUBSTANCE", 315, 320], ["cellular", "CELL", 333, 341], ["MERS-CoV", "SPECIES", 171, 179], ["Peripheral blood", "TEST", 0, 16], ["bone marrow", "PROBLEM", 87, 98], ["proceduresSARS-CoV", "TEST", 148, 166], ["MERS", "PROBLEM", 171, 175], ["CoV", "PROBLEM", 176, 179], ["blood products", "TREATMENT", 315, 329], ["cellular therapies", "TREATMENT", 333, 351], ["blood", "ANATOMY", 11, 16]]], ["WMDA has produced recommendations and the EBMT endorses these guidelines.Donor considerations ::: Prevention policies and proceduresIn case of diagnosis of COVID-19, donor must be excluded from donation.", [["WMDA", "CHEMICAL", 0, 4], ["COVID", "TEST", 156, 161], ["donor", "TREATMENT", 166, 171]]], ["At this time, it is not possible to give recommendations when such an individual can be cleared for donation, but 3-month deferral can be considered unless the need for donation is urgent, and case-specific considerations should be made.Donor considerations ::: Prevention policies and proceduresIn case of close contact with a person diagnosed with SARS-CoV-2, the donor shall be excluded from donation for at least 28 days.", [["SARS", "DISEASE", 350, 354], ["person", "SPECIES", 328, 334], ["SARS-CoV", "SPECIES", 350, 358], ["SARS", "PROBLEM", 350, 354], ["the donor", "TREATMENT", 362, 371]]], ["Donor should be closely monitored for the presence of COVID-19.", [["COVID-19", "CHEMICAL", 54, 62], ["Donor", "TREATMENT", 0, 5], ["COVID", "TEST", 54, 59]]], ["If the patient\u2019s need for transplant is urgent, the donor is completely well, a test is negative for SARS-CoV-2 and there are no suitable alternative donors, earlier collection may be considered subject to careful risk assessment.Donor considerations ::: Prevention policies and proceduresDonors within 28 days of donation should practice good hygiene and be as socially isolated as feasible during this period.", [["SARS", "DISEASE", 101, 105], ["patient", "ORGANISM", 7, 14], ["donors", "ORGANISM", 150, 156], ["patient", "SPECIES", 7, 14], ["SARS-CoV", "SPECIES", 101, 109], ["transplant", "TREATMENT", 26, 36], ["a test", "TEST", 78, 84], ["SARS", "PROBLEM", 101, 105], ["CoV", "TEST", 106, 109], ["careful risk assessment", "TEST", 206, 229], ["donation", "TREATMENT", 314, 322], ["no", "UNCERTAINTY", 126, 128]]], ["Donors should have been asymptomatic for at least 14 (preferably 21) days before donation.", [["Donors", "ORGANISM", 0, 6], ["asymptomatic", "PROBLEM", 24, 36]]], ["It is recommended that donors are tested for COVID-19 prior to starting the mobilization procedure.Diagnosis of COVID-19 ::: Diagnosis and management of COVID-19Diagnostic procedures for COVID-19 should follow national or local guidelines.", [["donors", "ORGANISM", 23, 29], ["COVID", "TEST", 45, 50], ["the mobilization procedure", "TREATMENT", 72, 98], ["COVID", "TEST", 112, 117], ["COVID", "TEST", 153, 158], ["COVID", "TEST", 187, 192]]], ["It is important to note that a test for SARS-CoV-2 in nasopharyngeal swab can be falsely negative and needs to be repeated if there is a strong clinical suspicion of COVID-19.", [["nasopharyngeal swab", "ANATOMY", 54, 73], ["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "ORGANISM", 40, 50], ["nasopharyngeal swab", "CANCER", 54, 73], ["SARS-CoV", "SPECIES", 40, 48], ["a test", "TEST", 29, 35], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48], ["nasopharyngeal swab", "TEST", 54, 73], ["COVID", "TEST", 166, 171], ["nasopharyngeal", "ANATOMY", 54, 68]]], ["The performance of testing is better in samples from the lower than from the upper respiratory tract.", [["samples", "ANATOMY", 40, 47], ["upper respiratory tract", "ANATOMY", 77, 100], ["upper respiratory", "ORGANISM_SUBDIVISION", 77, 94], ["tract", "ORGANISM_SUBDIVISION", 95, 100], ["testing", "TEST", 19, 26], ["lower", "ANATOMY_MODIFIER", 57, 62], ["upper", "ANATOMY_MODIFIER", 77, 82], ["respiratory tract", "ANATOMY", 83, 100]]], ["It is also important to test for other respiratory viral pathogens including influenza and RSV preferably by multiplex PCR.SARS-CoV-2 infected patients ::: Diagnosis and management of COVID-19Patients, who are positive for SARS-CoV-2 should not be treated in rooms with laminar air flow or other rooms (HEPA) with positive pressure unless the ventilation can be turned off.", [["respiratory viral pathogens", "DISEASE", 39, 66], ["influenza", "DISEASE", 77, 86], ["SARS-CoV-2 infected", "DISEASE", 123, 142], ["SARS", "DISEASE", 223, 227], ["RSV", "ORGANISM", 91, 94], ["SARS-CoV-2", "ORGANISM", 123, 133], ["patients", "ORGANISM", 143, 151], ["SARS-CoV-2", "ORGANISM", 223, 233], ["patients", "SPECIES", 143, 151], ["RSV", "SPECIES", 91, 94], ["SARS-CoV", "SPECIES", 223, 231], ["other respiratory viral pathogens", "PROBLEM", 33, 66], ["influenza", "PROBLEM", 77, 86], ["RSV", "PROBLEM", 91, 94], ["multiplex PCR", "TEST", 109, 122], ["COVID", "TEST", 184, 189], ["SARS", "PROBLEM", 223, 227], ["positive pressure", "TREATMENT", 314, 331], ["the ventilation", "TREATMENT", 339, 354], ["air flow", "OBSERVATION", 278, 286]]], ["All patients positive for SARS-CoV-2 in an upper respiratory tract sample should undergo chest imaging, preferably by CT, and evaluation of oxygenation impairment.", [["upper respiratory tract sample", "ANATOMY", 43, 73], ["chest", "ANATOMY", 89, 94], ["SARS", "DISEASE", 26, 30], ["oxygenation impairment", "DISEASE", 140, 162], ["patients", "ORGANISM", 4, 12], ["SARS-CoV-2", "ORGANISM", 26, 36], ["upper", "ORGANISM_SUBDIVISION", 43, 48], ["respiratory tract", "ORGANISM_SUBDIVISION", 49, 66], ["chest", "ORGAN", 89, 94], ["patients", "SPECIES", 4, 12], ["SARS-CoV", "SPECIES", 26, 34], ["SARS", "PROBLEM", 26, 30], ["CoV", "TEST", 31, 34], ["an upper respiratory tract sample", "PROBLEM", 40, 73], ["chest imaging", "TEST", 89, 102], ["CT", "TEST", 118, 120], ["evaluation", "TEST", 126, 136], ["oxygenation impairment", "PROBLEM", 140, 162], ["upper", "ANATOMY_MODIFIER", 43, 48], ["respiratory tract", "ANATOMY", 49, 66], ["chest", "ANATOMY", 89, 94]]], ["Routine bronchoalveolar lavage is not recommended if a patient tested positive for SARS-CoV-2 given risk of transmission amongst health care workers, unless a co-infection is suspected.", [["bronchoalveolar lavage", "ANATOMY", 8, 30], ["SARS", "DISEASE", 83, 87], ["co-infection", "DISEASE", 159, 171], ["patient", "ORGANISM", 55, 62], ["SARS-CoV-2", "ORGANISM", 83, 93], ["patient", "SPECIES", 55, 62], ["SARS-CoV", "SPECIES", 83, 91], ["Routine bronchoalveolar lavage", "TEST", 0, 30], ["SARS", "PROBLEM", 83, 87], ["CoV", "TEST", 88, 91], ["a co-infection", "PROBLEM", 157, 171], ["bronchoalveolar lavage", "OBSERVATION", 8, 30], ["co-infection", "OBSERVATION", 159, 171]]], ["Co-pathogens should be evaluated and treated.Treatment of COVID-19 positive transplant recipients and CAR T-cell patients ::: Treatment ::: Diagnosis and management of COVID-19Currently there is no approved treatment options in Europe and there is no available vaccine.", [["T-cell", "ANATOMY", 106, 112], ["COVID-19", "CANCER", 58, 66], ["recipients", "ORGANISM", 87, 97], ["CAR T-cell", "CELL", 102, 112], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Co-pathogens", "TREATMENT", 0, 12], ["COVID", "TEST", 58, 63], ["positive transplant recipients", "TREATMENT", 67, 97], ["COVID", "TEST", 168, 173], ["no", "UNCERTAINTY", 195, 197]]], ["Several drugs have been studied in prior coronavirus outbreaks (SARS-CoV and MERS-CoV) and though some benefit has been demonstrated, the data are inconclusive.", [["coronavirus outbreaks", "DISEASE", 41, 62], ["SARS-CoV and MERS-CoV", "DISEASE", 64, 85], ["coronavirus", "ORGANISM", 41, 52], ["SARS-CoV", "ORGANISM", 64, 72], ["MERS-CoV", "ORGANISM", 77, 85], ["SARS-CoV", "SPECIES", 64, 72], ["MERS-CoV", "SPECIES", 77, 85], ["Several drugs", "TREATMENT", 0, 13], ["prior coronavirus outbreaks", "PROBLEM", 35, 62], ["the data", "TEST", 134, 142], ["drugs", "OBSERVATION", 8, 13]]], ["Remdesivir has demonstrated in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are also coronaviruses and are structurally similar to SARS-CoV-2.", [["Remdesivir", "CHEMICAL", 0, 10], ["SARS", "DISEASE", 112, 116], ["SARS", "DISEASE", 179, 183], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["MERS", "GENE_OR_GENE_PRODUCT", 103, 107], ["SARS-CoV-2", "ORGANISM", 179, 189], ["SARS-CoV", "SPECIES", 179, 187], ["Remdesivir", "TREATMENT", 0, 10], ["the viral pathogens MERS", "PROBLEM", 83, 107], ["SARS", "PROBLEM", 112, 116], ["coronaviruses", "PROBLEM", 133, 146], ["CoV", "TEST", 184, 187], ["viral pathogens", "OBSERVATION", 87, 102]]], ["The limited preclinical data on remdesivir in MERS and SARS indicate that remdesivir may have potential activity against COVID-19 [9\u201311].", [["remdesivir", "CHEMICAL", 32, 42], ["SARS", "DISEASE", 55, 59], ["remdesivir", "CHEMICAL", 74, 84], ["remdesivir", "CHEMICAL", 32, 42], ["remdesivir", "CHEMICAL", 74, 84], ["COVID-19", "CHEMICAL", 121, 129], ["remdesivir", "SIMPLE_CHEMICAL", 32, 42], ["remdesivir", "SIMPLE_CHEMICAL", 74, 84], ["COVID", "TEST", 121, 126]]], ["Remdesivir is now approved by the FDA, and the EMA has recently granted compassionate use.", [["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "TREATMENT", 0, 10]]], ["Lopinavir/ritonavir has also been used but a recently published trial failed its primary endpoint [10, 12].", [["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 10, 19], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 10, 19], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["ritonavir", "SIMPLE_CHEMICAL", 10, 19], ["Lopinavir", "TREATMENT", 0, 9], ["ritonavir", "TREATMENT", 10, 19]]], ["Chloroquine and hydroxychloroquine have also been used with early data suggesting reduction of viral load and have been used for therapy [9, 13, 14].", [["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 16, 34], ["Chloroquine", "TREATMENT", 0, 11], ["hydroxychloroquine", "TREATMENT", 16, 34], ["viral load", "PROBLEM", 95, 105], ["therapy", "TREATMENT", 129, 136], ["viral load", "OBSERVATION", 95, 105]]], ["Interferon-\u03b1 and -\u03b2 are also being studied.Treatment of COVID-19 positive transplant recipients and CAR T-cell patients ::: Treatment ::: Diagnosis and management of COVID-19Since an important part of the pathology seems to be cytokine release, different therapies addressing this syndrome have been tested.", [["T-cell", "ANATOMY", 104, 110], ["COVID-19Since", "CHEMICAL", 166, 179], ["Interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 12], ["-\u03b2", "GENE_OR_GENE_PRODUCT", 17, 19], ["COVID-19", "CANCER", 56, 64], ["recipients", "ORGANISM", 85, 95], ["CAR T-cell", "CELL", 100, 110], ["patients", "ORGANISM", 111, 119], ["COVID-19Since", "SIMPLE_CHEMICAL", 166, 179], ["Interferon-\u03b1 and -\u03b2", "PROTEIN", 0, 19], ["cytokine", "PROTEIN", 227, 235], ["patients", "SPECIES", 111, 119], ["Interferon", "TREATMENT", 0, 10], ["COVID", "TEST", 56, 61], ["positive transplant recipients", "TREATMENT", 65, 95], ["management", "TREATMENT", 152, 162], ["COVID", "TEST", 166, 171], ["cytokine release", "TREATMENT", 227, 243], ["different therapies", "TREATMENT", 245, 264], ["this syndrome", "PROBLEM", 276, 289]]], ["Tocilizumab, which is approved for cytokine release syndrome after CAR T-cell therapy, have been used and is approved in China [15, 16].", [["T-cell", "ANATOMY", 71, 77], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["CAR T-cell", "CELL", 67, 77], ["cytokine", "PROTEIN", 35, 43], ["Tocilizumab", "TREATMENT", 0, 11], ["cytokine release syndrome", "PROBLEM", 35, 60], ["CAR T-cell therapy", "TREATMENT", 67, 85]]], ["Data on the use of corticosteroids are contradictory.", [["corticosteroids", "CHEMICAL", 19, 34], ["corticosteroids", "TREATMENT", 19, 34]]], ["However, short-term corticosteroid therapy was associated with lower mortality in immunocompetent patients with COVID-19-associated ARDS.Treatment of COVID-19 positive transplant recipients and CAR T-cell patients ::: Treatment ::: Diagnosis and management of COVID-19Some data suggest that use of angiotensin conversion enzyme inhibitors and angiotensin II receptor blocker might be implicated in development of organ failure in COVID-19 patients [17, 18] but lower mortality has also been reported with the use of these drugs [19].", [["T-cell", "ANATOMY", 198, 204], ["organ", "ANATOMY", 413, 418], ["COVID-19", "CHEMICAL", 112, 120], ["ARDS", "DISEASE", 132, 136], ["angiotensin", "CHEMICAL", 298, 309], ["angiotensin II", "CHEMICAL", 343, 357], ["organ failure", "DISEASE", 413, 426], ["COVID", "DISEASE", 430, 435], ["patients", "ORGANISM", 98, 106], ["COVID-19", "CANCER", 150, 158], ["recipients", "ORGANISM", 179, 189], ["CAR T-cell", "CELL", 194, 204], ["patients", "ORGANISM", 205, 213], ["angiotensin conversion enzyme", "GENE_OR_GENE_PRODUCT", 298, 327], ["angiotensin II receptor blocker", "GENE_OR_GENE_PRODUCT", 343, 374], ["organ", "ORGAN", 413, 418], ["patients", "ORGANISM", 439, 447], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 439, 447], ["short-term corticosteroid therapy", "TREATMENT", 9, 42], ["COVID", "TEST", 112, 117], ["ARDS", "PROBLEM", 132, 136], ["COVID", "TEST", 150, 155], ["positive transplant recipients", "TREATMENT", 159, 189], ["COVID", "TEST", 260, 265], ["angiotensin conversion enzyme inhibitors", "TREATMENT", 298, 338], ["angiotensin II receptor blocker", "TREATMENT", 343, 374], ["organ failure", "PROBLEM", 413, 426], ["COVID", "TEST", 430, 435], ["these drugs", "TREATMENT", 516, 527], ["immunocompetent", "OBSERVATION", 82, 97], ["ARDS", "OBSERVATION", 132, 136], ["organ", "ANATOMY", 413, 418], ["failure", "OBSERVATION", 419, 426]]], ["Similarly, it has been suggested that NSAIDs might have negative effects and therefore acetaminophen/paracetamol are preferred as anti-pyretics.Treatment of COVID-19 positive transplant recipients and CAR T-cell patients ::: Treatment ::: Diagnosis and management of COVID-19At this point no clear recommendations can be made on specific therapies due to limited data and unknown risk vs benefit.", [["T-cell", "ANATOMY", 205, 211], ["NSAIDs", "CHEMICAL", 38, 44], ["acetaminophen", "CHEMICAL", 87, 100], ["paracetamol", "CHEMICAL", 101, 112], ["acetaminophen", "CHEMICAL", 87, 100], ["paracetamol", "CHEMICAL", 101, 112], ["NSAIDs", "SIMPLE_CHEMICAL", 38, 44], ["acetaminophen", "SIMPLE_CHEMICAL", 87, 100], ["paracetamol", "SIMPLE_CHEMICAL", 101, 112], ["anti-pyretics", "SIMPLE_CHEMICAL", 130, 143], ["COVID-19", "CANCER", 157, 165], ["recipients", "ORGANISM", 186, 196], ["CAR T-cell", "CELL", 201, 211], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["NSAIDs", "TREATMENT", 38, 44], ["acetaminophen", "TREATMENT", 87, 100], ["paracetamol", "TREATMENT", 101, 112], ["anti-pyretics", "TREATMENT", 130, 143], ["COVID", "TEST", 157, 162], ["positive transplant recipients", "TREATMENT", 166, 196], ["COVID", "TEST", 267, 272], ["specific therapies", "TREATMENT", 329, 347]]], ["Even less data are available for pediatric patients.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51]]], ["Therapy should be given in close collaboration with specialists in infectious diseases.", [["infectious diseases", "DISEASE", 67, 86], ["Therapy", "TREATMENT", 0, 7]]], ["Despite FDA approval of remdesivir, it is still unclear if and when it optimally should be used.", [["remdesivir", "CHEMICAL", 24, 34], ["remdesivir", "CHEMICAL", 24, 34], ["remdesivir", "SIMPLE_CHEMICAL", 24, 34], ["remdesivir", "TREATMENT", 24, 34]]], ["Later in the course of the infection anti-inflammatory therapy with corticosteroids and/or tocilizumab has been shown to be of value in non-transplant patients.", [["infection", "DISEASE", 27, 36], ["corticosteroids", "CHEMICAL", 68, 83], ["tocilizumab", "CHEMICAL", 91, 102], ["corticosteroids", "CHEMICAL", 68, 83], ["corticosteroids", "SIMPLE_CHEMICAL", 68, 83], ["tocilizumab", "SIMPLE_CHEMICAL", 91, 102], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["the infection anti-inflammatory therapy", "TREATMENT", 23, 62], ["corticosteroids", "TREATMENT", 68, 83], ["tocilizumab", "TREATMENT", 91, 102], ["infection", "OBSERVATION_MODIFIER", 27, 36], ["anti-inflammatory therapy", "OBSERVATION", 37, 62]]], ["Supportive care is crucial including non-invasive ventilation and anti-coagulants to prevent thromboembolic complications, which can be frequent and severe in patients with COVID.", [["thromboembolic complications", "DISEASE", 93, 121], ["COVID", "DISEASE", 173, 178], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["Supportive care", "TREATMENT", 0, 15], ["non-invasive ventilation", "TREATMENT", 37, 61], ["anti-coagulants", "TREATMENT", 66, 81], ["thromboembolic complications", "PROBLEM", 93, 121], ["COVID", "TREATMENT", 173, 178], ["thromboembolic", "OBSERVATION", 93, 107], ["severe", "OBSERVATION_MODIFIER", 149, 155]]], ["Treatment of viral, bacterial and fungal co-pathogens should be optimized.", [["viral, bacterial and fungal co-pathogens", "PROBLEM", 13, 53], ["viral", "OBSERVATION", 13, 18], ["bacterial", "OBSERVATION_MODIFIER", 20, 29], ["fungal co-pathogens", "OBSERVATION", 34, 53]]], ["It is currently recommended that immunosuppressive prophylaxis/treatment is continued since there is no data supporting reducing immunosuppression and it might instead cause harm.JACIE and COVID-19In the light of substantial and ongoing disruption caused by the international COVID-19 pandemic, which has made normal JACIE accreditation services difficult or impossible to maintain in the foreseeable future, the EBMT took the decision to extend current accreditations by 12 months and to give coverage to those centers that are actively preparing for reaccreditation https://www.ebmt.org/covid-19-and-bmt.JACIE and COVID-19Even so, for centers already accredited (or preparing for accreditation) current and recent versions of JACIE standards include extensive reference to disaster planning within the clinical, collection (apheresis and bone marrow) and processing sections [20].", [["bone marrow", "ANATOMY", 840, 851], ["sections", "ANATOMY", 868, 876], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 840, 851], ["immunosuppressive prophylaxis", "TREATMENT", 33, 62], ["treatment", "TREATMENT", 63, 72], ["reducing immunosuppression", "TREATMENT", 120, 146], ["JACIE", "TEST", 179, 184], ["COVID", "TEST", 189, 194], ["ongoing disruption", "PROBLEM", 229, 247], ["the international COVID", "TEST", 258, 281], ["pandemic", "PROBLEM", 285, 293], ["JACIE standards", "TREATMENT", 728, 743], ["disaster planning", "TREATMENT", 775, 792], ["collection (apheresis and bone marrow)", "TREATMENT", 814, 852], ["processing sections", "TEST", 857, 876], ["bone marrow", "ANATOMY", 840, 851]]], ["Modifications to usual care should be considered within the broader organization according to ongoing quality management systems in the program and other JACIE accreditation requirements.", [["usual care", "TREATMENT", 17, 27]]], ["JACIE is currently evaluating whether more simplified versions of quality standards currently being applied to low and middle income countries, such as \u2018Stepwise\u2019 or other systems, will have value during the COVID-19 pandemic and its aftermath which may last for many months.DiscussionThe COVID-19 pandemic has resulted in previously unprecedented challenges to transplant programs and physicians performing stem cell transplantation.", [["stem cell", "ANATOMY", 408, 417], ["stem cell", "CELL", 408, 417], ["quality standards", "TREATMENT", 66, 83], ["transplant programs", "TREATMENT", 362, 381], ["stem cell transplantation", "TREATMENT", 408, 433], ["stem cell transplantation", "OBSERVATION", 408, 433]]], ["Although WHO and other international and national authorities have warned for the possibility of a new pandemic caused most likely by a viral pathogen such as SARS-CoV-1, SARS-CoV-2, a new influenza strain, or possibly a hemorrhagic fever such as Ebola or Lassa, the health care systems were caught unprepared for the COVID-19 pandemic.", [["SARS", "DISEASE", 159, 163], ["influenza strain", "DISEASE", 189, 205], ["hemorrhagic fever", "DISEASE", 221, 238], ["Ebola or Lassa", "DISEASE", 247, 261], ["SARS-CoV-1", "ORGANISM", 159, 169], ["SARS-CoV-2", "ORGANISM", 171, 181], ["Ebola", "ORGANISM", 247, 252], ["CoV-1", "SPECIES", 164, 169], ["Ebola", "SPECIES", 247, 252], ["SARS-CoV-1", "SPECIES", 159, 169], ["SARS-CoV-2", "SPECIES", 171, 181], ["a new pandemic", "PROBLEM", 97, 111], ["a viral pathogen", "PROBLEM", 134, 150], ["SARS", "PROBLEM", 159, 163], ["CoV", "TEST", 164, 167], ["SARS", "PROBLEM", 171, 175], ["CoV", "TEST", 176, 179], ["a new influenza strain", "PROBLEM", 183, 205], ["a hemorrhagic fever", "PROBLEM", 219, 238], ["Ebola", "PROBLEM", 247, 252], ["Lassa", "PROBLEM", 256, 261], ["the COVID", "TEST", 314, 323], ["pandemic", "PROBLEM", 327, 335], ["most likely", "UNCERTAINTY", 119, 130], ["new", "OBSERVATION_MODIFIER", 185, 188], ["influenza", "OBSERVATION", 189, 198], ["hemorrhagic", "OBSERVATION_MODIFIER", 221, 232], ["fever", "OBSERVATION", 233, 238]]], ["However, enormous activity has started from the beginning of the outbreak in China to learn more about the virus and the disease and to disseminate this knowledge across the world, Since the virus is new to the human population, it is likely that before long-term virus control is achieved a large proportion of the population will have to either have experienced the viral infection or have been vaccinated.", [["viral infection", "DISEASE", 368, 383], ["human", "ORGANISM", 211, 216], ["human", "SPECIES", 211, 216], ["human", "SPECIES", 211, 216], ["enormous activity", "PROBLEM", 9, 26], ["the virus", "PROBLEM", 103, 112], ["the disease", "PROBLEM", 117, 128], ["the virus", "PROBLEM", 187, 196], ["long-term virus control", "TREATMENT", 254, 277], ["the viral infection", "PROBLEM", 364, 383], ["enormous", "OBSERVATION_MODIFIER", 9, 17], ["activity", "OBSERVATION_MODIFIER", 18, 26], ["disease", "OBSERVATION", 121, 128], ["virus", "OBSERVATION", 191, 196], ["new", "OBSERVATION_MODIFIER", 200, 203], ["is likely", "UNCERTAINTY", 232, 241], ["large", "OBSERVATION_MODIFIER", 292, 297], ["viral", "OBSERVATION_MODIFIER", 368, 373], ["infection", "OBSERVATION", 374, 383]]], ["Therefore, continued international collaboration is necessary to increase our knowledge and thereby decrease the risk for harm to the very vulnerable group of patients either waiting for or having undergone the potentially life-saving procedure of HCT or cellular therapy.", [["cellular", "ANATOMY", 255, 263], ["patients", "ORGANISM", 159, 167], ["cellular", "CELL", 255, 263], ["patients", "SPECIES", 159, 167], ["saving procedure", "TREATMENT", 228, 244], ["HCT", "TREATMENT", 248, 251], ["cellular therapy", "TREATMENT", 255, 271]]], ["Scientific organizations such as the EBMT has a responsibility to the community to help gather and disseminate information including collecting cases of COVID-19 through its well established registry and also to actively participate in educational activities directed to all stakeholders in the transplant and cellular therapy activities.DiscussionOn a national level, EBMT cannot define the specifics of how centers need to work internally and with each other within networks and public health and the broader context of health care.", [["cellular", "ANATOMY", 310, 318], ["cellular", "CELL", 310, 318], ["COVID", "TEST", 153, 158], ["the transplant", "TREATMENT", 291, 305], ["cellular therapy activities", "TREATMENT", 310, 337], ["transplant", "ANATOMY", 295, 305], ["cellular therapy", "OBSERVATION", 310, 326]]], ["However, irrespective of center, nation or health service, transplant teams should work to put patients\u2019 interests first, values which are central to the Mission and Vision of EBMT.DiscussionFinally, we recommend that you follow https://www.ebmt.org/covid-19-and-bmt and participate in the EBMT IDWP prospective survey of the impact of COVID-19 on patients undergoing HCT and cell therapy.", [["cell", "ANATOMY", 376, 380], ["COVID-19", "CHEMICAL", 336, 344], ["COVID-19", "CHEMICAL", 336, 344], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 348, 356], ["HCT", "CELL", 368, 371], ["cell", "CELL", 376, 380], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 348, 356], ["COVID", "TEST", 336, 341], ["HCT", "TEST", 368, 371], ["cell therapy", "TREATMENT", 376, 388], ["cell therapy", "OBSERVATION", 376, 388]]]], "PMC7502228": [["IntroductionAs the number of coronavirus disease 2019 (COVID-19) cases rises across the globe, there is evidence from epidemiological studies that individuals of black and minority ethnic (BAME) ancestry may be at higher risk of adverse outcomes [[1], [2], [3]].", [["coronavirus disease", "DISEASE", 29, 48], ["coronavirus", "ORGANISM", 29, 40], ["coronavirus disease", "PROBLEM", 29, 48], ["COVID", "TEST", 55, 60], ["epidemiological studies", "TEST", 118, 141], ["black and minority ethnic (BAME) ancestry", "PROBLEM", 162, 203], ["adverse outcomes", "PROBLEM", 229, 245], ["coronavirus disease", "OBSERVATION", 29, 48], ["globe", "ANATOMY", 88, 93]]], ["In the US, a report from the Centers for Disease Control and Prevention (CDC) compiled using data from 14 states, described a disproportionate increase in the number of African Americans hospitalized for COVID-19 [4].", [["COVID-19", "CHEMICAL", 204, 212], ["Disease Control", "TREATMENT", 41, 56], ["COVID", "TEST", 204, 209], ["disproportionate", "OBSERVATION_MODIFIER", 126, 142], ["increase", "OBSERVATION_MODIFIER", 143, 151]]], ["It has been suggested that a clustering of co-morbidities (including hypertension, diabetes mellitus, cardiovascular disease, obesity, and chronic lung disease), as well as lower socio-economic status and greater social deprivation may be responsible for a higher overall rate of infection.", [["cardiovascular", "ANATOMY", 102, 116], ["lung", "ANATOMY", 147, 151], ["co-morbidities", "DISEASE", 43, 57], ["hypertension", "DISEASE", 69, 81], ["diabetes mellitus", "DISEASE", 83, 100], ["cardiovascular disease", "DISEASE", 102, 124], ["obesity", "DISEASE", 126, 133], ["chronic lung disease", "DISEASE", 139, 159], ["infection", "DISEASE", 280, 289], ["lung", "ORGAN", 147, 151], ["a clustering of co-morbidities", "PROBLEM", 27, 57], ["hypertension", "PROBLEM", 69, 81], ["diabetes mellitus", "PROBLEM", 83, 100], ["cardiovascular disease", "PROBLEM", 102, 124], ["obesity", "PROBLEM", 126, 133], ["chronic lung disease)", "PROBLEM", 139, 160], ["lower socio-economic status", "PROBLEM", 173, 200], ["a higher overall rate of infection", "PROBLEM", 255, 289], ["cardiovascular", "ANATOMY", 102, 116], ["obesity", "OBSERVATION", 126, 133], ["chronic", "OBSERVATION_MODIFIER", 139, 146], ["lung", "ANATOMY", 147, 151], ["disease", "OBSERVATION", 152, 159], ["infection", "OBSERVATION", 280, 289]]], ["In turn, this might explain the greater number of BAME patients requiring admission to critical care for COVID-19 compared to pre-COVID historic data (2017 \u2013 2019) [5].", [["BAME", "DISEASE", 50, 54], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["COVID", "TEST", 105, 110]]], ["UK data from 17.4 million suggest however, that increased risk in BAME may be only partly attributable to confounders (including age and socio-demographic characteristics) and that there may be an ethnic variation in response to COVID-19 infection [3].", [["COVID-19", "CHEMICAL", 229, 237], ["infection", "DISEASE", 238, 247], ["COVID-19", "CHEMICAL", 229, 237], ["BAME", "CANCER", 66, 70], ["COVID-19", "GENE_OR_GENE_PRODUCT", 229, 237], ["UK data", "TEST", 0, 7], ["increased risk in BAME", "PROBLEM", 48, 70], ["an ethnic variation", "PROBLEM", 194, 213], ["COVID-19 infection", "PROBLEM", 229, 247], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["may be", "UNCERTAINTY", 187, 193], ["ethnic variation", "OBSERVATION", 197, 213]]], ["In contrast, in a large US cohort from Louisiana, BAME ancestry was not associated with higher mortality than white race in those already hospitalized with COVID-19 [6].", [["COVID-19", "CHEMICAL", 156, 164], ["higher mortality than white race", "PROBLEM", 88, 120], ["COVID", "TEST", 156, 161], ["large", "OBSERVATION_MODIFIER", 18, 23]]], ["These discrepant epidemiological findings support the need for investigation into differences in the pathophysiological response to COVID-19 among BAME individuals infected with COVID-19.IntroductionElevated circulating levels of D-dimer and high-sensitivity cardiac troponin (HScTn) are both established powerful predictors of in-hospital mortality in patients with COVID-19 [7, 8].", [["COVID-19", "CHEMICAL", 132, 140], ["COVID-19", "CHEMICAL", 178, 186], ["COVID-19", "CHEMICAL", 132, 140], ["COVID-19", "CHEMICAL", 367, 375], ["D-dimer", "GENE_OR_GENE_PRODUCT", 230, 237], ["cardiac troponin", "GENE_OR_GENE_PRODUCT", 259, 275], ["HScTn", "GENE_OR_GENE_PRODUCT", 277, 282], ["patients", "ORGANISM", 353, 361], ["D-dimer", "PROTEIN", 230, 237], ["cardiac troponin", "PROTEIN", 259, 275], ["patients", "SPECIES", 353, 361], ["investigation", "TEST", 63, 76], ["COVID", "TEST", 132, 137], ["COVID", "TEST", 178, 183], ["Elevated circulating levels of D-dimer", "PROBLEM", 199, 237], ["cardiac troponin", "TEST", 259, 275], ["COVID", "TEST", 367, 372]]], ["Patients of black race are more likely to have a positive D-dimer than whites in conventional thromboembolic disease [9].", [["thromboembolic disease", "DISEASE", 94, 116], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["black race", "PROBLEM", 12, 22], ["a positive D-dimer", "PROBLEM", 47, 65], ["conventional thromboembolic disease", "PROBLEM", 81, 116], ["thromboembolic disease", "OBSERVATION", 94, 116]]], ["Given the post-mortem data highlighting the role of diffuse pulmonary small vessel endothelialitis and thrombus formation [10], together with evidence that injury to the RV (dilatation and dysfunction) is the primary cardiac manifestation of COVID-19 on transthoracic echocardiography (TTE) [[11], [12], [13], [14]], further investigation into the influence of ethnicity on the relationship between these biomarkers, echocardiographic findings and outcomes is warranted.IntroductionIn the UK, the Midlands urban catchment area has had a high prevalence of BAME minorities presenting late with COVID-19 disease, many of whom have required admission to the intensive care unit (ICU).", [["pulmonary small vessel", "ANATOMY", 60, 82], ["thrombus", "ANATOMY", 103, 111], ["RV", "ANATOMY", 170, 172], ["cardiac", "ANATOMY", 217, 224], ["thrombus", "DISEASE", 103, 111], ["injury to the RV (dilatation and dysfunction", "DISEASE", 156, 200], ["COVID-19", "CHEMICAL", 242, 250], ["vessel", "MULTI-TISSUE_STRUCTURE", 76, 82], ["thrombus", "PATHOLOGICAL_FORMATION", 103, 111], ["RV", "MULTI-TISSUE_STRUCTURE", 170, 172], ["[12], [13], [14]", "SIMPLE_CHEMICAL", 298, 314], ["the post-mortem data", "TEST", 6, 26], ["diffuse pulmonary small vessel endothelialitis", "PROBLEM", 52, 98], ["thrombus formation", "PROBLEM", 103, 121], ["injury to the RV (dilatation and dysfunction", "PROBLEM", 156, 200], ["COVID", "TEST", 242, 247], ["transthoracic echocardiography", "TEST", 254, 284], ["TTE", "TEST", 286, 289], ["further investigation", "TEST", 317, 338], ["these biomarkers", "TEST", 399, 415], ["echocardiographic findings", "TEST", 417, 443], ["diffuse", "OBSERVATION_MODIFIER", 52, 59], ["pulmonary", "ANATOMY", 60, 69], ["small vessel endothelialitis", "OBSERVATION", 70, 98], ["thrombus", "OBSERVATION", 103, 111], ["injury", "OBSERVATION", 156, 162], ["RV", "ANATOMY", 170, 172], ["dilatation", "OBSERVATION", 174, 184], ["high prevalence", "OBSERVATION_MODIFIER", 537, 552]]], ["The a priori hypothesis of this study is that BAME patients hospitalized with COVID-19 pneumonia develop greater right ventricular injury compared with white individuals, related to differences in fibrin formation and degradation (D-dimer), which is associated with increased early mortality.Materials and methods", [["right ventricular", "ANATOMY", 113, 130], ["fibrin", "ANATOMY", 197, 203], ["BAME", "DISEASE", 46, 50], ["pneumonia", "DISEASE", 87, 96], ["right ventricular injury", "DISEASE", 113, 137], ["BAME", "ORGANISM", 46, 50], ["patients", "ORGANISM", 51, 59], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 113, 130], ["fibrin", "GENE_OR_GENE_PRODUCT", 197, 203], ["D-dimer", "GENE_OR_GENE_PRODUCT", 231, 238], ["fibrin", "PROTEIN", 197, 203], ["D-dimer", "PROTEIN", 231, 238], ["patients", "SPECIES", 51, 59], ["this study", "TEST", 27, 37], ["COVID", "TEST", 78, 83], ["pneumonia", "PROBLEM", 87, 96], ["greater right ventricular injury", "PROBLEM", 105, 137], ["white individuals", "PROBLEM", 152, 169], ["fibrin formation", "PROBLEM", 197, 213], ["degradation (D-dimer", "PROBLEM", 218, 238], ["increased early mortality", "PROBLEM", 266, 291], ["pneumonia", "OBSERVATION", 87, 96], ["greater", "OBSERVATION_MODIFIER", 105, 112], ["right ventricular", "ANATOMY", 113, 130], ["injury", "OBSERVATION", 131, 137], ["fibrin formation", "OBSERVATION", 197, 213], ["associated with", "UNCERTAINTY", 250, 265], ["increased", "OBSERVATION_MODIFIER", 266, 275], ["early", "OBSERVATION_MODIFIER", 276, 281], ["mortality", "OBSERVATION", 282, 291]]]], "PMC5052424": [["IntroductionViruses are infective obligate parasites that can replicate only in the living cells of animals, plants, fungi, or bacteria.", [["cells", "ANATOMY", 91, 96], ["cells", "CELL", 91, 96], ["IntroductionViruses", "TREATMENT", 0, 19], ["infective obligate parasites", "PROBLEM", 24, 52], ["fungi", "PROBLEM", 117, 122], ["bacteria", "PROBLEM", 127, 135], ["infective", "OBSERVATION", 24, 33]]], ["Although extremely small in size and simple in structure, viruses cause numerous diseases such as cancer, autoimmune disease, and immunodeficiency as well as organ-specific infectious diseases including the common cold, influenza, diarrhea, hepatitis, etc. [1], [2], [3], [4].IntroductionRecent progress in the formulation of antiviral therapies and vaccines has helped to prevent, shorten the duration, or decrease the severity of viral infection [5], [6], [7].", [["cancer", "ANATOMY", 98, 104], ["organ", "ANATOMY", 158, 163], ["cancer", "DISEASE", 98, 104], ["autoimmune disease", "DISEASE", 106, 124], ["immunodeficiency", "DISEASE", 130, 146], ["infectious diseases", "DISEASE", 173, 192], ["influenza", "DISEASE", 220, 229], ["diarrhea", "DISEASE", 231, 239], ["hepatitis", "DISEASE", 241, 250], ["viral infection", "DISEASE", 432, 447], ["cancer", "CANCER", 98, 104], ["organ", "ORGAN", 158, 163], ["[2]", "SIMPLE_CHEMICAL", 262, 265], ["[3]", "SIMPLE_CHEMICAL", 267, 270], ["[4]", "SIMPLE_CHEMICAL", 272, 275], ["extremely small in size", "PROBLEM", 9, 32], ["viruses", "PROBLEM", 58, 65], ["numerous diseases", "PROBLEM", 72, 89], ["cancer", "PROBLEM", 98, 104], ["autoimmune disease", "PROBLEM", 106, 124], ["immunodeficiency", "PROBLEM", 130, 146], ["specific infectious diseases", "PROBLEM", 164, 192], ["the common cold", "PROBLEM", 203, 218], ["influenza", "PROBLEM", 220, 229], ["diarrhea", "PROBLEM", 231, 239], ["hepatitis", "PROBLEM", 241, 250], ["antiviral therapies", "TREATMENT", 326, 345], ["vaccines", "TREATMENT", 350, 358], ["viral infection", "PROBLEM", 432, 447], ["extremely", "OBSERVATION_MODIFIER", 9, 18], ["small", "OBSERVATION_MODIFIER", 19, 24], ["size", "OBSERVATION_MODIFIER", 28, 32], ["simple", "OBSERVATION_MODIFIER", 37, 43], ["viruses", "OBSERVATION_MODIFIER", 58, 65], ["numerous", "OBSERVATION_MODIFIER", 72, 80], ["diseases", "OBSERVATION", 81, 89], ["cancer", "OBSERVATION", 98, 104], ["autoimmune disease", "OBSERVATION", 106, 124], ["immunodeficiency", "OBSERVATION", 130, 146], ["infectious", "OBSERVATION", 173, 183], ["common cold", "ANATOMY", 207, 218], ["influenza", "OBSERVATION", 220, 229], ["diarrhea", "OBSERVATION", 231, 239], ["hepatitis", "OBSERVATION", 241, 250], ["viral", "OBSERVATION_MODIFIER", 432, 437], ["infection", "OBSERVATION", 438, 447]]], ["Most antiviral agents are designed to target viral components, but mutations in the viral genome often result in drug resistance and immune evasion, creating a major hurdle for antiviral therapies and vaccine development [8].", [["viral genome", "DNA", 84, 96], ["Most antiviral agents", "TREATMENT", 0, 21], ["target viral components", "PROBLEM", 38, 61], ["mutations in the viral genome", "PROBLEM", 67, 96], ["drug resistance", "PROBLEM", 113, 128], ["immune evasion", "TREATMENT", 133, 147], ["antiviral therapies", "TREATMENT", 177, 196], ["vaccine development", "TREATMENT", 201, 220]]], ["In addition, the continuous emergence of new infectious agents such as the Ebola virus and Middle East respiratory syndrome coronavirus (MERS-CoV) necessitate the advancement of novel therapeutic approaches.", [["Ebola virus", "DISEASE", 75, 86], ["Middle East respiratory syndrome coronavirus", "DISEASE", 91, 135], ["Ebola virus", "ORGANISM", 75, 86], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 91, 135], ["MERS-CoV", "ORGANISM", 137, 145], ["Ebola virus", "SPECIES", 75, 86], ["syndrome coronavirus", "SPECIES", 115, 135], ["Ebola virus", "SPECIES", 75, 86], ["Middle East respiratory syndrome coronavirus", "SPECIES", 91, 135], ["MERS-CoV", "SPECIES", 137, 145], ["new infectious agents", "TREATMENT", 41, 62], ["the Ebola virus", "PROBLEM", 71, 86], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 91, 135], ["novel therapeutic approaches", "TREATMENT", 178, 206], ["new", "OBSERVATION_MODIFIER", 41, 44], ["infectious", "OBSERVATION", 45, 55], ["Middle", "ANATOMY_MODIFIER", 91, 97], ["respiratory syndrome", "OBSERVATION", 103, 123]]], ["Accordingly, great attention has recently been drawn to the development of antivirals with broad-spectrum efficacy and immunomodulators which improve host resilience by increasing host resistance to the viral infection [9].IntroductionKorean ginseng (the root of Panax ginseng Meyer) is one of the most popular medicinal plants used in traditional medicine in East Asian countries including Korea [10].", [["root", "ANATOMY", 255, 259], ["viral infection", "DISEASE", 203, 218], ["IntroductionKorean ginseng (the root of Panax ginseng Meyer", "CHEMICAL", 223, 282], ["root", "ORGANISM_SUBDIVISION", 255, 259], ["ginseng", "SPECIES", 242, 249], ["Panax ginseng", "SPECIES", 263, 276], ["Panax ginseng Meyer", "SPECIES", 263, 282], ["antivirals", "TREATMENT", 75, 85], ["broad-spectrum efficacy", "TREATMENT", 91, 114], ["immunomodulators", "TREATMENT", 119, 135], ["the viral infection", "PROBLEM", 199, 218], ["host resistance", "OBSERVATION", 180, 195], ["viral", "OBSERVATION_MODIFIER", 203, 208], ["infection", "OBSERVATION", 209, 218]]], ["Ginseng contains various pharmacologically active substances such as ginsenosides, polysaccharides, polyacetylenes, phytosterols, and essential oils, and among those, ginsenosides are considered the major bioactive compounds [11].", [["oils", "ANATOMY", 144, 148], ["Ginseng", "CHEMICAL", 0, 7], ["ginsenosides", "CHEMICAL", 69, 81], ["polyacetylenes", "CHEMICAL", 100, 114], ["phytosterols", "CHEMICAL", 116, 128], ["ginsenosides", "CHEMICAL", 167, 179], ["ginsenosides", "CHEMICAL", 69, 81], ["polyacetylenes", "CHEMICAL", 100, 114], ["phytosterols", "CHEMICAL", 116, 128], ["ginsenosides", "CHEMICAL", 167, 179], ["Ginseng", "SIMPLE_CHEMICAL", 0, 7], ["ginsenosides", "SIMPLE_CHEMICAL", 69, 81], ["polysaccharides", "SIMPLE_CHEMICAL", 83, 98], ["polyacetylenes", "SIMPLE_CHEMICAL", 100, 114], ["phytosterols", "SIMPLE_CHEMICAL", 116, 128], ["ginsenosides", "SIMPLE_CHEMICAL", 167, 179], ["ginsenosides", "TREATMENT", 69, 81], ["polysaccharides", "TREATMENT", 83, 98], ["polyacetylenes", "TREATMENT", 100, 114], ["phytosterols", "TREATMENT", 116, 128], ["various pharmacologically", "OBSERVATION_MODIFIER", 17, 42], ["active", "OBSERVATION_MODIFIER", 43, 49], ["substances", "OBSERVATION", 50, 60]]], ["Korean Red Ginseng (KRG) is a heat-processed ginseng which is prepared by the repeated process of steaming and air-drying fresh ginseng [12].", [["Red Ginseng", "CHEMICAL", 7, 18], ["KRG", "CHEMICAL", 20, 23], ["KRG", "SIMPLE_CHEMICAL", 20, 23], ["ginseng", "ORGANISM", 45, 52]]], ["KRG has been shown to possess enhanced pharmacological activities and stability compared with fresh ginseng because of changes in its chemical constituents such as ginsenosides Rg2, Rg3 Rh1, and Rh2, which occur during the steaming process [13].IntroductionCurrently, numerous studies have reported the beneficial effects of KRG on diverse diseases such as cancer, immune system disorder, neuronal disease, and cardiovascular disease [14], [15], [16], [17].", [["cancer", "ANATOMY", 357, 363], ["immune system", "ANATOMY", 365, 378], ["neuronal", "ANATOMY", 389, 397], ["cardiovascular", "ANATOMY", 411, 425], ["KRG", "CHEMICAL", 0, 3], ["Rg3", "CHEMICAL", 182, 185], ["KRG", "CHEMICAL", 325, 328], ["cancer", "DISEASE", 357, 363], ["immune system disorder", "DISEASE", 365, 387], ["neuronal disease", "DISEASE", 389, 405], ["cardiovascular disease", "DISEASE", 411, 433], ["ginsenosides", "CHEMICAL", 164, 176], ["Rg3 Rh1, and Rh2", "CHEMICAL", 182, 198], ["KRG", "SIMPLE_CHEMICAL", 0, 3], ["ginsenosides Rg2", "SIMPLE_CHEMICAL", 164, 180], ["Rg3 Rh1", "SIMPLE_CHEMICAL", 182, 189], ["Rh2", "GENE_OR_GENE_PRODUCT", 195, 198], ["KRG", "SIMPLE_CHEMICAL", 325, 328], ["cancer", "CANCER", 357, 363], ["neuronal", "CELL", 389, 397], ["[15], [16], [17]", "SIMPLE_CHEMICAL", 440, 456], ["KRG", "TREATMENT", 0, 3], ["fresh ginseng", "TREATMENT", 94, 107], ["changes in its chemical constituents", "PROBLEM", 119, 155], ["numerous studies", "TEST", 268, 284], ["KRG", "PROBLEM", 325, 328], ["diverse diseases", "PROBLEM", 332, 348], ["cancer", "PROBLEM", 357, 363], ["immune system disorder", "PROBLEM", 365, 387], ["neuronal disease", "PROBLEM", 389, 405], ["cardiovascular disease", "PROBLEM", 411, 433], ["stability", "OBSERVATION_MODIFIER", 70, 79], ["Rh2", "ANATOMY_MODIFIER", 195, 198], ["neuronal disease", "OBSERVATION", 389, 405], ["cardiovascular", "ANATOMY", 411, 425]]], ["In addition, KRG and its purified components have also been shown to possess protective activities against microbial infections [18].", [["KRG", "CHEMICAL", 13, 16], ["microbial infections", "DISEASE", 107, 127], ["KRG", "SIMPLE_CHEMICAL", 13, 16], ["KRG", "PROTEIN", 13, 16], ["KRG", "TREATMENT", 13, 16], ["microbial infections", "PROBLEM", 107, 127]]], ["In this review, we summarize the current knowledge on the effects of KRG and its components on infections with human pathogenic viruses and discuss the therapeutic potential of KRG as an antiviral and vaccine adjuvant.Respiratory syncytial virusRespiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection.", [["lower respiratory tract", "ANATOMY", 303, 326], ["KRG", "CHEMICAL", 69, 72], ["infections", "DISEASE", 95, 105], ["KRG", "CHEMICAL", 177, 180], ["Respiratory syncytial virusRespiratory syncytial virus", "DISEASE", 218, 272], ["RSV", "DISEASE", 274, 277], ["lower respiratory tract infection", "DISEASE", 303, 336], ["KRG", "SIMPLE_CHEMICAL", 69, 72], ["human", "ORGANISM", 111, 116], ["KRG", "SIMPLE_CHEMICAL", 177, 180], ["Respiratory syncytial virusRespiratory syncytial virus", "ORGANISM", 218, 272], ["RSV", "ORGANISM", 274, 277], ["lower", "ORGANISM_SUBDIVISION", 303, 308], ["respiratory tract", "ORGANISM_SUBDIVISION", 309, 326], ["human", "SPECIES", 111, 116], ["syncytial virusRespiratory syncytial virus", "SPECIES", 230, 272], ["human", "SPECIES", 111, 116], ["Respiratory syncytial virusRespiratory syncytial virus", "SPECIES", 218, 272], ["RSV", "SPECIES", 274, 277], ["KRG", "TREATMENT", 69, 72], ["infections", "PROBLEM", 95, 105], ["human pathogenic viruses", "PROBLEM", 111, 135], ["KRG", "TREATMENT", 177, 180], ["an antiviral and vaccine adjuvant", "TREATMENT", 184, 217], ["Respiratory syncytial virusRespiratory syncytial virus", "PROBLEM", 218, 272], ["lower respiratory tract infection", "PROBLEM", 303, 336], ["syncytial", "OBSERVATION_MODIFIER", 230, 239], ["virusRespiratory syncytial virus", "OBSERVATION", 240, 272], ["lower", "ANATOMY_MODIFIER", 303, 308], ["respiratory tract", "ANATOMY", 309, 326], ["infection", "OBSERVATION", 327, 336]]], ["This viral infection shows mild and indistinguishable symptoms from common colds in adults and healthy children but can also cause severe lower respiratory tract diseases such as pneumonia and bronchiolitis in premature babies and infants with underlying health conditions and immunocompromised patients.", [["lower respiratory tract", "ANATOMY", 138, 161], ["viral infection", "DISEASE", 5, 20], ["colds", "DISEASE", 75, 80], ["lower respiratory tract diseases", "DISEASE", 138, 170], ["pneumonia", "DISEASE", 179, 188], ["bronchiolitis", "DISEASE", 193, 206], ["children", "ORGANISM", 103, 111], ["tract", "ORGANISM_SUBDIVISION", 156, 161], ["infants", "ORGANISM", 231, 238], ["patients", "ORGANISM", 295, 303], ["children", "SPECIES", 103, 111], ["infants", "SPECIES", 231, 238], ["patients", "SPECIES", 295, 303], ["This viral infection", "PROBLEM", 0, 20], ["mild and indistinguishable symptoms", "PROBLEM", 27, 62], ["severe lower respiratory tract diseases", "PROBLEM", 131, 170], ["pneumonia", "PROBLEM", 179, 188], ["bronchiolitis in premature babies", "PROBLEM", 193, 226], ["underlying health conditions", "PROBLEM", 244, 272], ["immunocompromised patients", "PROBLEM", 277, 303], ["infection", "OBSERVATION", 11, 20], ["mild", "OBSERVATION_MODIFIER", 27, 31], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["lower", "ANATOMY_MODIFIER", 138, 143], ["respiratory tract", "ANATOMY", 144, 161], ["pneumonia", "OBSERVATION", 179, 188], ["bronchiolitis", "OBSERVATION", 193, 206]]], ["No effective antiviral therapy or preventive vaccine in early life is currently available, but maternal vaccination is considered a possible strategy to provide RSV antibody protection to young infants [1].Respiratory syncytial virusThe Kang Laboratory (Georgia State University, GA) has published several studies on the immunomodulatory and antiviral effects of KRG extract (RGE) on RSV [19], [20], [21].", [["Respiratory syncytial virus", "DISEASE", 206, 233], ["KRG extract", "CHEMICAL", 363, 374], ["RGE", "CHEMICAL", 376, 379], ["RSV", "ORGANISM", 161, 164], ["infants", "ORGANISM", 194, 201], ["Respiratory syncytial virus", "ORGANISM", 206, 233], ["KRG", "SIMPLE_CHEMICAL", 363, 366], ["RGE", "SIMPLE_CHEMICAL", 376, 379], ["RSV", "ORGANISM", 384, 387], ["[20]", "SIMPLE_CHEMICAL", 394, 398], ["infants", "SPECIES", 194, 201], ["RSV", "SPECIES", 161, 164], ["Respiratory syncytial virus", "SPECIES", 206, 233], ["RSV", "SPECIES", 384, 387], ["effective antiviral therapy", "TREATMENT", 3, 30], ["preventive vaccine", "TREATMENT", 34, 52], ["maternal vaccination", "TREATMENT", 95, 115], ["RSV antibody protection", "TREATMENT", 161, 184], ["Respiratory syncytial virus", "PROBLEM", 206, 233], ["the immunomodulatory", "TREATMENT", 317, 337], ["antiviral effects", "TREATMENT", 342, 359], ["KRG extract", "TREATMENT", 363, 374], ["RSV", "TEST", 384, 387], ["effective", "OBSERVATION_MODIFIER", 3, 12], ["antiviral therapy", "OBSERVATION", 13, 30], ["syncytial virus", "OBSERVATION", 218, 233]]], ["Although a formalin-inactivated RSV (FI-RSV) vaccine was developed in the 1960s, immunization with FI-RSV was halted because vaccinated children experienced severe respiratory disease during the natural RSV infection.", [["respiratory", "ANATOMY", 164, 175], ["formalin", "CHEMICAL", 11, 19], ["respiratory disease", "DISEASE", 164, 183], ["RSV infection", "DISEASE", 203, 216], ["formalin", "CHEMICAL", 11, 19], ["formalin", "SIMPLE_CHEMICAL", 11, 19], ["RSV", "ORGANISM", 32, 35], ["FI-RSV", "ORGANISM", 37, 43], ["FI-RSV", "ORGANISM", 99, 105], ["children", "ORGANISM", 136, 144], ["RSV", "ORGANISM", 203, 206], ["children", "SPECIES", 136, 144], ["RSV", "SPECIES", 32, 35], ["RSV", "SPECIES", 40, 43], ["RSV", "SPECIES", 102, 105], ["RSV", "SPECIES", 203, 206], ["a formalin-inactivated RSV (FI-RSV) vaccine", "TREATMENT", 9, 52], ["immunization", "TREATMENT", 81, 93], ["RSV", "TREATMENT", 102, 105], ["severe respiratory disease", "PROBLEM", 157, 183], ["the natural RSV infection", "PROBLEM", 191, 216], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["respiratory disease", "OBSERVATION", 164, 183], ["natural RSV infection", "OBSERVATION", 195, 216]]], ["The severe form of the disease caused by the FI-RSV has been attributed to the strong T-helper type 2 (Th2) immune response, and RGE has been shown to mitigate such Th2 responses by enhancing the T-helper type 1 (Th1) response in F1-RSV immunized mice which have Th2-dominant immune response intrinsically [19].", [["RSV", "DISEASE", 48, 51], ["RGE", "CHEMICAL", 129, 132], ["FI-RSV", "ORGANISM", 45, 51], ["T-helper type 2", "GENE_OR_GENE_PRODUCT", 86, 101], ["Th2", "GENE_OR_GENE_PRODUCT", 103, 106], ["RGE", "GENE_OR_GENE_PRODUCT", 129, 132], ["T-helper type 1", "GENE_OR_GENE_PRODUCT", 196, 211], ["Th1", "GENE_OR_GENE_PRODUCT", 213, 216], ["F1-RSV", "ORGANISM", 230, 236], ["mice", "ORGANISM", 247, 251], ["Th2", "GENE_OR_GENE_PRODUCT", 263, 266], ["RGE", "PROTEIN", 129, 132], ["mice", "SPECIES", 247, 251], ["RSV", "SPECIES", 48, 51], ["RSV", "SPECIES", 233, 236], ["mice", "SPECIES", 247, 251], ["the disease", "PROBLEM", 19, 30], ["RSV", "PROBLEM", 48, 51], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["disease", "OBSERVATION", 23, 30], ["RSV", "OBSERVATION", 48, 51]]], ["Thus, RGE-treated mice that were immunized with FI-RSV showed improved clinical outcomes via an increase in the immunoglobulin G2a (IgG2a) antibodies level and interferon (IFN)-\u03b3 production accompanied by a decrease in IL-4 production and weight loss after RSV infection [19].", [["RGE", "CHEMICAL", 6, 9], ["weight loss", "DISEASE", 239, 250], ["RSV infection", "DISEASE", 257, 270], ["RGE", "SIMPLE_CHEMICAL", 6, 9], ["mice", "ORGANISM", 18, 22], ["FI-RSV", "ORGANISM", 48, 54], ["immunoglobulin G2a", "GENE_OR_GENE_PRODUCT", 112, 130], ["IgG2a", "GENE_OR_GENE_PRODUCT", 132, 137], ["interferon (IFN)-\u03b3", "GENE_OR_GENE_PRODUCT", 160, 178], ["IL-4", "GENE_OR_GENE_PRODUCT", 219, 223], ["RSV", "ORGANISM", 257, 260], ["immunoglobulin G2a", "PROTEIN", 112, 130], ["IgG2a", "PROTEIN", 132, 137], ["interferon (IFN)-\u03b3", "PROTEIN", 160, 178], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["RSV", "SPECIES", 51, 54], ["RSV", "SPECIES", 257, 260], ["RGE", "TEST", 6, 9], ["RSV", "PROBLEM", 51, 54], ["an increase", "PROBLEM", 93, 104], ["the immunoglobulin G2a", "TEST", 108, 130], ["IgG2a", "TEST", 132, 137], ["antibodies level", "TEST", 139, 155], ["interferon (IFN)", "PROBLEM", 160, 176], ["a decrease in IL", "PROBLEM", 205, 221], ["weight loss", "PROBLEM", 239, 250], ["RSV infection", "PROBLEM", 257, 270], ["increase", "OBSERVATION_MODIFIER", 96, 104], ["decrease", "OBSERVATION_MODIFIER", 207, 215]]], ["The data indicate that RGE possesses an immunomodulatory effect by balancing Th1 and Th2 immune responses, and protects the host from severe pulmonary inflammation upon FI-RSV immunization and RSV infection.Respiratory syncytial virusIn addition, RGE protected human epithelial cells from RSV-induced cell death and viral replication and inhibited the production of proinflammatory cytokines in vitro upon RSV infection [20], [21].", [["pulmonary", "ANATOMY", 141, 150], ["epithelial cells", "ANATOMY", 267, 283], ["cell", "ANATOMY", 301, 305], ["RGE", "CHEMICAL", 23, 26], ["pulmonary inflammation", "DISEASE", 141, 163], ["RSV infection", "DISEASE", 193, 206], ["Respiratory syncytial virusIn", "DISEASE", 207, 236], ["RGE", "CHEMICAL", 247, 250], ["death", "DISEASE", 306, 311], ["RSV infection", "DISEASE", 406, 419], ["RGE", "SIMPLE_CHEMICAL", 23, 26], ["Th1", "CELL", 77, 80], ["pulmonary", "ORGAN", 141, 150], ["FI-RSV", "ORGANISM", 169, 175], ["RSV", "ORGANISM", 193, 196], ["Respiratory syncytial virusIn", "ORGANISM", 207, 236], ["RGE", "SIMPLE_CHEMICAL", 247, 250], ["human", "ORGANISM", 261, 266], ["epithelial cells", "CELL", 267, 283], ["RSV", "ORGANISM", 289, 292], ["cell", "CELL", 301, 305], ["RSV", "ORGANISM", 406, 409], ["human epithelial cells", "CELL_TYPE", 261, 283], ["proinflammatory cytokines", "PROTEIN", 366, 391], ["human", "SPECIES", 261, 266], ["RSV", "SPECIES", 172, 175], ["RSV", "SPECIES", 193, 196], ["Respiratory syncytial virusIn", "SPECIES", 207, 236], ["human", "SPECIES", 261, 266], ["RSV", "SPECIES", 289, 292], ["RSV", "SPECIES", 406, 409], ["The data", "TEST", 0, 8], ["severe pulmonary inflammation", "PROBLEM", 134, 163], ["RSV immunization", "TREATMENT", 172, 188], ["RSV infection", "PROBLEM", 193, 206], ["Respiratory syncytial virusIn", "PROBLEM", 207, 236], ["RGE protected human epithelial cells", "PROBLEM", 247, 283], ["RSV", "PROBLEM", 289, 292], ["cell death", "PROBLEM", 301, 311], ["viral replication", "TREATMENT", 316, 333], ["proinflammatory cytokines", "PROBLEM", 366, 391], ["RSV infection", "PROBLEM", 406, 419], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["pulmonary", "ANATOMY", 141, 150], ["inflammation", "OBSERVATION", 151, 163], ["RSV infection", "OBSERVATION", 193, 206], ["syncytial virusIn", "OBSERVATION", 219, 236], ["epithelial cells", "OBSERVATION", 267, 283], ["cell death", "OBSERVATION", 301, 311], ["viral replication", "OBSERVATION", 316, 333], ["proinflammatory cytokines", "OBSERVATION", 366, 391]]], ["Moreover, RGE treatment improved clinical outcomes by preventing weight loss and increasing viral clearance and IFN-\u03b3 production in bronchoalveolar lavage cells in mice [20], [21].", [["bronchoalveolar lavage cells", "ANATOMY", 132, 160], ["RGE", "CHEMICAL", 10, 13], ["weight loss", "DISEASE", 65, 76], ["RGE", "SIMPLE_CHEMICAL", 10, 13], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 112, 117], ["bronchoalveolar lavage cells", "CELL", 132, 160], ["mice", "ORGANISM", 164, 168], ["IFN", "PROTEIN", 112, 115], ["bronchoalveolar lavage cells", "CELL_TYPE", 132, 160], ["mice", "SPECIES", 164, 168], ["RGE treatment", "TREATMENT", 10, 23], ["weight loss", "PROBLEM", 65, 76], ["increasing viral clearance", "PROBLEM", 81, 107], ["IFN", "TEST", 112, 115], ["bronchoalveolar lavage cells", "TEST", 132, 160], ["increasing", "OBSERVATION_MODIFIER", 81, 91], ["viral clearance", "OBSERVATION", 92, 107], ["bronchoalveolar lavage", "OBSERVATION", 132, 154]]], ["RGE also increased the numbers of CD11c+ dendritic cells, IFN-\u03b3-secreting CD8+ T cells, and CD4+ T cells in bronchoalveolar lavage fluids [20], [21].", [["CD11c+ dendritic cells", "ANATOMY", 34, 56], ["CD8+ T cells", "ANATOMY", 74, 86], ["CD4+ T cells", "ANATOMY", 92, 104], ["bronchoalveolar lavage fluids", "ANATOMY", 108, 137], ["RGE", "CHEMICAL", 0, 3], ["RGE", "SIMPLE_CHEMICAL", 0, 3], ["CD11c", "GENE_OR_GENE_PRODUCT", 34, 39], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 58, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 74, 77], ["CD4", "GENE_OR_GENE_PRODUCT", 92, 95], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 108, 130], ["CD11c", "PROTEIN", 34, 39], ["dendritic cells", "CELL_TYPE", 41, 56], ["IFN-\u03b3-secreting CD8+ T cells", "CELL_TYPE", 58, 86], ["CD4", "PROTEIN", 92, 95], ["T cells", "CELL_TYPE", 97, 104], ["CD11c", "TEST", 34, 39], ["dendritic cells", "PROBLEM", 41, 56], ["IFN", "TEST", 58, 61], ["secreting CD8", "TEST", 64, 77], ["T cells", "TEST", 79, 86], ["CD4", "TEST", 92, 95], ["bronchoalveolar lavage fluids", "TEST", 108, 137], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["CD11c", "ANATOMY", 34, 39], ["dendritic cells", "OBSERVATION", 41, 56], ["bronchoalveolar lavage", "OBSERVATION", 108, 130]]], ["Taken together, these studies demonstrate that ginseng has immunomodulatory and antiviral effects against RSV infection through multiple mechanisms, and further studies are required to elucidate the underlying immunoregulatory and antiviral mechanisms at the molecular level.RhinovirusRhinovirus is the major cause of the common cold.", [["RSV infection", "DISEASE", 106, 119], ["ginseng", "ORGANISM", 47, 54], ["RSV", "ORGANISM", 106, 109], ["RhinovirusRhinovirus", "ORGANISM", 275, 295], ["RSV", "SPECIES", 106, 109], ["Rhinovirus", "SPECIES", 275, 285], ["these studies", "TEST", 16, 29], ["immunomodulatory", "TREATMENT", 59, 75], ["antiviral effects", "TREATMENT", 80, 97], ["RSV infection", "PROBLEM", 106, 119], ["further studies", "TEST", 153, 168], ["the underlying immunoregulatory and antiviral mechanisms", "PROBLEM", 195, 251], ["RhinovirusRhinovirus", "PROBLEM", 275, 295], ["the common cold", "PROBLEM", 318, 333], ["immunomodulatory", "OBSERVATION_MODIFIER", 59, 75], ["antiviral", "OBSERVATION_MODIFIER", 80, 89], ["Rhinovirus", "OBSERVATION", 285, 295], ["common", "OBSERVATION_MODIFIER", 322, 328], ["cold", "OBSERVATION", 329, 333]]], ["Rhinovirus is transmitted from person-to-person via contact or aerosol and causes upper respiratory illness [22].", [["respiratory", "ANATOMY", 88, 99], ["Rhinovirus", "CHEMICAL", 0, 10], ["upper respiratory illness", "DISEASE", 82, 107], ["person", "SPECIES", 31, 37], ["person", "SPECIES", 41, 47], ["Rhinovirus", "SPECIES", 0, 10], ["Rhinovirus", "PROBLEM", 0, 10], ["upper respiratory illness", "PROBLEM", 82, 107], ["upper", "ANATOMY_MODIFIER", 82, 87], ["respiratory", "ANATOMY", 88, 99]]], ["Although generally mild and self-limiting, rhinovirus infection may cause asthma or chronic obstructive pulmonary disease in chronic infection and lead to severe complications for asthmatics, elderly people, and immunocompromised patients [23], [24].", [["pulmonary", "ANATOMY", 104, 113], ["rhinovirus infection", "DISEASE", 43, 63], ["asthma", "DISEASE", 74, 80], ["chronic obstructive pulmonary disease", "DISEASE", 84, 121], ["chronic infection", "DISEASE", 125, 142], ["asthmatics", "DISEASE", 180, 190], ["rhinovirus", "ORGANISM", 43, 53], ["pulmonary", "ORGAN", 104, 113], ["people", "ORGANISM", 200, 206], ["patients", "ORGANISM", 230, 238], ["people", "SPECIES", 200, 206], ["patients", "SPECIES", 230, 238], ["generally mild and self-limiting", "PROBLEM", 9, 41], ["rhinovirus infection", "PROBLEM", 43, 63], ["asthma", "PROBLEM", 74, 80], ["chronic obstructive pulmonary disease", "PROBLEM", 84, 121], ["chronic infection", "PROBLEM", 125, 142], ["severe complications", "PROBLEM", 155, 175], ["asthmatics", "PROBLEM", 180, 190], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["self-limiting", "OBSERVATION_MODIFIER", 28, 41], ["rhinovirus infection", "OBSERVATION", 43, 63], ["may cause", "UNCERTAINTY", 64, 73], ["chronic", "OBSERVATION_MODIFIER", 84, 91], ["obstructive", "OBSERVATION_MODIFIER", 92, 103], ["pulmonary", "ANATOMY", 104, 113], ["disease", "OBSERVATION", 114, 121], ["chronic", "OBSERVATION_MODIFIER", 125, 132], ["infection", "OBSERVATION", 133, 142], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["complications", "OBSERVATION", 162, 175]]], ["Currently there is no cure or prevention for rhinovirus infection, and treatment mainly relies on symptom alleviation using nonsteroidal anti-inflammatory drugs (NSAIDs), nasal decongestants, and antihistamines.", [["nonsteroidal", "ANATOMY", 124, 136], ["nasal", "ANATOMY", 171, 176], ["rhinovirus infection", "DISEASE", 45, 65], ["rhinovirus", "ORGANISM", 45, 55], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 124, 160], ["NSAIDs", "SIMPLE_CHEMICAL", 162, 168], ["nasal", "ORGANISM_SUBDIVISION", 171, 176], ["antihistamines", "SIMPLE_CHEMICAL", 196, 210], ["cure", "PROBLEM", 22, 26], ["rhinovirus infection", "PROBLEM", 45, 65], ["treatment", "TREATMENT", 71, 80], ["symptom alleviation", "PROBLEM", 98, 117], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 124, 160], ["NSAIDs)", "TREATMENT", 162, 169], ["nasal decongestants", "TREATMENT", 171, 190], ["antihistamines", "TREATMENT", 196, 210], ["no", "UNCERTAINTY", 19, 21], ["rhinovirus", "OBSERVATION_MODIFIER", 45, 55], ["infection", "OBSERVATION", 56, 65], ["nasal", "ANATOMY", 171, 176]]], ["Nonetheless, consistent effort has been made to identify effective preventions and antiviral medication for rhinovirus [25].RhinovirusIn an attempt to investigate the effects of ginsenosides on rhinovirus infection, Song et al [26] examined the antiviral activities of protopanaxatriol (PT)-type ginsenosides (Re, Rf, and Rg2), and protopanaxadiol (PD)-type ginsenosides (Rb1, Rb2, Rc, and Rd).", [["ginsenosides", "CHEMICAL", 178, 190], ["rhinovirus infection", "DISEASE", 194, 214], ["protopanaxatriol", "CHEMICAL", 269, 285], ["protopanaxadiol", "CHEMICAL", 332, 347], ["Rb1", "CHEMICAL", 372, 375], ["ginsenosides", "CHEMICAL", 178, 190], ["protopanaxatriol", "CHEMICAL", 269, 285], ["ginsenosides", "CHEMICAL", 296, 308], ["Re, Rf, and Rg2", "CHEMICAL", 310, 325], ["protopanaxadiol", "CHEMICAL", 332, 347], ["ginsenosides", "CHEMICAL", 358, 370], ["Rb1, Rb2, Rc, and Rd", "CHEMICAL", 372, 392], ["rhinovirus", "ORGANISM", 108, 118], ["ginsenosides", "SIMPLE_CHEMICAL", 178, 190], ["rhinovirus", "ORGANISM", 194, 204], ["protopanaxatriol", "SIMPLE_CHEMICAL", 269, 285], ["PT)-type ginsenosides", "SIMPLE_CHEMICAL", 287, 308], ["Re, Rf", "SIMPLE_CHEMICAL", 310, 316], ["Rg2", "SIMPLE_CHEMICAL", 322, 325], ["protopanaxadiol (PD)-type ginsenosides", "SIMPLE_CHEMICAL", 332, 370], ["Rb1", "SIMPLE_CHEMICAL", 372, 375], ["Rb2", "SIMPLE_CHEMICAL", 377, 380], ["Rc", "SIMPLE_CHEMICAL", 382, 384], ["Rd", "SIMPLE_CHEMICAL", 390, 392], ["Rb1", "PROTEIN", 372, 375], ["effective preventions", "TREATMENT", 57, 78], ["antiviral medication", "TREATMENT", 83, 103], ["rhinovirus", "PROBLEM", 108, 118], ["RhinovirusIn", "TREATMENT", 124, 136], ["ginsenosides", "PROBLEM", 178, 190], ["rhinovirus infection", "PROBLEM", 194, 214], ["the antiviral activities of protopanaxatriol", "TREATMENT", 241, 285], ["type ginsenosides", "PROBLEM", 291, 308], ["Rg2)", "TREATMENT", 322, 326], ["protopanaxadiol (PD", "TREATMENT", 332, 351], ["type ginsenosides", "PROBLEM", 353, 370]]], ["The results showed that PT-type ginsenosides protected HeLa cells from human rhinovirus 3 (HRV3)-induced cell death as determined by sulforhodamine B staining of viable cells and morphological assessment [26].", [["HeLa cells", "ANATOMY", 55, 65], ["cell", "ANATOMY", 105, 109], ["cells", "ANATOMY", 169, 174], ["PT-type ginsenosides", "CHEMICAL", 24, 44], ["death", "DISEASE", 110, 115], ["sulforhodamine B", "CHEMICAL", 133, 149], ["ginsenosides", "CHEMICAL", 32, 44], ["sulforhodamine B", "CHEMICAL", 133, 149], ["PT-type ginsenosides", "SIMPLE_CHEMICAL", 24, 44], ["HeLa cells", "CELL", 55, 65], ["human", "ORGANISM", 71, 76], ["rhinovirus 3", "ORGANISM", 77, 89], ["HRV3", "ORGANISM", 91, 95], ["cell", "CELL", 105, 109], ["sulforhodamine B", "GENE_OR_GENE_PRODUCT", 133, 149], ["cells", "CELL", 169, 174], ["HeLa cells", "CELL_LINE", 55, 65], ["viable cells", "CELL_TYPE", 162, 174], ["human", "SPECIES", 71, 76], ["human rhinovirus", "SPECIES", 71, 87], ["HRV3", "SPECIES", 91, 95], ["PT", "TEST", 24, 26], ["type ginsenosides", "PROBLEM", 27, 44], ["HeLa cells", "PROBLEM", 55, 65], ["human rhinovirus", "PROBLEM", 71, 87], ["cell death", "PROBLEM", 105, 115], ["morphological assessment", "TEST", 179, 203], ["cell death", "OBSERVATION", 105, 115]]], ["However, PD-type ginsenosides did not show any protective effects and even stimulated the HRV3-induced cell death significantly, implying a structure-dependent effect of ginsenosides on HRV3.", [["cell", "ANATOMY", 103, 107], ["PD-type ginsenosides", "CHEMICAL", 9, 29], ["HRV3", "CHEMICAL", 90, 94], ["death", "DISEASE", 108, 113], ["ginsenosides", "CHEMICAL", 170, 182], ["ginsenosides", "CHEMICAL", 17, 29], ["ginsenosides", "CHEMICAL", 170, 182], ["HRV3", "SIMPLE_CHEMICAL", 90, 94], ["cell", "CELL", 103, 107], ["ginsenosides", "SIMPLE_CHEMICAL", 170, 182], ["HRV3", "GENE_OR_GENE_PRODUCT", 186, 190], ["HRV3", "PROTEIN", 90, 94], ["PD-type ginsenosides", "TEST", 9, 29], ["induced cell death", "PROBLEM", 95, 113], ["a structure-dependent effect of ginsenosides", "PROBLEM", 138, 182], ["HRV3", "TREATMENT", 186, 190], ["cell death", "OBSERVATION", 103, 113], ["dependent", "OBSERVATION_MODIFIER", 150, 159]]], ["The selective antiviral activities of panaxatriol-type ginsenosides were also found in the case of coxsackievirus, as described below.", [["panaxatriol-type ginsenosides", "CHEMICAL", 38, 67], ["panaxatriol", "CHEMICAL", 38, 49], ["ginsenosides", "CHEMICAL", 55, 67], ["panaxatriol-type ginsenosides", "SIMPLE_CHEMICAL", 38, 67], ["coxsackievirus", "ORGANISM", 99, 113], ["panaxatriol-type ginsenosides", "TREATMENT", 38, 67], ["coxsackievirus", "PROBLEM", 99, 113], ["selective", "OBSERVATION_MODIFIER", 4, 13], ["antiviral activities", "OBSERVATION", 14, 34], ["coxsackievirus", "OBSERVATION", 99, 113]]], ["Future studies are needed to elucidate the relationship between the antiviral activities and structural differences among panaxadiol- and panaxatriol-type ginsenosides.Influenza virusInfluenza virus is the most common human respiratory pathogen that causes annual endemic and periodic pandemic infection.", [["panaxadiol- and panaxatriol-type ginsenosides", "CHEMICAL", 122, 167], ["Influenza virus", "DISEASE", 168, 183], ["Influenza virus", "DISEASE", 183, 198], ["respiratory pathogen", "DISEASE", 224, 244], ["infection", "DISEASE", 294, 303], ["panaxadiol", "CHEMICAL", 122, 132], ["panaxatriol", "CHEMICAL", 138, 149], ["ginsenosides", "CHEMICAL", 155, 167], ["panaxadiol", "SIMPLE_CHEMICAL", 122, 132], ["panaxatriol-type ginsenosides", "SIMPLE_CHEMICAL", 138, 167], ["Influenza virusInfluenza virus", "ORGANISM", 168, 198], ["human", "ORGANISM", 218, 223], ["Influenza virusInfluenza virus", "SPECIES", 168, 198], ["human", "SPECIES", 218, 223], ["Influenza virusInfluenza virus", "SPECIES", 168, 198], ["human", "SPECIES", 218, 223], ["Future studies", "TEST", 0, 14], ["the antiviral activities", "TREATMENT", 64, 88], ["panaxadiol", "TREATMENT", 122, 132], ["panaxatriol", "TREATMENT", 138, 149], ["Influenza virusInfluenza virus", "PROBLEM", 168, 198], ["annual endemic", "PROBLEM", 257, 271], ["periodic pandemic infection", "PROBLEM", 276, 303], ["endemic", "OBSERVATION_MODIFIER", 264, 271], ["periodic", "OBSERVATION_MODIFIER", 276, 284], ["pandemic", "OBSERVATION_MODIFIER", 285, 293], ["infection", "OBSERVATION", 294, 303]]], ["There are three types of influenza viruses: A, B, and C. Human influenza A and B viruses cause seasonal disease nearly every winter, whereas the influenza C virus causes mild respiratory disease.", [["respiratory", "ANATOMY", 175, 186], ["influenza viruses", "DISEASE", 25, 42], ["influenza A and B viruses", "DISEASE", 63, 88], ["influenza C virus", "DISEASE", 145, 162], ["respiratory disease", "DISEASE", 175, 194], ["influenza viruses", "ORGANISM", 25, 42], ["B", "GENE_OR_GENE_PRODUCT", 47, 48], ["C.", "ORGANISM", 54, 56], ["Human influenza A and B viruses", "ORGANISM", 57, 88], ["influenza C virus", "ORGANISM", 145, 162], ["Human influenza A", "SPECIES", 57, 74], ["influenza C virus", "SPECIES", 145, 162], ["Human influenza A", "SPECIES", 57, 74], ["B viruses", "SPECIES", 79, 88], ["influenza C virus", "SPECIES", 145, 162], ["influenza viruses", "PROBLEM", 25, 42], ["seasonal disease", "PROBLEM", 95, 111], ["the influenza C virus", "PROBLEM", 141, 162], ["mild respiratory disease", "PROBLEM", 170, 194], ["three types", "OBSERVATION_MODIFIER", 10, 21], ["influenza viruses", "OBSERVATION", 25, 42], ["mild", "OBSERVATION_MODIFIER", 170, 174], ["respiratory disease", "OBSERVATION", 175, 194]]], ["Influenza A viruses are the most virulent human pathogens, and their serotypes are further classified and termed based on the viral surface proteins hemagglutinin (H) and neuraminidase (N).", [["Influenza A viruses", "DISEASE", 0, 19], ["Influenza A viruses", "ORGANISM", 0, 19], ["human", "ORGANISM", 42, 47], ["hemagglutinin (H)", "GENE_OR_GENE_PRODUCT", 149, 166], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 171, 184], ["viral surface proteins", "PROTEIN", 126, 148], ["hemagglutinin", "PROTEIN", 149, 162], ["H", "PROTEIN", 164, 165], ["neuraminidase (N)", "PROTEIN", 171, 188], ["Influenza A viruses", "SPECIES", 0, 19], ["human", "SPECIES", 42, 47], ["Influenza A viruses", "SPECIES", 0, 19], ["human", "SPECIES", 42, 47], ["Influenza A viruses", "PROBLEM", 0, 19], ["the viral surface proteins hemagglutinin", "TREATMENT", 122, 162], ["neuraminidase (N)", "TREATMENT", 171, 188], ["viruses", "OBSERVATION", 12, 19]]], ["Novel mutant strains continuously emerge causing influenza pandemic outbreaks, and there were some historically renowned lethal strains such as \u201cSpanish influenza (H1N1)\u201d, \u201cAsian influenza (H2N2)\u201d, \u201cRussian influenza (H1N1)\u201d, \u201cHong Kong influenza (H5N1)\u201d, and swine-origin H1N1 influenza recently found in Mexico [27], [28].Influenza virusAmple studies have been conducted to demonstrate the antiviral activities of RGE and purified compounds present in ginseng on influenza virus A infection in vitro and in vivo.", [["influenza pandemic", "DISEASE", 49, 67], ["Spanish influenza (H1N1)\u201d", "DISEASE", 145, 170], ["Asian influenza (H2N2)\u201d", "DISEASE", 173, 196], ["Russian influenza (H1N1)\u201d", "DISEASE", 199, 224], ["influenza (H5N1)\u201d", "DISEASE", 237, 254], ["influenza", "DISEASE", 278, 287], ["RGE", "CHEMICAL", 416, 419], ["influenza virus A infection", "DISEASE", 465, 492], ["\u201c", "ORGANISM", 172, 173], ["Asian influenza", "ORGANISM", 173, 188], ["\u201c", "ORGANISM", 198, 199], ["Russian influenza", "ORGANISM", 199, 216], ["Hong Kong influenza", "ORGANISM", 227, 246], ["swine-origin H1N1 influenza", "ORGANISM", 260, 287], ["RGE", "SIMPLE_CHEMICAL", 416, 419], ["ginseng", "ORGANISM", 454, 461], ["influenza virus A", "ORGANISM", 465, 482], ["Asian influenza", "SPECIES", 173, 188], ["H5N1", "SPECIES", 248, 252], ["swine", "SPECIES", 260, 265], ["H1N1 influenza", "SPECIES", 273, 287], ["influenza virus", "SPECIES", 465, 480], ["Russian influenza (H1N1)", "SPECIES", 199, 223], ["Hong Kong influenza (H5N1)", "SPECIES", 227, 253], ["influenza virus A", "SPECIES", 465, 482], ["Novel mutant strains", "PROBLEM", 0, 20], ["influenza pandemic outbreaks", "PROBLEM", 49, 77], ["influenza", "PROBLEM", 179, 188], ["H1N1 influenza", "PROBLEM", 273, 287], ["Influenza virusAmple studies", "TEST", 324, 352], ["the antiviral activities of RGE", "PROBLEM", 388, 419], ["purified compounds", "PROBLEM", 424, 442], ["influenza virus A infection", "PROBLEM", 465, 492], ["influenza virus", "OBSERVATION", 465, 480], ["infection", "OBSERVATION", 483, 492]]], ["RGE treatment improved the viability of human alveolar epithelial A549 cells upon H1N1 infection accompanied by a decrease in virus-induced cytokine secretion and reactive oxygen species (ROS) formation [29].", [["alveolar epithelial A549 cells", "ANATOMY", 46, 76], ["RGE", "CHEMICAL", 0, 3], ["infection", "DISEASE", 87, 96], ["oxygen", "CHEMICAL", 172, 178], ["ROS", "CHEMICAL", 188, 191], ["oxygen", "CHEMICAL", 172, 178], ["RGE", "SIMPLE_CHEMICAL", 0, 3], ["human", "ORGANISM", 40, 45], ["alveolar epithelial A549 cells", "CELL", 46, 76], ["H1N1", "ORGANISM", 82, 86], ["reactive oxygen species", "SIMPLE_CHEMICAL", 163, 186], ["ROS", "SIMPLE_CHEMICAL", 188, 191], ["human alveolar epithelial A549 cells", "CELL_LINE", 40, 76], ["cytokine", "PROTEIN", 140, 148], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["RGE treatment", "TREATMENT", 0, 13], ["human alveolar epithelial A549 cells", "PROBLEM", 40, 76], ["H1N1 infection", "PROBLEM", 82, 96], ["a decrease in virus", "PROBLEM", 112, 131], ["cytokine secretion", "PROBLEM", 140, 158], ["reactive oxygen species", "PROBLEM", 163, 186], ["viability", "OBSERVATION_MODIFIER", 27, 36], ["alveolar", "ANATOMY_MODIFIER", 46, 54], ["epithelial", "OBSERVATION", 55, 65], ["A549 cells", "OBSERVATION", 66, 76], ["H1N1", "OBSERVATION_MODIFIER", 82, 86], ["infection", "OBSERVATION", 87, 96], ["decrease", "OBSERVATION_MODIFIER", 114, 122], ["virus", "OBSERVATION", 126, 131], ["cytokine secretion", "OBSERVATION", 140, 158], ["reactive", "OBSERVATION_MODIFIER", 163, 171], ["oxygen species", "OBSERVATION", 172, 186]]], ["Protopanaxatriol-type ginsenoside Re has been shown to protect human umbilical vein endothelial cells (HUVECs) from avian H9N2/G1 influenza-induced apoptosis by inhibiting virus-induced interferon-inducible protein-10 (IP-10) production [30].", [["human umbilical vein endothelial cells", "ANATOMY", 63, 101], ["HUVECs", "ANATOMY", 103, 109], ["Protopanaxatriol-type ginsenoside", "CHEMICAL", 0, 33], ["Re", "CHEMICAL", 34, 36], ["influenza", "DISEASE", 130, 139], ["Protopanaxatriol", "CHEMICAL", 0, 16], ["ginsenoside", "CHEMICAL", 22, 33], ["Re", "CHEMICAL", 34, 36], ["Protopanaxatriol", "SIMPLE_CHEMICAL", 0, 16], ["ginsenoside", "SIMPLE_CHEMICAL", 22, 33], ["Re", "GENE_OR_GENE_PRODUCT", 34, 36], ["human umbilical vein endothelial cells", "CELL", 63, 101], ["HUVECs", "CELL", 103, 109], ["avian H9N2/G1 influenza", "ORGANISM", 116, 139], ["interferon-inducible protein-10", "GENE_OR_GENE_PRODUCT", 186, 217], ["IP-10", "GENE_OR_GENE_PRODUCT", 219, 224], ["human umbilical vein endothelial cells", "CELL_TYPE", 63, 101], ["HUVECs", "CELL_LINE", 103, 109], ["interferon", "PROTEIN", 186, 196], ["human", "SPECIES", 63, 68], ["avian H9N2", "SPECIES", 116, 126], ["human", "SPECIES", 63, 68], ["Protopanaxatriol", "TREATMENT", 0, 16], ["type ginsenoside", "TREATMENT", 17, 33], ["HUVECs", "TEST", 103, 109], ["avian H9N2", "TEST", 116, 126], ["G1 influenza", "PROBLEM", 127, 139], ["apoptosis", "PROBLEM", 148, 157], ["inhibiting virus", "PROBLEM", 161, 177], ["inducible protein", "TEST", 197, 214], ["IP", "TEST", 219, 221], ["umbilical vein", "ANATOMY", 69, 83], ["endothelial cells", "OBSERVATION", 84, 101]]], ["The inhibitory effects of RGE on viral replication were also tested in Madin\u2013Darby canine kidney (MDCK) cells using the 2009 pandemic H1N1 virus [31].", [["canine kidney (MDCK) cells", "ANATOMY", 83, 109], ["RGE", "CHEMICAL", 26, 29], ["RGE", "SIMPLE_CHEMICAL", 26, 29], ["Madin\u2013Darby canine kidney (MDCK) cells", "CELL", 71, 109], ["pandemic H1N1 virus", "ORGANISM", 125, 144], ["Madin\u2013Darby canine kidney (MDCK) cells", "CELL_LINE", 71, 109], ["pandemic H1N1 virus", "SPECIES", 125, 144], ["canine", "SPECIES", 83, 89], ["2009 pandemic H1N1 virus", "SPECIES", 120, 144], ["RGE", "PROBLEM", 26, 29], ["viral replication", "TREATMENT", 33, 50], ["pandemic H1N1 virus", "TREATMENT", 125, 144], ["kidney", "ANATOMY", 90, 96]]], ["In in vivo studies, RGE, ginseng polysaccharide (GP), or ginseng saponin was orally administered to mice or ferrets prior to viral infection, and their protective effects were evaluated by measuring body weight, survival rate, lung viral titers, cytokine production, histopathology, etc. The antiviral effects on the H1N1 strain have been most widely tested, and those on H3N2, H9N2/G1 (avian influenza), and H5N1 were also examined.", [["body", "ANATOMY", 199, 203], ["lung", "ANATOMY", 227, 231], ["RGE, ginseng polysaccharide (GP), or ginseng saponin", "CHEMICAL", 20, 72], ["viral infection", "DISEASE", 125, 140], ["avian influenza), and H5N1", "DISEASE", 387, 413], ["saponin", "CHEMICAL", 65, 72], ["RGE", "SIMPLE_CHEMICAL", 20, 23], ["ginseng polysaccharide", "SIMPLE_CHEMICAL", 25, 47], ["GP", "SIMPLE_CHEMICAL", 49, 51], ["ginseng", "ORGANISM", 57, 64], ["saponin", "SIMPLE_CHEMICAL", 65, 72], ["mice", "ORGANISM", 100, 104], ["ferrets", "ORGANISM", 108, 115], ["body", "ORGANISM_SUBDIVISION", 199, 203], ["lung", "ORGAN", 227, 231], ["H1N1 strain", "ORGANISM", 317, 328], ["H3N2", "ORGANISM", 372, 376], ["H9N2/G1 (avian influenza", "ORGANISM", 378, 402], ["H5N1", "ORGANISM", 409, 413], ["cytokine", "PROTEIN", 246, 254], ["ginseng", "SPECIES", 57, 64], ["mice", "SPECIES", 100, 104], ["ferrets", "SPECIES", 108, 115], ["avian influenza", "SPECIES", 387, 402], ["H5N1", "SPECIES", 409, 413], ["mice", "SPECIES", 100, 104], ["ferrets", "SPECIES", 108, 115], ["H5N1", "SPECIES", 409, 413], ["vivo studies", "TEST", 6, 18], ["ginseng saponin", "TREATMENT", 57, 72], ["viral infection", "PROBLEM", 125, 140], ["body weight", "TEST", 199, 210], ["survival rate", "TEST", 212, 225], ["lung viral titers", "PROBLEM", 227, 244], ["cytokine production", "PROBLEM", 246, 265], ["histopathology", "PROBLEM", 267, 281], ["The antiviral effects", "TREATMENT", 288, 309], ["the H1N1 strain", "PROBLEM", 313, 328], ["H3N2", "PROBLEM", 372, 376], ["H9N2", "TEST", 378, 382], ["influenza", "PROBLEM", 393, 402], ["H5N1", "PROBLEM", 409, 413], ["viral", "OBSERVATION_MODIFIER", 125, 130], ["infection", "OBSERVATION", 131, 140], ["lung", "ANATOMY", 227, 231], ["viral titers", "OBSERVATION", 232, 244], ["antiviral effects", "OBSERVATION", 292, 309]]], ["In detail, RGE has been reported to have antiviral effects on H1N1, H3N2, and H5N1 [31], [32]; GP has effects on H1N1 and H3N2 [33]; and saponin has an effect on H1N1 [34].", [["RGE", "CHEMICAL", 11, 14], ["H5N1", "DISEASE", 78, 82], ["saponin", "CHEMICAL", 137, 144], ["saponin", "CHEMICAL", 137, 144], ["RGE", "GENE_OR_GENE_PRODUCT", 11, 14], ["H3N2", "ORGANISM", 68, 72], ["H5N1 [31]", "ORGANISM", 78, 87], ["GP", "ORGANISM", 95, 97], ["H1N1", "ORGANISM", 113, 117], ["H3N2 [33", "ORGANISM", 122, 130], ["saponin", "SIMPLE_CHEMICAL", 137, 144], ["RGE", "PROTEIN", 11, 14], ["antiviral effects", "PROBLEM", 41, 58], ["H1N1", "PROBLEM", 62, 66], ["H3N2", "PROBLEM", 68, 72], ["H5N1", "PROBLEM", 78, 82], ["H1N1", "PROBLEM", 113, 117], ["H3N2", "PROBLEM", 122, 126], ["saponin", "TREATMENT", 137, 144], ["H1N1", "PROBLEM", 162, 166]]], ["The antiviral activities of RGE, GP, and ginseng saponin fraction have also been compared using the H1N1 strain.", [["RGE", "CHEMICAL", 28, 31], ["saponin", "CHEMICAL", 49, 56], ["RGE", "SIMPLE_CHEMICAL", 28, 31], ["GP", "SIMPLE_CHEMICAL", 33, 35], ["ginseng saponin", "SIMPLE_CHEMICAL", 41, 56], ["ginseng", "SPECIES", 41, 48], ["ginseng saponin fraction", "TEST", 41, 65], ["the H1N1 strain", "PROBLEM", 96, 111], ["antiviral", "OBSERVATION_MODIFIER", 4, 13], ["H1N1", "OBSERVATION", 100, 104]]], ["Yin et al [34] showed that GP was the most effective in improving the symptoms of influenza virus infection, followed by RGE and saponin in that order.Influenza virusIn addition to antiviral activity, RGE also plays a role as a mucosal adjuvant against influenza virus A/PR8 during viral infection [35].", [["mucosal", "ANATOMY", 228, 235], ["influenza virus infection", "DISEASE", 82, 107], ["saponin", "CHEMICAL", 129, 136], ["RGE", "CHEMICAL", 201, 204], ["viral infection", "DISEASE", 282, 297], ["saponin", "CHEMICAL", 129, 136], ["GP", "GENE_OR_GENE_PRODUCT", 27, 29], ["influenza virus", "ORGANISM", 82, 97], ["RGE", "SIMPLE_CHEMICAL", 121, 124], ["saponin", "SIMPLE_CHEMICAL", 129, 136], ["Influenza virusIn", "ORGANISM", 151, 168], ["RGE", "SIMPLE_CHEMICAL", 201, 204], ["mucosal", "ORGANISM_SUBDIVISION", 228, 235], ["influenza virus A", "ORGANISM", 253, 270], ["PR8", "ORGANISM", 271, 274], ["influenza virus", "SPECIES", 82, 97], ["Influenza", "SPECIES", 151, 160], ["influenza virus", "SPECIES", 253, 268], ["influenza virus", "SPECIES", 82, 97], ["influenza virus A/PR8", "SPECIES", 253, 274], ["influenza virus infection", "PROBLEM", 82, 107], ["saponin", "TREATMENT", 129, 136], ["Influenza virusIn", "TREATMENT", 151, 168], ["antiviral activity", "TREATMENT", 181, 199], ["a mucosal adjuvant", "TREATMENT", 226, 244], ["influenza virus", "PROBLEM", 253, 268], ["viral infection", "PROBLEM", 282, 297], ["most effective", "OBSERVATION_MODIFIER", 38, 52], ["influenza virus infection", "OBSERVATION", 82, 107]]], ["When administered with inactivated virus and RGE intranasally, immunized mice produced increased levels of influenza virus-specific antibodies with improved neutralizing activities in blood and mucosal secretions, notably the IgA antibody in the lung.", [["blood", "ANATOMY", 184, 189], ["mucosal secretions", "ANATOMY", 194, 212], ["lung", "ANATOMY", 246, 250], ["RGE intranasally", "ORGANISM", 45, 61], ["mice", "ORGANISM", 73, 77], ["influenza virus", "ORGANISM", 107, 122], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["mucosal secretions", "ORGANISM_SUBSTANCE", 194, 212], ["IgA antibody", "GENE_OR_GENE_PRODUCT", 226, 238], ["lung", "ORGAN", 246, 250], ["influenza virus-specific antibodies", "PROTEIN", 107, 142], ["IgA antibody", "PROTEIN", 226, 238], ["mice", "SPECIES", 73, 77], ["influenza virus", "SPECIES", 107, 122], ["mice", "SPECIES", 73, 77], ["inactivated virus", "PROBLEM", 23, 40], ["RGE intranasally", "TREATMENT", 45, 61], ["increased levels", "PROBLEM", 87, 103], ["influenza virus", "PROBLEM", 107, 122], ["specific antibodies", "TEST", 123, 142], ["improved neutralizing activities in blood and mucosal secretions", "PROBLEM", 148, 212], ["the IgA antibody", "TEST", 222, 238], ["influenza virus", "OBSERVATION", 107, 122], ["mucosal", "ANATOMY", 194, 201], ["secretions", "OBSERVATION", 202, 212], ["lung", "ANATOMY", 246, 250]]], ["RGE plus virus immunization also resulted in the enhanced secretion of Th1 and Th2-type cytokines in splenocytes upon challenge infection, although a Th2 type response was more remarkable.", [["splenocytes", "ANATOMY", 101, 112], ["RGE", "CHEMICAL", 0, 3], ["infection", "DISEASE", 128, 137], ["RGE", "GENE_OR_GENE_PRODUCT", 0, 3], ["Th1", "GENE_OR_GENE_PRODUCT", 71, 74], ["splenocytes", "CELL", 101, 112], ["Th1 and Th2-type cytokines", "PROTEIN", 71, 97], ["splenocytes", "CELL_TYPE", 101, 112], ["RGE plus virus immunization", "TREATMENT", 0, 27], ["the enhanced secretion of Th1", "PROBLEM", 45, 74], ["splenocytes", "PROBLEM", 101, 112], ["challenge infection", "PROBLEM", 118, 137], ["a Th2 type response", "TEST", 148, 167], ["splenocytes", "ANATOMY", 101, 112], ["infection", "OBSERVATION", 128, 137]]], ["This adjuvant effect of RGE was comparable to that of conventional adjuvants such as aluminum hydroxide and cholera toxin.", [["RGE", "CHEMICAL", 24, 27], ["aluminum hydroxide", "CHEMICAL", 85, 103], ["cholera toxin", "CHEMICAL", 108, 121], ["aluminum hydroxide", "CHEMICAL", 85, 103], ["RGE", "SIMPLE_CHEMICAL", 24, 27], ["aluminum hydroxide", "SIMPLE_CHEMICAL", 85, 103], ["cholera toxin", "SIMPLE_CHEMICAL", 108, 121], ["RGE", "PROBLEM", 24, 27], ["conventional adjuvants", "TREATMENT", 54, 76], ["aluminum hydroxide", "TREATMENT", 85, 103], ["cholera toxin", "TREATMENT", 108, 121]]], ["Additionally, immunization of mice with inactivated H3N2 influenza antigen and ginsenoside Re resulted in increased immune responses by elevating both Th1 and Th2 cell activities [2].", [["Th2 cell", "ANATOMY", 159, 167], ["ginsenoside Re", "CHEMICAL", 79, 93], ["ginsenoside Re", "CHEMICAL", 79, 93], ["mice", "ORGANISM", 30, 34], ["H3N2 influenza antigen", "ORGANISM", 52, 74], ["ginsenoside Re", "SIMPLE_CHEMICAL", 79, 93], ["Th1", "CELL", 151, 154], ["Th2 cell", "CELL", 159, 167], ["mice", "SPECIES", 30, 34], ["H3N2 influenza", "SPECIES", 52, 66], ["mice", "SPECIES", 30, 34], ["immunization of mice", "TREATMENT", 14, 34], ["inactivated H3N2 influenza antigen", "TREATMENT", 40, 74], ["increased immune responses", "PROBLEM", 106, 132], ["Th2 cell", "OBSERVATION", 159, 167]]], ["The secretion of serum-specific IgG1 and IgG2a and hemagglutination inhibition titers were all increased, and in vitro stimulation of splenocytes produced higher levels of Th1 and Th2 cytokines in ginsenoside Re-administered mice.", [["serum", "ANATOMY", 17, 22], ["splenocytes", "ANATOMY", 134, 145], ["ginsenoside", "CHEMICAL", 197, 208], ["ginsenoside", "CHEMICAL", 197, 208], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["IgG1", "GENE_OR_GENE_PRODUCT", 32, 36], ["IgG2a", "GENE_OR_GENE_PRODUCT", 41, 46], ["splenocytes", "CELL", 134, 145], ["Th1", "GENE_OR_GENE_PRODUCT", 172, 175], ["ginsenoside", "SIMPLE_CHEMICAL", 197, 208], ["mice", "ORGANISM", 225, 229], ["IgG1", "PROTEIN", 32, 36], ["IgG2a", "PROTEIN", 41, 46], ["splenocytes", "CELL_TYPE", 134, 145], ["Th1 and Th2 cytokines", "PROTEIN", 172, 193], ["mice", "SPECIES", 225, 229], ["mice", "SPECIES", 225, 229], ["The secretion of serum", "TEST", 0, 22], ["specific IgG1", "TEST", 23, 36], ["IgG2a", "TEST", 41, 46], ["hemagglutination inhibition titers", "TEST", 51, 85], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["splenocytes", "ANATOMY", 134, 145]]], ["Furthermore, dietary intake of RGE and Korean Red Ginseng saponin (KRGS) has also been shown to improve H1N1 vaccine efficacy by increasing anti-influenza virus A-specific IgG titers and survival rates [36].", [["RGE", "CHEMICAL", 31, 34], ["Korean Red Ginseng saponin", "CHEMICAL", 39, 65], ["KRGS", "CHEMICAL", 67, 71], ["saponin", "CHEMICAL", 58, 65], ["RGE", "SIMPLE_CHEMICAL", 31, 34], ["Ginseng saponin", "SIMPLE_CHEMICAL", 50, 65], ["KRGS", "SIMPLE_CHEMICAL", 67, 71], ["anti-influenza virus", "ORGANISM", 140, 160], ["IgG", "GENE_OR_GENE_PRODUCT", 172, 175], ["Korean Red Ginseng saponin", "SPECIES", 39, 65], ["anti-influenza virus", "SPECIES", 140, 160], ["RGE", "PROBLEM", 31, 34], ["Korean Red Ginseng saponin", "TREATMENT", 39, 65], ["H1N1 vaccine efficacy", "TREATMENT", 104, 125], ["increasing anti-influenza virus", "TREATMENT", 129, 160], ["IgG titers", "TEST", 172, 182], ["survival rates", "TEST", 187, 201]]], ["In addition, GP induced cross-protective vaccine efficacy.", [["GP induced cross-protective vaccine efficacy", "TREATMENT", 13, 57]]], ["When mice were vaccinated with influenza virus-like particles (VLPs) originating from H1N1 together with GP, the immunized mice developed heterosubtypic protection and survived a lethal challenge with the H3N2 virus.", [["mice", "ORGANISM", 5, 9], ["influenza virus-like particles", "ORGANISM", 31, 61], ["VLPs", "ORGANISM", 63, 67], ["H1N1", "ORGANISM", 86, 90], ["mice", "ORGANISM", 123, 127], ["H3N2 virus", "ORGANISM", 205, 215], ["mice", "SPECIES", 5, 9], ["influenza virus", "SPECIES", 31, 46], ["mice", "SPECIES", 123, 127], ["H3N2 virus", "SPECIES", 205, 215], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 123, 127], ["H3N2 virus", "SPECIES", 205, 215], ["influenza virus", "PROBLEM", 31, 46], ["H1N1", "PROBLEM", 86, 90], ["the immunized mice", "TREATMENT", 109, 127], ["heterosubtypic protection", "TREATMENT", 138, 163], ["a lethal challenge", "TREATMENT", 177, 195], ["the H3N2 virus", "PROBLEM", 201, 215]]], ["Taken together, the data suggest the use of RGE, KRGS, ginsenoside Re, and GP as adjuvant or dietary supplements to enhance the vaccine-induced immune response and improve protection against influenza virus infection.Human immunodeficiency virusHuman immunodeficiency virus (HIV) belongs to the genus Lentivirus in the family Retroviridae, and two types of HIV have been characterized: HIV-1 and HIV-2 [37].", [["RGE", "CHEMICAL", 44, 47], ["KRGS", "CHEMICAL", 49, 53], ["ginsenoside Re", "CHEMICAL", 55, 69], ["influenza virus infection", "DISEASE", 191, 216], ["Human immunodeficiency virusHuman immunodeficiency virus", "DISEASE", 217, 273], ["KRGS", "CHEMICAL", 49, 53], ["ginsenoside Re", "CHEMICAL", 55, 69], ["RGE", "SIMPLE_CHEMICAL", 44, 47], ["KRGS", "SIMPLE_CHEMICAL", 49, 53], ["ginsenoside Re", "SIMPLE_CHEMICAL", 55, 69], ["GP", "SIMPLE_CHEMICAL", 75, 77], ["influenza virus", "ORGANISM", 191, 206], ["Human immunodeficiency virusHuman immunodeficiency virus", "ORGANISM", 217, 273], ["HIV", "ORGANISM", 275, 278], ["Lentivirus", "ORGANISM", 301, 311], ["HIV", "ORGANISM", 357, 360], ["HIV-1", "ORGANISM", 386, 391], ["HIV-2", "ORGANISM", 396, 401], ["influenza virus", "SPECIES", 191, 206], ["Human immunodeficiency virusHuman immunodeficiency virus (HIV", "SPECIES", 217, 278], ["HIV", "SPECIES", 357, 360], ["HIV-1", "SPECIES", 386, 391], ["HIV", "SPECIES", 396, 399], ["influenza virus", "SPECIES", 191, 206], ["Human immunodeficiency virusHuman immunodeficiency virus", "SPECIES", 217, 273], ["HIV", "SPECIES", 275, 278], ["HIV", "SPECIES", 357, 360], ["HIV-1", "SPECIES", 386, 391], ["HIV-2", "SPECIES", 396, 401], ["RGE, KRGS", "TREATMENT", 44, 53], ["ginsenoside Re", "TREATMENT", 55, 69], ["adjuvant", "TREATMENT", 81, 89], ["dietary supplements", "TREATMENT", 93, 112], ["the vaccine", "TREATMENT", 124, 135], ["immune response", "PROBLEM", 144, 159], ["influenza virus infection", "PROBLEM", 191, 216], ["Human immunodeficiency virusHuman immunodeficiency virus (HIV)", "PROBLEM", 217, 279], ["HIV", "PROBLEM", 357, 360], ["HIV", "TEST", 386, 389], ["HIV", "TEST", 396, 399], ["genus Lentivirus", "OBSERVATION", 295, 311]]], ["HIV-1 is the major type of HIV accounting for 95% of infections worldwide and is more virulent and infectious than HIV-2 [38].", [["HIV", "DISEASE", 27, 30], ["infections", "DISEASE", 53, 63], ["HIV-1", "ORGANISM", 0, 5], ["HIV", "ORGANISM", 27, 30], ["HIV-2", "ORGANISM", 115, 120], ["HIV-1", "SPECIES", 0, 5], ["HIV", "SPECIES", 27, 30], ["HIV-", "SPECIES", 115, 119], ["HIV-1", "SPECIES", 0, 5], ["HIV", "SPECIES", 27, 30], ["HIV-2", "SPECIES", 115, 120], ["HIV", "PROBLEM", 0, 3], ["HIV", "PROBLEM", 27, 30], ["infections", "PROBLEM", 53, 63], ["infections", "OBSERVATION", 53, 63], ["more virulent", "OBSERVATION_MODIFIER", 81, 94]]], ["HIV-2 is mainly seen in West Africa and has lower infectivity [39], [40].", [["HIV-2", "ORGANISM", 0, 5], ["HIV-2", "SPECIES", 0, 5], ["HIV-2", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["lower infectivity", "PROBLEM", 44, 61]]], ["There are well-defined stages of HIV disease progression from acute infection, clinical latency, and acquired immunodeficiency syndrome AIDS, and an HIV-positive patient is diagnosed with AIDS when his/her CD4+ cell count falls < 200 cells/mm3.", [["CD4+ cell", "ANATOMY", 206, 215], ["cells", "ANATOMY", 234, 239], ["HIV disease", "DISEASE", 33, 44], ["acute infection", "DISEASE", 62, 77], ["acquired immunodeficiency syndrome", "DISEASE", 101, 135], ["AIDS", "DISEASE", 136, 140], ["HIV-positive", "DISEASE", 149, 161], ["AIDS", "DISEASE", 188, 192], ["HIV", "ORGANISM", 33, 36], ["HIV", "ORGANISM", 149, 152], ["patient", "ORGANISM", 162, 169], ["CD4", "GENE_OR_GENE_PRODUCT", 206, 209], ["cell", "CELL", 211, 215], ["CD4", "PROTEIN", 206, 209], ["HIV", "SPECIES", 33, 36], ["patient", "SPECIES", 162, 169], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 149, 152], ["HIV disease progression", "PROBLEM", 33, 56], ["acute infection", "PROBLEM", 62, 77], ["clinical latency", "PROBLEM", 79, 95], ["acquired immunodeficiency syndrome AIDS", "PROBLEM", 101, 140], ["an HIV", "TEST", 146, 152], ["AIDS", "PROBLEM", 188, 192], ["his/her CD4", "TEST", 198, 209], ["cell count falls", "TEST", 211, 227], ["well-defined", "OBSERVATION_MODIFIER", 10, 22], ["stages", "OBSERVATION_MODIFIER", 23, 29], ["HIV disease", "OBSERVATION", 33, 44], ["progression", "OBSERVATION_MODIFIER", 45, 56], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["infection", "OBSERVATION", 68, 77], ["immunodeficiency syndrome", "OBSERVATION", 110, 135]]], ["HIV treatment or highly active antiretroviral therapy (HAART) involves the combination of multiple drugs with different mechanisms of action.", [["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV treatment", "TREATMENT", 0, 13], ["highly active antiretroviral therapy", "TREATMENT", 17, 53], ["HAART", "TREATMENT", 55, 60], ["multiple drugs", "TREATMENT", 90, 104], ["active", "OBSERVATION_MODIFIER", 24, 30], ["antiretroviral therapy", "OBSERVATION", 31, 53]]], ["HAART can effectively suspend or prevent disease progression from one stage to the next and prolong the lives of HIV-positive patients dramatically by lowering the viral load, maintaining immune system function, and preventing opportunistic infections [7], [41]Human immunodeficiency virusWhen combined with zidovudine monotherapy or HAART, RGE has been shown to exert antiviral effects by maintaining CD4+ T cell counts [42], [43], [44], [45] and delaying the occurrence of resistance mutation [42], [43], [46] in HIV-1 patients.", [["immune system", "ANATOMY", 188, 201], ["CD4+ T cell", "ANATOMY", 402, 413], ["HIV-positive", "DISEASE", 113, 125], ["opportunistic infections", "DISEASE", 227, 251], ["Human immunodeficiency virusWhen", "DISEASE", 261, 293], ["zidovudine", "CHEMICAL", 308, 318], ["RGE", "CHEMICAL", 341, 344], ["zidovudine", "CHEMICAL", 308, 318], ["HIV", "ORGANISM", 113, 116], ["patients", "ORGANISM", 126, 134], ["Human", "ORGANISM", 261, 266], ["zidovudine", "SIMPLE_CHEMICAL", 308, 318], ["RGE", "SIMPLE_CHEMICAL", 341, 344], ["CD4", "GENE_OR_GENE_PRODUCT", 402, 405], ["HIV-1", "ORGANISM", 515, 520], ["patients", "ORGANISM", 521, 529], ["CD4", "PROTEIN", 402, 405], ["patients", "SPECIES", 126, 134], ["Human", "SPECIES", 261, 266], ["HIV-1", "SPECIES", 515, 520], ["patients", "SPECIES", 521, 529], ["HIV", "SPECIES", 113, 116], ["Human immunodeficiency virusWhen", "SPECIES", 261, 293], ["HIV-1", "SPECIES", 515, 520], ["HAART", "TREATMENT", 0, 5], ["disease progression", "PROBLEM", 41, 60], ["HIV", "PROBLEM", 113, 116], ["the viral load", "TEST", 160, 174], ["opportunistic infections", "PROBLEM", 227, 251], ["Human immunodeficiency virusWhen", "TREATMENT", 261, 293], ["zidovudine monotherapy", "TREATMENT", 308, 330], ["HAART", "TREATMENT", 334, 339], ["antiviral effects", "TREATMENT", 369, 386], ["T cell counts", "TEST", 407, 420], ["resistance mutation", "PROBLEM", 475, 494], ["HIV", "TEST", 515, 518], ["viral load", "OBSERVATION", 164, 174]]], ["RGE treatment alone even showed significant antiHIV effects [44], [47], [48], [49], implying that RGE intake may become an alternative form of treatment for HIV-1 patients.", [["RGE", "CHEMICAL", 0, 3], ["RGE", "CHEMICAL", 98, 101], ["RGE", "SIMPLE_CHEMICAL", 0, 3], ["RGE", "SIMPLE_CHEMICAL", 98, 101], ["HIV-1", "ORGANISM", 157, 162], ["patients", "ORGANISM", 163, 171], ["HIV-1", "SPECIES", 157, 162], ["patients", "SPECIES", 163, 171], ["antiHIV", "SPECIES", 44, 51], ["HIV-1", "SPECIES", 157, 162], ["RGE treatment", "TREATMENT", 0, 13], ["significant antiHIV effects", "PROBLEM", 32, 59], ["HIV", "PROBLEM", 157, 160]]], ["Negative factor (Nef) is a virulence factor required for achieving high virus load and the progression to AIDS [50].", [["AIDS", "DISEASE", 106, 110], ["Nef", "GENE_OR_GENE_PRODUCT", 17, 20], ["Negative factor", "PROTEIN", 0, 15], ["Nef", "PROTEIN", 17, 20], ["virulence factor", "PROTEIN", 27, 43], ["a virulence factor", "PROBLEM", 25, 43], ["high virus load", "PROBLEM", 67, 82]]], ["The 5\u2032 long terminal repeat (LTR) acts as a promoter of the entire viral genome and stimulates viral genome replication, whereas group-specific antigen (gag) promotes the formation of fully infectious HIV-1 virions.", [["LTR", "ANATOMY", 29, 32], ["long terminal repeat", "CELLULAR_COMPONENT", 7, 27], ["LTR", "CELLULAR_COMPONENT", 29, 32], ["group-specific antigen", "GENE_OR_GENE_PRODUCT", 129, 151], ["gag", "GENE_OR_GENE_PRODUCT", 153, 156], ["HIV-1 virions", "ORGANISM", 201, 214], ["5\u2032 long terminal repeat", "DNA", 4, 27], ["LTR", "DNA", 29, 32], ["promoter", "DNA", 44, 52], ["viral genome", "DNA", 67, 79], ["group-specific antigen", "PROTEIN", 129, 151], ["gag", "PROTEIN", 153, 156], ["HIV-1", "SPECIES", 201, 206], ["HIV-1", "SPECIES", 201, 206], ["The 5\u2032 long terminal repeat (LTR)", "TREATMENT", 0, 33], ["the entire viral genome", "TREATMENT", 56, 79], ["stimulates viral genome replication", "PROBLEM", 84, 119], ["fully infectious HIV", "PROBLEM", 184, 204], ["viral genome", "OBSERVATION", 67, 79], ["viral genome", "OBSERVATION", 95, 107], ["infectious", "OBSERVATION", 190, 200]]], ["Interestingly, RGE intake increases the frequency of gross deletions in Nef genes [51], [52], [53], [54] and the 5\u2032 LTR/gag gene [53], [55], [56], leading to a delay in disease progression and increase of survival rate in HIV-1 patients.Human immunodeficiency virusAlthough most studies evaluating the effects of ginseng on HIV-1 have been carried out in HIV-1 patients, several in vitro studies have also been performed.", [["RGE", "CHEMICAL", 15, 18], ["Human immunodeficiency virusAlthough", "DISEASE", 237, 273], ["RGE", "SIMPLE_CHEMICAL", 15, 18], ["Nef", "GENE_OR_GENE_PRODUCT", 72, 75], ["LTR", "CELLULAR_COMPONENT", 116, 119], ["gag", "GENE_OR_GENE_PRODUCT", 120, 123], ["HIV-1", "ORGANISM", 222, 227], ["patients", "ORGANISM", 228, 236], ["Human", "ORGANISM", 237, 242], ["ginseng", "ORGANISM", 313, 320], ["HIV-1", "ORGANISM", 324, 329], ["HIV-1", "ORGANISM", 355, 360], ["patients", "ORGANISM", 361, 369], ["Nef genes", "DNA", 72, 81], ["LTR", "DNA", 116, 119], ["gag gene", "DNA", 120, 128], ["HIV-1", "SPECIES", 222, 227], ["patients", "SPECIES", 228, 236], ["Human", "SPECIES", 237, 242], ["HIV-1", "SPECIES", 324, 329], ["HIV-1", "SPECIES", 355, 360], ["patients", "SPECIES", 361, 369], ["HIV-1", "SPECIES", 222, 227], ["Human immunodeficiency virusAlthough", "SPECIES", 237, 273], ["HIV-1", "SPECIES", 324, 329], ["HIV-1", "SPECIES", 355, 360], ["gross deletions", "PROBLEM", 53, 68], ["a delay in disease progression", "PROBLEM", 158, 188], ["survival rate", "TEST", 205, 218], ["Human immunodeficiency virusAlthough", "PROBLEM", 237, 273], ["vitro studies", "TEST", 382, 395], ["disease", "OBSERVATION", 169, 176], ["increase", "OBSERVATION_MODIFIER", 193, 201]]], ["For example, a homodimeric protein, quinqueginsin, isolated from the roots of American ginseng Panax quinquefolium, and xylanase, isolated from the roots of Panax notoginseng, have been shown to inhibit reverse transcriptase in a cell-free system [57], [58].", [["roots", "ANATOMY", 69, 74], ["roots", "ANATOMY", 148, 153], ["cell", "ANATOMY", 230, 234], ["quinqueginsin", "CHEMICAL", 36, 49], ["quinqueginsin", "CHEMICAL", 36, 49], ["quinqueginsin", "GENE_OR_GENE_PRODUCT", 36, 49], ["roots", "ORGANISM_SUBDIVISION", 69, 74], ["American ginseng", "ORGANISM", 78, 94], ["Panax quinquefolium", "ORGANISM", 95, 114], ["xylanase", "GENE_OR_GENE_PRODUCT", 120, 128], ["roots", "ORGANISM_SUBDIVISION", 148, 153], ["Panax notoginseng", "ORGANISM", 157, 174], ["cell", "CELL", 230, 234], ["homodimeric protein", "PROTEIN", 15, 34], ["quinqueginsin", "PROTEIN", 36, 49], ["xylanase", "PROTEIN", 120, 128], ["reverse transcriptase", "PROTEIN", 203, 224], ["ginseng", "SPECIES", 87, 94], ["Panax quinquefolium", "SPECIES", 95, 114], ["Panax notoginseng", "SPECIES", 157, 174], ["American ginseng", "SPECIES", 78, 94], ["Panax quinquefolium", "SPECIES", 95, 114], ["Panax notoginseng", "SPECIES", 157, 174], ["a homodimeric protein", "PROBLEM", 13, 34], ["quinqueginsin", "TREATMENT", 36, 49], ["American ginseng Panax quinquefolium", "TREATMENT", 78, 114], ["xylanase", "TREATMENT", 120, 128], ["Panax notoginseng", "TREATMENT", 157, 174]]], ["Additionally, ginsenoside Rh1, ginsenoside Rb1, and compound K have been reported to inhibit cytoprotective effects which may contribute to the long-term survival and persistent HIV-1 production in cells constitutively expressing transactivator (Tat) proteins [59], [60], [61].Human immunodeficiency virusIn addition to antiviral effects, ginseng interacts with antiHIV drugs and changes their pharmacokinetic properties.", [["cells", "ANATOMY", 198, 203], ["ginsenoside Rh1", "CHEMICAL", 14, 29], ["ginsenoside Rb1", "CHEMICAL", 31, 46], ["compound K", "CHEMICAL", 52, 62], ["Human immunodeficiency virusIn", "DISEASE", 277, 307], ["ginsenoside Rh1", "CHEMICAL", 14, 29], ["ginsenoside Rb1", "CHEMICAL", 31, 46], ["ginsenoside Rh1", "SIMPLE_CHEMICAL", 14, 29], ["ginsenoside Rb1", "SIMPLE_CHEMICAL", 31, 46], ["compound K", "SIMPLE_CHEMICAL", 52, 62], ["HIV-1", "GENE_OR_GENE_PRODUCT", 178, 183], ["cells", "CELL", 198, 203], ["Tat", "GENE_OR_GENE_PRODUCT", 246, 249], ["Human immunodeficiency virusIn", "ORGANISM", 277, 307], ["ginseng", "ORGANISM", 339, 346], ["transactivator (Tat) proteins", "PROTEIN", 230, 259], ["HIV-1", "SPECIES", 178, 183], ["Human", "SPECIES", 277, 282], ["HIV-1", "SPECIES", 178, 183], ["Human immunodeficiency virusIn", "SPECIES", 277, 307], ["antiHIV", "SPECIES", 362, 369], ["ginsenoside Rh1", "TEST", 14, 29], ["ginsenoside Rb1", "TEST", 31, 46], ["compound K", "TEST", 52, 62], ["cytoprotective effects", "PROBLEM", 93, 115], ["the long-term survival", "PROBLEM", 140, 162], ["persistent HIV", "PROBLEM", 167, 181], ["Human immunodeficiency virusIn", "PROBLEM", 277, 307], ["antiviral effects", "TREATMENT", 320, 337], ["antiHIV drugs", "TREATMENT", 362, 375], ["immunodeficiency", "OBSERVATION", 283, 299]]], ["Shi et al [62] have reported that ginsenoside Rh2 increased the accumulation and decreased the efflux of ritonavir through P-glycoprotein (P-gp) in Caco-2 cells and MDCK-MDR1 cells.", [["Caco-2 cells", "ANATOMY", 148, 160], ["MDCK-MDR1 cells", "ANATOMY", 165, 180], ["ginsenoside Rh2", "CHEMICAL", 34, 49], ["ritonavir", "CHEMICAL", 105, 114], ["ginsenoside Rh2", "CHEMICAL", 34, 49], ["ritonavir", "CHEMICAL", 105, 114], ["ginsenoside Rh2", "SIMPLE_CHEMICAL", 34, 49], ["ritonavir", "SIMPLE_CHEMICAL", 105, 114], ["P-gp", "GENE_OR_GENE_PRODUCT", 139, 143], ["Caco-2 cells", "CELL", 148, 160], ["MDCK-MDR1 cells", "CELL", 165, 180], ["P-glycoprotein (P-gp", "PROTEIN", 123, 143], ["Caco-2 cells", "CELL_LINE", 148, 160], ["MDCK", "CELL_LINE", 165, 169], ["MDR1 cells", "CELL_LINE", 170, 180], ["ginsenoside Rh2", "PROBLEM", 34, 49], ["the accumulation", "PROBLEM", 60, 76], ["ritonavir", "TREATMENT", 105, 114], ["Caco", "TEST", 148, 152], ["MDCK-MDR1 cells", "TREATMENT", 165, 180], ["decreased", "OBSERVATION_MODIFIER", 81, 90], ["MDR1 cells", "OBSERVATION", 170, 180]]], ["An in vivo study using rats confirmed that intravenous administration of ginsenoside Rh2 inhibited ritonavir efflux and increased the plasma level of ritonavir.", [["intravenous", "ANATOMY", 43, 54], ["plasma", "ANATOMY", 134, 140], ["ginsenoside Rh2", "CHEMICAL", 73, 88], ["ritonavir", "CHEMICAL", 99, 108], ["ritonavir", "CHEMICAL", 150, 159], ["ginsenoside Rh2", "CHEMICAL", 73, 88], ["ritonavir", "CHEMICAL", 99, 108], ["ritonavir", "CHEMICAL", 150, 159], ["rats", "ORGANISM", 23, 27], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 54], ["ginsenoside Rh2", "SIMPLE_CHEMICAL", 73, 88], ["ritonavir", "SIMPLE_CHEMICAL", 99, 108], ["plasma", "ORGANISM_SUBSTANCE", 134, 140], ["ritonavir", "SIMPLE_CHEMICAL", 150, 159], ["rats", "SPECIES", 23, 27], ["An in vivo study", "TEST", 0, 16], ["intravenous administration", "TREATMENT", 43, 69], ["ginsenoside Rh2", "TREATMENT", 73, 88], ["ritonavir efflux", "TREATMENT", 99, 115], ["ritonavir", "TREATMENT", 150, 159]]], ["However, American ginseng, Panax quinquefolium, did not affect the pharmacokinetics of an antiHIV drug cotreated in humans, although it induced phase 2 enzyme quinone reductase [63].", [["quinone", "CHEMICAL", 159, 166], ["American ginseng", "ORGANISM", 9, 25], ["Panax quinquefolium", "ORGANISM", 27, 46], ["antiHIV", "SIMPLE_CHEMICAL", 90, 97], ["humans", "ORGANISM", 116, 122], ["quinone reductase", "GENE_OR_GENE_PRODUCT", 159, 176], ["enzyme quinone reductase", "PROTEIN", 152, 176], ["ginseng", "SPECIES", 18, 25], ["Panax quinquefolium", "SPECIES", 27, 46], ["humans", "SPECIES", 116, 122], ["American ginseng", "SPECIES", 9, 25], ["Panax quinquefolium", "SPECIES", 27, 46], ["antiHIV", "SPECIES", 90, 97], ["humans", "SPECIES", 116, 122], ["an antiHIV drug", "TREATMENT", 87, 102]]], ["Kaempferol isolated from ginseng has also been reported to inhibit P-gp-mediated efflux of ritonavir and cytochrome P-450 3A4 (CYP3A4) activities in vitro[64], but it has not been confirmed whether kaempferol would indeed induce the level of ritonavir in vivo.Human herpesvirusThe herpesviruses are a group of large DNA viruses causing lytic, persistent, and latent/recurrent infections [65].", [["Kaempferol", "CHEMICAL", 0, 10], ["ritonavir", "CHEMICAL", 91, 100], ["kaempferol", "CHEMICAL", 198, 208], ["ritonavir", "CHEMICAL", 242, 251], ["infections", "DISEASE", 376, 386], ["Kaempferol", "CHEMICAL", 0, 10], ["ritonavir", "CHEMICAL", 91, 100], ["kaempferol", "CHEMICAL", 198, 208], ["ritonavir", "CHEMICAL", 242, 251], ["Kaempferol", "SIMPLE_CHEMICAL", 0, 10], ["ginseng", "ORGANISM", 25, 32], ["P-gp", "GENE_OR_GENE_PRODUCT", 67, 71], ["ritonavir", "SIMPLE_CHEMICAL", 91, 100], ["cytochrome P-450 3A4", "GENE_OR_GENE_PRODUCT", 105, 125], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 127, 133], ["kaempferol", "SIMPLE_CHEMICAL", 198, 208], ["ritonavir", "SIMPLE_CHEMICAL", 242, 251], ["Human", "ORGANISM", 260, 265], ["herpesvirus", "ORGANISM", 266, 277], ["herpesviruses", "ORGANISM", 281, 294], ["DNA", "CELLULAR_COMPONENT", 316, 319], ["P-gp", "PROTEIN", 67, 71], ["CYP3A4", "PROTEIN", 127, 133], ["Human", "SPECIES", 260, 265], ["Human herpesvirus", "SPECIES", 260, 277], ["Kaempferol", "TREATMENT", 0, 10], ["ritonavir", "TREATMENT", 91, 100], ["cytochrome P", "TREATMENT", 105, 117], ["kaempferol", "TREATMENT", 198, 208], ["ritonavir", "TREATMENT", 242, 251], ["Human herpesvirus", "PROBLEM", 260, 277], ["The herpesviruses", "PROBLEM", 277, 294], ["large DNA viruses", "PROBLEM", 310, 327], ["lytic", "PROBLEM", 336, 341], ["latent/recurrent infections", "PROBLEM", 359, 386], ["herpesviruses", "OBSERVATION", 281, 294], ["large", "OBSERVATION_MODIFIER", 310, 315], ["DNA viruses", "OBSERVATION", 316, 327], ["lytic", "OBSERVATION_MODIFIER", 336, 341], ["persistent", "OBSERVATION_MODIFIER", 343, 353], ["latent", "OBSERVATION_MODIFIER", 359, 365], ["recurrent", "OBSERVATION_MODIFIER", 366, 375], ["infections", "OBSERVATION", 376, 386]]], ["The human herpesviruses (HHV) are further divided into three subfamilies, alphaherpesvirinae [including herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), and varicella-zoster virus (VZV)], betaherpesvirinae, and gammaherpesvirinae based on the differences in factors such as tissue tropism, pathogenesis, and site of latent infection [66].", [["tissue", "ANATOMY", 289, 295], ["herpes simplex virus", "DISEASE", 104, 124], ["herpes simplex virus", "DISEASE", 136, 156], ["varicella-zoster virus (VZV)]", "DISEASE", 172, 201], ["infection", "DISEASE", 338, 347], ["human", "ORGANISM", 4, 9], ["herpesviruses", "ORGANISM", 10, 23], ["HHV", "GENE_OR_GENE_PRODUCT", 25, 28], ["alphaherpesvirinae [including", "ORGANISM", 74, 103], ["herpes simplex virus-1", "ORGANISM", 104, 126], ["HSV-1", "ORGANISM", 128, 133], ["herpes simplex virus-2", "ORGANISM", 136, 158], ["HSV-2", "ORGANISM", 160, 165], ["varicella-zoster virus", "ORGANISM", 172, 194], ["VZV", "ORGANISM", 196, 199], ["tissue", "TISSUE", 289, 295], ["human", "SPECIES", 4, 9], ["herpes simplex virus-1", "SPECIES", 104, 126], ["HSV-1", "SPECIES", 128, 133], ["herpes simplex virus-2", "SPECIES", 136, 158], ["HSV-2", "SPECIES", 160, 165], ["varicella-zoster virus", "SPECIES", 172, 194], ["human herpesviruses", "SPECIES", 4, 23], ["HHV", "SPECIES", 25, 28], ["herpes simplex virus-1", "SPECIES", 104, 126], ["HSV-1", "SPECIES", 128, 133], ["herpes simplex virus-2 (HSV-2", "SPECIES", 136, 165], ["varicella-zoster virus", "SPECIES", 172, 194], ["VZV", "SPECIES", 196, 199], ["The human herpesviruses (HHV", "PROBLEM", 0, 28], ["alphaherpesvirinae", "TEST", 74, 92], ["herpes simplex virus", "TEST", 104, 124], ["HSV", "TEST", 128, 131], ["herpes simplex virus", "TEST", 136, 156], ["HSV", "TEST", 160, 163], ["varicella-zoster virus", "PROBLEM", 172, 194], ["betaherpesvirinae", "TREATMENT", 203, 220], ["gammaherpesvirinae", "TREATMENT", 226, 244], ["tissue tropism", "PROBLEM", 289, 303], ["pathogenesis", "PROBLEM", 305, 317], ["latent infection", "PROBLEM", 331, 347], ["varicella", "ANATOMY", 172, 181], ["zoster virus", "OBSERVATION", 182, 194], ["latent", "OBSERVATION_MODIFIER", 331, 337], ["infection", "OBSERVATION", 338, 347]]], ["HSV-1 is typically transmitted during childhood by contact with infected skin and is associated with orofacial infections and encephalitis [67], [68], although HSV-2 is transmitted by sexual activity and causes genital herpes mostly [68].Human herpesvirusNotoginsenoside ST-4 is a dammarane-type saponin of Panax notoginseng and has been reported to show antiHSV activity by inhibiting the penetration of HSV-1 into Vero cells [69].", [["skin", "ANATOMY", 73, 77], ["orofacial", "ANATOMY", 101, 110], ["Vero cells", "ANATOMY", 416, 426], ["infected skin", "DISEASE", 64, 77], ["orofacial infections", "DISEASE", 101, 121], ["encephalitis", "DISEASE", 126, 138], ["HSV-2 is transmitted by sexual activity", "DISEASE", 160, 199], ["genital herpes", "DISEASE", 211, 225], ["Notoginsenoside ST-4", "CHEMICAL", 255, 275], ["dammarane-type saponin of Panax notoginseng", "CHEMICAL", 281, 324], ["dammarane", "CHEMICAL", 281, 290], ["saponin", "CHEMICAL", 296, 303], ["HSV-1", "ORGANISM", 0, 5], ["skin", "ORGAN", 73, 77], ["orofacial", "ORGANISM_SUBDIVISION", 101, 110], ["HSV-2", "ORGANISM", 160, 165], ["genital herpes", "ORGANISM", 211, 225], ["Human", "ORGANISM", 238, 243], ["herpesvirusNotoginsenoside ST-4", "ORGANISM", 244, 275], ["dammarane-type saponin", "SIMPLE_CHEMICAL", 281, 303], ["Panax notoginseng", "ORGANISM", 307, 324], ["antiHSV", "CANCER", 355, 362], ["HSV-1", "ORGANISM", 405, 410], ["Vero cells", "CELL", 416, 426], ["Vero cells", "CELL_LINE", 416, 426], ["HSV-1", "SPECIES", 0, 5], ["HSV-", "SPECIES", 160, 164], ["Human", "SPECIES", 238, 243], ["Panax notoginseng", "SPECIES", 307, 324], ["HSV-1", "SPECIES", 405, 410], ["HSV-1", "SPECIES", 0, 5], ["HSV-2", "SPECIES", 160, 165], ["Human herpesvirusNotoginsenoside ST-4", "SPECIES", 238, 275], ["Panax notoginseng", "SPECIES", 307, 324], ["antiHSV", "SPECIES", 355, 362], ["HSV-1", "SPECIES", 405, 410], ["HSV", "TEST", 0, 3], ["infected skin", "PROBLEM", 64, 77], ["orofacial infections", "PROBLEM", 101, 121], ["encephalitis", "PROBLEM", 126, 138], ["HSV", "TEST", 160, 163], ["genital herpes", "PROBLEM", 211, 225], ["Human herpesvirusNotoginsenoside ST", "TEST", 238, 273], ["Panax notoginseng", "TREATMENT", 307, 324], ["HSV", "TEST", 405, 408], ["infected", "OBSERVATION", 64, 72], ["skin", "ANATOMY", 73, 77], ["associated with", "UNCERTAINTY", 85, 100], ["orofacial", "ANATOMY", 101, 110], ["infections", "OBSERVATION", 111, 121], ["encephalitis", "OBSERVATION", 126, 138], ["genital", "ANATOMY", 211, 218]]], ["Another in vitro study has shown that ginsenoside Rb1 promotes cell proliferation and inhibits the apoptosis of human glioma cells upon HSV infection, suggesting the potential application of ginsenoside Rb1 to prevent neuronal cell death in viral encephalitis [70].", [["cell", "ANATOMY", 63, 67], ["glioma cells", "ANATOMY", 118, 130], ["neuronal cell", "ANATOMY", 218, 231], ["ginsenoside Rb1", "CHEMICAL", 38, 53], ["glioma", "DISEASE", 118, 124], ["HSV infection", "DISEASE", 136, 149], ["ginsenoside Rb1", "CHEMICAL", 191, 206], ["neuronal cell death", "DISEASE", 218, 237], ["viral encephalitis", "DISEASE", 241, 259], ["ginsenoside Rb1", "CHEMICAL", 38, 53], ["ginsenoside Rb1", "CHEMICAL", 191, 206], ["ginsenoside Rb1", "GENE_OR_GENE_PRODUCT", 38, 53], ["cell", "CELL", 63, 67], ["human", "ORGANISM", 112, 117], ["glioma cells", "CELL", 118, 130], ["HSV", "ORGANISM", 136, 139], ["ginsenoside Rb1", "GENE_OR_GENE_PRODUCT", 191, 206], ["neuronal cell", "CELL", 218, 231], ["ginsenoside Rb1", "PROTEIN", 38, 53], ["human glioma cells", "CELL_TYPE", 112, 130], ["ginsenoside Rb1", "PROTEIN", 191, 206], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["HSV", "SPECIES", 136, 139], ["Another in vitro study", "TEST", 0, 22], ["ginsenoside Rb1 promotes cell proliferation", "PROBLEM", 38, 81], ["human glioma cells", "PROBLEM", 112, 130], ["HSV infection", "PROBLEM", 136, 149], ["ginsenoside Rb1", "TREATMENT", 191, 206], ["neuronal cell death", "PROBLEM", 218, 237], ["viral encephalitis", "PROBLEM", 241, 259], ["ginsenoside Rb1", "OBSERVATION", 38, 53], ["promotes cell proliferation", "OBSERVATION", 54, 81], ["human glioma cells", "OBSERVATION", 112, 130], ["neuronal cell death", "OBSERVATION", 218, 237], ["viral encephalitis", "OBSERVATION", 241, 259]]], ["The antiHSV-1 activity of RGE has also been reported in vivo.", [["RGE", "CHEMICAL", 26, 29], ["antiHSV-1", "GENE_OR_GENE_PRODUCT", 4, 13], ["RGE", "SIMPLE_CHEMICAL", 26, 29], ["antiHSV", "PROTEIN", 4, 11], ["RGE", "PROTEIN", 26, 29], ["The antiHSV", "TEST", 0, 11]]], ["When Balb/c mice were administered 200 mg/kg or 400 mg/kg of RGE orally for 10 days and infected with HSV-1, the RGE-treated mice became more resistant to vaginal and systemic infection as shown by a decrease in clinical severity and increase in survival rate and viral clearance.", [["vaginal", "ANATOMY", 155, 162], ["RGE", "CHEMICAL", 61, 64], ["RGE", "CHEMICAL", 113, 116], ["systemic infection", "DISEASE", 167, 185], ["Balb/c mice", "ORGANISM", 5, 16], ["RGE", "SIMPLE_CHEMICAL", 61, 64], ["HSV-1", "ORGANISM", 102, 107], ["RGE", "SIMPLE_CHEMICAL", 113, 116], ["mice", "ORGANISM", 125, 129], ["vaginal", "ORGANISM_SUBDIVISION", 155, 162], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 12, 16], ["HSV-1", "SPECIES", 102, 107], ["mice", "SPECIES", 125, 129], ["Balb/c mice", "TREATMENT", 5, 16], ["HSV", "TEST", 102, 105], ["the RGE", "TEST", 109, 116], ["vaginal and systemic infection", "PROBLEM", 155, 185], ["a decrease in clinical severity", "PROBLEM", 198, 229], ["survival rate", "TEST", 246, 259], ["viral clearance", "PROBLEM", 264, 279], ["vaginal", "ANATOMY", 155, 162], ["systemic", "OBSERVATION_MODIFIER", 167, 175], ["infection", "OBSERVATION", 176, 185], ["decrease", "OBSERVATION_MODIFIER", 200, 208], ["increase", "OBSERVATION_MODIFIER", 234, 242], ["viral clearance", "OBSERVATION", 264, 279]]], ["RGE also stimulated IFN-\u03b3 secretion in vaginal lavage fluid and increased the expression of IFN-\u03b3, granzyme B, and Fas-Ligand mRNA in lymph nodes and vaginal tissue, suggesting that RGE protects the host from HSV-1 infection by stimulating natural killer (NK) cell activities [71].", [["vaginal lavage fluid", "ANATOMY", 39, 59], ["lymph nodes", "ANATOMY", 134, 145], ["vaginal tissue", "ANATOMY", 150, 164], ["natural killer (NK) cell", "ANATOMY", 240, 264], ["RGE", "CHEMICAL", 0, 3], ["RGE", "CHEMICAL", 182, 185], ["infection", "DISEASE", 215, 224], ["RGE", "SIMPLE_CHEMICAL", 0, 3], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 20, 25], ["vaginal lavage fluid", "ORGANISM_SUBSTANCE", 39, 59], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 92, 97], ["granzyme B", "GENE_OR_GENE_PRODUCT", 99, 109], ["Fas-Ligand", "GENE_OR_GENE_PRODUCT", 115, 125], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 134, 145], ["vaginal tissue", "TISSUE", 150, 164], ["RGE", "GENE_OR_GENE_PRODUCT", 182, 185], ["HSV-1", "ORGANISM", 209, 214], ["natural killer (NK) cell", "CELL", 240, 264], ["IFN", "PROTEIN", 20, 23], ["\u03b3", "PROTEIN", 24, 25], ["IFN", "PROTEIN", 92, 95], ["granzyme B", "PROTEIN", 99, 109], ["Fas-Ligand mRNA", "RNA", 115, 130], ["natural killer (NK) cell", "CELL_TYPE", 240, 264], ["HSV-1", "SPECIES", 209, 214], ["HSV-1", "SPECIES", 209, 214], ["IFN", "TEST", 20, 23], ["secretion in vaginal lavage fluid", "TEST", 26, 59], ["IFN", "TEST", 92, 95], ["granzyme B", "PROBLEM", 99, 109], ["Fas-Ligand mRNA in lymph nodes", "PROBLEM", 115, 145], ["vaginal tissue", "PROBLEM", 150, 164], ["RGE protects", "PROBLEM", 182, 194], ["HSV", "PROBLEM", 209, 212], ["1 infection", "PROBLEM", 213, 224], ["vaginal", "ANATOMY", 39, 46], ["lymph nodes", "OBSERVATION", 134, 145], ["vaginal tissue", "ANATOMY", 150, 164]]], ["Given the diverse antiviral activities of RGE through the inhibition of viral penetration and cell death and NK cell activation, prophylactic use of RGE would be beneficial for preventing or alleviating primary and recurrent HSV infection in combination with conventional antiviral drugs [72].Hepatitis A virusHepatitis A virus (HAV) is a positive-sense, single-stranded RNA virus, belonging to the family Picornaviridae.", [["cell", "ANATOMY", 94, 98], ["NK cell", "ANATOMY", 109, 116], ["RGE", "CHEMICAL", 42, 45], ["death", "DISEASE", 99, 104], ["RGE", "CHEMICAL", 149, 152], ["HSV infection", "DISEASE", 225, 238], ["Hepatitis A virusHepatitis", "DISEASE", 293, 319], ["HAV", "DISEASE", 329, 332], ["RGE", "SIMPLE_CHEMICAL", 42, 45], ["cell", "CELL", 94, 98], ["NK cell", "CELL", 109, 116], ["RGE", "SIMPLE_CHEMICAL", 149, 152], ["HSV", "ORGANISM", 225, 228], ["Hepatitis A virusHepatitis A virus", "ORGANISM", 293, 327], ["HAV", "ORGANISM", 329, 332], ["Hepatitis A virusHepatitis A virus", "SPECIES", 293, 327], ["HSV", "SPECIES", 225, 228], ["Hepatitis A virusHepatitis A virus", "SPECIES", 293, 327], ["HAV", "SPECIES", 329, 332], ["viral penetration", "PROBLEM", 72, 89], ["cell death", "PROBLEM", 94, 104], ["NK cell activation", "TREATMENT", 109, 127], ["prophylactic use of RGE", "TREATMENT", 129, 152], ["alleviating primary and recurrent HSV infection", "PROBLEM", 191, 238], ["conventional antiviral drugs", "TREATMENT", 259, 287], ["Hepatitis A virusHepatitis", "PROBLEM", 293, 319], ["A virus (HAV", "PROBLEM", 320, 332], ["single-stranded RNA virus", "PROBLEM", 355, 380], ["Picornaviridae", "TREATMENT", 406, 420], ["diverse", "OBSERVATION_MODIFIER", 10, 17], ["antiviral activities", "OBSERVATION", 18, 38], ["viral penetration", "OBSERVATION", 72, 89], ["NK cell", "OBSERVATION", 109, 116], ["recurrent", "OBSERVATION_MODIFIER", 215, 224], ["HSV infection", "OBSERVATION", 225, 238]]], ["Unlike hepatitis B virus (HBV), which is transmitted through exposure to blood and various body fluids of infected people, HAV is largely transmitted by the fecal\u2013oral route and causes acute hepatitis.", [["blood", "ANATOMY", 73, 78], ["body fluids", "ANATOMY", 91, 102], ["hepatitis B", "DISEASE", 7, 18], ["HAV", "DISEASE", 123, 126], ["hepatitis", "DISEASE", 191, 200], ["hepatitis B virus", "ORGANISM", 7, 24], ["HBV", "ORGANISM", 26, 29], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["body", "ORGANISM_SUBDIVISION", 91, 95], ["people", "ORGANISM", 115, 121], ["HAV", "ORGANISM", 123, 126], ["hepatitis B virus", "SPECIES", 7, 24], ["people", "SPECIES", 115, 121], ["hepatitis B virus", "SPECIES", 7, 24], ["HBV", "SPECIES", 26, 29], ["HAV", "SPECIES", 123, 126], ["hepatitis B virus", "PROBLEM", 7, 24], ["HBV", "PROBLEM", 26, 29], ["blood", "TEST", 73, 78], ["HAV", "PROBLEM", 123, 126], ["acute hepatitis", "PROBLEM", 185, 200], ["hepatitis", "OBSERVATION", 7, 16], ["infected", "OBSERVATION", 106, 114], ["acute", "OBSERVATION_MODIFIER", 185, 190], ["hepatitis", "OBSERVATION", 191, 200]]], ["Although hepatitis A infection does not lead to chronic liver disease and has very low mortality, it may cause enervating symptoms and fulminant hepatitis (acute liver failure) [4].", [["liver", "ANATOMY", 56, 61], ["liver", "ANATOMY", 162, 167], ["hepatitis A infection", "DISEASE", 9, 30], ["chronic liver disease", "DISEASE", 48, 69], ["hepatitis", "DISEASE", 145, 154], ["acute liver failure", "DISEASE", 156, 175], ["hepatitis A", "ORGANISM", 9, 20], ["liver", "ORGAN", 56, 61], ["liver", "ORGAN", 162, 167], ["hepatitis A", "SPECIES", 9, 20], ["hepatitis A infection", "PROBLEM", 9, 30], ["chronic liver disease", "PROBLEM", 48, 69], ["very low mortality", "PROBLEM", 78, 96], ["enervating symptoms", "PROBLEM", 111, 130], ["fulminant hepatitis", "PROBLEM", 135, 154], ["acute liver failure", "PROBLEM", 156, 175], ["hepatitis", "OBSERVATION", 9, 18], ["infection", "OBSERVATION", 21, 30], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["liver", "ANATOMY", 56, 61], ["disease", "OBSERVATION", 62, 69], ["very", "OBSERVATION_MODIFIER", 78, 82], ["low mortality", "OBSERVATION_MODIFIER", 83, 96], ["fulminant", "OBSERVATION_MODIFIER", 135, 144], ["hepatitis", "OBSERVATION", 145, 154], ["acute", "OBSERVATION_MODIFIER", 156, 161], ["liver", "ANATOMY", 162, 167], ["failure", "OBSERVATION", 168, 175]]], ["Currently, no specific antiviral agent is available for HAV, and thus, prevention via vaccination and improvement of hygiene and sanitation is the most effective approach against the HAV infection.Hepatitis A virusLee et al [73] examined the antiviral effects of RGE and purified ginsenosides Rb1 and Rg1 against HAV infection.", [["HAV", "DISEASE", 56, 59], ["HAV infection", "DISEASE", 183, 196], ["Hepatitis", "DISEASE", 197, 206], ["RGE", "CHEMICAL", 263, 266], ["Rb1", "CHEMICAL", 293, 296], ["Rg1", "CHEMICAL", 301, 304], ["HAV infection", "DISEASE", 313, 326], ["ginsenosides Rb1 and Rg1", "CHEMICAL", 280, 304], ["HAV", "ORGANISM", 56, 59], ["HAV", "ORGANISM", 183, 186], ["RGE", "SIMPLE_CHEMICAL", 263, 266], ["Rb1", "GENE_OR_GENE_PRODUCT", 293, 296], ["Rg1", "SIMPLE_CHEMICAL", 301, 304], ["HAV", "ORGANISM", 313, 316], ["HAV", "SPECIES", 56, 59], ["HAV", "SPECIES", 183, 186], ["HAV", "SPECIES", 313, 316], ["specific antiviral agent", "TREATMENT", 14, 38], ["HAV", "PROBLEM", 56, 59], ["vaccination", "TREATMENT", 86, 97], ["hygiene", "TREATMENT", 117, 124], ["sanitation", "TREATMENT", 129, 139], ["the HAV infection", "PROBLEM", 179, 196], ["Hepatitis", "PROBLEM", 197, 206], ["RGE", "TEST", 263, 266], ["purified ginsenosides Rb1", "TEST", 271, 296], ["HAV infection", "PROBLEM", 313, 326], ["no", "UNCERTAINTY", 11, 13], ["infection", "OBSERVATION", 187, 196], ["infection", "OBSERVATION", 317, 326]]], ["They demonstrated that pretreatment or cotreatment with RGE and ginsenosides Rb1 and Rg1 on FRhK-4 cells derived from the monkey kidney decreased the HAV titer upon HAV infection in vitro.", [["FRhK-4 cells", "ANATOMY", 92, 104], ["kidney", "ANATOMY", 129, 135], ["RGE", "CHEMICAL", 56, 59], ["ginsenosides Rb1", "CHEMICAL", 64, 80], ["Rg1", "CHEMICAL", 85, 88], ["FRhK-4", "CHEMICAL", 92, 98], ["HAV infection", "DISEASE", 165, 178], ["ginsenosides Rb1", "CHEMICAL", 64, 80], ["RGE", "SIMPLE_CHEMICAL", 56, 59], ["ginsenosides Rb1", "SIMPLE_CHEMICAL", 64, 80], ["Rg1", "SIMPLE_CHEMICAL", 85, 88], ["FRhK-4 cells", "CELL", 92, 104], ["monkey", "ORGANISM", 122, 128], ["kidney", "ORGAN", 129, 135], ["HAV", "ORGANISM", 150, 153], ["HAV", "ORGANISM", 165, 168], ["FRhK-4 cells", "CELL_LINE", 92, 104], ["monkey", "SPECIES", 122, 128], ["HAV", "SPECIES", 150, 153], ["HAV", "SPECIES", 165, 168], ["cotreatment", "TREATMENT", 39, 50], ["RGE", "TEST", 56, 59], ["ginsenosides Rb1", "TEST", 64, 80], ["Rg1", "TEST", 85, 88], ["FRhK", "TEST", 92, 96], ["the HAV titer", "PROBLEM", 146, 159], ["HAV infection", "PROBLEM", 165, 178], ["kidney", "ANATOMY", 129, 135], ["decreased", "OBSERVATION", 136, 145], ["HAV titer", "OBSERVATION_MODIFIER", 150, 159], ["infection", "OBSERVATION", 169, 178]]], ["Although the antiviral effect of RGE and ginsenosides remained limited to the in vitro model, the report suggested that regular intake of KRG as a dietary supplement may help prevent HAV infection.Hepatitis B virusHepatitis B virus (HBV) is a double-stranded DNA virus classified as being in the family Hepadnaviridae [74].", [["RGE", "CHEMICAL", 33, 36], ["ginsenosides", "CHEMICAL", 41, 53], ["KRG", "CHEMICAL", 138, 141], ["HAV infection", "DISEASE", 183, 196], ["Hepatitis B virusHepatitis B", "DISEASE", 197, 225], ["ginsenosides", "CHEMICAL", 41, 53], ["RGE", "SIMPLE_CHEMICAL", 33, 36], ["ginsenosides", "SIMPLE_CHEMICAL", 41, 53], ["KRG", "SIMPLE_CHEMICAL", 138, 141], ["HAV", "ORGANISM", 183, 186], ["Hepatitis B virusHepatitis B virus", "ORGANISM", 197, 231], ["HBV", "ORGANISM", 233, 236], ["DNA", "CELLULAR_COMPONENT", 259, 262], ["Hepatitis B virusHepatitis B virus", "SPECIES", 197, 231], ["HAV", "SPECIES", 183, 186], ["Hepatitis B virusHepatitis B virus", "SPECIES", 197, 231], ["HBV", "SPECIES", 233, 236], ["RGE and ginsenosides", "PROBLEM", 33, 53], ["KRG", "TREATMENT", 138, 141], ["a dietary supplement", "TREATMENT", 145, 165], ["HAV infection", "PROBLEM", 183, 196], ["Hepatitis B virusHepatitis B virus (HBV", "PROBLEM", 197, 236], ["a double-stranded DNA virus", "PROBLEM", 241, 268], ["antiviral", "OBSERVATION_MODIFIER", 13, 22], ["infection", "OBSERVATION", 187, 196]]], ["HBV can cause acute hepatitis, but it can also develop into a long-term, chronic infection.", [["hepatitis", "DISEASE", 20, 29], ["infection", "DISEASE", 81, 90], ["HBV", "ORGANISM", 0, 3], ["HBV", "SPECIES", 0, 3], ["HBV", "PROBLEM", 0, 3], ["acute hepatitis", "PROBLEM", 14, 29], ["a long-term", "PROBLEM", 60, 71], ["chronic infection", "PROBLEM", 73, 90], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["hepatitis", "OBSERVATION", 20, 29], ["long-term", "OBSERVATION_MODIFIER", 62, 71], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["infection", "OBSERVATION", 81, 90]]], ["As chronic hepatitis B can lead to life-threatening cirrhosis or hepatocarcinoma, HBV infection is one of the most serious health problems worldwide [75].", [["hepatocarcinoma", "ANATOMY", 65, 80], ["chronic hepatitis B", "DISEASE", 3, 22], ["cirrhosis", "DISEASE", 52, 61], ["hepatocarcinoma", "DISEASE", 65, 80], ["HBV infection", "DISEASE", 82, 95], ["hepatocarcinoma", "CANCER", 65, 80], ["HBV", "ORGANISM", 82, 85], ["HBV", "SPECIES", 82, 85], ["chronic hepatitis B", "PROBLEM", 3, 22], ["life-threatening cirrhosis", "PROBLEM", 35, 61], ["hepatocarcinoma", "PROBLEM", 65, 80], ["HBV infection", "PROBLEM", 82, 95], ["chronic", "OBSERVATION_MODIFIER", 3, 10], ["hepatitis", "OBSERVATION", 11, 20], ["threatening", "OBSERVATION_MODIFIER", 40, 51], ["cirrhosis", "OBSERVATION", 52, 61], ["hepatocarcinoma", "OBSERVATION", 65, 80], ["HBV", "OBSERVATION_MODIFIER", 82, 85], ["infection", "OBSERVATION", 86, 95]]], ["During viral replication, large amounts of HBV surface antigen (HBsAg), HBV envelope antigen (HBeAg), and virions are released in the blood, and accordingly, diagnostic tests for HBV infection involve the detection of those viral antigens, virions, and antibodies to the viral antigens.Hepatitis B virusThe antiHBV effect of ginsenoside Rg3 has been well-described [76].", [["virions", "ANATOMY", 106, 113], ["blood", "ANATOMY", 134, 139], ["virions", "ANATOMY", 240, 247], ["HBsAg", "CHEMICAL", 64, 69], ["HBeAg", "CHEMICAL", 94, 99], ["HBV infection", "DISEASE", 179, 192], ["Hepatitis B", "DISEASE", 286, 297], ["ginsenoside Rg3", "CHEMICAL", 325, 340], ["ginsenoside Rg3", "CHEMICAL", 325, 340], ["HBV surface antigen", "GENE_OR_GENE_PRODUCT", 43, 62], ["HBsAg", "GENE_OR_GENE_PRODUCT", 64, 69], ["HBV envelope antigen", "GENE_OR_GENE_PRODUCT", 72, 92], ["HBeAg", "GENE_OR_GENE_PRODUCT", 94, 99], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["HBV", "ORGANISM", 179, 182], ["Hepatitis B virus", "ORGANISM", 286, 303], ["ginsenoside Rg3", "SIMPLE_CHEMICAL", 325, 340], ["HBV surface antigen", "PROTEIN", 43, 62], ["HBsAg", "PROTEIN", 64, 69], ["HBV envelope antigen", "PROTEIN", 72, 92], ["HBeAg", "PROTEIN", 94, 99], ["viral antigens", "PROTEIN", 224, 238], ["antibodies", "PROTEIN", 253, 263], ["viral antigens", "PROTEIN", 271, 285], ["Hepatitis B virus", "SPECIES", 286, 303], ["HBV", "SPECIES", 43, 46], ["HBV", "SPECIES", 72, 75], ["HBV", "SPECIES", 179, 182], ["Hepatitis B virus", "SPECIES", 286, 303], ["viral replication", "TREATMENT", 7, 24], ["HBV surface antigen", "TEST", 43, 62], ["HBsAg", "TEST", 64, 69], ["HBV envelope antigen", "TEST", 72, 92], ["HBeAg", "TEST", 94, 99], ["virions", "PROBLEM", 106, 113], ["diagnostic tests", "TEST", 158, 174], ["HBV infection", "PROBLEM", 179, 192], ["the detection", "TEST", 201, 214], ["those viral antigens", "PROBLEM", 218, 238], ["virions", "TEST", 240, 247], ["Hepatitis B virus", "PROBLEM", 286, 303], ["ginsenoside Rg3", "TREATMENT", 325, 340], ["viral replication", "OBSERVATION", 7, 24], ["large", "OBSERVATION_MODIFIER", 26, 31], ["amounts", "OBSERVATION_MODIFIER", 32, 39]]], ["Ginsenoside Rg3 remarkably inhibited the secretion of HBsAg, HBeAg, and viral particles in HBV-infected HepG2.2.15 cells.", [["HepG2.2.15 cells", "ANATOMY", 104, 120], ["Ginsenoside Rg3", "CHEMICAL", 0, 15], ["HBsAg", "CHEMICAL", 54, 59], ["HBeAg", "CHEMICAL", 61, 66], ["Ginsenoside Rg3", "CHEMICAL", 0, 15], ["Ginsenoside Rg3", "SIMPLE_CHEMICAL", 0, 15], ["HBsAg", "GENE_OR_GENE_PRODUCT", 54, 59], ["HBeAg", "GENE_OR_GENE_PRODUCT", 61, 66], ["HBV", "ORGANISM", 91, 94], ["HepG2.2.15 cells", "CELL", 104, 120], ["HBsAg", "PROTEIN", 54, 59], ["HBV-infected HepG2.2.15 cells", "CELL_LINE", 91, 120], ["HBV", "SPECIES", 91, 94], ["Ginsenoside Rg3", "TEST", 0, 15], ["the secretion", "TEST", 37, 50], ["HBsAg", "TEST", 54, 59], ["HBeAg", "TEST", 61, 66], ["viral particles", "PROBLEM", 72, 87], ["HBV", "TEST", 91, 94], ["viral particles", "OBSERVATION", 72, 87]]], ["Another mechanistic study revealed that ginsenoside Rg3 downregulated TNF receptor-associated factor 6 (TRAF6)/transforming growth factor \u03b2 activated kinase-1 (TAK1) and inhibited the mitogen-activated protein kinase (MAPK) signaling pathway by impeding c-Jun phosphorylation and reducing AP-1 expression.", [["ginsenoside Rg3", "CHEMICAL", 40, 55], ["ginsenoside Rg3", "CHEMICAL", 40, 55], ["ginsenoside Rg3", "SIMPLE_CHEMICAL", 40, 55], ["TNF receptor-associated factor 6", "GENE_OR_GENE_PRODUCT", 70, 102], ["TRAF6", "GENE_OR_GENE_PRODUCT", 104, 109], ["transforming growth factor \u03b2 activated kinase-1", "GENE_OR_GENE_PRODUCT", 111, 158], ["TAK1", "GENE_OR_GENE_PRODUCT", 160, 164], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 184, 216], ["MAPK", "GENE_OR_GENE_PRODUCT", 218, 222], ["c-Jun", "GENE_OR_GENE_PRODUCT", 254, 259], ["AP-1", "GENE_OR_GENE_PRODUCT", 289, 293], ["TNF receptor-associated factor 6", "PROTEIN", 70, 102], ["TRAF6", "PROTEIN", 104, 109], ["transforming growth factor \u03b2 activated kinase-1", "PROTEIN", 111, 158], ["TAK1", "PROTEIN", 160, 164], ["mitogen-activated protein kinase", "PROTEIN", 184, 216], ["MAPK", "PROTEIN", 218, 222], ["Jun", "PROTEIN", 256, 259], ["AP", "PROTEIN", 289, 291], ["Another mechanistic study", "TEST", 0, 25], ["ginsenoside", "TEST", 40, 51], ["TNF receptor", "TEST", 70, 82], ["factor", "TEST", 94, 100], ["TRAF6", "TEST", 104, 109], ["transforming growth factor", "TEST", 111, 137], ["activated kinase", "TEST", 140, 156], ["the mitogen", "TEST", 180, 191], ["activated protein kinase", "TREATMENT", 192, 216], ["c-Jun phosphorylation", "TREATMENT", 254, 275]]], ["Consequently, the expression of proinflammatory cytokines such as IL-8 and TNF-\u03b1 was reduced.", [["IL-8", "GENE_OR_GENE_PRODUCT", 66, 70], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 75, 80], ["proinflammatory cytokines", "PROTEIN", 32, 57], ["IL-8", "PROTEIN", 66, 70], ["TNF", "PROTEIN", 75, 78], ["proinflammatory cytokines", "PROBLEM", 32, 57], ["IL", "TEST", 66, 68], ["TNF", "TEST", 75, 78]]], ["Although the anti-inflammatory activity of ginsenoside Rg3 is explicitly described, it is unclear how the anti-inflammatory effect of ginsenoside Rg3 affects HBV replication.", [["ginsenoside Rg3", "CHEMICAL", 43, 58], ["ginsenoside Rg3", "CHEMICAL", 134, 149], ["ginsenoside Rg3", "CHEMICAL", 43, 58], ["ginsenoside Rg3", "CHEMICAL", 134, 149], ["ginsenoside Rg3", "SIMPLE_CHEMICAL", 43, 58], ["ginsenoside Rg3", "SIMPLE_CHEMICAL", 134, 149], ["HBV", "ORGANISM", 158, 161], ["HBV", "SPECIES", 158, 161], ["ginsenoside Rg3", "TREATMENT", 43, 58], ["ginsenoside Rg3", "TREATMENT", 134, 149], ["HBV replication", "TREATMENT", 158, 173], ["anti-inflammatory", "OBSERVATION_MODIFIER", 13, 30]]], ["Future studies should strive to better understand the link between antiHBV and anti-inflammatory activities of ginsenoside Rg3.NorovirusNorovirus is a positive-sense, single-stranded RNA virus causing nausea, vomiting, abdominal pain, and diarrhea in humans [77].", [["abdominal", "ANATOMY", 219, 228], ["ginsenoside Rg3", "CHEMICAL", 111, 126], ["NorovirusNorovirus", "CHEMICAL", 127, 145], ["nausea", "DISEASE", 201, 207], ["vomiting", "DISEASE", 209, 217], ["abdominal pain", "DISEASE", 219, 233], ["diarrhea", "DISEASE", 239, 247], ["ginsenoside Rg3", "CHEMICAL", 111, 126], ["antiHBV", "CANCER", 67, 74], ["ginsenoside Rg3", "SIMPLE_CHEMICAL", 111, 126], ["NorovirusNorovirus", "GENE_OR_GENE_PRODUCT", 127, 145], ["abdominal", "ORGANISM_SUBDIVISION", 219, 228], ["humans", "ORGANISM", 251, 257], ["humans", "SPECIES", 251, 257], ["humans", "SPECIES", 251, 257], ["Future studies", "TEST", 0, 14], ["antiHBV", "TREATMENT", 67, 74], ["ginsenoside Rg3", "TREATMENT", 111, 126], ["NorovirusNorovirus", "TEST", 127, 145], ["single-stranded RNA virus", "PROBLEM", 167, 192], ["nausea", "PROBLEM", 201, 207], ["vomiting", "PROBLEM", 209, 217], ["abdominal pain", "PROBLEM", 219, 233], ["diarrhea in humans", "PROBLEM", 239, 257], ["abdominal", "ANATOMY", 219, 228], ["pain", "OBSERVATION", 229, 233], ["diarrhea", "OBSERVATION", 239, 247]]], ["The virus is spread through the fecal\u2013oral route by ingestion of contaminated water or food, especially fish and shellfish [78].", [["fish", "ORGANISM_SUBDIVISION", 104, 108], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["As human norovirus is not culturable, norovirus surrogates such as feline calicivirus (FCV), murine norovirus (MNV), and Tulane virus (TV) are used to test the antiviral activity of natural or chemical compounds against norovirus [79].", [["norovirus", "DISEASE", 9, 18], ["feline calicivirus", "DISEASE", 67, 85], ["norovirus", "DISEASE", 220, 229], ["human", "ORGANISM", 3, 8], ["norovirus", "ORGANISM", 38, 47], ["feline calicivirus", "ORGANISM", 67, 85], ["FCV", "ORGANISM", 87, 90], ["murine norovirus", "ORGANISM", 93, 109], ["MNV", "ORGANISM", 111, 114], ["Tulane virus", "ORGANISM", 121, 133], ["norovirus", "ORGANISM", 220, 229], ["human", "SPECIES", 3, 8], ["feline calicivirus", "SPECIES", 67, 85], ["murine", "SPECIES", 93, 99], ["Tulane virus", "SPECIES", 121, 133], ["human", "SPECIES", 3, 8], ["feline calicivirus", "SPECIES", 67, 85], ["FCV", "SPECIES", 87, 90], ["murine norovirus", "SPECIES", 93, 109], ["MNV", "SPECIES", 111, 114], ["Tulane virus", "SPECIES", 121, 133], ["human norovirus", "PROBLEM", 3, 18], ["norovirus surrogates", "PROBLEM", 38, 58], ["feline calicivirus", "PROBLEM", 67, 85], ["murine norovirus", "PROBLEM", 93, 109], ["Tulane virus", "TREATMENT", 121, 133], ["norovirus", "PROBLEM", 220, 229]]], ["FCV and MNV have a similar genome organization, physical properties, and replication cycle to those of human norovirus and can be cultivated in Crandell\u2013Reese feline kidney (CRFK) cells and murine Raw264.7 cells, respectively [80].NorovirusLee et al [81] have shown that pretreatment of CRFK or RAW264.7 cells with RGE and ginsenosides Rb1 or Rg1 significantly reduced FCV and MNV titers in vitro, whereas cotreatment or posttreatment had no antiviral effects.", [["kidney (CRFK) cells", "ANATOMY", 166, 185], ["Raw264.7 cells", "ANATOMY", 197, 211], ["CRFK", "ANATOMY", 287, 291], ["RAW264.7 cells", "ANATOMY", 295, 309], ["norovirus", "DISEASE", 109, 118], ["RGE", "CHEMICAL", 315, 318], ["ginsenosides Rb1", "CHEMICAL", 323, 339], ["Rg1", "CHEMICAL", 343, 346], ["ginsenosides Rb1", "CHEMICAL", 323, 339], ["Rg1", "CHEMICAL", 343, 346], ["FCV", "ORGANISM", 0, 3], ["MNV", "CANCER", 8, 11], ["human", "ORGANISM", 103, 108], ["feline", "ORGANISM", 159, 165], ["kidney", "ORGAN", 166, 172], ["CRFK) cells", "CELL", 174, 185], ["murine", "ORGANISM", 190, 196], ["Raw264.7 cells", "CELL", 197, 211], ["CRFK", "GENE_OR_GENE_PRODUCT", 287, 291], ["RAW264.7 cells", "CELL", 295, 309], ["RGE", "SIMPLE_CHEMICAL", 315, 318], ["ginsenosides Rb1", "SIMPLE_CHEMICAL", 323, 339], ["Rg1", "SIMPLE_CHEMICAL", 343, 346], ["FCV", "ORGANISM", 369, 372], ["MNV", "ORGANISM", 377, 380], ["Reese feline kidney (CRFK) cells", "CELL_LINE", 153, 185], ["murine Raw264.7 cells", "CELL_LINE", 190, 211], ["CRFK", "CELL_LINE", 287, 291], ["RAW264.7 cells", "CELL_LINE", 295, 309], ["human", "SPECIES", 103, 108], ["feline", "SPECIES", 159, 165], ["murine", "SPECIES", 190, 196], ["FCV", "SPECIES", 0, 3], ["MNV", "SPECIES", 8, 11], ["human norovirus", "SPECIES", 103, 118], ["FCV", "SPECIES", 369, 372], ["MNV", "SPECIES", 377, 380], ["human norovirus", "PROBLEM", 103, 118], ["Reese feline kidney (CRFK) cells", "TEST", 153, 185], ["murine Raw", "TEST", 190, 200], ["cells", "TEST", 206, 211], ["CRFK", "PROBLEM", 287, 291], ["RAW264.7 cells", "PROBLEM", 295, 309], ["RGE", "TEST", 315, 318], ["ginsenosides Rb1", "TEST", 323, 339], ["Rg1", "PROBLEM", 343, 346], ["reduced FCV", "PROBLEM", 361, 372], ["MNV titers", "TEST", 377, 387], ["antiviral effects", "PROBLEM", 442, 459], ["kidney", "ANATOMY", 166, 172], ["no", "UNCERTAINTY", 439, 441], ["antiviral effects", "OBSERVATION", 442, 459]]], ["In a subsequent study, the same research group demonstrated that RGE and ginsenosides pretreatment induced antiviral proteins in FCV-infected CRFK cells.", [["CRFK cells", "ANATOMY", 142, 152], ["RGE", "CHEMICAL", 65, 68], ["ginsenosides", "CHEMICAL", 73, 85], ["ginsenosides", "CHEMICAL", 73, 85], ["RGE", "SIMPLE_CHEMICAL", 65, 68], ["ginsenosides", "SIMPLE_CHEMICAL", 73, 85], ["FCV", "ORGANISM", 129, 132], ["CRFK cells", "CELL", 142, 152], ["antiviral proteins", "PROTEIN", 107, 125], ["FCV-infected CRFK cells", "CELL_LINE", 129, 152], ["FCV", "SPECIES", 129, 132], ["a subsequent study", "TEST", 3, 21], ["RGE and ginsenosides", "PROBLEM", 65, 85], ["antiviral proteins in FCV", "PROBLEM", 107, 132], ["infected CRFK cells", "PROBLEM", 133, 152], ["infected", "OBSERVATION_MODIFIER", 133, 141], ["CRFK cells", "OBSERVATION", 142, 152]]], ["The expressions of IFN-\u03b1, IFN-\u03b2, IFN-\u03c9, zinc finger antiviral protein shorter isoform (ZAPS), and Mx protein, an IFN-inducible protein with antiviral activity, were all increased which contributed to the decrease of viral titers in CRFK cells.", [["CRFK cells", "ANATOMY", 232, 242], ["zinc", "CHEMICAL", 40, 44], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 19, 24], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["IFN-\u03c9", "GENE_OR_GENE_PRODUCT", 33, 38], ["zinc finger antiviral protein", "GENE_OR_GENE_PRODUCT", 40, 69], ["ZAPS", "GENE_OR_GENE_PRODUCT", 87, 91], ["Mx protein", "GENE_OR_GENE_PRODUCT", 98, 108], ["CRFK cells", "CELL", 232, 242], ["IFN", "PROTEIN", 19, 22], ["\u03b1", "PROTEIN", 23, 24], ["IFN", "PROTEIN", 26, 29], ["\u03b2", "PROTEIN", 30, 31], ["IFN", "PROTEIN", 33, 36], ["\u03c9", "PROTEIN", 37, 38], ["zinc finger antiviral protein shorter isoform", "PROTEIN", 40, 85], ["ZAPS", "PROTEIN", 87, 91], ["Mx protein", "PROTEIN", 98, 108], ["IFN", "PROTEIN", 113, 116], ["CRFK cells", "CELL_LINE", 232, 242], ["The expressions", "TEST", 0, 15], ["IFN", "TEST", 19, 22], ["\u03b1", "TEST", 23, 24], ["IFN", "TEST", 26, 29], ["IFN", "TEST", 33, 36], ["zinc finger antiviral protein shorter isoform", "PROBLEM", 40, 85], ["Mx protein", "TEST", 98, 108], ["an IFN", "TEST", 110, 116], ["inducible protein", "PROBLEM", 117, 134], ["antiviral activity", "PROBLEM", 140, 158], ["viral titers in CRFK cells", "PROBLEM", 216, 242], ["antiviral activity", "OBSERVATION", 140, 158], ["decrease", "OBSERVATION_MODIFIER", 204, 212], ["viral titers", "OBSERVATION", 216, 228], ["CRFK cells", "OBSERVATION", 232, 242]]], ["Future studies are needed to establish a culture system for human norovirus and subsequently evaluate the antiviral effects of RGE and ginsenosides against human norovirus.RotavirusRotavirus is the leading cause of acute gastroenteritis in young children age \u2264 5 years [82].", [["norovirus", "DISEASE", 66, 75], ["RGE", "CHEMICAL", 127, 130], ["ginsenosides", "CHEMICAL", 135, 147], ["norovirus", "DISEASE", 162, 171], ["RotavirusRotavirus", "DISEASE", 172, 190], ["gastroenteritis", "DISEASE", 221, 236], ["ginsenosides", "CHEMICAL", 135, 147], ["human", "ORGANISM", 60, 65], ["RGE", "SIMPLE_CHEMICAL", 127, 130], ["ginsenosides", "SIMPLE_CHEMICAL", 135, 147], ["human", "ORGANISM", 156, 161], ["norovirus", "ORGANISM", 162, 171], ["RotavirusRotavirus", "ORGANISM", 172, 190], ["children", "ORGANISM", 246, 254], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 156, 161], ["children", "SPECIES", 246, 254], ["human norovirus", "SPECIES", 60, 75], ["human norovirus", "SPECIES", 156, 171], ["RotavirusRotavirus", "SPECIES", 172, 190], ["Future studies", "TEST", 0, 14], ["a culture system", "TEST", 39, 55], ["human norovirus", "PROBLEM", 60, 75], ["RGE and ginsenosides", "TREATMENT", 127, 147], ["human norovirus", "PROBLEM", 156, 171], ["RotavirusRotavirus", "PROBLEM", 172, 190], ["acute gastroenteritis", "PROBLEM", 215, 236], ["leading cause of", "UNCERTAINTY", 198, 214], ["acute", "OBSERVATION_MODIFIER", 215, 220], ["gastroenteritis", "OBSERVATION", 221, 236]]], ["Two live oral rotavirus vaccines (Rotarix by GlaxoSmithKline, Unitied Kingdom, and RotaTeq by Merck, United States) are available, and the implementation of rotavirus vaccines in childhood immunization programs has significantly reduced the morbidity and mortality associated with Rotavirus infection [6].", [["oral", "ANATOMY", 9, 13], ["Rotarix", "CHEMICAL", 34, 41], ["Rotavirus infection", "DISEASE", 281, 300], ["oral", "ORGANISM_SUBDIVISION", 9, 13], ["rotavirus", "ORGANISM", 14, 23], ["rotavirus", "ORGANISM", 157, 166], ["rotavirus", "SPECIES", 14, 23], ["rotavirus", "SPECIES", 157, 166], ["Two live oral rotavirus vaccines", "TREATMENT", 0, 32], ["Rotarix", "TREATMENT", 34, 41], ["rotavirus vaccines", "TREATMENT", 157, 175], ["childhood immunization programs", "TREATMENT", 179, 210], ["the morbidity", "PROBLEM", 237, 250], ["Rotavirus infection", "PROBLEM", 281, 300]]], ["Nevertheless, there is no antiviral drug to treat rotavirus infection, and mostly, therapeutics involve the prevention of dehydration [83], [84].RotavirusIn traditional medicine, ginseng has been known to improve gastrointestinal function and prevent gastrointestinal problems such as diarrhea [3].", [["gastrointestinal", "ANATOMY", 213, 229], ["gastrointestinal", "ANATOMY", 251, 267], ["rotavirus infection", "DISEASE", 50, 69], ["dehydration", "DISEASE", 122, 133], ["RotavirusIn", "CHEMICAL", 145, 156], ["gastrointestinal problems", "DISEASE", 251, 276], ["diarrhea", "DISEASE", 285, 293], ["rotavirus", "ORGANISM", 50, 59], ["ginseng", "ORGANISM", 179, 186], ["gastrointestinal", "ORGAN", 213, 229], ["gastrointestinal", "ORGANISM_SUBDIVISION", 251, 267], ["rotavirus", "SPECIES", 50, 59], ["antiviral drug", "TREATMENT", 26, 40], ["rotavirus infection", "PROBLEM", 50, 69], ["dehydration", "PROBLEM", 122, 133], ["RotavirusIn traditional medicine", "TREATMENT", 145, 177], ["gastrointestinal problems", "PROBLEM", 251, 276], ["diarrhea", "PROBLEM", 285, 293], ["no", "UNCERTAINTY", 23, 25], ["antiviral drug", "OBSERVATION", 26, 40], ["infection", "OBSERVATION", 60, 69], ["gastrointestinal", "ANATOMY", 251, 267]]], ["A recent study researched the active constituent in ginseng and reported that two pectic polysaccharides isolated from hot water extract of ginseng prevented cell death from viral infection [3].", [["cell", "ANATOMY", 158, 162], ["hot water extract of ginseng", "CHEMICAL", 119, 147], ["death", "DISEASE", 163, 168], ["viral infection", "DISEASE", 174, 189], ["ginseng", "ORGANISM", 52, 59], ["ginseng", "ORGANISM", 140, 147], ["cell", "CELL", 158, 162], ["A recent study", "TEST", 0, 14], ["two pectic polysaccharides", "PROBLEM", 78, 104], ["cell death", "PROBLEM", 158, 168], ["viral infection", "PROBLEM", 174, 189], ["cell death", "OBSERVATION", 158, 168], ["viral infection", "OBSERVATION", 174, 189]]], ["The polysaccharides, named GP50-dHR and GP50-her, did not have virucidal effects but inhibited viral attachment to the host cells thereby protecting them from virus-induced cell death.", [["cells", "ANATOMY", 124, 129], ["cell", "ANATOMY", 173, 177], ["death", "DISEASE", 178, 183], ["polysaccharides", "SIMPLE_CHEMICAL", 4, 19], ["GP50-dHR", "SIMPLE_CHEMICAL", 27, 35], ["host cells", "CELL", 119, 129], ["cell", "CELL", 173, 177], ["GP50", "PROTEIN", 40, 44], ["host cells", "CELL_TYPE", 119, 129], ["The polysaccharides", "TEST", 0, 19], ["GP50", "TEST", 40, 44], ["virucidal effects", "PROBLEM", 63, 80], ["viral attachment", "PROBLEM", 95, 111], ["induced cell death", "PROBLEM", 165, 183], ["cell death", "OBSERVATION", 173, 183]]], ["Given these results and an additional report that other pectin-type polysaccharides in ginseng inhibited the adherence of Helicobacter pylori to gastric epithelial cells and the ability of Porphyromonas gingivalis to agglutinate erythrocytes [85], further evaluation of the antimicrobial effects of acidic polysaccharides with the structure of pectin is merited.EnterovirusHuman enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) are the two major causes of hand-foot-and-mouth disease (HFMD) in young children [86].", [["gastric epithelial cells", "ANATOMY", 145, 169], ["erythrocytes", "ANATOMY", 229, 241], ["hand", "ANATOMY", 460, 464], ["mouth", "ANATOMY", 474, 479], ["pectin-type polysaccharides", "CHEMICAL", 56, 83], ["EnterovirusHuman enterovirus 71 (EV71) and coxsackievirus A16", "DISEASE", 362, 423], ["hand-foot-and-mouth disease", "DISEASE", 460, 487], ["HFMD", "DISEASE", 489, 493], ["pectin-type polysaccharides", "SIMPLE_CHEMICAL", 56, 83], ["ginseng", "ORGANISM", 87, 94], ["Helicobacter pylori", "ORGANISM", 122, 141], ["gastric epithelial cells", "CELL", 145, 169], ["Porphyromonas gingivalis", "GENE_OR_GENE_PRODUCT", 189, 213], ["erythrocytes", "CELL", 229, 241], ["acidic polysaccharides", "SIMPLE_CHEMICAL", 299, 321], ["pectin", "SIMPLE_CHEMICAL", 344, 350], ["EnterovirusHuman enterovirus 71", "ORGANISM", 362, 393], ["EV71", "ORGANISM", 395, 399], ["coxsackievirus A16", "ORGANISM", 405, 423], ["CVA16", "ORGANISM", 425, 430], ["hand", "ORGANISM_SUBDIVISION", 460, 464], ["mouth", "ORGAN", 474, 479], ["children", "ORGANISM", 504, 512], ["gastric epithelial cells", "CELL_TYPE", 145, 169], ["agglutinate erythrocytes", "CELL_TYPE", 217, 241], ["Helicobacter pylori", "SPECIES", 122, 141], ["Porphyromonas gingivalis", "SPECIES", 189, 213], ["EnterovirusHuman enterovirus", "SPECIES", 362, 390], ["coxsackievirus A16", "SPECIES", 405, 423], ["foot-and-mouth disease", "SPECIES", 465, 487], ["children", "SPECIES", 504, 512], ["Helicobacter pylori", "SPECIES", 122, 141], ["Porphyromonas gingivalis", "SPECIES", 189, 213], ["EnterovirusHuman enterovirus 71", "SPECIES", 362, 393], ["EV71", "SPECIES", 395, 399], ["coxsackievirus A16", "SPECIES", 405, 423], ["CVA16", "SPECIES", 425, 430], ["other pectin-type polysaccharides", "PROBLEM", 50, 83], ["Helicobacter pylori", "PROBLEM", 122, 141], ["gastric epithelial cells", "PROBLEM", 145, 169], ["Porphyromonas gingivalis", "PROBLEM", 189, 213], ["agglutinate erythrocytes", "TEST", 217, 241], ["further evaluation", "TEST", 248, 266], ["the antimicrobial effects", "TREATMENT", 270, 295], ["acidic polysaccharides", "PROBLEM", 299, 321], ["EnterovirusHuman enterovirus", "TEST", 362, 390], ["coxsackievirus A16 (CVA16", "TEST", 405, 430], ["mouth disease", "PROBLEM", 474, 487], ["Helicobacter pylori", "OBSERVATION", 122, 141], ["gastric", "ANATOMY", 145, 152], ["epithelial cells", "OBSERVATION", 153, 169], ["hand", "ANATOMY", 460, 464], ["foot", "ANATOMY", 465, 469], ["mouth", "ANATOMY", 474, 479]]], ["Although HFMD is a mild and self-limited disease characterized by fever, rash, bumps, blisters, or ulcers in the mouth, feet, hands, and buttocks, some affected children may develop neurological, cardiovascular, and respiratory complications in rare cases [87], [88].", [["blisters", "ANATOMY", 86, 94], ["ulcers", "ANATOMY", 99, 105], ["mouth", "ANATOMY", 113, 118], ["feet", "ANATOMY", 120, 124], ["hands", "ANATOMY", 126, 131], ["buttocks", "ANATOMY", 137, 145], ["neurological", "ANATOMY", 182, 194], ["cardiovascular", "ANATOMY", 196, 210], ["respiratory", "ANATOMY", 216, 227], ["HFMD", "DISEASE", 9, 13], ["fever", "DISEASE", 66, 71], ["rash", "DISEASE", 73, 77], ["blisters", "DISEASE", 86, 94], ["ulcers", "DISEASE", 99, 105], ["neurological, cardiovascular, and respiratory complications", "DISEASE", 182, 241], ["blisters", "PATHOLOGICAL_FORMATION", 86, 94], ["ulcers", "PATHOLOGICAL_FORMATION", 99, 105], ["mouth", "ORGANISM_SUBDIVISION", 113, 118], ["feet", "ORGANISM_SUBDIVISION", 120, 124], ["hands", "ORGANISM_SUBDIVISION", 126, 131], ["buttocks", "ORGANISM_SUBDIVISION", 137, 145], ["children", "ORGANISM", 161, 169], ["children", "SPECIES", 161, 169], ["HFMD", "PROBLEM", 9, 13], ["a mild and self-limited disease", "PROBLEM", 17, 48], ["fever", "PROBLEM", 66, 71], ["rash", "PROBLEM", 73, 77], ["bumps", "PROBLEM", 79, 84], ["blisters", "PROBLEM", 86, 94], ["ulcers in the mouth, feet, hands, and buttocks", "PROBLEM", 99, 145], ["neurological, cardiovascular, and respiratory complications", "PROBLEM", 182, 241], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["fever", "OBSERVATION", 66, 71], ["bumps", "OBSERVATION_MODIFIER", 79, 84], ["blisters", "OBSERVATION", 86, 94], ["ulcers", "OBSERVATION", 99, 105], ["mouth", "ANATOMY", 113, 118], ["feet", "ANATOMY", 120, 124], ["hands", "ANATOMY", 126, 131], ["buttocks", "ANATOMY", 137, 145], ["respiratory", "ANATOMY", 216, 227]]], ["Presently, there are no specific treatments or vaccines for HFMD.EnterovirusIn order to identify ginsenosides with antiviral activity against EV71, Song et al [26] tested panaxadiol-type ginsenosides (Rb1, Rb2, Rc, and Rd) and panaxatriol-type ginsenosides (Re, Rf, and Rg2).", [["HFMD", "DISEASE", 60, 64], ["ginsenosides", "CHEMICAL", 97, 109], ["panaxadiol", "CHEMICAL", 171, 181], ["Rb1", "CHEMICAL", 201, 204], ["panaxatriol", "CHEMICAL", 227, 238], ["ginsenosides", "CHEMICAL", 97, 109], ["panaxadiol", "CHEMICAL", 171, 181], ["ginsenosides", "CHEMICAL", 187, 199], ["Rb1, Rb2, Rc, and Rd", "CHEMICAL", 201, 221], ["panaxatriol", "CHEMICAL", 227, 238], ["ginsenosides", "CHEMICAL", 244, 256], ["Re, Rf, and Rg2", "CHEMICAL", 258, 273], ["ginsenosides", "SIMPLE_CHEMICAL", 97, 109], ["EV71", "ORGANISM", 142, 146], ["panaxadiol-type ginsenosides", "SIMPLE_CHEMICAL", 171, 199], ["Rb1", "SIMPLE_CHEMICAL", 201, 204], ["Rb2", "SIMPLE_CHEMICAL", 206, 209], ["Rc", "SIMPLE_CHEMICAL", 211, 213], ["Rd", "SIMPLE_CHEMICAL", 219, 221], ["panaxatriol-type ginsenosides", "SIMPLE_CHEMICAL", 227, 256], ["Re, Rf", "SIMPLE_CHEMICAL", 258, 264], ["Rg2", "SIMPLE_CHEMICAL", 270, 273], ["EV71", "SPECIES", 142, 146], ["specific treatments", "TREATMENT", 24, 43], ["vaccines", "TREATMENT", 47, 55], ["HFMD", "PROBLEM", 60, 64], ["EnterovirusIn", "TREATMENT", 65, 78], ["antiviral activity", "TREATMENT", 115, 133], ["EV71", "PROBLEM", 142, 146], ["panaxadiol", "TEST", 171, 181], ["type ginsenosides", "PROBLEM", 182, 199], ["Rb1", "TEST", 201, 204], ["Rb2", "TEST", 206, 209], ["Rc", "TEST", 211, 213], ["panaxatriol", "TEST", 227, 238], ["no", "UNCERTAINTY", 21, 23]]], ["They found that only ginsenoside Rg2 had antiviral activity against EV71 infection in Vero cells, but it has not been determined whether the anticytopathic effect of Rg2 is due to the virucidal activity or the inhibition of viral attachment.CoxsackievirusCoxsackievirus is a positive-sense, single-stranded RNA virus, belonging to Picornaviridae.", [["Vero cells", "ANATOMY", 86, 96], ["ginsenoside Rg2", "CHEMICAL", 21, 36], ["EV71 infection", "DISEASE", 68, 82], ["Rg2", "CHEMICAL", 166, 169], ["CoxsackievirusCoxsackievirus", "CHEMICAL", 241, 269], ["ginsenoside Rg2", "CHEMICAL", 21, 36], ["ginsenoside Rg2", "SIMPLE_CHEMICAL", 21, 36], ["EV71", "ORGANISM", 68, 72], ["Vero cells", "CELL", 86, 96], ["Rg2", "SIMPLE_CHEMICAL", 166, 169], ["Vero cells", "CELL_LINE", 86, 96], ["EV71", "SPECIES", 68, 72], ["ginsenoside Rg2", "PROBLEM", 21, 36], ["antiviral activity", "PROBLEM", 41, 59], ["EV71 infection in Vero cells", "PROBLEM", 68, 96], ["the anticytopathic effect of Rg2", "PROBLEM", 137, 169], ["the virucidal activity", "PROBLEM", 180, 202], ["viral attachment", "PROBLEM", 224, 240], ["CoxsackievirusCoxsackievirus", "TEST", 241, 269], ["single-stranded RNA virus", "PROBLEM", 291, 316], ["Picornaviridae", "TREATMENT", 331, 345], ["Vero cells", "OBSERVATION", 86, 96], ["viral attachment", "OBSERVATION", 224, 240], ["positive", "OBSERVATION", 275, 283]]], ["Coxsackieviruses are divided into the group A virus with 23 serotypes and the group B virus with six serotypes [89], [90].", [["group B virus", "ORGANISM", 78, 91], ["A virus", "SPECIES", 44, 51], ["B virus", "SPECIES", 84, 91], ["Coxsackieviruses", "PROBLEM", 0, 16], ["23 serotypes", "PROBLEM", 57, 69], ["the group B virus", "PROBLEM", 74, 91], ["six serotypes", "TEST", 97, 110]]], ["Among those, the most common pathogens are coxsackievirus A16 (CVA16) causing HFMD as described above and coxsackievirus B3 (CVB3) causing myocarditis, aseptic meningitis, and pancreatitis [91], [92].", [["coxsackievirus A16", "DISEASE", 43, 61], ["HFMD", "DISEASE", 78, 82], ["myocarditis", "DISEASE", 139, 150], ["meningitis", "DISEASE", 160, 170], ["pancreatitis", "DISEASE", 176, 188], ["coxsackievirus A16", "ORGANISM", 43, 61], ["CVA16", "ORGANISM", 63, 68], ["coxsackievirus B3", "ORGANISM", 106, 123], ["CVB3", "ORGANISM", 125, 129], ["coxsackievirus A16", "SPECIES", 43, 61], ["coxsackievirus B3", "SPECIES", 106, 123], ["coxsackievirus A16", "SPECIES", 43, 61], ["CVA16", "SPECIES", 63, 68], ["coxsackievirus B3", "SPECIES", 106, 123], ["CVB3", "SPECIES", 125, 129], ["coxsackievirus A16", "PROBLEM", 43, 61], ["HFMD", "PROBLEM", 78, 82], ["coxsackievirus B3 (CVB3", "PROBLEM", 106, 129], ["myocarditis", "PROBLEM", 139, 150], ["aseptic meningitis", "PROBLEM", 152, 170], ["pancreatitis", "PROBLEM", 176, 188], ["coxsackievirus", "OBSERVATION", 43, 57], ["myocarditis", "OBSERVATION", 139, 150], ["aseptic", "OBSERVATION_MODIFIER", 152, 159], ["meningitis", "OBSERVATION", 160, 170], ["pancreatitis", "OBSERVATION", 176, 188]]], ["At present, there is no effective therapeutic agent against CVB3, and only ribavirin is available for CVB3 infection despite its weak antiviral activity [93].Coxsackievirus20(S)-Protopanaxtriol is one of the major triterpenes isolated from Panax notoginseng[94].", [["CVB3", "DISEASE", 60, 64], ["ribavirin", "CHEMICAL", 75, 84], ["CVB3 infection", "DISEASE", 102, 116], ["Coxsackievirus20", "CHEMICAL", 158, 174], ["S)-Protopanaxtriol", "CHEMICAL", 175, 193], ["ribavirin", "CHEMICAL", 75, 84], ["(S)-Protopanaxtriol", "CHEMICAL", 174, 193], ["triterpenes", "CHEMICAL", 214, 225], ["CVB3", "ORGANISM", 60, 64], ["ribavirin", "SIMPLE_CHEMICAL", 75, 84], ["CVB3", "ORGANISM", 102, 106], ["S)-Protopanaxtriol", "SIMPLE_CHEMICAL", 175, 193], ["Panax notoginseng", "ORGANISM", 240, 257], ["Panax notoginseng", "SPECIES", 240, 257], ["CVB3", "SPECIES", 60, 64], ["CVB3", "SPECIES", 102, 106], ["Panax notoginseng", "SPECIES", 240, 257], ["CVB3", "PROBLEM", 60, 64], ["ribavirin", "TREATMENT", 75, 84], ["CVB3 infection", "PROBLEM", 102, 116], ["its weak antiviral activity", "PROBLEM", 125, 152], ["Protopanaxtriol", "TREATMENT", 178, 193], ["the major triterpenes", "TREATMENT", 204, 225], ["Panax notoginseng", "TREATMENT", 240, 257], ["no effective", "UNCERTAINTY", 21, 33]]], ["It has been shown that 20(S)-protopanaxtriol has potent antiCVB3 activities in vitro and in vivo.", [["20(S)-protopanaxtriol", "CHEMICAL", 23, 44], ["20(S)-protopanaxtriol", "CHEMICAL", 23, 44], ["20(S)-protopanaxtriol", "SIMPLE_CHEMICAL", 23, 44], ["antiCVB3", "SIMPLE_CHEMICAL", 56, 64], ["antiCVB3", "PROTEIN", 56, 64]]], ["The IC50 of 20(S)-protopanaxtriol for inhibition of CVB3 replication in HeLa cells was even lower than that of ribavirin, indicating a stronger antiviral effect than ribavirin.", [["HeLa cells", "ANATOMY", 72, 82], ["20(S)-protopanaxtriol", "CHEMICAL", 12, 33], ["ribavirin", "CHEMICAL", 111, 120], ["ribavirin", "CHEMICAL", 166, 175], ["20(S)-protopanaxtriol", "CHEMICAL", 12, 33], ["ribavirin", "CHEMICAL", 111, 120], ["ribavirin", "CHEMICAL", 166, 175], ["20(S)-protopanaxtriol", "SIMPLE_CHEMICAL", 12, 33], ["CVB3", "ORGANISM", 52, 56], ["HeLa cells", "CELL", 72, 82], ["ribavirin", "SIMPLE_CHEMICAL", 111, 120], ["ribavirin", "SIMPLE_CHEMICAL", 166, 175], ["HeLa cells", "CELL_LINE", 72, 82], ["CVB3", "SPECIES", 52, 56], ["The IC50", "TEST", 0, 8], ["protopanaxtriol", "TREATMENT", 18, 33], ["CVB3 replication in HeLa cells", "TREATMENT", 52, 82], ["ribavirin", "TREATMENT", 111, 120], ["ribavirin", "TREATMENT", 166, 175], ["HeLa cells", "OBSERVATION", 72, 82]]], ["In vivo experiments showed that treatment of CVB3-infected mice with 20(S)-protopanaxtriol significantly improved CVB3-induced myocarditis represented by a decrease in the activities of lactase dehydrogenase and creatine kinase, markers for myocardial injury.CoxsackievirusIn addition, panaxatriol-type ginsenosides such as ginsenosides Re, Rf, and Rg2 also showed significant antiCVB3 activity represented by a decrease in the CVB3-induced cytopathic effect and an increase in the cell viability of infected Vero cells [26].", [["myocardial", "ANATOMY", 241, 251], ["cell", "ANATOMY", 482, 486], ["Vero cells", "ANATOMY", 509, 519], ["CVB3-infected", "DISEASE", 45, 58], ["20(S)-protopanaxtriol", "CHEMICAL", 69, 90], ["myocarditis", "DISEASE", 127, 138], ["creatine", "CHEMICAL", 212, 220], ["myocardial injury", "DISEASE", 241, 258], ["panaxatriol", "CHEMICAL", 286, 297], ["ginsenosides", "CHEMICAL", 324, 336], ["20(S)-protopanaxtriol", "CHEMICAL", 69, 90], ["creatine", "CHEMICAL", 212, 220], ["panaxatriol", "CHEMICAL", 286, 297], ["ginsenosides", "CHEMICAL", 303, 315], ["ginsenosides Re, Rf, and Rg2", "CHEMICAL", 324, 352], ["CVB3", "ORGANISM", 45, 49], ["mice", "ORGANISM", 59, 63], ["20(S)-protopanaxtriol", "SIMPLE_CHEMICAL", 69, 90], ["CVB3", "ORGANISM", 114, 118], ["lactase dehydrogenase", "GENE_OR_GENE_PRODUCT", 186, 207], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 212, 227], ["myocardial", "MULTI-TISSUE_STRUCTURE", 241, 251], ["CoxsackievirusIn", "GENE_OR_GENE_PRODUCT", 259, 275], ["panaxatriol-type ginsenosides", "SIMPLE_CHEMICAL", 286, 315], ["ginsenosides Re", "SIMPLE_CHEMICAL", 324, 339], ["Rf", "GENE_OR_GENE_PRODUCT", 341, 343], ["Rg2", "SIMPLE_CHEMICAL", 349, 352], ["antiCVB3", "GENE_OR_GENE_PRODUCT", 377, 385], ["CVB3", "ORGANISM", 428, 432], ["cell", "CELL", 482, 486], ["Vero cells", "CELL", 509, 519], ["lactase dehydrogenase", "PROTEIN", 186, 207], ["creatine kinase", "PROTEIN", 212, 227], ["antiCVB3", "PROTEIN", 377, 385], ["infected Vero cells", "CELL_LINE", 500, 519], ["mice", "SPECIES", 59, 63], ["CVB3", "SPECIES", 45, 49], ["mice", "SPECIES", 59, 63], ["CVB3", "SPECIES", 114, 118], ["CVB3", "SPECIES", 428, 432], ["CVB3", "TEST", 45, 49], ["CVB3", "PROBLEM", 114, 118], ["myocarditis", "PROBLEM", 127, 138], ["a decrease", "PROBLEM", 154, 164], ["lactase dehydrogenase", "TEST", 186, 207], ["creatine kinase", "TEST", 212, 227], ["myocardial injury", "PROBLEM", 241, 258], ["CoxsackievirusIn", "TREATMENT", 259, 275], ["panaxatriol", "TREATMENT", 286, 297], ["type ginsenosides", "PROBLEM", 298, 315], ["Rg2", "TEST", 349, 352], ["significant antiCVB3 activity", "PROBLEM", 365, 394], ["a decrease", "PROBLEM", 410, 420], ["the CVB3", "PROBLEM", 424, 432], ["cytopathic effect", "PROBLEM", 441, 458], ["infected Vero cells", "PROBLEM", 500, 519], ["CVB3", "OBSERVATION", 114, 118], ["myocarditis", "OBSERVATION", 127, 138], ["decrease", "OBSERVATION_MODIFIER", 156, 164], ["myocardial", "ANATOMY", 241, 251], ["injury", "OBSERVATION", 252, 258], ["decrease", "OBSERVATION_MODIFIER", 412, 420], ["cytopathic", "OBSERVATION_MODIFIER", 441, 451], ["increase", "OBSERVATION_MODIFIER", 466, 474], ["cell", "OBSERVATION", 482, 486], ["viability", "OBSERVATION_MODIFIER", 487, 496], ["infected", "OBSERVATION_MODIFIER", 500, 508], ["Vero cells", "OBSERVATION", 509, 519]]], ["The antiCVB3 activity of ginsenosides Re and Rf was comparable to that of ribavirin.", [["ginsenosides Re", "CHEMICAL", 25, 40], ["ribavirin", "CHEMICAL", 74, 83], ["ginsenosides Re", "CHEMICAL", 25, 40], ["ribavirin", "CHEMICAL", 74, 83], ["antiCVB3", "GENE_OR_GENE_PRODUCT", 4, 12], ["ginsenosides Re", "SIMPLE_CHEMICAL", 25, 40], ["Rf", "SIMPLE_CHEMICAL", 45, 47], ["ribavirin", "SIMPLE_CHEMICAL", 74, 83], ["Rf", "TREATMENT", 45, 47], ["ribavirin", "TREATMENT", 74, 83], ["ribavirin", "OBSERVATION", 74, 83]]], ["However, panaxadiol-type ginsenosides such as Rb1, Rb2, Rc, and Rd did not exhibit antiCVB3 activity.ConclusionThe swift emergence of new infectious viruses and drug-resistant variants has limited the availability of effective antiviral agents and vaccines.", [["panaxadiol-type ginsenosides", "CHEMICAL", 9, 37], ["Rb1", "CHEMICAL", 46, 49], ["infectious viruses", "DISEASE", 138, 156], ["panaxadiol", "CHEMICAL", 9, 19], ["ginsenosides", "CHEMICAL", 25, 37], ["Rb1, Rb2, Rc, and Rd", "CHEMICAL", 46, 66], ["panaxadiol-type ginsenosides", "SIMPLE_CHEMICAL", 9, 37], ["Rb1", "GENE_OR_GENE_PRODUCT", 46, 49], ["Rb2", "GENE_OR_GENE_PRODUCT", 51, 54], ["Rc", "GENE_OR_GENE_PRODUCT", 56, 58], ["Rd", "GENE_OR_GENE_PRODUCT", 64, 66], ["antiCVB3", "GENE_OR_GENE_PRODUCT", 83, 91], ["Rb1", "PROTEIN", 46, 49], ["Rb2", "PROTEIN", 51, 54], ["Rc", "PROTEIN", 56, 58], ["antiCVB3", "PROTEIN", 83, 91], ["panaxadiol", "TREATMENT", 9, 19], ["type ginsenosides", "TREATMENT", 20, 37], ["Rb1", "TEST", 46, 49], ["new infectious viruses", "PROBLEM", 134, 156], ["drug-resistant variants", "PROBLEM", 161, 184], ["effective antiviral agents", "TREATMENT", 217, 243], ["vaccines", "TREATMENT", 248, 256], ["new", "OBSERVATION_MODIFIER", 134, 137], ["infectious", "OBSERVATION", 138, 148]]], ["Thus, the development of broad-spectrum antivirals and immunomodulating agents that stimulate host immunity and improve host resilience is essential.", [["broad-spectrum antivirals", "TREATMENT", 25, 50], ["immunomodulating agents", "TREATMENT", 55, 78]]], ["Although ginseng itself can exert direct antiviral effects by inhibiting viral attachment, membrane penetration, and replication, the foremost antiviral activities of ginseng are attributed to the enhancement of host immunity.", [["membrane", "ANATOMY", 91, 99], ["ginseng", "ORGANISM", 9, 16], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["ginseng", "ORGANISM", 167, 174], ["direct antiviral effects", "TREATMENT", 34, 58], ["viral attachment", "PROBLEM", 73, 89], ["membrane penetration", "PROBLEM", 91, 111], ["replication", "TREATMENT", 117, 128], ["antiviral effects", "OBSERVATION", 41, 58], ["host immunity", "OBSERVATION", 212, 225]]], ["Future studies should include the identification of essential components responsible for the enhanced immunity against any viral attack.Conflicts of interestNone declared.", [["Future studies", "TEST", 0, 14], ["essential components", "PROBLEM", 52, 72], ["any viral attack", "PROBLEM", 119, 135]]]], "5adf6613fe8688c9c324efb8cc68844c3535c81f": [["therapy.", [["therapy", "TREATMENT", 0, 7]]], ["Sequence analysis of the viral protein 1 gene revealed that both of these viruses clustered with the major outbreak strain from the United States.", [["viral protein 1", "GENE_OR_GENE_PRODUCT", 25, 40], ["viral protein 1 gene", "DNA", 25, 45], ["Sequence analysis", "TEST", 0, 17], ["the viral protein", "TEST", 21, 38], ["these viruses", "PROBLEM", 68, 81], ["viruses", "OBSERVATION", 74, 81]]], ["Partial gene sequences of viral protein 1 were deposited in the GenBank database under accession nos.", [["viral protein 1", "GENE_OR_GENE_PRODUCT", 26, 41], ["viral protein 1", "PROTEIN", 26, 41], ["viral protein 1", "PROBLEM", 26, 41], ["accession nos", "OBSERVATION", 87, 100]]], ["KP247599 and KP247600.", [["KP247599", "CHEMICAL", 0, 8], ["KP247600", "CHEMICAL", 13, 21], ["KP247599", "CHEMICAL", 0, 8], ["KP247600", "CHEMICAL", 13, 21], ["KP247599", "SIMPLE_CHEMICAL", 0, 8], ["KP247600", "SIMPLE_CHEMICAL", 13, 21]]]]}